

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment
ISSN (print): 0250-7005; ISSN (online): 1791-7530

VOLUME 33
2013

This volume is dedicated to the memory of

J.L. BIEDLER

R.B. HERBERMAN

M.F. RAJEWSKY

G. WEBER

Editorial Board

B. B. Aggarwal	Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
A. Argiris	Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA
J. P. Armand	Institut Claudius Regaud, Toulouse, France
V. I. Avramis	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
R. C. Bast	Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
G. Bauer	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
E. E. Baulieu	INSERM U488 and College de France, Le Kremlin-Bicetre, France
Y. Becker	Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel
E. J. Benz, Jr.	Dana-Farber Cancer Institute, Boston, MA, USA
J. Bergh	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
D. D. Bigner	Department of Pathology, Duke University Medical Center, Durham, NC, USA
A. Böcking	Institute for Cytopathology, University of Düsseldorf, Germany
G. Bonadonna	Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
F. T. Bosman	Institute of Pathology, University of Lausanne, Switzerland
G. Broich	Gruppo Policlinico di Monza, Monza, Italy
J. M. Brown	Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA
Ø. S. Bruland	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
M. M. Burger	Novartis, Basel, Switzerland
M. Carbone	Cancer Research Center of Hawaii, Honolulu, HI, USA
J. Carlsson	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
A. F. Chambers	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
P. Chandra	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
L. Cheng	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
J.-G. Chung	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
E. De Clercq	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
W. De Loecker	Department of Biochemistry, Katholieke Universiteit Leuven, Belgium
W. Den Otter	VUMC, Department of Urology, Amsterdam, The Netherlands
E. P. Diamandis	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
G. Th. Diamandopoulos	Department of Pathology, Harvard Medical School, Boston, MA, USA
W. Ebert	Thoraxclinic HD-Rohrbach, Heidelberg, Germany
D.W. Felsher	Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
J. A. Fernandez-Pol	Metalloproteomics, LLC, Chesterfield, MO, USA
I. J. Fidler	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
A.P. Fields	Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA
G. Gabbiani	Department of Pathology, University of Geneva, Switzerland
R. Ganapathi	Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
A. F. Gazdar	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
J.H. Geschwind	Interventional Radiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
A. Giordano	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
G. Gitsch	Department of Gynecology and Obstetrics, University of Freiburg, Germany
R. H. Goldfarb	Trudeau Institute, Saranac Lake, NY, USA
J. W. Gorrod	Toxicology Unit, John Tabor Laboratories, University of Essex, Colchester, Essex, UK
S. Hammarström	Department of Immunology, University of Umeå, Sweden
I. Hart	Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart's and The London, Queen Mary's School of Medicine and Dentistry, London, UK

- I. Hellström** Harborview Medical Center, Seattle, WA, USA
L. Helson Sign Path Pharma, Inc., Quakertown, PA, USA
R. B. Herberman Intrexon Corporation, Germantown, MD, USA
R. M. Hoffman Department of Surgery, University of California, San Diego, CA, USA
C. G. Ioannides Department of Gynecology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
K.-S. Jeong Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, South Korea
S. C. Jhanwar Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

J. V. Johannessen Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
B. Kaina Institute of Toxicology, University of Mainz, Germany
B. K. Keppler School of Medicine, University of Vienna, Austria
D. G. Kieback Department of Obstetrics and Gynecology, Elblandklinikum Riesa, Riesa (Dresden), Germany
R. Klapdor Medical Clinic, University of Hamburg, Germany
U. R. Kleeberg Hämatologisch - Onkologisch - Praxis Altona, Hamburg, Germany
P. Kleihues Department of Pathology, University Hospital Zürich, Switzerland
E. Klein Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden
S. von Kleist Institut für Immunologie der Universität der Freiburg, Germany
S. D. Kottaridis Department of Virology, Hellenic Anticancer Institute, Athens, Greece
G. R. F. Krueger Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
D. W. Kufe Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA
Pat M. Kumar Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
Shant Kumar Department Pathology, University of Manchester Medical School, Manchester, UK
M. Kuroki Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan
O. D. Laerum Department of Pathology, The Gade Institute, University of Bergen, Norway
F. J. Lejeune Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
L. F. Liu Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
D. M. Lopez Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
E. Lundgren Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
H. T. Lynch Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA
J. Maher Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital Campus, London, UK

J. Marescaux IRCAD, University of Strasbourg, France
J. Mark Department of Pathology, Kärnshjukhuset, Skövde, Sweden
J. F. Marshall Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart's and The London, Queen Mary's School of Medicine and Dentistry, London, UK

D. Medina Department of Cell Biology, Baylor College of Medicine, Houston, TX, USA
S. Mitra The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
M. Mueller Research Group of Tumor and Microenvironment (A101), German Cancer Research Center (DKFZ), Heidelberg, Germany

F. M. Muggia New York University Cancer Institute, School of Medicine, NY, USA
M. J. Murphy, Jr. Hipple Cancer Research Center, Dayton, OH, USA
R. Narayanan Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
K. Nilsson Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
J. F. Novak Department of Biology, Bucknell University, Lewisburg, PA, USA
S. Pathak Department of Cell Biology, University of Texas, Houston, TX, USA
S. Pestka Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA

G. J. Pilkington Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK

C. D. Platsoucas	College of Sciences, Old Dominion University, Norfolk, VA, USA
F. Podo	Laboratory of Cell Biology, Istituto Superiore di Sanità, Rome, Italy
A. Polliack	Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
M. F. Rajewsky	Institute of Cell Biology, University of Essen Medical School, Essen, Germany
G. Rebel	IRCAD, Hopitaux Universitaires, Strasbourg, France
M. Rigaud	Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, France
U. Ringborg	Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
M. Roselli	Department of Medical Oncology, University of Rome "Tor Vergata", Italy
A. Schauer	Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
M. Schneider	Department of Organic Chemistry, Bergische University, Wuppertal, Germany
A. Seth	Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
G. V. Sherbet	Cancer Research Unit, University of Newcastle-upon-Tyne, UK
G.-I. Soma	Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan
G. S. Stein	Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
T. Stigbrand	Department of Immunology, Umeå University, Umeå, Sweden
D. Tarin	University of California at San Diego, Cancer Center, La Jolla, CA, USA
T. M. Theophanides	Department of Chemistry, Technical University of Athens, Greece
B. Toth	The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USA
P. M. Ueland	Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
P. T. Vihko	Department of Clinical Chemistry, University of Oulu, Finland
R.G. Vile	Department of Immunology, Mayo Clinic, Rochester, MN, USA
M. Volm	German Cancer Research Center, Heidelberg, Germany
G. Weber	Laboratory of Experimental Oncology, Indiana University, Indianapolis, IN, USA
B. Westermark	Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
Y. Yen	Department of Molecular Pharmacology, City of Hope, Duarte, CA, USA
B. Zumoff	Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

Acknowledgements

The following Organizations supported many of the works published in Anticancer Research, Volume 33, 2013.

- 90th Anniversary of Chulalongkorn University Fund,
Chulalongkorn University, Bangkok, Thailand
- A.P. Møller and Chastine Mc-Kinney Møller Foundation for
General Purposes, Copenhagen, Denmark
- Abdulrahman Abdulmalik Research Fund
- Advisory Research Committee, Queen's University, Kingston,
ON, Canada
- Agreement for Doctoral Education, Region Västra Götaland,
Sweden
- AIL La Spezia - Sezione "Francesca Lanzone", La Spezia,
Italy
- Akdeniz University Research Units, Antalya, Turkey
- Albert Hung Foundation, Hong Kong, China
- Alex's Lemonade Stand Foundation, Wynnewood, PA, U.S.A.
- Alma Toorock Memorial for Cancer Research, Brooklyn, NY,
U.S.A.
- American Association of Colleges of Pharmacy (AACP),
Alexandria, VA, U.S.A.
- American Heart Association, Dallas, TX, U.S.A.
- American Lebanese Syrian Associated Charities , St. Jude
Children's Research Hospital, Memphis, TN, U.S.A.
- Anna-Lisa and Bror Björnsson Research Foundation,
Gothenburg, Sweden
- AOR, Inc., Denver, CO, U.S.A.
- Araucaria Foundation, Coronado, CA, U.S.A.
- Arjuna Natural Extracts Ltd., Kochi, India
- ARUP laboratories, Salt Lake City, UT, U.S.A.
- Asan Institute for Life Sciences, Seoul, Republic of Korea
- ASCO, Alexandria, VA, U.S.A.
- ASK Science Products, Inc., Kingston, ON, Canada
- Assar Gabrielsson Foundation for Cancer Research,
Gothenburg, Sweden
- Association Espoir, Colmar, France
- Associazione Italiana Ricerca sul Cancro (AIRC), Milan, Italy
- Asta Medica, Hamburg, Germany
- ATIP Hyperbaric Medical Center, Padua, Italy
- Austrian Cancer Aid, Styria, Austria
- Austrian Research Promotion Agency (FFG), Vienna, Austria
- Austrian Science Fund (FWF), Vienna, Austria
- AZ Middelheim, Antwerp, Belgium
- Banque de tissus et de données, Réseau de recherche sur le
cancer, Fonds de la recherche en santé du Québec (FRSQ),
Montréal, QC, Canada
- Bauer Research Foundation, Inc., Vero Beach, FL, U.S.A.
- Bayer HealthCare Pharmaceuticals, Montville, NJ, U.S.A.
- Becton Dickinson, Franklin Lakes, NJ, U.S.A.
- Bettina Bräu Stiftung, Fürstenfeldbruck, Germany
- Biohit HealthCare, Helsinki, Finland
- Biomedical Laboratory and Clinical Sciences Programs,
Department of Veterans Affairs, Washington, DC, U.S.A.
- Biomedical Research Core, Graduate School of Medicine,
Tohoku University, Sendai, Japan
- Bio-Rad Laboratories, Inc., Hercules, CA, U.S.A.
- Bio-Rad Laboratories, Ltd., Hercules, CA, U.S.A.
- BioVision, Milpitas, CA, U.S.A.
- Breast Cancer Action Kingston, Kingston, ON, Canada
- Breast Cancer Hope Foundation, London, U.K.
- Bretonneau University Hospital, Tours, France
- Bristol Urological Institute, Bristol, U.K.
- Buddhist Tzu Chi General Hospital, Hualien City, Taiwan
- Bundang Jesaeng General Hospital, Seongnam, Republic of
Korea
- Canadian Breast Cancer Foundation, Toronto, ON, Canada
- Canadian Breast Cancer Research Alliance, Toronto, ON,
Canada
- Canadian Cancer Society Research Institute, Toronto, ON,
Canada
- Canadian Cancer Society, Toronto, ON, Canada
- Canadian Institute of Health Information (CIHI), Ottawa, ON,
Canada
- Canadian Research Society, Montreal, QC, Canada
- Canadian Tumor Repository Network, Canada
- Cancer Council of South Australia (CCSA), Australia
- Cancer Research and Treatment, Graduate School of Medical
Sciences, Kyushu University, Fukuoka, Japan
- Cancer Research Fund, Fukuoka Foundation for Sound
Health, Fukuoka, Japan
- Cancer Research Wales, Wales, U.K.
- Cancéropôle Nord-Ouest, Lille, France
- Celgene Corp., Summit, NJ, U.S.A.
- Center for the Advancement of Medical Training, Toyama
University Hospital, Toyama, Japan
- Center of Commercialization of Fluorescence Technologies,
Fort Worth, TX, U.S.A.
- Central-Taiwan University of Science and Technology,
Taichung, Taiwan R.O.C.
- Centre de recherche Clinique-Étienne Le Bel, Sherbrooke,
QC, Canada

- Centre National de la Recherche Scientifique (CNRS), Paris, France
- Chang Gung Medical Research Fund, Chang Gung University, Kwei Shan, Taiwan, R.O.C.
- Charles University Research Fund, Charles University in Prague, Prague, Czech Republic
- Chase after a Cure Foundation, Houston, TX, U.S.A.
- Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C.
- Chilean National Commission for Scientific and Technological Research (CONICYT), Santiago, Chile
- China Medical Scholarship, Cardiff University, Wales, U.K.
- China Medical University and Hospital, Taichung, Taiwan, R.O.C.
- Chittaranjan National Cancer Institute, Kolkata, India
- Chonnam National University Hospital, Gwangju, Republic of Korea
- Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C.
- Clare Nelson Bequest Fund, Queen's University, Kingston, ON, Canada
- Clinical Pathology Division, Sant'Andrea Hospital, La Spezia, Italy
- Collaborative Ependymoma Research Network (CERN), Dayton, OH, U.S.A.
- Compagnia di San Paolo, Turin, Italy
- Competitive Research Funding, Tampere University Hospital, Tampere, Finland
- Computerforum, Elmshorn, Germany
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasilia, Brazil
- Converging Research Center Program, Ministry of Education, Science and Technology of Korea, Republic of Korea
- Cooperation in Science and Technology (COST), EU RTD Framework Program, Brussels, Belgium
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasilia, Brazil
- Cornell University, Ithaca, NY, U.S.A.
- Cotton Incorporated, Cary, NC, U.S.A.
- Council of Scientific and Industrial Research, New Delhi, India
- County Council of Östergötland, Linköping, Sweden
- CREST, Tokyo, Japan
- Dafra Pharma, Turnhout, Belgium
- Daiichi Sankyo Co., Ltd., Tokyo, Japan.
- Das Land Steiermark, Graz, Austria
- Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia
- Department of Biotechnology (DBT), New Delhi, India
- Department of Biotechnology, Ministry of Science and Technology, New Delhi, India
- Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, U.S.A.
- Department of Cytology and Pathology, National Cancer Hospital, Hanoi, Vietnam
- Department of Defense Breast Cancer Program, Fort Detrick, MD, U.S.A.
- Department of Defense, Arlington County, VA, U.S.A.
- Department of Health, Taipei, Taiwan, R.O.C.
- Department of Histology and Embryology, Medical University in Wroclaw, Wroclaw, Poland
- Department of Immunology/Immunopathology, Faculty of Medicine, Kagawa University, Takamatsu, Japan
- Department of Molecular Cell Biology, Jikei University School of Medicine, Tokyo, Japan
- Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, U.S.A.
- Department of Otolaryngology, Head and Neck Surgery, University of Marburg, Marburg, Germany,
- Department of Pathology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,
- Department of Pathology, Shizuoka Cancer Center, Shizuoka, Japan
- Department of Pathology, Tohoku University School of Medicine, Sendai, Japan
- Department of Public Health, School of Medicine, Aichi Medical University, Nagakute, Japan
- Department of Pulmonary and Critical Care Medicine, College of Medicine, Mayo Clinic, Rochester, MN, U.S.A.
- Department of Surgery, University of Michigan, Ann Arbor, MI, U.S.A.
- Department of Urology, General Hospital in Campobasso, Campobasso, Italy
- Departments of Radiology, Obstetrics and Gynecology, Anesthesiology and Nursing, Kyoto Prefectural University of Medicine, Kyoto, Japan
- Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany
- Deutsche Gesellschaft für Psychosomatische Frauenheilkunde und Geburtshilfe (DGPF), Dresden, Germany
- Deutsche José Carreras Leukämie Stiftung, Munich, Germany
- Deutsche Krebshilfe, Bonn, Germany
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
- Division of General Thoracic Surgery, School of Medicine, Keio University, Tokyo, Japan
- Doktor Robert Pflieger Foundation, Bamberg, Germany

- Dorothea Olivia, Karl Walter, and Jarl Walter Perklén
Foundation, Finland
- Dougherty Foundation, Phoenix, AZ, U.S.A.
- Dr. Helmut Legerlotz Stiftung, Zurich, Switzerland
- Duluth Medical Research Institute, Duluth, MN, U.S.A.
- Dynamic Solutions, Madrid, Spain
- East Japan Chesters Group, Department of Respiratory
Medicine, Respiratory Section, Saitama Cancer Center,
Saitama, Japan
- École pratique des hautes études (EPHE), Paris, France
- Eli Lilly, Indianapolis, IN, U.S.A.
- Euclides da Cunha Foundation, Universidad Federal
Fluminense, Niterói, Brazil
- Europe Against Infant Brain Injury, Siena, Italy
- European Lung Cancer Working Party, Brussels, Belgium
- European Regional Development Fund, Brussels,
Belgium
- European Social Fund, Brussels, Belgium
- Experimental Physiology, National and Kapodistrian
University of Athens, Athens, Greece
- Extramural Research Facilities Program, National Center for
Research Resources, Bethesda, MD, U.S.A.
- F. Hoffmann-La Roche, Ltd., Basel, Switzerland
- Faculty of Health and Medical Sciences, Copenhagen
University, Copenhagen, Denmark
- Faculty of Physiology, University of Santiago de Compostela,
Santiago de Compostela, Spain
- Farma S.A., Leioa, Spain
- Finska Läkaresällskapet, Helsinki, Finland
- Florida Department of Health, Tallahassee, FL, U.S.A.
- Flow Cytometry Laboratory, ETH Hönggerberg Zurich,
Zürich, Switzerland
- Fondation des hôpitaux Enfant-Jésus-Saint-Sacrement,
Canada
- Fonds de la Recherche en Santé du Québec, Montreal, QC,
Canada
- Fonds de Recherche en Santé du Québec (FRSQ), Montreal,
QC, Canada
- Foundation of Clinical Cancer Research, Jönköping,
Sweden
- Foundation of Innovative Research Team of Educational
Commission of Zhejiang Province, P.R. China
- Foundation of University of Medicine and Dentistry of New
Jersey, New Jersey, U.S.A.
- Foundation Savings and Loan Company of Verona Vicenza
Belluno and Ancona, Italy
- Frank A Campini Foundation, San Francisco, CA, U.S.A.
- Fund for Scientific Research – Flanders (FWO - Vlaanderen),
Brussels, Belgium
- Fundação Amazônia Paraense do Estado do Pará (FAPESPA),
São Paulo, Brazil
- Fundação Calouste Gulbenkian, Lisbon, Portugal
- Fundação de Amparo à Pesquisa do Estado de São Paulo
(FAPESP) São Paulo, Brazil
- Fundação para a Ciência e a Tecnologia, Ministério da
Ciência e Ensino Superior, Portugal
- Fundamental Research Funds for the Central Universities,
Xi'an, P.R. China
- Fundamental Research Funds, Xi'an Jiaotong University,
Funding Program for Next Generation World-Leading
Researchers, Tokyo, Japan
- Futurum the Academy of Healthcare, County Council of
Jönköping, Jönköping, Sweden
- GE Medical Systems Functional Imaging GmbH, Münster,
Germany
- Geconcerteerde Onderzoeksactie (GOA), Ghent University,
Ghent, Belgium
- GEFLUC, Paris, France
- German Academic Exchange Service (DAAD), New York,
NY, U.S.A.
- German Federal State of Mecklenburg-Vorpommern, Germany
- Gittlen Cancer Research Foundation, Pennsylvania
Department of Health, Harrisburg, PA, U.S.A.
- GlaxoSmithKline, London, U.K.
- Global Center of Excellence (GCOE), Ministry of Education,
Culture, Sports, Science and Technology of Japan, Tokyo,
Japan
- Global COE Program for Metabolomics Systems Biology,
Keio University, Tokyo, Japan
- Gothenburg Medical Society, Gothenburg, Sweden
- Gothenburg University, Gothenburg, Sweden
- Government Health Grant, Sweden
- Government of Malaysia, Malaysia
- Grand Forks Human Nutrition Research Center, Washington,
DC, U.S.A.
- Grants-in-Aid for Scientific Research (KAKENHI), Japan
Society for the Promotion of Science, Tokyo, Japan
- Greek Ministry of Health, Greece
- Grupo Gallego de Investigaciones Oncológicas (GGIO),
Spain
- Guangdong Province Leadership Grant, P.R. China
- Guangxi Scientific Research and Technological Development
Program, Guangxi University of Science and Technology,
Guangxi, P. R. China
- GW Pharmaceuticals Ltd., Salisbury, U.K.

- Hadassah School of Dental Medicine, Jerusalem, Israel
 Health Service Center, University of Tokushima, Tokushima, Japan
- Held-Hecker foundation, Frankfurt, Germany
- Hellenic Anticancer Society, Athens, Greece
- Helsinki University Hospital, Helsinki, Finland
- Henry R. Shibata Fellowship, Cedars Cancer Institute, Montreal, QC, Canada
- Herbert Wertheim School of Medicine, Florida International University, Miami, FL, USA,
- Histology Research Laboratory, Norwegian Radium Hospital, Oslo, Norway
- Histology Section, Tissue Core, H. Lee Moffitt Cancer Center & Research Institute. Tampa, FL, U.S.A.
- Histopathology and Cytopathology Division, Sant' Andrea Hospital, La Spezia, Italy
- Histopathology Laboratory, UC Davis, Davis, CA, U.S.A.
- Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, U.S.A.
- Holley Pharmaceuticals, Tustin, CA, U.S.A.
- Hoogland Medical Heesch, Oss, The Netherlands
- Howard Hughes Medical Institute (HHMI), Chevy Chase, MD, U.S.A.
- Howard University Funds for Academic Excellence, Howard University, Washington, D.C., U.S.A.
- Hyundai Hope on Wheels, Los Angeles, CA, U.S.A.
- Ida och Henning Persson Foundation, Sweden
- Imgenex Corp., San Diego, CA, U.S.A.
- Immunotherapy Platform Leuven, Leuven, Belgium
- Imperial Biomedical Research Centre (BRC), London, U.K.
- Imperial Life Science (P) Ltd., Haryana, India
- INCT/CNPq-Inovação Farmacêutica, Brazil
- Innovation Norway, Norway
- Innovative Research Team of Ningbo, Ningbo, P. R. China
- INSERM Research Unit 403, Lyon, France
- Institut de la Santé et la Recherche Médicale (INSERM), Paris, France
- Institut de Recherche Pierre Fabre, Paris, France
- Institute of Medical Statistics , University Hospital of Aachen, Aachen , Germany
- Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
- Institutos Nacionais de Ciência e Tecnologia (INCTs), Brazil
- Interdisciplinary Center for Clinical Research (IZKF), Münster, Germany
- International Atomic Energy Agency (IAEA), Vienna, Austria
- Intramural Research Program , National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.
- Intramural Research Support Program, University of Mississippi Medical Center, Jackson, MS, U.S.A.
- Israel Cancer Research Fund, New York, NY, U.S.A.
- Italian Ministry of Education, Universities and Research, Rome, Italy
- Italian Ministry of Health , Rome, Italy
- Jack Cole Chair in Pediatric Hematology/Oncology.
- James and Esther King Florida Biomedical Research Program, Florida Department of Health, Tallahassee, FL, U.S.A.
- Japan Science and Technology Agency (JST), Kawaguchi, Japan
- Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
- Jarislowsky Foundation, Canada
- Jarrow Formulas, Inc., Los Angeles, CA, U.S.A.
- Jiangsu Provincial Department of Health, P.R. China
- Jikei University Research Fund, Tokyo, Japan
- Joint Research Grant, The Hebrew University of Jerusalem, Jerusalem, Israel
- K.C. Wong Magna Fund, Ningbo University, Ningbo, P.R. China
- Kanazawa University, Kanazawa, Japan
- Kano-grant, Japanese Society of Myeloma, Japan
- Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
- Karolinska Institutet, Stockholm, Sweden
- Keio University, Tokyo, Japan
- King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia
- Kingsmill Farm II, Wake Forest, NC, U.S.A.
- Kinki Central Hospital for Mutual Aid Association of Public School Teachers, Higashiōsaka, Japan
- Korea Basic Science Institute, Daejeon, Republic of Korea
- Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
- KU Leuven, Leuven, Belgium
- Kurt and Doris Palanders Foundation for Medical Research, Helsinki, Finland
- Kwon Laboratory, University of Pittsburgh, Pittsburgh, PA, U.S.A.
- Kyungpook National University, Daegu, Republic of Korea
- L'Association Biologie du Cancer et Dynamiques
- L'Université Paris-Sud Orsay, Paris, France

- Leica Microsystems, Wetzlar, Germany
 Life Science Discovery Fund , Seattle, WA, U.S.A.
 Life Technologies, Carlsbad, CA, U.S.A.
 Ligue contre le Cancer , Paris, France
 Lions Cancer Research Foundation, Uppsala University Hospital, Uppsala, Sweden
 Lipidomics Shared Resource, Medical University of South Carolina, Charleston, SC, U.S.A.
 Lloyd Carr-Harris Foundations, Canada
 Luminex Corporation, Austin, TX, U.S.A.
 Lund University, Lund, Sweden
 Lung Cancer Registry, Berlin, Germany
- Major University of San Andrés, La Paz, Bolivia
 Malmö Cancer Foundation, Malmö, Sweden
 Mama Mare Breast Cancer Foundation, Easton, PA, U.S.A.
 Maugeri Foundation, Pavia, Italy
 MD Anderson Cancer Center, Houston, TX, U.S.A.
 Medical University of Lodz, Łódź, Poland
 Medical University of Lublin, Lublin, Poland
 Medicinska understödsföreningen Liv och Hälsa, Helsinki, Finland
 Merck & Co., Inc., Whitehouse Station, NJ, U.S.A.
 Metaxas Cancer Hospital, Athens, Greece
 Mildred-Scheel-Stiftung (Deutsche Krebshilfe), Bonn, Germany
 Miles of Hope Breast Cancer Foundation, Lagrangeville, NY, U.S.A.
 Mine City Hospital, Mine, Japan
 Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea
 Ministry of Economics, P.R. China
 Ministry of Education and Science, Lisbon, Portugal
 Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan
 Ministry of Education, Science and Technology, Seoul, Republic of Korea
 Ministry of Education, Youth and Sport, Prague, Czech Republic
 Ministry of Health and Welfare, Seoul, Republic of Korea
 Ministry of Health of the Czech Republic, Prague, Czech Republic
 Ministry of Health, Labor and Welfare, Tokyo, Japan
 Ministry of Higher Education, Malaysia
 Ministry of Industry and Trade of the Czech Republic, Prague, Czech Republic
 Ministry of National Education, Bucharest, Romania
 Ministry of Oceans and Fisheries, Republic of Korea
- Ministry of Research and Innovation of the Province of Ontario, Canada
 Ministry of Science and Higher Education of Poland, Warsaw, Poland
 Ministry of Science and Technology, Seoul, Republic of Korea
 Ministry of Science and Technology, Vietnam
 Ministry of Science, Education and Sports, Republic of Croatia
 Ministry of Science, ICT & Future Planning (MSIP), Republic of Korea
 Mishima Memorial Foundation, Japan
 Mitsui Life Social Welfare Foundation , Japan
 Molecular Carcinogenesis and Chemoprevention Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH, U.S.A.
 Monika Kutzner Stiftung, Berlin, Germany
 Mount Sinai Hospital, New York, NY, USA,
 Müller Fahnenberg Stiftung, University of Freiburg, Freiburg im Breisgau, Germany
 Murdoch Children’s Research Institute, Melbourne, Australia
- Nancy and Stephen Grand Philanthropic Fund
 National Agency for Scientific Research, Tripoli, Libya
 National and Kapodistrian University of Athens, Athens, Greece
 National Cancer Center, Tokyo, Japan.
 National Cancer Institute (NCI), Paris, France
 National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
 National Center for Tumour Diseases, University of Heidelberg, Heidelberg, Germany
 National Central University, Jhongli City, Taiwan R.O.C.
 National Cerebral and Cardiovascular Center Research Institute, Suita, Japan
 National Chiao Tung University, Hsinchu, Taiwan R.O.C.
 National Health and Medical Research Council (NHMRC), Australia
 National Health Research Institutes, Taipei, Taiwan R.O.C.
 National Hospital Organization Toneyama National Hospital, Toyonaka, Japan
 National Hospital Organization, Omura, Japan
 National Hospital, Bloemfontein, South Africa
 National Institute for Academic Anaesthesia (NIAA), London, U.K.
 National Institute of Neurological Disorders and Stroke (NINDS), NIH Neurological Institute, Bethesda, MD, U.S.A.
 National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.

- National Natural Science Foundation of China, Guangdong, P.R. China
- National Research & Development Program for Cancer Control, Ministry of Health and Welfare, Seoul, Republic of Korea
- National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
- National Science Centre (NCN), Poland
- National Science Council of Taiwan, Taipei, Taiwan, R.O.C.
- National Science Council of the Republic of China, P.R. China
- National Spanish R&D Programme CENIT, Spanish Ministry of Science and Technology, Spain
- National Tsing Hua University, Beijing, P.R. China
- National Tsing Hua University, Hsinchu, Taiwan R.O.C.
- National Yang-Ming University, Taipei, Taiwan R.O.C.
- Natural Science Foundation of Guangdong Province, P.R. China
- Natural Science Foundation of Science & Technology, Department of Guangxi Province, P.R. China
- Natural Sciences and Engineering Research Council of Canada (NSERC), Canada
- Nature Science Foundation of Ningbo City, Ningbo, P.R. China
- Nebraska Tobacco Settlement Biomedical Research Fund, U.S.A.
- Neidorf Family Foundation, Los Angeles, CA, U.S.A.
- New Hungary Development Plan, Hungary
- New Jersey Commission on Cancer Research, Trenton, NJ, U.S.A.
- New Taipei City Hospital, Taipei, Taiwan, R.O.C.
- New York University, New York, NY, U.S.A.
- NewChapter, Inc., Brattleboro, VT, U.S.A.
- NHS Grampian Endowments, National Health Service, London, U.K.
- NIH Brain Tumor SP0RE Grant, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.
- Nikon Instruments, Minneapolis, MN, U.S.A.
- Nishinomiya Municipal Central Hospital, Nishinomiya, Japan
- NKBIO Co., Ltd., Seongnam, Republic of Korea
- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), Berlin, Germany
- Northwestern University, Chicago, IL, U.S.A.
- Novartis International AG, Basel, Switzerland
- NSW Clinical Cancer Registry (ClinCR), Alexandria, Australia
- Nuclear Medicine Department, IRCCS San Martino- IST, Genoa, Italy
- Nursing Department, Technological Institute of Crete, Heraklion, Greece
- Office for Clinical Research Support, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
- Olga Mayenfisch Foundation, Zurich, Switzerland
- Olivia Hendrickx Research Fund, Herentals, Belgium
- OmniActive Health Technologies, Ltd., Morristown, NJ, U.S.A.
- Ono Cancer Research Fund, Japan
- ONO Pharmaceutical Co., Osaka, Japan
- Onoda Red Cross Hospital, Sanyo-Onoda, Japan
- Ontario Centers of Excellence, Ottawa, ON, Canada
- Onyx Pharmaceuticals, South San Francisco, CA, U.S.A.
- Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
- Osaka Medical Research Foundation for Incurable Diseases, Osaka, Japan
- Osaka Police Hospital, Osaka, Japan
- Osaka University Graduate School of Medicine, Osaka, Japan
- Osaka University of Health and Sport Sciences, Kumatori, Japan
- Oxford Centre for Innovation, Oxford, U.K.
- Oxford University Press, Oxford, U.K.
- Palacký University, Olomouc, Czech Republic
- Parent-Bridge Programme, Foundation for Polish Science, Warsaw, Poland
- Pathology and Laboratory Medicine Service, Minneapolis VA Medical Center, Minneapolis, MN, U.S.A.
- Pfizer, Inc., New York City, NY, U.S.A.
- Pharmaceutical Research Instrument Center, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
- Physiology Department, Medical School, University of Athens, Athens, Greece
- Pink Ribbon Foundation, Lake Success, NY, U.S.A.
- Pipeline Biotech A/S, Trige, Denmark
- Pneumology Division, San Bartolomeo Hospital, Sarzana, Italy
- Pomorskie Voivodeship Budget, Operational Programme Human Capital, Warsaw, Poland
- Priority Research Project, Knowledge Hub Aichi, Japan
- Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade Federal do Pará, Belém, Brazil

- Proteogenomic Research Program , National Research Foundation of Korea, Korean Ministry of Education, Science and Technology, Seoul, Republic of Korea
- Proteomics Unit at the University of Bergen (PROBE), University of Bergen, Bergen, Norway
- Public Welfare & Safety Research Program, National Research Foundation of Korea (NRF), Seoul, Republic of Korea
- Queen's University, Kingston, ON, Canada
- Radiological Translational Research Program, Korea Science and Engineering Foundation, Seoul, Republic of Korea
- Rajiv Gandhi Center for Biotechnology, Thiruvananthapuram, India
- Rally Foundation for Childhood Cancer Research, Sandy Springs, GA, U.S.A.
- Ratchadaphiseksompot Endowment Fund, Chulalongkorn University, Bangkok, Thailand
- Regional Technology Innovation Program, Ministry of Knowledge Economy (MKE), Republic of Korea
- Regione Piemonte, Progetti di Ricerca Sanitaria Finalizzata, Turin, Italy
- Reinhard Nagel Stiftung, German Association of Urology, Germany
- Reliable Cancer Therapies, Verbier, Switzerland
- Research Fund of the University Hospital Leuven, Leuven, Belgium
- Research Institute of Medical Sciences, Chonnam National University, Gwangju, Republic of Korea
- Research Project Biomedreg, Olomouc, Czech Republic
- Research Service, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, U.S.A.
- Ricerca Sanitaria, Regione Liguria, Italy
- Rio de Janeiro Research Foundation (FAPERJ), Rio de Janeiro, Brazil
- Robert Bosch Stiftung, Stuttgart, Germany
- Roche Farma S.A., Spain
- Rudolf Bartling Stiftung, Hannover, Germany
- Ruth Estrin Goldberg Foundation, Union, NJ, U.S.A.
- S. Daniel Abraham Honors Program, Stern College for Women, Yeshiva University, New York, NY, U.S.A.
- Sabine Dörge Stiftung, Ludwigsburg, Germany
- Sabinsa Corporation, Princeton, NJ, U.S.A.
- Saisei Mirai Clinics, Japan
- Samsung Biomedical Research Institute, Seoul, Republic of Korea
- Sanofi S.A., Paris, France
- Sanofi-Aventis Canada, Laval, QC, Canada
- School of Medicine, Keio University, Tokyo, Japan
- Science and Engineering Foundation (KOSEF) Grant, Seoul, Republic of Korea
- Science Research Promotion Fund, Promotion and Mutual Aid Corporation for Private Schools of Japan, Japana
- Scientific Innovation Team Project of Ningbo, Ningbo, P.R. China
- Seneca Foundation, Coordination Research Centre of the Region of Murcia, Spain
- Seoul National University, Seoul, Republic of Korea
- Seoul R&BD Program , Seoul, Republic of Korea
- Shinnanyo Hospital, Shunan, Japan
- SIGNO, Berlin, Germany
- SignPath Pharma, Inc., PA, U.S.A.
- Sigrid Jusélius Foundation, Helsinki, Finland
- Sisk Healthcare Foundation, Dublin , Ireland
- Skåne University Hospital Foundation, Lund, Sweden
- SMDC Foundation, Essentia Health, Duluth, MN, U.S.A.
- SNUBH Research Fund, Seoul National University Bundang Hospital, Seoul, Republic of Korea
- Southern and Eastern Norway Regional Health Authority (RHF), Hamar, Norway
- Spanish Association Against Cancer, Madrid, Spain
- SPUR3, University of the West of England, Bristol, U.K.
- Squid and Squash Foundation, Los Angeles, CA, U.S.A.
- SRC Research Center for Women's Diseases, Sookmyung Women's University, Seoul, Republic of Korea
- St. Savvas, Regional Anticancer Oncology Hospital of Athens, Athens, Greece
- State Committee for Scientific Research, Warsaw, Poland
- Stichting Nationaal Fonds tegen Kanker (SNFK), Amsterdam, The Netherlands
- Stockholm City Council, Stockholm, Sweden
- Stockholm County Council, Stockholm, Sweden
- Stony-Wold Herbert Fund Fellowship, New York, NY, U.S.A.
- Sun Pharmaceuticals Ltd., Mumbai, India
- Surgical Pathology, Minneapolis VA Medical Center, Minneapolis, MN, USA.
- Susan G. Komen Breast Cancer Foundation, Dallas, TX, U.S.A.
- Suzuken Memorial Foundation, Nagoya, Japan
- Swedish Cancer Foundation, Stockholm, Sweden
- Swedish Cancer Society (Cancerfonden), Stockholm, Sweden
- Swedish Cancer Society, Stockholm, Sweden
- Swedish International Development Cooperation Agency (SIDA), Stockholm, Sweden
- Swedish Medical Research Council, Stockholm, Sweden
- Swedish National Research Council, Stockholm, Sweden
- Swiss National Science Foundation (SNF), Bern, Switzerland

- Szeged Foundation for Cancer Research (Szegedi Rákkutatásért Alapítvány), Szeged, Hungary
- Taiho Pharmaceutical Co. Ltd., Princeton, NJ, U.S.A.
- Taipei Medical University's Wan Fang Hospital, Taipei City, Taiwan R.O.C.
- Taipei Veterans General Hospital, Taipei City, Taiwan R.O.C.
- Taiwan Department of Health, Taipei City, Taiwan R.O.C.
- Takaokashimin Hospital, Takaoka, Japan
- Takeda Science Foundation, Japan
- Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan R.O.C.
- Terry Fox Cancer Research Foundation, Chilliwack, BC, Canada
- Texas A&M Health Science Center Cancer Research Council Seed Grant, Round Rock, TX, U.S.A.
- The Academy of Finland, Helsinki, Finland
- The V Foundation, Cary, NC, U.S.A.
- Thermo Fisher Scientific, Waltham, MA, U.S.A.
- Third-Term Comprehensive 10-Year Strategy for Cancer Control, Ministry of Health, Labour and Welfare of Japan, Japan
- Thoraxklinik, Heidelberg University, Heidelberg, Germany
- Thuréus foundation, Uppsala, Sweden
- Tissue Acquisition and Cellular/Molecular Analysis Shared Service, University of the Arizona Cancer Center, Tucson, AZ, U.S.A.
- Tissue Bank, China Medical University, Taichung, Taiwan R.O.C.
- Tokyo Dental College, Chiba, Japan
- Tokyo Institute of Technology, Yokohama, Japan
- Tokyo University of Agriculture, Tokyo, Japan
- TumorTec GmbH, Cologne, Germany
- U.S. Department of Agriculture, ARS, Northern Plains Area, Fort Collins, CO, U.S.A.
- UCLA Tumor Cell Biology Program, Los Angeles, CA, U.S.A.
- United States Health and Human Services, Washington, DC, U.S.A.
- University College of Health Sciences, Jönköping, Sweden
- University Grant Commission (UGC), New Delhi, India
- University Hospital Eppendorf, Hamburg, Germany
- University of Calabria, Rende Cosenza, Italy
- University of Cologne, Cologne, Germany
- University of Crete, Heraklion, Greece
- University of Hawaii, Hilo, Hawaii
- University of KinDAI Himeji, Himeji, Japan
- University of Malaya, Kuala Lumpur, Malaysia
- University of Minnesota, Minneapolis, MN, U.S.A.
- University of Missouri, Columbia, MO, U.S.A.
- University of Munich (LMU excellence initiative), Munich, Germany
- University of Nottingham (NPM), Nottingham, U.K.
- University of Palermo, Palermo, Italy
- University of Siena, Siena, Italy
- University of Texas at Arlington, Arlington, TX, U.S.A.
- University of Texas Health Science Centre, Tyler, TX, U.S.A.
- University of Toronto, Toronto, ON, Canada
- University of Turin, Turin, Italy
- University of Virginia, Charlottesville, VA, U.S.A.
- University of Wroclaw, Wroclaw, Poland
- University Research Funding, Niteroi, Brazil
- UNTHSC Microscopy Core Facility, Fort Worth, TX, U.S.A.
- UOEH Research Grant for the Promotion of Occupational Health, Kitakyushu, Japan
- US Department of Defense Breast Cancer Research Programs, Frederick, MD, U.S.A.
- Utrecht Faculty of Veterinary Medicine, Utrecht, The Netherlands
- VDx Research Services, Davis, CA, U.S.A.
- Verein für Tumorforschung, Innsbruck, Austria
- Verelst Uterine Cancer Fund, Leuven, Belgium
- Veterans Administration Merit Awards, Washington, DC, U.S.A.
- Veterans General Hospital, Taipei City, Taiwan R.O.C.
- VU University Amsterdam, Amsterdam, The Netherlands
- Werner and Klara Kreitz Stiftung, Bad Segeberg, Germany
- West Virginia University School of Medicine Research Grant, Morgantown, WV, U.S.A.
- Wilkes University, Wilkes-Barre, PA, U.S.A.
- Women's Cancer Association, University of Miami, Miami, FL, U.S.A.
- World Class University, National Research Foundation, Ministry of Education, Science and Technology, Republic of Korea
- Wroclaw Medical University, Wroclaw, Poland
- Wroclaw Research Centre EIT+, Wroclaw, Poland
- Yale Cancer Center, New Haven, CT, U.S.A.
- Yamaguchi University, Yamaguchi, Japan
- Yonsei University Wonju College of Medicine, Seoul, Republic of Korea
- ZonMw, The Netherlands Organisation for Health Research and Development, Den Haag, The Netherlands

Contents, Volume 33, 2013

Number 1

Reviews

- Neurofibromatosis Type 2 Protein, NF2: An Unconventional Cell Cycle Regulator. S. BELTRAMI, R. KIM, J. GORDON (*Philadelphia, PA, USA*) 1
- Anticancer Efficacy of the Metabolic Blocker 3-Bromopyruvate: Specific Molecular Targeting. S. GANAPATHY-KANNIAPPAN, R. KUNJITHAPATHAM, J.-F. GESCHWIND (*Baltimore, MD, USA*) 13
- The Mammalian Target of Rapamycin Inhibitors in Breast Cancer: Current Evidence and Future Directions. P. MALAGUTI, S. VARI, F. COGNETTI, A. FABI (*Rome, Italy*) 21
- Vaginal Intraepithelial Neoplasia: A Therapeutical Dilemma. A. FREGA, F. SOPRACORDEVOLLE, C. ASSORGI, D. LOMBARDI, V. DE SANCTIS, A. CATALANO, E. MATTEUCCI, G.N. MILAZZO, E. RICCIARDI, M. MOSCARINI (*Rome; Aviano, Italy*) 29
- Genistein and Daidzein: Different Molecular Effects on Prostate Cancer. M. ADJAKLY, M. NGOLLO, J.-P. BOITEUX, Y.-J. BIGNON, L. GUY, D. BERNARD-GALLON (*Clermont-Ferrand, France*) 39

Experimental Studies

- Silencing of the ARP2/3 Complex Disturbs Pancreatic Cancer Cell Migration. H.E. RAUHALA, S. TEPPONEN, S. NIEMELÄ, A. KALLIONIEMI (*Tampere, Finland*) 45
- LATS2 Is a Modulator of Estrogen Receptor Alpha. L.C. LIT, S. SCOTT, H. ZHANG, J. STEBBING, A. PHOTIOU, G. GIAMAS (*London, UK*) 53
- Anticancer Activity of β -Elemene and its Synthetic Analogs in Human Malignant Brain Tumor Cells. Q.Q. LI, R.X. LEE, H. LIANG, Y. ZHONG (*Guangxi, PR China; Morgantown, WV; Bethesda, MD, USA*) 65
- Dihydroceramide Desaturase Knockdown Impacts Sphingolipids and Apoptosis after Photodamage in Human Head and Neck Squamous Carcinoma Cells. P. BREEN, N. JOSEPH, K. THOMPSON, J.M. KRAVEKA, T.I. GUDZ, L. LI, M. RAHMANIYAN, J. BIELAWSKI, J.S. PIERCE, E. VAN BUREN, G. BHATTI, D. SEPAROVIC (*Detroit, MI; Charleston, SC, USA*) 77
- Evaluating Antigen Targeting and Anti-tumor Activity of a New Anti-CD37 Radioimmunoconjugate Against Non-Hodgkin's Lymphoma. J. DAHLE, A.H.V. REPETTO-LLAMAZARES, C.S. MOLLATT, K.B. MELHUS, Ø.S. BRULAND, A. KOLSTAD, R.H. LARSEN (*Oslo, Norway*) 85
- Primer Dosing of *S. typhimurium* A1-R Potentiates Tumor-Targeting and Efficacy in Immunocompetent Mice. Y. TOME, Y. ZHANG, M. MOMIYAMA, H. MAEHARA, F. KANAYA, K. TOMITA, H. TSUCHIYA, M. BOUVET, R.M. HOFFMAN, M. ZHAO (*San Diego, CA, USA; Okinawa; Kanazawa, Japan*) 97
- Subcellular Real-Time Imaging of the Efficacy of Temozolomide on Cancer Cells in the Brain of Live Mice. M. MOMIYAMA, A. SUETSUGU, T. CHISHIMA, M. BOUVET, I. ENDO, R.M. HOFFMAN (*San Diego, CA, USA; Yokohama, Japan*) 103
- Enhanced Resection of Orthotopic Red-fluorescent Protein-expressing Human Glioma by Fluorescence-guided Surgery in Nude Mice. M. MOMIYAMA, Y. HIROSHIMA, A. SUETSUGU, Y. TOME, S. MII, S. YANO, M. BOUVET, T. CHISHIMA, I. ENDO, R.M. HOFFMAN (*San Diego, CA, USA; Yokohama, Japan*) 107

PPP2R1A Mutation Is a Rare Event in Ovarian Carcinoma Across Histological Subtypes. M. RAHMAN, K. NAKAYAMA, M.T. RAHMAN, N. NAKAYAMA, H. KATAGIRI, A. KATAGIRI, T. ISHIBASHI, M. ISHIKAWA, K. IIDA, Y. OTSUKI, S. NAKAYAMA, K. MIYAZAKI (<i>Izumo; Hamamatsu, Japan</i>).....	113
Immunohistochemical Expression of PTTG in Brain Tumors. F. SALEHI, B.W. SCHEITHAUER, S. SHARMA, K. KOVACS, R.V. LLOYD, M.D. CUSIMANO, D.G. MUNOZ (<i>Toronto, ON, Canada; Rochester, MN, USA</i>)	119
Effects of Transferrin Conjugates of Artemisinin and Artemisinin Dimer on Breast Cancer Cell Lines. Y. GONG, B.M. GALLIS, D.R. GOODLETT, Y. YANG, H. LU, E. LACOSTE, H. LAI, T. SASAKI (<i>Seattle, WA, USA</i>)	123
Interaction between Gambogic Acid and Dihydrofolate Reductase and Synergistic Lethal Effects with Methotrexate on Hepatoma Cells. J. DESCHATRETTE, K. NG-BONAVENTURE, L. PHILIPPE, C. WOLFROM (<i>Orsay; Châtenay-Malabry, France</i>).....	133
The Nanoparticulate Quillaja Saponin BBE Is Selectively Active Towards Renal Cell Carcinoma. S.B. HASSAN, J. GULLBO, K. HU, S. BERENJIAN, B. MOREIN, P. NYGREN (<i>Uppsala, Sweden</i>)	143
Proteomic Analysis Showed Down-regulation of Nucleophosmin in Progressive Tumor Cells Compared to Regressive Tumor Cells. T. TAKENAWA, Y. KURAMITSU, Y. WANG, F. OKADA, K. TOKUDA, T. KITAGAWA, Y. UEYAMA, K. NAKAMURA (<i>Yamaguchi; Yonago, Japan</i>)	153
Intratumoural Interleukin-2 Therapy Can Induce Regression of Non-resectable Mastocytoma in Dogs. P.G.P.M. ZIEKMAN, W. DEN OTTER, J.F.V. TAN, E. TESKE, J. KIRPENSTEIJN, J.-W. KOTEN, J.J.L. JACOBS (<i>Amsterdam; Oisterwijk; Gouda; Utrecht, Netherlands</i>)	161
Expression and Function of <i>FERMT</i> Genes in Colon Carcinoma Cells. K. KIRIYAMA, Y. HIROHASHI, T. TORIGOE, T. KUBO, Y. TAMURA, T. KANASEKI, A. TAKAHASHI, E. NAKAZAWA, E. SAKA, C. RAGNARSSON, M. NAKATSUGAWA, S. INODA, H. ASANUMA, H. TAKASU, T. HASEGAWA, T. YASOSHIMA, K. HIRATA, N. SATO (<i>Sapporo; Osaka, Japan</i>)	167
Establishment and Characterization of a Novel Xenograft Model of Human Gastrointestinal Stromal Tumor in Mice. M. MORIYAMA, Y. SHIMADA, T. NAGATA, T. OMURA, S. SEKINE, K. MATSUI, I. YOSHIOKA, T. OKUMURA, S. SAWADA, T. YOSHIDA, K. TSUKADA (<i>Toyama, Japan</i>)	175
Induction of Death of Leukemia Cells by TW-74, A Novel Derivative of Chloro-naphthoquinone. M. HALLAK, B.K. THAKUR, T. WINN, O. SHPILBERG, S. BITTNER, Y. GRANOT, I. LEVY, I. NATHAN (<i>Beer Sheva; Petah Tikva, Israel; Hannover, Germany; Kyaukse, Myanmar</i>)	183
Study of Genetic and Epigenetic Alterations in Urine Samples as Diagnostic Markers for Prostate Cancer. E. DIMITRIADIS, T. KALOGEROPOULOS, S. VELAETI, S. SOTIRIOU, E. VASSILIOU, L. FASOULIS, V. KLAPSAS, M. SYNESIOU, A. APOSTOLAKI, T. TRANGAS, N. PANDIS (<i>Athens; Ioannina; Chios, Greece</i>).....	191
Expression Profile of Receptor Activator of Nuclear- κ B (RANK), RANK Ligand (RANKL) and Osteoprotegerin (OPG) in Breast Cancer. S. OWEN, L. YE, A.J. SANDERS, M.D. MASON, W.G. JIANG (<i>Cardiff, UK</i>).....	199
<i>HAVcR-1</i> Expression in Human Colorectal Cancer and its Effects on Colorectal Cancer Cells <i>In Vitro</i> . Y. WANG, T.A. MARTIN, W.G. JIANG (<i>Cardiff, UK; Beijing, China</i>)	207
ROS Mediate Proapoptotic and Antisurvival Activity of Oleanane Triterpenoid CDDO-Me in Ovarian Cancer Cells. X. GAO, Y. LIU, D. DEEB, P. LIU, A. LIU, A.S. ARBAB, S.C. GAUTAM (<i>Detroit, MI, USA</i>)	215

Sprague-Dawley Rats Bearing McA-RH7777 Cells for Study of Hepatoma and Transarterial Chemoembolization. H.R. CHO, J.W. CHOI, H.-C. KIM, Y.S. SONG, G.M. KIM, K.R. SON, J.W. CHUNG (Seoul, South Korea)	223
Role of Pesticides in the Induction of Tumor Angiogenesis. S.P. BHARATHI, H.M. RAJ, S. JAIN, B.D. BANERJEE, T. AHMED, V.K. ARORA (Mysore, Karnataka; New Delhi, India)	231
<i>Clinical Studies</i>	
Treatment of Vaginal Recurrences in Endometrial Carcinoma by High-dose-rate Brachytherapy. B. SORBE, K. SÖDERSTRÖM (Örebro; Umeå, Sweden)	241
Interstitial HDR Brachytherapy for Advanced Recurrent Squamous Cell Carcinoma of the Head and Neck. S. WIEGAND, A.M. SESTERHENN, A.P. ZIMMERMANN, G. STRASSMANN, T. WILHELM, J.A. WERNER (Marburg; Borna, Germany)	249
CEA Fluctuation During a Single Fluorouracil-based Chemotherapy Cycle for Metastatic Colorectal Cancer. K. HERMUNEN, C. HAGLUND, P. OSTERLUND (Helsinki, Finland)	253
Phase I Clinical and Pharmacokinetic Study of Bi-weekly Carboplatin/Paclitaxel Chemotherapy in Elderly Patients with Advanced Non-small Cell Lung Cancer. Y. TSUBATA, T. OKIMOTO, K. MIURA, F. KARINO, S. IWAMOTO, M. TADA, T. HONDA, S. HAMAGUCHI, M. OHE, A. SUTANI, T. KURAKI, A. HAMADA, T. ISOBE (Shimane; Tokyo, Japan)	261
Extensive Distal Pancreatectomy for Pancreatic Tumor. M. NAKAMURA, T. OHTSUKA, H. NAKASHIMA, Y. NAGAYOSHI, H. KONO, K. TSUTSUMI, S. TAKAHATA, M. TANAKA (Kurashiki; Fukuoka, Japan)	267
Prognostic Impact of Circulating miR-21 in the Plasma of Patients with Gastric Carcinoma. S. KOMATSU, D. ICHIKAWA, M. TSUJIURA, H. KONISHI, H. TAKESHITA, H. NAGATA, T. KAWAGUCHI, S. HIRAJIMA, T. ARITA, A. SHIOZAKI, T. KUBOTA, H. FUJIWARA, K. OKAMOTO, E. OTSUJI (Kyoto, Japan)	271
Prognostic Impact of Prophylactic Splenectomy for Upper-third Gastric Cancer: A Cohort Study. H. ITO, H. INOUE, N. ODAKA, H. SATODATE, S. MUKAI, T. OMOTO, Y. TAKEHARA, S.-E. KUDO (Yokohama, Japan)	277
Selection of Patients with Advanced-stage Cervical Cancer for Para-aortic Lymphadenectomy in the Era of PET/CT. A.-L. MARGULIES, A. PERES, E. BARRANGER, I. PERRETI, J.-F. BROULAND, E. TOUBET, L.-E. SARDA-MANTEL, A. THOURY, C. CHIS, F. WALKER, D. LUTON, Y. DELPECH, M. KOSKAS (Paris, France)	283
Glucose and Lipid Metabolism in Patients with Advanced Pancreatic Cancer Receiving Palliative Chemotherapy. K. ZEISS, K.G. PARHOFER, V. HEINEMANN, M. HAAS, R.P. LAUBENDER, S. HOLDENRIEDER, C. SCHULZ, S. BOECK (Munich, Germany)	287
The Prognostic Significance of LIAISON® CA15-3 Assay in Primary Breast Cancer. B. NISMAN, O. MAIMON, T. ALLWEIS, L. KADOURI, B. MALY, T. HAMBURGER, T. PERETZ (Jerusalem, Israel)	293
Granocyte-colony Stimulating Factor (G-CSF) Has Significant Efficacy as Secondary Prophylaxis of Chemotherapy-induced Neutropenia in Patients with Solid Tumors: Results of a Prospective Study. G. FREYER, N. JOVENIN, G. YAZBEK, C. VILLANUEVA, A. HUSSAIN, A. BERTHUNE, M. ROTARSKI, H. SIMON, V. BOULANGER, M. HUMMELSBERGER, C. FALANDRY (Lyon; Reims; Besançon; Quimper; Saint Cloud; Bayonne; Brest; Carcassonne; Béziers, France)	301

Lack of Association of Proteinuria and Clinical Outcome in Patients Treated with Bevacizumab for Metastatic Colorectal Cancer. S. IWASA, T.E. NAKAJIMA, K. NAGASHIMA, Y. HONMA, K. KATO, T. HAMAGUCHI, Y. YAMADA, Y. SHIMADA (<i>Tokyo; Kanagawa; Saitama, Japan</i>)	309
Long-term Results of Brachytherapy in Early Mobile Tongue Cancer with 10-Year Minimal Follow-up. M.M. ABDALMEAR, M. TOMITA, H. SHIBUYA (<i>Tokyo, Japan</i>).....	317
Long-term Follow-up after Preoperative Chemotherapy Using Pemetrexed (Alimta) in Rectal Cancer. T. SWARTLING, K. KODEDA, B. GUSTAVSSON, K. DERWINGER (<i>Gothenburg, Sweden</i>)	325
Utility of Mesothelin, L1CAM and Afamin as Biomarkers in Primary Ovarian Cancer. B. AKTAS, S. KASIMIR-BAUER, P. WIMBERGER, R. KIMMIG, M. HEUBNER (<i>Essen, Germany</i>).....	329
Second Primary Cancer in Patients with Papillary Thyroid Carcinoma. C. ZAFON, G. OBIOLS, J. MESA (<i>Barcelona, Spain</i>)	337
Association of pre-miR-146a rs2910164 Polymorphism with the Risk of Head and Neck Cancer. Z. ORSÓS, I. SZANYI, A. CSEJTEI, I. GERLINGER, I. EMBER, I. KISS (<i>Pécs; Szombathely, Hungary</i>)	341

Number 2

Experimental Studies

Characterization of Structure and Direct Antigen Presentation by Dendritic/Tumor-fused Cells as Cancer Vaccines. S. KOIDO, J. GONG (<i>Boston, MA, USA; Kashiwa, Chiba, Japan</i>)	347
Fenbendazole as a Potential Anticancer Drug. Q. DUAN, Y. LIU, S. ROCKWELL (<i>New Haven, CT, USA</i>)	355
Expression and Localization of Serotonin Receptors in Human Breast Cancer. P.K. KOPPARAPU, M. TINZL, L. ANAGNOSTAKI, J.L. PERSSON, N. DIZEYI (<i>Malmö, Sweden</i>)	363
Prognostic Impact of Fascin-1 (FSCN1) in Epithelial Ovarian Cancer. L.C. HANKER, T. KARN, U. HOLTRICH, M. GRAESER, S. BECKER, J. REINHARD, E. RUCKHÄBERLE, H. GEVENSLEBEN, A. RODY (<i>Frankfurt; Hamburg; Lübeck, Germany; London, UK</i>).....	371
Collagen I Provides a Survival Advantage to MD-1483 Head and Neck Squamous Cell Carcinoma Cells Through Phosphoinositol 3-Kinase Signaling. E. COHEN, T. TENDLER, H. LU, C.K. HANSEN, J. KURTSMAN, J. BARRIOS, R. WIEDER (<i>Newark, NJ, USA</i>).....	379
ABCC4 Decreases Docetaxel and Not Cabazitaxel Efficacy in Prostate Cancer Cells <i>In Vitro</i> . D.E. OPREALAGER, I.V. BIJNSDORP, R.J.A. VAN MOORSELAAR, A.J.M. VAN DEN EERTWEGH, O.S. HOEKSTRA, A.A. GELDOLF (<i>Amsterdam, Netherlands</i>)	387
Protein Kinases D2 and D3 Are Novel Growth Regulators in HCC1806 Triple-negative Breast Cancer Cells. Q. HAO, R. MCKENZIE, H. GAN, H. TANG (<i>Tyler, TX, USA</i>)	393
Regulation of the Proliferation of Colon Cancer Cells by Compounds that Affect Glycolysis, Including 3-Bromopyruvate, 2-Deoxyglucose and Biguanides. M.A. LEA, M.S. QURESHI, M. BUXHOEVEDEN, N. GENDEL, J. KLEINSCHMIT, C. desBORDES (<i>Newark, NJ; Brooklyn, NY, USA</i>)	401

VEGF-C ShRNA Inhibits Pancreatic Cancer Growth and Lymphangiogenesis in an Orthotopic Fluorescent Nude Mouse Model. Y. SHI, M. TONG, Y. WU, Z. YANG, R.M. HOFFMAN, Y. ZHANG, Y. TIAN, M. QI, Y. LIN, Y. LIU, L. DAI, Y. SUN, Z. WANG (<i>Shanghai; Jiangsu; Chongqing, PR China; San Diego, CA, USA</i>)	409
Intraoperative Imaging of Metastatic Lymph Nodes Using a Fluorophore-conjugated Antibody in an Orthotopic Breast Cancer Mouse Model of HER2/neu. J. WU, R. MA, H. CAO, Z. WANG, C. JING, Y. SUN, Y. ZHANG, Z. YANG, R.M. HOFFMAN, J. TANG (<i>Jiangsu, PR China; San Diego, CA, USA</i>)	419
Azatyrosinamides: Novel RAS-related Anticancer Agents. C.-L. WANG, O. LEE, C.-F. HUANG, E.I-C. LI, C.-M. TENG, S.-L. PAN, J.-F. LIAN, F.-S. CHANG, J.-P. LIOU, H.-P. WANG (<i>Taipei; Hsinchu City; Tainan; Miaoli County, Taiwan, ROC</i>)	425
Combined Colonic Cancer Treatment with Vitamin D Analogs and Irinotecan or Oxaliplatin. M. MILCZAREK, S. ROSIŃSKA, M. PSURSKI, M. MACIEJEWSKA, A. KUTNER, J. WIETRZYK (<i>Wroclaw; Warsaw; Czestochowa, Poland</i>).....	433
MicroRNA 181a Influences the Expression of HMGB1 and CD4 in Acute Leukemias. M. DAHLHAUS, C. SCHULT, S. LANGE, M. FREUND, C. JUNGHANSS (<i>Rostock, Germany</i>)	445
New Biological Activities of Rhinacanthins from the Root of <i>Rhinacanthus nasutus</i> . H. HORII, R. SUZUKI, H. SAKAGAMI, M. TOMOMURA, A. TOMOMURA, Y. SHIRATAKI (<i>Sakado, Saitama, Japan</i>).....	453
Anti-phosphohistone H3 as an Independent Prognostic Factor in Human Esophageal Squamous Cell Carcinoma. S. NAKASHIMA, A. SHIOZAKI, D. ICHIKAWA, S. KOMATSU, H. KONISHI, D. IITAKA, T. KUBOTA, H. FUJIWARA, K. OKAMOTO, M. KISHIMOTO, E. OTSUJI (<i>Kyoto, Japan</i>)	461
Gene Amplification of Ribosomal Protein S6 Kinase-1 and -2 in Gastric Cancer. S. YOSHIDA, K. MATSUMOTO, T. ARAO, H. TANIGUCHI, I. GOTO, T. HANAFUSA, K. NISHIO, Y. YAMADA (<i>Osaka; Tokyo, Japan</i>).....	469
Effect of Different Degrees of Hydrogenated Fish Oil on Intestinal Carcinogenesis in <i>Min/+</i> mice. M. MOLIN, P. BERSTAD, J.Š. BENTH, J. ALEXANDER, J.E. PAULSEN, K. ALMENDINGEN (<i>Oslo; Lørenskog; Aas, Norway</i>)	477
Kinase Activity of Protein Kinase C α in Serum as a Diagnostic Biomarker of Human Lung Cancer. J.-H. KANG, T. MORI, H. KITAZAKI, T. NIIDOME, K. TAKAYAMA, Y. NAKANISHI, Y. KATAYAMA (<i>Fukuoka, Japan</i>).....	485
Proteomic Profiling of Trastuzumab (Herceptin [®])-sensitive and -resistant SKBR-3 Breast Cancer Cells. G. DI CARA, G. MARENGO, N.N. ALBANESE, M.R. MARABETI, R. MUSSO, P. CANCEMI, I. PUCCI-MINAFRA (<i>Palermo, Italy</i>)	489
Ecteinascidin 770, a Tetrahydroisoquinoline Alkaloid, Sensitizes Human Lung Cancer Cells to Anoikis. P. POWAN, N. SAITO, K. SUWANBORIRUX, P. CHANVORACHOTE (<i>Bangkok, Thailand; Tokyo, Japan</i>)	505
Functional Polymorphism in the MicroRNA-367 Binding Site as a Prognostic Factor for Colonic Cancer. Y.S. CHAE, J.G. KIM, B.W. KANG, S.J. LEE, Y.J. LEE, J.S. PARK, G.S. CHOI, W.K. LEE, H.-S. JEON (<i>Daegu, South Korea</i>).....	513
Pharmacokinetic Drug Interactions between Ondansetron and Tamoxifen in Female Sprague-Dawley Rats with DMBA-induced Mammary Tumor. S.H. YANG, J.H. SUH, M.G. LEE, S.H. KIM (<i>Seoul; Bucheon; Suwon, South Korea</i>)	521
The Contribution of <i>XRCC6/Ku70</i> to Hepatocellular Carcinoma in Taiwan. C.-M. HSU, M.-D. YANG, W.-S. CHANG, L.-B. JENG, M.-H. LEE, M.-C. LU, S.-C. CHANG, C.-W. TSAI, Y. TSAI, F.-J. TSAI, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>).....	529

COX-2 Overexpression Induced by Gene Transfer Reduces Sensitivity of TE13 Esophageal Carcinoma Cells to 5-Fluorouracil and Cisplatin. H. OKAMURA, H. FUJIWARA, S. UMEHARA, S. OKAMURA, M. TODO, A. FURUTANI, M. YONEDA, A. SHIOZAKI, S. KOMATSU, T. KUBOTA, D. ICHIKAWA, K. OKAMOTO, T. OCHIAI, C. SAKAKURA, Y. TAKAHASHI, T. YOSHIMOTO, E. OTSUJI (<i>Kyoto; Okayama; Kanazawa, Japan</i>)	537
<i>Clinical Studies</i>	
Sunlight, Polymorphisms of Vitamin D-related Genes and Risk of Breast Cancer. B.J. FUHRMAN, D.M. FREEDMAN, P. BHATTI, M.M. DOODY, Y.-P. FU, S.-C. CHANG, M.S. LINET, A.J. SIGURDSON (<i>Bethesda; Gaithersburg, MD; Seattle, WA; San Francisco, CA, USA</i>)	543
Predicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort. M. SALAGIERSKI, P. MULDER, J.A. SCHALKEN (<i>Łódź, Poland; Nijmegen, Netherlands</i>)	553
Prognosis of Rectal Carcinoma after Multimodal Treatment: ypTNM Classification and Tumor Regression Grading Are Essential. P. HERMANEK, S. MERKEL, W. HOHENBERGER (<i>Erlangen, Germany</i>)	559
Pancreatic Resection for Metastatic Melanoma Originating from the Nasal Cavity: A Case Report and Literature Review. M. SUGIMOTO, N. GOTOHDA, Y. KATO, S. TAKAHASHI, T. KINOSHITA, H. SHIBASAKI, M. KOJIMA, A. OCHIAI, S. ZENDA, T. AKIMOTO, M. KONISHI (<i>Kashiwa, Chiba, Japan</i>).....	567
Expression of Hepatocyte Growth Factor Activator Inhibitor Type-1 (HAI-1) in Prostate Cancer. K. YASUDA, A. KOMIYA, A. WATANABE, A. MORII, T. OYA, O. NAGAKAWA, Y. FUJIUCHI, H. FUSE (<i>Toyama, Toyama; Jyousetsu-shi, Niigata, Japan</i>)	575
Perineural Invasion and Preoperative Serum CA19-9 as Predictors of Survival in Biliary Tract Cancer. H. KAWAMATA, K. YAMASHITA, K. NAKAMURA, H. KATAGIRI, K. ISHII, Y. TAKAHASHI, K. FURUTA, Y. KUMAMOTO, M. WATANABE (<i>Kanagawa, Japan</i>)	583
Long-term Survival of Advanced Small Cell Carcinoma of the Esophagus after Resection: A Case Report. K. MUGURUMA, M. OHIRA, H. TANAKA, N. KUBO, Y. YAMASHITA, T. SAWADA, K. WAKASA, K. HIRAKAWA (<i>Osaka, Japan</i>)	595
Clinical Outcomes and Prognosis after Thoracoscopic Esophagectomy with Two-field Lymph Node Dissection for Lower Thoracic Esophageal Cancer. M. TAKEMURA, T. HORI, Y. FUJIWARA (<i>Hyogo; Osaka, Japan</i>)	601
Correlation of Aquaporin-1 Water Channel Protein Expression with Tumor Angiogenesis in Human Astrocytoma. N. EL HINDY, A. BANKFALVI, A. HERRING, M. ADAMZIK, N. LAMBERTZ, Y. ZHU, W. SIFFERT, U. SURE, I.E. SANDALCIOGLU (<i>Essen, Germany</i>)	609
Primary Vesical Clear Cell Adenocarcinoma Arising in Endometriosis: A Rare Case of Mullerian Origin. K. LAH, D. DESAI, P. HADWAY, J. PERRY-KEENE, G. COUGHLIN (<i>Herston, QLD, Australia</i>)	615
Endometrial Carcinoma in the Baby Boomer Generation. Tumor Characteristics and Clinical Outcome. M.A. ELSHAIKH, R. CATTANEO II, M. SHAH, S. PATEL, M. MAHAN, T. BUEKERS, F. SIDDIQUI (<i>Detroit, MI, USA</i>)	619
Practical Utility of Circulating Tumour Cells as Biomarkers in Cancer Chemotherapy for Advanced Colorectal Cancer. K. OTSUKA, H. IMAI, H. SOEDA, K. KOMINE, C. ISHIOKA, H. SHIBATA (<i>Akita; Sendai, Japan</i>)	625
Sun Exposure Habits and Health Risk-related Behaviours Among Individuals with Previous History of Skin Cancer. M. FALK, Å. FARESJÖ, T. FARESJÖ (<i>Linköping, Sweden</i>)	631

Double Inv(3)(q21q26), a Rare but Recurrent Chromosomal Abnormality in Myeloid Hemopathies. E. DE BRAEKELEER, N. DOUET-GUILBERT, M.-J. LE BRIS, J.-C. IANOTTO, C. BERTHOU, N. GUEGANIC, C. BOVO, A. BASINKO, F. MOREL, M. DE BRAEKELEER (<i>Brest, France</i>)	639
Feasibility Trial for Daily Oral Administration of the Hypoxic Sensitizer AK-2123 (Sanazole) in Radiotherapy. H. YAMAZAKI, S. NAKAMURA, K. KOBAYASHI, T. TSUBOKURA, N. KODANI, N. AIBE, K. YOSHIDA, T. KAGIYA, M. KOIZUMI, K. YAMADA (<i>Kyoto; Osaka, Japan</i>)	643
Immunoexpression of DIABLO, AIF and Cytochrome c in Gastric Adenocarcinoma Assessed by Tissue Microarray. L.C. DA SILVA, N.M. FORONES, D.A. RIBEIRO, S.S. IHARA, T.S. GOMES, R.A. NETO, C.T. OSHIMA (<i>São Paulo, SP, Brazil</i>)	647
Ablative or Palliative Stereotactic Body Radiotherapy with Helical Tomotherapy for Primary or Metastatic Lung Tumor. M. MARCENARO, S. VAGGE, L. BELGIOIA, D. AGNESE, G. LAMANNA, E. MANTERO, M. GUSINU, S. GARELLI, F. CAVAGNETTO, S. AGOSTINELLI, R. CORVÒ (<i>Genoa, Italy</i>)	655
Levels of Sirolimus in Saliva vs. Blood – the Rationale of Topical Oral Use for Oral Malignancy. Z. NUDELMAN, N. KESHET, M. DRANITZKI ELHALAL, M. FRIEDMAN, R. CZERNINSKI (<i>Jerusalem, Israel</i>)	661
A Method to Assess the Distribution and Frequency of Plasma Cells and Plasma Cell Precursors in Autoimmune Hepatitis. C.A. RUBIO, K. TRUSKAITE, R. RAJANI, A. KAUFELDT, M.-L. LINDSTRÖM (<i>Stockholm, Sweden</i>)	665
The Contribution of <i>Caveolin-1</i> Genotype and Phenotype to Hepatocellular Carcinoma. C.-M. HSU, M.-D. YANG, C.-W. TSAI, C.-Y. HO, W.-S. CHANG, S.-C. CHANG, L.-B. JENG, Y. TSAI, F.-J. TSAI, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	671
Lenograstim in Preventing Chemotherapy-induced Febrile Neutropenia in Patients with Soft Tissue Sarcoma. G. BADALAMENTI, L. INCORVAIA, S. PROVENZANO, G. BRONTE, G. LETO, F. FULFARO, G. MALTESE (<i>Palermo, Italy</i>)	679
Adenocarcinoma Associated with Perianal Fistulas in Crohn's Disease. H. OGAWA, S. HANEDA, C. SHIBATA, K. MIURA, M. NAGAO, S. OHNUMA, A. KOHYAMA, M. UNNO (<i>Sendai, Japan</i>)	685
Antioxidant Effects of Potassium Ascorbate with Ribose in Costello Syndrome. C. ANICHINI, F. LOTTI, A. PIETRINI, C. LO RIZZO, M. LONGINI, F. PROIETTI, C. FELICI, G. BUONOCORE (<i>Siena, Italy</i>)	691
Biweekly Docetaxel and S-1 Combination Chemotherapy as First-line Treatment for Elderly Patients with Advanced Gastric Cancer. C. KUNISAKI, M. TAKAHASHI, H.A. ONO, S. HASEGAWA, K. TSUCHIDA, T. OSHIMA, M. OTA, T. FUKUSHIMA, M. TOKUHISA, Y. IZUMISAWA, R. TAKAGAWA, J. KIMURA, T. KOSAKA, H. MAKINO, H. AKIYAMA, I. ENDO (<i>Yokohama, Japan</i>)	697
Postoperative Peak Serum C-Reactive Protein Predicts Outcome of Hepatic Resection for Hepatocellular Carcinoma. H. SHIBA, K. FURUKAWA, Y. FUJIWARA, Y. FUTAGAWA, K. HARUKI, S. WAKIYAMA, Y. ISHIDA, T. MISAWA, K. YANAGA (<i>Tokyo, Japan</i>)	705
Abnormal Cytology during Pregnancy – A Retrospective Analysis of Patients in a Dysplasia Clinic. M. HENES, F. NEIS, K. RALL, T. IFTNER, A. STAEBLER, T. FEHM, R. ROTHMUND (<i>Tuebingen, Germany</i>)	711
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study). R. LÓPEZ, C. MÉNDEZ MÉNDEZ, M. JORGE FERNÁNDEZ, C. ROMERO REINOSO, G. QUINTERO ALDANA, M. SALGADO FERNÁNDEZ, J. DE LA CÁMARA GÓMEZ, M. REBOREDO LÓPEZ, M. RAMOS VÁZQUEZ, S. CANDAMIO FOLGAR (<i>Santiago de Compostela; A Coruña; Vigo; Lugo; Ourense, Spain</i>)	717

Long-term Results of Preoperative 5-Fluorouracil-Oxaliplatin Chemoradiation Therapy in Locally Advanced Rectal Cancer. E. FONTANA, F. PUCCI, R. CAMISA, S. BUI, S. GALDY, F. LEONARDI, F.V. NEGRI, E. ANSEMI, P.L. LOSARDO, L. RONCORONI, P. DELL'ABATE, P. CRAFA, S. CASCINU, A. ARDIZZONI (<i>Parma; Bergamo; Piacenza; Ancona, Italy</i>)	725
Lumpectomy <i>versus</i> Mastopexy – A Post-surgery Patient Survey. C. EICHLER, M. KOLSCH, A. SAUERWALD, A. BACH, O. GLUZ, M. WARM (<i>Cologne; Düren; Eschweiler; Moenchengladbach, Germany</i>).....	731
Screening of Circulating TGF- β Levels and Its Clinicopathological Significance in Human Breast Cancer. C. PANIS, A.C. HERRERA, V.J. VICTORINO, A.M.F. ARANOME, R. CECCHINI (<i>Londrina, Paraná, Brazil</i>)	737
Errata	743
Retraction	744
Book Reviews	745

Number 3

Review

Radiotherapy Targeting Cancer Stem Cells: Current Views and Future Perspectives. K. OGAWA, Y. YOSHIOKA, F. ISOHASHI, Y. SEO, K. YOSHIDA, H. YAMAZAKI (<i>Osaka; Kyoto, Japan</i>)	747
---	-----

Experimental Studies

Poly (ADP-Ribose) Polymerase Inhibitor MK-4827 together with Radiation as a Novel Therapy for Metastatic Neuroblastoma. S. MUELLER, S. BHARGAVA, A.M. MOLINARO, X. YANG, I. KOLKOWITZ, A. OLOW, N. WEHMEIJER, S. ORBACH, J. CHEN, K.K. MATTHAY, D.A. HAAS-KOGAN (<i>San Francisco, CA; New York, NY, USA; Amsterdam, Netherlands</i>)	755
Molecular Characteristics of Cancer Stem-like Cells Derived from Human Breast Cancer Cells. Y.D. YOO, D.H. HAN, J.M. JANG, A. ZAKRZEWSKA, S.-Y. KIM, C.Y. CHOI, Y.J. LEE, Y.T. KWON (<i>Seoul; Suwon, South Korea; Pittsburgh, PA, USA</i>)	763
Serum DNA Hypermethylation in Patients with Bladder Cancer: Results of a Prospective Multicenter Study. S. HAUSER, M. KOGEJ, G. FECHNER, J. VON PEZOLD, R. VORREUTHER, G. LÜMMEN, S.C. MÜLLER, J. ELLINGER (<i>Bonn; Lindlar; Troisdorf, Germany</i>).....	779
Inhibition of AKT in Human Pancreatic, Renal and Colorectal Cancer Cells by Four Cardiac Hormones. W.P. SKELTON IV, M. SKELTON, D.L. VESELY (<i>Gainesville; Tampa, FL, USA</i>)	785
Progesterone and Estrogen Prevent Cisplatin-induced Apoptosis of Lung Cancer Cells. M. GROTT, S. KARAKAYA, F. MAYER, F. BAERTLING, C. BEYER, M. KIPP, H.-G. KOPP (<i>Aachen; Tuebingen, Germany</i>).....	791
The Role of Notch and Gamma-secretase Inhibition in an Ovarian Cancer Model. M.M. SHAH, M. ZERLIN, B.Y. LI, T.J. HERZOG, J.K. KITAJEWSKI, J.D. WRIGHT (<i>Birmingham, AL; New York, NY, USA</i>)	801
Comparative Effects of PP242 and Rapamycin on mTOR Signalling and NOTCH Signalling in Leukemia Cells. A. ONO, R. OIKE, Y. OKUHASHI, Y. TAKAHASHI, M. ITOH, N. NARA, S. TOHDA (<i>Yushima, Tokyo, Japan</i>).....	809

Dihydrotestosterone and Bicalutamide Do Not Affect Periostin Expression in Androgen-dependent LNCaP Prostate Cancer Cell Lines. F. ARGELLATI, P.V. NUZZO, F. RICCI, R. MANGERINI, A. RUBAGOTTI, F. BOCCARDO (<i>Genoa, Italy</i>)	815
Increased Alternative Lengthening of Telomere Phenotypes of Telomerase-negative Immortal Cells upon Trichostatin – A Treatment. A.R. JUNG, J.E. YOO, Y.-H. SHIM, Y.-N. CHOI, H.-C. JEUNG, H.C. CHUNG, S.Y. RHA, B.-K. OH (<i>Seoul, South Korea</i>)	821
Bone Marrow-derived Cells Participate in the Formation of Normal and Neoplastic Lung Stroma. S. D’COSTA, L. BORST, Y. KIM (<i>Raleigh, NC, USA; Seoul, South Korea</i>)	831
Analysis of Protein Expression Profile of Oral Squamous Cell Carcinoma by MALDI-TOF-MS. E. ROMAN, M.L. LUNDE, T. MIRON, S. WARNAKULASAURIYA, A.C. JOHANNESSEN, E.N. VASSTRAND, S.O. IBRAHIM (<i>Bergen, Norway; Rehovot, Israel; London, UK</i>)	837
RNA Interference Targeting Sensitive-to-Apoptosis Gene Potentiates Doxorubicin- and Staurosporine-induced Apoptosis of PC3 Cells. E.S. YANG, Y.J. HUH, J.-W. PARK (<i>Daegu, South Korea</i>)	847
The Influence of Phenothiazine Derivatives on Intracellular Accumulation of Cationic Cyanine Dye DiOC ₆ (3) in LoVo-DX Cells. A. POŁA, D. MOSIĄDZ, J. SACZKO, T. MODRZYCKA, K. MICHALAK (<i>Wroclaw, Poland</i>)	857
RNA Interference with EAG1 Enhances Interferon Gamma Injury to Glioma Cells <i>In Vitro</i> . L.C. CUNHA, E. DEL BEL, L. PARDO, W. STÜHMER, R. TITZE-DE-ALMEIDA (<i>Brasília, DF; Ribeirão Preto, SP, Brazil; Göttingen, Germany</i>)	865
<i>In Vitro</i> Activity of the $\alpha_v\beta_3$ Integrin Antagonist RGDechi-hCit on Malignant Melanoma Cells. M. PISANO, I. DE PAOLA, V. NIEDDU, I. SASSU, S. COSSU, G. GALLERI, A. DEL GATTO, M. BUDRONI, A. COSSU, M. SAVIANO, G. PALMIERI, L. ZACCARO, C. ROZZO (<i>Sassari; Napoli; Alghero; Bari, Italy</i>)	871
Validation of a Simple Assay for the Quantification of the Capecitabine Metabolites 5’-DFCR and 5’-DFUR for Drug Monitoring in Patients Receiving Outpatient Chemotherapy. P. BUCHNER, E. MIHOLA, A. SAHMANOVIC, T. STEININGER, C. DITTRICH, M. CZEJKA (<i>Vienna, Austria</i>)	881
Naftopidil Induces Apoptosis in Malignant Mesothelioma Cell Lines Independently of α_1 -Adrenoceptor Blocking. E. MASACHIKA, T. KANNO, T. NAKANO, A. GOTOH, T. NISHIZAKI (<i>Nishinomiya, Japan</i>)	887
Hepatocyte Growth Factor Promotes Lung Carcinogenesis in Transgenic Mice Treated with Diethylnitrosamine. A. KOJIMA, N. Horiguchi, S. KAKIZAKI, H. TAKAYAMA, M. MORI (<i>Maebashi, Japan</i>)	895
Combination Effect of Equol and TRAIL against Human Cervical Cancer Cells. E.Y. KIM, A.K. KIM (<i>Seoul, South Korea</i>)	903
The Role of p16 Expression as a Predictive Marker in HPV-positive Oral SCCHN – A Retrospective Single-center Study. C. GEIBLER, A. TAHTALI, M. DIENSTHUBER, D. GASSNER, T. STÖVER, J. WAGENBLAST (<i>Frankfurt am Main, Germany</i>)	913
Satisfactory Sampling in Cytological Cervical Diagnosis: Comparison Between a Conventional and a New Sampling Device. A. LUKIC, S. IANNAACCIO, R. HEYN, S. VILLANI, F. NOBILI, E. GIARNIERI, R. MANCINI, M. MOSCARINI, M.R. GIOVAGNOLI (<i>Rome, Italy</i>)	917
Transcriptional Specificity in Various p53-Mutant Cells. K. OKAICHI, N. IZUMI, Y. TAKAMURA, S. FUKUI, T. KUDO (<i>Nagasaki, Japan</i>)	923

β-Elementene and Taxanes Synergistically Induce Cytotoxicity and Inhibit Proliferation in Ovarian Cancer and Other Tumor Cells. B. ZOU, Q.Q. LI, J. ZHAO, J.M. LI, C.F. CUFF, E. REED (<i>Ningbo, PR China; Morgantown, WV; Baltimore; Bethesda, MD, USA</i>)	929
Formation of Sex Hormone Transients Resulting from Attack of Free Radicals. N. GETOFF, H. SCHITTL, M. GERSCHPACHER, R.M. QUINT (<i>Vienna, Austria; Munich, Germany</i>)	941
(-)-Gossypol-enriched Cottonseed Oil Inhibits Proliferation and Adipogenesis of Human Breast Pre-adipocytes. S. ZHONG, J. LEONG, W. YE, P. XU, S.-H. LIN, J.-Y. LIU, Y.C. LIN (<i>Guangdong, China; Columbus, OH, USA</i>)	949
Interplay between Mast Cells and Lymphatic Vessels in Different Molecular Types of Breast Cancer. M. RAICA, A.M. CIMPEAN, R. CEAUȘU, D. RIBATTI, P. GAJE (<i>Timisoara, Romania; Bari, Italy</i>)	957
Expression of Metallothionein-III in Patients with Non-small Cell Lung Cancer. B. WERYNSKA, B. PULA, B. MUSZCZYNSKA-BERNHARD, A. GOMULKIEWICZ, A. JETHON, M. PODHORSKA-OKOLOW, R. JANKOWSKA, P. DZIEGIEL (<i>Wroclaw, Poland</i>)	965
<i>Clinical Studies</i>	
Pelvic Peritonectomy without Intraperitoneal Chemotherapy for Localized Peritoneal Carcinomatosis. T. SATO, S. YAMAGUCHI, M. HARADA, I. KOYAMA, M.F. BRENNAN (<i>Hidaka; Iruma, Saitama, Japan; New York, NY, USA</i>)	975
Lack of Prognostic Significance of Neuroendocrine Differentiation and Stem Cell Antigen Co-Expression in Resected Early-stage Non-small Cell Lung Cancer. S. GOTTSCHLING, K. JENSEN, F.J.F. HERTH, M. THOMAS, P.A. SCHNABEL, E. HERPEL (<i>Heidelberg, Germany</i>)	981
A Case Report of an Intraabdominal Microcystic and Pseudopapillary Spindle and Round Cell Neoplasm and a Comparison to Other Intraabdominal Mesenchymal Tumors. A. BRADATSCH, P. KORNPAT, J. HAYBAECK, H.-J. MISCHINGER (<i>Graz, Austria</i>)	991
Fucosylated Fraction of Alpha-fetoprotein as a Serological Marker of Early Hepatocellular Carcinoma. S. MORIYA, M. MORIMOTO, K. NUMATA, A. NOZAKI, Y. SHIMOYAMA, M. KONDO, M. NAKANO, S. MAEDA, K. TANAKA (<i>Yokohama; Kamakura, Japan</i>)	997
A Population-based Series of Ovarian Carcinosarcomas with Long-term Follow-up. G. PAULSSON, S. ANDERSSON, B. SORBE (<i>Skövde; Eskilstuna; Örebro, Sweden</i>)	1003
Is the α/β Ratio for Prostate Tumours Really Low and Does It Vary with the Level of Risk at Diagnosis? J.F. FOWLER, I. TOMA-DASU, A. DASU (<i>Madison, WI, USA; Stockholm; Linköping, Sweden</i>)	1009
Serum VEGF as a Tumor Marker in Patients with HCV-related Liver Cirrhosis and Hepatocellular Carcinoma. T. MUKOZU, H. NAGAI, D. MATSUI, T. KANEKAWA, Y. SUMINO (<i>Tokyo, Japan</i>)	1013
Functional Polymorphism in the CAVI T29107A Gene and Its Association with Prostate Cancer Risk among Japanese Men. S. SUGIE, H. TSUKINO, T. YAMAUCHI, S. MUKAI, M. FUJII, N. SHIBATA, Y. KURODA, T. KAMOTO (<i>Miyazaki, Japan</i>)	1023
Progression-free Survival Is Accurately Predicted in Patients Treated with Chemotherapy for Epithelial Ovarian Cancer by the Histoculture Drug Response Assay in a Prospective Correlative Clinical Trial at a Single Institution. P.-S. JUNG, D.-Y. KIM, M.-B. KIM, S.-W. LEE, J.-H. KIM, Y.-M. KIM, Y.-T. KIM, R.M. HOFFMAN, J.-H. NAM (<i>Seoul, South Korea; San Diego, CA, USA</i>)	1029

Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Gastroesophageal Adenocarcinoma. U. PLUSCHNIG, S.F. SCHOPPMANN, M. PREUSSER, P. DATLER, R. ASARI, A. BA-SSALAMAH, K. SCHWAMEIS, P. BIRNER, J. ZACHERL, M. HEJNA (<i>Vienna, Austria</i>).....	1035
Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy as Salvage Treatment for a Late Wound Recurrence of Endometrial Cancer. D.A. SANTEUFEMIA, F. LUMACHI, S.M.M. BASSO, S. TUMOLO, G. LO RE, G. CAPOBIANCO, S. BERTOZZI, E.M. PASQUAL (<i>Pordenone; Padova; Sassari; Udine, Italy</i>)	1041
Evaluation of the Two Intraoperative Examination Methods for Sentinel Lymph Node Assessment: A Multicentric and Retrospective Study on more than 2,000 Nodes. C. ARLICOT, A. LE LOUARN, F. ARBION, J. LEVEQUE, S. LORAND, J. KINN, B. CHAZE, A. GARRIGUE, G. BODY (<i>Tours; Rennes; Angers; Nantes; Poitiers, France</i>)	1045
Comparative Effectiveness of 5-Fluorouracil with and without Oxaliplatin in the Treatment of Colorectal Cancer in Clinical Practice. E. HEALEY, G.E. STILLFRIED, S. ECKERMANN, J.P. DAWBER, P.R. CLINGAN, M. RANSON (<i>Wollongong, NSW, Australia</i>)	1053
Long-lasting Clinical Benefit of Sunitinib Malate in the Treatment of a Case of Heavily Pre-treated Metastatic Liposarcoma. R. PORZIO, M.A. BELLA, G. ROSSI, A. ARDIZZONI (<i>Parma; Reggio Emilia, Italy</i>).....	1061
Brain Metastases of Gastro-oesophageal Cancer: Evaluation of Molecules with Relevance for Targeted Therapies. M. PREUSSER, A.S. BERGHOFF, A. ILHAN-MUTLU, C. DINHOF, M. MAGERLE, C. MAROSI, M. HEJNA, D. CAPPER, A. VON DEIMLING, S.F. SCHOPPMANN, P. BIRNER (<i>Vienna, Austria; Heidelberg, Germany</i>)	1065
Phase II Study of Carboplatin and Weekly Irinotecan Combination Chemotherapy in Recurrent Ovarian Cancer: A Kansai Clinical Oncology Group Study (KCOG0330). H. TSUBAMOTO, R. KAWAGUCHI, K. ITO, T. SHIOZAKI, S. TAKEUCHI, Y. ITANI, A. ARAKAWA, T. TABATA, S. TOYODA (<i>Nishinomiya; Amagasaki; Tsu; Morioka; Nara; Nagoya, Japan</i>)	1073
Analysis of Orbital Plain Radiographs for Orbital Deformities in Neurofibromatosis Type 1 Patients, with Special Reference to Alterations of the Orbital Rim as Indicators of Adjacent Plexiform Neurofibroma. R.E. FRIEDRICH, J. ROTHER, G. CHRIST, M. LEHMANN, C. GRÄFIN ZU EULENBURG, M. GIESE, H.A. SCHEUER (<i>Hamburg, Germany</i>).....	1081
Prognostic Value of p53 Protein Overexpression in Upper Tract Urothelial Carcinomas in Taiwan. Y-C. LEE, W.-J. WU, W.-M. LI, H.-H. LIN, C.-N. HUANG, C.-Y. CHAI, L.-L. CHANG, H.-L. LIN, H.-L. KE (<i>Kaohsiung; Pingtung, Taiwan, ROC</i>)	1091
Tumor Necrosis in Patients with TNM Stage IV Colorectal Cancer without Residual Disease (R0 Status) Is Associated with a Poor Prognosis. K. KOMORI, Y. KANEMITSU, K. KIMURA, N. HATTORI, T. SANO, S. ITO, T. ABE, Y. SENDA, K. MISAWA, Y. ITO, N. UEMURA, Y. SHIMIZU (<i>Aichi, Japan</i>)	1099
Biomarkers as Prognostic Factors for cN2 or 3 Non-small Cell Lung Cancer Treated by Induction Chemoradiotherapy and Surgery. H. YOKOMISE, D. LIU, S. CHANG, T. GO, S. ISHIKAWA, N. MISAKI, N. NAKASHIMA (<i>Kagawa, Japan</i>).....	1107
Alternating Chemotherapy with Amrubicin Plus Cisplatin and Weekly Administration of Irinotecan Plus Cisplatin for Extensive-stage Small Cell Lung Cancer. R. NORO, A. YOSHIMURA, K. YAMAMOTO, A. MIYANAGA, H. MIZUTANI, Y. MINEGISHI, M. SEIKE, K. KUBOTA, S. KOSAIHIRA, M. HINO, M. ANDO, K. NOMURA, T. OKANO, K. KOBAYASHI, K. UEMATSU, A. GEMMA, The East Japan Chesters Group (<i>Tokyo; Imzai, Chiba; Koriyama, Fukushima; Hidaka; Kawagoe, Saitama, Japan</i>).....	1117

Influence of Acetic Acid on a Pap Smear of Dysplastic Lesion. F. HOELLEN, M.K. BOHLMANN, J. BRADE, A. RODY, K. DIEDRICH, W.-D. HUSSTEDT, A. HORNEMANN (<i>Luebeck; Mannheim, Germany</i>).....	1125
Pitfall in Assessing the Size of Tumor Phantoms on Mammograms. C.A. RUBIO, G. SVANE, G. ILESCU, B. ADALSTEINSSON, T. MATHIESEN, M. THOLIN, M. MACHIDA, E.C. CERVANTES, L. MATTSSON, E. AZAVEDO (<i>Stockholm, Sweden</i>)	1131
Induction Docetaxel-Cisplatin Followed by Extended-field Radiotherapy in Patients with Cervical Metastases from Unknown Primary Carcinoma. F. PERRI, F. IONNA, P. MUTO, C. BUONERBA, G. DELLA VITTORIA SCARPATI, D. BOSSO, F. FULCINITI, A. DAPONTE, A. ARGENONE, F. SANDOMENICO, G. DI LORENZO, F. CAPONIGRO (<i>Naples; Salerno, Italy</i>)	1135
The Value of PET Compared to MRI in Malignant Head and Neck Tumors. T. GUENZEL, A. FRANZEN, S. WIEGAND, S. KRAETSCHMER, J.L. JAHN, R. MIRONCZUK, T. WILHELM, T. SCHROM (<i>Frankfurt [Oder]; Neuruppin; Marburg; Borna; Bad Saarow, Germany</i>)	1141
Efficacy of Androgen Deprivation Therapy for Localized Prostate Cancer: Analysis of pT0 Evaluated by Radical Prostatectomy Specimen. Y. KADONO, H. YAEGASHI, K. IZUMI, S. UENO, Y. KITAGAWA, A. MIZOKAMI, H. ASAH, K. KOBASHI, K. KOSHIDA, M. NAMIKI (<i>Kanazawa; Kaga, Japan</i>)	1147
Statistical Identification of Predictors for Paclitaxel-induced Peripheral Neuropathy in Patients with Breast or Gynaecological Cancer. Y. KANBAYASHI, T. HOSOKAWA, J. KITAWAKI, T. TAGUCHI (<i>Kyoto, Japan</i>).....	1153
Tumor Response after Low-dose Preoperative Radiotherapy Combined with Chemotherapy for Squamous Cell Esophageal Carcinoma. N. KOBAYASHI, H. NAKAYAMA, Y. OSAKA, S. TACHIBANA, S. NOGI, Y. TAJIMA, M. OKUBO, R. MIKAMI, N. KANESAKA, S. SUGAHARA, S. HOSHINO, A. TSUCHIDA, K. TOKUUYE (<i>Tokyo, Japan</i>).....	1157
Phase II Study of Triplet Chemotherapy Using Tegafur-Uracil, Vinorelbine, Gemcitabine for Advanced Non-small Cell Lung Cancer. S. MINOMO, K. ASAMI, K. OKISHIO, T. KAWAGUCHI, Y. FUJITA, S. TAKATA, A. TAMURA, R. SAITOU, S. ATAGI (<i>Sakai; Asahikawa; Koga; Kiyose; Shibukawa, Japan</i>)	1163
An Evaluation of Focal Adhesion Kinase in Breast Cancer by Tissue Microarrays. S.-M. SHEEN-CHEN, C.-Y. HUANG, Y.-C. CHAN, C.-H. TSAI, S.-Y. CHI, S.-C. WU, C.-C. HUANG, R.-P. TANG, H.-L. ENG, S.-F. KO, Y.-W. LEE, J.-L. LIANG, E.-Y. HUANG, H.-C. CHEN, K.-M. RAU (<i>Kaohsiung; Linkou, Taiwan</i>).....	1169
Safety and Efficacy of Platinum Agents plus Etoposide for Patients with Small Cell Lung Cancer with Interstitial Lung Disease. T. YOSHIDA, K. YOH, K. GOTO, S. NIHO, S. UMEMURA, H. OHMATSU, Y. OHE (<i>Kashiwa, Japan</i>)	1175
Pre-treatment C-Reactive Protein as a Prognostic Factor for Recurrence after Surgical Resection of Hepatocellular Carcinoma. H. NISHIKAWA, A. ARIMOTO, T. WAKASA, R. KITA, T. KIMURA, Y. OSAKI (<i>Osaka, Japan</i>)	1181
Individual Tumor Response Testing in Multiple Relapsed Acute Myeloid Leukemia in Children. J. STYCZYNSKI, M. PIATKOWSKA, K. CZYZEWSKI, M. POGORZALA, M. WYSOCKI (<i>Bydgoszcz, Poland</i>)	1189
Prostate Cancer Detection at Repeat Biopsy: Can Pelvic Phased-array Multiparametric MRI Replace Saturation Biopsy? P. PEPE, A. GARUFI, G. PRIOLO, G. CANDIANO, F. PIETROPAOLO, M. PENNISI, F. FRAGGETTA, F. ARAGONA (<i>Catania, Italy</i>).....	1195
Hepatic Arterial Infusion for Biliary Tract Carcinoma: Single-center Experience. B. MELICHAR, Z. VOBOŘIL, J. DVOŘAK, A. FERKO, T. ROZKOŠ, A. KRAJINA (<i>Olomouc; Hradec Králové, Czech Republic</i>)	1201

DNA Ploidy: A Prognostic Factor of Response to Chemotherapy and Survival in Metastatic Gastric Adenocarcinoma. J. SYRIOS, G. KECHAGIAS, G. AGROGIANNIS, I.D. XYNOS, N. KAVANTZAS, A.C. LAZARIS, S. AMPTOULACH, A. MOURATI, S. SOUGIOULTZIS, E.S. PATSOURIS, N. TSAVARIS (<i>Athens, Greece</i>)	1209
Inactivation of 9q22.3 Tumor Suppressor Genes Predict Outcome for Patients with Head and Neck Squamous Cell Carcinoma. A. GHOSH, G.P. MAITI, M.N. BANDOPADHYAY, J. CHAKRABORTY, J. BISWAS, S. ROYCHOUDHURY, C.K. PANDA (<i>Kolkata, India</i>)	1215
Microwave Ablation of Hepatocellular Carcinoma Using a New Percutaneous Device: Preliminary Results. G. POGGI, B. MONTAGNA, P. DI CESARE, G. RIVA, G. BERNARDO, M. MAZZUCCO, A. RICCARDI (<i>Pavia; Padova, Italy</i>)	1221
Exclusive Electron Intraoperative Radiotherapy in Early-stage Breast Cancer: A Monoinstitutional Experience. M.F. OSTI, A. CARNEVALE, S. BRACCI, C. AMANTI, A. LOMBARDI, S. MAGGI, V. DE SANCTIS, M. VALERIANI, R.M. ENRICI (<i>Rome, Italy</i>)	1229
Can Concurrent Chemoradiotherapy Replace Surgery and Postoperative Radiation for Locally Advanced Stage III/IV Tonsillar Squamous Cell Carcinoma? G. PARK, S.-W. LEE, S.Y. KIM, S.Y. NAM, S.-H. CHOI, S.-B. KIM, J.-L. ROH, D.H. YOON, S.S. KIM, J.-H. PARK, Y.S. KIM, S.M. YOON, S.Y. SONG, J.H. KIM, E.K. CHOI, S.D. AHN (<i>Seoul, South Korea</i>)	1237
Errata	1245

Number 4

Reviews

Aryl Hydrocarbon Receptor and Lung Cancer. J.J. TSAY, K.-M. TCHOU-WONG, A.K. GREENBERG, H. PASS, W.N. ROM (<i>New York, NY, USA</i>)	1247
A Review on Biomarkers for Prediction of Treatment Outcome in Gastric Cancer. F. PIETRANTONIO, F. DE BRAUD, V. DA PRAT, F. PERRONE, M.A. PIEROTTI, M. GARIBOLDI, G. FANETTI, P. BIONDANI, A. PELLEGRINELLI, I. BOSSI, M. DI BARTOLOMEO (<i>Milan, Italy</i>)	1257
The Influence of Glutamate Receptors on Proliferation and Metabolic Cell Activity of Neuroendocrine Tumors. H.S. HAAS, R. PFRAGNER, N.G. TABRIZI-WIZSY, K. ROHRER, I. LUEFTENEGGER, C. HORWATH, N. ALLARD, B. RINNER, A. SADJAK (<i>Graz, Austria</i>)	1267
<i>In Vitro</i> and <i>In Vivo</i> Experimental Models as Tools to Investigate the Efficacy of Antineoplastic Drugs on Urinary Bladder Cancer. R. ARANTES-RODRIGUES, A. COLAÇO, R. PINTO-LEITE, P.A. OLIVEIRA (<i>Vila Real, Portugal</i>)	1273

Experimental Studies

Evaluation of Quercetin as a Potential Drug in Osteosarcoma Treatment. K. BERNDT, C. CAMPANILE, R. MUFF, E. STREHLER, W. BORN, B. FUCHS (<i>Zurich, Switzerland; Rochester, MN, USA</i>)	1297
PTEN Regulates Sensitivity of Melanoma Cells to RO4929097, the γ -Secretase Inhibitor. J.S. NAIR, T. SHEIKH, A.L. HO, G.K. SCHWARTZ (<i>New York, NY, USA</i>)	1307
Characterization and Evaluation of Pre-clinical Suitability of a Syngeneic Orthotopic Mouse Ovarian Cancer Model. S. CHO, Y. SUN, A.P. SOISSON, M.K. DODSON, C.M. PETERSON, E.A. JARBOE, A.M. KENNEDY, M.M. JANAT-AMSBURY (<i>Salt Lake City, UT, USA</i>)	1317

Establishment and Evaluation of a Bead-based Luminex Assay Allowing Simultaneous Quantification of Equine IL-12 and IFN- γ . M.C. DURAN, S. WILLENBROCK, J.-M. V. MÜLLER, I. NOLTE, K. FEIGE, H.M. ESCOBAR (<i>Hannover, Germany</i>).....	1325
Secretory Phospholipase A ₂ Mediates Human Esophageal Adenocarcinoma Cell Growth and Proliferation via ERK 1/2 Pathway. M.R. SADARIA, J.A. YU, X. MENG, D.A. FULLERTON, T.B. REECE, M.J. WEYANT (<i>Aurora, CO, USA</i>)	1337
Effects of Pyridine Analogs of Curcumin on Growth, Apoptosis and NF- κ B Activity in Prostate Cancer PC-3 Cells. X. WEI, D. ZHOU, H. WANG, N. DING, X.-X. CUI, H. WANG, M. VERANO, K. ZHANG, A.H. CONNEY, X. ZHENG, Z.-Y. DU (<i>Guangzhou; Jiangmen, Guangdong, PR China; Piscataway, NJ, USA</i>)	1343
The Histone Deacetylase Inhibitor Trichostatin A Promotes Apoptosis and Antitumor Immunity in Glioblastoma Cells. E. HÖRING, O. PODLECH, B. SILKENSTEDT, I.A. ROTA, E. ADAMOPOULOU, U. NAUMANN (<i>Tübingen, Germany</i>)	1351
A Color-coded Imaging Model of the Interaction of α_v Integrin-GFP Expressed in Osteosarcoma Cells and RFP Expressing Blood Vessels in Gelfoam [®] Vascularized <i>In Vivo</i> . F. UEHARA, Y. TOME, S. YANO, S. MIWA, S. MII, Y. HIROSHIMA, M. BOUVET, H. MAEHARA, F. KANAYA, R.M. HOFFMAN (<i>San Diego, CA, USA; Okinawa, Japan</i>)	1361
Dynamic Subcellular Imaging of Cancer Cell Mitosis in the Brain of Live Mice. M. MOMIYAMA, A. SUETSUGU, H. KIMURA, T. CHISHIMA, M. BOUVET, I. ENDO, R.M. HOFFMAN (<i>San Diego, CA, USA; Yokohama, Japan</i>)	1367
Single Cell Time-lapse Imaging of Focus Formation by the DNA Damage-Response Protein 53BP1 after UVC Irradiation of Human Pancreatic Cancer Cells. S. MIWA, Y. TOME, S. YANO, Y. HIROSHIMA, F. UEHARA, S. MII, H. KIMURA, K. HAYASHI, H. TSUCHIYA, M. BOUVET, E.V. EFIMOVA, R.M. HOFFMAN (<i>San Diego, CA; Chicago, IL, USA; Okinawa; Kanazawa, Ishikawa, Japan</i>)	1373
ABCG2 Inhibitor YHO-13351 Sensitizes Cancer Stem/ Initiating-like Side Population Cells to Irinotecan. Y. SHISHIDO, S. UENO, R. YAMAZAKI, M. NAGAOKA, T. MATSUZAKI (<i>Kunitachi-shi, Tokyo, Japan</i>)	1379
Combining Celecoxib with Sorafenib Synergistically Inhibits Hepatocellular Carcinoma Cells <i>In Vitro</i> . T. MORISAKI, M. UMEBAYASHI, A. KIYOTA, N. KOYA, H. TANAKA, H. ONISHI, M. KATANO (<i>Fukuoka, Japan</i>).....	1387
Regression of Canine Cutaneous Histiocytoma: Reduced Proliferation or Increased Apoptosis? I. PIRES, A. ALVES, F.L. QUEIROGA, F. SILVA, C. LOPES (<i>Vila Real; Porto, Portugal</i>)	1397
Expression and Prognostic Significance of the Oncogenic K2P Potassium Channel KCNK9 (TASK-3) in Ovarian Carcinoma. A. INNAMAA, L. JACKSON, V. ASHER, G. VAN SHALKWYK, A. WARREN, D. HAY, A. BALI, H. SOWTER, R. KHAN (<i>Derby, UK</i>)	1401
Association of Copper Transporter Expression with Platinum Resistance in Epithelial Ovarian Cancer. H. YOSHIDA, M. TERAMAE, M. YAMAUCHI, T. FUKUDA, T. YASUI, T. SUMI, K.-I. HONDA, O. ISHIKO (<i>Osaka, Japan</i>)	1409
Heterogeneous Sensitivity of Hepatocellular Carcinoma to Sorafenib Revealed by the Short-term Culture of Tumor Fragments. C. GODIN, S. DUPONT, Z. EZZOUKHRY, C. LOUANDRE, D. CHATELAIN, L. HENAUT, C. SABBAGH, J.-M. REGIMBEAU, J.-C. MAZIERE, J.-C. BARBARE, B. CHAUFFERT, A. GALMICHE (<i>Amiens, France</i>).....	1415
β -Elemene Promotes Cisplatin-induced Cell Death in Human Bladder Cancer and Other Carcinomas. Q.Q. LI, G. WANG, H. LIANG, J.M. LI, F. HUANG, P.K. AGARWAL, Y. ZHONG, E. REED (<i>Beihai, Guangxi, PR China; Bethesda; Baltimore, MD; Morgantown, WV, USA</i>)	1421

Thrombospondin-1 Receptor Mediates Autophagy of RAS-expressing Cancer Cells and Triggers Tumour Growth Inhibition. W. KALAS, E. SWIDEREK, M. ŚWITALSKA, J. WIETRZYK, J. RAK, L. STRZAŁAŁA (<i>Wroclaw, Poland; Montreal, QC, Canada</i>)	1429
Establishment of a Novel Model of Peritoneal Carcinomatosis of Peritoneal Extension Type. M. IMANO, T. ITOH, T. SATOU, A. KIDO, M. TSUBAKI, A. YASUDA, H. KATO, H. IMAMOTO, S. NISHIDA, H. FURUKAWA, Y. TAKEYAMA, K. OKUNO, H. SHIOZAKI (<i>Osaka-Sayama; Higashi-Osaka, Osaka, Japan; Kashihara, Nara, Japan</i>).....	1439
Impact of Different Tumour Stroma Assessment Methods Regarding Podoplanin Expression on Clinical Outcome in Patients with Invasive Ductal Breast Carcinoma. B. PULA, A. WOJNAR, B. WERYNSKA, A. AMBICKA, A. KRUCZAK, W. WITKIEWICZ, M. UGORSKI, M. PODHORSKA-OKOŁOW, P. DZIEGIEL (<i>Wroclaw; Krakow, Poland</i>).....	1447
Salinomycin Induces Apoptosis via Death Receptor-5 Up-regulation in Cisplatin-resistant Ovarian Cancer Cells. B. PARAJULI, S.-J. SHIN, S.-H. KWON, S.-D. CHA, R. CHUNG, W.-J. PARK, H.-G. LEE, C.-H. CHO (<i>Daegu, Republic of Korea</i>)	1457
Murine Double Minute 2 and Its Association with Chemoradioresistance of Esophageal Squamous Cell Carcinoma. H. OKAMOTO, F. FUJISHIMA, Y. NAKAMURA, M. ZUGUCHI, G. MIYATA, T. KAMEI, T. NAKANO, K. KATSURA, S. ABE, Y. TANIYAMA, J. TESHIMA, M. WATANABE, A. SATO, N. OHUCHI, H. SASANO (<i>Sendai, Miyagi, Japan</i>)	1463
Chemosensitivity Induced by Down-regulation of MicroRNA-21 in Gemcitabine-resistant Pancreatic Cancer Cells by Indole-3-Carbinol. W.H. PAIK, H.R. KIM, J.K. PARK, B.J. SONG, S.H. LEE, J.-H. HWANG (<i>Seoul; Seongnam, South Korea</i>)	1473
Overexpression of IL-6 by Gene Transfer Stimulates IL-8-mediated Invasiveness of KYSE170 Esophageal Carcinoma Cells. S. OKAMURA, H. FUJIWARA, M. YONEDA, A. FURUTANI, M. TODO, A. IKAI, H. TADA, H. OKAMURA, S. UMEHARA, A. SHIOZAKI, T. KUBOTA, S. KOMATSU, D. ICHIKAWA, K. OKAMOTO, T. OCHIAI, E. OTSUJI (<i>Kyoto, Japan</i>)	1483
Circulating Levels of Transforming Growth Factor-β (TGF-β) and Chemokine (C-X-C Motif) Ligand-1 (CXCL1) as Predictors of Distant Seeding of Circulating Tumor Cells in Patients with Metastatic Breast Cancer. R. DIVELLA, A. DANIELE, E. SAVINO, F. PALMA, A. BELLIZZI, F. GIOTTA, G. SIMONE, M. LIOCE, M. QUARANTA, A. PARADISO, A. MAZZOCCA (<i>Bari, Italy</i>)	1491
The Impact of Angio-associated Migratory Cell Protein (AAMP) on Breast Cancer Cells <i>In Vitro</i> and Its Clinical Significance. Y. YIN, A.J. SANDERS, W.G. JIANG (<i>Cardiff, UK; Jinan, Shandong, PR China</i>)	1499
miRNA Expression Profiles of Oral Squamous Cell Carcinomas. K. GOMBOS, R. HORVÁTH, E. SZELE, K. JUHÁSZ, K. GÓCZE, K. SOMLAI, G. PAJKOS, I. EMBER, L. OLASZ (<i>Pécs; Veszprém; Kecskemét, Hungary</i>)	1511
Effect of an Extract of <i>Withania somnifera</i> Root on Estrogen Receptor-positive Mammary Carcinomas. K.F. KHAZAL, T. SAMUEL, D.L. HILL, C.J. GRUBBS (<i>Tuskegee; Birmingham, AL, USA</i>).....	1519
Normal Mammary Fibroblasts Induce Reversion of the Malignant Phenotype in Human Primary Breast Cancer. A.-M. RÖMER, I. LÜHR, A. KLEIN, A. FRIEDL, S. SEBENS, F. RÖSEL, N. ARNOLD, A. STRAUSS, W. JONAT, M. BAUER (<i>Kiel; Berlin, Germany; Madison, WI, USA</i>)	1525
Design and Evaluation of Novel Radiolabelled VIP Derivatives for Tumour Targeting. C. RANGGER, A. HELBOK, M. OCAK, T. RADOLF, F. ANDREAE, I.J. VIRGOLINI, E. VON GUGGENBERG, C. DECRISTOFORO (<i>Innsbruck; Graz, Austria; Istanbul, Turkey</i>).....	1537

Influence of Gefitinib and Erlotinib on Apoptosis and c-MYC Expression in H23 Lung Cancer Cells. M. SUENAGA, M. YAMAMOTO, S. TABATA, S. ITAKURA, M. MIYATA, S. HAMASAKI, T. FURUKAWA (<i>Kagoshima, Japan</i>).....	1547
Clinical Significance of Galectin-7 in Epithelial Ovarian Cancer. H.-J. KIM, H.-K. JEON, J.-K. LEE, C.O. SUNG, I.-G. DO, C.H. CHOI, T.-J. KIM, B.-G. KIM, D.-S. BAE, J.-W. LEE (<i>Gunpo; Seoul, South Korea</i>).....	1555
Novel Topical Photodynamic Therapy of Prostate Carcinoma Using Hydroxy-aluminum Phthalocyanine Entrapped in Liposomes. K. SUTORIS, J. RAKUSAN, M. KARASKOVA, J. MATTOVA, J. BENES, M. NEKVASIL, P. JEZEK, M. ZADINOVA, P. POUCKOVA, D. VETVICKA (<i>Prague; Rybitvi, Czech Republic</i>).....	1563
Influence of Bacteriophage Preparations on Migration of HL-60 Leukemia Cells <i>In Vitro</i> . A. KURZEPA-SKARADZINSKA, G. SKARADZINSKI, B. WEBER-DABROWSKA, M. ZACZEK, T. MAJ, A. SLAWEK, M. SWITALSKA, M. MACIEJEWSKA, J. WIETRZYK, W. RYMOWICZ, A. GORSKI (<i>Wroclaw; Warsaw, Poland</i>).....	1569
<i>Clinical Studies</i>	
EGFR and Phosphorylated EGFR in Relation to HPV and Clinical Outcome in Tonsillar Cancer. M. ROMANITAN, A. NÄSMAN, E. MUNCK-WIKLAND, T. DALIANIS, T. RAMQVIST (<i>Stockholm, Sweden</i>).....	1575
<i>Clostridium septicum</i> Can Cause Distant Myonecrosis in Patients with Ovarian Cancer. S. ZURMEYER, C. FOTOPOULOU, J. SEHOULI, E. BRAICU, U. SCHLICHTING (<i>Berlin, Germany</i>).....	1585
Chromopertubation – Presentation of a Modification of the Standard Technique. E. PETRI, S. BERLIT, M. SÜTTERLIN, A. HORNEMANN (<i>Mannheim, Germany</i>).....	1591
Obesity and Physical Inactivity Are Related to Impaired Physical Health of Breast Cancer Survivors. A. ELME, M. UTRIAINEN, P. KELLOKUMPU-LEHTINEN, T. PALVA, R. LUOTO, R. NIKANDER, R. HUOVINEN, H. KAUTIAINEN, S. JÄRVENPÄÄ, H.M. PENTTINEN, L. VEHMANEN, A.-S. JÄÄSKELÄINEN, J. RUOHOLA, C. BLOMQVIST, T. SAARTO (<i>Tampere; Helsinki; Turku; Jyväskylä; Äänekoski, Finland</i>).....	1595
High-dose FOLFIRI, Surgery, and Radiofrequency Ablation for Patients with Unresectable Liver Metastases from Colorectal Cancer. M. HEBBAR, S. TRUANT, C. DESAUW, G. SERGENT-BAUDSON, S. CATTAN, G. PIESSEN, F.-R. PRUVOT (<i>Lille, France</i>).....	1603
Postoperative Survival of Lung Cancer Patients: Are There Predictors Beyond TNM? G. FRIEDEL, P. FRITZ, S. GOLETZ, R. KRISTEN, F. BRINKMANN, R. DIERKESMANN, M. SCHWAB, G. OTT, J. DIPPON, M.D. ALSCHER (<i>Gerlingen; Stuttgart, Germany</i>).....	1609
Better Outcomes by Monitoring Tumour Dynamics Using Sensitive Tumour Markers in Patients with Recurrent Gastric Cancer. S. KOMATSU, D. ICHIKAWA, Y. NISHIMURA, T. KUBOTA, K. OKAMOTO, A. SHIOZAKI, H. FUJIWARA, H. KONISHI, Y. MURAYAMA, Y. KURIU, H. IKOMA, M. NAKANISHI, E. OTSUJI (<i>Kyoto, Japan</i>).....	1621
Delayed Radiotherapy for Patients with Localized Prostate Cancer: Validation by Propensity Score Matching. H. NAKAYAMA, A. KANEMOTO, K. KIKUCHI, K. MATSUKI, M. TOMOBE, S. TSUKAMOTO, H. TAKESHIMA, Y. OSHIRO, S. SUGAHARA, K. TOKUUYE (<i>Tsukuba; Ushiku; Ryugasaki, Ibaraki; Tokyo, Japan</i>).....	1629
Successful Resection of Esophageal Cancer with Right Aortic Arch by Video-Assisted Thoracoscopic Surgery: A Case Report. N. KUBO, M. OHIRA, T. LEE, K. SAKURAI, T. TOYOKAWA, H. TANAKA, K. MUGURUMA, K. KIMURA, H. NAGAHARA, E. NODA, R. AMANO, H. OHTANI, Y. YAMASHITA, M. YASHIRO, K. MAEDA, K. HIRAKAWA (<i>Osaka, Japan</i>).....	1635

Advances in Esophageal Surgery in Elderly Patients with Thoracic Esophageal Cancer. M. MORITA, H. OTSU, H. KAWANO, R. KUMASHIRO, K. TAKETANI, Y. KIMURA, H. SAEKI, K. ANDO, S. IDA, E. OKI, E. TOKUNAGA, T. IKEDA, T. KUSUMOTO, Y. MAEHARA (<i>Fukuoka, Japan</i>)	1641
Association between EGFR-TKI Resistance and Efficacy of Radiotherapy for Brain Metastases from <i>EGFR</i> -mutant Lung Adenocarcinoma. H. HIRATA, K. NAKAMURA, N. KUNITAKE, Y. SHIOYAMA, T. SASAKI, S. OHGA, T. NONOSHITA, T. YOSHITAKE, K. ASAI, K. INOUE, A. NAGASHIMA, M. ONO, H. HONDA (<i>Kitakyushu; Fukuoka, Japan</i>)	1649
Phase II Study of Bevacizumab and Temsirolimus Combination Therapy for Recurrent Glioblastoma Multiforme. U. LASSEN, M. SORENSEN, T.B. GAZIEL, B. HASSELBALCH, H.S. POULSEN (<i>Copenhagen, Denmark</i>)	1657
The Role of Completion Surgery After Concurrent Radiochemotherapy in Locally Advanced Stages IB2-IIB Cervical Cancer. E. CHEREAU, C. DE LA HOSSERAYE, M. BALLESTER, L. MONNIER, R. ROUZIER, E. TOUBOUL, E. DARAI (<i>Paris; Marseille, France</i>)	1661
Adipose Tissue Fatty Acid Composition in Greek Patients with Breast Cancer <i>versus</i> Those with Benign Breast Tumors. E. DE BREE, G. MAMALAKIS, E. SANIDAS, C. HATZIS, I. ASKOXYLAKIS, M. DASKALAKIS, V. CHARALAMPAKIS, G. TSIBINOS, D.D. TSIFTSIS, A. KAFATOS (<i>Heraklion, Greece</i>)	1667
HE4 Tissue Expression in Borderline Ovarian Tumors: A Pilot Study by the Tumorbank Ovarian Cancer Network. M. NASSIR, S. DARB-ESFAHANI, R. RICHTER, R. CHEKEROV, C. HALL, M.Z. MUALLEM, C. DENKERT, F. STAMATIAN, C. FOTOPOULOU, J. SEHOULI, E.I. BRAICU (<i>Berlin, Germany; Goteborg, Sweden; Cluj-Napoca, Romania</i>)	1673
Comparison of Calculated Dose by Helical Tomotherapy Treatment Planning Machine and Measured Dose of Radiophotoluminescence Glass Dosimeter in Lung Lesions Using Rando Phantom. H. YAMAZAKI, K. IWAMA, T. NISHIMURA, Y. IWAI, N. AIBE, T. TAKENAKA, S. MIYAKE, E. TANAKA, K. YOSHIDA, Y. OOTA, H. IKENO, S. NAKAMURA, H. OKABE (<i>Kyoto; Uji, Kyoto; Osaka City, Osaka, Japan</i>)	1679
Intensity-modulated Radiation Therapy with Hypoxic Sensitizer AK-2123 (Sanazole) for Glioblastoma Multiforme Using Simultaneous Integrated Boost Technique. H. YAMAZAKI, S. NAKAMURA, T. NISHIMURA, H. OKABE, N. AIBE, K. YOSHIDA, T. KAGIYA (<i>Kyoto; Uji, Kyoto; Takatsuki, Osaka, Japan</i>)	1685
Anatomical Hepatectomy for Hepatocellular Carcinoma in Patients with Preserved Liver Function. T. OCHIAI, H. IKOMA, Y. YAMAMOTO, H. KONISHI, Y. MURAYAMA, A. SHIOZAKI, S. KOMATSU, Y. KURIU, T. KUBOTA, M. NAKANISHI, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, E. OTSUJI (<i>Kyoto, Japan</i>)	1689
Negative Impact of Surgical Site Infection on Long-term Outcomes after Hepatic Resection for Colorectal Liver Metastases. K. HARUKI, H. SHIBA, Y. FUJIWARA, K. FURUKAWA, S. WAKIYAMA, M. OGAWA, Y. ISHIDA, T. MISAWA, K. YANAGA (<i>Tokyo, Japan</i>)	1697
Gene Mutations in Squamous Cell NSCLC: Insignificance of <i>EGFR</i> , <i>KRAS</i> and <i>PIK3CA</i> Mutations in Prediction of EGFR-TKI Treatment Efficacy. O. FIALA, M. PESEK, J. FINEK, L. BENESOVA, Z. BORTLICEK, M. MINARIK (<i>Prague; Brno, Czech Republic</i>)	1705
Small Cell Carcinoma of the Colon Arising in a Carcinoid Tumor. M.W. SAIF (<i>Boston, MA, USA</i>)	1713
Factors Predicting Trastuzumab-related Cardiotoxicity in a Realworld Population of Women with HER2+ Breast Cancer. D. NAUMANN, V. RUSIUS, C. MARGIOTTA, A. NEVILL, A. CARMICHAEL, D. REA, M. SINTLER (<i>Westmidlands; Birmingham; Walsall, UK</i>)	1717

Single-dose Palonosetron and Dose-reduced Regimen of Dexamethasone in Preventing Nausea and Vomiting by Anthracycline-including Chemotherapy in Patients with Early Breast Cancer. U. PACETTI, E. VELTRI, S.I.S. FATTORUSO, F. D'ASSISI CARDILLO, S. EVANGELISTA, F. COGNETTI, A. FABI (<i>Terracina; Latina; Gaeta; Rome, Italy</i>)	1721
Thrombocytosis Has a Negative Prognostic Value in Lung Cancer. A. MARÁZ, J. FURÁK, Z. VARGA, Z. KAHÁN, L. TISZLAVICZ, K. HIDEGHITY (<i>Szeged, Hungary</i>)	1725
Expression of <i>MAGE</i> A1-6 and the Clinical Characteristics of Papillary Thyroid Carcinoma. H.S. LEE, S.W. KIM, J.C. HONG, S.B. JUNG, C.-H. JEON, J.W. PARK, S.Y. PARK, K.D. LEE (<i>Busan; Daegu, Chungju, South Korea</i>)	1731
Acute Oesophageal Toxicity Related to Paclitaxel-based Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer. A. MARÁZ, J. FURÁK, Z. VARGA, E. FODOR, Z. EGYÜD, E. BORZÁSI, Z. KAHÁN, R. PÁLFÖLDI, L. TISZLAVICZ, K. HIDEGHÉTY (<i>Szeged, Hungary</i>)	1737
Traditional Serrated Adenoma in a Patient with Barrett's Esophagus. C.A. RUBIO, K. TANAKA, R. BEFRITS (<i>Stockholm, Sweden</i>)	1743
Factors Predictive of Recurrence after Surgery for Gastric Cancer Followed by Adjuvant S-1 Chemotherapy. T. WADA, C. KUNISAKI, S. HASEGAWA, R. TAKAGAWA, M. MOMIYAMA, T. KOSAKA, H. MAKINO, H.A. ONO, T. OSHIMA, H. AKIYAMA, I. ENDO (<i>Yokohama, Japan</i>)	1747
Adenocarcinoma ExGoblet Cell Carcinoid in a Renal Transplant Patient: A Case Report and Review of the Literature. M.W. SAIF (<i>Boston, MA, USA</i>)	1753
Cone Beam Computed Tomography in the Differential Diagnosis of Mental Neuropathy (Numb Chin Syndrome) in Metastatic Colon Cancer. R.E. FRIEDRICH, M. HEILAND, A.T. ASSAF, B. RIECKE (<i>Hamburg, Germany</i>)	1757
Airway Stenting for Tracheal Obstruction Due to Lymph Node Metastasis of Hepatocellular Carcinoma. Y. HAMAI, J. HIHARA, Y. AOKI, J. TAOMOTO, I. KISHIMOTO, Y. KOBAYASHI, Y. MIYATA, H. AIKATA, K. CHAYAMA, M. OKADA (<i>Hiroshima, Japan</i>)	1761
Response to Chemotherapy in Metastatic Colorectal Cancer After Exposure to Oxaliplatin in the Adjuvant Setting. L.-C. MOREAU, R. RAJAN, M.P. THIRLWELL, T. ALCINDOR (<i>Montreal, QC, Canada</i>).....	1765
Usefulness of Circulating Tumor Cells after Preliminary Chemotherapy for Prediction of Response to Further Anticancer Therapy in Patients with Initially Unresectable Metastatic Colorectal Cancer. K. NEKI, H. KAWAHARA, K. WATANABE, Y. TOYAMA, T. AKIBA, K. YANAGA (<i>Chiba; Tokyo, Japan</i>).....	1769
Hypofractionated Stereotactic Radiotherapy with the Hypoxic Sensitizer AK-2123 (Sanazole) for Reirradiation of Brain Metastases: A Preliminary Feasibility Report. H. YAMAZAKI, S. NAKAMURA, T. NISHIMURA, N. KODANI, T. TSUBOKURA, T. KIMOTO, H. SIHOMI, N. AIBE, K. YOSHIDA, M. KOIZUMI, T. KAGIYA (<i>Kyoto; Uji, Kyoto; Takatsuki; Suita, Osaka, Japan</i>)	1773
Meeting Report: Leaders in Translational Cancer Research Meet in Udaipur, a Historical Town of India: An International Symposium on Translational Cancer Research: Cancer Prevention. Udaipur, Rajasthan, India, December 16-19, 2011. V. GANDHI, K. MEHTA, S. PATHAK, B.B. AGGARWAL (<i>Houston, TX, USA</i>).....	1777
Errata	1783

Number 5*Reviews*

Current Status in Chemotherapy for Advanced Pancreatic Adenocarcinoma. H. CAO, D. LE, L.-X. YANG
(*San Francisco, CA, USA*) 1785

Denosumab and Anti-angiogenetic Drug-related Osteonecrosis of the Jaw: An Uncommon but Potentially
Severe Disease. S. SIVOLELLA, F. LUMACHI, E. STELLINI, L. FAVERO (*Padova, Italy*) 1793

Experimental Studies

Hydrogen Peroxide Enhances Radiation-induced Apoptosis and Inhibition of Melanoma Cell Proliferation. Y.
FANG, B.J. MOORE, Q. BAI, K.M. COOK, E.J. HERRICK, M.B. NICHOLL (*Columbia, MO, USA*) 1799

Premalignant Lesions Skew Spleen Cell Responses to Immune Modulation by Adipocytes. S.A. VIELMA,
R.L. KLEIN, C.A. LEVINGSTON, M.R.I. YOUNG (*Charleston, SC, USA; Merida, Venezuela*) 1809

Safety and Efficacy Field Study of Artesunate for Dogs with Non-resectable Tumours. G.R. RUTTEMAN,
S.A. ERICH, J.A. MOL, B. SPEE, G.C.M. GRINWIS, L. FLECKENSTEIN, C.A. LONDON, T. EFFERTH
(*Utrecht; Wageningen, Netherlands; Iowa City, IA; Columbus, OH, USA; Mainz, Germany*) 1819

Ellagic Acid, a Dietary Polyphenol, Selectively Cytotoxic to HSC-2 Oral Carcinoma Cells. J.H.
WEISBURG, A.G. SCHUCK, S.E. REISS, B.J. WOLF, S.R. FERTEL, H.L. ZUCKERBRAUN, H.
BABICH (*New York, NY, USA*) 1829

Salmonella typhimurium A1-R Tumor Targeting in Immunocompetent Mice Is Enhanced by a Traditional
Chinese Medicine Herbal Mixture. Y. ZHANG, N. ZHANG, S. SU, R.M. HOFFMAN, M. ZHAO (*San
Diego, CA, USA; Shanghai, China*) 1837

The mTOR Inhibitor RAD001 Potentiates Autophagic Cell Death Induced by Temozolomide in a Glioblastoma
Cell Line. E. JOSSET, H. BURCKEL, G. NOËL, P. BISCHOFF (*Strasbourg Cedex, France*) 1845

Identification of HLA Class I-binding Peptides Derived from Unique Cancer-associated Proteins by Mass
Spectrometric Analysis. Y. KAMATA, A. KUHARA, T. IWAMOTO, K. HAYASHI, S. KOIDO, T.
KIMURA, S. EGAWA, S. HOMMA (*Tokyo, Japan*) 1853

Antiproliferative and Apoptosis-inducing Activity of Curcumin against Human Gallbladder Adenocarcinoma
Cells. M. ONO, T. HIGUCHI, M. TAKESHIMA, C. CHEN, S. NAKANO (*Fukuoka, Japan*) 1861

The Indole-3-carbinol Cyclic Tetrameric Derivative CTet Synergizes with Cisplatin and Doxorubicin in
Triple-negative Breast Cancer Cell Lines. M. DE SANTI, L. GALLUZZI, A. DURANTI, M. MAGNANI,
G. BRANDI (*Urbino, Italy*) 1867

Broussonflavonol B Restricts Growth of ER-negative Breast Cancer Stem-like Cells. M. GUO, M. WANG,
X. ZHANG, H. DENG, Z.-Y. WANG (*Omaha, NE, USA*) 1873

Changes in CO₂ Concentration Increase the Invasive Ability of Colon Cancer Cells. S. OBATA, T. GOI, T.
NAKAZAWA, Y. KIMURA, K. KATAYAMA, A. YAMAGUCHI (*Fukui, Japan*) 1881

Blood Oxygen Level-dependent MRI for Evaluation of Early Response of Liver Tumors to
Chemoembolization: An Animal Study. J.W. CHOI, H. KIM, H.-C. KIM, Y. LEE, J. KWON, R.-E. YOO,
H.R. CHO, S.H. CHOI, J.W. CHUNG (*Seoul, Republic of Korea*) 1887

Increased Plasma Caveolin-1 Levels Are Associated with Progression of Prostate Cancer among Japanese
Men. S. SUGIE, S. MUKAI, H. TSUKINO, Y. TODA, T. YAMAUCHI, I. NISHIKATA, Y. KURODA, K.
MORISHITA, T. KAMOTO (*Miyazaki; Tenri, Nara, Japan*) 1893

Mutations in Adenosine Deaminase-like (ADAL) Protein Confer Resistance to the Antiproliferative Agents <i>N</i> ₆ -Cyclopropyl-PMEDAP and GS-9219. C.R. FREY, G. ANDREI, I. VOTRUBA, C. CANNIZZARO, B. HAN, W. FUNG, M. HUNG, X. LIU, R. GELEZIUNAS, P. FITEN, G. OPDENAKKER, R. SNOECK, T. CIHLAR (<i>Foster City, CA, USA; Leuven, Belgium; Prague, Czech Republic</i>).....	1899
Angiogenesis of Lung Cancer Utilizes Existing Blood Vessels Rather than Developing New Vessels Using Signals from Carcinogenesis. H. URAMOTO, S. YAMADA, F. TANAKA (<i>Kitakyushu, Japan</i>)	1913
Expression of Bone Morphogenetic Protein-10 (BMP10) in Human Urothelial Cancer of the Bladder and its Effects on the Aggressiveness of Bladder Cancer Cells <i>In Vitro</i> . N. ZHANG, L. YE, L. WU, X. DENG, Y. YANG, W.G. JIANG (<i>Beijing; Xinjiang, P.R. China; Cardiff, UK</i>)	1917
Tumor-derived Tenascin-C Promotes the Epithelial– Mesenchymal Transition in Colorectal Cancer Cells. Y. TAKAHASHI, G. SAWADA, J. KURASHIGE, T. MATSUMURA, R. UCHI, H. UEO, M. ISHIBASHI, Y. TAKANO, S. AKIYOSHI, T. IWAYA, H. EGUCHI, T. SUDO, K. SUGIMACHI, H. YAMAMOTO, Y. DOKI, M. MORI, K. MIMORI (<i>Beppu; Suita, Japan</i>)	1927
<i>Thymidylate Synthase</i> Gene Copy Number as a Predictive Marker for Response to Pemetrexed Treatment of Lung Adenocarcinoma. D. KASAI, H. OZASA, T. OGURI, M. MIYAZAKI, T. UEMURA, O. TAKAKUWA, E. KUNII, H. OHKUBO, K. MAENO, A. NIIMI (<i>Nagoya, Japan</i>)	1935
Quercetin Inhibits Migration and Invasion of SAS Human Oral Cancer Cells through Inhibition of NF- κ B and Matrix Metalloproteinase-2/-9 Signaling Pathways. W.-W. LAI, S.-C. HSU, F.-S. CHUEH, Y.-Y. CHEN, J.-S. YANG, J.-P. LIN, J.-C. LIEN, C.-H. TSAI, J.-G. CHUNG (<i>Taichung, Taiwan, ROC</i>)	1941
Chemotherapeutic Alteration of VEGF, PDGF and PDGFR α/β Expression Under 5-FU vs. Docetaxel in HPV-transformed Squamous Cell Carcinoma Compared to HPV-negative HNSCC <i>In Vitro</i> . C. ADERHOLD, C. UMBREIT, A. FABER, A. SAUTER, J.U. SOMMER, R. BIRK, P. ERBEN, R.-D. HOFHEINZ, J. STERN-STRÄETER, K. HÖRMANN, J.D. SCHULTZ (<i>Mannheim, Germany</i>)	1951
Influence of Sex Differences on the Progression of Cancer-induced Bone Pain. S. FALK, M. ULDALL, C. APPEL, M. DING, A.-M. HEEGAARD (<i>Copenhagen; Odense, Denmark</i>)	1963
Evaluation of E-Cadherin, Ki-67 and Lymphatic Vessel Invasion in Abdominal Metastases of Human Breast Cancer. M. DEBALD, C. KAISER, A. ABRAMIAN, H.U. SCHILDHAUS, P. LOCHER, M. WOLFGARTEN, W. KUHN, M. BRAUN (<i>Bonn; Wittlich; Munich, Germany</i>)	1971
Mitogen-inducible Gene-2 (MIG2) and Migfilin Expression Is Reduced in Samples of Human Breast Cancer. V. GKRETSI, V. PAPANIKOLAOU, L.C. ZACHARIA, E. ATHANASSIOU, C. WU, A. TSEZOU (<i>Larissa, Greece; Pittsburgh, PA, USA</i>).....	1977
Characterization of Low Molecular Weight Protein Tyrosine Phosphatase Isoforms in Human Breast Cancer Epithelial Cell Lines. I. ALHO, L. COSTA, M. BICHO, C. COELHO (<i>Lisbon, Portugal</i>)	1983
Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, and Gastric Cancer Cell Lines in a Short-term Exposure Model of Chemosaturation Therapy by Percutaneous Hepatic Perfusion. R.P. UZGARE, T.P. SHEETS, D.S. JOHNSTON (<i>Queensbury, NY, USA</i>)	1989
Human Lung Cancer-associated Fibroblasts Enhance Motility of Non-small Cell Lung Cancer Cells in Co-culture. S.-H. KIM, C. CHOE, Y.-S. SHIN, M.-J. JEON, S.-J. CHOI, J. LEE, G.-Y. BAE, H.-J. CHA, J. KIM (<i>Seoul, Republic of Korea</i>)	2001
<i>Ex Vivo</i> Expansion of Natural Killer Cells Using Cryopreserved Irradiated Feeder Cells. H.-J. BAEK, J.-S. KIM, M. YOON, J.-J. LEE, M.-G. SHIN, D.-W. RYANG, H. KOOK, S.-K. KIM, D. CHO (<i>Gwangju; Jeollanamdo; Yesan, Republic of Korea</i>)	2011

Effects of Two Disiloxanes ALIS-409 and ALIS-421 on Chemoprevention in Model Experiments. H. TOKUDA, T. MAOKA, N. SUZUKI, J. HOHMANN, A. VASAS, H. ENGI, I. MUCSI, U. OLSZEWSKI, G. HAMILTON, L. AMARAL, J. MOLNAR (<i>Kanazawa; Kyoto, Japan; Szeged, Hungary; Vienna, Austria</i>)	2021
Regulation of Target Genes of PAX3–FOXO1 in Alveolar Rhabdomyosarcoma. E.H. AHN (<i>Philadelphia, PA; Seattle, WA, USA</i>).....	2029
Antifolate Response in Replication Arrest Mutants of <i>Saccharomyces cerevisiae</i> . K. DORNFELD (<i>Duluth, MN, USA</i>)	2037
Comparison of Antitumor Effects of Native and Recombinant Human Interferon- α on Non-small Cell Lung Cancer Cells. G. ŠANTAK, M. ŠANTAK, D. FORČIĆ (<i>Požega; Zagreb, Croatia</i>).....	2043
<i>Clinical Studies</i>	
Autologous Tumor Lysate-pulsed Dendritic Cell Immunotherapy for Pediatric Patients with Newly Diagnosed or Recurrent High-grade Gliomas. J.L. LASKY III, E.H. PANOSYAN, A. PLANT, T. DAVIDSON, W.H. YONG, R.M. PRINS, L.M. LIAU, T.B. MOORE (<i>Torrance; Los Angeles, CA, USA</i>)	2047
Prolonged Survival Patients with Breast Cancer-related Leptomeningeal Metastases. E. LE RHUN, S. TAILLIBERT, F. ZAIRI, D. PANNIER, T. BOULANGER, C. ANDRE, J.L. CAZIN, F. DUBOIS, J. BONNETERRE, M.C. CHAMBERLAIN (<i>Lille; Paris, France; Seattle, WA, USA</i>)	2057
VEGFR1 and NRP1 Endothelial Expressions Predict Distant Relapse after Radical Prostatectomy in Clinically Localized Prostate Cancer. M. TALAGAS, A. UGUEN, R. GARLANTEZEC, G. FOURNIER, L. DOUCET, E. GOBIN, P. MARCORELLES, A. VOLANT, M. DE BRAEKELEER (<i>Brest, France</i>)	2065
Transarterial Chemoembolization Using DEBIRI for Treatment of Hepatic Metastases from Colorectal Cancer. G. NARAYANAN, K. BARBERY, R. SUTHAR, G. GUERRERO, G. ARORA (<i>Miami, FL, USA</i>)	2077
The Implementation of Minimally-invasive Esophagectomy Does Not Impact Short-term Outcome in a High-volume Center. K. SCHWAMEIS, A. BA-SSALAMAH, F. WRBA, P. BIRNER, G. PRAGER, M. HEJNA, R. SCHMID, R. ASARI, J. ZACHERL, S.F. SCHOPPMANN (<i>Vienna, Austria</i>)	2085
D-Dimer Elevation and Paresis Predict Thromboembolic Events During Bevacizumab Therapy for Recurrent Malignant Glioma. M. MISCH, M. CZABANKA, J. DENGLER, M. STOFFELS, G. AUF, P. VAJKOCZY, F. STOCKHAMMER (<i>Berlin; Göttingen, Germany</i>)	2093
Role of Marker Lesion when Applying Intravesical Instillations of IL-2 for Non-muscle-invasive Bladder Cancer Comparison of the Therapeutic Effects in Two Pilot Studies. W. DEN OTTER, R.J. VAN MOORSELAAR, J.J. JACOBS, R. TER HAAR, J.W. KOTEN, Z. DOBROWOLSKI, W. LIPCZYNSKI, V. PAŠUKONIENĖ, D. CHARACIEJUS, F. JANKEVIČIUS, R. EIDUKEVIČIUS, T.M. DE REIJKE (<i>Amsterdam, Netherlands; Krakow, Poland; Vilnius, Lithuania</i>)	2099
Clinical Significances of Cancer Stem Cells Markers in Patients with Intrahepatic Cholangiocarcinoma who Underwent Hepatectomy. A. NANASHIMA, G. HATACHI, T. TSUCHIYA, H. MATSUMOTO, J. ARAI, T. ABO, G. MURAKAMI, T. TOMINAGA, K. TAKAGI, T. NAGAYASU (<i>Nagasaki, Japan</i>)	2107
A Trial of Autologous <i>Ex vivo</i> -expanded NK Cell-enriched Lymphocytes with Docetaxel in Patients with Advanced Non-small Cell Lung Cancer as Second- or Third-line Treatment: Phase IIa Study. Y.J. YANG, J.C. PARK, H.K. KIM, J.H. KANG, S.Y. PARK (<i>Daejeon; Suwon; Seoul, Republic of Korea</i>).....	2115
Clinical Significance of Expression of Cancer/testis Antigen and Down-regulation of HLA Class-I in Patients with Stage I Non-small Cell Lung Cancer. T. HANAGIRI, Y. SHIGEMATSU, S. SHINOHARA, M. TAKENAKA, S. OKA, Y. CHIKAISHI, Y. NAGATA, T. BABA, H. URAMOTO, T. SO, S. YAMADA (<i>Kitakyushu, Japan</i>)	2123

<p><i>KRAS</i> Mutations in Patients with Colorectal Cancer As Detected by High-resolution Melting Analysis and Direct Sequencing. K. AKIYOSHI, Y. YAMADA, Y. HONMA, S. IWASA, K. KATO, T. HAMAGUCHI, Y. SHIMADA, H. TANIGUCHI, K. FURUTA (<i>Tokyo, Japan</i>)</p>	2129
<p>Synchronous Quadruple Primary Tumors of Thyroid, Breast, Pancreas, and Stomach: A Case Report. J.-S. KIM, C.-Y. CHUNG, H.-C. PARK, D.-S. MYUNG, S.-B. CHO, W.-S. LEE, J.-J. MIN, Y.-E. JOO (<i>Gwangju, Republic of Korea</i>)</p>	2135
<p>Evaluation of Current Prognostic and Predictive Markers in Breast Cancer: A Validation Study of Tissue Microarrays. A. BATISTATOU, D. TELEVANTOU, M. BOBOS, A.G. ELEFThERAKI, E. KOUVARAS, S. CHRISAFI, G.K. KOUKOULIS, V. MALAMOU-MITSI, G. FOUNTZILAS (<i>Ioannina; Thessaloniki; Athens; Larissa, Greece</i>)</p>	2139
<p>The Lynch Syndrome: A Management Dilemma. P. PALUMBO, C. AMATUCCI, B. PEROTTI, C. DEZZI, M. GIROLAMI, G. ILLUMINATI, A.M. ANGELICI (<i>Rome, Italy</i>)</p>	2147
<p>Radiation Therapy in the Treatment of HIV-related Kaposi's Sarcoma. V. DONATO, R. GUARNACCIA, J. DOGNINI, G. DE PASCALIS, C. CARUSO, R. BELLAGAMBA, A. MORRONE (<i>Rome, Italy</i>)</p>	2153
<p>Surgical Resection of Brain Metastases from Breast Cancer in the Modern Era: Clinical Outcome and Prognostic Factors. E. TABOURET, P. METELLUS, A. TALLET-RICHARD, D. FIGARELLA-BRANGER, E. CHARAFFE-JAUFFRET, P. VIENS, A. GONÇALVES (<i>Marseille, France</i>)</p>	2159
<p>Complete Necrosis of a Giant Cell Tumor with High Expression of PPARγ: A Case Report. A. TAKEUCHI, N. YAMAMOTO, H. NISHIDA, H. KIMURA, H. IKEDA, H. TSUCHIYA (<i>Kanazawa, Japan</i>)</p>	2169
<p>Radiotherapy in the Management of Pancreatic Neuroendocrine Tumors (PNET): Experience at Three Institutions. M.W. SAIF, R. OVE, J. NG, S. RUSSO (<i>Boston, MA; New York, NY; Mobile, AL, USA</i>)</p>	2175
<p>The mRNA Expression of Inhibitors of DNA Binding 1 and 2 Is Associated with Advanced Tumour Stage and Adverse Clinical Outcome in Human Breast Cancer. U. WAZIR, W.G. JIANG, A.K. SHARMA, R.F. NEWBOLD, K. MOKBEL (<i>London; Cardiff, Wales, UK</i>)</p>	2179
<p>P14^{ARF} Is Down-regulated During Tumour Progression and Predicts the Clinical Outcome in Human Breast Cancer. U. WAZIR, W.G. JIANG, H. YASAEI, H. LINNE, R.F. NEWBOLD, K. MOKBEL (<i>London; Cardiff, Wales, UK</i>)</p>	2185
<p>Contribution of Immunohistochemical Profile in Assessing Histological Grade of Endometrial Cancer. G. CANLORBE, E. LAAS, S. BENDIFALLAH, E. DARAÍ, M. BALLESTER (<i>Paris, France</i>).....</p>	2191
<p>Postoperative Radiotherapy for Uterine Cervical Cancer: Impact of Lymph Node and Histological Type on Survival. G. KASUYA, K. OGAWA, S. IRAHA, Y. NAGAI, M. HIRAKAWA, T. TOITA, Y. KAKINOHANA, W. KUDAKA, M. INAMINE, T. ARIGA, Y. AOKI, S. MURAYAMA (<i>Okinawa; Osaka, Japan</i>)</p>	2199
<p>Missense Polymorphisms in XIAP-Associated Factor-1 (<i>XAF1</i>) and Risk of Papillary Thyroid Cancer: Correlation with Clinicopathological Features. S.K. KIM, H.J. PARK, H. SEOK, H.S. JEON, J.W. KIM, J.-H. CHUNG, K.H. KWON, S.-H. WOO, B.W. LEE, H.H. BAIK (<i>Seoul; Anyang, Republic of Korea</i>)</p>	2205
<p>Relation Between Antibody to Hepatitis B Core Antigen and Survival after Curative Therapy for Non-B Non-C Hepatocellular Carcinoma. H. NISHIKAWA, Y. OSAKI, A. ARIMOTO, R. KITA, T. KIMURA (<i>Osaka, Japan</i>).....</p>	2211
<p>Normalization of Serum p53 Antibody Levels in Patients after Curative Resection for Colorectal Cancer. H. KAWAHARA, K. WATANABE, H. ENOMOTO, Y. TOYAMA, T. AKIBA, K. YANAGA (<i>Chiba; Tokyo, Japan</i>)</p>	2221

Prognostic Factors For Male Breast Cancer: Similarity to Female Counterparts. E. YU, L. STITT, O. VUJOVIC, K. JOSEPH, A. ASSOULINE, J. AU, J. YOUNUS, F. PERERA, P. TAI (<i>London, ON; Edmonton, AB; Regina, SK, Canada; Paris, France; Hong Kong, China</i>).....	2227
Relationship Between Circulating Tumor Cells and Peripheral T-Cells in Patients with Primary Breast Cancer. I. GRUBER, N. LANDENBERGER, A. STAEBLER, M. HAHN, D. WALLWIENER, T. FEHM (<i>Tübingen; Freiburg, Germany</i>)	2233
Monitoring of Circulating Tumor Cells in Patients Undergoing Surgery for Hepatic Metastases from Colorectal Cancer. M. PESTA, J. FICHTL, V. KULDA, O. TOPOLCAN, V. TRESKA (<i>Prague, Czech Republic</i>)	2239
ABSTRACTS OF THE 23rd ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO). 9-11 June, 2013, Florence, Italy	2245
Errata	2343
Book Reviews	2345
Announcements	2351

Number 6

Reviews

Junctional Adhesion Molecules in Cerebral Endothelial Tight Junction and Brain Metastasis. W. JIA, T.A. MARTIN, G. ZHANG, W.G. JIANG (<i>Beijing, PR China; Cardiff, UK</i>).....	2353
Inguinal Canal Tumors of Adulthood. V. VAGNONI, E. BRUNOCILLA, R. SCHIAVINA, M. BORGHESI, G. PASSARETTI, G. GENTILE, M. FIORENTINO, G. MARTORANA (<i>Bologna, Italy</i>)	2361
Endoscopic and Endobronchial Ultrasound-guided Needle Aspiration in the Mediastinal Staging of Non-small Cell Lung Cancer. T. RAPTAKIS, P. BOURA, S. TSIMPOUKIS, I. GKIOZOS, K.N. SYRIGOS (<i>Ierapetra; Athens, Greece</i>).....	2369
Is there a Benefit from Addiction to Anti-VEGF Therapy in Patients with Colorectal Cancer? M.W. SAIF (<i>Boston, MA, USA</i>)	2377

Experimental Studies

Expression of VEGF and Its receptors VEGFR1/VEGFR2 is Associated with Invasiveness of Bladder Cancer. P.K. KOPPARAPU, S.A. BOORJIAN, B.D. ROBINSON, M. DOWNES, L.J. GUDAS, N.P. MONGAN, J.L. PERSSON (<i>Malmö, Sweden; Rochester, MN; New York, NY, USA; Nottingham, UK</i>)	2381
Acetaminophen Enhances Cisplatin- and Paclitaxel-mediated Cytotoxicity to SKOV3 Human Ovarian Carcinoma. Y.J. WU, A.J. NEUWELT, L.L. MULDOON, E.A. NEUWELT (<i>Portland, OR, USA</i>)	2391
Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Requires E-Cadherin in Esophageal Cancer and Malignant Pleural Mesothelioma. H.-W. XIN, J.-H. YANG, D.M. NGUYEN (<i>Bethesda, MD; Miami, FL, USA; Hubei, PR China</i>).....	2401 2409
Central Role of β -Catenin in Anticancer Effects of Cardiac Hormones. W.P. SKELTON IV, M. SKELTON, D.L. VESELY (<i>Tampa, FL, USA</i>)	

Hedgehog Targeting by Cyclopamine Suppresses Head and Neck Squamous Cell Carcinoma and Enhances Chemotherapeutic Effects. C. MOZET, M. STOEHR, K. DIMITROVA, A. DIETZ, G. WICHMANN (<i>Leipzig, Germany</i>)	2415
Hyaluronic Acid-decorated PLGA-PEG Nanoparticles for Targeted Delivery of SN-38 to Ovarian Cancer. K.K. VANGARA, J.L. LIU, S. PALAKURTHI (<i>Kingsville, TX, USA</i>)	2425
Targeting Renal Cancer with a Combination of WNT Inhibitors and a Bi-Functional Peptide. C.M. KOLLER, Y. KIM, I.G.H. SCHMIDT-WOLF (<i>Bonn, Germany</i>)	2435
IGF-IEc Expression Is Associated with Advanced Clinical and Pathological Stage of Prostate Cancer. A. SAVVANI, C. PETRAKI, P. MSAOUEL, E. DIAMANTI, I. XOXAKOS, M. KOUTSILIERIS (<i>Athens; Piraeus, Greece; Bronx, NY, USA</i>)	2441
Changes in Thymidine Phosphorylase Gene Expression Related to Treatment of Rectal Cancer. K. DERWINGER, E.B. LINDSKOG, E. PALMQVIST, Y. WETTERGREN (<i>Gothenburg, Sweden</i>)	2447
Assessment of Planning Target Volume Margin for a Small Number of Vertebral Metastatic Lesions Using Image-guided Intensity-modulated Radiation Therapy by Helical Tomotherapy. T. NISHIMURA, H. YAMAZAKI, K. IWAMA, T. KOTANI, Y. OOTA, H. AIBE, S. NAKAMURA, H. IKENO, K. YOSHIDA, F. ISOHASHI, H. OKABE (<i>Uji; Kyoto; Moriguchi; Takatsuki; Suita, Osaka, Japan</i>)	2453
Unexpected Alteration of β -Catenin and c-KIT Expression by 5-FU and Docetaxel in p16-positive Squamous Cell Carcinoma Compared to HPV-negative HNSCC Cells <i>In Vitro</i> . C. UMBREIT, C. ADERHOLD, A. FABER, J.U. SOMMER, A. SAUTER, R.-D. HOFHEINZ, J. STERN-STRÄTER, K. HOERMANN, J.D. SCHULTZ (<i>Mannheim, Germany</i>)	2457
Lipid Profiles for HER2-positive Breast Cancer. I.C. KIM, J.H. LEE, G. BANG, S.H. CHOI, Y.H. KIM, K.P. KIM, H.K. KIM, J. RO (<i>Gyeonggi; Seoul; Ochang; Daejeon, Republic of Korea</i>)	2467
Antiestrogens Suppress Effects of Transforming Growth Factor- β in Breast Cancer Cells <i>via</i> the Signaling Axis Estrogen Receptor- α and Y-box Binding Protein-1. S.L. POPP, C. JOFFROY, M.B. STOPE, M.B. BUCK, P. FRITZ, C. KNABBE (<i>Stuttgart; Greifswald; Bad Oeynhausen, Germany</i>)	2473
Cytokine Changes in Response to Radio-/chemotherapeutic Treatment in Head and Neck Cancer. S. REERS, A.-C. PFANNERSTILL, D. RADES, R. MAUSHAGEN, M. ANDRATSCHKE, R. PRIES, B. WOLLENBERG (<i>Lübeck; Dachau, Germany</i>)	2481
The AutoDiSC: Development and Validation of a Novel Chemotherapy Sensitivity and Resistance Assay. T. SCHINKÖTHE, D. THIRUCHITTAMPALAM, A. SCHMIDT, N. BOMHOLT, P. STAIB (<i>Munich; Cologne; Eschweiler, Germany</i>)	2491
Combination of CYP Inhibitor with MEK/ERK Inhibitor Enhances the Inhibitory Effect on ERK in BRAF Mutant Colon Cancer Cells. S.M. LIM, J.W. HWANG, J.B. AHN, S.K. BAE, C.H. PARK, K.-Y. KIM, S.Y. RHA, H.C. CHUNG, J.K. ROH, S.J. SHIN (<i>Seoul, Republic of Korea</i>)	2499
Correlation of Phosphorylated HER2 with Clinicopathological Characteristics and Efficacy of Trastuzumab Treatment for Breast Cancer. S. RAMIĆ, K. ASIĆ, M. PERIĆ BALJA, F. PAIĆ, V. BENKOVIĆ, F. KNEŽEVIĆ (<i>Zagreb, Croatia</i>)	2509
Design, Synthesis and <i>In Vitro</i> Anticancer Evaluation of a Stearic Acid-based Ester Conjugate. A.A. KHAN, A.M. ALANAZI, M. JABEEN, A. CHAUHAN, A.S. ABDELHAMEED (<i>Riyadh, Saudi Arabia; Aligarh, India; Grand Forks, ND, USA</i>)	2517
Immunological Characterization of Glioblastoma Cells for Immunotherapy. T.-Y. JUNG, Y.-D. CHOI, Y.-H. KIM, J.-J. LEE, H.-S. KIM, J.-S. KIM, S.-K. KIM, S. JUNG, D. CHO (<i>Hwasun; Jeollanam-do, Gwangju; Yesan, Republic of Korea</i>)	2525

Oral Chemoprevention of Skin Cancer in Mice by Benzophenone Sunscreens Dioxybenzone and Octabenzone in Drinking Water. G.S. RAO, H. TOKUDA, E. ICHIISHI, M. TAKASAKI, A. IIDA, N. SUZUKI, T. KONOSHIMA, G.J. KAPADIA (<i>Streamwood, IL; Washington, DC, USA; Ishikawa; Tochigi; Nara; Chiba, Japan</i>).....	2535
Cannabinoid Receptor Agonist as an Alternative Drug in 5-Fluorouracil-resistant Gastric Cancer Cells. X.-S. XIAN, H. PARK, M.-G. CHOI, J.M. PARK (<i>Seoul; Republic of Korea; Yantai, Shandong, PR China</i>).....	2541
Lack of Relevance of <i>HIF-1α</i> Polymorphisms in Breast Cancer in a Portuguese Population. A.L. RIBEIRO, J.F. GASPAR, T. PEREIRA, V. RIBEIRO (<i>Faro; Lisbon, Portugal; Stockholm, Sweden</i>)	2549
Up-regulation of DDX39 in Human Malignant Pleural Mesothelioma Cell Lines Compared to Normal Pleural Mesothelial Cells. Y. KURAMITSU, W. TOMINAGA, B. BARON, K. TOKUDA, Y. WANG, T. KITAGAWA, K. NAKAMURA (<i>Ube, Yamaguchi, Japan</i>)	2557
Unique MicroRNA Expression Profiles in Cervical Cancer. K. GOCZE, K. GOMBOS, K. JUHASZ, K. KOVACS, B. KAJTAR, M. BENCZIK, P. GOCZE, B. PATCZAI, I. ARANY, I. EMBER (<i>Pecs; Budapest, Hungary; Jackson, MS, USA</i>)	2561
<i>Clinical Studies</i>	
Alcohol and <i>HER2</i> Polymorphisms as Risk Factor for Cardiotoxicity in Breast Cancer Treated with Trastuzumab. J. LEMIEUX, C. DIORIO, M.-A. CÔTÉ, L. PROVENCHER, F. BARABÉ, S. JACOB, C. ST-PIERRE, É. DEMERS, R. TREMBLAY-LEMAY, C. NADEAU-LAROCHELLE, A. MICHAUD, C. LAFLAMME (<i>Quebec, QC, Canada</i>).....	2569
Novel Technique for Dissection of Subcarinal and Main Bronchial Lymph Nodes Using a Laparoscopic Transhiatal Approach for Esophageal Cancer. A. SHIOZAKI, H. FUJIWARA, H. KONISHI, R. MORIMURA, Y. MURAYAMA, S. KOMATSU, Y. KURIU, H. IKOMA, T. KUBOTA, M. NAKANISHI, D. ICHIKAWA, K. OKAMOTO, C. SAKAKURA, E. OTSUJI (<i>Kyoto, Japan</i>)	2577
The Role of Trastuzumab in the Management of Salivary Ductal Carcinomas. A.J. PERISSINOTTI, M.L. PIERCE, M.B. PACE, A. EL-NAGGAR, M.S. KIES, M. KUPFERMAN (<i>Houston, TX; Salt Lake City, UT; Washington, DC, USA</i>).....	2587
Carboxy-terminal Telopeptide (CTX) and Amino-terminal Propeptide (PINP) of Type I Collagen as Markers of Bone Metastases in Patients with Non-small Cell Lung Cancer. F. LUMACHI, D.A. SANTEUFEMIA, A. DEL CONTE, F. MAZZA, R. TOZZOLI, G.B. CHIARA, S.M. M. BASSO (<i>Padova; Pordenone, Italy</i>).....	2593
Incidence and Survival in Sarcoma in the United States: A Focus on Musculoskeletal Lesions. V.Y. NG, T.J. SCHARSCHMIDT, J.L. MAYERSON, J.L. FISHER (<i>Columbus, OH, USA</i>).....	2597
Prognostic Value of Complete Response in Patients with Muscle-invasive Bladder Cancer Undergoing Concurrent Chemoradiotherapy. C.-E. WU, Y.-C. LIN, J.-H. HONG, C.-K. CHUANG, S.-T. PANG, C.-C. LIAW (<i>Taoyuan, Taiwan, ROC</i>).....	2605
Wide-field Pulsed Reduced Dose Rate Radiotherapy (PRDR) for Recurrent Ependymoma in Pediatric and Young Adult Patients. P. MOHINDRA, H.I. ROBINS, W.A. TOMÉ, L. HAYES, S.P. HOWARD (<i>Madison, WI; Bronx, NY, USA</i>)	2611
A Pilot Study of Salvage Irinotecan Monotherapy for Advanced Biliary Tract Cancer. T. SASAKI, H. ISAYAMA, Y. NAKAI, N. TAKAHARA, Y. SATOH, D. TAKAI, H. KOGURE, N. YAMAMOTO, K. HIRANO, M. TADA, Y. YATOMI, K. KOIKE (<i>Tokyo, Japan</i>).....	2619
Weekly Paclitaxel – An Effective Treatment for Advanced Breast Cancer. P. KELLOKUMPU-LEHTINEN, T. TUUNANEN, R. ASOLA, L. ELOMAA, M. HEIKKINEN, R. KOKKO, R. JÄRVENPÄÄ, I. LEHTINEN, A. MAICHE, J. KALEVA-KEROLA, M. HUUSKO, K. MÖYKKYNNEN, T. ALA-LUHTALA (<i>Tampere; Pori; Turku; Oulu; Hämeenlinna; Rovaniemi; Kemi; Kajaani; Lappeenranta; Seinäjoki, Finland</i>)	2623

Combination Phase II Study of Weekly Paclitaxel and 5'-DFUR for Unresectable or Recurrent Gastric Cancer. S. YOSHINO, T. FURUYA, R. SHIMIZU, H. OZASA, T. NISHIMURA, S. FUKUDA, T. KAWAOKA, S. HAZAMA, M. OKA (<i>Ube; Shimonoseki; Yamaguchi, Yamaguchi, Japan</i>)	2629
Primary Neuroendocrine Carcinoma of the Appendix: A Case Report and Review of the Literature. K. TOMIOKA, Y. FUKOE, Y. LEE, M. LEE, Y. WADA, T. AOKI, M. MURAKAMI (<i>Ota, Gunma; Tokyo, Japan</i>)	2635
An Isolated Penile Mass in a Young Adult Turned Out To Be A Primary Marginal Zone Lymphoma of the Penis. A Case Report and a Review of Literature. G. GENTILE, A. BROCCOLI, E. BRUNOCILLA, R. SCHIAVINA, M. BORGHESI, D. ROMAGNOLI, L. BIANCHI, E. DERENZINI, C. AGOSTINELLI, A. FRANCESCHELLI, F. COLOMBO, P.L. ZINZANI (<i>Bologna, Italy</i>)	2639
Immunohistochemical Expression of Telomerase in Patients with Non-Small Cell Lung Cancer: Prediction of Metastasis and Prognostic Significance. G. ARAS, D. KANMAZ, H.N. ÜRER, S. PURISA, F. KADAKAL, E. YENTÜRK, E. TUNCAY (<i>Istanbul, Turkey</i>)	2643
The Impact of Breast Cancer Screening Among Younger Women in the Barretos Region, Brazil. J.S. DE CASTRO MATTOS, E.C. MAUAD, K. SYRJÄNEN, A. LONGATTO-FILHO, R.L. HAIKEL, R.A. DA COSTA VIEIRA, T. BUOSI SILVA, N. DE BARROS (<i>Barretos; São Paulo, SP, Brazil; Turku, Finland; Gualtar, Portugal</i>)	2651
Phase II Study of a Triple Combination of Oral Vinorelbine, Capecitabine and Trastuzumab as First-line Treatment in HER2-positive Metastatic Breast Cancer. A. CHAN, P.-F. CONTE, L. PETRUZELKA, N. TUBIANA-MATHIEU, V. GANJU, A. LLOMBART, M. ESPIE, F. MAJOIS, M. GIL GIL, N. VAISSIERE, G. VILLANOVA (<i>Perth, WA; Frankston, VIC, Australia; Modena, Italy; Prague, Czech Republic; Limoges, France; Valencia; L'Hospitalet de Llobregat, Spain; Paris; Boulogne-Billancourt, France; Haine St Paul, Belgium</i>)	2657
¹⁸ F-FDG-PET/CT in Potentially Advanced Renal Cell Carcinoma: A Role in Treatment Decisions and Prognosis Estimation. J. FERDA, E. FERDOVA, M. HORA, ON. HES, J. FINEK, O. TOPOLCAN, B. KREUZBERG (<i>Plzen, Czech Republic</i>)	2665
Adenomatoid Odontogenic Tumor: A Case Report with Immunohistological Profile. F. ANGIERO, R. CRIPPA (<i>Genoa; Milan, Italy</i>)	2673
Prognostic Role of Bone Sialoprotein in Clear Cell Renal Carcinoma. L. RIGHI, E. BOLLITO, P. CEPPI, D. MIRABELLI, V. TAVAGLIONE, L. CHIUSA, F. PORPIGLIA, M. BRUNELLI, G. MARTIGNONI, C. TERRONE, M. PAPOTTI (<i>Turin; Verona; Novara, Italy</i>)	2679
NX-PVKA Levels Before and After Hepatectomy of Hepatocellular Carcinoma as Predictors of Patient Survival: A Preliminary Evaluation of an Improved Assay for PIVKA-II. A. NANASHIMA, T. ABO, N. TAURA, H. SHIBATA, T. ICHIKAWA, K. TAKAGI, J. ARAI, S. OYAMA, T. NAGAYASU (<i>Nagasaki, Japan</i>)	2689
Prognostic Impact of Tumor IL-6 Expression after Preoperative Chemoradiotherapy in Patients with Advanced Esophageal Squamous Cell Carcinoma. M. YONEDA, H. FUJIWARA, A. FURUTANI, A. IKAI, H. TADA, A. SHIOZAKI, S. KOMATSU, T. KUBOTA, D. ICHIKAWA, K. OKAMOTO, H. KONISHI, Y. MURAYAMA, Y. KURIU, H. IKOMA, M. NAKANISHI, T. OCHIAI, E. OTSUJI (<i>Kyoto, Japan</i>)	2699
Mesothelin Is More Useful in Pleural Effusion than in Serum in the Diagnosis of Pleural Mesothelioma. P. FERRO, P.A. CANESSA, E. BATTOLLA, P. DESSANTI, M.C. FRANCESCHINI, L. CHIAFFI, A. MORABITO, V. FONTANA, R. PEZZI, F. FEDELI, M.P. PISTILLO, S. RONCELLA (<i>Genova, Italy</i>)	2707
Glasgow Prognostic Score Predicts Therapeutic Outcome after Pancreaticoduodenectomy for Carcinoma of the Ampulla of Vater. H. SHIBA, T. MISAWA, Y. FUJIWARA, Y. FUTAGAWA, K. FURUKAWA, K. HARUKI, R. IWASE, S. WAKIYAMA, Y. ISHIDA, K. YANAGA (<i>Tokyo, Japan</i>)	2715

Negative Impact of Fresh-frozen Plasma Transfusion on Prognosis after Hepatic Resection for Liver Metastases from Colorectal Cancer. H. SHIBA, Y. ISHIDA, K. HARUKI, K. FURUKAWA, Y. FUJIWARA, R. IWASE, M. OHKUMA, M. OGAWA, T. MISAWA, K. YANAGA (<i>Tokyo, Japan</i>)	2723
Different Impact of IL10 Haplotype on Prognosis in Lung Squamous Cell Carcinoma and Adenocarcinoma. Y.-C. WANG, W.-W. SUNG, L. WANG, Y.-W. CHENG, C.-Y. CHEN, T.-C. WU, S.-H. SHIEH, H. LEE (<i>Taichung; Taipei, Taiwan, ROC</i>)	2729
Prognostic Factors in Early-stage Triple-negative Breast Cancer: Lessons and Limits from Clinical Practice. M. PISTELLI, A. PAGLIACCI, N. BATTELLI, A. SANTINELLI, T. BISCOTTI, Z. BALLATORE, R. BERARDI, S. CASCINU (<i>Ancona, Italy</i>)	2737
Mitomycin-C and Capecitabine (MIXE) as Salvage Treatment in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. M.W. SAIF, K. KALEY, M. BRENNAN, M.C. GARCON, G. RODRIGUEZ (<i>Boston, MA; New Haven, CT; New York, NY, USA</i>)	2743
Unresectable Perihilar Cholangiocarcinoma: Multimodal Palliative Treatment. C. MOSCONI, M. RENZULLI, E. GIAMPALMA, A. GALUPPI, C. BALACCHI, G. BRANDI, G. ERCOLANI, G. BIANCHI, R. GOLFIERI (<i>Bologna, Italy</i>)	2747
Early-onset Neutropenia during Perioperative Chemotherapy Is Predictive of Increased Survival in Patients with Completely Resected Non-small Cell Lung Cancer: A Retrospective Analysis. C.Y. LEE, S.Y. PARK, T.R. SHIN, Y.-B. PARK, C.-H. KIM, S.H. JANG, J.-W. LEE (<i>Anyang, Gyeonggi, Republic of Korea</i>)	2755
Identification of FKBP11 as a Biomarker for Hepatocellular Carcinoma. I-Y. LIN, C.-H. YEN, Y.-J. LIAO, S.-E. LIN, H.-P. MA, Y.-J. CHAN, Y.-M.A. CHEN (<i>Taipei, Kaohsiung, Taiwan, ROC</i>)	2763
Laparoscopic Supracervical Hysterectomy with Concomitant Bilateral Salpingectomy – Why not? S. BERLIT, B. TUSCHY, S. KEHL, J. BRADE, M. SÜTTERLIN, A. HORNEMANN (<i>Mannheim, Germany</i>)	2771
The Contribution of DNA Apurinic/Apyrimidinic Endonuclease Genotype and Smoking Habit to Taiwan Lung Cancer Risk. W.-C. CHEN, C.-W. TSAI, T.-C. HSIA, W.-S. CHANG, L.-Y. LIN, S.-J. LIANG, C.-Y. TU, W.-E. CHENG, H.-J. CHEN, S.-M. WANG, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	2775
IgG4-related Inflammation of the Orbit Simulating Malignant Lymphoma. S. KASE, M. NODA, K. ISHIJIMA, T. YAMAMOTO, K. HATANAKA, S. ISHIDA (<i>Sapporo, Japan</i>)	2779
Hypofractionated Intensity-modulated Radiotherapy with Simultaneous Integrated Boost after Radical Prostatectomy: Preliminary Results of a Phase II Trial. M. MASSACCESI, S. CILLA, F. DEODATO, C. DIGESÙ, G. MACCHIA, L. CARAVATTA, E. IPPOLITO, V. PICARDI, M. FERRO, S. MIGNOGNA, G.C. MATTIUCCI, V. VALENTINI, A. PIERMATTEI, A.G. MORGANTI (<i>Campobasso; Rome, Italy</i>)	2785
A Role of Multifactorial Evaluation of Prostatic 3T MRI in Patients with Elevated Prostatic-specific Antigen Levels: Prospective Comparison with Ultrasound-guided Transrectal Biopsy. J. FERDA, J. KASTNER, M. HORA, O. HES, J. FÍNEK, O. TOPOLČAN, B. KREUZBERG (<i>Plzen, Czech Republic</i>)	2791
Phase I Adjuvant Trial of Sorafenib in Patients with Hepatocellular Carcinoma after Orthotopic Liver Transplantation. N. JIA, I. LIOU, J. HALLDORSON, R. CARITHERS, J. PERKINS, J. REYES, M. YEY, E. STOHR, S. RAO, E.H. LIN (<i>Beijing, PR China; Seattle, WA; South San Francisco, CA, USA</i>)	2797

Number 7

**Proceedings of the 16th Annual Meeting of the Society of Biotherapeutic Approaches,
8 December 2012, Tokyo, Japan. Special Issue Edited by M. Kuroki and G.-I. Soma**

Preface..... 2803

Reviews

Novel Curcumin Oral Delivery Systems. T. KURITA, Y. MAKINO (*Kagawa; Noda, Japan*) 2807

Tumor-targeted Photodynamic Therapy. N. SHIRASU, S. O. NAM, M. KUROKI (*Fukuoka, Japan*) 2823

Roles of ZFAT in Haematopoiesis, Angiogenesis and Cancer Development. T. TSUNODA, S. SHIRASAWA (*Fukuoka, Japan*)..... 2833

Lymph Node Evaluation and Survival in Colorectal Cancer: Review of Population-based, Prospective Studies. Y. AKAGI, Y. ADACHI, T. KINUGASA, Y. OKA, T. MIZOBE, K. SHIROUZU (*Fukuoka, Japan*) 2839

Effects of Interactions between Intestinal Microbiota and Intestinal Macrophages on Health. K. NAKATA, M. YAMAMOTO, H. INAGAWA, G. -I. SOMA (*Soja; Kagawa; Tokushima, Japan*) 2849

Possible Therapeutic Targets Among the Molecules Involved in the Warburg Effect in Tumor Cells. S. O. NAM, F. YOTSUMOTO, K. MIYATA, N. SHIRASU, S. MIYAMOTO, M. KUROKI (*Fukuoka, Japan*) ... 2855

Experimental Studies

Antitumor Effect of Combination of Hyperthermotherapy and 5-Aminolevulinic acid (ALA). K. TAKAHASHI, T. HASEGAWA, T. ISHII, A. SUZUKI, M. NAKAJIMA, K. UNO, I. YASUDA, A. KISHI, K. SADAMOTO, F. ABE, T. TANAKA (*Tokyo; Kyoto, Japan*) 2861

Primary Culture of Breast Cancer: A Model System for Epithelial-Mesenchymal Transition and Cancer Stem Cells. T. NISHIKATA, M. ISHIKAWA, T. MATSUYAMA, K. TAKAMATSU, T. FUKUHARA, Y. KONISHI (*Kobe; Osaka, Japan*) 2867

Induction of Nitric Oxide Production in RAW264.7 Cells under Serum-free Conditions by *O*-antigen Polysaccharide of Lipopolysaccharide. T. KADOWAKI, S. OHNO, Y. TANIGUCHI, H. INAGAWA, C. KOHCHI, G.-I. SOMA (*Kagawa; Tokushima, Japan*) 2875

Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and *In Vivo* Antitumor Activity. D. KUCHIIKE, Y. UTO, H. MUKAI, N. ISHIYAMA, C. ABE, D. TANAKA, T. KAWAI, K. KUBO, M. METTE, T. INUI, Y. ENDO, H. HORI (*Tokushima; Osaka; Kobe; Kanazawa, Japan*) 2881

Heat-shock Pre-treatment Reduces Liver Injury and Aids Liver Recovery After Partial Hepatectomy in Mice. Y. OKA, Y. AKAGI, T. KINUGASA, N. ISHIBASHI, N. IWAKUMA, I. SHIRATSUCHI, K. SHIROUZU (*Fukuoka, Japan*)..... 2887

Angiogenesis-, Metastasis- and Signaling Pathway-related Factor Dynamics in Human Colon Cancer Cells Following Interaction with Monocytes. T. HONDA, I. YAMAMOTO, H. INAGAWA (*Sagamihara; Kagawa, Japan*) 2895

Profiles of ILY, VLY and Sm-hPAF Interaction with Human CD59. Y. KAWAGUCHI, A. TABATA, H. NAGAMUNE, K. OHKURA (<i>Choshi; Tokushima; Suzuka, Japan</i>)	2901
Construction of an Improved Drug Delivery System Tool with Enhanced Versatility in Cell-targeting. A. TABATA, Y. OHKUBO, M. TAMURA, T. TOMOYASU, K. OHKURA, H. NAGAMUNE (<i>Tokushima; Suzuka, Japan</i>)	2905
Antitumor Effect of Degalactosylated Gc-Globulin on Orthotopic Grafted Lung Cancer in Mice. K. HIROTA, Y. NAKAGAWA, R. TAKEUCHI, Y. UTO, H. HORI, S. ONIZUKA, H. TERADA (<i>Noda; Tokyo; Tokushima; Nagasaki, Japan</i>).....	2911
 <i>Clinical Studies</i>	
Clinical Experience of Integrative Cancer Immunotherapy with GcMAF. T. INUI, D. KUCHIIKE, K. KUBO, M. METTE, Y. UTO, H. HORI, N. SAKAMOTO (<i>Tokushima; Osaka; Kobe, Japan</i>).....	2917
Lateral Lymph-node Dissection for Rectal Cancer: Meta-analysis of all 944 Cases Undergoing Surgery During 1975-2004. T. KINUGASA, Y. AKAGI, T. OCHI, Y. ISHIBASHI, N. TANAKA, Y. OKA, T. MIZOBE, K. YUGE, S. FUJINO, S. KIBE, K. SHIROUZU (<i>Fukuoka, Japan</i>)	2921
Gemcitabine with Paclitaxel Therapy Against Mesocolic Leiomyosarcoma: A Case Report. T. MIZOBE, Y. AKAGI, H. ISHIKAWA, I. SHIRATSUCHI, Y. OKA, T. KINUGASA, K. OHSHIMA, K. SETOJIMA, K. SHIROUZU (<i>Fukuoka; Tosu, Japan</i>)	2929
Virchow Lymph Node Metastatic Recurrence of Sigmoid Colon Cancer with Severe Lymph Node Metastases Successfully Treated Using Systemic Chemotherapy Combined with Radiotherapy. T. OHCHI, Y. AKAGI, T. KINUGASA, Y. ISHIBASHI, N. TANAKA, S. FUJINO, S. KIBE, K. YUGE, T. SASATOMI, T. MIZOBE, Y. OKA, K. D. HONG, K. SHIROUZU (<i>Fukuoka, Japan; Seoul, Republic of Korea</i>)	2935
Expression of Monocarboxylate Transporter (MCT)-4 in Colorectal Cancer and its Role: MCT4 Contributes to the Growth of Colorectal Cancer with Vascular Endothelial Growth Factor. Y. GOTANDA, Y. AKAGI, A. KAWAHARA, T. KINUGASA, T. YOSHIDA, Y. RYU, I. SHIRATSUCHI, M. KAGE, K. SHIROUZU (<i>Fukuoka, Japan</i>).....	2941
Estimation of the Number of Metastatic Lymph Nodes in Dukes' C Colorectal Cancer. T. FUKUSHIMA, Y. AKAGI, H. MURAKAMI, M. USHIJIMA, Y. OGATA, K. SHIROUZU, K. MUROTANI (<i>Fukuoka, Japan</i>)	2949
A Patient with Scirrhus Stomach Cancer Treated with Combination of Hyperthermotherapy and 5-Aminolevulinic acid (ALA). M. SAITO, K. YANO, T. KAMIGAKI, S. GOTO (<i>Tokyo; Tsuchiura-shi, Japan; New York, NY, U.S.A.</i>).....	2957
Prognostic Impact of Lymphatic Invasion of Colorectal Cancer: A Single-center Analysis of 1,616 Patients Over 24 Years. Y. AKAGI, Y. ADACHI, T. OHCHI, T. KINUGASA, K. SHIROUZU (<i>Fukuoka, Japan</i>).....	2965
Immunotherapy of Autologous Tumor Lysate-loaded Dendritic Cell Vaccines by a Closed-flow Electroporation System for Solid Tumors. T. KAMIGAKI, T. KANEKO, K. NAITOH, M. TAKAHARA, T. KONDO, H. IBE, E. MATSUDA, R. MAEKAWA, S. GOTO (<i>Tokyo, Japan</i>)	2971
Cancer of the Small Intestine in Patients with Crohn's Disease. D. HIGASHI, K. FUTAMI, D. KOJIMA, R. FUTATSUKI, Y. ISHIBASHI, T. MAEKAWA, Y. YANO, N. TAKATSU, F. HIRAI, T. MATSUI, A. IWASHITA (<i>Fukuoka, Japan</i>).....	2977

Number 8*Reviews*

- Antineoplastic Activity of Zoledronic Acid and Denosumab. P. ZWOLAK, A.Z. DUDEK (*Chicago, IL, USA*).... 2981
- DNA Methyltransferase Inhibitors and Their Emerging Role in Epigenetic Therapy of Cancer. A. GNYSZKA, Z. JASTRZĘBSKI, S. FLIS (*Warsaw, Poland*) 2989

Experimental Studies

- PD-0332991, a Potent and Selective Inhibitor of Cyclin-dependent Kinase 4/6, Demonstrates Inhibition of Proliferation in Renal Cell Carcinoma at Nanomolar Concentrations and Molecular Markers Predict for Sensitivity. J.E. LOGAN, N. MOSTOFIZADEH, A.J. DESAI, E. VON EUW, D. CONKLIN, V. KONKANKIT, H. HAMIDI, M. ECKARDT, L. ANDERSON, H.-W. CHEN, C. GINTHER, E. TASCHEREAU, P.H. BUI, J.G. CHRISTENSEN, A.S. BELLDEGRUN, D.J. SLAMON, F.F. KABBINAVAR (*Los Angeles; San Diego, CA, USA*)..... 2997
- Efficacy of Cisplatin and Lipoplatin™ in Combined Treatment with Radiation of a Colorectal Tumor in Nude Mouse. T. TIPPAYAMONTRI, R. KOTB, B. PAQUETTE, L. SANCHE (*Sherbrooke, QC; Victoria, BC, Canada*) 3005
- Correlation of Immunohistopathological Expression of Somatostatin Receptor-2 in Breast Cancer and Tumor Detection with ⁶⁸Ga-DOTATOC and ¹⁸F-FDG PET Imaging in an Animal Model. E. CHEREAU, L. DURAND, A. FRATI, A. PRIGNON, J.-N. TALBOT, R. ROUZIER (*Paris; Marseille, France*) 3015
- Real-time Imaging of αv Integrin Molecular Dynamics in Osteosarcoma Cells *In Vitro* and *In Vivo*. Y. TOME, N. SUGIMOTO, S. YANO, M. MOMIYAMA, S. MII, H. MAEHARA, M. BOUVET, H. TSUCHIYA, F. KANAYA, R.M. HOFFMAN (*San Diego, CA, USA; Okinawa; Kanazawa, Japan*) 3021
- Antiproliferative and Erythroid Differentiation of Piperazine and Triphenyl Derivatives Against K-562 Human Chronic Myelogenous Leukemia. A.M. SAAB, M. DOBMEIER, B. KOENIG, E. FABRI, A. FINOTTI, M. BORGATTI, I. LAMPRONTI, F. BERNARDI, T. EFFERTH, R. GAMBARI (*Ferrara, Italy; Beirut, Lebanon; Regensburg; Mainz, Germany*) 3027
- Combination Chemoprevention with Diclofenac, Calcipotriol and Difluoromethylornithine Inhibits Development of Non-melanoma Skin Cancer in Mice. H.-C. POMMERGAARD, J. BURCHARTH, J. ROSENBERG, H. RASKOV (*Copenhagen; Frederiksberg, Denmark*) 3033
- Color-coded Imaging of Spontaneous Vessel Anastomosis *In Vivo*. F. UEHARA, Y. TOME, J. REYNOSO, S. MII, S. YANO, S. MIWA, M. BOUVET, H. MAEHARA, F. KANAYA, A.R. MOOSSA, R.M. HOFFMAN (*San Diego, CA, USA; Okinawa, Japan*) 3041
- Nicotinamide Phosphoribosyltransferase and SIRT3 Expression Are Increased in Well-differentiated Thyroid Carcinomas. R. SHACKELFORD, S. HIRSH, K. HENRY, A. ABDEL-MAGEED, E. KANDIL, D. COPPOLA (*New Orleans; Gretna, LA; Tampa, FL, USA*)..... 3047
- The Growing Galectin Network in Colon Cancer and Clinical Relevance of Cytoplasmic Galectin-3 Reactivity. H. DAWSON, S. ANDRÉ, E. KARAMITOPOULOU, I. ZLOBEC, H.-J. GABIUS (*Bern, Switzerland; Munich, Germany*)..... 3053
- Evaluation of Cytotoxicity and Tumor-specificity of Licorice Flavonoids Based on Chemical Structure. H. OHNO, D. ARAHO, Y. UESAWA, H. KAGAYA, M. ISHIHARA, H. SAKAGAMI, M. YAMAMOTO (*Shibuya; Kiyose, Tokyo; Sakado, Saitama, Japan*) 3061

HMGA2 Expression in the PC-3 Prostate Cancer Cell Line Is Autonomous of Growth Factor Stimulation. M.H. MÜLLER, N. DRIESCHNER, T. FOCKEN, S. BARTNITZKE, N. WINTER, M. KLEMKE, J. BULLERDIEK (<i>Bremen, Germany</i>)	3069
Effects of Artonin E on Migration and Invasion Capabilities of Human Lung Cancer Cells. K. PLAIBUA, V. PONGRAKHANANON, P. CHUNHACHA, B. SRITULARAK, P. CHANVORACHOTE (<i>Bangkok, Thailand</i>)	3079
Polycyclic Aromatic Hydrocarbon-induced Oxidative Stress, Antioxidant Capacity, and the Risk of Lung Cancer: A Pilot Nested Case-control Study. S.-Y. EOM, D.-H. YIM, S.I. MOON, J.-W. YOUN, H.-J. KWON, H.C. OH, J.J. YANG, S.K. PARK, K.-Y. YOO, H.S. KIM, K.-S. LEE, S.-H. CHANG, Y.-D. KIM, J.-W. KANG, H. KIM (<i>Cheongju; Seoul; Chungju, South Korea</i>)	3089
Effects of the HIF1 Inhibitor, Echinomycin, on Growth and NOTCH Signalling in Leukaemia Cells. S. YONEKURA, M. ITOH, Y. OKUHASHI, Y. TAKAHASHI, A. ONO, N. NARA, S. TOHDA (<i>Tokyo, Japan</i>)	3099
Drug Interaction Between Sunitinib and Cimetidine and Contribution of the Efflux Transporter ATP-binding Cassette C2 to Biliary Excretion of Sunitinib in Rats. M. ARAKAWA-TODO, J. UEYAMA, H. NOMURA, F. ABE, I. TSUKIYAMA, K. MATSUURA, T. HASEGAWA (<i>Nagakute; Nagoya, Aichi, Japan</i>)	3105
Keratinocytes and Head and Neck Squamous Cell Carcinoma Cells Regulate Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Fibroblasts. M. HAKELIUS, A. KOSKELA, M. IVARSSON, R. GRENMAN, K. RUBIN, B. GERDIN, D. NOWINSKI (<i>Uppsala; Örebro, Sweden; Turku, Finland</i>)	3113
The Role of p66shc in Taxol- and Dichloroacetic Acid-dependent Renal Toxicity. I ARANY, J.S. CLARK, D. REED, I. SZABÓ, I. EMBER, L.A. JUNCOS (<i>Jackson, MS, USA; Pécs, Hungary</i>)	3119
Expression of the mTOR Pathway Regulators in Human Pituitary Adenomas Indicates the Clinical Course. W. JIA, A.J. SANDERS, G. JIA, X. LIU, R. LU, W.G. JIANG (<i>Beijing, PR China; Cardiff, UK</i>)	3123
Up-regulation of DDX39 in Human Pancreatic Cancer Cells with Acquired Gemcitabine Resistance Compared to Gemcitabine-sensitive Parental Cells. Y. KURAMITSU, S. SUENAGA, Y. WANG, K. TOKUDA, T. KITAGAWA, T. TANAKA, J. AKADA, S.-I. MAEHARA, Y. MAEHARA, K. NAKAMURA (<i>Ube, Yamaguchi; Fukuokashi, Fukuoka, Japan</i>)	3133
High Cyclooxygenase-2 Expression Is Associated with Advanced Stages in Colorectal Cancer. A. ELZAGHEID, F. EMAETIG, L. ALKIKHIA, A. BUHMEIDA, K. SYRJÄNEN, O. EL-FAITORI, M. LATTO, Y. COLLAN, S. PYRHÖNEN (<i>Benghazi; Tripoli, Libya; Jeddah, Saudi Arabia; Turku, Finland; Barretos, SP, Brazil</i>)	3137
Sonodynamically-induced Anticancer Effects by Functionalized Fullerenes. N. YUMITA, Y. IWASE, T. IMAIZUMI, A. SAKURAZAWA, Y. KAYA, K. NISHI, T. IKEDA, S.-I. UMEMURA, F.-S. CHEN, Y. MOMOSE (<i>Yokohama, Kanagawa; Sendai; Funabashi, Chiba, Japan; Hualien, Taiwan, ROC</i>)	3145
Curcumin Reduces Trabecular and Cortical Bone in Naïve and Lewis Lung Carcinoma-bearing Mice. L. YAN, J.A. YEE, J. CAO (<i>Grand Forks, ND; Omaha, NE, USA</i>)	3153
9-Norbornyl-6-chloropurine Is a Novel Antileukemic Compound Interacting with Cellular GSH. P. PLAČKOVÁ, N. ROZUMOVÁ, H. HŘEBABECKÝ, M. ŠÁLA, R. NENCKA, T. ELBERT, A. DVOŘÁKOVÁ, I. VOTRUBA, H. MERTLÍKOVÁ-KAISEROVÁ (<i>Prague, Czech Republic</i>)	3163
Proliferation of Small Cell Lung Cancer Cell Line Reduced by Knocking-down PROX1 via shRNA in Lentivirus. S-H. ZHU, C.-J. SHAN, Z.-F. WU, S.-Z. XU (<i>Jiangsu, PR China; Rochester, MN, USA</i>)	3169
The Effect of Surgical Wound on Ovarian Carcinoma Growth in an Animal Model. J.-W. LEE, Y.-A. PARK, Y.-J. CHO, K.-H. KANG, J.-J. CHOI, Y.-Y. LEE, T.-J. KIM, C.H. CHOI, B.-G. KIM, D.-S. BAE (<i>Seoul, South Korea; New York, NY, USA</i>)	3177

Circulating Long Non-coding RNAs in Plasma of Patients with Gastric Cancer. T. ARITA, D. ICHIKAWA, H. KONISHI, S. KOMATSU, A. SHIOZAKI, K. SHODA, T. KAWAGUCHI, S. HIRAJIMA, H. NAGATA, T. KUBOTA, H. FUJIWARA, K. OKAMOTO, E. OTSUJI (<i>Kyoto, Japan</i>)	3185
Evaluation of MicroRNA Expression Pattern of Gastric Adenocarcinoma Associated with Socioeconomic, Environmental and Lifestyle Factors in Northwestern Hungary. I. STÁNITZ, K. JUHÁSZ, C. TÓTH, K. GOMBOS, P.G. NATALI, I. EMBER (<i>Pécs; Szombathely, Hungary; Rome, Italy</i>)	3195
Cell Harvesting Method Influences Results of Apoptosis Analysis by Annexin V Staining. A. BUNDSCHERER, M. MALSY, R. LANGE, P. HOFMANN, T. METTERLEIN, B.M. GRAF, M. GRUBER (<i>Regensburg, Germany</i>)	3201
Parthenolide Complements the Cell Death-inducing Activity of Doxorubicin in Melanoma Cells. M. WOZNIAK, A. SZULAWSKA-MROCZEK, M.L. HARTMAN, D. NEJC, M. CZYZ (<i>Lodz, Poland</i>)	3205
Probabilities of Identifying a Micrometastasis in a Cervical Lymph Node from Laryngeal Cancer. A Stereometric Approach. A. DELIDES, M. MANIADAKIS, E. STATHOPOULOS (<i>Athens; Heraklion, Greece</i>)	3213
Effects of Bisphosphonates in Combination with Ionizing Radiation and Antioxidants on the Growth of Prostate and Melanoma Cells Lines. M. ALCARAZ, A. OLIVARES, D.G. ACHEL, M. ALCARAZ-SAURA (<i>Murcia, Spain; Legon-Accra, Ghana</i>)	3217
15,16-Dihydrotanshinone I-induced Apoptosis in Human Colorectal Cancer Cells: Involvement of ATF3. F.-M. SUK, W.-J. JOU, R.-J. LIN, S.-Y. LIN, F.-Y. TZENG, Y.-C. LIANG (<i>Taipei, Taiwan, ROC</i>)	3225
A <i>miR-146a</i> Polymorphism (rs2910164) Predicts Risk of and Survival from Colorectal Cancer. Y.S. CHAE, J.G. KIM, S.J. LEE, B.W. KANG, Y.J. LEE, J.Y. PARK, H.-S. JEON, J.S. PARK, G.S. CHOI (<i>Daegu, Republic of Korea</i>)	3233
<i>Clinical Studies</i>	
<i>c-MET</i> and <i>HGF</i> mRNA Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Survival. C.S.-P. ANG, M.Y. SUN, D.F. HUITZIL-MELENDZ, J.F.-L. CHOU, M. CAPANU, W. JARNAGIN, Y. FONG, R.P. DEMATTEO, M. D'ANGELICA, P. ALLEN, C.-T. CHEN, E.M. O'REILLY, M.R. WEISER, G.K. ABOU-ALFA (<i>New York, NY, USA; Mexico City, Mexico</i>)	3241
Gene Polymorphism of Matrix Metalloproteinase-12 and -13 and Association with Colorectal Cancer in Swedish Patients. S. VAN NGUYEN, M. SKARSTEDT, S. LÖFGREN, N. ZAR, R.E. ANDERSSON, M. LINDH, A. MATUSSEK, J. DIMBERG (<i>Da Nang, Vietnam; Jönköping Sweden</i>)	3247
Primary Central Nervous System Lymphoma in the Elderly: The Cleveland Clinic Experience. H. XIE, S. DAHIYA, E.S. MURPHY, S.T. CHAO, J.H. SUH, G.H.J. STEVENS, D.M. PEEREBOOM, M.S. AHLUWALIA (<i>Cleveland, OH, USA</i>)	3251
Collagenous Fibroma (Desmoplastic Fibroblastoma) with Trisomy 8 as the Sole Cytogenetic Abnormality. J. NISHIO, H. IWASAKI, S. YANO, M. NAITO (<i>Fukuoka, Japan</i>)	3259
Fatal Herpes Encephalitis in a Patient with Small Cell Lung Cancer Following Prophylactic Cranial Radiation - A Case Report with Review of Literature. S. CHAKRABORTY, M. DONNER, D. COLAN (<i>Omaha; Grand Island, NE, USA</i>)	3263
Laparoscopic Minimally Invasive Total Gastrectomy with Linear Stapled Oesophagojejunostomy – Experience from the First Thirty Procedures. T.I. PETERSEN, E. PAHLE, T. SOMMER, T. ZILLING (<i>Aarhus, Denmark</i>)	3269
Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC). D.S. NØRØXE, S. WALLERER, J.B. SØRENSEN (<i>Copenhagen, Denmark</i>)	3275

Comparison of the Time-to-response Between Radiotherapy and Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitors for Advanced Non-small Cell Lung Cancer with <i>EGFR</i> Mutation. H. IMAI, T. SHUKUYA, T. TAKAHASHI, S. FUJIWARA, K. MORI, A. ONO, H. AKAMATSU, T. TAIRA, H. KENMOTSU, T. NAITO, K. KAIRA, H. MURAKAMI, H. HARADA, M. ENDO, T. NAKAJIMA, N. YAMAMOTO (<i>Shizuoka, Japan</i>)	3279
Outpatient Oral Chemotherapy with S-1 for Unresectable or Distant Metastatic Head and Neck Cancer. M. MAEDA, T. YAMASHITA, T. MATSUNOBU, K. ARAKI, M. TOMIFUJI, A. SHIOTANI (<i>Saitama, Japan</i>)...	3285
A High Preoperative Neutrophil-to-lymphocyte Ratio Is Associated with Poor Survival in Patients with Colorectal Cancer. M. SHIBUTANI, K. MAEDA, H. NAGAHARA, E. NODA, H. OHTANI, Y. NISHIGUCHI, K. HIRAKAWA (<i>Osaka, Japan</i>)	3291
Increased Phosphorylation of AKT in High-risk Gastric Mucosa. T. SASAKI, H. KUNIYASU, Y. LUO, M. KITAYOSHI, E. TANABE, D. KATO, S. SHINYA, K. FUJII, H. OHMORI, Y. YAMASHITA (<i>Fukuoka; Kashihara, Japan</i>)	3295
Low Expression of Claudin-1 and Presence of Poorly- differentiated Tumor Clusters Correlate with Poor Prognosis in Colorectal Cancer. M. SHIBUTANI, E. NODA, K. MAEDA, H. NAGAHARA, H. OHTANI, K. HIRAKAWA (<i>Osaka, Japan</i>)	3301
Etoposide Improves Survival in High-grade Glioma: A Meta-Analysis. A. LEONARD, J.E. WOLFF (<i>Boston, MA, USA</i>).....	3307
Efficacy of Postoperative Oxaliplatin- or Irinotecan-based Chemotherapy After Curative Resection of Synchronous Liver Metastases from Colorectal Cancer. H.-C. HSU, W.-C. CHOU, W.-C. SHEN, C.-E. WU, J.-S. CHEN, C.-T. LIAU, Y.-C. LIN, T.-S. YANG (<i>Tao-Yuan, Taiwan, ROC</i>).....	3317
Pemetrexed and Cisplatin for Advanced Non-squamous Non-small Cell Lung Cancer in Japanese Patients: Phase II Study. Y. KAWANO, F. OHYANAGI, N. YANAGITANI, K. KUDO, A. HORIIKE, A. TANIMOTO, H. NISHIZAWA, A. ICHIKAWA, T. SAKATANI, K. NAKATOMI, S. HAGIWARA, H. NINOMIYA, N. MOTOI, Y. ISHIKAWA, T. HORAI, M. NISHIO (<i>Tokyo, Japan</i>)	3327
Detectable Wilms' Tumor-1 Transcription at Treatment Completion Is Associated with Poor Prognosis of Acute Myeloid Leukemia: A Single Institution's Experience. T. YAMAUCHI, E. NEGORO, S. LEE, M. TAKAI, Y. MATSUDA, K. TAKAGI, S. KISHI, K. TAI, N. HOSONO, T. TASAKI, S. IKEGAYA, A. YOSHIDA, Y. URASAKI, H. IWASAKI, T. UEDA (<i>Eiheiji, Fukui, Japan</i>)	3335
Beta-2 Microglobulin as a Diagnostic Parameter in Non-Hodgkin Lymphoma: A Comparative Study with FDG-PET. D.F. TOTH, M. RADERER, W. WADSAK, G. KARANIKAS (<i>Vienna, Austria</i>)	3341
Predictability of Oral and Laryngopharyngeal Function for Aspiration and Limitation of Oral Intake in Patients After Surgery for Head and Neck Cancer. C. HEY, B.P. LANGE, C. AERE, S. EBERLE, Y. ZARETSKY, R. SADER, T. STÖVER, J. WAGENBLAST (<i>Frankfurt/Main; Göttingen, Germany</i>)	3347
Significant Efficacy of New Transcatheter Arterial Chemoembolization Technique for Hepatic Metastases of Pancreatic Neuroendocrine Tumors. T. AKAHORI, M. SHO, T. TANAKA, H. NISHIOFUKU, S. KINOSHITA, M. NAGAI, K. KICHIKAWA, Y. NAKAJIMA (<i>Nara, Japan</i>)	3355
Intragastric SILS for GIST, a New Challenge in Oncologic Surgery: First Experiences. K. DE VOGELAERE, N. VAN DE WINKEL, C. SIMOENS, G. DELVAUX (<i>Brussels, Belgium</i>)	3359
Nevus of Hoffmann-Zurhelle: A Case Around the Right Parotid Duct. F. ANGIERO, R. CRIPPA (<i>Genoa, Italy</i>).....	3365
Investigation of <i>FANCA</i> Mutations in Greek Patients. N. SELENTI, C. SOFOCLEOUS, A. KATTAMIS, A. KOLIALEXI, S. KITSIOU, E. FRYSSIRA, S. POLYCHRONOPOULOU, E. KANAVAKIS, A. MAVROU (<i>Athens, Greece</i>)	3369

Survey among German Gynecologists on the Clinical Management of Patients with Sarcomas of the Uterus. F.C.-K. CHEN, M. DAVID, R. RICHTER, M.Z. MUALLEM, R. CHEKEROV, J. SEHOULI (<i>Berlin, Germany</i>).....	3375
Continuous Tamoxifen and Dose-dense Temozolomide in Recurrent Glioblastoma. A. DI CRISTOFORI, G. CARRABBA, G. LANFRANCHI, C. MENGHETTI, P. RAMPINI, M. CAROLI (<i>Milan, Italy</i>)	3383
Association of Interleukin-10 (<i>IL10</i>) Promoter Genotypes with Nasopharyngeal Carcinoma Risk in Taiwan. C.-W. TSAI, M.-H. TSAI, L.-C. SHIH, W.-S. CHANG, C.-C. LIN, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>).....	3391
Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type <i>EGFR</i> Gene: Second-line Pemetrexed Followed by Third-line Erlotinib <i>versus</i> the Reverse Sequence. O. FIALA, M. PESEK, J. FINEK, L. BENESOVA, Z. BORTLICEK, M. MINARIK (<i>Pilsen; Prague; Brno, Czech Republic</i>)	3397
Whole-body <i>versus</i> Segmental Bioelectrical Impedance Analysis in Patients with Edema of the Upper Limb After Breast Cancer Treatment. S. BERLIT, J. BRADE, B. TUSCHY, E. FÖLDI, U. WALZ-ESCHENLOHR, H. LEWELING, M. SÜTTERLIN (<i>Mannheim; Hinterzarten, Germany</i>)	3403
<i>Nab</i> -Paclitaxel Monotherapy as a Treatment of Patients with Metastatic Breast Cancer in Routine Clinical Practice. J. AIGNER, F. MARMÉ, K. SMETANAY, F. SCHUETZ, D. JAEGER, A. SCHNEEWEISS (<i>Heidelberg, Germany</i>)	3407
Relationship between Cancer-related Fatigue and Physical Activity in Inpatient Cancer Rehabilitation. F. KUMMER, S. CATUOGNO, J.M. PERSEUS, W. BLOCH, F.T. BAUMANN (<i>Cologne, Germany; Davos, Switzerland</i>)	3415
UDP-glucuronosyltransferase (UGT) 1A1*28 Polymorphism-directed Phase II Study of Irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for Metastatic Colorectal Cancer. S. KANEKIYO, S. HAZAMA, H. KONDO, A. NAGASHIMA, R. ETO, S. YOSHIDA, R. SHIMIZU, A. ARAKI, T. YAMAMOTO, T. UCHIYAMA, S. YOSHINO, N. OKAYAMA, Y. HINODA, M. OKA (<i>Ube, Yamaguchi, Japan</i>)	3423
Reduction in γ -Glutamyl Hydrolase Expression Is Associated with Response to Uracil and Tegafur/Leucovorin Chemotherapy in Patients with Colorectal Cancer. S. SADAHIRO, T. SUZUKI, A. TANAKA, K. OKADA, A. KAMIJO, H. NAGASE, J. UCHIDA (<i>Kanagawa; Tokushima, Japan</i>)	3431
Post-operative Lymphocyte Count May Predict the Outcome of Radical Resection for Gallbladder Carcinoma. R. IWASE, H. SHIBA, K. HARUKI, Y. FUJIWARA, K. FURUKAWA, Y. FUTAGAWA, S. WAKIYAMA, T. MISAWA, K. YANAGA (<i>Tokyo, Japan</i>)	3439
High Efficacy of Chemoradiation Therapy Sensitized by Weekly Docetaxel for Anaplastic Thyroid Cancer. N. ONODA, S. KASHIWAGI, S. NODA, H. KAWAJIRI, T. TAKASHIMA, T. ISHIKAWA, K. HIRAKAWA (<i>Osaka, Japan</i>).....	3445
Laparoscopic Radical Hysterectomy and Lymph Node Dissection Learning Experience at Campus Virchow – Charité. M.Z. MUALLEM, A. FELDHEISER, J. SEHOULI (<i>Berlin, Germany</i>)	3449
Comparison Between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Adenocarcinoma of the Upper Gastrointestinal Tract. A. ILHAN-MUTLU, M. PREUSSER, S.F. SCHOPPMANN, R. ASARI, A. BASSALAMAH, K. SCHWAMEIS, U. PLUSCHNIG, P. BIRNER, A. PÜSPÖK, J. ZACHERL, M. HEJNA (<i>Vienna, Austria</i>)	3455
Comparison of Prognostic Compatibility between Seventh AJCC/TNM of the Esophagus and 14th JCGC Staging Systems in Siewert Type II Adenocarcinoma. T. KAWAGUCHI, S. KOMATSU, D. ICHIKAWA, T. KUBOTA, K. OKAMOTO, A. SHIOZAKI, H. FUJIWARA, H. KONISHI, R. MORIMURA, Y. MURAYAMA, Y. KURIU, H. IKOMA, M. NAKANISHI, C. SAKAKURA, E. OTSUJI (<i>Kyoto, Japan</i>)	3461

Prolonged Administration of Adjuvant Temozolomide Improves Survival in Adult Patients with Glioblastoma. A. DARLIX, C. BAUMANN, V. LORGIS, F. GHIRINGHELLI, M. BLONSKI, B. CHAUFFERT, S. ZOUAOUI, C. PINELLI, F. RECH, P. BEAUCHESNE, L. TAILLANDIER (<i>Nancy; Dijon; Amiens; Montpellier, France</i>)	3467
Overexpression of <i>Survivin</i> Levels in Circulation and Tissue Samples of Lung Cancer Patients. G. KAPELLOS, K. POLONIFI, D. FARMAKIS, E. SPARTALIS, P. TOMOS, A. AESSOPOS, A. POLIZOS, M. MANTZOURANI (<i>Athens, Greece</i>)	3475
HPV Status and Overall Survival of Patients with Oropharyngeal Squamous Cell Carcinoma – A Retrospective Study of a German Head and Neck Cancer Center. A. TAHTALI, C. HEY, C. GEISSLER, N. FILMAN, M. DIENSTHUBER, M. LEINUNG, T. STÖVER, J. WAGENBLAST (<i>Frankfurt am Main, Germany</i>)	3481
Sorafenib plus Daily Low-dose Temozolomide for Relapsed Glioblastoma: A Phase II Study. F. ZUSTOVICH, L. LANDI, G. LOMBARDI, C. PORTA, L. GALLI, A. FONTANA, D. AMOROSO, C. GALLI, M. ANDREUCCETTI, A. FALCONE, V. ZAGONEL (<i>Padova; Livorno; Pavia; Pisa; Viareggio; Firenze, Italy</i>)	3487
Treatment Outcomes and Prognostic Factors for Thoracic Esophageal Cancer with Clinical Evidence of Adjacent Organ Invasion. Y. HAMAI, J. HIHARA, M. EMI, J. TAOMOTO, Y. AOKI, I. KISHIMOTO, Y. IBUKI, M. OKADA (<i>Hiroshima, Japan</i>)	3495
Two Different Hypofractionated Breast Radiotherapy Schedules for 113 Patients with Ductal Carcinoma <i>In Situ</i> : Preliminary Results. M. GUENZI, F. GIANNELLI, D. BOSETTI, G. BLANDINO, M.L. MILANESE, F. PUPILLO, R. CORVÒ, A. FOZZA (<i>Genoa, Italy</i>)	3503
Cessation of Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myelogenous Leukemia Following Durable Complete Molecular Response: A Single Center Facing the Dilemma. T. ILIAKIS, V. PAPAPOPOULOU, P.T. DIAMANTOPOULOS, P. PANAYIOTIDIS, K. ZERVAKIS, N. GIANNAKOPOULOU, G. TILIMIDOS, M. ANGELOPOULOU, M.P. SIAKANTARIS, G. PANGALIS, M. MANTZOURANI, E. VARIAMI, N.A. VINIOU (<i>Athens, Greece</i>)	3509
Intrathecal Liposomal Cytarabine and Leptomeningeal Medulloblastoma Relapse: A Valuable Therapeutic Option. A. MASTRONUZZI, F. DEL BUFALO, A. IACONO, D.E. SECCO, A. SERRA, G.S. COLAFATI, M.A. DE IORIS, T. CORSETTI (<i>Rome, Italy</i>)	3515
Errata	3519
Book Reviews	3521

Number 9

Reviews

Ubiquitination and the Ubiquitin – Proteasome System in the Pathogenesis and Treatment of Squamous Head and Neck Carcinoma. I. A. VOUTSADAKIS (<i>Sault Ste Marie, Canada</i>)	3527
Mitochondrial DNA Damage Is Uncommon in Cancer but Can Promote Aggressive Behaviour. B. D. MAYBURY (<i>Cardiff, U.K.</i>)	3543
The Value of Pemetrexed for the Treatment of Malignant Pleural Mesothelioma: A Comprehensive Review. C. C.L.M. BOONS, M. W. VAN TULDER, J. A. BURGERS, J. J. BECKERINGH, C. WAGNER, J. G. HUGTENBURG (<i>Amsterdam; Amstelveen; Utrecht, the Netherlands</i>)	3553

Experimental Studies

APO010, A Synthetic Hexameric CD95 Ligand, Induces Death of Human Glioblastoma Stem-like Cells. G. EISELE, F. WOLPERT, G. DECREY, M. WELLER (*Zurich, Switzerland*) 3563

Targeting Ovarian Cancer and Chemoresistance Through Selective Inhibition of Sphingosine Kinase-2 with ABC294640. M. D. WHITE, L. CHAN, J. W. ANTOON, B. S. BECKMAN (*New Orleans, LA, U.S.A.*) 3573

Comparing the Effects of COX and Non-COX-inhibiting NSAIDs on Enhancement of Apoptosis and Inhibition of Aberrant Crypt Foci Formation in a Rat Colorectal Cancer Model. J. E. MARTIN, G. P. YOUNG, R. K. LE LEU, Y. HU (*Adelaide, Australia*) 3581

HOCl-dependent Singlet Oxygen and Hydroxyl Radical Generation Modulate and Induce Apoptosis of Malignant Cells. G. BAUER (*Freiburg, Germany*) 3589

Efficacy of Liposomal Curcumin in a Human Pancreatic Tumor Xenograft Model: Inhibition of Tumor Growth and Angiogenesis. A. P. RANJAN, A. MUKERJEE, L. HELSON, R. GUPTA, J. K. VISHWANATHA (*Fort Worth, TX; Quakertown, PA, U.S.A.*) 3603

Stable Knockdown of *hCGβ* mRNA Expression in Bladder Cancer Cells Results in Significant Growth Inhibition. B. BURCZYNSKA, M. J. BOOTH, R. K. ILES, A. SHAH, A. SHILED, S. A. BUTLER (*London; Crieff, Scotland, U.K.; Poznan, Poland*) 3611

Antitumor Activity of Elacytarabine Combined with Bevacizumab, Cetuximab and Trastuzumab in Human NSCLC Xenografts. S. BRUHEIM, M. L. SANDVOLD, G. M. MÆLANDSMO, Ø. FODSTAD (*Oslo, Norway*) 3615

High Lung-metastatic Variant of Human Osteosarcoma Cells, Selected by Passage of Lung Metastasis in Nude Mice, Is Associated with Increased Expression of $\alpha_v\beta_3$ Integrin. Y. TOME, H. KIMURA, H. MAEHARA, N. SUGIMOTO, M. BOUVET, H. TSUCHIYA, F. KANAYA, R. M. HOFFMAN (*San Diego, CA, U.S.A.; Okinawa; Kanazawa, Japan*) 3623

Effect of Liposomal Curcumin on Red Blood Cells *In Vitro*. A. STORKA, B. VCELAR, U. KLICKOVIC, G. GOUYA, S. WEISSHAAR, S. ASCHAUER, L. HELSON, M. WOLZT (*Vienna; Klosterneuburg, Austria; Quakertown, PA, U.S.A.*) 3629

Prediction of Immune Surveillance Responsive Metastatic Prostate Cancer in Pelvic Lymph Node and Emergence of Surveillance Unresponsive/Resistant Metastatic Cells. A. A. SINHA, E. T. FERNANDES, S. L. EWING, M. J. WILSON (*Minneapolis, MN, U.S.A.*) 3635

Enhanced Redox Factor 1 (REF1)-modulated p53 Stabilization and JNK1 Dissociation in Response to Selenomethionine. H. J. JUNG, H. L. KIM, Y. R. SEO (*Bronx, NY, U.S.A.; Seoul, Republic of Korea*) ... 3645

The Neutrophil Elastase Inhibitor Sivelestat Suppresses Accelerated Gastrointestinal Tumor Growth via Peritonitis After Cecal Ligation and Puncture. K. KUMAGAI, Y. SAIKAWA, H. TAKEUCHI, K. SUDA, K. FUKUDA, R. NAKAMURA, T. TAKAHASHI, H. KAWAKUBO, N. WADA, T. MIYASHO, Y. KITAGAWA (*Tokyo; Hokkaido, Japan*) 3653

Malignant Progressive Tumor Cell Clone Exhibits Significant Up-regulation of Cofilin-2 and 27-kDa Modified Form of Cofilin-1 Compared to Regressive Clone. Y. KURAMITSU, Y. WANG, F. OKADA, B. BARON, K. TOKUDA, T. KITAGAWA, J. AKADA, K. NAKAMURA (*Ube; Yonago, Japan*) 3661

Effects of Dietary Calcium on *Helicobacter pylori*-induced Gastritis in Mongolian Gerbils. M. IIMURO, S. NAKAMURA, T. ARAKAWA, K. WAKABAYASHI, M. MUTOH (*Hyogo; Osaka; Shizuoka; Tokyo, Japan*) 3667

Vagus Nerve Regulates Breast Cancer Metastasis to the Adrenal Gland. N. ERIN, G. A. BARKAN, G. A. CLAWSON (<i>Antalya, Turkey; Maywood, IL; Hershey, PA, U.S.A.</i>)	3675
Association of Slow Acetylation Profile of <i>NAT2</i> with Breast and Gastric Cancer Risk in Brazil. M. R. FERNANDES, D. C. DE CARVALHO, Â. K. C. R. DOS SANTOS, S. E. B. DOS SANTOS, P. P. DE ASSUMPÇÃO, R. M. R. BURBANO, N. P. C. DOS SANTOS (<i>Belém, Brazil</i>)	3683
Fluoxetine-induced Apoptosis in Hepatocellular Carcinoma Cells. A -R. MUN, S. -J. LEE, G. -B. KIM, H. -S. KANG, J. -S. KIM, S. -J. KIM (<i>Jeonju, Republic of Korea</i>)	3691
Tropomyosin-related Kinase B Inhibitor Has Potential for Tumor Regression and Relapse Prevention in Pulmonary Large Cell Neuroendocrine Carcinoma. S. ODATE, H. ONISHI, K. NAKAMURA, M. KOJIMA, A. UCHIYAMA, M. KATO, M. KATANO (<i>Fukuoka, Japan</i>)	3699
<i>HER2/neu</i> Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy. M. BRUNELLI, E. MANFRIN, E. BRIA, F. MASSARI, G. TORTORA, E. BRUNELLO, L. CARBOGNIN, A. NOTTEGAR, J. FURLANETTO, A. MOLINO, E. FIORIO, M. CHILOSI, B. JASANI, M. VERGINE, L. MARCOLINI, D. FILIPPINI, A. SCARPA, G. MARTIGNONI, F. BONETTI (<i>Verona, Italy; Cardiff; Brighton, U.K.</i>)	3705
Differential Expression of p-mTOR in Cutaneous Basal and Squamous Cell Carcinomas Likely Explains their Different Response to mTOR Inhibitors in Organ-transplant Recipients. G. KARAYANNOPOULOU, S. EUVRARD, J. KANITAKIS (<i>Thessaloniki, Greece; Lyon, France</i>)	3711
Tumor-stromal Interactions with Direct Cell Contacts Enhance Motility of Non-small Cell Lung Cancer Cells Through the Hedgehog Signaling Pathway. C. CHOE, Y. -S. SHIN, S. -H. KIM, M. -J. JEON, S. -J. CHOI, J. LEE, J. KIM (<i>Seoul, Republic of Korea</i>)	3715
The Diagnostic Value of Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Measurement in the Sera of Patients with Endometrial Cancer. K. ORYWAL, W. JELSKI, M. ZDRODOWSKI, M. SZMITKOWSKI (<i>Bialystok, Poland</i>)	3725
Utility of ATP7B in Prediction of Response to Platinum-based Chemotherapy in Urothelial Bladder Cancer. S. C. SCHMID, T. SCHUSTER, T. HORN, J. GSCHWEND, U. TREIBER, G. WEIRICH (<i>Munich, Germany</i>)	3731
Antitumorigenic Effect of Dietary Natural Compounds via Lipid Metabolism Modulation in <i>Apc^{Min/+}</i> Mice. M. NOTARNICOLA, V. TUTINO, A. TAFARO, F. AMATULLI, M. G. CARUSO (<i>Bari, Italy</i>)	3739
Expression of α B-Crystallin and Vascular Endothelial Growth Factor in Conjunctival Squamous Cell Carcinoma. Z. DONG, S. KASE, R. ANDO, J. FUKUHARA, S. KINOSHITA, Y. DONG, S. TAKASHINA, A. KANDA, M. NODA, K. NODA, S. ISHIDA (<i>Sapporo, Japan</i>)	3745
Combination of the EGFR Tyrosine Kinase Inhibitor AG1478 and 5-FU: No Synergistic Effect on EGFR Phosphorylation, Cell Proliferation and Apoptosis Induction. V. YAGUBLU, Z. AHMADOVA, Y. HAJIYEVA, M. HAFNER, M. KEESE (<i>Mannheim; Frankfurt, Germany</i>)	3753
PTK7 Expression in Triple-negative Breast Cancer. B. ATASEVEN, R. ANGERER, R. KATES, A. GUNESCH, P. KNYAZEV, B. HÖGEL, C. BECKER, W. EIERMANN, N. HARBECK (<i>Munich; Essen; Martinsried, Germany</i>)	3759
Frequent Promoter Methylation of <i>CDH1</i> in Non-neoplastic Mucosa of Sporadic Diffuse Gastric Cancer. K. H. LEE, D. HWANG, K. Y. KANG, S. LEE, D. Y. KIM, Y. E. JOO, J. H. LEE (<i>Gwangju; Namwon, Republic of Korea</i>)	3765

<i>ESR1</i> Gene Amplification in Endometrial Carcinomas: A Clinicopathological Analysis. M. T. RAHMAN, K. NAKAYAMA, M. RAHMAN, M. ISHIKAWA, H. KATAGIRI, A. KATAGIRI, T. ISHIBASHI, E. SATO, K. IIDA, N. ISHIKAWA, N. NAKAYAMA, K. MIYAZAKI (<i>Izumo, Japan</i>)	3775
Macrophage Apolipoprotein E and Proliferation of MCF-7 Breast Cancer Cells: Role of LXR. A. EL ROZ, J. -M. BARD, S. VALIN, J. -M. HUVELIN, H. NAZIH (<i>Nantes, France</i>)	3783
Lewis Lung Carcinoma Progression Is Facilitated by TIG-3 Fibroblast Cells. Y. YAMAUCHI, Y. IZUMI, K. ASAKURA, K. KAWAI, M. WAKUI, M. OHMURA, M. SUEMATSU, H. NOMORI (<i>Tokyo; Kanagawa, Japan</i>)	3791
Multiple Anticancer Effects of Damsin and Coronopilin Isolated from <i>Ambrosia arborescens</i> on Cell Cultures. R. VILLAGOMEZ, G. C. RODRIGO, I. G. COLLADO, M. A. CALZADO, E. MUÑOZ, B. ÅKESSON, O. STERNER, G. R. ALMANZA, R. -D. DUAN (<i>La Paz, Bolivia; Lund, Sweden; Cadiz; Córdoba, Spain</i>)	3799
Zoledronic Acid-induced Cytotoxicity Through Endoplasmic Reticulum Stress Triggered REDD1-mTOR Pathway in Breast Cancer Cells. Y.-C. LAN, C. -L. CHANG, M. -T. SUNG, P. -H. YIN, C. -C. HSU, K. -C. WANG, H. -C. LEE, L. -M. TSENG, C. -W. CHI (<i>Taipei, Taiwan, R.O.C.</i>)	3807
Vascular Endothelial Growth Inhibitor (VEGI) Is an Independent Indicator for Invasion in Human Pituitary Adenomas. W. JIA, A. J. SANDER, G. JIA, M. NI, X. LIU, R. LU, W. G. JIANG (<i>Beijing, P. R. China; Cardiff, U.K.</i>)	3815
<i>Clinical Studies</i>	
Combination Metronomic Oral Topotecan and Pazopanib: A Pharmacokinetic Study in Patients with Gynecological Cancer. D. C. TURNER, T. D. TILLMANN, K. E. HARSTEAD, S. L. THROM, C. F. STEWART (<i>Memphis, TN, U.S.A.</i>)	3823
Docetaxel in the Treatment of Non-small Cell Lung Cancer (NSCLC) – An Observational Study Focusing on Symptom Improvement. A. PIRCHER, I. K. WASLE, M. MIAN, G. GAMERITH, E. ULSPERGER, M. STUDNICKA, A. MOHN-STAUDNER, W. HILBE, M. FIEGL (<i>Innsbruck; Vienna; Salzburg, Austria</i>)	3831
Efficacy of Combined Androgen Blockade with Zoledronic Acid Treatment in Prostate Cancer with Bone Metastasis: The ZABTON-PC (Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer) Study. S. UENO, A. MIZOKAMI, T. FUKAGAI, N. FUJIMOTO, H. OH-OKA, Y. KONDO, G. ARAI, H. IDE, S. HORIE, O. UEKI, K. KAWAGUCHI, M. SHIMAMURA, M. ORITO, T. ISHIDA, D. IKEDA, M. NAMIKI (<i>Kanazawa; Tokyo; Fukuoka; Kobe; Koshigaya; Nanao; Takaoka, Japan</i>)	3837
Pharmacokinetic Assessment of Irinotecan, SN-38, and SN-38-Glucuronide: A Substudy of the FIRIS Study. T. SATOH, H. YASUI, K. MURO, Y. KOMATSU, S. SAMESHIMA, K. YAMAGUCHI, K. SUGIHARA (<i>Suita; Shizuoka; Nagoya; Sapporo; Saitama; Tokyo, Japan</i>)	3845
Immunological Response after <i>WT1</i> mRNA-loaded Dendritic Cell Immunotherapy in Ovarian Carcinoma and Carcinosarcoma. A. COOSEMANS, A. VANDERSTRAETEN, S. TUYAERTS, T. VERSCHUERE, P. MOERMAN, Z. BERNEMAN, I. VERGOTE, F. AMANT, S. W. VAN GOOL (<i>Leuven; Antwerp, Belgium</i>)	3855
Vitamin D Favorably Alters the Cancer Promoting Prostaglandin Cascade. W. QIN, C. SMITH, M. JENSEN, M. F. HOLICK, E. R. SAUTER (<i>Tyler, TX; Fargo, ND; Boston, MA, U.S.A.</i>)	3861
Morbid Obesity Does Not Disadvantage Patients with <i>In Situ</i> or Early-stage Carcinoma Undergoing Breast-conserving Surgery. F. AMPIL, G. CALDITO, B. LI, S. DEVARAKONDA, G. BURTON, R. H. KIM, Q. CHU (<i>Shreveport, LA, U.S.A.</i>)	3867

<i>In Vitro</i> Demonstration of Synergy/Additivity Between ¹⁸⁸ Rhenium and Sorafenib on Hepatoma Lines: Preliminary Results. M. PRACHT, J. EDELINE, N. LEPAREUR, L. LENOIR, V. ARDISSON, B. CLEMENT, J. -L. RAOUL, O. AUDRAIN, E. BOUCHER, E. GARIN (<i>Rennes; Marseille, France</i>)	3871
Brentuximab Vedotin: First-line Agent for Advanced Hodgkin Lymphoma. H. CAO, K. YAMAMOTO, L. -X. YANG, R. WEBER (<i>San Francisco, CA, U.S.A.</i>)	3879
Number of Involved Extracranial Organs Predicts Survival in Patients with Brain Metastasis from Small Cell Lung Cancer. L. GERDAN, B. ŠEGEDIN, T. VENINGA, S. E. SCHILD, D. RADES (<i>Lübeck, Germany; Ljubljana, Slovenia; Tilburg, the Netherlands; Scottsdale, AZ, U.S.A.</i>).....	3887
Definition of p53 Overexpression and its Association with the Clinicopathological Features in Luminal/HER2-negative Breast Cancer. S. KIKUCHI, R. NISHIMURA, T. OSAKO, Y. OKUMURA, Y. NISHIYAMA, Y. TOYOZUMI, N. ARIMA (<i>Kumamoto, Japan</i>)	3891
Stereotactic Radiosurgery Plays a Critical Role in Enhancing Long-term Survival in a Patient with Pancreatic Cancer Metastatic to the Brain. P. RAJAPPA, K. MARGETIS, G. WERNICKE, P. GINTER, W. COPE, D. L. SHERR, E. LAVI, R. L. FINE, T. H. SCHWARTZ, H. BRUCKNER, S. C. PANNULLO (<i>New York, NY, U.S.A.</i>)	3899
Circulating Tumor Cell (CTC) Count and Epithelial Growth Factor Receptor Expression on CTCs as Biomarkers for Cetuximab Efficacy in Advanced Colorectal Cancer. Y. KUBOKI, S. MATSUSAKA, S. MINOWA, H. SHIBATA, M. SUENAGA, E. SHINOZAKI, N. MIZUNUMA, M. UENO, T. YAMAGUCHI, K. HATAKE (<i>Tokyo, Japan</i>).....	3905
A Rare Occurrence of Biphasic Pulmonary Blastoma in an Elderly Male. A. SHARMA, K. O'GORMAN, C. AMAN, D. RASSL, W. MOHAMID, A. POLYCHRONIS (<i>Northwood; Cambridge; Stevenage, U.K.</i>)	3911
Consideration of Primary Diseases and Concomitant Therapies. A. T. ASSAF, R. SMEETS, B. RIECKE, E. WEISE, A. GRÖBE, M. BLESSMANN, T. STEINER, J. WIKNER, R. E. FRIEDRICH, M. HEILAND, F. HOELZLE, F. GERHARDS (<i>Hamburg; Aachen, Germany</i>)	3917
Prediction of Nodal Metastasis and Prognosis of Breast Cancer by ANN-based Assessment of Tumour Size and p53, Ki-67 and Steroid Receptor Expression. S. MOJARAD, B. VENTURINI, P. FULGENZI, R. PAPALEO, M. BRISIGOTTI, F. MONTI, D. CANUTI, A. RAVAIOLI, L. WOO, S. DLAY, G. V. SHERBET (<i>Newcastle upon Tyne, U.K.; Rimini, Italy; Huntington Beach, CA, U.S.A.</i>).....	3925
The Surgeon as the Most Important Factor in Lymph Node Harvest During Axillary Clearance. D. N. NAUMANN, M. SINTLER (<i>Birmingham, U.K.</i>)	3935
Impact of Chemotherapy with S-1 and Oxaliplatin (SOX) in Combination with Molecular-targeting Agents on Colorectal Liver Metastases. K. WATANABE, H. KAWAHARA, H. ENOMOTO, Y. TOYAMA, T. AKIBA, K. YANAGA (<i>Chiba; Tokyo, Japan</i>)	3941
A High Serum Uric Acid Level Is Associated with Poor Prognosis in Patients with Acute Myeloid Leukemia. T. YAMAUCHI, E. NEGORO, S. LEE, M. TAKAI, Y. MATSUDA, K. TAKAGI, S. KISHI, K. TAI, N. HOSONO, T. TASAKI, S. IKEGAYA, K. INAI, A. YOSHIDA, Y. URASAKI, H. IWASAKI, T. UEDA (<i>Eiheiji, Japan</i>)	3947
Prognostic Value of Nuclear Translocation of Aryl Hydrocarbon Receptor for Non-small Cell Lung Cancer. J. -M. SU, P. LIN, H. CHANG (<i>Taichung; Zhunan, Taiwan, R.O.C.</i>).....	3953
Comparisons of Late Vaginal Mucosal Reactions Between Interstitial and Conventional Intracavitary Brachytherapy in Patients with Gynecological Cancer: Speculation on the Relation Between Pallor Reaction and Stenosis. K. YOSHIDA, H. YAMAZAKI, S. NAKAMURA, K. MASUI, T. KOTSUMA, S. J. BAEK, H. AKIYAMA, E. TANAKA, Y. YOSHIOKA (<i>Takatsuki; Kyoto; Osaka; Suita, Japan</i>).....	3963

Podoplanin and VEGF-C Immunoexpression in Oral Squamous Cell Carcinomas: Prognostic Significance. A. D. S. ALMEIDA, D. T. OLIVEIRA, M. C. PEREIRA, S. E. S. FAUSTINO, S. NONOGAKI, A. L. CARVALHO, L. P. KOWALSKI (<i>Bauru; Divinópolis; São Paulo; Barretos, Brazil</i>)	3969
Microsatellite Instability Analysis for the Screening of Synchronous Endometrial and Ovarian Cancer in Lynch Syndrome. A. -S. BATS, H. ROUSSEL, C. NARJOZ, M. -A. LE FRERE-BELDA, F. CHAMMING'S, H. BLONS, P. LAURENT-PUIG, F. LECURU (<i>Paris, France</i>)	3977
<i>TXNDC5</i> Gene Polymorphism Contributes to Increased Risk of Hepatocellular Carcinoma in the Korean Male Population. M. -S. PARK, S. K. KIM, H. P. SHIN, S. -M. LEE, J. -H. CHUNG (<i>Seoul, Republic of Korea</i>)..	3983
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Sarcomatosis: Long-term Outcome from a Single Institution Experience. A. SOMMARIVA, S. PASQUALI, P. DEL FIORE, M. C. MONTESCO, P. L. PILATI, M. RASTRELLI, J. NIBA, D. NITTI, C. R. ROSSI (<i>Padova, Italy</i>).....	3989
Influence of Age on Short-term Complications after Intraoperative Radiotherapy in Women After Breast-conserving Surgery. B. TUSCHY, S. BERLIT, S. ROMERO, E. SPERK, F. WENZ, S. KEHL, M. SÜTTERLIN (<i>Mannheim, Germany</i>)	3995
Pancreatic Neuroendocrine Tumor with Ectopic Adrenocorticotropin Production: A Case Report and Review of Literature. F. B. PATEL, S. KHAGI, K. P. DALY, R. M. LECHAN, V. UMMARITCHOT, M. W. SAIF (<i>Boston, MA, U.S.A.</i>).....	4001
E6/E7 mRNA Expression of High-risk HPV Types in 849 Greek Women. E. ARGYRI, E. TSIMPLAKI, D. DASKALOPOULOU, D. J. STRAVOPODIS, O. KOUIKOGLOU, E. TERZAKIS, E. PANOTOPOULOU (<i>Athens, Greece</i>)	4007
Low-dose Fotemustine as Second-line Chemotherapy for Recurrent Glioblastoma Multiforme. F. DE FELICE, N. BULZONETTI, D. MUSIO, A. D'ELIA, M. SALVATI, V. TOMBOLINI (<i>Rome, Italy</i>)	4013
Water Swallow Screening Test for Patients After Surgery for Head and Neck Cancer: Early Identification of Dysphagia, Aspiration and Limitations of Oral Intake. C. HEY, B. P. LANGE, S. EBERLE, Y. ZARETSKY, R. SADER, T. STÖVER, J. WAGENBLAST (<i>Frankfurt/Main; Göttingen, Germany</i>)	4017
Clinical Influence of Endoscopic Resection on Subsequent Laparoscopic Gastrectomy for Gastric Cancer. S. KOMATSU, D. ICHIKAWA, T. KUBOTA, K. OKAMOTO, A. SHIOZAKI, H. FUJIWARA, H. KONISHI, R. MORIMURA, Y. MURAYAMA, Y. KURIU, H. IKOMA, M. NAKANISHI, C. SAKAKURA, T. OCHIAI, E. OTSUJI (<i>Kyoto, Japan</i>).....	4023
Feasibility Study of Oxaliplatin with Oral S-1 or Capecitabine as First-line Therapy for Patients with Metastases from Colorectal Cancer. K. WATANABE, H. KAWAHARA, H. ENOMOTO, Y. TOYAMA, T. AKIBA, K. YANAGA (<i>Chiba; Tokyo, Japan</i>)	4029
Effect of Thrombosis-related Gene Polymorphisms upon Oral Cancer: A Regression Analysis. A. VYLLIOTIS, C. YAPIJAKIS, E. NKENKE, T. NISYRIOS, D. AVGOUSTIDIS, M. ADAMOPOULOU, V. RAGOS, S. VASSILIOU, N. KORONELLOS, E. VAIRAKTARIS (<i>Athens; Ioannina, Greece; Nuernberg, Germany</i>)	4033
Negative Impact of Fresh-frozen Plasma Transfusion on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. H. SHIBA, T. MISAWA, Y. FUJIWARA, Y. FUTAGAWA, K. FURUKAWA, K. HARUKI, T. IIDA, R. IWASE, K. YANAGA (<i>Tokyo, Japan</i>)	4041
Genetic Profile and Determinants of Homocysteine Levels in Kazakhstan Patients with Breast Cancer. A. AKILZHANOVA, Z. NURKINA, K. MOMYNALIEV, E. RAMANCULOV, Z. ZHUMADILOV, T. RAKHYPBEKOV, N. HAYASHIDA, M. NAKASHIMA, N. TAKAMURA (<i>Nagasaki, Japan; Astana; Semey, Kazakhstan</i>).....	4049

Bevacizumab as Front-line Treatment of Brain Metastases from Solid Tumors: A Case Series. F. ZUSTOVICH, A. FERRO, G. LOMBARDI, V. ZAGONEL, P. FIDUCCIA, P. FARINA (<i>Padua, Italy</i>)	4061
Effects of Ataxia Telangiectasia Mutated (<i>ATM</i>) Genotypes and Smoking Habits on Lung Cancer Risk in Taiwan. T. -C. HSIA, C. -W. TSAI, S. -J. LIANG, W. -S. CHANG, L. -Y. LIN, W. -C. CHEN, C. -Y. TU, C. -H. TSAI, D. -T. BAU (<i>Taichung, Taiwan, R.O.C.</i>).....	4067
Phosphorylated S6 Kinase-1: A Breast Cancer Marker Predicting Resistance to Neoadjuvant Chemotherapy. E. -K. KIM, J. H. KIM, H. -A. KIM, H. SEOL, M. -K. SEONG, J. -Y. LEE, J. BYEON, Y. J. SOHN, J. S. KOH, I. -C. PARK, W. C. NOH (<i>Seoul, Korea</i>)	4073
Patient Outcome After Complete Surgery for Retroperitoneal Sarcoma. C. R. ROSSI, A. VAROTTO, S. PASQUALI, L. G. CAMPANA, S. MOCELLIN, A. SOMMARIVA, M. C. MONTESCO, M. RASTRELLI, A. VECCHIATO, P. PILATI, D. NITTI (<i>Padova, Italy</i>)	4081
Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study. M. SALGADO, M. REBOREDO, J. C. MENDEZ, G. QUINTERO, M. L. PELLÓN, C. ROMERO, M. JORGE, A. F. MONTES, M. VALLADARES-AYERBES, M. RAMOS, S. VARELA, M. Á. ALONSO (<i>Ourense; A Coruña; Ferrol; Vigo, Spain</i>)	4089
Urinary Neopterin Concentration and Toxicity of Radiotherapy in Patients with Head and Neck Carcinoma During External Beam Radiation. P. HOLEČKOVÁ, L. KRČMOVÁ, J. LÉTAL, A. SVOBODNÍK, H. KALÁBOVÁ, M. KAŠPAROVÁ, J. PLÍŠEK, M. PÁLA, P. VÍTEK, D. SOLICHOVÁ, M. ZEŽULOVÁ, H. ŠTUDENTOVÁ, M. DOLEŽEL, B. MELICHAR (<i>Prague; Hradec Králové; Brno; Olomouc; Czech Republic</i>).....	4097
Aberrant Expression of CXCR4 and β -Catenin in Pancreatic Cancer. Z. WANG, Q. MA, P. LI, H. SHA, X. LI, J. XU (<i>Xi'an, P.R. China</i>)	4103
Anal Carcinoma: Surgery Does Not Influence Prognosis When Performed Prior to Concurrent Radiochemotherapy. H. BADA KHSHI, V. BUDACH, P. WUST, R. GRAF (<i>Berlin, Germany</i>)	4111
Image-guided Radiotherapy with Implanted Markers and Kilovoltage Imaging and 6-dimensional Position Corrections for Intrafractional Motion of the Prostate. H. BADA KHSHI, P. WUST, V. BUDACH, R. GRAF (<i>Berlin, Germany</i>)	4117
Prognostic Factors of Metastatic or Recurrent Esophageal Squamous Cell Carcinoma in Patients Receiving Three-drug Combination Chemotherapy. W. -W. CHEN, C. -C. LIN, T. -C. HUANG, A. -L. CHENG, K. -H. YEH, C. -H. HSU (<i>Taipei; Yunlin, Taiwan, R.O.C</i>)	4123
Predictive Factors for Recurrence and Survival in Hepatocellular Carcinoma in South Korea. C. H. JUN, D. W. SIM, S. H. KIM, H. J. HONG, M. W. CHUNG, E. MYOUNG, H. R. KOH, S. B. CHO, H. S. KIM, S. K. CHOI, J. S. REW (<i>Gwangju; Mokpo, Republic of Korea</i>)	4129
Errata	4135

Number 10

Reviews

Epidermal Growth Factor Receptor (EGFR)-targeted Therapies in Esophagogastric Cancer. S. AYYAPPAN, D. PRABHAKAR, N. SHARMA (<i>Cleveland, OH, USA</i>)	4139
Overcoming Platinum Drug Resistance with Copper-lowering Agents. H.H.W. CHEN, M.T. KUO (<i>Tainan, Taiwan; Houston, TX, USA</i>)	4157

Chemoprevention of Prostate Cancer by Major Dietary Phytochemicals. A. BOMMAREDDY, W. EGGLESTON, S. PRELEWICZ, A. ANTAL, Z. WITCZAK, D.F. MCCUNE, A.L. VANWERT (<i>Wilkes-Barre, PA, USA</i>)	4163
Musculoskeletal Sarcomas in the Forearm and Hand: Standard Treatment and Microsurgical Reconstruction for Limb Salvage. K. MURAMATSU, K. IHARA, K. YOSHIDA, Y. TOMINAGA, T. HASHIMOTO, T. TAGUCHI (<i>Ube; Shimonoseki, Yamaguchi, Japan</i>)	4175
Saving Ears and Kidneys from Cisplatin. K.U. WENSING, G. CIARIMBOLI (<i>Münster, Germany</i>)	4183
<i>Experimental Studies</i>	
Antigen-specific <i>In Vitro</i> Expansion of Functional Redirected NY-ESO-1-specific Human CD8+ T-Cells in a Cell-free System. G. JAKKA, P.C. SCHUBERTH, M. THIEL, G. HELD, F. STENNER, M. VAN DEN BROEK, C. RENNER, A. MISCHO, U. PETRAUSCH (<i>Zurich; Basel, Switzerland; Homburg/Saar, Germany</i>)	4189
Immunohistochemical Quantification of the Vitamin B12 Transport Protein (TCII), Cell Surface Receptor (TCII-R) and Ki-67 in Human Tumor Xenografts. A.M. SYSEL, V.E. VALLI, R.B. NAGLE, J.A. BAUER (<i>Akron, OH; Davis, CA; Tucson, AZ, USA</i>)	4203
A Novel Mouse Model of Metastatic Thyroid Carcinoma Using Human Adipose Tissue-Derived Stromal/Stem Cells. E. KANDIL, A. HAUCH, P. FRIEDLANDER, K. TSUMAGARI, A. SAEED, J.M. GIMBLE, B.G. ROWAN (<i>New Orleans; Baton Rouge, LA, USA</i>)	4213
Biological Correlation of ¹⁸ F-FDG Uptake on PET in Pulmonary Neuroendocrine Tumors. K. KAIRA, H. MURAKAMI, M. ENDO, Y. OHDE, T. NAITO, H. KONDO, T. NAKAJIMA, N. YAMAMOTO, T. TAKAHASHI (<i>Shizuoka, Japan</i>)	4219
Imaging Nuclear - Cytoplasm Dynamics of Cancer Cells in the Intravascular Niche of Live Mice. A. SUETSUGU, P. JIANG, H. MORIWAKI, S. SAJI, M. BOUVET, R.M. HOFFMAN (<i>San Diego, CA, USA; Gifu, Japan</i>)	4229
Therapy with siRNA for <i>Vegf-c</i> but Not for <i>Vegf-d</i> Suppresses Widespectrum Organ Metastasis in an Immunocompetent Xenograft Model of Metastatic Mammary Cancer. M.-A. SHIBATA, E. SHIBATA, J. MORIMOTO, M. HARADA-SHIBA (<i>Osaka; Suita; Takatsuki, Osaka, Japan</i>)	4237
Prevention of Carboplatin-induced Resistance in Human Ovarian Tumor Xenografts by Selenite. P.B. CAFFREY, G.D. FRENKEL (<i>California, PA; Newark, NJ, USA</i>)	4249
Effects of Sevoflurane on Breast Cancer Cell Function <i>In Vitro</i> . P. ECIMOVIC, B. MCHUGH, D. MURRAY, P. DORAN, D.J. BUGGY (<i>Dublin, Ireland; Cleveland, OH, USA</i>)	4255
Expression of High Mobility Group A Proteins in Oral Leukoplakia. L. LARSSON, F. JÄWERT, B. MAGNUSSON, B. HASSÉUS, G. KJELLER (<i>Gothenburg, Sweden</i>)	4261
Fully-automated Radiosynthesis and <i>In Vitro</i> Uptake Investigation of [<i>N</i> -methyl- ¹¹ C]methylene Blue. L.F. SCHWEIGER, T.A.D. SMITH (<i>Aberdeen, UK</i>)	4267
Id4 Promotes Senescence and Sensitivity to Doxorubicin-induced Apoptosis in DU145 Prostate Cancer Cells. J.P. CAREY, A.E. KNOWELL, S. CHINARANAGARI, J. CHAUDHARY (<i>Atlanta, GA, USA</i>)	4271
Ursolic Acid Inhibits the Growth of Colon Cancer-initiating Cells by Targeting STAT3. W. WANG, C. ZHAO, D. JOU, J. LÜ, C. ZHANG, L. LIN, J. LIN (<i>Wuhan, PR China; Columbus, OH, USA</i>)	4279
Development and Pharmacokinetic Evaluation of a Curcumin Co-solvent Formulation. M.K. JOHN, H. XIE, E.C. BELL, D. LIANG (<i>Houston, TX, USA</i>)	4285

<i>NOTCH</i> Knockdown Affects the Proliferation and mTOR Signaling of Leukemia Cells. Y. OKUHASHI, M. ITOH, N. NARA, S. TOHDA (<i>Tokyo, Japan</i>)	4293
Establishment of New Intraperitoneal Paclitaxel-Resistant Gastric Cancer Cell Lines and Comprehensive Gene Expression Analysis. H. MURAKAMI, S. ITO, H. TANAKA, E. KONDO, Y. KODERA, H. NAKANISHI (<i>Nagoya, Japan</i>)	4299
Aberrant Expression of EZH2 Is Associated with Pathological Findings and P53 Alteration. S. SHIOGAMA, S. YOSHIBA, D. SOGA, H. MOTOHASHI, S. SHINTANI (<i>Tokyo, Japan</i>)	4309
Eicosapentaenoic Acid Modifies Cytokine Activity and Inhibits Cell Proliferation in an Oesophageal Cancer Cell Line. H. KUBOTA, H. MATSUMOTO, M. HIGASHIDA, H. MURAKAMI, H. NAKASHIMA, Y. OKA, H. OKUMURA, M. YAMAMURA, M. NAKAMURA, T. HIRAI (<i>Okayama Japan</i>)	4319
Loss of 5-Hydroxymethylcytosine and TET2 in Oral Squamous Cell Carcinoma. F. JÄWERT, B. HASSÉUS, G. KJELLER, B. MAGNUSSON, L. SAND, L. LARSSON (<i>Gothenburg; Uppsala, Sweden</i>)	4325
Prognostic Significance of p21 Expression in Patients with Esophageal Squamous Cell Carcinoma. A. SHIOZAKI, S. NAKASHIMA, D. ICHIKAWA, H. FUJIWARA, H. KONISHI, S. KOMATSU, T. KUBOTA, K. OKAMOTO, D. IITAKA, H. SHIMIZU, Y. NAKO, K. TAKEMOTO, M. KISHIMOTO, E. OTSUJI (<i>Kyoto, Japan</i>).....	4329
Radiation-induced Dimer Formation of EGFR: Implications for the Radiosensitizing Effect of Cetuximab. M. KIYOZUKA, T. AKIMOTO, M. FUKUTOME, A. MOTEGI, N. MITSUHASHI (<i>Tokyo, Tokyo; Kashiwa, Chiba, Japan</i>).....	4337
7-Substituted Coumarins Inhibit Proliferation and Migration of Laryngeal Cancer Cells <i>In Vitro</i> . M. KIEŁBUS, K. SKALICKA-WOŹNIAK, A. GRABARSKA, W. JELENIEWICZ, M. DMOSZYŃSKA-GRANICZKA, A. MARSTON, K. POLBERG, P. GAWDA, J. KLATKA, A. STEPULAK (<i>Lublin, Poland; Bloemfontein, Republic of South Africa</i>)	4347
Differential Protein Expression of Lymph Node Metastases of Papillary Thyroid Carcinoma Harboring the <i>BRAF</i> Mutation. W.S. PARK, K.-W. CHUNG, M.S. YOUNG, S.-K. KIM, Y.J. LEE, E.K. LEE (<i>Seoul; Goyang, Republic of Korea</i>)	4357
Anti-proliferative and Pro-apoptotic Effects from Sequenced Combinations of Andrographolide and Cisplatin on Ovarian Cancer Cell Lines. N.M. YUNOS, S.S.M. MUTALIP, M.H. JAURI, J.Q. YU, F. HUQ (<i>Kepong, Selangor, Malaysia; Lidcombe, NSW, Australia</i>)	4365
Enhancing the Activity of Cannabidiol and Other Cannabinoids <i>In Vitro</i> Through Modifications to Drug Combinations and Treatment Schedules. K.A. SCOTT, S. SHAH, A.G. DALGLEISH, W.M. LIU (<i>London, UK</i>)	4373
Circumvention of Inherent or Acquired Cytotoxic Drug Resistance <i>In Vitro</i> Using Combinations of Modulating Agents. D. CADAGAN, S. MERRY (<i>Stoke-on-Trent, UK</i>).....	4381
Cytotoxicity of Dihydroartemisinin Toward Molt-4 Cells Attenuated by <i>N-Tert</i> -butyl-alphaphenylnitron and Deferoxamine. H.W. CHAN, N.P. SINGH, H.C. LAI (<i>Seattle, WA, USA</i>)	4389
Conjugated Linoleate Reduces Prostate Cancer Viability Whereas the Effects of Oleate and Stearate Are Cell Line-dependent. R.M. HAGEN, A. RHODES, M.R. LADOMERY (<i>Bristol, UK; Kuala Lumpur, Malaysia</i>)	4395
Effects of SRC and STAT3 upon Gap Junctional, Intercellular Communication in Lung Cancer Lines. M. GELETU, S. GUY, L. RAPTIS (<i>Kingston; Mississauga, ON, Canada</i>)	4401

Citric Acid Induces Cell-cycle Arrest and Apoptosis of Human Immortalized Keratinocyte Cell Line (HaCaT) via Caspase and Mitochondrial-dependent Signaling Pathways. T.-H. YING, C.-W. CHEN, Y.-P. HSIAO, S.-J. HUNG, J.-G. CHUNG, J.-H. YANG (<i>Taichung; Hualien, Taiwan, ROC</i>)	4411
Adipose-derived Stem Cells Induced EMT-like Changes in H358 Lung Cancer Cells. Y.M. PARK, S.H. YOO, S.-H. KIM (<i>Seongnam, Republic of Korea</i>)	4421
Nox4-derived ROS Signaling Contributes to TGF- β -induced Epithelial-mesenchymal Transition in Pancreatic Cancer Cells. R. HIRAGA, M. KATO, S. MIYAGAWA, T. KAMATA (<i>Nagano, Japan</i>)	4431
<i>In Vitro</i> Induction of Apoptosis and Necrosis by New Derivatives of Daunorubicin. M. STOJAK, L. MAZUR, M. OPYDO-CHANEK, M. ŁUKAWSKA, I. OSZCZAPOWICZ (<i>Cracow; Warsaw, Poland</i>)	4439
AG11, A Novel Dichloroflavanone Derivative with Anti-mitotic Activity Towards Human Bladder Cancer Cells. A. JUHEM, A. BOUMENDJEL, B. TOUQUET, A. GUILLOT, A. POPOV, X. RONOT, V. MARTEL-FRACHET (<i>Grenoble, France</i>)	4445
Repression of Cell Proliferation and Androgen Receptor Activity in Prostate Cancer Cells by 2'-Hydroxyflavanone. M. OFUDE, A. MIZOKAMI, M. KUMAKI, K. IZUMI, H. KONAKA, Y. KADONO, Y. KITAGAWA, M. SHIN, J. ZHANG, E.T. KELLER, M. NAMIKI (<i>Kanazawa, Ishikawa, Japan; Guangxi, PR China; Ann Arbor, MI, USA</i>)	4453
Activity of LaSOM 65, a Monastrol-derived Compound, Against Glioblastoma Multiforme Cell Lines. C.S. STUEPP, F. FIGUEIRÓ, F.B. MENDES, E. BRAGANHOL, A. BERNARDI, R.L. FROZZA, C.G. SALBEGO, R.F.S. CANTO, D. RUSSOWSKY, V.L. EIFLER-LIMA, A.M.O. BATTASTINI (<i>Porto Alegre, Rio Grande do Sul, Brazil</i>)	4463
Low Production of Reactive Oxygen Species and High DNA Repair: Mechanism of Radioresistance of Prostate Cancer Stem Cells. Y.S. KIM, M.J. KANG, Y.M. CHO (<i>Seoul, Republic of Korea</i>)	4469
<i>Clinical Studies</i>	
Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer. A.A. TARHINI, H. ZAHOOR, B. MCLAUGHLIN, W.E. GOODING, J.C. SCHMITZ, J.M. SIEGFRIED, M.A. SOCINSKI, A. ARGIRIS (<i>Pittsburgh, PA; San Antonio, TX, USA</i>)	4475
Comprehensive Head and Neck Radiotherapy Dose-Volume Constraints Do Not Apply to Smaller Volumes. W.F. MOURAD, D. SHASHA, D.M. BLAKAJ, A.S. KHORSANDI, R.A. SHOURBAJI, J. GLANZMAN, R. KABARRITI, R. YOUNG, S. PATEL, E. KATSOULAKIS, M. GÁMEZ, R. WOODE, C. LAZARUS, C. CONCERT, K.S. HU, L.B. HARRISON (<i>New York, NY, USA</i>)	4483
Early-stage Central Lung Cancer and Volumetric Modulated Arc Therapy: A Dosimetric Case Study with Literature Review. V. VALAKH, P. CHAN, K. D'ADAMO, B. MICAILY (<i>Philadelphia, PA, USA</i>)	4491
Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer. Y. KITAGAWA, K. IZUMI, S. MIWA, Y. KADONO, H. KONAKA, A. MIZOKAMI, M. NAMIKI (<i>Kanazawa, Ishikawa, Japan</i>)	4497
Survival in Patients with Metastatic Spinal Cord Compression from Prostate Cancer Is Associated with the Number of Extra-spinal Organs Involved. A. WEBER, T. BARTSCHT, J.H. KARSTENS, S.E. SCHILD, D. RADES (<i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i>)	4505
Predictive Factors of Non-sentinel Lymph Node Involvement in Patients with Invasive Breast Cancer and Sentinel Node Micrometastases. D. FRIEDMAN, M. GIPPONI, F. MURELLI, P. MESZAROS, N. SOLARI, M. MASSA, F. DEPAOLI, P. BACCINI, F. CARLI, M. GALLO, F. CAFIERO (<i>Genoa, Italy</i>)	4509

Thoracoscopic Esophagectomy in the Prone Position for Esophageal Cancer with Right Aortic Arch: Case Report. S. KANAJI, T. NAKAMURA, Y. OTOWA, M. YAMAMOTO, K. YAMASHITA, T. IMANISHI, Y. SUMI, S. SUZUKI, K. TANAKA, Y. KAKEJI (<i>Kobe, Hyogo, Japan</i>)	4515
Free Circulating DNA as a Biomarker of Prostate Cancer: Comparison of Quantitation Methods. K. RAMACHANDRAN, C.G. SPEER, S. FIDDY, I.M. REIS, R. SINGAL (<i>Miami, FL, USA</i>)	4521
Therapeutic Response of Untreatable Hepatocellular Carcinoma After Application of the Immune Modulators IL-2, BCG and Melatonin. B. TOMOV, D. POPOV, R. TOMOVA, N. VLADOV, W. DEN OTTER, Z. KRASTEVA (<i>Sofia, Bulgaria; Amsterdam, Netherlands</i>)	4531
Hypofractionation with VMAT versus 3DCRT in Post-operative Patients with Prostate Cancer. F. ALONGI, L. COZZI, A. FOGLIATA, C. IFTODE, T. COMITO, A. CLIVIO, E. VILLA, F. LOBEFALO, P. NAVARRIA, G. REGGIORI, P. MANCOSU, E. CLERICI, S. TOMATIS, G. TAVERNA, P. GRAZIOTTI, M. SCORSETTI (<i>Rozzano-Milan, Italy; Bellinzona, Switzerland</i>)	4537
Paraneoplastic Thrombocytosis in Breast Cancer. A. RAJKUMAR, A. SZALLASI (<i>Long Branch, NJ, USA</i>)	4545
Weekly Paclitaxel as Second-line Chemotherapy in Japanese Patients with Advanced Gastric Cancer. M. KADOKURA, S. IWASA, Y. HONMA, K. KATO, T. HAMAGUCHI, Y. YAMADA, N. ENOMOTO, Y. SHIMADA (<i>Yamanashi; Tokyo, Japan</i>)	4547
Whole-body Bioelectrical Impedance Analysis in Assessing Upperlimb Lymphedema After Breast Cancer Therapy. S. BERLIT, J. BRADE, B. TUSCHY, A. HORNEMANN, H. LEWELING, V. EGHARDT, M. SÜTTERLIN (<i>Mannheim, Germany</i>)	4553
Postoperative 5-FU based Radiochemotherapy in Rectal Cancer: Retrospective Long Term Results and Prognostic Factors of a Pooled Analysis on 1,338 Patients. D. GENOVESI, R.J. MYERSON, G.A. CÈFARO, A. VINCIGUERRA, A. AUGURIO, M. TRIGNANI, M. DI TOMMASO, M. NUZZO, M. LUPATTELLI, C. ARISTEI, R. BELLAVITA, L. SCANDOLARO, D. COSENTINO, G. PANI, L. ZICCARELLI, M.A. GAMBACORTA, M.C. BARBA, E. MARANZANO, F. TRIPPA, P. SCIACERO, R. NIESPOLO, C. LEONARDI, T. IANNONE, M.E. ROSETTO, V. FUSCO, P. SANPAOLO, A. MELANO, F. VALVO, C. CAPIRCI, A. DE PAOLI, M. DI NICOLA, G. MANTELLO, V. VALENTINI, ON BEHALF OF THE G.I. A.I.R.O. WORKING GROUP (<i>Chieti; Perugia; Como; Trento; Cosenza; Rome; Terni; Ivrea; Monza; Milan; Belluno; Viterbo; Rionero in Vulture; Cuneo; Rovigo; Aviano; Ancona, Italy; St. Louis, MO, USA</i>)	4557
First Description of a Hybrid Tumor of the Sublingual Gland. W. EICHHORN, C. PRECHT, M. WEHRMANN, E. HICKMANN, M. EICHHORN, J. ZEUCH, T. LÖNING, R.E. FRIEDRICH, M. HEILAND, J. HOFFMANN (<i>Hamburg; Balingen; Heidelberg, Germany</i>)	4567
The Prognostic Significance of WNT Pathway in Surgically-treated Colorectal Cancer: β -Catenin Expression Predicts for Disease-free Survival. K. KAMPOSIORAS, A. KONSTANTARA, V. KOTOULA, S. LAKIS, G. KOUVATSEAS, E. AKRIVIADIS, E. VRETTOU, D. DIONYSOPOULOS, D. KRIKELIS, K. PAPADOPOULOU, E. CHARALAMBOUS, S. CHRISAFI, C. KONSTANTARAS, G. FOUNTZILAS (<i>Larissa; Thessaloniki; Athens, Greece</i>).....	4573
Radiotherapy and Concurrent Metronomic Chemotherapy in Hormone-refractory Prostate Carcinoma: A Phase I Study. A.G. MORGANTI, M. MASSACCESI, L. CARAVATTA, G. MACCHIA, V. PICARDI, F. DEODATO, E. IPPOLITO, S. MIGNOGNA, M. FERRO, S. CILLA, G.C. MATTIUCCI, V. VALENTINI (<i>Campobasso; Rome, Italy</i>).....	4585
Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Clinical Outcome in Patients with Stage II and III Colon Cancer. G. ABSENGER, J. SZKANDERA, M. STOTZ, U. POSTLMAYR, M. PICHLER, A.L. RESS, R. SCHABERL-MOSER, H. LOIBNER, H. SAMONIGG, A. GERGER (<i>Graz; Vienna, Austria</i>)	4591

Prevalence of <i>H. pylori</i> Infection and Atrophic Gastritis Among Symptomatic and Dyspeptic Adults in Kazakhstan. A Hospital-based Screening Study Using a Panel of Serum Biomarkers. V. BENBERIN, R. BEKTAYEVA, R. KARABAYEVA, A. LEBEDEV, K. AKEMEYEVA, L. PALOHEIMO, K. SYRJÄNEN (<i>Astana, Kazakhstan; Helsinki; Turku, Finland; Barretos, SP, Brazil</i>)	4595
Weekly Non-pegylated Liposomal Doxorubicin Chemotherapy in Heavily Pre-treated Patients with Metastatic Breast Cancer. G. MASCI, C. GANDINI, M. ZURADELLI, A. LOSURDO, R. TORRISI, S. ROTA, G. GULLO, L. VELUTTI, L. GIORDANO, A. SANTORO (<i>Milan, Italy; Dublin, Republic of Ireland</i>)	4603
Thymidylate Synthase, Topoisomerase-1 and Microsatellite Instability: Relationship with Outcome in Mucinous Colorectal Cancer Treated with Fluorouracil. F.V. NEGRI, C. AZZONI, L. BOTTARELLI, N. CAMPANINI, A. MANDOLESI, A. WOTHERSPOON, D. CUNNINGHAM, M. SCARTOZZI, S. CASCINU, C. TINELLI, E.M. SILINI, A. ARDIZZONI (<i>Parma; Ancona; Pavia; Italy; London, UK</i>)	4611
Effects of Single Nucleotide Polymorphisms on Treatment Outcomes and Toxicity in Patients Treated with Sunitinib. C.H. MAENG, J.H. YI, J. LEE, J.Y. HONG, M.K. CHOI, H.A. JUNG, J.O. PARK, S.H. PARK, Y.S. PARK, W.K. KANG, H.Y. LIM (<i>Seoul, Republic of Korea</i>)	4619
Oxaliplatin-based Chemotherapy in Patients Aged 75 Years or Older with Metastatic Colorectal Cancer. M. FUKUCHI, K. ISHIBASHI, Y. TAJIMA, N. OKADA, M. YOKOYAMA, N. CHIKA, S. HATANO, T. MATSUZAWA, K. KUMAMOTO, Y. KUMAGAI, H. BABA, E. MOCHIKI, H. ISHIDA (<i>Saitama, Japan</i>)	4627
Carboplatin plus Either Docetaxel or Paclitaxel for Japanese Patients with Advanced Non-small Cell Lung Cancer. M. KAWAHARA, S. ATAGI, K. KOMUTA, H. YOSHIOKA, M. KAWASAKI, Y. FUJITA, T. YONEI, F. OGUSHI, K. KUBOTA, N. NOGAMI, M. TSUCHIYA, K. SHIBATA, Y. TOMIZAWA, K. MINATO, K. FUKUOKA, K. ASAMI, T. YAMANAKA; THE JAPAN MULTINATIONAL TRIAL ORGANIZATION (<i>Osaka; Sakai, Osaka; Kurashiki, Okayama; Koga, Fukuoka; Asahikawa, Hokkaido; Okayama, Okayama; Kochi, Kochi; Tokyo; Matsuyama, Ehime; Kyoto; Takaoka, Toyama; Shibukawa; Ota, Gunma; Nishinomiya, Hyogo; Kashiwa, Chiba; Japan; Nagoya, Aichi, Japan</i>)	4631
Image-guided Stereotactic Radiosurgery for Cranial Lesions: Large Margins Compensate for Reduced Image Guidance Frequency. H. BADAQSHI, D. KAUL, P. WUST, E. WIENER, V. BUADCH, R. GRAF (<i>Berlin, Germany</i>)	4639
Postoperative Follow-up of Patients with Gastric Cancer According to Nodal Status. K. SHODA, D. ICHIKAWA, S. KOMATSU, T. KUBOTA, K. OKAMOTO, H. KONISHI, A. SHIOZAKI, H. FUJIWARA, E. OTSUJI (<i>Kyoto, Kyoto, Japan</i>)	4645
Serum DNA Hypermethylation in Patients with Kidney Cancer: Results of a Prospective Study. S. HAUSER, T. ZAHALKA, G. FECHNER, S.C. MÜLLER, J. ELLINGER (<i>Bonn, Germany</i>)	4651
Biopsy and Radical Prostatectomy Pathological Patterns Influence Prostate Cancer Gene 3 (PCA3) Score. S. DE LUCA, R. PASSERA, E. BOLLITO, A. MILILLO, R.M. SCARPA, M. PAPOTTI, R. CODA, D.F. RANDONE (<i>Torino; Orbassano, Italy</i>)	4657
Outcome of Allografts in Patients with Chronic-phase Chronic Myeloid Leukemia Following Imatinib Failure: Prognosis Revisited. Y.-C. LIU, H.-H. HSIAO, C.-S. CHANG, T.-C. LIU, W.-C. YANG, J.-F. HSU, C.-T. HUANG, S.-F. CHO, C.-H. WU, Y.-F. TSAI, S.-F. LIN (<i>Kaohsiung, Taiwan, ROC</i>)	4663
Preserved Renal Function After Percutaneous Radiofrequency Ablation for Renal Tumors: Experience of a Single Institution. M. OFUDE, Y. KITAGAWA, W. KODA, S. UENO, Y. KADONO, H. KONAKA, A. MIZOKAMI, T. GABATA, M. NAMIKI (<i>Kanazawa, Ishikawa, Japan</i>)	4669
Platinum-based Combination Chemotherapy vs. Weekly Cisplatin During Adjuvant CCRT in Early Cervical Cancer with Pelvic LN Metastasis. Y.-Y. LEE, W. PARK, S.J. HUH, A. YOON, J.-Y. PARK, C.H. CHOI, T.-J. KIM, J.-W. LEE, B.-G. KIM, D.-S. BAE (<i>Seoul, Republic of Korea</i>)	4675

Number 11*Reviews*

- The Paradox of the Unfolded Protein Response in Cancer. Y.-P. VANDEWYNCKEL, D. LAUKENS, A. GEERTS, E. BOGAERTS, A. PARIDAENS, X. VERHELST, S. JANSSENS, F. HEINDRYCKX, H. VAN VLIERBERGHE (*Ghent, Belgium; Uppsala, Sweden*) 4683
- Therapeutic Value of Quinazoline-based Compounds in Prostate Cancer. J. BILBRO, M. MART, N. KYPRIANOU (*Lexington, KY, USA*) 4695
- State of the Art in the Treatment of Laryngeal Cancer. F. JENCKE, R. KNECHT (*Hamburg, Germany*) 4701
- Delivery Approaches of Gene Therapy in Hepatocellular Carcinoma. F. DUAN, M.G.E.H. LAM (*Beijing, China; Utrecht, Netherlands*) 4711

Experimental Studies

- Targeting the Wnt/Beta-Catenin Pathway in Multiple Myeloma. L.C. SCHMEEL, F.C. SCHMEEL, Y. KIM, T. ENDO, D. LU, I.G.H. SCHMIDT-WOLF (*Bonn, Germany; Sapporo, Hokkaido, Japan; La Jolla, CA, USA*) 4719
- Growth Inhibition by Novel Liposomes Including Trehalose Surfactant Against Hepatocarcinoma Cells Along with Apoptosis. Y. MATSUMOTO, E. CAO, R. UEOKA (*Kumamoto, Japan*) 4727
- Pre-clinical Validation of Orthotopically-implanted Pulmonary Tumor by Imaging with 18F-Fluorothymidine-Positron Emission Tomography/Computed Tomography. H. FUSHIKI, S. MIYOSHI, A. NODA, Y. MURAKAMI, H. SASAKI, M. JITSUOKA, K. MITSUOKA, I. MATSUNARI, S. NISHIMURA (*Tsukuba, Ibaraki; Hakui, Ishikawa, Japan*) 4741
- A Preclinical Murine Model for the Detection of Circulating Human Tumor Cells. J.-Y. AHN, H.-Y. MIN, J.-H. JEONG, Y. BYUN, H.-Y. LEE (*Seoul, Republic of Korea*) 4751
- Chemoprevention of Oral Cancer by Lyophilized Strawberries. B.C. CASTO, T.J. KNOBLOCH, R.L. GALIOTO, Z. YU, B.T. ACCURSO, B.M. WARNER (*Columbus, OH, USA*) 4757
- Chemoprevention with Acetylsalicylic Acid, Vitamin D and Calcium Reduces Risk of Carcinogen-induced Lung Tumors. HANS-CHRISTIAN POMMERGAARD, JAKOB BURCHARTH, J. ROSENBERG, HANS RASKOV (*Herlev; Frederiksberg, Denmark*) 4767
- ID3 Mutations Are Recurrent Events in Double-hit B-Cell Lymphomas. N. GEBAUER, V. BERNARD, A.C. FELLER, H. MERZ (*Luebeck, Germany*) 4771
- Comprehensive Survey of *HRAS*, *KRAS*, and *NRAS* Mutations in Proliferative Thyroid Lesions from an Ethnically Diverse Population. H.-J. SCHULTEN, S. SALAMA, A. AL-AHMADI, Z. AL-MANSOURI, Z. MIRZA, K. AL-GHAMDI, O.A. AL-HAMOUR, E. HUWAIT, M. GARI, M.H. AL-QAHTANI, J. AL-MAGHRABI (*Jeddah, Saudi Arabia*) 4779
- MCP-1 Promotes Invasion and Adhesion of Human Ovarian Cancer Cells. S. FURUKAWA, S. SOEDA, Y. KIKO, O. SUZUKI, Y. HASHIMOTO, T. WATANABE, H. NISHIYAMA, K. TASAKI, H. HOJO, M. ABE, K. FUJIMORI (*Fukushima City, Fukushima, Japan*) 4785
- Impact of Interleukin-10 on Phenotype and Gene Expression During Early Monocyte Differentiation into Dendritic Cells. A.M. SCHWARZ, U. BANNING-EICHENSEER, K. SEIDEL, C. MAUZ-KÖRHOLZ, D. KÖRHOLZ, M.S. STAEGE (*Leipzig; Halle, Germany*) 4791

Therapeutic Efficacy for Hepatocellular Carcinoma by Boric Acidmediated Boron Neutron Capture Therapy in a Rat Model. S.-Y. LIN, C.-J. LIN, J.-W. LIAO, J.-J. PEIR, W.-L. CHEN, C.-W. CHI, Y.-C. LIN, Y.-M. LIU, F.-I. CHOU (<i>Hsinchu; Taichung; Taipei, Taiwan, ROC</i>)	4799
Identification of Androgen-responsive microRNAs and Androgenrelated Genes in Breast Cancer. K. NAKANO, Y. MIKI, S. HATA, A. EBATA, K. TAKAGI, K.M. MCNAMARA, M. SAKURAI, M. MASUDA, H. HIRAKAWA, T. ISHIDA, T. SUZUKI, N. OHUCHI, H. SASANO (<i>Sendai, Japan</i>)	4811
Human Pancreatic Cancer Cells with Acquired Gemcitabine Resistance Exhibit Significant Up-regulation of Peroxiredoxin-2 Compared to Sensitive Parental Cells. S. SUENAGA, Y. KURAMITSU, Y. WANG, B. BARON, T. KITAGAWA, J. AKADA, K. TOKUDA, S. KAINO, S.-I. MAEHARA, Y. MAEHARA, I. SAKAIDA, K. NAKAMURA (<i>Ube, Yamaguchi; Fukuoka, Fukuoka, Japan</i>)	4821
Effect of Hyperbaric Oxygenation and Gemcitabine on Apoptosis of Pancreatic Ductal Tumor Cells <i>In Vitro</i> . G. BOSCO, L. GUIZZON, Z. YANG, E. CAMPORESI, A. CASAROTTO, C. BOSIO, D. MANGAR, C. CHEN, M. CANNATO, L. TONIOLO, G. GARETTO, E. NASOLE, C. BASSI (<i>Padova; Verona, Italy; Syracuse, NY; Tampa, FL, USA</i>)	4827
DNA Methylation of MAPK Signal-inhibiting Genes in Papillary Thyroid Carcinoma. E.K. LEE, K.-W. CHUNG, S.K. YANG, M.J. PARK, H.S. MIN, S.W. KIM, H.S. KANG (<i>Goyang; Seoul, Republic of Korea</i>)	4833
Protein-bound Polysaccharide K Reduced the Invasive Ability of Colon Cancer Cell Lines. S. UWAFUJI, T. GOI, T. NARUSE, H. KUREBAYASHI, T. NAKAZAWA, Y. HIRONO, A. YAMAGUCHI (<i>Fukui, Japan</i>)	4841
Anticancer Activity of a Hydrogel Containing Folic Acid Towards MCF-7 and MDA-MB-231 Cells. S. TROMBINO, T. FERRARELLI, M. PELLEGRINO, E. RICCHIO, L. MAURO, S. ANDÒ, N. PICCI, R. CASSANO (<i>Cosenza, Italy</i>)	4847
Differential Expression and Prognostic Role of Selected Genes in Colorectal Cancer Patients. P. PITULE, O. VYCITAL, J. BRUHA, P. NOVAK, P. HOSEK, V. TRESKA, I. HLAVATA, P. SOUCEK, M. KRALICKOVA, V. LISKA (<i>Pilsen; Kladno; Prague, Czech Republic</i>)	4855
Effects of Chitosan on Xenograft Models of Melanoma in C57BL/6 Mice and Hepatoma Formation in SCID Mice. M.-Y. YEH, M.-F. WU, H.-S. SHANG, J.-B. CHANG, Y.-L. SHIH, Y.-L. CHEN, H.-F. HUNG, H.-F. LU, C. YEH, W. GIBSON WOOD, F.-M. HUNG, J.-G. CHUNG (<i>Taipei; Hsinchu; New Taipei City; Houlong Township; Taichung, Taiwan, ROC; Minneapolis, MN, USA</i>)	4867
Co-existence of Epithelioid and Fibroblastoid Subsets in a Sarcomatoid Renal Carcinoma Cell Line Revealed by Clonal Studies. C.-H. HSIEH, H.-C. CHEN, Y.-H. CHANG, S.-T. PANG, M.-L. KUO, C.-K. CHUANG, S.-K. LIAO (<i>Taoyuan; Taipei, Taiwan, ROC</i>)	4875
Synergistic Anti-leukemic Effects of CK2 Inhibitors and Pentabromobenzyliothioureas <i>In Vitro</i> . M. KORONKIEWICZ, Z. CHILMONCZYK, ZYGMUNT KAZIMIERCZUK (<i>Warsaw, Poland</i>)	4891
Calcitonin-induced NF- κ B Activation Up-regulates Fibronectin Expression in MG63 Osteosarcoma Cells. I. TSAGARAKI, C. PHENEKOS, E. TSILIBARY, A. TZINIA (<i>Athens, Greece</i>)	4901
Significant Association of Caveolin-1 (<i>CAVI</i>) Genotypes with Upper Urothelial Tract Cancer. W.-S. CHANG, S.-S. LIN, F.-J. LI, C.-W. TSAI, L.-Y. LI, C.-S. LIEN, W.-L. LIAO, H.-C. WU, C.-H. TSAI, T.-C. SHIH, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	4907
Targeting Biliverdin Reductase Overcomes Multidrug Resistance in Leukemia HL60 Cells. S.S. KIM, S. SEONG, S.H. LIM, S.Y. KIM (<i>Seoul, Republic of Korea; Beijing, China</i>)	4913

Shortened Isoforms of the Androgen Receptor Are Regulated by the Cytoprotective Heat-shock Protein HSPB1 and the Tumorsuppressive MicroRNA miR-1 in Prostate Cancer Cells. M.B. STOPE, J. BRADL, S. PETERS, A. STREITBÖRGER, M. WEISS, U. ZIMMERMANN, R. WALTHER, C.H. LILLIG, M. BURCHARDT (*Greifswald, Germany*) 4921

Clinical Studies

25-Year Follow-up of HIV-positive Patients with Benign Lymphoepithelial Cysts of the Parotid Glands: A Retrospective Review. W.F. MOURAD, R. YOUNG, R. KABARRITI, D.M. BLAKAJ, R.A. SHOURBAJI, J. GLANZMAN, S. PATEL, N. OHRI, R. YAPARPALVI, J.J. BEITLER, S. KALNICKI, M.K. GARG (*New York, NY, USA*) 4927

Electrocardiography Changes During Adjuvant Breast Cancer Therapy: Incidence and Risk Factors. A. ELME, T. SAARTO, K.J. TÖTTERMAN, M. UTRIANEN, H. KAUTIAINEN, S. JÄRVENPÄÄ, M. TENHUEN, C. BLOMQUIST (*Helsinki; Jyväskylä; Äänekoski, Finland*) 4933

Bi-weekly Paclitaxel and Capecitabine as a Second- or Third-line Treatment for Advanced Breast Cancer: A Pilot Study. P.-L. KELLOKUMPU-LEHTINEN, T. TUUNANEN, A.-L. KAUTIO, I. LEHTINEN, M. TANNER (*Tampere, Finland*) 4941

Detection of Cytomegalovirus DNA in Colorectal Tissue from Swedish and Vietnamese Patients with Colorectal Cancer. J. DIMBERG, T.T. HONG, M. SKARSTEDT, S. LÖFGREN, N. ZAR, A. MATUSSEK (*Jönköping, Sweden; Hanoi, Vietnam*) 4947

Gut Peptide Profile and Chemotherapy-associated Dyspepsia Syndrome in Patients with Breast Cancer Undergoing FEC60 Chemotherapy. G. RIEZZO, C. CLEMENTE, M. LINSALATA, B. D'ATTOMA, A. ORLANDO, G. CAMPANELLA, F. GIOTTA, F. RUSSO (*Bari, Italy*) 4951

The Feasibility and Efficacy of Stereotactic Body Radiotherapy for Centrally-located Lung Tumors. W. TAKAHASHI, H. YAMASHITA, M. OMORI, M. KITAGUCHI, S. SHIBATA-KOBAYASHI, A. SAKUMI, K. NAKAGAWA (*Tokyo, Japan*) 4959

The E3 Ubiquitin Ligase SIAH2 Is a Prosurvival Factor Overexpressed in Oral Cancer. S.-C. HSIEH, S.-N. KUO, Y.-H. ZHENG, M.-H. TSAI, Y.-S. LIN, J.-H. LIN (*Taipei; Tainan; Taichung, Taiwan, ROC*) 4965

Concordance of HER2 Status in Primary Tumour and Lymph Node Metastases in Patients with Esophageal Carcinoma. A.M. KÖNIG, M. REEH, A.-M. DANCAU, M. RATHJENS, S. GROS, F.G. UZUNOGLU, M. BOCKHORN, R. SIMON, G. SAUTER, A. MARX, J.R. IZBICKI (*Hamburg, Germany*) 4975

Improved Survival of Baby Boomer Women with Early-stage Uterine Cancer: A Surveillance, Epidemiology and End Results (SEER) Study. M.A. ELSHAIKH, J. RUTERBUSCH, M.L. COTE, R. CATTANEO II, A.R. MUNKARAH (*Detroit, MI, USA*) 4983

Radiation Therapy for Stage IVA Cervical Cancer. N. MURAKAMI, T. KASAMATSU, M. MOROTA, M. SUMI, K. INABA, Y. ITO, J. ITAMI (*Tokyo, Japan*) 4989

Predicting Skin Toxicity According to EGFR Polymorphisms in Patients with Colorectal Cancer Receiving Antibody Against EGFR. R. SAITO, H. SUZUKI, T. YAMADA, S. ENDO, T. MORIWAKI, T. UENO, M. HIROSE, S. HIRAI, K. YAMATO, Y. MIZOKAMI, I. HYODO (*Tsukuba, Ibaraki, Japan*) 4995

A Retrospective Analysis of Two Different Sequences of Therapy Lines for Advanced Kidney Cancer. C. PAGLINO, G. PROCOPIO, R. SABBATINI, J. BELLMUNT, M. SCHMIDINGER, A. BEARZ, A. BAMIAS, B. MELICHAR, I. IMARISIO, C. TINELLI, C. PORTA (*Pavia; Milan; Modena; Aviano, Italy; Barcelona, Spain; Vienna, Austria; Athens, Greece; Olomouc, Czech Republic*) 4999

A Novel Postoperative Inflammatory Score Predicts Postoperative Pancreatic Fistula After Pancreatic Resection. Y. FUJIWARA, T. MISAWA, H. SHIBA, Y. SHIRAI, R. IWASE, K. HARUKI, K. FURUKAWA, Y. FUTAGAWA, K. YANAGA (<i>Tokyo, Japan</i>)	5005
Transumbilical Defunctioning Ileostomy: A New Approach for Patients at Risks of Anastomotic Leakage After Laparoscopic Low Anterior Resection. K. ETO, N. OMURA, K. HARUKI, Y. UNO, M. OHKUMA, S. NAKAJIMA, T. ANAN, M. KOSUGE, T. FUJITA, K. ISHIDA, K. YANAGA (<i>Tokyo, Japan</i>)	5011
VEGF Expression and Response to Sunitinib in Patients with Metastatic Clear Cell Renal Cell Carcinoma. D. MINARDI, G. LUCARINI, M. SANTONI, R. MAZZUCHELLI, L. BURATTINI, M. PISTELLI, M. BIANCONI, R. DI PRIMIO, M. SCARTOZZI, R. MONTIRONI, S. CASCINU, G. MUZZONIGRO (<i>Ancona, Italy</i>)	5017
Tumor Budding and E-Cadherin Expression Are Useful Predictors of Nodal Involvement in T1 Esophageal Squamous Cell Carcinoma. Y. NAKAGAWA, M. OHIRA, N. KUBO, Y. YAMASHITA, K. SAKURAI, T. TOYOKAWA, H. TANAKA, K. MUGURUMA, M. SHIBUTANI, S. YAMAZOE, K. KIMURA, H. NAGAHARA, R. AMANO, H. OHTANI, M. YASHIRO, K. MAEDA, K. HIRAKAWA (<i>Osaka, Japan</i>)	5023
Meta-analysis of Laparoscopic and Open Surgery for Gastric Gastrointestinal Stromal Tumor. H. OHTANI, K. MAEDA, E. NODA, H. NAGAHARA, M. SHIBUTANI, M. OHIRA, K. MUGURUMA, H. TANAKA, N. KUBO, T. TOYOKAWA, K. SAKURAI, Y. YAMASHITA, A. YAMAMOTO, K. HIRAKAWA (<i>Osaka, Japan</i>)	5031
Management of Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib and Clinical Outcomes. M. ARAKAWA-TODO, T. YOSHIZAWA, K. ZENNAMI, G. NISHIKAWA, Y. KATO, I. KOBAYASHI, K. KAJIKAWA, Y. YAMADA, K. MATSUURA, I. TSUKIYAMA, H. SAITO, T. HASEGAWA, K. NAKAMURA, M. SUMITOMO (<i>Nagakute; Nagoya, Aichi; Kani, Gifu, Japan</i>)	5043
C-Reactive Protein Is a Negative Independent Factor in Patients with Stage IV Colorectal Cancer Undergoing Oxaliplatin-based Chemotherapy. M. FUKUCHI, K. KUWABARA, Y. TSUJI, H. BABA, K. ISHIBASHI, N. CHIKA, S. HATANO, T. MATSUZAWA, K. KUMAMOTO, Y. KUMAGAI, E. MOCHIKI, H. ISHIDA (<i>Saitama, Japan</i>)	5051
Clinical Outcomes After First-line EGFR Inhibitor Treatment for Patients with NSCLC, EGFR Mutation, and Poor Performance Status. Y. OKUMA, Y. HOSOMI, M. NAGAMATA, Y. YAMADA, K. SEKIHARA, K. KATO, T. HISHIMA, T. OKAMURA (<i>Tokyo, Japan</i>)	5057
C-Reactive Protein as Predictor of Recurrence in Patients with Rectal Cancer Undergoing Chemoradiotherapy Followed by Surgery. Y. TOIYAMA, Y. INOUE, S. SAIGUSA, M. KAWAMURA, A. KAWAMOTO, Y. OKUGAWA, J. HIRO, K. TANAKA, Y. MOHRI, M. KUSUNOKI (<i>Mie, Japan</i>)	5065
A New β -Tricalcium Phosphate with Uniform Triple Superporous Structure as a Filling Material After Curettage of Bone Tumor. S. SETO, K. MURAMATSU, T. HASHIMOTO, Y. TOMINAGA, T. TAGUCHI (<i>Ube, Yamaguchi, Japan</i>)	5075
Clinical Significance of Erlotinib Monotherapy for Gefitinib-resistant Non-small Cell Lung Cancer with EGFR Mutations. N. KOYAMA, Y. UCHIDA (<i>Saitama, Japan</i>)	5083
The E-Cadherin Expression vs. Tumor Cell Proliferation Paradox in Endometrial Cancer. I. GONZÁLEZ-RODILLA, L. ALLER, J. LLORCA, A.-B. MUÑOZ, V. VERNA, J. ESTÉVEZ, J. SCHNEIDER (<i>Santander, Spain</i>)	5091
Changing Trends in Long-term Outcomes After Hepatic Resection for Hepatocellular Carcinoma: A 30-Year, Single-center Experience. Y. YAMAMOTO, H. IKOMA, R. MORIMURA, H. KONISHI, Y. MURAYAMA, S. KOMATSU, A. SHIOZAKI, Y. KURIU, T. KUBOTA, M. NAKANISHI, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, C. SAKAKURA, T. OCHIAI, E. OTSUJI (<i>Kyoto, Japan</i>)	5097

Non-randomized Comparison Between Irinotecan plus Mitomycin C and Irinotecan Alone in Patients with Advanced Gastric Cancer Refractory to Fluoropyrimidine and Platinum. A. UEDA, A. HOSOKAWA, K. OGAWA, H. YOSHITA, H. MIHARA, T. ANDO, S. KAJIURA, H. FUJINAMI, J. NISHIKAWA, M. MINEMURA, M. TERADA, T. KOBAYASHI, N. HORIKAWA, K. YABUSHITA, M. NOTE, T. SUGIYAMA (<i>Toyama; Takaoka, Toyama, Japan</i>)	5107
Clinical Significance of Total Colonoscopy for Screening of Colon Lesions in Patients with Esophageal Cancer. T. MIYAZAKI, N. TANAKA, A. SANŌ, S. SUZUKI, M. SAKAI, T. YOKOBORI, T. INOSE, M. SOHDA, M. NAKAJIMA, M. FUKUCHI, H. OJIMA, H. KATO, H. KUWANO (<i>Gunma; Tochigi, Japan</i>)	5113
Early-onset Brain Metastases in a Breast Cancer Patient After Pathological Complete Response to Neoadjuvant Chemotherapy. K. SHIMADA, T. ISHIKAWA, S. YONEYAMA, K. KITA, K. NARUI, S. SUGAE, D. SHIMIZU, M. TANABE, T. SASAKI, T. CHISHIMA, Y. ICHIKAWA, I. ENDO (<i>Yokohama, Japan</i>)	5119
Concurrent Chemoradiotherapy for Non-bulky Stage IB/II Cervical Cancer Without Pelvic Node Enlargement. A. WAKAYAMA, M. INAMINE, W. KUDAKA, Y. NAGAI, T. NAKAMOTO, T. OYAMA, T. ARIGA, G. KASUYA, T. TOITA, Y. AOKI (<i>Okinawa, Japan</i>)	5123
High-throughput Molecular Genotyping for Small Biopsy Samples in Advanced Non-small Cell Lung Cancer Patients. C.H. MAENG, H.Y. LEE, Y.W. KIM, M.K. CHOI, J.Y. HONG, H.A. JUNG, K.S. LEE, H. KIM, O J. KWON, J.-M. SUN, J.S. AHN, K. PARK, S.-W. UM, M.-J. AHN (<i>Seoul, South Korea</i>)	5127
Lymphadenectomy Alone Is a Feasible Option in Managing Incidentally-detected Early-stage Cervical Cancer After Simple Hysterectomy without Intermediate-risk Factors: An Application of the Concept of Less Radical Surgery. H.W. JEON, D.H. SUH, K. KIM, J.H. NO, Y.-B. KIM (<i>Seoul; Seongnam, Republic of Korea</i>)	5135
Histological Inflammatory Cell Infiltration Is Associated with the Number of Lymph Nodes Retrieved in Colorectal Cancer. Y.W. KIM, K.M. JAN, D.H. JUNG, M.Y. CHO, N.K. KIM (<i>Wonju; Seoul, Republic of Korea</i>)	5143
Ethnic Variation in Toxicity and Outcome of Adjuvant Chemoradiation for Gastric Cancer in Israel. R.M. BRENNER, S. KIVITY, Y. KUNDEL, O. PURIM, N. PELED, E. IDELEVICH, K. LAVRENKOV, S. KOVEL, E. FENIG, A. SULKES, B. BRENNER (<i>Holon; Petach-Tiqva; Tel-Hashomer; Rehovot; Beer Sheva; Zerifin; Ramat-Aviv; Jerusalem, Israel</i>)	5151
A9 Region in <i>EPHB2</i> Mutation Is Frequent in Tumors with Microsatellite Instability. Analysis of Prognosis. S. RAFAEL, M. VIDAURRETA, S. VEGANZONES, V. DE LA ORDEN, B. MEDIERO, M.L. GUTIERREZ, M.L. MAESTRO (<i>Madrid; Leon, Spain</i>)	5159
Effect of Hospital Volume on Long-term Outcomes of Laparoscopic Gastrectomy for Clinical Stage I Gastric Cancer. D. ICHIKAWA, S. KOMATSU, T. KUBOTA, K. OKAMOTO, K. DEGUCHI, H. TAMAI, T. OBAYASHI, K. KITAGAWA, K. SOGA, K. INOUE, N. YAMAOKA, T. IMANISHI, A. HAGIWARA, E. OTSUJI (<i>Kyoto; Osaka; Wakayama, Japan</i>)	5165
Predictors of Long-term Survival in Hepatocellular Carcinomas: A Longitudinal Follow-up of 108 Patients with Small Tumors. H.-C. CHANG, Y.-M. LIN, A.M.-F. YEN, S.L.-S. CHEN, W.Y.-Y. WU, S.Y.-H. CHIU, J.C.-Y. FANN, Y.-S. LIN, H.-H. CHEN, C.-S. LIAO (<i>Taipei; Tao-Yuan, Taiwan, ROC</i>)	5171
A Survey of c-MET Expression and Amplification in 287 Patients with Hepatocellular Carcinoma. S.J. LEE, J. LEE, I. SOHN, M. MAO, W. KAI, C.-K. PARK, H.Y. LIM (<i>Seoul, Republic of Korea; San Diego, CA, USA</i>)	5179
Chemoradiation as a Definitive Treatment for Cervical Lymph Node Metastases from Unknown Primary Cancer. H. KAIZU, I. OGINO, M. HATA, M.S. OBA, O. SHIONO, M. KOMATSU, T. INOUE (<i>Yokohama, Japan</i>)	5187

Outcome Analysis of ¹⁸ F-Fluorodeoxyglucose Positron–Emission Tomography in Patients with Lung Cancer After Partial Volume Correction. K. OHTAKA, Y. HIDA, K. KAGA, S. OKAMOTO, T. SHIGA, N. TAMAKI, J. MUTO, R. NAKADA-KUBOTA, S. HIRANO, Y. MATSUI (<i>Sapporo, Japan</i>)	5193
Aberrant Methylation of the <i>Ras-related Associated with Diabetes</i> Gene in Human Primary Esophageal Cancer. Z. JIN, X. FENG, Q. JIAN, Y. CHENG, Y. GAO, X. ZHANG, L. WANG, Y. ZHANG, W. HUANG, X. FAN, S. CHEN, H. YU, Z. ZHAO, M. DONG, J. LIU, Y. MORI, S.J. MELTZER (<i>Guangdong; Shenzhen, China; Baltimore, MD, USA</i>)	5199
Testis-sparing Surgery for the Conservative Management of Small Testicular Masses: An Update. E. BRUNOCILLA, G. GENTILE, R. SCHIAVINA, M. BORGHESI, A. FRANCESCHELLI, C.V. PULTRONE, F. CHESSA, D. ROMAGNOLI, S.M. GHANEM, M. GACCI, G. MARTORANA, F. COLOMBO (<i>Bologna; Florence, Italy</i>)	5205
Errata	5211

Number 12

Experimental Studies

Detection of Micrometastases of Squamous Cell Carcinoma Tumor Cells in Muscle Tissue. S. STEINBACH, E.L. YUH, M. BURBELKO, W. HUNDT (<i>Marburg, Germany; Stanford, CA, USA</i>)	5213
Genomic Aberrations Associated with Erlotinib Resistance in Non-small Cell Lung Cancer Cells. M. SERIZAWA, T. TAKAHASHI, N. YAMAMOTO, Y. KOH (<i>Shizuoka; Kiiidera, Wakayama, Japan</i>)	5223
Expression of Cyclin D1 and Its Association with Disease Characteristics in Bladder Cancer. P.K. KOPPARAPU, S.A. BOORJIAN, B.D. ROBINSON, M. DOWNES, L.J. GUDAS, N.P. MONGAN, J.L. PERSSON (<i>Malmö, Sweden; Rochester, MN; New York, NY, USA; Nottingham, UK</i>)	5235
Reliable Housekeeping Gene Combination for Quantitative PCR of Lymph Nodes in Patients with Prostate Cancer. I. TSAUR, M. RENNINGER, J. HENNENLOTTER, E. OPPERMANN, M. MUNZ, U. KUEHS, A. STENZL, D. SCHILLING (<i>Frankfurt; Tuebingen, Germany</i>)	5243
DNA Hypermethylation as a Predictor of PSA Recurrence in Patients with Low- and Intermediate-grade Prostate Cancer. R. MORITZ, J. ELLINGER, P. NUHN, A. HAESE, S.C. MÜLLER, M. GRAEFEN, T. SCHLOMM, P.J. BASTIAN (<i>Muenster; Bonn; Hamburg; Munich; Duesseldorf, Germany</i>)	5249
<i>In Vitro</i> Analysis of the Relationships Between Metallothionein Expression and Cisplatin Sensitivity of Non-small Cellular Lung Cancer Cells. T. GANSUKH, P. DONIZY, A. HALON, H. LAGE, P. SUROWIAK (<i>Ulan Bator, Mongolia; Wroclaw, Poland; Berlin, Germany</i>).....	5255
Soluble Epoxide Hydrolase Deficiency Inhibits Dextran Sulfate Sodium-induced Colitis and Carcinogenesis in Mice. W. ZHANG, H. LI, H. DONG, J. LIAO, B.D. HAMMOCK, G.-Y. YANG (<i>Chicago, IL; Davis, CA, USA</i>)	5261
Activation of DNA Damage Response by Antitumor Therapy Counteracts the Activity of Vinca Alkaloids. H. EHRHARDT, S. PFEIFFER, D. SCHREMBBS, F. WACHTER, M. GRUNERT, I. JEREMIAS (<i>Munich, Germany</i>).....	5273
Expression of mRNAs of Urocortin in the STKM-1 Gastric Cancer Cell Line. K. AKIYOSHI, M. KAMADA, K. FUJIOKA, K. IKEDA, K. TOJO, Y. MANOME (<i>Tokyo, Japan</i>).....	5289

Zoledronic Acid as an Antimetastatic Agent for Different Human Tumor Cell Lines. L. MUINELO-ROMAY, D. GARCIA, L. ALONSO-ALCONADA, M. VIEITO, M. CARMONA, N. MARTÍNEZ, S. AGUÍN, M. ABAL, R. LÓPEZ-LÓPEZ (<i>Santiago de Compostela, Spain</i>)	5295
Silicate Fiber-based 3D Cell Culture System for Anticancer Drug Screening. Y. YAMAGUCHI, D. DENG, Y. SATO, Y.-T. HOU, R. WATANABE, K. SASAKI, M. KAWABE, E. HIRANO, T. MORINAGA (<i>Kurume, Fukuoka; Koga, Ibaraki, Japan</i>)	5301
Prokineticin 1 Expression in Gastrointestinal Tumors. T. GOI, T. NAKAZAWA, Y. HIRONO, A. YAMAGUCHI (<i>Fukui, Japan</i>)	5311
Regulations of <i>ABCB1</i> and <i>ABCG2</i> Expression Through MAPK Pathways in Acute Lymphoblastic Leukemia Cell Lines. H. TOMIYASU, M. WATANABE, K. SUGITA, Y. GOTO-KOSHINO, Y. FUJINO, K. OHNO, S. SUGANO, H. TSUJIMOTO (<i>Tokyo; Chuo, Yamanishi, Japan</i>)	5317
Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells. V.R. MOSELEY, J. MORRIS, R.W. KNACKSTEDT, M.J. WARGOVICH (<i>Charleston, SC; San Antonio, TX, USA</i>)	5325
Genetically-engineered Human Neural Stem Cells with Rabbit Carboxyl Esterase Can Target CNS Lymphoma. W. KANG, J. JIN, H. YANG, H.J. SEOL, K.H. KIM, J.-I. LEE, S.U. KIM, K.M. JOO, D.-H. NAM (<i>Seoul; Suwon, South Korea; Vancouver, BC, Canada</i>)	5335
EGFRvIII – A Stable Target for Anti-EGFRvIII Therapy. M. BANASZCZYK, E. STOCZYNSKA-FIDELUS, M. WINIECKA-KLIMEK, M. BIENKOWSKI, W. OCH, P. RIESKE, S. PIASKOWSKI (<i>Lodz; Olsztyn, Poland</i>)	5343
Dichamanetin Inhibits Cancer Cell Growth by Affecting ROS-related Signaling Components Through Mitochondrial-mediated Apoptosis. Y. YONG, S. MATTHEW, J. WITTEWER, L. PAN, Q. SHEN, A.D. KINGHORN, S.M. SWANSON, E.J. DE BLANCO (<i>Columbus, OH; Chicago, IL, USA</i>)	5349
Lung Cancer Cell Line Sensitivity to Zoledronic Acid Is BAX-dependent. T. AOYAGI, T. MORII, K. OHTSUKA, H. OHNISHI, T. TAJIMA, A. YOSHIYAMA, K. MOCHIZUKI, K. SATOMI, S. ICHIMURA (<i>Mitaka; Tokyo, Japan</i>)	5357
Suppression of OCT4B Enhances Sensitivity of Lung Adenocarcinoma A549 Cells to Cisplatin <i>via</i> Increased Apoptosis. L. CORTES-DERICKS, E. FARASHAHI YAZD, S.J. MOWLA, R.A. SCHMID, G. KAROUBI (<i>Berne, Switzerland; Tehran; Yazd, Iran</i>)	5365
Comparison of Minichromosome Maintenance Proteins (MCM-3, MCM-7) and Metallothioneins (MT-I/II, MT-III) Expression in Relation to Clinicopathological Data in Ovarian Cancer. C. KOBIERZYCKI, B. PULA, M. SKIBA, K. JABLONSKA, K. LATKOWSKI, M. ZABEL, E. NOWAK-MARKWITZ, M. SPACZYNSKI, W. KĘDZIA, M. PODHORSKA-OKOLOW, P. DZIEGIEL (<i>Wroclaw; Poznan, Poland</i>)	5375
Small Molecule-based Chemotherapeutic Approach in p16-positive and -negative HNSCC <i>In Vitro</i> . C. ADERHOLD, A. FABER, G.M. GROBSCHMIDT, A. CHAKRABORTY, A. BOCKMAYER, C. UMBREIT, R. BIRK, J. STERN-STRAETER, K. HÖRMANN, J.D. SCHULTZ (<i>Mannheim, Germany</i>)	5385
Association of X-ray Repair Cross-complementing-6 Genotypes with Childhood Leukemia. J.-S. PEI, Y.-M. LEE, H.-H. LO, Y.-N. HSU, S.-S. LIN, D.-T. BAU (<i>Taoyuan; Taichung, Taiwan, ROC</i>)	5395
Associations of <i>Cyclooxygenase 2</i> Polymorphic Genotypes with Bladder Cancer Risk in Taiwan. W.-S. CHANG, C.-W. TSAI, H.-X. JI, H.-C. WU, Y.-T. CHANG, C.-S. LIEN, W.-L. LIAO, W.-C. SHEN, C.-H. TSAI, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	5401

A Novel Chemotherapeutic Arene Ruthenium(II) Drug Rawq01 Altered the Effect of microRNA-21 on PTEN/AKT Signaling Pathway in Esophageal Cancer Cells. W. WENG, Q. WU, Y. YU, W. MEI, X. WANG (Shanghai; Guangzhou; Beijing, PR China)	5407
E2F5 as an Independent Prognostic Factor in Esophageal Squamous Cell Carcinoma. T. ISHIMOTO, A. SHIOZAKI, D. ICHIKAWA, H. FUJIWARA, H. KONISHI, S. KOMATSU, T. KUBOTA, K. OKAMOTO, S. NAKASHIMA, H. SHIMIZU, Y. NAKO, M. KISHIMOTO, E. OTSUJI (Kyoto, Japan)	5415
Evaluation of Stem Cell Marker Gene Expression in Canine Prostate Carcinoma- and Prostate Cyst-derived Cell Lines. M. MOULAY, W. LIU, S. WILLENBROCK, K.A. STERENCZAK, R. CARLSON, A. NGEZAHAYO, H.M. ESCOBAR, I. NOLTE (Hannover; Rostock, Germany)	5421
Acquired Resistance to Chemotherapy in Lung Cancer Cells Mediated by Prolonged Nitric Oxide Exposure. P. WONGVARANON, V. PONGRAKHANANON, P. CHUNHACHA, P. CHANVORACHOTE (Bangkok, Thailand)	5433
Lobarstin Enhances Chemosensitivity in Human Glioblastoma T98G Cells. S. KIM, S. JO, H. LEE, T.U. KIM, I.-C. KIM, J.H. YIM, H. CHUNG (Wonju, Gangwon-do; Seoul; Incheon, Republic of Korea)	5445
Antibody Against Tumor Necrosis Factor- α Reduces Bortezomib-induced Allodynia in a Rat Model. A. CHIORAZZI, A. CANTA, C. MEREGALLI, V. CAROZZI, B. SALA, N. OGGIONI, J. MONBALIU, H. VAN DE VELDE, G. CAVALETTI (Monza, Italy; Beerse, Belgium)	5453
Epithelial-mesenchymal Transition and Cancer Stem Cells in Endometrial Cancer. A. SUPERNAT, S. ŁAPIŃSKA-SZUMCZYK, H. MAJEWSKA, J. GULCZYŃSKI, W. BIERNAT, D. WYDRA, A.J. ŻACZEK (Gdańsk, Poland)	5461
 <i>Clinical Studies</i> 	
Advanced Microtubular Colorectal Adenomas: A 10-Year Survey at a Single Hospital. C.A. RUBIO, E. JARAMILLO (Stockholm, Sweden)	5471
An ELCWP Phase III Trial Comparing Ifosfamide and Cisplatin Regimens in Advanced NSCLC. T. BERGHMANS, J.-J. LAFITTE, A. SCHERPEREEL, M. PAESMANS, J. LECOMTE, V. GINER MARCO, A.-P. MEERT, N. LECLERCQ, J.-P. SCULIER for The European Lung Cancer Working Party (Brussels; Charleroi, Belgium; Lille, France; Valencia, Spain)	5477
Levels of Circulating Polychlorinated Biphenyls and Mammographic Breast Density. C. DIORIO, I. DUMAS, T.M. SANDANGER, P. AYOTTE (Quebec City, QC, Canada; Tromsø, Norway)	5483
Disease Outcome of Patients with Pancreatic Cancer in a Cohort Treated Outside Clinical Trials. H.M. KOSKELA, K. SYRJÄNEN, E.A. KORKEILA (Turku; Helsinki, Finland; Sao Paolo, Brazil)	5491
Wilms' Tumor Gene 1 (WT1) – loaded Dendritic Cell Immunotherapy in Patients with Uterine Tumors: A Phase I/II Clinical Trial. A. COOSEMANS, A. VANDERSTRAETEN, S. TUYAERTS, T. VERSCHUERE, P. MOERMAN, Z.N. BERNEMAN, I. VERGOTE, F. AMANT, S.W. VAN GOOL (Leuven; Antwerp, Belgium)	5495
Factors Predictive of Oncological Outcome After Nephroureterectomy: Comparison Between Laparoscopic and Open Procedures. K. IZUMI, S. ITAI, Y. TAKAHASHI, R. TAKAHASHI, A. MAOLAKE, M. OFUDE, S. UENO, Y. KADONO, Y. KITAGAWA, H. KONAKA, A. MIZOKAMI, M. NAMIKI (Kanazawa, Japan)	5501
Exceptionally High Incidence of Grade 2-3 Late Rectal Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy. T. NISHIMURA, H. YAMAZAKI, N. AIBE, S. NAKAMURA, K. YOSHIDA, H. OKABE (Uji; Kyoto; Takatsuki, Osaka, Japan)	5507

Long-term Outcome of Seropositive HIV Patients with Head and Neck Squamous Cell Carcinoma Treated with Radiation Therapy and Chemotherapy. W.F. MOURAD, K.S. HU, D. SHASHA, C. CONCERT, D. ISHIHARA, W. LIN, M.E. GAMEZ, J.J. LUKENS, R.A. SHOURBAJI, M. RYNIK, Z. LI, B.E. CULLINEY, A.S. KHORSANDI, T. TRAN, A. JACOBSON, S. MANOLIDIS, S. SCHANTZ, M. URKEN, M.S. PERSKY, L.B. HARRISON (<i>New York, NY, USA</i>)	5511
YKL-40 and Mesothelin in the Blood of Patients with Malignant Mesothelioma, Lung Cancer and Asbestosis. M. CORRADI, M. GOLDONI, R. ALINOVI, M. TISEO, L. AMPOLLINI, S. BONINI, P. CARBOGNANI, A. CASALINI, A. MUTTI (<i>Parma, Italy</i>)	5517
The Need for Repeated Urological Evaluation in Low-risk Patients with Microscopic Hematuria After Negative Diagnostic Work-up. R. PICHLER, I. HEIDEGGER, N. LEONHARTSBERGER, B. STÖHR, F. AIGNER, J. BEKTIC, W. HORNINGER, H. STEINER (<i>Innsbruck, Austria</i>).....	5525
Gemcitabine for the Treatment of Classic Kaposi's Sarcoma: A Case Series. F. ZUSTOVICH, A. FERRO, S. TOSO (<i>Padua; Adria, Italy</i>)	5531
Phase II trial of Pemetrexed Continuation – Maintenance after Carboplatin-based Induction in Untreated Non-squamous Non-small Cell Lung Cancer. S. MINAMI, T. KIJIMA, K. KOMUTA, T. KUMAGAI, F. IMAMURA, S. YOKOTA, Y. TAKEUCHI, T. NAKATANI, I. TACHIBANA, I. KAWASE (<i>Osaka; Suita; Toyonaka, Osaka, Japan</i>)	5535
Quality of Life Assessment in Taiwanese Patients with Bone Metastases from Breast Cancer Receiving Zoledronic Acid. T.-C. CHAO, D.-R. CHEN, T.-Y. CHAO, S.-C. CHEN, D.-C. YEH, H.-C. WANG, W.-T. HUANG, K.-M. RAU, K.-J. CHANG, T.-L. YANG, K.-D. LEE, C.-J. TAI, L.-M. TSENG, M.-F. HOU (<i>Taipei; Changhua; New Taipei City; Taichung; Tainan; Kaohsiung; Chiayi, Taiwan, ROC</i>)	5543
Improvement of Adherence to Guidelines for Antiemetic Medication Enhances Emetic Control in Patients with Colorectal Cancer Receiving Chemotherapy of Moderate Emetic Risk. H. FUJII, H. IIHARA, M. ISHIHARA, T. TAKAHASHI, K. YOSHIDA, Y. ITOH (<i>Gifu, Japan</i>)	5549
Octreotide Acetate–Steroid Combination Therapy for Malignant Gastrointestinal Obstruction. H. MURAKAMI, H. MATSUMOTO, M. NAKAMURA, T. HIRAI, Y. YAMAGUCHI (<i>Okayama, Japan</i>)	5557
Non-surgical Multimodality Treatment for Locally Advanced (T3-4) Hypopharyngeal Cancer: The Impact of Pre-treatment Hemoglobin Level. G. SUZUKI, E. OGO, T. ABE, N. HAYABUCHI, H. UMENO, T. NAKASHIMA, H. YAMAZAKI, S. NAKAMURA, K. YOSHIDA (<i>Kurume, Fukuoka, Japan; Kyoto; Takatsuki, Osaka, Japan</i>).....	5561
Prognostic Value of Preoperative Inflammation-based Prognostic Scores in Patients with Stage IV Colorectal Cancer who Undergo Palliative Resection of Asymptomatic Primary Tumors. K. MAEDA, M. SHIBUTANI, H. OTANI, H. NAGAHARA, K. SUGANO, T. IKEYA, R. AMANO, K. KIMURA, K. SAKURAI, N. KUBO, K. MUGURUMA, H. TANAKA, T. INOUE, K. HIRAKAWA (<i>Osaka, Japan</i>)	5567
Radiotherapy for Early-stage Primary Ocular Adnexal Mucosa-associated Lymphoid Tissue Lymphoma. S. OHGA, K. NAKAMURA, Y. SHIOYAMA, T. SASAKI, T. YOSHITAKE, K. ATSUMI, K. TERASHIMA, K. ASAI, K. MATSUMOTO, H. YOSHIKAWA, Y.-I. KAWANO, H. HONDA (<i>Fukuoka, Japan</i>)	5575
Usefulness of ¹⁸ F-fluorodeoxyglucose Positron Emission Tomography as Predictor of Distant Metastasis in Preoperative Carbon-ion Radiotherapy for Pancreatic Cancer. M. SHINOTO, S. YAMADA, K. YOSHIKAWA, S. YASUDA, Y. SHIOYAMA, H. HONDA, T. KAMADA, H. TSUJII (<i>Tosu, Saga; Chiba, Chiba; Fukuoka, Kyushu, Japan</i>)	5579
Adjuvant Hepatic Arterial Infusion Chemotherapy with 5-Fluorouracil and Interferon After Curative Resection of Hepatocellular Carcinoma: A Preliminary Report. T. KUMAMOTO, K. TANAKA, K. MATSUO, K. TAKEDA, K. NOJIRI, R. MORI, K. TANIGUCHI, R. MATSUYAMA, M. UEDA, H. AKIYAMA, Y. ICHIKAWA, M. OTA, I. ENDO (<i>Yokohama, Japan</i>)	5585

C-reactive Protein as a Significant Prognostic Factor for Stage IV Gastric Cancer Patients. H. BABA, K. KUWABARA, T. ISHIGURO, S. HATANO, T. MATSUZAWA, M. FUKUCHI, Y. KUMAGAI, K. ISHIBASHI, E. MOCHIKI, H. ISHIDA (<i>Saitama, Japan</i>)	5591
Chemotherapy Followed by Surgery on the Basis of Biomarker Examination for Patients with Advanced Non-small Cell Lung Cancer. H. YOKOMISE, D. LIU, S. ISHIKAWA, T. GO, M. GOTOH, M. OKUDA, S. TARUMI, Y. KASAI, N. MATSUURA (<i>Kagawa, Japan</i>)	5597
Efficacy of Transcatheter Arterial Chemoembolization with Miriplatin–Lipiodol Water-soluble Contrast Agent Emulsion in Patients with Hepatocellular Carcinoma. K. OKIMOTO, S. OGASAWARA, T. CHIBA, Y. OOKA, M. OOBU, R. AZEMOTO, N. KANOGAWA, T. MOTOYAMA, E. SUZUKI, A. TAWADA, M. YOSHIKAWA, O. YOKOSUKA (<i>Chiba; Kisarazu, Chiba, Japan</i>)	5603
Immunopositivity of Beclin-1 and ATG5 as Indicators of Survival and Disease Recurrence in Oral Squamous Cell Carcinoma. J.-Y. TANG, Y.-Y. FANG, E. HSI, Y.-C. HUANG, N.C.-H. HSU, W.-C. YANG, H.-W. CHANG, C.-Y. CHAI, P.-Y. CHU (<i>Kaohsiung; Chiayi; New Taipei City, Taiwan, ROC</i>)	5611
Association of <i>GSTP1</i> Methylation with Aggressive Phenotype in ER-positive Breast Cancer. T. MIYAKE, T. NAKAYAMA, N. KAGARA, N. YAMAMOTO, Y. NAKAMURA, Y. OTANI, K. UJI, Y. NAOI, M. SHIMODA, N. MARUYAMA, A. SHIMOMURA, K. SHIMAZU, S.J. KIM, S. NOGUCHI (<i>Osaka; Kobe, Hyogo, Japan</i>)	5617
Long-term Outcome in Patients with Recurrent Malignant Glioma Treated with Perillyl Alcohol Inhalation. C.O. DA FONSECA, R.M. TEIXEIRA, J.C.T. SILVA, J. DE SALDANHA DA GAMA FISCHER, O.C. MEIRELLES, J.A. LANDEIRO, T. QUIRICO-SANTOS (<i>Niteroi; Ipanema; Rio de Janeiro, RJ; Curitiba, PR, Brazil</i>)	5625
Analytical and Clinical Performance of Kroma iT, A Compact Fully-automated Immunochemistry Analyzer for Fecal Occult Hemoglobin. J.M. AUGE, C. RODRIGUEZ, M. PELLISE, A. BERNAL, J. GRAU, A. CASTELLS, X. FILELLA, R. MOLINA (<i>Barcelona, Spain</i>)	5633
Cancer Treatment of Severely-III Patients Not Eligible for Chemotherapy. M. RANDÉN, S. RUNESDOTTER, P. STRANG (<i>Stockholm, Sweden</i>)	5639
Patients with Brain Metastases from Colorectal Cancer Are Not Condemned. D. MEGE, M. OUAISSI, D. FUKS, P. METELLUS, J. PELTIER, H. DUFOUR, J.-M. REGIMBEAU, L. DAHAN, I. SIELEZNEFF, B. SASTRE (<i>Marseille; Amiens, France</i>)	5645
Definitive Fractionated Re-irradiation for Local Recurrence Following Stereotactic Body Radiotherapy for Primary Lung Cancer. T. YOSHITAKE, Y. SHIOYAMA, K. NAKAMURA, T. SASAKI, S. OHGA, M. SHINOTO, K. TERASHIMA, K. ASAI, K. MATSUMOTO, H. HIRATA, H. HONDA (<i>Fukuoka, Kyushu, Japan</i>)	5649
A Higher Body Mass Index and Fat Mass Are Factors Predictive of Docetaxel Dose Intensity. S. GOUÉRANT, M. LEHEURTEUR, M. CHAKER, R. MODZELEWSKI, O. RIGAL, C. VEYRET, G. LAURIDANT, F. CLATOT (<i>Rouen; Caen; Lille, France</i>)	5655
Dynamic Contrast-enhanced Magnetic Resonance Imaging in the Early Evaluation of Anti-angiogenic Therapy in Metastatic Renal Cell Carcinoma. V. PANEBIANCO, R. IACOVELLI, F. BARCHETTI, A. ALTAVILLA, V. FORTE, A. SCIARRA, E. CORTESI, C. CATALANO (<i>Rome, Italy</i>)	5663
Importance of FOXP3 in Prognosis and Its Relationship with p16 in Tonsillar Squamous Cell Carcinoma. K. PARK, K.J. CHO, M. LEE, D.H. YOON, S.-B. KIM (<i>Seoul, Republic of Korea</i>)	5667
Analysis of Intrafractional Organ Motion for Patients with Prostate Cancer Using Soft Tissue Matching Image-guided Intensity-modulated Radiation Therapy by Helical Tomotherapy. K. IWAMA, H. YAMAZAKI, T. NISHIMURA, Y. OOTA, H. AIBE, S. NAKAMURA, H. IKENO, K. YOSHIDA, H. OKABE (<i>Uji; Kyoto, Kyoto; Takatsuki, Osaka, Japan</i>)	5675

Post-transplantation Consolidation and Maintenance Therapy with Lenalidomide for Japanese Patients with Multiple Myeloma. H. TAKAMATSU, S. MUNEMOTO, R. MURATA, Y. TERASAKI, K. NAKAJIMA, S. NAKAO (<i>Kanazawa; Toyama, Japan</i>)	5681
Re-irradiation Using Interstitial Brachytherapy Increases Vaginal Mucosal Reaction Compared to Initial Brachytherapy in Patients with Gynecological Cancer. K. YOSHIDA, H. YAMAZAKI, S. NAKAMURA, K. MASUI, T. KOTSUMA, H. AKIYAMA, E. TANAKA, Y. YOSHIOKA (<i>Takatsuki; Osaka; Suita, Osaka; Kyoto, Kyoto, Japan</i>)	5687
Rituximab in the Treatment of EBV-positive Low Grade B-Cell Lymphoma. P.T. DIAMANTOPOULOS, K. POLONYFI, M. SOFOTASIOU, V. PAPADOPOULOU, F. KALALA, T. ILIAKIS, K. ZERVAKIS, G. TSILIMIDOS, P. KOUZIS, M.-C. KYRTSONIS, T. VASSILAKOPOULOS, M. ANGELOPOULOU, M. SIAKANTARIS, G. VAYOPOULOS, P. KOLLIA, G. PANGALIS, N.-A. VINIOU (<i>Athens, Greece</i>)	5693
Phase I Pharmacokinetic Study of S-1 Granules and Nedaplatin for Advanced Head and Neck Cancer. H. HAYASHI, I. OKAMOTO, S. UEDA, K. TANAKA, K. OKAMOTO, H. KAWAKAMI, S. NISHINA, M. TAKEDA, Y. FUJISAKA, T. SATOH, K. TERAOKA, Y. NISHIMURA, K. DOI, K. NAKAGAWA (<i>Osaka; Suita; Takatsuki, Osaka; Kishiwada; Fukuoka, Japan</i>)	5699
Errata	5707
Book Reviews	5709
Announcements	5712
Reviews in Volume 33, pages: 1, 13, 21, 29, 39, 747, 1247, 1257, 1267, 1273, 1785, 1793, 2353, 2361, 2369, 2377, 2807, 2823, 2833, 2839, 2849, 2855, 2981, 2989, 3527, 3543, 3553, 4139, 4157, 4163, 4175, 4183, 4683, 4695, 4701, 4711.	

Subject Index

(Figures refer to page numbers)

- A₁-adrenoceptor blocker, apoptosis, mmalignant mesothelioma, caspase, NCI-H28, NCI-H2052, NCI-H2452, MSTO-211H, 887
- A172, apoptosis, brain cancer, Chinese medicine, β -elemene, U-87MG, CCF-STTG1 cells, synthetic analogs, 65
- A2780cis cells, salinomycin, DR4, DR5, apoptosis, ovarian cancer, 1457
- A431 cells, *EGFR*, dimerization, radiation, cetuximab, radiosensitivity, 4337
- A549 cells, apoptosis, cisplatin, estrogen, progesterone, lung cancer, 791
- A549, metastasis, migration, invasion, artonin E, lung cancer cells, H460, H23, H292 cells, 3079
- A549, OCT4B, cisplatin, chemoresistance, apoptosis, 5365
- AAMP, angio-associated migratory cell protein, breast cancer, prognosis, MCF-7, MDA-MB-231 cells, 1499
- AB-Crystallin, vascular endothelial growth factor, conjunctival squamous cell carcinoma, 3745
- ABC294640, ovarian cancer, sphingolipids, chemoresistance, sphingosine kinase-2, experimental therapeutics, sphingosine-1-phosphate, BG-1, Caov-3 cells, 3573
- ABCB5, doxorubicin, melanoma, NF- κ B, p53, parthenolide, 3205
- (Abcc2), biliary excretion, cimetidine, drug interaction, pharmacokinetics, multidrug resistance-associated protein-2 (Mrp2), sunitinib, 3105
- ABCC4, prostate cancer cell lines, cabazitaxel, docetaxel resistance, 387
- ABCG2* antigens, neuroendocrine differentiation, CD117, CD133, non-small cell lung cancer, stem cell antigens, 981
- ABCG2*, ALL, BCRP, MAPK, multidrug resistance, 5317
- ABCG2*, YHO-13351, side population cell, irinotecan, 1379
- Abdominal metastasis, breast cancer, E-cadherin, Ki-67, lymphatic vessel invasion, 1971
- ABVD, brentuximad venodin, Hodgkin lymphoma, CD30 antibody, case report, BEACOPP, CD30, 3879
- Acetaminophen, glutathione, chemo-enhancement, cisplatin, ovarian cancer, SKOV3 cells, 2391
- Acetic acid, pap smear, dysplasia, colposcopy, cervical cancer, 1125
- Acetylsalicylic acid, chemoprevention, lung cancer, experimental model, tobacco carcinogens, combination therapy, vitamin D, calcium, 4767
- ACF, NSAIDS, colon cancer, prevention, COX inhibition, apoptosis, rat model, 3581
- Achlorhydria, gastric cancer, atrophic gastritis, antrum, corpus, *Helicobacter pylori*, risk factors, biomarker panel, pepsinogens, gastrin-17, blood test, 4595
- Acquired resistance to gefitinib, non-small lung cancer, epidermal growth factor receptor, erlotinib, gefitinib, adverse events, 5083
- Activating transcription factor 6, cancer, endoplasmic reticulum, stress, unfolded protein response, molecular chaperones, PERK kinase, inositol requiring enzyme-1, review, 4683
- Activating transcription factor-3, 15, 16-dihydrotranthinone I, colorectal cancer, SW480, SW620, SW420 cells, 3225
- Acute exacerbation, interstitial lung disease, small cell lung cancer, chemotherapy, cisplatin, carboplatin, etoposide, 1175
- Acute leukemias, miR-181a, HMGB1, CD4, 445
- Acute myeloid leukemia, *ex vivo* drug resistance, individualized tumor response testing, children, relapse, minimal residual disease, 1189
- ADAL, deamination, GS-9219, PMEG, 1899
- Adenocarcinoma, Barrett's mucosa, serrated adenoma, 1743
- Adenocarcinoma, epirubicin, oxaliplatin, capecitabine, docetaxel, cisplatin, 5-fluorouracil, G-CSF, gastroesophageal cancer, 3455
- Adenocarcinoma, epirubicin, oxaliplatin, capecitabine, gastroesophageal cancer, 1035
- Adenocarcinoma, *IL10*, haplotype, prognosis, squamous cell carcinoma, lung cancer, 2729
- Adenocarcinoma, pancreatic cancer, disease outcome, 5491
- Adenocarcinoma, pemetrexed, erlotinib, NSCLC, second-line, third-line, sequence, 3397
- Adenocarcinoma, renal transplant, goblet cell carcinoid, colon, 1753
- Adenomatoid tumor, odontogenic tumor, jaws tumor, 2673
- Adherence, colorectal cancer, moderately emetic chemotherapy, chemotherapy-induced nausea and vomiting, dexamethasone, 5549
- Adherence, sunitinib, adverse events, early management, pharmacist, blood pressure, 5043
- Adherent cells, apoptosis, cancer, annexin V staining, cell harvesting, 3201
- Adhesion, gastric cancer, endoscopic resection, laparoscopic gastrectomy, perforation, 4023
- Adipocytes, cytokines, immune regulation, inflammation, premalignant lesion cells, 1809
- Adipogenesis, (-)-gossypol-enriched cottonseed oil, proliferation, human breast pre-adipocytes, 949
- Adipose tissue, breast cancer, benign breast tumours, fatty acids, diet, biomarkers, 1667
- Adipose tissue, thyroid cancer, stem cells, xenografts, mouse model, 4213
- Adjuvant chemotherapy, breast cancer, dyspepsia, gastrin, ghrelin, leptin, motilin, pepsinogens, 4951
- Adjuvant chemotherapy, dysphagia, long-term cancer survival, radical resection, small cell carcinoma of the esophagus, 595
- Adjuvant chemotherapy, gastric cancer, S-1, recurrence, 1747

- Adjuvant chemotherapy, hepatocellular carcinoma, hepatic arterial infusion chemotherapy, 5585
- Adjuvant therapy, breast cancer, electrocardiography (ECG), cardiotoxicity, radiotherapy, 4933
- Adjuvant therapy, phase I, sorafenib, hepatocellular carcinoma, orthotopic liver transplantation, 2797
- Adjuvant therapy, rectal cancer, staging, prognostic factors, 4557
- Adjuvant treatment, chemotherapy, colorectal cancer, oxaliplatin, metastatic disease, 1765
- AdnaGen, colorectal cancer, liver metastases, circulating tumor cells, tumor markers, 2239
- Adrenal, medulla, vagus, breast cancer, histology, metastasis, 3675
- ADSC, EMT, H358 cells, tumor microenvironment, cancer-associated fibroblasts, α SMA, 4421
- Advanced adenomas, microtubular configurations, invasive carcinoma, colorectal adenoma, 5471
- Advanced gastric cancer, chemotherapy, docetaxel, elderly, S-1, 697
- Advanced non-small cell lung cancer, non-platinum triplet chemotherapy, UFT, vinorelbine, gemcitabine, 1163
- Adverse effect, centrally-located lung tumor, SBRT, local control, lung cancer, 4959
- Adverse events, non-small lung cancer, epidermal growth factor receptor, erlotinib, gefitinib, acquired resistance to gefitinib, 5083
- Adverse events, sunitinib, early management, pharmacist, adherence, blood pressure, 5043
- Afamin, LICAM, mesothelin, serum marker, ovarian cancer, 329
- Aflibercept, bevacizumab, antiangiogenesis, mCRC, TKI, VEGF, regorafenib, 2377
- Age groups, breast cancer, screening, risk, younger women, 2651
- Aged patient, elderly, non-small cell lung cancer, chemotherapy, pharmacokinetics, quality of life, carboplatin, paclitaxel, maximum tolerated dose, 261
- AIF, gastric adenocarcinoma, Immunohistochemistry, (Smac) DIABLO, cytochrome *c*, 647
- AJCC, esophagogastric junctional carcinoma, Siewert type II adenocarcinoma, TNM, JCGC, staging system, 3461
- AKT, breast cancer, mTOR inhibitor, endocrine resistance, Everolimus, TemSirolimus, review, PI3K, 21
- AKT, breast cancer, neoadjuvant chemotherapy, chemoresponsiveness, S6 kinase 1 (S6K1), 4073
- AKT, cardiac hormones, colorectal adenocarcinomas, pancreatic carcinomas, renal adenocarcinoma, 785
- AKT, celecoxib, sorafenib, apoptosis, hepatocellular carcinoma, synergism, HCC, 1387
- AKT, esophageal squamous cell carcinoma, Ruthenium, microRNA-21, *PTEN*, 5407
- AKT, hTERT, iNOS, oxidative stress, 3295
- AKT, ovarian cancer, CDDO-Me, apoptosis, ROS, NF- κ B, mTOR, 215
- ALA, 5-aminolevulinic acid, protoporphyrin IX, hyperthermia, animal tumor model, 2861
- ALA, DCA, hyperthermotherapy, cellular immunotherapy, stomach cancer, 2957
- Alapha/beta, prostate cancer, radiation therapy, LQ model, 1009
- Alcohol dehydrogenase isoenzymes, aldehyde dehydrogenase, alcohol metabolism, endometrial cancer, 3725
- Alcohol metabolism, alcohol dehydrogenase isoenzymes, aldehyde dehydrogenase, endometrial cancer, 3725
- Alcohol, body-mass index, smoking, neoplasms, multiple primary tumors, esophageal cancer, colonoscopy, 5113
- Alcohol, *HER2* polymorphism, trastuzumab, cardiac risk factors, 2569
- Aldehyde dehydrogenase, alcohol dehydrogenase isoenzymes, alcohol metabolism, endometrial cancer, 3725
- Alimta, rectal cancer, preoperative, chemotherapy, follow-up, outcome, pemetrexed, 325
- ALK*, pemetrexed, cisplatin, non-squamous NSCLC, Japanese, 3327
- ALL, *ABCG2*, BCRP, MAPK, multidrug resistance, 5317
- Allodynia, bortezomib-induced neuropathy, tumor necrosis factor- α , anti-TNF α , 5453
- Allotransplantation, chronic myeloid leukemia, hematopoietic stem cell transplantation, tyrosine kinase inhibitor, imatinib, 4663
- Alpha lipoic acid, immunotherapy, GeMAF, hyper T/NK cells, high-dose vitamin C, 2917
- Alpha-fetoprotein, fucosylated fraction of alpha-fetoprotein, early hepatocellular carcinoma, Gd-EOB-DTPA-enhanced MRI, 997
- ALT mechanism, telomere, chromatin, telomerase, trichostatin A, recombination, 821
- Alternating chemotherapy, extensive-stage small cell lung cancer, amrubicin, irinotecan, cisplatin, 1117
- Alternative therapy, metabotropic glutamate receptors, cell proliferation, tumor biology, neuroendocrine tumors, review, 1267
- Ambrosia arborescens*, damsine, coronopilin, chemoselective bromination, sesquiterpenes, cell proliferation, STAT3, NF- κ B, apoptosis, 3799
- 5-aminolevulinic acid, ALA, protoporphyrin IX, hyperthermia, animal tumor model, 2861
- AML, prognosis, uric acid, 3947
- AML, WT-1, MRD, relapse, 3335
- Amplification, *EGFR*-TKI resistance, erlotinib, copy-number alteration, CRKL, non-small cell lung cancer, 5223
- Amrubicin, extensive-stage small cell lung cancer, alternating chemotherapy, irinotecan, cisplatin, 1117
- Anaesthesia, sevoflurane, breast cancer, 4255

- Anal carcinoma, radiochemotherapy, local control, prognosis, 4111
- Anal fistula, Crohn's disease, anorectal carcinoma, infliximab, 685
- Analyzer evaluation, colorectal cancer, fecal occult hemoglobin, Kroma iT, 5633
- Anaplastic thyroid carcinoma, chemoradiation therapy, docetaxel, local control, palliative management, 3445
- Anaplastic, glioblastoma multiforme, high-grade glioma, etoposide, irinotecan, topotecan, teniposide, meta-analysis, 3307
- Anastomosis, green fluorescent protein, blood vessels, nestin, angiogenesis, red fluorescent protein, Gelfoam[®], transgenic nude mice, confocal microscopy, color-coded imaging, vascularization, 3041
- Anatomical hepatectomy, hepatocellular carcinoma, surgery, preserved liver function, ICG-R15, 1689
- Androgen deprivation therapy, prostate cancer, radical prostatectomy, prostate-specific antigen, 1147
- Androgen receptor, isoform, heat-shock protein HSPB1, microRNA miR-1, 4921
- Androgen receptor, prostate cancer, 2'-hydroxyflavanone, androgen, 4453
- Androgen, breast cancer, microRNA, IQWD1, 4811
- Androgen, prostate cancer, androgen receptor, 2'-hydroxyflavanone, 4453
- Androgens, periostin, prostate cancer, LNCaP cell line, antiandrogens, 815
- Andrographolide, cisplatin, ovarian cancer, apoptosis, synergism, anti-proliferative, 4365
- Anemia, chemoradiotherapy, esophageal cancer, nutrition, prognostic factor, 3495
- Angio-associated migratory cell protein, AAMP, breast cancer, prognosis, MCF-7, MDA-MB-231 cells, 1499
- Angiogenesis, ¹⁸F-FDG PET, pulmonary neuroendocrine tumor, GLUT1, hypoxia, glucose metabolism, 4219
- Angiogenesis, astrocytoma, Immunohistochemistry, aquaporin-1, infiltration zone, 609
- Angiogenesis, azatyrosinamides, ras, antitumour agent, NIH3T3, SW620 human colon xenograft, 425
- Angiogenesis, green fluorescent protein, blood vessels, nestin, anastomosis, red fluorescent protein, Gelfoam[®], transgenic nude mice, confocal microscopy, color-coded imaging, vascularization, 3041
- Angiogenesis, lung cancer, *EGFR*, 1913
- Angiogenesis, lung cancer, non-small cell lung cancer, NSCLC, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, brain metastases, humanized monoclonal antibody, vascular endothelial growth factor A (VEGF-A), pulmonary haemorrhage, 3275
- Angiogenesis, metastatic renal cell carcinoma, targeted therapies, MRI, peak enhancement, 5663
- Angiogenesis, monocyte, colon cancer cell, co-culture, metastasis, signaling pathway, DLD-1, THP-1 cells, 2895
- Angiogenesis, pesticides, cancer, xenoestrogen, 231
- Angiogenesis, prostate cancer, Immunohistochemistry, *VEGFR1*, *NRP1*, tissue array analysis, prostatectomy, 2065
- Angiogenesis, VEGF, *VEGFR1*, *VEGFR2*, bladder cancer, disease recurrence, 2381
- Angiogenesis, ZFAT, transcription factor, haematopoietic system, haematopoietic malignancies, *TAL1*, review, 2833
- Angiotensin-converting enzyme, oral cancer, SNPs, coagulation factors, angiotensinogen, serpine1, regression analysis, 4033
- Angiotensinogen, oral cancer, SNPs, coagulation factors, angiotensin-converting enzyme, serpine1, regression analysis, 4033
- Animal model, hepatocellular carcinoma, rat, chemoembolization, 223
- Animal tumor model, 5-aminolevulinic acid, ALA, protoporphyrin IX, hyperthermia, 2861
- Annexin A2, curcumin, pancreatic cancer, xenograft, liposomal curcumin, MiaPaCa cells, 3603
- Annexin V staining, apoptosis, adherent cells, cancer, cell harvesting, 3201
- Anoikis, ecteinascidin, tetrahydroisoquinoline, *MCL1*, metastasis, lung cancer cells, 505
- Anoikis, quinazoline, doxazosin, terazosin, DZ-50, prostate cancer, vascularity, review, 4695
- Anorectal carcinoma, Crohn's disease, anal fistula, infliximab, 685
- Anthracycline resistance, *PTK7*, triple-negative breast cancer, prognosis, 3759
- Anthracycline, breast cancer, non-pegylated liposomal doxorubicin, metastatic breast cancer, 4603
- Antiandrogens, periostin, prostate cancer, LNCaP cell line, androgens, 815
- Antiangiogenesis, bevacizumab, aflibercept, mCRC, TKI, VEGF, regorafenib, 2377
- Antibody, *HER2*, fluorophore, rhodamine, breast cancer, 4T1, GFP, orthotopic model, lymph node, metastasis, imaging, 419
- Anticancer activity, vitamin D analogs, combined treatment, oxaliplatin, irinotecan, colonic cancer, 433
- Anticancer agent, ester conjugate, fatty acid, cytotoxicity, cancer cell lines, MDA-MB-361, MCF-7, MDA-MB-231, 2517
- Anticancer agents, antioxidant protein, siRNA, apoptosis, redox status, PC3 cells, 847
- Anticancer agents, antiproliferative activity, piperazine derivatives, triphenyl derivatives, erythroid differentiation, 3027
- Anticancer drug screening, three-dimensional (3D) culture, silicate fiber scaffold, drug resistance, 5301

- Anticancer therapy, zoledronic acid, denosumab, tumor growth, review, 2981
- Anti-estrogen, estrogen receptor, Y-box binding protein-1, transforming growth factor β , resistance, 2473
- Antigen presentation, dendritic cell, cancer vaccine, fusion, 347
- Antigenic peptide, HLA class-I, cancer associated antigen, prostate cancer, mass spectrometric analysis, 1853
- Anti-idiotypic antibody, redirected T-cells, expansion, NY-ESO-1, peptide specific, chimeric antigen receptor, 4189
- Antimitotic agents, bladder carcinoma, cell cycle, tubulin, flavanone, 4445
- Antineoplastic drugs, urinary bladder cancer, *in vitro* models, *in vivo* models, review, 1273
- Antioxidant capacity, polycyclic aromatic hydrocarbon, oxidative stress, lung cancer, nested case-control study, 1-hydroxypyrene, thiobarbituric acid, 8-hydroxydeoxyguanosine, cotinine, 2-Naphthol, 3089
- Antioxidant protein, siRNA, apoptosis, redox status, anticancer agents, PC3 cells, 847
- Antioxidant, ellagic acid, pro-oxidant, antiproliferative, apoptosis, H5C-2 oral carcinoma cells, 1829
- Anti-oxidant, hydrogel, ellagic acid, glycine, folic acid, breast cancer, implant, 4847
- Antioxidants, benzophenone sunscreens, dioxybenzone, octabenzene, mouse skin papillomas, oral chemoprevention, 2535
- Antiproliferative activity, piperazine derivatives, triphenyl derivatives, erythroid differentiation, anticancer agents, 3027
- Anti-proliferative, andrographolide, cisplatin, ovarian cancer, apoptosis, synergism, 4365
- Antiproliferative, ellagic acid, pro-oxidant, antioxidant, apoptosis, H5C-2 oral carcinoma cells, 1829
- Anti-promotion, disiloxanes, chemoprevention, EBV-induced early antigen, two-stage mouse skin carcinogenesis, co-existence of tumor and normal cells, 2021
- Anti-TNF α , bortezomib-induced neuropathy, allodynia, tumor necrosis factor- α , 5453
- Antitumor activity, degalactosylated Gc-globulin, a precursor of Gc-derived macrophage activating factor, subtypes of Gc-globulin, injection route, 2911
- Antitumor activity, glioma, KSP inhibitors, LaSOM 65, 4463
- Antitumor immune response, colorectal cancer, inflammatory cell infiltration, CD3, CD8, lymph node retrieval, 5143
- Antitumor immunity, glioblastoma, HDAC inhibition, 1351
- Antitumor agent, azatyrosinamides, ras, NIH3T3, SW620 human colon xenograft, angiogenesis, 425
- Antrum, gastric cancer, atrophic gastritis, corpus, *Helicobacter pylori*, risk factors, biomarker panel, pepsinogens, gastrin-17, achlorhydria, blood test, 4595
- APEX1, single-nucleotide polymorphism, lung cancer, smoking habit, Taiwanese, 2775
- ApoE, LXR, MCF-7, proliferation, apoptosis, THP-1, MCF-7 cells, 3783
- Apoptosis induction, *Rhinacanthus nasutus*, cytotoxicity, osteoclastogenesis, HSC-2, HSC-3, HSC-4, HL-60 cells, 453
- Apoptosis, adherent cells, cancer, annexin V staining, cell harvesting, 3201
- Apoptosis, *Ambrosia arborescens*, damsine, coronopilin, chemoselective bromination, sesquiterpenes, cell proliferation, STAT3, NF- κ B, 3799
- Apoptosis, andrographolide, cisplatin, ovarian cancer, synergism, anti-proliferative, 4365
- Apoptosis, antioxidant protein, siRNA, redox status, anticancer agents, PC3 cells, 847
- Apoptosis, ApoE, LXR, MCF-7, proliferation, THP-1, MCF-7 cells, 3783
- Apoptosis, bladder cancer, cisplatin resistance, Chinese medicine, β -elemene, caspases, 1421
- Apoptosis, brain cancer, Chinese medicine, β -elemene, A172, U-87MG, CCF-STTG1 cells, synthetic analogs, 65
- Apoptosis, canine cutaneous histiocytoma, proliferation, Ki-67, TUNEL, 1397
- Apoptosis, celecoxib, sorafenib, AKT, hepatocellular carcinoma, synergism, HCC, 1387
- Apoptosis, ceramide, dihydroceramide desaturase, dihydroceramide, PDT, sphingolipids, UM-SCC-22A cells, HNSCC, 77
- Apoptosis, chinese medicine, β -elemene, taxanes, synergism, ovarian cancer, prostate cancer, cell cycle arrest, 929
- Apoptosis, cisplatin, estrogen, progesterone, A549 cells, lung cancer, 791
- Apoptosis, citric acid, HaCaT, cell cycle, cytotoxic effect, 4411
- Apoptosis, CK2 inhibitors, pentabromobenzylisothioureas, KG-1 cells, flow cytometry, 4891
- Apoptosis, curcumin, human gallbladder adenocarcinoma, G2/M arrest, 1861
- Apoptosis, daunorubicin derivatives, human acute leukemia cells, necrosis, mitochondrial membrane potential, 4439
- Apoptosis, ellagic acid, pro-oxidant, antioxidant, antiproliferative, H5C-2 oral carcinoma cells, 1829
- Apoptosis, esophageal cancer, eicosapentaenoic acid, NF- κ B, cytokines, TE-1 cells, 4319
- Apoptosis, fluoxetine, hepatocellular carcinoma, mitogen-activated protein kinase, Hep3B cells, 3691
- Apoptosis, gastric cancer, cannabinoids, fluorouracil, drug resistance, 2541
- Apoptosis, gefitinib, erlotinib, H23 cells, cell cycle arrest, c-MYC, 1547
- Apoptosis, GFP, RFP, mitosis, subcellular dynamics, brain cancer, mouse models, temozolomide, *in vivo* imaging, 103
- Apoptosis, giant cell tumor of bone, peroxisome proliferator-activated receptor gamma (PPAR γ), 2169

- Apoptosis, glioma stem cell, CD95 ligand, temozolomide, 3563
- Apoptosis, glycosylation, invasion, lectin, prognosis, 3053
- Apoptosis, high-performance counter current chromatography, umbelliferone, herniarin, scoparone, laryngeal cancer cells, proliferation, migration, cell cycle, 4347
- Apoptosis, HT-1080, fibrosarcoma, intravascular, extravasation, GFP, RFP, mitosis, nude mice, confocal microscopy, 4229
- Apoptosis, hydrogen peroxide, radiation, proliferation, melanoma, 1799
- Apoptosis, Id4, senescence, E2F1, DU145, 4271
- Apoptosis, naphthoquinones, chronic lymphocytic leukemia (CLL), MAPKs, cytochrome C, mitochondria, BCL2, 183
- Apoptosis, native human interferon alpha, recombinant human interferon alpha, non-small cell lung cancer, tumor proliferation, *p21*, survivin, 2043
- Apoptosis, NSAIDS, colon cancer, prevention, COX inhibition, ACF, rat model, 3581
- Apoptosis, OCT4B, cisplatin, chemoresistance, A549, 5365
- Apoptosis, oral cancer, Siah2, ubiquitin ligase, 4965
- Apoptosis, osteosarcoma, quercetin, cell-cycle arrest, migration, 143B cells, 1297
- Apoptosis, ovarian cancer, CDDO-Me, ROS, AKT, NF- κ B, mTOR, 215
- Apoptosis, prostate cancer, curcumin analogues, proliferation, PC-3 cells, 1343
- Apoptosis, salinomycin, DR4, DR5, ovarian cancer, A2780cis cells, 1457
- Apoptosis, survivin, non-small cell lung cancer, real-time RT-PCR, mRNA, proliferation, 3475
- Apoptosis, TRAIL, cervical cancer cells, equol, caspases, death receptors, 903
- Apoptosis, trehalose, liposome, hepatocarcinoma, Hep-G2, HuH-7 cells, 4727
- Apoptosis, α_1 -adrenoceptor blocker, mmalignant mesothelioma, caspase, NCI-H28, NCI-H2052, NCI-H2452, MSTO-211H, 887
- Apoptotic index, pancreatic ductal adenocarcinoma, gemcitabine, hyperbaric oxygen therapy, PANC-1, AsPc-1 cells, 4827
- Apoptotic pathway, biomarkers, gastric cancer, *HER2*, DNA repair systems, fluoropyrimidine metabolism, chemotherapy, targeted therapy, review, 1257
- Appendix, neuroendocrine, carcinoma, NET, NEC, 2635
- Aquaporin-1, astrocytoma, Immunohistochemistry, angiogenesis, infiltration zone, 609
- Arginine, *Salmonella typhimurium*, auxotroph, leucine, GFP, tumor-targeting, primer dosing, high dose, Lewis lung carcinoma, immunocompetent mice syngeneic mouse model, 97
- ARP2/3 complex, pancreatic cancer, cell migration, 45
- Artemisinin, transferrin, breast cancer, *HER2*, survivin, c-Myc, cyclin D1, DV145, MCF7 cells, 123
- Artesunate, cancer, safety study, dog, comparative oncology, 1819
- Artificial neural networks, cancer prognosis, ki-67, p53, oestrogen/progesterone receptors, prediction of nodal status, 3925
- Artonin E, metastasis, migration, invasion, lung cancer cells, H460, H23, A549, H292 cells, 3079
- Aryl hydrocarbon receptor, epidermal growth factor receptor, non-small cell lung cancer, prognosis, 3953
- Aryl hydrocarbon receptor, lung cancer, tumorigenesis, dioxin, polycyclic aromatic hydrocarbons, cigarette smoke, review, 1247
- Ashkenazi, gastric cancer, chemoradiation, ethnicity, Israel, 5151
- ASMA, ADSC, EMT, H358 cells, tumor microenvironment, cancer-associated fibroblasts, 4421
- Aspartate aminotransferase, hepatocellular carcinoma, percutaneous ethanol injection, survival, transcatheter arterial chemoembolization, Child-Pugh score, 5171
- AsPc-1 cells, pancreatic ductal adenocarcinoma, gemcitabine, hyperbaric oxygen therapy, apoptotic index, PANC-1, 4827
- Assessment methods, breast cancer, podoplanin, cancer-associated fibroblasts, IHC, 1447
- Astrocytoma, brain neoplasms, glioblastoma multiforme IV, PTTG, pituitary tumor-transforming gene, 119
- Astrocytoma, Immunohistochemistry, aquaporin-1, angiogenesis, infiltration zone, 609
- Asymmetric cell division, cancer stem-like cells, OCT4, MDA-MB453, stemness, differentiation, 763
- Asymptomatic primary tumor, colorectal cancer, stage IV, palliative surgery, Glasgow prognostic score, neutrophil to lymphocyte ratio, 5567
- ATM*, ATR, Chk1, p53, *p21*, cell-cycle arrest, vinca alkaloids, DNA damage, 5273
- ATM*, polymorphism, genotype, lung cancer, smoking, 4067
- ATP7B, cisplatin, chemotherapy, LOH, urothelial carcinoma, bladder cancer, 3731
- ATR, *ATM*, Chk1, p53, *p21*, cell-cycle arrest, vinca alkaloids, DNA damage, 5273
- Atrophic gastritis, gastric cancer, antrum, corpus, *Helicobacter pylori*, risk factors, biomarker panel, pepsinogens, gastrin-17, achlorhydria, blood test, 4595
- Autoimmune hepatitis, liver, biopsies, plasma cells, plasma cell precursors, multiple myeloma oncogene-1 (MUM1), 665
- Autologous stem-cell transplantation, multiple myeloma, consolidation and maintenance therapy, bortezomib, lenalidomide, 5681
- Autophagy, CD47, CD36, TSP-1, 4N1K, cancer, 1429

- Autophagy, glioblastoma, RAD001, temozolomide, γ -radiation, 1845
- Autophagy, I3C derivative CTet, synergy, triple-negative breast cancer, *MAP1LC3B*, MDA-MB-231, BT-20 cells, 1867
- Auxotroph, *Salmonella typhimurium*, leucine, arginine, GFP, tumor-targeting, primer dosing, high dose, Lewis lung carcinoma, immunocompetent mice syngeneic mouse model, 97
- Av integrin, green fluorescent protein, blood vessels, red fluorescent protein, Gelfoam[®], osteosarcoma, transgenic nude mouse, confocal microscopy, 1361
- Av integrin, green fluorescent protein, osteosarcoma, fibronectin, *in vitro*, *in vivo*, nude mouse, metastasis, real-time imaging, confocal microscopy, 3021
- A α β 3 integrin, overexpression, green fluorescent protein, red fluorescent protein, osteosarcoma, nude mice, lung metastasis, passage, variants, 3623
- Axilla, lymph nodes, breast cancer, axillary clearance, surgeon, 3935
- Axillary clearance, axilla, lymph nodes, breast cancer, surgeon, 3935
- Ayre's spatula, pap test, cervical sampling device, cytobrush, 917
- Azatyrosinamides, ras, antitumour agent, NIH3T3, SW620 human colon xenograft, angiogenesis, 425
- B16F10 cells, HOCl, superoxide anion, singlet oxygen, hydroxyl radical, SOD, MKN45, 3589
- B16F10 cells, radiation effects, bisphosphonates, radiosensitizers, radioprotectors, PNT2, TRAMP-C1, 3217
- B-catenin, 5-FU, docetaxel, c-KIT, head and neck squamous cell carcinoma, extracellular matrix, protein tyrosine kinase, human papillomavirus (HPV), epithelial mesenchymal transition (EMT), 2457
- B-catenin, cardiac hormones, human pancreatic cancer, human colorectal adenocarcinoma, human renal adenocarcinoma, 2409
- B-catenin, colorectal cancer, WNT, prognosis, E-cadherin, SFRP, invasive front, 4573
- B-catenin, pancreatic cancer, tumor progression, CXCR4, 4103
- B-elemene, apoptosis, bladder cancer, cisplatin resistance, Chinese medicine, caspases, 1421
- B-elemene, apoptosis, brain cancer, Chinese medicine, A172, U-87MG, CCF-STTG1 cells, synthetic analogs, 65
- B-elemene, chinese medicine, taxanes, synergism, ovarian cancer, prostate cancer, apoptosis, cell cycle arrest, 929
- B-Tricalcium phosphate, bone tumor, filling material, resorption, bone remodeling, 5075
- Baby boomers, endometrial carcinoma, early stage, obesity, outcome, prognosis, 619
- Baby boomers, endometrial carcinoma, early stage, SEER, survival, prognosis, 4983
- Bacteriophages, phage therapy, leukemia, HL-60, phage-cancer interactions, phage-mammalian interactions, 1569
- Barrett's mucosa, serrated adenoma, adenocarcinoma, 1743
- Basal cell carcinoma, mTOR, phospho-mTOR, squamous cell carcinoma, Sirolimus, Everolimus, Immunohistochemistry, organ transplantation, immunosuppression, skin, 3711
- BAX, lung cancer, drug resistance, zoledronic acid, 5357
- BBE, renal cell carcinoma, nanoparticle, desacyl-saponin, *in vitro*, *in vivo*, xenograft, 143
- BCG, hepatocellular carcinoma, HCC, immunotherapy, interleukin-2, IL-2, melatonin, 4531
- BCL2, naphthoquinones, chronic lymphocytic leukemia (CLL), MAPKs, cytochrome C, apoptosis, mitochondria, 183
- BCRP, *ABCG2*, ALL, MAPK, multidrug resistance, 5317
- BEACOPP, brentuximad venodin, Hodgkin lymphoma, CD30 antibody, case report, ABVD, CD30, 3879
- Bead-based-assay, equine melanoma, IL-12, IFN- γ , 1325
- Benign breast tumours, breast cancer, fatty acids, adipose tissue, diet, biomarkers, 1667
- Benign lymphoepithelial cysts (BLEC), radiation therapy (RT), parotid gland hyperplasia, HIV positive, highly active antiretroviral therapy (HAART), 4927
- Benzamizoles, fenbendazole, tumor microenvironments, radiation therapy, hypoxia, EMT6 cells, 355
- Benzophenone sunscreens, dioxybenzone, octabenzene, mouse skin papillomas, oral chemoprevention, antioxidants, 2535
- Beta-2 microglobulin, Non-Hodgkin lymphoma, positron-emission tomography, FDG, 3341
- Bevacizumab, aflibercept, antiangiogenesis, mCRC, TKI, VEGF, regorafenib, 2377
- Bevacizumab, colorectal cancer, predictive marker, proteinuria, 309
- Bevacizumab, lung cancer, non-small cell lung cancer, NSCLC, platinum-based chemotherapy, overall survival, progression-free survival, brain metastases, humanized monoclonal antibody, angiogenesis, vascular endothelial growth factor A (VEGF-A), pulmonary haemorrhage, 3275
- Bevacizumab, non-small cell lung cancer, *in vivo* antitumor activity, elacytarabine, cetuximab, trastuzumab, xenograft, 3615
- Bevacizumab, osteonecrosis of the jaw, ONJ, denosumab, sunitinib, risk factors, review, 1793
- Bevacizumab, recurrent malignant glioma, deep venous thrombosis, D-dimer, 2093
- Bevacizumab, temSirolimus, glioblastoma multiforme, phase II study, PI3K, protein kinase B (AKT), mTOR, rapamycin, 1657

- BG-1, ovarian cancer, sphingolipids, chemoresistance, sphingosine kinase-2, experimental therapeutics, sphingosine-1-phosphate, ABC294640, Caov-3 cells, 3573
- Bi-functional peptide, renal cancer, WNT inhibitors, targeted therapy, 2435
- Biliary excretion, cimetidine, drug interaction, pharmacokinetics, multidrug resistance-associated protein-2 (Mrp2), sunitinib, (Abcc2), 3105
- Biliary tract cancer, irinotecan, refractory, gemcitabine, cisplatin, fluoropyrimidine, 2619
- Biliary tract cancer, perineural invasion, CA19-9, CEA, 583
- Biliary tract cancer, single nucleotide polymorphism, VEGF, VEGFR, sunitinib, gastric cancer, 4619
- Biliary tract neoplasms, brachytherapy, radiotherapy, Yridium radioisotopes, expandable metallic stents, 2747
- Biliverdin reductase, leukemia, multidrug resistance, reactive oxygen species, 4913
- Bioavailability, curcumin, oral absorption, drug delivery system, review, 2807
- Biological markers, oral cancer, 5-hydroxymethylcytosine, DNA methylation, ten-eleven-translocation 2, 4325
- Biomarker panel, gastric cancer, atrophic gastritis, antrum, corpus, *Helicobacter pylori*, risk factors, pepsinogens, gastrin-17, achlorhydria, blood test, 4595
- Biomarker, bladder cancer, cyclin D1, muscle-invasive, 5235
- Biomarker, cell-free DNA, CpG-island, hypermethylation, kidney cancer, serum, 4651
- Biomarker, chemotherapy, lung cancer surgery, lung cancer biology, 5597
- Biomarker, gastric cancer, long non-coding RNAs, plasma, 3185
- Biomarker, gastric cancer, microRNA, plasma, prognosis, circulating nucleic acids, miR-21, 271
- Biomarker, prostate cancer, cell-free DNA, screening, quantitative PCR, PicoGreen, 4521
- Biomarkers, breast cancer, benign breast tumours, fatty acids, adipose tissue, diet, 1667
- Biomarkers, colorectal cancer, circulating tumour cells, chemotherapy, 625
- Biomarkers, gastric cancer, HER2, DNA repair systems, fluoropyrimidine metabolism, apoptotic pathway, chemotherapy, targeted therapy, review, 1257
- Biopsies, liver, autoimmune hepatitis, plasma cells, plasma cell precursors, multiple myeloma oncogene-1 (MUM1), 665
- Bisphosphonate, osteonecrosis, mandible, cytostatic therapy, risk factors, 3917
- Bisphosphonates, radiation effects, radiosensitizers, radioprotectors, PNT2, TRAMP-C1, B16F10 cells, 3217
- Bladder cancer, apoptosis, cisplatin resistance, Chinese medicine, β -elemene, caspases, 1421
- Bladder cancer, ATP7B, cisplatin, chemotherapy, LOH, urothelial carcinoma, 3731
- Bladder cancer, biomarker, cyclin D1, muscle-invasive, 5235
- Bladder cancer, concurrent chemoradiotherapy, complete response, hydronephrosis, 2605
- Bladder cancer, Cox-2, polymorphism, genotype, 5401
- Bladder cancer, hematuria, second malignancy, urinary tract malignancy, repeat evaluation, screening, 5525
- Bladder cancer, hypermethylation, cell-free DNA, serum, 779
- Bladder cancer, VEGF, VEGFR1, VEGFR2, disease recurrence, angiogenesis, 2381
- Bladder carcinoma, antimetabolic agents, cell cycle, tubulin, flavanone, 4445
- Bladder carcinoma, lentiviral siRNA, hCG β , silencing, stable gene knockdown SCaBER cells, 3611
- Bladder invasion, radiation therapy, cervical cancer, FIGO IVA, rectum invasion, EQD2, 4989
- Bladder tumor, clear cell adenocarcinoma, endometrial neoplasm, pelvic exenteration, Mullerian tumour, 615
- Blood oxygen level-dependent MRI, hepatocellular carcinoma, chemoembolization, 1887
- Blood pressure, sunitinib, adverse events, early management, pharmacist, adherence, 5043
- Blood test, gastric cancer, atrophic gastritis, antrum, corpus, *Helicobacter pylori*, risk factors, biomarker panel, pepsinogens, gastrin-17, achlorhydria, 4595
- Blood transfusion, fresh-frozen plasma, prognosis, pancreatic cancer, pancreatic resection, post-operative recurrence, 4041
- Blood transfusion, prognosis, colorectal cancer, liver metastasis, hepatic resection, 2723
- Blood vessels, green fluorescent protein, nestin, angiogenesis, anastomosis, red fluorescent protein, Gelfoam[®], transgenic nude mice, confocal microscopy, color-coded imaging, vascularization, 3041
- Blood vessels, hepatocellular carcinoma (HCC), boron neutron capture therapy (BNCT), boric acid, therapeutic efficacy, tumor size, 4799
- Blood vessels, α v integrin, green fluorescent protein, red fluorescent protein, Gelfoam[®], osteosarcoma, transgenic nude mouse, confocal microscopy, 1361
- Blood, diagnosis, protein kinase, peptide substrate, phosphorylation, 485
- BMI1, EZH2, p53, human oral squamous cell carcinoma, 4309
- BMP10, urothelial cancer of bladder, growth, motility and adhesion, T24 cells, 1917
- Body-mass index, smoking, alcohol, neoplasms, multiple primary tumors, esophageal cancer, colonoscopy, 5113
- Bone marrow-derived cells, lung cancer, mouse mode, green fluorescent protein, 831
- Bone metastases, zoledronic acid, breast cancer, quality of life, 5543
- Bone metastasis, cancer-induced bone pain, sex differences, pain, 1963

- Bone metastasis, lung cancer, NSCLC, CEA, CTX, CYFRA 21-1, PINP, TRAP5b, 2593
- Bone metastasis, prostate cancer, combined androgen blockade, zoledronic acid, 3837
- Bone metastasis, RANK, RANKL, osteoprotegerin, OPG, breast cancer, oestrogen, MCF-7, MDA-MB-231, 199
- Bone remodeling, β -tricalcium phosphate, bone tumor, filling material, resorption, 5075
- Bone sialoprotein, osteopontin, prognosis, renal cell carcinoma, 2679
- Bone tumor, β -tricalcium phosphate, filling material, resorption, bone remodeling, 5075
- Bone, curcumin, morphometrics, remodeling, mice, 3153
- Borderline ovarian tumors, HE4, ovarian cancer, 1673
- Boric acid, hepatocellular carcinoma (HCC), boron neutron capture therapy (BNCT), therapeutic efficacy, tumor size, blood vessels, 4799
- Boron neutron capture therapy (BNCT), hepatocellular carcinoma (HCC), boric acid, therapeutic efficacy, tumor size, blood vessels, 4799
- Bortezomib, multiple myeloma, autologous stem-cell transplantation, consolidation and maintenance therapy, lenalidomide, 5681
- Bortezomib-induced neuropathy, allodynia, tumor necrosis factor- α , anti-TNF α , 5453
- 53BP1, GFP, focus, UVC, DNA damage, pancreatic cancer, 1373
- Brachytherapy, biliary tract neoplasms, radiotherapy, Yridium radioisotopes, expandable metallic stents, 2747
- Brachytherapy, endometrial carcinoma, vaginal recurrence, radiotherapy, 241
- Brachytherapy, gynecological cancer, high dose rate, late vaginal mucosal reaction, stenosis, pallor reaction, 3963
- Brachytherapy, gynecological cancer, high dose rate, late vaginal mucosal reaction, interstitial brachytherapy, re-irradiation, 5687
- Brachytherapy, head and neck cancer, recurrence, 249
- BRAF* mutation, thyroid neoplasms, proteomics, chaperonin 60, lymph node metastases, 4357
- BRAF* mutations, *HRAS*, *KRAS*, *NRAS* mutations, *KRAS* codon 59 deletion, follicular-patterned thyroid lesions, 4779
- BRAF*, ovarian carcinoma, *PPP2R1A*, *PIK3CA*, *KRAS*, mutation, 113
- Brain cancer, apoptosis, Chinese medicine, β -elemene, A172, U-87MG, CCF-STTG1 cells, synthetic analogs, 65
- Brain cancer, GFP, RFP, apoptosis, mitosis, subcellular dynamics, mouse models, temozolomide, *in vivo* imaging, 103
- Brain cancer, GFP, RFP, mitosis, subcellular dynamics, brain metastasis, mouse model, craniotomy window, *in vivo* imaging, 1367
- Brain metastases, breast cancer, surgical resection, prognostic factors, 2159
- Brain metastases, colorectal cancer, surgical approach, WBRT, 5645
- Brain metastases, gastro-oesophageal cancer, GI cancer, molecules, targeted therapy, 1065
- Brain metastases, hypoxic radiosensitizer, reirradiation, stereotactic irradiation, CyberKnife, 1773
- Brain metastases, lung adenocarcinoma, *EGFR*, TKI, radiotherapy, resistance, 1649
- Brain metastases, lung cancer, non-small cell lung cancer, NSCLC, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, humanized monoclonal antibody, angiogenesis, vascular endothelial growth factor A (VEGF-A), pulmonary haemorrhage, 3275
- Brain metastases, multimodality treatment, pancreatic cancer, stereotactic radiosurgery, 3899
- Brain metastasis blood-brain barrier (BBB), junctional adhesion molecules (JAMs), tight junctions (TJs), review, 2353
- Brain metastasis, breast cancer, locally advanced tumor, HER-2, neoadjuvant chemotherapy, pathological complete response, radiation, prophylactic cranial irradiation, 5119
- Brain metastasis, GFP, RFP, mitosis, subcellular dynamics, brain cancer, mouse model, craniotomy window, *in vivo* imaging, 1367
- Brain metastasis, SCLC, extracranial organs, prognostic factors, survival, 3887
- Brain neoplasms, astrocytoma, glioblastoma multiforme IV, PTTG, pituitary tumor-transforming gene, 119
- Brain tumor, liposomal cytarabine, intrathecal, medulloblastoma, relapse/progression, case series, 3515
- Breast cancer prevention, vitamin D, prostaglandin inhibition, 3861
- Breast cancer staging, sentinel lymph node, micrometastases, 4509
- Breast cancer, 5-HTRs, serotonin, malignant, non-malignant, invasive ductal carcinoma, invasive lobular carcinoma, 363
- Breast cancer, abdominal metastasis, E-cadherin, Ki-67, lymphatic vessel invasion, 1971
- Breast cancer, adjuvant chemotherapy, dyspepsia, gastrin, ghrelin, leptin, motilin, pepsinogens, 4951
- Breast cancer, adjuvant therapy, electrocardiography (ECG), cardiotoxicity, radiotherapy, 4933
- Breast cancer, adrenal, medulla, vagus, histology, metastasis, 3675
- Breast cancer, anaesthesia, sevoflurane, 4255
- Breast cancer, androgen, microRNA, IQWD1, 4811
- Breast cancer, angio-associated migratory cell protein, AAMP, prognosis, MCF-7, MDA-MB-231 cells, 1499
- Breast cancer, artemisinin, transferrin, *HER2*, survivin, c-Myc, cyclin D1, DV145, MCF7 cells, 123
- Breast cancer, axilla, lymph nodes, axillary clearance, surgeon, 3935

- Breast cancer, benign breast tumours, fatty acids, adipose tissue, diet, biomarkers, 1667
- Breast cancer, brain metastases, surgical resection, prognostic factors, 2159
- Breast cancer, circulating tumor cell, immunosurveillance, tumor cell dormancy, T-cell, FAS, 2233
- Breast cancer, circulating tumor cells, TGF- β , CXCL1, metastasis, chemokines, cytokines, 1491
- Breast cancer, ductal carcinoma *in situ*, hypofractionated radiotherapy, 3503
- Breast cancer, exercise intervention, cardiovascular risk factors, health behavior, obesity, physical activity, physical health, 1595
- Breast cancer, FAK, tissue microarray, 1169
- Breast cancer, folate, homocysteine, MTHFR, FTO, polymorphism, Kazakhstan, 4049
- Breast cancer, glutathione S-transferase P1 (GSTP1), DNA methylation, microdissection, ER-positive breast cancer, 5617
- Breast cancer, HER-2 oncoprotein, SKBR-3 cells, trastuzumab resistance, proteomics, 489
- Breast cancer, *HER2*, antibody, fluorophore, rhodamine, 4T1, GFP, orthotopic model, lymph node, metastasis, imaging, 419
- Breast cancer, *HER2*, phosphorylation, trastuzumab, 2509
- Breast cancer, hydrogel, ellagic acid, glycine, folic acid, anti-oxidant, implant, 4847
- Breast cancer, hypoxia-inducible factor, polymorphism, transcriptional activity, MCF-7 cells, 2549
- Breast cancer, inhibitor of differentiation, inhibitor of DNA binding, ID1, ID2, qPCR, helix-loop-helix, cell cycle, 2179
- Breast cancer, intraoperative radiotherapy, partial breast irradiation, 1229
- Breast cancer, IORT, elderly, morbidity, short-term outcome, 3995
- Breast cancer, LATS2, estrogen receptor, NCoR, ER α , 53
- Breast cancer, leptomeningeal metastases, neoplastic meningitis, intra-CSF chemotherapy, liposomal cytarabine, multimodality treatment, 2057
- Breast cancer, locally advanced tumor, HER-2, brain metastasis, neoadjuvant chemotherapy, pathological complete response, radiation, prophylactic cranial irradiation, 5119
- Breast cancer, lymphatic microvessel density, mast cells, molecular classification, prognosis, 957
- Breast cancer, MALDI, *HER2*, lipid, profiles, 2467
- Breast cancer, male, female, prognostic factors, survival, 2227
- Breast cancer, mastopexy, breast-conserving surgery, lumpectomy, 731
- Breast cancer, mitogen-inducible gene-2, MIG2, migfilin, 1977
- Breast cancer, morbid obesity, breast-conservation surgery, radiotherapy, chemotherapy, 3867
- Breast cancer, mTOR inhibitor, endocrine resistance, Everolimus, TemSirolimus, review, PI3K, AKT, 21
- Breast cancer, *NAT2*, cancer susceptibility, SNP, IAM, gastric cancer, 3683
- Breast cancer, neoadjuvant chemotherapy, chemoresponsiveness, S6 kinase 1 (S6K1), AKT, 4073
- Breast cancer, non-pegylated liposomal doxorubicin, anthracycline, metastatic breast cancer, 4603
- Breast cancer, p14, p16, cell cycle, cell senescence, qPCR, 2185
- Breast cancer, paclitaxel, capecitabine, metastasis, response, 4941
- Breast cancer, paclitaxel, metastasis, docetaxel, time-to-progression, survival, 2623
- Breast cancer, phenotypic reversion, microenvironment, mammary fibroblasts, primary cells, 1525
- Breast cancer, podoplanin, cancer-associated fibroblasts, IHC, assessment methods, 1447
- Breast cancer, polychlorinated biphenyl, PCB, organochlorine, mammographic breast density, 5483
- Breast cancer, prognosis, CA15-3, 293
- Breast cancer, protein kinase D, triple-negative breast cancer cells, 393
- Breast cancer, RANK, RANKL, osteoprotegerin, OPG, oestrogen, bone metastasis, MCF-7, MDA-MB-231, 199
- Breast cancer, screening, age groups, risk, younger women, 2651
- Breast cancer, segmental bioelectrical impedance analysis, whole-body bioelectrical impedance analysis, edema of the upper limb, 3403
- Breast cancer, Sentinel lymph node, intraoperative examination, frozen section, imprint cytology, 1045
- Breast cancer, single-frequency bioelectrical impedance, lymphedema of the upper limb, 4553
- Breast cancer, TGF- β 1, prognostic factors, 737
- Breast cancer, thrombocytosis, predictive value, 4545
- Breast cancer, TMA, ER, PgR, *HER2*, Ki67, 2139
- Breast cancer, trastuzumab, cardiotoxicity, *HER2*, 1717
- Breast cancer, vitamin D, sunlight, polymorphisms, gene, case-control, 543
- Breast cancer, zoledronic acid, bone metastases, quality of life, 5543
- Breast cancer, zoledronic acid, mTOR, REDD1, endoplasmic reticulum stress, MCF-7, MDA-MB-231 cells, 3807
- Breast, mammograms, tumor phantoms, tumor size, 1131
- Breast, synchronous cancer, thyroid, stomach, pancreas, 2135
- Breast, tumour, size, lymphovascular, triple-negative, cancer, 2737
- Breast-conservation surgery, morbid obesity, breast cancer, radiotherapy, chemotherapy, 3867

- Breast-conserving surgery, mastopexy, lumpectomy, breast cancer, 731
- Brentuximab venodin, Hodgkin lymphoma, CD30 antibody, case report, ABVD, BEACOPP, CD30, 3879
- 3-Bromopyruvate, colon cancer, metformin, phenformin, 2-deoxyglucose, 401
- 3-Bromopyruvate, GAPDH, glucose metabolism, glycolysis, HCC, locoregional therapy, molecular targeting, review, 13
- Brousoflavonol B, estrogen receptor, cancer stem-like cells, 1873
- BT-20 cells, I3C derivative CTet, synergy, triple-negative breast cancer, autophagy, *MAP1LC3B*, MDA-MB-231, 1867
- C57/BL6 mice, *Salmonella typhimurium* A1-R, GFP, TCM, tumor targeting, combination, Lewis lung carcinoma, RFP, 1837
- C57BL/6J-*Min*+/+ mice, carcinogenesis, hydrogenated fish oil, *trans* fatty acids, colorectal cancer, 477
- CA15-3, breast cancer, prognosis, 293
- CA19-9, biliary tract cancer, perineural invasion, CEA, 583
- CA19-9, gastric cancer, tumour marker, surveillance, recurrence, chemotherapy, 1621
- Cabazitaxel, prostate cancer cell lines, ABCC4, docetaxel resistance, 387
- Cadherin, EMT, epithelial-mesenchymal transition, CSC, cancer stem cell, CD44, musashi, 2867
- CAFs, NFs, lung cancer, stromal NSCLC, direct co-culture, indirect co-culture, EMT, proliferation, SMAD3, Hedgehog signaling pathway, 3715
- Calcitonin, fibronectin, MG63 cells, matrix metalloproteinase 9, integrins. NF- κ B activation, 4901
- Calcium, chemoprevention, lung cancer, experimental model, tobacco carcinogens, combination therapy, acetylsalicylic acid, vitamin D, 4767
- Calcium, gastritis, *Helicobacter pylori*, fish meal, Mongolian gerbils, 3667
- Cancer associated antigen, HLA class-I, antigenic peptide, prostate cancer, mass spectrometric analysis, 1853
- Cancer cell lines, ester conjugate, fatty acid, anticancer agent, cytotoxicity, MDA-MB-361, MCF-7, MDA-MB-231, 2517
- Cancer prevention, India internaional symposium, Udaipur, Rajasthan, translational cancer research, 1777
- Cancer prevention, JNK, p53, redox factor 1, selenomethionine, ubiquitination, protein stability, 3645
- Cancer prognosis, artificial neural networks, ki-67, p53, oestrogen/progesterone receptors, prediction of nodal status, 3925
- Cancer stem cell, EMT, epithelial-mesenchymal transition, CSC, CD44, musashi, cadherin, 2867
- Cancer stem cells, epithelial-mesenchymal transition, molecular markers, quantitative PCR, endometrial cancer, 5461
- Cancer stem cells, intrahepatic cholangiocarcinoma, hepatic resection, CD44, GLI1, 2107
- Cancer stem cells, prostate cancer, stem cell marker, canine, CT1258, CT1258-EGFP, CT1258-EGFP-*HMG2A* cell lines, 5421
- Cancer stem cells, radiotherapy, radioresistance, therapeutic targets, review, 747
- Cancer stem-like cells, brousoflavonol B, estrogen receptor, 1873
- Cancer stem-like cells, OCT4, MDA-MB453, stemness, differentiation, asymmetric cell division, 763
- Cancer susceptibility, *NAT2*, SNP, IAM, breast cancer, gastric cancer, 3683
- Cancer therapy, epigenetics, DNA methylation, DNMT inhibitors, review, 2989
- Cancer vaccine, dendritic cell, antigen presentation, fusion, 347
- Cancer, apoptosis, adherent cells, annexin V staining, cell harvesting, 3201
- Cancer, artesunate, safety study, dog, comparative oncology, 1819
- Cancer, CD47, CD36, TSP-1, 4N1K, autophagy, 1429
- Cancer, endoplasmic reticulum, stress, unfolded protein response, molecular chaperones, activating transcription factor 6, PERK kinase, inositol requiring enzyme-1, review, 4683
- Cancer, fatigue, physical activity, inpatient rehabilitation, dose response relationship, 3415
- Cancer, pesticides, angiogenesis, xenoestrogen, 231
- Cancer, telomerase, lung, metastasis, 2643
- Cancer, tumour, size, lymphovascular, triple-negative, breast, 2737
- Cancer/testis antigen, non-small cell lung cancer, HLA class-I expression, surgery, prognosis, immune escape, 2123
- Cancer-associated fibroblasts, ADSC, EMT, H358 cells, tumor microenvironment, α SMA, 4421
- Cancer-associated fibroblasts, breast cancer, podoplanin, IHC, assessment methods, 1447
- Cancer-associated fibroblasts, normal fibroblasts, NFs, lung cancer, NSCLC, co-culture, EMT, proliferation, SMAD3, 2001
- Cancer-induced bone pain, sex differences, bone metastasis, pain, 1963
- Cancer-initiating cells, ursolic acid, STAT3, colon cancer, 4279
- Canine cutaneous histiocytoma, proliferation, apoptosis, Ki-67, TUNEL, 1397
- Canine, prostate cancer, cancer stem cells, stem cell marker, CT1258, CT1258-EGFP, CT1258-EGFP-*HMG2A* cell lines, 5421
- Cannabinoids, drug combination, drug schedule, leukaemia, 4373

- Cannabinoids, gastric cancer, fluorouracil, drug resistance, apoptosis, 2541
- Caov-3 cells, ovarian cancer, sphingolipids, chemoresistance, sphingosine kinase-2, experimental therapeutics, sphingosine-1-phosphate, ABC294640, BG-1, 3573
- Capecitabine, breast cancer, paclitaxel, metastasis, response, 4941
- Capecitabine, chemotherapy, fluorouracil, mitomycin-C, colon cancer, 2743
- Capecitabine, colorectal cancer, 5-fluorouracil, oxaliplatin, comparative effectiveness research, treatment effectiveness, cost effectiveness, 1053
- Capecitabine, colorectal cancer, gemcitabine, refractory, 4089
- Capecitabine, epirubicin, oxaliplatin, docetaxel, cisplatin, 5-fluorouracil, G-CSF, gastroesophageal cancer, adenocarcinoma, 3455
- Capecitabine, epirubicin, oxaliplatin, gastroesophageal cancer, adenocarcinoma, 1035
- Capecitabine, erlotinib, first-line treatment, metastases, pancreatic cancer, 717
- Capecitabine, metabolites, 5'-DFCR, 5'-DFUR, pharmacokinetics, HPLC, GLP, 881
- Capecitabine, PNET, 5-FU, chemoradiation, 2175
- Capecitabine, radiotherapy, pemetrexed, rectal cancer, thymidine phosphorylase, chemotherapy, 2447
- Capsaicin, prostate cancer, lycopene, resveratrol, curcumin, dietary phytochemicals, review, 4163
- Carbocyclic nucleoside analogs, substituted 6-chloropurines, glutathione-S-transferase, glutathione depletion, 3163
- Carbon-ion radiotherapy, FDG-PET, preoperative, distant metastasis, prognostic factor, 5579
- Carboplatin, aged patient, elderly, non-small cell lung cancer, chemotherapy, pharmacokinetics, quality of life, paclitaxel, maximum tolerated dose, 261
- Carboplatin, chemosensitivity, HDRA, histoculture drug response assay, epithelial ovarian cancer, taxol, prospective clinical trial, correlation, prediction, individualized therapy, 1029
- Carboplatin, interstitial lung disease, small cell lung cancer, chemotherapy, cisplatin, etoposide, acute exacerbation, 1175
- Carboplatin, irinotecan, chemotherapy, ovarian cancer, 1073
- Carboplatin, lung cancer, panobinostat, etoposide, 4475
- Carboplatin, pemetrexed, non-squamous non-small cell lung cancer, phase II trial, 5535
- Carboplatin, selenite, ovarian cancer, xenografts, drug resistance, 4249
- Carboxyl esterase (CE), irinotecan, CNS lymphoma, neural stem cells, rabbit, 5335
- Carcinogenesis, C57BL/6J-*Min*/+ mice, hydrogenated fish oil, *trans* fatty acids, colorectal cancer, 477
- Carcinogenesis, head and neck carcinoma, squamous, ubiquitination, ubiquitin-proteasome system, ubiquitin ligases, review, 3527
- Carcinogenesis, mitochondrial DNA, DNA repair, metastasis, review, 3543
- Carcinogenesis, soluble epoxide hydrolase, dextran sulfate sodium, colitis, mice, 5261
- Carcinogenesis, VEGF, HCV infection, tumor marker, HCC, 1013
- Carcinogenicity, testosterone, estrone, sex hormones, free radicals, electron emission, hormone regeneration, 941
- Carcinoid tumor, colon cancer, small cell carcinoma, 1713
- Carcinoma of the ampulla of Vater, glasgow prognostic score, prognosis, pancreatoduodenectomy, 2715
- Carcinoma, neuroendocrine, appendix, NET, NEC, 2635
- Carcinoma, prostatic neoplasms, gene expression, diagnostic markers, urine, 191
- Carcinosarcoma, WT1, DC immunotherapy, ovarian cancer, 3855
- Cardiac hormones, AKT, colorectal adenocarcinomas, pancreatic carcinomas, renal adenocarcinoma, 785
- Cardiac hormones, β -catenin, human pancreatic cancer, human colorectal adenocarcinoma, human renal adenocarcinoma, 2409
- Cardiac risk factors, alcohol, *HER2* polymorphism, trastuzumab, 2569
- Cardiotoxicity, breast cancer, adjuvant therapy, electrocardiography (ECG), radiotherapy, 4933
- Cardiotoxicity, trastuzumab, breast cancer, *HER2*, 1717
- Cardiovascular risk factors, breast cancer, exercise intervention, health behavior, obesity, physical activity, physical health, 1595
- Carotid vasculopathy, radiation induced dysphagia, radiation therapy, early glottic cancer, constrictors, 4483
- Case report, brentuximab vedotin, Hodgkin lymphoma, CD30 antibody, ABVD, BEACOPP, CD30, 3879
- Case report, hypoxic radiosensitizer, intensity-modulated radiation therapy, simultaneous integrated boost, glioblastoma multiforme, 1685
- Case report, numb chin syndrome, mental neuropathy, mandibular metastasis, inferior alveolar nerve, orthopantomogram, cone beam tomography, colonic cancer, 1757
- Case series, brain tumor, liposomal cytarabine, intrathecal, medulloblastoma, relapse/progression, 3515
- Case series, Kaposi's sarcoma, gemcitabine, chemotherapy, 5531
- Case-control, vitamin D, sunlight, polymorphisms, breast cancer, gene, 543
- Caspase, α_1 -adrenoceptor blocker, apoptosis, mmalignant mesothelioma, NCI-H28, NCI-H2052, NCI-H2452, MSTO-211H, 887

- Caspases, apoptosis, bladder cancer, cisplatin resistance, Chinese medicine, β -elemene, 1421
- Caspases, TRAIL, cervical cancer cells, equol, death receptors, apoptosis, 903
- Castration-resistant prostate cancer, CRPC, HAI-1, prostate cancer, 575
- CAVI, polymorphism, genotype, upper urothelial track cancer, 4907
- Caveolin-1, hepatocellular carcinoma, polymorphism, genotype, real-time quantitative reverse transcription, western blot, 671
- Caveolin-1, prostate cancer, ELISA, progression, 1893
- Caveolin-1, prostate cancer, polymorphism, oncogene, 1023
- C-C motif chemokine receptor-2 (CCR2) antagonist, ovarian cancer, SKOV-3 cell line, tumor-associated macrophages (TAMs), monocyte chemoattractant protein-1 (MCP-1), 4785
- CCF-STTG1 cells, apoptosis, brain cancer, Chinese medicine, β -elemene, A172, U-87MG, synthetic analogs, 65
- CD117, neuroendocrine differentiation, CD133, *ABCG2* antigens, non-small cell lung cancer, stem cell antigens, 981
- CD133, neuroendocrine differentiation, CD117, *ABCG2* antigens, non-small cell lung cancer, stem cell antigens, 981
- CD3, colorectal cancer, antitumor immune response, inflammatory cell infiltration, CD8, lymph node retrieval, 5143
- CD30 antibody, brentuximad venodin, Hodgkin lymphoma, case report, ABVD, BEACOPP, CD30, 3879
- CD30, brentuximad venodin, Hodgkin lymphoma, CD30 antibody, case report, ABVD, BEACOPP, 3879
- CD36, CD47, TSP-1, 4N1K, autophagy, cancer, 1429
- CD37, radioimmunotherapy, non-Hodgkin's lymphoma, ^{177}Lu , 85
- CD4, acute leukemias, miR-181a, HMGB1, 445
- CD4, HIV, viral load, squamous cell carcinoma, head and neck cancer, radiation therapy, IMRT, chemotherapy, concurrent chemoradiotherapy, 5511
- CD44, EMT, epithelial-mesenchymal transition, CSC, cancer stem cell, musashi, cadherin, 2867
- CD44, intrahepatic cholangiocarcinoma, hepatic resection, cancer stem cells, GLI1, 2107
- CD44-targeted delivery, PLGA nanoparticles, hyaluronic acid, surface decoration, SN-38, ovarian cancer, CTAB assay, 2425
- CD47, CD36, TSP-1, 4N1K, autophagy, cancer, 1429
- CD59, cytolysin, cholesterol-independent, human-specific, ILY, VLY, Sm-hPAF, 2901
- CD8, colorectal cancer, antitumor immune response, inflammatory cell infiltration, CD3, lymph node retrieval, 5143
- CD95 ligand, glioma stem cell, apoptosis, temozolomide, 3563
- CDDO-Me, ovarian cancer, apoptosis, ROS, AKT, NF- κ B, mTOR, 215
- CDKN2A, renal cell carcinoma, PD-0322991, palbociclib, cell-cycle inhibition, p16, E2F1, 2997
- CEA, biliary tract cancer, perineural invasion, CA19-9, 583
- CEA, chemotherapy, fluctuation, metastatic colorectal cancer, tumor flare, 253
- CEA, lung cancer, bone metastasis, NSCLC, CTX, CYFRA 21-1, PINP, TRAP5b, 2593
- Cecal ligation and puncture, CT26 murine colon cancer, neutrophil elastase inhibitor, sivelestat, compensatory anti-inflammatory response syndrome, 3653
- Celecoxib, sorafenib, AKT, apoptosis, hepatocellular carcinoma, synergism, HCC, 1387
- Cell adhesion, malignant melanoma, integrin $\alpha_v\beta_3$, RGD peptide, cell migration, 871
- Cell cycle arrest, chinese medicine, β -elemene, taxanes, synergism, ovarian cancer, prostate cancer, apoptosis, 929
- Cell cycle arrest, gefitinib, erlotinib, H23 cells, apoptosis, c-MYC, 1547
- Cell cycle, bladder carcinoma, antimetabolic agents, tubulin, flavanone, 4445
- Cell cycle, citric acid, HaCaT, apoptosis, cytotoxic effect, 4411
- Cell cycle, high-performance counter current chromatography, umbelliferone, herniarin, scoparone, laryngeal cancer cells, proliferation, migration, apoptosis, 4347
- Cell cycle, inhibitor of differentiation, inhibitor of DNA binding, ID1, ID2, qPCR, breast cancer, helix-loop-helix, 2179
- Cell cycle, NF2, merlin, tumor suppressor, review, 1
- Cell cycle, p14, p16, cell senescence, qPCR, breast cancer, 2185
- Cell harvesting, apoptosis, adherent cells, cancer, annexin V staining, 3201
- Cell line and clonal sublines, clear cell renal carcinoma, sarcomatoid differentiation, xenotransplantation, de-differentiation, epithelioid, fibroblastoid, 4875
- Cell migration, ARP2/3 complex, pancreatic cancer, 45
- Cell migration, malignant melanoma, integrin $\alpha_v\beta_3$, RGD peptide, cell adhesion, 871
- Cell proliferation, *Ambrosia arborescens*, damsine, coronopilin, chemoselective bromination, sesquiterpenes, STAT3, NF- κ B, apoptosis, 3799
- Cell proliferation, E2F5, esophageal squamous cell carcinoma, 5415
- Cell proliferation, metabotropic glutamate receptors, tumor biology, neuroendocrine tumors, alternative therapy, review, 1267
- Cell proliferation, PROX1, small cell lung cancer, shRNA, Lentivirus, viral knockdown, 3169

- Cell senescence, p14, p16, cell cycle, qPCR, breast cancer, 2185
- Cell signaling, ERK, U0126, CYP inhibitor, MEK/ERK inhibitor, colorectal cancer, HT29, HCT116, 2499
- Cell-cycle arrest, *ATM*, *ATR*, *Chk1*, *p53*, *p21*, vinca alkaloids, DNA damage, 5273
- Cell-cycle arrest, osteosarcoma, quercetin, apoptosis, migration, 143B cells, 1297
- Cell-cycle inhibition, renal cell carcinoma, PD-0322991, palbociclib, *CDKN2A*, p16, *E2F1*, 2997
- Cell-free DNA, bladder cancer, hypermethylation, serum, 779
- Cell-free DNA, prostate cancer, biomarker, screening, quantitative PCR, PicoGreen, 4521
- Cellular immunotherapy, ALA, DCA, hyperthermotherapy, stomach cancer, 2957
- Centrally-located lung tumor, SBRT, adverse effect, local control, lung cancer, 4959
- Cephalometry, orbit, orbital rim, orbital neurofibromatosis, NF1, plexiform neurofibroma, sphenoid wing dysplasia, orbital dysplasia, plain radiographs, 1081
- Ceramide, apoptosis, dihydroceramide desaturase, dihydroceramide, PDT, sphingolipids, UM-SCC-22A cells, HNSCC, 77
- Cervical cancer cells, TRAIL, equol, caspases, death receptors, apoptosis, 903
- Cervical cancer, completion surgery, pelvic lymphadenectomy, para-aortic lymphadenectomy, locally advanced cervical cancer, 1661
- Cervical cancer, lymph node metastasis, chemotherapy, radiation therapy, consolidation, 4675
- Cervical cancer, microRNA expression, HPV, clinical grading, 2561
- Cervical cancer, non-bulky, stage IB1/II, radiotherapy, concurrent chemoradiotherapy, 5123
- Cervical cancer, pap smear, acetic acid, dysplasia, colposcopy, 1125
- Cervical cancer, pregnancy, dysplasia, delivery, 711
- Cervical cancer, radiation therapy, FIGO IVA, bladder invasion, rectum invasion, EQD2, 4989
- Cervical cancer, simple hysterectomy, intermediate risk factor, less radical surgery, 5135
- Cervical lymph node metastasis, primary unknown, chemoradiation, lymph node level, 5187
- Cervical metastases, extended field, induction chemotherapy, radiotherapy, unknown primary tumor, 1135
- Cervical sampling device, pap test, Ayre's spatula, cytobrush, 917
- Cetuximab, *EGFR*, dimerization, radiation, radiosensitivity, A431 cells, 4337
- Cetuximab, esophageal cancer, gastric cancer, *EGFR*, trastuzumab, review, 4139
- Cetuximab, HRMA, colorectal cancer, *KRAS* mutation, sequencing, 2129
- Cetuximab, mCRC, circulating tumor cells, colorectal cancer, 3905
- Cetuximab, non-small cell lung cancer, *in vivo* antitumor activity, elacytarabine, bevacizumab, trastuzumab, xenograft, 3615
- Chaperonin 60, thyroid neoplasms, *BRAF* mutation, proteomics, lymph node metastases, 4357
- Characterization, glioblastoma, immunotherapy, tumor-associated antigens, U251, U87, U343 cells, 2525
- Chemical descriptor, licorice flavonoids, QSAR, cytotoxicity, tumor-specificity index, 3061
- Chemoembolization, hepatocellular carcinoma, animal model, rat, 223
- Chemoembolization, hepatocellular carcinoma, blood oxygen level-dependent MRI, 1887
- Chemo-enhancement, acetaminophen, glutathione, cisplatin, ovarian cancer, SKOV3 cells, 2391
- Chemokines, circulating tumor cells, TGF- β , CXCL1, metastasis, breast cancer, cytokines, 1491
- Chemoprevention, disiloxanes, anti-promotion, EBV-induced early antigen, two-stage mouse skin carcinogenesis, co-existence of tumor and normal cells, 2021
- Chemoprevention, lung cancer, experimental model, tobacco carcinogens, combination therapy, acetylsalicylic acid, vitamin D, calcium, 4767
- Chemoprevention, non-melanoma skin cancer, UV radiation-induced skin tumors, experimental model, combination therapy, 3033
- Chemoprevention, oral cancer, strawberries, hamster cheek pouch, 4757
- Chemoprevention, *Withania somnifera*, mammary cancer, rats, Ki67, PCNA, 1519
- Chemoradiation therapy, anaplastic thyroid carcinoma, docetaxel, local control, palliative management, 3445
- Chemoradiation, combined treatment, neoadjuvant therapy, colorectal adenocarcinoma, long-term outcome, 725
- Chemoradiation, gastric cancer, ethnicity, Israel, Ashkenazi, 5151
- Chemoradiation, hormone-refractory prostate cancer, metronomic chemotherapy, phase I study, 4585
- Chemoradiation, PNET, capecitabine, 5-FU, 2175
- Chemoradiation, primary unknown, cervical lymph node metastasis, lymph node level, 5187
- Chemoradiotherapy, anemia, esophageal cancer, nutrition, prognostic factor, 3495
- Chemoradiotherapy, C-reactive protein, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, rectal cancer, prognosis, 5065
- Chemoradiotherapy, esophageal carcinoma, surgery, squamous cell, 1157
- Chemoradiotherapy, hypopharyngeal cancer, larynx preservation, hyperthermia, intra-arterial infusion chemotherapy, 5561

- Chemoradiotherapy, lung cancer surgery, lung cancer biology, ERCC1, tubulin, TYMS, RRM1, 1107
- Chemoradiotherapy, tumor IL-6, esophageal squamous cell carcinoma, prognosis, 2699
- Chemoresistance, OCT4B, cisplatin, apoptosis, A549, 5365
- Chemoresistance, ovarian cancer, sphingolipids, sphingosine kinase-2, experimental therapeutics, sphingosine-1-phosphate, ABC294640, BG-1, Caov-3 cells, 3573
- Chemo-responsiveness, breast cancer, neoadjuvant chemotherapy, S6 kinase 1 (S6K1), AKT, 4073
- Chemosaturation therapy, percutaneous hepatic perfusion, melphalan, taxanes, platinum agents, 1989
- Chemoselective bromination, *Ambrosia arborescens*, dansin, coronopilin, sesquiterpenes, cell proliferation, STAT3, NF- κ B, apoptosis, 3799
- Chemosensitivity, esophageal carcinoma, COX-2, 5-fluorouracil, cisplatin, gene transfer, TE13 cells, 537
- Chemosensitivity, HDRA, histoculture drug response assay, epithelial ovarian cancer, taxol, carboplatin, prospective clinical trial, correlation, prediction, individualized therapy, 1029
- Chemosensitivity, lobarstin, glioblastoma, temozolomide, DNA repair, 5445
- Chemotherapeutic resistance, cisplatin, doxorubicin, etoposide, nitric oxide, lung cancer, 5433
- Chemotherapy resistance, ovarian cancer, copper transporter, 1409
- Chemotherapy, adjuvant treatment, colorectal cancer, oxaliplatin, metastatic disease, 1765
- Chemotherapy, advanced gastric cancer, docetaxel, elderly, S-1, 697
- Chemotherapy, aged patient, elderly, non-small cell lung cancer, pharmacokinetics, quality of life, carboplatin, paclitaxel, maximum tolerated dose, 261
- Chemotherapy, ATP7B, cisplatin, LOH, urothelial carcinoma, bladder cancer, 3731
- Chemotherapy, biomarkers, gastric cancer, *HER2*, DNA repair systems, fluoropyrimidine metabolism, apoptotic pathway, targeted therapy, review, 1257
- Chemotherapy, CEA, fluctuation, metastatic colorectal cancer, tumor flare, 253
- Chemotherapy, cervical cancer, lymph node metastasis, radiation therapy, consolidation, 4675
- Chemotherapy, colorectal cancer, circulating tumour cells, biomarkers, 625
- Chemotherapy, colorectal carcinoma, SW 480 cells, *EGFR* phosphorylation, 3753
- Chemotherapy, CSRA, DiSC assay, pretherapeutic *ex vivo* testing, 2491
- Chemotherapy, diabetes mellitus, insulin, pancreatic cancer, 287
- Chemotherapy, fluorouracil, mitomycin-C, colon cancer, capecitabine, 2743
- Chemotherapy, fotemustine, glioblastoma, low-dose, second-line therapy, 4013
- Chemotherapy, gastric cancer, irinotecan, mitomycin C, 5107
- Chemotherapy, gastric cancer, tumour marker, surveillance, recurrence, CA19-9, 1621
- Chemotherapy, glioblastoma, relapse, sorafenib, temozolomide, 3487
- Chemotherapy, HIV, viral load, CD4, squamous cell carcinoma, head and neck cancer, radiation therapy, IMRT, concurrent chemoradiotherapy, 5511
- Chemotherapy, interstitial lung disease, small cell lung cancer, cisplatin, carboplatin, etoposide, acute exacerbation, 1175
- Chemotherapy, irinotecan, carboplatin, ovarian cancer, 1073
- Chemotherapy, Kaposi's sarcoma, gemcitabine, case series, 5531
- Chemotherapy, leiomyosarcoma, mesocolic, paclitaxel, gemcitabine, recurrence, 2929
- Chemotherapy, lung cancer surgery, lung cancer biology, biomarker, 5597
- Chemotherapy, lymphoma, radiation, elderly, performance status, 3251
- Chemotherapy, mesothelioma, pemetrexed, treatment outcome, quality of life, health economics, review, 3553
- Chemotherapy, metastatic breast cancer, *nab*-paclitaxel, 3407
- Chemotherapy, morbid obesity, breast cancer, breast-conservation surgery, radiotherapy, 3867
- Chemotherapy, non-small cell lung cancer, randomized phase 2, ethnicity, docetaxel, paclitaxel carboplatin, 4631
- Chemotherapy, ovarian carcinosarcomas, prophylactic pelvic irradiation, surgery, prognosis, 1003
- Chemotherapy, pancreatic adenocarcinoma, gemcitabine, FOLFIRINOX, combined therapy, clinical trials, review, 1785
- Chemotherapy, pancreatic neoplasm, indole-3-carbinol, gemcitabine, microRNA, Panc-1 cells, 1473
- Chemotherapy, pancreatic neuroendocrine tumors, transcatheter arterial chemoembolization, hepatic metastasis, 3355
- Chemotherapy, peripheral neuropathy, paclitaxel, *nab*-paclitaxel, opioids, 1153
- Chemotherapy, radiotherapy, concomitant therapy, colorectal cancer, cisplatin, Lipoplatin™, 3005
- Chemotherapy, radiotherapy, pemetrexed, capecitabine, rectal cancer, thymidine phosphorylase, 2447
- Chemotherapy, rectal cancer, preoperative, follow-up, outcome, Alimta, pemetrexed, 325
- Chemotherapy-induced nausea and vomiting, colorectal cancer, moderately emetic chemotherapy, adherence, dexamethasone, 5549
- Chemotherapy-induced neutropenia, febrile neutropenia, G-CSF, pegfilgrastim, secondary prophylaxis, 301

- Chemotherapy-induced neutropenia, non-small cell lung cancer, surgery, early-onset, prognosis, 2755
- Childhood leukemia, *XRCC6/Ku70*, non-homologous end-joining, polymorphisms, genotyping, 5395
- Child-Pugh score, hepatocellular carcinoma, percutaneous ethanol injection, survival, transcatheter arterial chemoembolization, aspartate aminotransferase, 5171
- Children, *ex vivo* drug resistance, individualized tumor response testing, acute myeloid leukemia, relapse, minimal residual disease, 1189
- Chimera protein, cholesterol-dependent cytolysin, drug delivery system, Z-domain, 2905
- Chimeric antigen receptor, redirected T-cells, anti-idiotypic antibody, expansion, NY-ESO-1, peptide specific, 4189
- Chinese medicine, apoptosis, bladder cancer, cisplatin resistance, β -elemene, caspases, 1421
- Chinese medicine, apoptosis, brain cancer, β -elemene, A172, U-87MG, CCF-STTG1 cells, synthetic analogs, 65
- Chinese medicine, β -elemene, taxanes, synergism, ovarian cancer, prostate cancer, apoptosis, cell cycle arrest, 929
- Chitosan, lung metastasis, hepatoma formation, xenograft models, 4867
- Chk1, *ATM*, *ATR*, p53, p21, cell-cycle arrest, vinca alkaloids, DNA damage, 5273
- Cholangiocarcinoma, gallbladder carcinoma, hepatic arterial infusion, 1201
- Cholesterol-dependent cytolysin, drug delivery system, Z-domain, chimera protein, 2905
- Cholesterol-independent, cytolysin, human-specific, ILY, VLY, Sm-hPAF, CD59, 2901
- Chromatin, telomere, telomerase, trichostatin A, ALT mechanism, recombination, 821
- Chromopertubation, fallopian-tube patency, transurethral catheter, 1591
- Chromosomal abnormality, *Inv(3)(q21q26)*, fluorescent *in situ* hybridization, myeloid hemopathies, 639
- Chronic lymphocytic leukemia (CLL), naphthoquinones, MAPKs, cytochrome C, apoptosis, mitochondria, BCL2, 183
- Chronic myeloid leukemia, hematopoietic stem cell transplantation, tyrosine kinase inhibitor, imatinib, allotransplantation, 4663
- Chronic-phase CML, TKI, complete molecular response, 3509
- Cigarette smoke, aryl hydrocarbon receptor, lung cancer, tumorigenesis, dioxin, polycyclic aromatic hydrocarbons, review, 1247
- Cimetidine, biliary excretion, drug interaction, pharmacokinetics, multidrug resistance-associated protein-2 (*Mrp2*), sunitinib, (*Abcc2*), 3105
- Circulating nucleic acids, gastric cancer, microRNA, plasma, biomarker, prognosis, miR-21, 271
- Circulating tumor cell, breast cancer, immunosurveillance, tumor cell dormancy, T-cell, FAS, 2233
- Circulating tumor cell, colorectal cancer, prediction of progression, 1769
- Circulating tumor cells, colorectal cancer, liver metastases, tumor markers, AdnaGen, 2239
- Circulating tumor cells, mCRC, cetuximab, colorectal cancer, 3905
- Circulating tumor cells, renal subcapsular implantation, metastasis, murine model, RCC, 4751
- Circulating tumor cells, TGF- β , CXCL1, metastasis, breast cancer, chemokines, cytokines, 1491
- Circulating tumour cells, colorectal cancer, biomarkers, chemotherapy, 625
- Cisplatin resistance 97/97, non-small cell lung cancer, metallothionein, immunocytochemistry, DV90 cells, 5255
- Cisplatin resistance, apoptosis, bladder cancer, Chinese medicine, β -elemene, caspases, 1421
- Cisplatin, acetaminophen, glutathione, chemo-enhancement, ovarian cancer, SKOV3 cells, 2391
- Cisplatin, andrographolide, ovarian cancer, apoptosis, synergism, anti-proliferative, 4365
- Cisplatin, apoptosis, estrogen, progesterone, A549 cells, lung cancer, 791
- Cisplatin, ATP7B, chemotherapy, LOH, urothelial carcinoma, bladder cancer, 3731
- Cisplatin, biliary tract cancer, irinotecan, refractory, gemcitabine, fluoropyrimidine, 2619
- Cisplatin, chemotherapeutic resistance, doxorubicin, etoposide, nitric oxide, lung cancer, 5433
- Cisplatin, epirubicin, oxaliplatin, capecitabine, docetaxel, 5-fluorouracil, G-CSF, gastroesophageal cancer, adenocarcinoma, 3455
- Cisplatin, esophageal carcinoma, COX-2, 5-fluorouracil, chemosensitivity, gene transfer, TE13 cells, 537
- Cisplatin, extensive-stage small cell lung cancer, alternating chemotherapy, amrubicin, irinotecan, 1117
- Cisplatin, head and neck squamous cell carcinoma (HNSCC), Hedgehog pathway, cyclopamine, docetaxel, synergism, 2415
- Cisplatin, high-affinity human copper transporter 1 (*hCtr1*), copper chelator, review, 4157
- Cisplatin, interstitial lung disease, small cell lung cancer, chemotherapy, carboplatin, etoposide, acute exacerbation, 1175
- Cisplatin, non-small cell lung cancer, ifosfamide, docetaxel, survival, phase III trial, 5477
- Cisplatin, OCT4B, chemoresistance, apoptosis, A549, 5365
- Cisplatin, pemetrexed, *ALK*, non-squamous NSCLC, Japanese, 3327
- Cisplatin, radiotherapy, chemotherapy, concomitant therapy, colorectal cancer, Lipoplatin™, 3005
- Cisplatin, transporters, tumor, uptake, protection, toxicity, review, 4183
- Citric acid, HaCaT, cell cycle, apoptosis, cytotoxic effect, 4411

- CK2 inhibitors, pentabromobenzyloisothioureas, apoptosis, KG-1 cells, flow cytometry, 4891
- C-KIT, 5-FU, docetaxel, β -catenin, head and neck squamous cell carcinoma, extracellular matrix, protein tyrosine kinase, human papillomavirus (HPV), epithelial mesenchymal transition (EMT), 2457
- Claudin, colorectal cancer, prognosis, recurrence, poorly-differentiated component, 3301
- Clear cell adenocarcinoma, endometrial neoplasm, bladder tumor, pelvic exenteration, Mullerian tumour, 615
- Clear cell renal carcinoma, sarcomatoid differentiation, xenotransplantation, cell line and clonal sublines, de-differentiation, epithelioid, fibroblastoid, 4875
- Clinical grading, cervical cancer, microRNA expression, HPV, 2561
- Clinical management, Lynch syndrome, NNPCC, colorectal cancer, 2147
- Clinical predictors, swallowing disorder, dysphagia, head and neck cancer, post-surgical screening, 3347
- Clinical trials, pancreatic adenocarcinoma, chemotherapy, gemcitabine, FOLFIRINOX, combined therapy, review, 1785
- Clinicopathological features, Immunohistochemistry, luminal/*HER2*-negative breast cancer, p53 cut-off point, p53 overexpression, prognostic factor, 3891
- Clinicopathological features, papillary thyroid cancer, polymorphism, *XAF1*, 2205
- Clostridium septicum*, distant myonecrosis, gas gangrene, ovarian cancer, distant myonecrosis in ovarian cancer, 1585
- C-MET, hepatocellular carcinoma, Immunohistochemistry, copy number variation, prognosis, 5179
- C-MET, hepatocyte growth factor (*HGF*), hepatocellular carcinoma, 3241
- C-Met, hepatocyte growth factor, *HGF* transgenic mice, lung tumor, diethylnitrosamine, 895
- C-Myc, artemisinin, transferrin, breast cancer, *HER2*, survivin, cyclin D1, DV145, MCF7 cells, 123
- C-MYC, gefitinib, erlotinib, H23 cells, apoptosis, cell cycle arrest, 1547
- CNS lymphoma, irinotecan, carboxyl esterase (CE), neural stem cells, rabbit, 5335
- CO₂, colon cancer, invasion, laparoscopy, insufflation, 1881
- Coagulation factors, oral cancer, SNPs, angiotensin-converting enzyme, angiotensinogen, serpine1, regression analysis, 4033
- Co-culture, cancer-associated fibroblasts, normal fibroblasts, NFs, lung cancer, NSCLC, EMT, proliferation, SMAD3, 2001
- Co-culture, monocyte, colon cancer cell, angiogenesis, metastasis, signaling pathway, DLD-1, THP-1 cells, 2895
- Co-existence of tumor and normal cells, disiloxanes, chemoprevention, anti-promotion, EBV-induced early antigen, two-stage mouse skin carcinogenesis, 2021
- Cofilin-1, cofilin-2, progression, regression, fibrosarcoma, 3661
- Cofilin-2, cofilin-1, progression, regression, fibrosarcoma, 3661
- Colitis, soluble epoxide hydrolase, dextran sulfate sodium, carcinogenesis, mice, 5261
- Collagen I, squamous cell carcinoma, head and neck cancer, phosphoinositol-3 kinase, MD-1483 cells, 379
- Collagenous fibroma, cytogenetics, desmoplastic fibroblastoma, magnetic resonance imaging, trisomy 8, 3259
- Colon 26, ultrasound, nanomedicine, fullerenes, sonodynamic therapy, sarcoma 180, 3145
- Colon cancer cell, monocyte, co-culture, angiogenesis, metastasis, signaling pathway, DLD-1, THP-1 cells, 2895
- Colon cancer, 3-bromopyruvate, metformin, phenformin, 2-deoxyglucose, 401
- Colon cancer, chemotherapy, fluorouracil, mitomycin-C, capecitabine, 2743
- Colon cancer, CO₂, invasion, laparoscopy, insufflation, 1881
- Colon cancer, epigenetics, EGCG, green tea, epigallocatechin 3-gallate, DNMT3A, HDAC3, 5325
- Colon cancer, neutrophil-to-lymphocyte ratio, 4591
- Colon cancer, NSAIDS, prevention, COX inhibition, apoptosis, ACF, rat model, 3581
- Colon cancer, polysaccharide K, invasion, 4841
- Colon cancer, ursolic acid, STAT3, cancer-initiating cells, 4279
- Colon cancer, Virchow lymph node metastasis, combination therapy, 2935
- Colon carcinoma, invasion, *FERMT1*, DNA microarray, fermitin family, 167
- Colon cancer, carcinoid tumor, small cell carcinoma, 1713
- Colonic cancer, numb chin syndrome, mental neuropathy, mandibular metastasis, inferior alveolar nerve, orthopantomogram, cone beam tomography, case report, 1757
- Colonic cancer, polymorphism, microRNA, microRNA-binding site, rs1044129, prognosis, 513
- Colonic cancer, vitamin D analogs, combined treatment, oxaliplatin, irinotecan, anticancer activity, 433
- Colonoscopy, body-mass index, smoking, alcohol, neoplasms, multiple primary tumors, esophageal cancer, 5113
- Color-coded imaging, green fluorescent protein, blood vessels, nestin, angiogenesis, anastomosis, red fluorescent protein, Gelfoam[®], transgenic nude mice, confocal microscopy, vascularization, 3041
- Colorectal adenocarcinoma, β -catenin, cardiac hormones pancreatic cancer, renal cancer, 2409
- Colorectal adenocarcinoma, chemoradiation, combined treatment, neoadjuvant therapy, long-term outcome, 725

- Colorectal adenocarcinomas, AKT, cardiac hormones, pancreatic carcinomas, renal adenocarcinoma, 785
- Colorectal adenoma, advanced adenomas, microtubular configurations, invasive carcinoma, 5471
- Colorectal cancer, 15, 16-dihydrotanshinone I, activating transcription factor-3, SW480, SW620, SW420 cells, 3225
- Colorectal cancer, 5-fluorouracil, capecitabine, oxaliplatin, comparative effectiveness research, treatment effectiveness, cost effectiveness, 1053
- Colorectal cancer, adjuvant treatment, chemotherapy, oxaliplatin, metastatic disease, 1765
- Colorectal cancer, antitumor immune response, inflammatory cell infiltration, CD3, CD8, lymph node retrieval, 5143
- Colorectal cancer, bevacizumab, predictive marker, proteinuria, 309
- Colorectal cancer, blood transfusion, prognosis, liver metastasis, hepatic resection, 2723
- Colorectal cancer, brain metastases, surgical approach, WBRT, 5645
- Colorectal cancer, capecitabine, gemcitabine, refractory, 4089
- Colorectal cancer, carcinogenesis, C57BL/6J-*Min*⁺ mice, hydrogenated fish oil, *trans* fatty acids, 477
- Colorectal cancer, cell signaling, ERK, U0126, CYP inhibitor, MEK/ERK inhibitor, HT29, HCT116, 2499
- Colorectal cancer, circulating tumor cell, prediction of progression, 1769
- Colorectal cancer, circulating tumour cells, biomarkers, chemotherapy, 625
- Colorectal cancer, claudin, prognosis, recurrence, poorly-differentiated component, 3301
- Colorectal cancer, cytomegalovirus, viral DNA, Vietnamese, Swedish, 4947
- Colorectal cancer, *EGFR* gene polymorphism, skin toxicity, *EGFR* antibody, 4995
- Colorectal cancer, fecal occult hemoglobin, analyzer evaluation, Kroma iT, 5633
- Colorectal cancer, HAVcR-1, hepatitis A virus cellular receptor-1, prognosis, invasion, 207
- Colorectal cancer, HRMA, cetuximab, *KRAS* mutation, sequencing, 2129
- Colorectal cancer, irinotecan, IRIS, S-1, FIRIS, 3845
- Colorectal cancer, irinotecan, radiofrequency ablation, liver metastases, 1603
- Colorectal cancer, liver metastases, circulating tumor cells, tumor markers, AdnaGen, 2239
- Colorectal cancer, lymph node metastasis, lymph node harvest, lymph node ratio, survival, population-based study, prospective study, review, 2839
- Colorectal cancer, lymphatic invasion, prognosis, 2965
- Colorectal cancer, Lynch syndrome, NNPCC, clinical management, 2147
- Colorectal cancer, mCRC, cetuximab, circulating tumor cells, 3905
- Colorectal cancer, MCT4, VEGF, tumor growth, 2941
- Colorectal cancer, *miR-146a* polymorphism, rs2910164, risk, prognosis, 3233
- Colorectal cancer, MMP12, MMP13, SNP, 3247
- Colorectal cancer, moderately emetic chemotherapy, chemotherapy-induced nausea and vomiting, adherence, dexamethasone, 5549
- Colorectal cancer, neutrophil-to-lymphocyte ratio, systemic inflammatory response, 3291
- Colorectal cancer, olive oil, polyunsaturated fatty acids (PUFAs), lipid metabolism, gene expression, 3739
- Colorectal cancer, oxaliplatin, S-1, SOX, molecular target, liver metastasis, 3941
- Colorectal cancer, oxaliplatin, S-1, SOX, XELOX, metastasis, 4029
- Colorectal cancer, peritoneal carcinomatosis, peritonectomy, 975
- Colorectal cancer, prognostic markers, gene expression, 4855
- Colorectal cancer, radiotherapy, chemotherapy, concomitant therapy, cisplatin, Lipoplatin™, 3005
- Colorectal cancer, serum p53 antibody, tumor marker, recurrence, curative resection, 2221
- Colorectal cancer, stage IV, asymptomatic primary tumor, palliative surgery, Glasgow prognostic score, neutrophil to lymphocyte ratio, 5567
- Colorectal cancer, tegafur-uracil, leucovorin, folate, γ -glutamyl hydrolase (GGH), gene expression, 3431
- Colorectal cancer, tenascin-C, TNC, EMT, 1927
- Colorectal cancer, TNM classification, node category (N-category), retrieved lymph node number (RLN), Dukes' C, 2949
- Colorectal cancer, transarterial chemoembolization, drug eluting beads with irinotecan, 2077
- Colorectal cancer, WNT, β -catenin, prognosis, E-cadherin, SFRP, invasive front, 4573
- Colorectal carcinoma, SW 480 cells, *EGFR* phosphorylation, chemotherapy, 3753
- Colorectal liver metastases, surgical site infection, Glasgow prognostic score, systemic inflammatory response, 1697
- Colorectal liver metastasis, postoperative chemotherapy, irinotecan, synchronous metastasis, oxaliplatin, 5-fluorouracil, leucovorin, FOLFOX, FOLFIRI, 3317
- Colposcopy, pap smear, acetic acid, dysplasia, cervical cancer, 1125
- Combination chemotherapy, esophageal squamous cell carcinoma, metastasis, old age, risk factors, taxane, 4123
- Combination therapy, chemoprevention, lung cancer, experimental model, tobacco carcinogens, acetylsalicylic acid, vitamin D, calcium, 4767
- Combination therapy, chemoprevention, non-melanoma skin cancer, UV radiation-induced skin tumors, experimental model, 3033

- Combination therapy, colon cancer, Virchow lymph node metastasis, 2935
- Combination, *Salmonella typhimurium* A1-R, GFP, TCM, tumor targeting, Lewis lung carcinoma, RFP, C57/BL6 mice, 1837
- Combined androgen blockade, prostate cancer, bone metastasis, zoledronic acid, 3837
- Combined therapy, pancreatic adenocarcinoma, chemotherapy, gemcitabine, FOLFORINOX, clinical trials, review, 1785
- Combined treatment, chemoradiation, neoadjuvant therapy, colorectal adenocarcinoma, long-term outcome, 725
- Combined treatment, vitamin D analogs, oxaliplatin, irinotecan, anticancer activity, colonic cancer, 433
- Comorbidity, lung cancer, survival, lung function, random forest method, 1609
- Comparative effectiveness research, colorectal cancer, 5-fluorouracil, capecitabine, oxaliplatin, treatment effectiveness, cost effectiveness, 1053
- Comparative oncology, artesunate, cancer, safety study, dog, 1819
- Compensatory anti-inflammatory response syndrome, CT26 murine colon cancer, neutrophil elastase inhibitor, sivelestat, cecal ligation and puncture, 3653
- Complete molecular response, chronic-phase CML, TKI, 3509
- Complete response, bladder cancer, concurrent chemoradiotherapy, hydronephrosis, 2605
- Completion surgery, cervical cancer, pelvic lymphadenectomy, para-aortic lymphadenectomy, locally advanced cervical cancer, 1661
- Concomitant therapy, radiotherapy, chemotherapy, colorectal cancer, cisplatin, Lipoplatin™, 3005
- Concurrent chemoradiotherapy, bladder cancer, complete response, hydronephrosis, 2605
- Concurrent chemoradiotherapy, HIV, viral load, CD4, squamous cell carcinoma, head and neck cancer, radiation therapy, IMRT, chemotherapy, 5511
- Concurrent chemoradiotherapy, non-bulky, cervical cancer, stage IB1/II, radiotherapy, 5123
- Concurrent chemoradiotherapy, tonsil cancer, surgery, radiotherapy, 1237
- Cone beam tomography, numb chin syndrome, mental neuropathy, mandibular metastasis, inferior alveolar nerve, orthopantomogram, colonic cancer, case report, 1757
- Confocal microscopy, green fluorescent protein, blood vessels, nestin, angiogenesis, anastomosis, red fluorescent protein, Gelfoam®, transgenic nude mice, color-coded imaging, vascularization, 3041
- Confocal microscopy, HT-1080, fibrosarcoma, intravascular, extravasation, GFP, RFP, mitosis, apoptosis, nude mice, 4229
- Confocal microscopy, αv integrin, green fluorescent protein, blood vessels, red fluorescent protein, Gelfoam®, osteosarcoma, transgenic nude mouse, 1361
- Confocal microscopy, αv integrin, green fluorescent protein, osteosarcoma, fibronectin, *in vitro*, *in vivo*, nude mouse, metastasis, real-time imaging, 3021
- Conjunctival squamous cell carcinoma, αB -crystallin, vascular endothelial growth factor, 3745
- Consolidation and maintenance therapy, multiple myeloma, autologous stem-cell transplantation, bortezomib, lenalidomide, 5681
- Consolidation, cervical cancer, lymph node metastasis, chemotherapy, radiation therapy, 4675
- Constrictors, radiation induced dysphagia, carotidvasculopathy, radiation therapy, early glottic cancer, 4483
- Copper chelator, cisplatin, high-affinity human copper transporter 1 (hCtr1), review, 4157
- Copper transporter, ovarian cancer, chemotherapy resistance, 1409
- Copy number variation, hepatocellular carcinoma, *c-MET*, Immunohistochemistry, prognosis, 5179
- Copy-number alteration, *EGFR*-TKI resistance, erlotinib, amplification, CRKL, non-small cell lung cancer, 5223
- Coronopilin, *Ambrosia arborescens*, damsin, chemoselective bromination, sesquiterpenes, cell proliferation, STAT3, NF- κ B, apoptosis, 3799
- Corpus, gastric cancer, atrophic gastritis, antrum, *Helicobacter pylori*, risk factors, biomarker panel, pepsinogens, gastrin-17, achlorhydria, blood test, 4595
- Correlation, chemosensitivity, HDRA, histoculture drug response assay, epithelial ovarian cancer, taxol, carboplatin, prospective clinical trial, prediction, individualized therapy, 1029
- Corticotrophin-releasing factor receptors, urocortin, gastric cancer, STKM-1 cell line, 5289
- Cost effectiveness, colorectal cancer, 5-fluorouracil, capecitabine, oxaliplatin, comparative effectiveness research, treatment effectiveness, 1053
- Cost-effectiveness, screen-detected breast carcinoma, screening, *HER2*, gene amplification, targeted therapy, 3705
- Costello syndrome, oxidative stress, potassium ascorbate with ribose, 691
- Cotinine, polycyclic aromatic hydrocarbon, oxidative stress, antioxidant capacity, lung cancer, nested case-control study, 1-hydroxypyrene, thiobarbituric acid, 8-hydroxydeoxyguanosine, 2-Naphthol, 3089
- COX inhibition, NSAIDS, colon cancer, prevention, apoptosis, ACF, rat model, 3581
- COX2* expression, CRC, IHC, prognosis, 3137
- COX-2, esophageal carcinoma, 5-fluorouracil, cisplatin, chemosensitivity, gene transfer, TE13 cells, 537

- Cox-2, polymorphism, bladder cancer, genotype, 5401
- CpG-island, cell-free DNA, hypermethylation, kidney cancer, biomarker, serum, 4651
- Craniotomy window, GFP, RFP, mitosis, subcellular dynamics, brain cancer, brain metastasis, mouse model, *in vivo* imaging, 1367
- Craniotomy window, glioma, U87, RFP, orthotopic, imaging, fluorescence, surgery, survival, 107
- CRC, *COX2* expression, IHC, prognosis, 3137
- C-reactive protein, hepatocellular carcinoma, hepatic resection, 705
- C-reactive protein, hepatocellular carcinoma, surgical resection, prognostic factor, 1181
- C-reactive protein, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, rectal cancer, prognosis, chemoradiotherapy, 5065
- C-reactive protein, stage IV gastric cancer, prognosis, cut-off value, 5591
- C-reactive protein, survival, stage IV colorectal cancer, oxaliplatin-based chemotherapy, 5051
- CRKL, *EGFR*-TKI resistance, erlotinib, amplification, copy-number alteration, non-small cell lung cancer, 5223
- Crohn's disease, anal fistula, anorectal carcinoma, infliximab, 685
- Crohn's disease, small intestine cancer, surgical operation, 2977
- CRPC, castration-resistant prostate cancer, HAI-1, prostate cancer, 575
- Cryopreservation, feeder cells, K562, natural killer cell, expansion, 2011
- CSC, EMT, epithelial-mesenchymal transition, cancer stem cell, CD44, musashi, cadherin, 2867
- CSRA, DiSC assay, chemotherapy, pretherapeutic *ex vivo* testing, 2491
- CT1258, prostate cancer, cancer stem cells, stem cell marker, canine, CT1258-EGFP, CT1258-EGFP-*HMG2* cell lines, 5421
- CT1258-EGFP, prostate cancer, cancer stem cells, stem cell marker, canine, CT1258, CT1258-EGFP-*HMG2* cell lines, 5421
- CT1258-EGFP-*HMG2* cell lines, prostate cancer, cancer stem cells, stem cell marker, canine, CT1258, CT1258-EGFP, 5421
- CT26 murine colon cancer, neutrophil elastase inhibitor, sivelestat, cecal ligation and puncture, compensatory anti-inflammatory response syndrome, 3653
- CTAB assay, CD44-targeted delivery, PLGA nanoparticles, hyaluronic acid, surface decoration, SN-38, ovarian cancer, 2425
- CTX, lung cancer, bone metastasis, NSCLC, CEA, CYFRA 21-1, PINP, TRAP5b, 2593
- Cucumin, liposomes, red blood cells, morphology, echinocyte, 3629
- 3D culture assays, zoledronic acid, metastasis, invasion, 5295
- Curative resection, serum p53 antibody, colorectal cancer, tumor marker, recurrence, 2221
- Curative therapy, hepatitis B core antigen antibody, non-B non-C hepatocellular carcinoma, overall survival, recurrence-free survival, 2211
- Curcumin analogues, prostate cancer, proliferation, apoptosis, PC-3 cells, 1343
- Curcumin formulation, pharmacokinetics, intramuscular, 4285
- Curcumin, bone, morphometrics, remodeling, mice, 3153
- Curcumin, human gallbladder adenocarcinoma, *G2/M* arrest, apoptosis, 1861
- Curcumin, oral absorption, bioavailability, drug delivery system, review, 2807
- Curcumin, pancreatic cancer, xenograft, liposomal curcumin, annexin A2, MiaPaCa cells, 3603
- Curcumin, prostate cancer, lycopene, resveratrol, capsaicin, dietary phytochemicals, review, 4163
- Cushing's syndrome, pancreatic neuroendocrine tumor, ectopic ACTH syndrome, gastroenteropancreatic neuroendocrine tumor, 4001
- Cut-off value, stage IV gastric cancer, prognosis, C-reactive protein, 5591
- CXCL1, circulating tumor cells, TGF- β , metastasis, breast cancer, chemokines, cytokines, 1491
- CXCR4, pancreatic cancer, tumor progression, β -catenin, 4103
- Cyanine dyes, LoVo, LoVo/DX, intracellular accumulation, phenothiazines, 857
- CyberKnife, hypoxic radiosensitizer, reirradiation, brain metastases, stereotactic irradiation, 1773
- Cyclin D1, artemisinin, transferrin, breast cancer, *HER2*, survivin, c-Myc, DV145, MCF7 cells, 123
- Cyclin D1, biomarker, bladder cancer, muscle-invasive, 5235
- Cyclopamine, head and neck squamous cell carcinoma (HNSCC), Hedgehog pathway, cisplatin, docetaxel, synergism, 2415
- CYFRA 21-1, lung cancer, bone metastasis, NSCLC, CEA, CTX, PINP, TRAP5b, 2593
- CYP inhibitor, cell signaling, ERK, U0126, MEK/ERK inhibitor, colorectal cancer, HT29, HCT116, 2499
- CYP2D, pharmacokinetic interaction, ondansetron, tamoxifen, hepatic and intestinal, CYP3A1/2, DMBA rats, 521
- CYP3A1/2, pharmacokinetic interaction, ondansetron, tamoxifen, hepatic and intestinal, CYP2D, DMBA rats, 521
- Cytobrush, pap test, cervical sampling device, Ayre's spatula, 917
- Cytochrome *c*, gastric adenocarcinoma, Immunohistochemistry, (Smac) DIABLO, AIF, 647

- Cytochrome C, naphthoquinones, chronic lymphocytic leukemia (CLL), MAPKs, apoptosis, mitochondria, BCL2, 183
- Cytogenetic and molecular investigation, fanconi anemia, FANCA gene, mutation, Greek patients, 3369
- Cytogenetics, collagenous fibroma, desmoplastic fibroblastoma, magnetic resonance imaging, trisomy 8, 3259
- Cytokines, adipocytes, immune regulation, inflammation, premalignant lesion cells, 1809
- Cytokines, circulating tumor cells, TGF- β , CXCL1, metastasis, breast cancer, chemokines, 1491
- Cytokines, esophageal cancer, eicosapentaenoic acid, apoptosis, NF- κ B, TE-1 cells, 4319
- Cytokines, HNSCC, radio-/chemotherapeutic treatment head and neck cancer, 2481
- Cytolysin, cholesterol-independent, human-specific, ILY, VLY, Sm-hPAF, CD59, 2901
- Cytomegalovirus, colorectal cancer, viral DNA, Vietnamese, Swedish, 4947
- Cytoreductive surgery, endometrial carcinoma, late wound recurrence, hyperthermic intraperitoneal chemotherapy, 1041
- Cytoreductive surgery, peritoneal sarcomatosis, HIPEC, locoregional treatment, 3989
- Cytostatic therapy, bisphosphonate, osteonecrosis, mandible, risk factors, 3917
- Cytotoxic effect, citric acid, HaCaT, cell cycle, apoptosis, 4411
- Cytotoxicity, ester conjugate, fatty acid, anticancer agent, cancer cell lines, MDA-MB-361, MCF-7, MDA-MB-231, 2517
- Cytotoxicity, licorice flavonoids, QSAR, tumor-specificity index, chemical descriptor, 3061
- Cytotoxicity, piperaceae, *Piper sarmentosum*, dichamanetin, NF- κ B inhibition, DNA binding, mitochondrial membrane potential, PARP-1, ROS, 5349
- Cytotoxicity, *Rhinacanthus nasutus*, apoptosis induction, osteoclastogenesis, HSC-2, HSC-3, HSC-4, HL-60 cells, 453
- Daidzein genistein, prostate cancer, soy phytoestrogens, diet, epigenetics, isoflavones, review, 39
- Damsin, *Ambrosia arborescens*, coronopilin, chemoselective bromination, sesquiterpenes, cell proliferation, STAT3, NF- κ B, apoptosis, 3799
- Daunorubicin derivatives, human acute leukemia cells, apoptosis, necrosis, mitochondrial membrane potential, 4439
- DC immunotherapy, WT1, ovarian cancer, carcinosarcoma, 3855
- DC immunotherapy, WT1, uterine cancer, endometrial carcinoma, uterine sarcoma, 5495
- DCA, ALA, hyperthermotherapy, cellular immunotherapy, stomach cancer, 2957
- D-dimer, recurrent malignant glioma, bevacizumab, deep venous thrombosis, 2093
- DDX39, gemcitabine, pancreatic cancer, drug-resistant KLM1 cells, 3133
- DDX39, malignant pleural mesothelioma, DEAD-box RNA helicase, 2557
- DEAD-box RNA helicase, DDX39, malignant pleural mesothelioma, 2557
- Deamination, ADAL, GS-9219, PMEG, 1899
- Death receptor-3, pituitary adenoma, VEGI, invasion, 3815
- Death receptors, TRAIL, cervical cancer cells, equol, caspases, apoptosis, 903
- De-differentiation, clear cell renal carcinoma, sarcomatoid differentiation, xenotransplantation, cell line and clonal sublines, epithelioid, fibroblastoid, 4875
- Deep venous thrombosis, recurrent malignant glioma, bevacizumab, D-dimer, 2093
- Deferoxamine, dihydroartemisinin, N-tert-butyl-alpha-phenylnitron, Molt-4 cells, free radical, iron, 4389
- Definitive chemoradiotherapy, esophagus, squamous cell carcinoma, salvage esophagectomy, murine double minute 2, p16, Ki-67, 1463
- Defunctioning ileostomy, laparoscopic surgery, low anterior resection, 5011
- Degalactosylated Gc-globulin, a precursor of Gc-derived macrophage activating factor, subtypes of Gc-globulin, antitumor activity, injection route, 2911
- Degalactosylated/desialylated human serum, GcMAF, macrophage phagocytic activity, *in vivo* antitumor activity, 2881
- Delayed radiotherapy, prostate cancer, propensity score, 1629
- Delivery approach, gene therapy, hepatocellular carcinoma (HCC), intravenous intra-arterial, intra-tumoral, intra-portal, intra-biliary injection, review, 4711
- Delivery, pregnancy, dysplasia, cervical cancer, 711
- Dendritic cell vaccine, electroporation, tumor lysate, solid tumor, 2971
- Dendritic cell vaccine, pediatric neuro-oncology, high grade glioma, immunotherapy, 2047
- Dendritic cell, cancer vaccine, antigen presentation, fusion, 347
- Dendritic cells, interleukin-10, gene expression, differentiation, 4791
- Denosumab, osteonecrosis of the jaw, ONJ, bevacizumab, sunitinib, risk factors, review, 1793
- Denosumab, zoledronic acid, anticancer therapy, tumor growth, review, 2981
- 5'-Deoxy-5-fluorouridine (5'-DFUR), metastatic colorectal cancer, irinotecan, UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism, 3423

- 2-Deoxyglucose, colon cancer, 3-bromopyruvate, metformin, phenformin, 401
- Desacyl-saponin, renal cell carcinoma, nanoparticle, BBE, *in vitro*, *in vivo*, xenograft, 143
- Desmoplastic fibroblastoma, collagenous fibroma, cytogenetics, magnetic resonance imaging, trisomy 8, 3259
- Dexamethasone, colorectal cancer, moderately emetic chemotherapy, chemotherapy-induced nausea and vomiting, adherence, 5549
- Dexamethasone, palonosetron, early breast cancer, 1721
- Dextran sulfate sodium, soluble epoxide hydrolase, colitis, carcinogenesis, mice, 5261
- 5'-DFCR, capecitabine, metabolites, 5'-DFUR, pharmacokinetics, HPLC, GLP, 881
- 5'-DFUR, capecitabine, metabolites, 5'-DFCR, pharmacokinetics, HPLC, GLP, 881
- 5'-DFUR, paclitaxel, gastric cancer, phase II study, 2629
- DFS, postoperative follow-up, gastric cancer, nodal status, recurrence, 4645
- Diabetes mellitus, chemotherapy, insulin, pancreatic cancer, 287
- Diagnosis, prostate cancer, nomogram, prostate cancer antigen 3, 553
- Diagnosis, protein kinase, blood, peptide substrate, phosphorylation, 485
- Diagnostic markers, prostatic neoplasms, carcinoma, gene expression, urine, 191
- Dichamanetin, piperaceae, *Piper sarmentosum*, cytotoxicity, NF- κ B inhibition, DNA binding, mitochondrial membrane potential, PARP-1, ROS, 5349
- Dichloroacetic acid, taxol, p66shc, renal, toxicity, 3119
- Diet, breast cancer, benign breast tumours, fatty acids, adipose tissue, biomarkers, 1667
- Diet, prostate cancer, soy phytoestrogens, daidzein genistein, epigenetics, isoflavones, review, 39
- Dietary phytochemicals, prostate cancer, lycopene, resveratrol, capsaicin, curcumin, review, 4163
- Diethylnitrosamine, hepatocyte growth factor, *HGF* transgenic mice, lung tumor, c-Met, 895
- Differential regulation, head and neck cancer, keratinocytes, PAI-1, uPA, 3113
- Differentiation, cancer stem-like cells, OCT4, MDA-MB453, stemness, asymmetric cell division, 763
- Differentiation, dendritic cells, interleukin-10, gene expression, 4791
- Diffuse gastric cancer, methylation, human CDH1 protein; stomach neoplasm, methylation-specific polymerase chain reaction, pyrosequencing, 3765
- Dihydroartemisinin, N-tert-butyl-alpha-phenylnitron, deferoxamine, Molt-4 cells, free radical, iron, 4389
- Dihydroceramide desaturase, apoptosis, ceramide, dihydroceramide, PDT, sphingolipids, UM-SCC-22A cells, HNSCC, 77
- Dihydroceramide, apoptosis, ceramide, dihydroceramide desaturase, PDT, sphingolipids, UM-SCC-22A cells, HNSCC, 77
- Dihydrofolate reductase, gambogic acid, methotrexate, hepatoma, synergy, 133
- 15, 16-dihydrotanshinone I, colorectal cancer, activating transcription factor-3, SW480, SW620, SW420 cells, 3225
- 16-dihydrotanshinone I, 15, colorectal cancer, activating transcription factor-3, SW480, SW620, SW420 cells, 3225
- Dimerization, *EGFR*, radiation, cetuximab, radiosensitivity, A431 cells, 4337
- Dioxin, aryl hydrocarbon receptor, lung cancer, tumorigenesis, polycyclic aromatic hydrocarbons, cigarette smoke, review, 1247
- Dioxybenzone, benzophenone sunscreens, octabenzene, mouse skin papillomas, oral chemoprevention, antioxidants, 2535
- Direct co-culture, CAFs, NFs, lung cancer, stromal NSCLC, indirect co-culture, EMT, proliferation, SMAD3, Hedgehog signaling pathway, 3715
- DiSC assay, CSRA, chemotherapy, pretherapeutic *ex vivo* testing, 2491
- Disease outcome, pancreatic cancer, adenocarcinoma, 5491
- Disease recurrence, VEGF, *VEGFR1*, *VEGFR2*, bladder cancer, angiogenesis, 2381
- Disease, intestinal macrophage, intestinal microbiota, homeostasis, health, review, 2849
- Disease-free survival, hepatocellular carcinoma, PIVKA-II, NX-PVKA-R, post-curative treatment change, protein-induced vitamin K absence or antagonist-II, 2689
- Disease-free survival, kinase receptor family, tumor suppressor, sporadic cancer, molecular markers, 5159
- Disease-free survival, retroperitoneal sarcoma, overall survival, soft tissue sarcoma, 4081
- Disiloxanes, chemoprevention, anti-promotion, EBV-induced early antigen, two-stage mouse skin carcinogenesis, co-existence of tumor and normal cells, 2021
- Distal pancreatectomy, metastatic pancreatic tumor, melanoma of nasal cavity, 567
- Distant metastasis, FDG-PET, carbon-ion radiotherapy, preoperative, prognostic factor, 5579
- Distant metastasis-free survival, renal cell carcinoma, vascular endothelial growth factor, overall survival, 5017
- Distant myonecrosis in ovarian cancer, clostridium septicum, distant myonecrosis, gas gangrene, ovarian cancer, 1585
- Distant myonecrosis, clostridium septicum, gas gangrene, ovarian cancer, distant myonecrosis in ovarian cancer, 1585
- DLD-1, monocyte, colon cancer cell, co-culture, angiogenesis, metastasis, signaling pathway, THP-1 cells, 2895
- DMBA rats, pharmacokinetic interaction, ondansetron, tamoxifen, hepatic and intestinal, CYP2D, CYP3A1/2, 521

- DNA binding, piperaceae, *Piper sarmentosum*, dichamanetin, cytotoxicity, NF- κ B inhibition, mitochondrial membrane potential, PARP-1, ROS, 5349
- DNA damage, *ATM*, *ATR*, *Chk1*, *p53*, *p21*, cell-cycle arrest, vinca alkaloids, 5273
- DNA damage, GFP, 53BP1, focus, UVC, pancreatic cancer, 1373
- DNA hypermethylation, prostate cancer, methylation, prognosis, PTGS2, RARB, 5249
- DNA methylation, breast cancer, glutathione S-transferase P1 (*GSTP1*), microdissection, ER-positive breast cancer, 5617
- DNA methylation, epigenetics, DNMT inhibitors, cancer therapy, review, 2989
- DNA methylation, oral cancer, 5-hydroxymethylcytosine, ten-eleven-translocation 2, biological markers, 4325
- DNA microarray, colon carcinoma, invasion, *FERMT1*, fermitin family, 167
- DNA ploidy index, gastric adenocarcinoma, overall survival, prognostic factor, response to chemotherapy, 1209
- DNA repair systems, biomarkers, gastric cancer, *HER2*, fluoropyrimidine metabolism, apoptotic pathway, chemotherapy, targeted therapy, review, 1257
- DNA repair, lobarstin, glioblastoma, temozolomide, chemosensitivity, 5445
- DNA repair, metastatic neuroblastoma, PARP inhibition, radiation, MK-4827, 755
- DNA repair, mitochondrial DNA, carcinogenesis, metastasis, review, 3543
- DNA repair, prostatic neoplasms, neoplastic stem cells, radiotherapy, reactive oxygen species, radioresistance, 4469
- DNMT inhibitors, epigenetics, DNA methylation, cancer therapy, review, 2989
- DNMT3A, epigenetics, EGCG, colon cancer, green tea, epigallocatechin 3-gallate, HDAC3, 5325
- Docetaxel (Taxotere[®]), non-small cell lung cancer (NSCLC), symptom control, observational study, 3831
- Docetaxel resistance, prostate cancer cell lines, cabazitaxel, ABCC4, 387
- Docetaxel, 5-FU, β -catenin, c-KIT, head and neck squamous cell carcinoma, extracellular matrix, protein tyrosine kinase, human papillomavirus (HPV), epithelial mesenchymal transition (EMT), 2457
- Docetaxel, advanced gastric cancer, chemotherapy, elderly, S-1, 697
- Docetaxel, anaplastic thyroid carcinoma, chemoradiation therapy, local control, palliative management, 3445
- Docetaxel, breast cancer, paclitaxel, metastasis, time-to-progression, survival, 2623
- Docetaxel, early breast cancer, obesity, fat mass, dose intensity, toxicity, 5655
- Docetaxel, epirubicin, oxaliplatin, capecitabine, cisplatin, 5-fluorouracil, G-CSF, gastroesophageal cancer, adenocarcinoma, 3455
- Docetaxel, head and neck squamous cell carcinoma (HNSCC), Hedgehog pathway, cyclophosphamide, cisplatin, synergism, 2415
- Docetaxel, NK cell-enriched lymphocytes (NKL), MICA/B, NKG2D, NSCLC, phase II study, 2115
- Docetaxel, non-small cell lung cancer, chemotherapy, randomized phase 2, ethnicity, paclitaxel carboplatin, 4631
- Docetaxel, non-small cell lung cancer, cisplatin, ifosfamide, survival, phase III trial, 5477
- Docetaxel, vascular endothelial growth factor, platelet-derived growth factor, PDGFR α/β , head and neck squamous cell carcinoma, fluorouracil, 1951
- Dog, artesunate, cancer, safety study, comparative oncology, 1819
- Dogs, mastocytoma, interleukin-2, local therapy, immunotherapy, 161
- Dose intensity, early breast cancer, docetaxel, obesity, fat mass, toxicity, 5655
- Dose response relationship, cancer, fatigue, physical activity, inpatient rehabilitation, 3415
- Dose-dense schedule, lioblastoma, tamoxifen, temozolomide, 3383
- Double-hit lymphomas, *ID3*, unclassifiable B-cell lymphoma, 4771
- Doxazosin, quinazoline, terazosin, DZ-50, prostate cancer, vascularity, anoikis, review, 4695
- Doxorubicin, ABCB5, melanoma, NF- κ B, *p53*, parthenolide, 3205
- Doxorubicin, chemotherapeutic resistance, cisplatin, etoposide, nitric oxide, lung cancer, 5433
- Doxorubicin, multidrug resistance, modulating agents, drug accumulation, vincristine, paclitaxel, L929 murine cell line, MCF7 breast cancer cell line, 4381
- DR4, salinomycin, DR5, apoptosis, ovarian cancer, A2780cis cells, 1457
- DR5, salinomycin, DR4, apoptosis, ovarian cancer, A2780cis cells, 1457
- Drug accumulation, multidrug resistance, modulating agents, doxorubicin, vincristine, paclitaxel, L929 murine cell line, MCF7 breast cancer cell line, 4381
- Drug combination, cannabinoids, drug schedule, leukaemia, 4373
- Drug delivery system, cholesterol-dependent cytolysin, Z-domain, chimera protein, 2905
- Drug delivery system, curcumin, oral absorption, bioavailability, review, 2807
- Drug delivery, photodynamic therapy, photosensitizer, tumor targeting, review, 2823
- Drug drug interaction, metronomic topotecan, pazopanib, pharmacokinetics, gynecological cancer, 3823
- Drug eluting beads with irinotecan, transarterial chemoembolization, colorectal cancer, 2077

- Drug interaction, biliary excretion, cimetidine, pharmacokinetics, multidrug resistance-associated protein-2 (Mrp2), sunitinib, (Abcc2), 3105
- Drug resistance, carboplatin, selenite, ovarian cancer, xenografts, 4249
- Drug resistance, gastric cancer, cannabinoids, fluorouracil, apoptosis, 2541
- Drug resistance, lung cancer, zoledronic acid, BAX, 5357
- Drug resistance, peroxiredoxin, gemcitabine, pancreatic cancer, 4821
- Drug resistance, three-dimensional (3D) culture, silicate fiber scaffold, anticancer drug screening, 5301
- Drug schedule, cannabinoids, drug combination, leukaemia, 4373
- Drug sequence, kidney cancer, sorafenib, sunitinib, Everolimus, temisrolimus, 4999
- Drug-resistant KLM1 cells, DDX39, gemcitabine, pancreatic cancer, 3133
- DU145, Id4, senescence, E2F1, apoptosis, 4271
- Ductal carcinoma *in situ*, breast cancer, hypofractionated radiotherapy, 3503
- Dukes' C, TNM classification, node category (N-category), retrieved lymph node number (RLN), colorectal cancer, 2949
- DV145, artemisinin, transferrin, breast cancer, *HER2*, survivin, c-Myc, cyclin D1, MCF7 cells, 123
- DV90 cells, non-small cell lung cancer, metallothionein, immunocytochemistry, cisplatin resistance 97/97, 5255
- Dyspepsia, adjuvant chemotherapy, breast cancer, gastrin, ghrelin, leptin, motilin, pepsinogens, 4951
- Dysphagia, adjuvant chemotherapy, long-term cancer survival, radical resection, small cell carcinoma of the esophagus, 595
- Dysphagia, clinical predictors, swallowing disorder, head and neck cancer, post-surgical screening, 3347
- Dysphagia, swallowing disorder, head and neck cancer, postsurgical, screening, 4017
- Dysplasia, pap smear, acetic acid, colposcopy, cervical cancer, 1125
- Dysplasia, pregnancy, cervical cancer, delivery, 711
- 2-D western blotting, two-dimensional gel electrophoresis, LC-MS/MS, nucleophosmin, tumor progression, 153
- DZ-50, quinazoline, doxazosin, terazosin, prostate cancer, vascularity, anoikis, review, 4695
- E2F1, Id4, senescence, apoptosis, DU145, 4271
- E2F1, renal cell carcinoma, PD-0322991, palbociclib, cell-cycle inhibition, CDKN2A, p16, 2997
- E2F5, esophageal squamous cell carcinoma, cell proliferation, 5415
- E6, HPV, E7, Greece, 4007
- E7, HPV, E6, Greece, 4007
- EAC, RRAD, hypermethylation, ESCC, 5199
- EAG1, glioma, glioblastoma multiforme, RNAi, IFN- γ , gene therapy, 865
- Early breast cancer, docetaxel, obesity, fat mass, dose intensity, toxicity, 5655
- Early breast cancer, palonosetron, dexamethasone, 1721
- Early glottic cancer, radiation induced dysphagia, carotidvasculopathy, radiation therapy, constrictors, 4483
- Early hepatocellular carcinoma, alpha-fetoprotein, fucosylated fraction of alpha-fetoprotein, Gd-EOB-DTPA-enhanced MRI, 997
- Early management, sunitinib, adverse events, pharmacist, adherence, blood pressure, 5043
- Early stage, endometrial carcinoma, baby boomers, obesity, outcome, prognosis, 619
- Early stage, endometrial carcinoma, baby boomers, SEER, survival, prognosis, 4983
- Early-onset, non-small cell lung cancer, surgery, chemotherapy-induced neutropenia, prognosis, 2755
- EBV-induced early antigen, disiloxanes, chemoprevention, anti-promotion, two-stage mouse skin carcinogenesis, co-existence of tumor and normal cells, 2021
- E-cadherin, breast cancer, abdominal metastasis, Ki-67, lymphatic vessel invasion, 1971
- E-cadherin, colorectal cancer, WNT, β -catenin, prognosis, SFRP, invasive front, 4573
- E-cadherin, endometrial carcinoma, proliferation, 5091
- E-cadherin, epidermal growth factor receptor, tyrosine kinase inhibitor, esophageal cancer, malignant pleural mesothelioma, epithelial to mesenchymal transition (EMT), 2401
- E-cadherin, T1 esophageal cancer, tumor budding, nodal metastasis, 5023
- Echinocyte, cucumin, liposomes, red blood cells, morphology, 3629
- Echinomycin, leukaemia, HIF, NOTCH, NB4, Jurkat cells, 3099
- Echoendoscope, staging, mediastinal lymph nodes, surgical procedure, endosonographic evaluation, review, 2369
- Ecteinascidin, tetrahydroisoquinoline, MCL1, anoikis, metastasis, lung cancer cells, 505
- Ectopic ACTH syndrome, pancreatic neuroendocrine tumor, Cushing's syndrome, gastroenteropancreatic neuroendocrine tumor, 4001
- Edema of the upper limb, segmental bioelectrical impedance analysis, whole-body bioelectrical impedance analysis, breast cancer, 3403
- EGCG, epigenetics, colon cancer, green tea, epigallocatechin 3-gallate, DNMT3A, HDAC3, 5325
- EGFR* amplification, glioblastoma, *EGFRvIII*, polysomy 7p, 5343
- EGFR* antibody, *EGFR* gene polymorphism, skin toxicity, colorectal cancer, 4995

- EGFR* gene polymorphism, skin toxicity, colorectal cancer, *EGFR* antibody, 4995
- EGFR* inhibitor, lung cancer, epidermal growth factor receptor, gefitinib, molecular targeted drug, gefitinib, 5057
- EGFR* phosphorylation, colorectal carcinoma, SW 480 cells, chemotherapy, 3753
- EGFR*, angiogenesis, lung cancer, 1913
- EGFR*, dimerization, radiation, cetuximab, radiosensitivity, A431 cells, 4337
- EGFR*, esophageal cancer, gastric cancer, trastuzumab, cetuximab, review, 4139
- EGFR*, lung adenocarcinoma, brain metastases, TKI, radiotherapy, resistance, 1649
- EGFR*, phosphorylated *EGFR*, HPV, tonsillar cancer, 1575
- EGFR*, squamous cell lung cancer, NSCLC, targeted-therapy, *KRAS*, *PIK3CA*, mutation, *EGFR*-TKI, 1705
- EGFR*-TKI resistance, erlotinib, amplification, copy-number alteration, CRKL, non-small cell lung cancer, 5223
- EGFR*-TKI, squamous cell lung cancer, NSCLC, targeted-therapy, *EGFR*, *KRAS*, *PIK3CA*, mutation, 1705
- EGFRvIII*, glioblastoma, *EGFR* amplification, polysomy 7p, 5343
- Eicosapentaenoic acid, esophageal cancer, apoptosis, NF- κ B, cytokines, TE-1 cells, 4319
- Elacytarabine, non-small cell lung cancer, *in vivo* antitumor activity, bevacizumab, cetuximab, trastuzumab, xenograft, 3615
- Elderly patients, esophageal cancer, esophagectomy, 1641
- Elderly patients, oxaliplatin-based chemotherapy, metastatic colorectal cancer, 4627
- Elderly, advanced gastric cancer, chemotherapy, docetaxel, S-1, 697
- Elderly, aged patient, non-small cell lung cancer, chemotherapy, pharmacokinetics, quality of life, carboplatin, paclitaxel, maximum tolerated dose, 261
- Elderly, IORT, breast cancer, morbidity, short-term outcome, 3995
- Elderly, lymphoma, chemotherapy, radiation, performance status, 3251
- Elderly, pulmonary blastoma, lung malignancy, relapse, 3911
- Electrocardiography (ECG), breast cancer, adjuvant therapy, cardiotoxicity, radiotherapy, 4933
- Electron emission, testosterone, estrone, sex hormones, free radicals, hormone regeneration, carcinogenicity, 941
- Electroporation, dendritic cell vaccine, tumor lysate, solid tumor, 2971
- ELISA, caveolin-1, prostate cancer, progression, 1893
- Ellagic acid, hydrogel, glycine, folic acid, anti-oxidant, breast cancer, implant, 4847
- Ellagic acid, pro-oxidant, antioxidant, antiproliferative, apoptosis, H5C-2 oral carcinoma cells, 1829
- EMT, ADSC, H358 cells, tumor microenvironment, cancer-associated fibroblasts, α SMA, 4421
- EMT, CAFs, NFs, lung cancer, stromal NSCLC, direct co-culture, indirect co-culture, proliferation, SMAD3, Hedgehog signaling pathway, 3715
- EMT, cancer-associated fibroblasts, normal fibroblasts, NFs, lung cancer, NSCLC, co-culture, proliferation, SMAD3, 2001
- EMT, epithelial-mesenchymal transition, CSC, cancer stem cell, CD44, musashi, cadherin, 2867
- EMT, Nox4, TGF- β , pancreatic cancer, 4431
- EMT, tenascin-C, TNC, colorectal cancer, 1927
- EMT6 cells, fenbendazole, benzamidazoles, tumor microenvironments, radiation therapy, hypoxia, 355
- Emulsion, hepatocellular carcinoma, transcatheter arterial chemoembolization, miriplatin, suspension, 5603
- Encephalitis, herpes simplex virus-1, small cell lung cancer, radiation, immunosuppression, 3263
- Endocrine resistance, breast cancer, mTOR inhibitor, Everolimus, TemSirolimus, review, PI3K, AKT, 21
- Endometrial cancer, alcohol dehydrogenase isoenzymes, aldehyde dehydrogenase, alcohol metabolism, 3725
- Endometrial cancer, epithelial-mesenchymal transition, cancer stem cells, molecular markers, quantitative PCR, 5461
- Endometrial cancer, Immunohistochemistry, histological grade, estrogen receptor, progesteron receptor, Ki67, p53, predictive model, 2191
- Endometrial cancer, Lynch syndrome, ovarian cancer, synchronous tumour, microsatellite instability, 3977
- Endometrial carcinoma, baby boomers, early stage, obesity, outcome, prognosis, 619
- Endometrial carcinoma, baby boomers, early stage, SEER, survival, prognosis, 4983
- Endometrial carcinoma, cytoreductive surgery, late wound recurrence, hyperthermic intraperitoneal chemotherapy, 1041
- Endometrial carcinoma, E-cadherin, proliferation, 5091
- Endometrial carcinoma, *ESR1*, gene amplification, ER/PR, 3775
- Endometrial carcinoma, vaginal recurrence, radiotherapy, brachytherapy, 241
- Endometrial carcinoma, WT1, DC immunotherapy, uterine cancer, uterine sarcoma, 5495
- Endometrial neoplasm, clear cell adenocarcinoma, bladder tumor, pelvic exenteration, Mullerian tumour, 615
- Endoplasmic reticulum stress, breast cancer, zoledronic acid, mTOR, REDD1, MCF-7, MDA-MB-231 cells, 3807
- Endoplasmic reticulum, cancer, stress, unfolded protein response, molecular chaperones, activating transcription factor 6, PERK kinase, inositol requiring enzyme-1, review, 4683
- Endoscopic resection, gastric cancer, adhesion, laparoscopic gastrectomy, perforation, 4023

- Endosonographic evaluation, staging, mediastinal lymph nodes, surgical procedure, echoendoscope, review, 2369
- Environmental factors, gastric adenocarcinoma, gastric tumorigenesis, lifestyle factors, microRNA, socioeconomic factors, 3195
- Enzymatic activity, protein tyrosine phosphorylation, LMW-PTP isoforms, genotype, mRNA expression, 1983
- EOC, human epithelial ovarian cancer, mouse ovarian surface epithelium, MOSE, orthotopic ovarian cancer, immuno-competent C57BL/6, 1317
- Ependymoma, re-irradiation, pulsed reduced dose-rate radiotherapy, 2611
- Epidemiology, sarcoma, lesion, SEER, NCI, 2597
- Epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, erlotinib, non-small cell lung cancer, radiotherapy, 3279
- Epidermal growth factor receptor, aryl hydrocarbon receptor, non-small cell lung cancer, prognosis, 3953
- Epidermal growth factor receptor, E-cadherin, tyrosine kinase inhibitor, esophageal cancer, malignant pleural mesothelioma, epithelial to mesenchymal transition (EMT), 2401
- Epidermal growth factor receptor, lung cancer, gefitinib, molecular targeted drug, *EGFR* inhibitor, gefitinib, 5057
- Epidermal growth factor receptor, non-small lung cancer, erlotinib, gefitinib, acquired resistance to gefitinib, adverse events, 5083
- Epigallocatechin 3-gallate, epigenetics, EGCG, colon cancer, green tea, DNMT3A, HDAC3, 5325
- Epigenetics, DNA methylation, DNMT inhibitors, cancer therapy, review, 2989
- Epigenetics, EGCG, colon cancer, green tea, epigallocatechin 3-gallate, DNMT3A, HDAC3, 5325
- Epigenetics, prostate cancer, soy phytoestrogens, daidzein, genistein, diet, isoflavones, review, 39
- Epirubicin, oxaliplatin, capecitabine, docetaxel, cisplatin, 5-fluorouracil, G-CSF, gastroesophageal cancer, adenocarcinoma, 3455
- Epirubicin, oxaliplatin, capecitabine, gastroesophageal cancer, adenocarcinoma, 1035
- Epithelial mesenchymal transition (EMT), 5-FU, docetaxel, β -catenin, c-KIT, head and neck squamous cell carcinoma, extracellular matrix, protein tyrosine kinase, human papillomavirus (HPV), 2457
- Epithelial ovarian cancer, chemosensitivity, HDRA, histoculture drug response assay, taxol, carboplatin, prospective clinical trial, correlation, prediction, individualized therapy, 1029
- Epithelial to mesenchymal transition (EMT), E-cadherin, epidermal growth factor receptor, tyrosine kinase inhibitor, esophageal cancer, malignant pleural mesothelioma, 2401
- Epithelial-mesenchymal transition, cancer stem cells, molecular markers, quantitative PCR, endometrial cancer, 5461
- Epithelial-mesenchymal transition, EMT, CSC, cancer stem cell, CD44, musashi, cadherin, 2867
- Epithelioid, clear cell renal carcinoma, sarcomatoid differentiation, xenotransplantation, cell line and clonal sublines, de-differentiation, fibroblastoid, 4875
- Epstein Barr virus, low-grade B-cell lymphoma, rituximab, 5693
- EQD2, radiation therapy, cervical cancer, FIGO IVA, bladder invasion, rectum invasion, 4989
- Equine melanoma, IL-12, IFN- γ , bead-based-assay, 1325
- Equol, TRAIL, cervical cancer cells, caspases, death receptors, apoptosis, 903
- ER, breast cancer, TMA, PgR, *HER2*, Ki67, 2139
- ER/PR, *ESR1*, gene amplification, endometrial carcinoma, 3775
- ERCC1, chemoradiotherapy, lung cancer surgery, lung cancer biology, tubulin, TYMS, RRM1, 1107
- ERK 1/2, secretory phospholipase A2, esophageal adenocarcinoma, growth, proliferation, 1337
- ERK, cell signaling, U0126, CYP inhibitor, MEK/ERK inhibitor, colorectal cancer, HT29, HCT116, 2499
- Erlotinib, capecitabine, first-line treatment, metastases, pancreatic cancer, 717
- Erlotinib, *EGFR*-TKI resistance, amplification, copy-number alteration, CRKL, non-small cell lung cancer, 5223
- Erlotinib, epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, non-small cell lung cancer, radiotherapy, 3279
- Erlotinib, gefitinib, H23 cells, apoptosis, cell cycle arrest, c-MYC, 1547
- Erlotinib, non-small lung cancer, epidermal growth factor receptor, gefitinib, acquired resistance to gefitinib, adverse events, 5083
- Erlotinib, pemetrexed, adenocarcinoma, NSCLC, second-line, third-line, sequence, 3397
- ER-positive breast cancer, breast cancer, glutathione S-transferase P1 (GSTP1), DNA methylation, microdissection, 5617
- Erythroid differentiation, antiproliferative activity, piperazine derivatives, triphenyl derivatives, anticancer agents, 3027
- ER α , LATS2, breast cancer, estrogen receptor, NCoR, 53
- ESCC, RRAD, hypermethylation, EAC, 5199
- Esophageal adenocarcinoma, secretory phospholipase A2, growth, proliferation, ERK 1/2, 1337
- Esophageal cancer, anemia, chemoradiotherapy, nutrition, prognostic factor, 3495
- Esophageal cancer, body-mass index, smoking, alcohol, neoplasms, multiple primary tumors, colonoscopy, 5113

- Esophageal cancer, E-cadherin, epidermal growth factor receptor, tyrosine kinase inhibitor, malignant pleural mesothelioma, epithelial to mesenchymal transition (EMT), 2401
- Esophageal cancer, eicosapentaenoic acid, apoptosis, NF- κ B, cytokines, TE-1 cells, 4319
- Esophageal cancer, elderly patients, esophagectomy, 1641
- Esophageal cancer, gastric cancer, *EGFR*, trastuzumab, cetuximab, review, 4139
- Esophageal cancer, laparoscopic transhiatal approach, subcarinal and main bronchial lymph node dissection, 2577
- Esophageal cancer, minimally-invasive esophagectomy, outcome, 2085
- Esophageal cancer, phospho-histone H3, prognostic factor, 461
- Esophageal cancer, right aortic arch, thoracoscopic esophagectomy, prone position, 4515
- Esophageal cancer, right aortic arch, video-assisted thoracoscopic surgery (VATS), 1635
- Esophageal carcinoma, chemoradiotherapy, surgery, squamous cell, 1157
- Esophageal carcinoma, COX-2, 5-fluorouracil, cisplatin, chemosensitivity, gene transfer, TE13 cells, 537
- Esophageal carcinoma, IL-6, IL-8, invasiveness, KYSE170 cells, 1483
- Esophageal squamous cell carcinoma, combination chemotherapy, metastasis, old age, risk factors, taxane, 4123
- Esophageal squamous cell carcinoma, E2F5, cell proliferation, 5415
- Esophageal squamous cell carcinoma, *p21*, prognostic factor, 4329
- Esophageal squamous cell carcinoma, Ruthenium, microRNA-21, *PTEN*, *AKT*, 5407
- Esophageal squamous cell carcinoma, tumor IL-6, chemoradiotherapy, prognosis, 2699
- Esophagectomy, esophageal cancer, elderly patients, 1641
- Esophagogastric junctional carcinoma, Siewert type II adenocarcinoma, AJCC, TNM, JCGC, staging system, 3461
- Esophagus, *HER2*, survival, metastasis, 4975
- Esophagus, squamous cell carcinoma, definitive chemoradiotherapy, salvage esophagectomy, murine double minute 2, p16, Ki-67, 1463
- ESR1*, gene amplification, ER/PR, endometrial carcinoma, 3775
- Ester conjugate, fatty acid, anticancer agent, cytotoxicity, cancer cell lines, MDA-MB-361, MCF-7, MDA-MB-231, 2517
- Estrogen receptor, brousoflavonol B, cancer stem-like cells, 1873
- Estrogen receptor, endometrial cancer, Immunohistochemistry, histological grade, progesteron receptor, Ki67, p53, predictive model, 2191
- Estrogen receptor, LATS2, breast cancer, NCoR, ER α , 53
- Estrogen receptor, Y-box binding protein-1, transforming growth factor β , antiestrogen, resistance, 2473
- Estrogen, apoptosis, cisplatin, progesterone, A549 cells, lung cancer, 791
- Estrone, testosterone, sex hormones, free radicals, electron emission, hormone regeneration, carcinogenicity, 941
- Ethnicity, gastric cancer, chemoradiation, Israel, Ashkenazi, 5151
- Ethnicity, non-small cell lung cancer, chemotherapy, randomized phase 2, docetaxel, paclitaxel carboplatin, 4631
- Etoposide, anaplastic, glioblastoma multiforme, high-grade glioma, irinotecan, topotecan, teniposide, meta-analysis, 3307
- Etoposide, chemotherapeutic resistance, cisplatin, doxorubicin, nitric oxide, lung cancer, 5433
- Etoposide, interstitial lung disease, small cell lung cancer, chemotherapy, cisplatin, carboplatin, acute exacerbation, 1175
- Etoposide, lung cancer, panobinostat, carboplatin, 4475
- Everolimus, breast cancer, mTOR inhibitor, endocrine resistance, TemSirolimus, review, PI3K, *AKT*, 21
- Everolimus, kidney cancer, drug sequence, sorafenib, sunitinib, temisrolimus, 4999
- Everolimus, mTOR, phospho-mTOR, squamous cell carcinoma, basal cell carcinoma, Sirolimus, Immunohistochemistry, organ transplantation, immunosuppression, skin, 3711
- Everolimus, tyrosine kinase inhibitor, mTOR, PDGFR, HIF, head and neck squamous cell carcinoma, sorafenib, sunitinib, 5385
- Ex vivo* drug resistance, individualized tumor response testing, acute myeloid leukemia, children, relapse, minimal residual disease, 1189
- ExDP, extensive distal pancreatectomy, pancreatic body cancer, gastroduodenal artery, 267
- Exercise intervention, breast cancer, cardiovascular risk factors, health behavior, obesity, physical activity, physical health, 1595
- Expandable metallic stents, biliary tract neoplasms, brachytherapy, radiotherapy, Yridium radioisotopes, 2747
- Expansion, cryopreservation, feeder cells, K562, natural killer cell, 2011
- Expansion, redirected T-cells, anti-idiotypic antibody, NY-ESO-1, peptide specific, chimeric antigen receptor, 4189
- Experimental model, chemoprevention, lung cancer, tobacco carcinogens, combination therapy, acetylsalicylic acid, vitamin D, calcium, 4767
- Experimental model, chemoprevention, non-melanoma skin cancer, UV radiation-induced skin tumors, combination therapy, 3033

- Experimental therapeutics, ovarian cancer, sphingolipids, chemoresistance, sphingosine kinase-2, sphingosine-1-phosphate, ABC294640, BG-1, Caov-3 cells, 3573
- Extended field, induction chemotherapy, cervical metastases, radiotherapy, unknown primary tumor, 1135
- Extensive distal pancreatectomy, ExDP, pancreatic body cancer, gastroduodenal artery, 267
- Extensive-stage small cell lung cancer, alternating chemotherapy, amrubicin, irinotecan, cisplatin, 1117
- Extracellular matrix, 5-FU, docetaxel, β -catenin, c-KIT, head and neck squamous cell carcinoma, protein tyrosine kinase, human papillomavirus (HPV), epithelial mesenchymal transition (EMT), 2457
- Extracranial organs, brain metastasis, SCLC, prognostic factors, survival, 3887
- Extra-spinal organs, prostate cancer, metastatic spinal cord compression, irradiation, survival, prognosis, 4505
- Extravasation, HT-1080, fibrosarcoma, intravascular, GFP, RFP, mitosis, apoptosis, nude mice, confocal microscopy, 4229
- EZH2, BMI1, p53, human oral squamous cell carcinoma, 4309
- FAK, breast cancer, tissue microarray, 1169
- Fallopian-tube patency, chromopertubation, transurethral catheter, 1591
- FANCA gene, fanconi anemia, cytogenetic and molecular investigation, mutation, Greek patients, 3369
- FANCC, head and neck squamous cell carcinoma, *PTCH1*, radiotherapy, prognosis, tumor suppressor genes 9q22.3, 1215
- Fanconi anemia, FANCA gene, cytogenetic and molecular investigation, mutation, Greek patients, 3369
- FAS, breast cancer, circulating tumor cell, immunosurveillance, tumor cell dormancy, T-cell, 2233
- Fascin-1, ovarian cancer, expression, prognosis Immunohistochemistry, 371
- Fat mass, early breast cancer, docetaxel, obesity, dose intensity, toxicity, 5655
- Fatigue, cancer, physical activity, inpatient rehabilitation, dose response relationship, 3415
- Fatty acid, ester conjugate, anticancer agent, cytotoxicity, cancer cell lines, MDA-MB-361, MCF-7, MDA-MB-231, 2517
- Fatty acids, breast cancer, benign breast tumours, adipose tissue, diet, biomarkers, 1667
- Fatty acids, prostate cancer, proliferation, linoleate, 4395
- FDG, Non-Hodgkin lymphoma, positron-emission tomography, beta-2 microglobulin, 3341
- FDG-PET, carbon-ion radiotherapy, preoperative, distant metastasis, prognostic factor, 5579
- ^{18}F -FDG PET, pulmonary neuroendocrine tumor, GLUT1, hypoxia, angiogenesis, glucose metabolism, 4219
- ^{18}F -FDG, ^{68}Ga -DOTATOC, PET, SSTR2, immunohistochemistry, somatostatin analogs, 3015
- ^{18}F -FDG, lung cancer, PET, lymph nodes, 5193
- ^{18}F -FDG-PET/CT, renal cell carcinoma, hybrid imaging, prognosis, SUV_{max} , 2665
- Febrile neutropenia, chemotherapy-induced neutropenia, G-CSF, pegfilgrastim, secondary prophylaxis, 301
- Febrile neutropenia, soft tissue sarcomas, lenograstim, G-CSF, 679
- Fecal occult hemoglobin, colorectal cancer, analyzer evaluation, Kroma iT, 5633
- Feeder cells, cryopreservation, K562, natural killer cell, expansion, 2011
- Female, male, breast cancer, prognostic factors, survival, 2227
- Fenbendazole, benzamidazoles, tumor microenvironments, radiation therapy, hypoxia, EMT6 cells, 355
- Fermitin family, colon carcinoma, invasion, *FERMT1*, DNA microarray, 167
- FERMT1*, colon carcinoma, invasion, DNA microarray, fermitin family, 167
- Fibroblast, lung cancer, invasion, TGF-beta, TIG-3, LLC cells, 3791
- Fibroblast, peritoneal carcinomatosis, rat model, mesothelial cells, submesothelial layer, RCN-9 cells, 1439
- Fibroblastoid, clear cell renal carcinoma, sarcomatoid differentiation, xenotransplantation, cell line and clonal sublines, de-differentiation, epithelioid, 4875
- Fibrolipoma, nevus superficialis, nevus cutaneous, 3365
- Fibronectin, calcitonin, MG63 cells, matrix metalloproteinase 9, integrins. NF- κ B activation, 4901
- Fibronectin, α v integrin, green fluorescent protein, osteosarcoma, *in vitro*, *in vivo*, nude mouse, metastasis, real-time imaging, confocal microscopy, 3021
- Fibrosarcoma, cofilin-1, cofilin-2, progression, regression, 3661
- Fibrosarcoma, HT-1080, intravascular, extravasation, GFP, RFP, mitosis, apoptosis, nude mice, confocal microscopy, 4229
- 2-field lymph node dissection, thoracoscopic esophagectomy, lower thoracic esophageal cancer, 601
- FIGO IVA, radiation therapy, cervical cancer, bladder invasion, rectum invasion, EQD2, 4989
- Filling material, β -tricalcium phosphate, bone tumor, resorption, bone remodeling, 5075
- FIRIS, irinotecan, colorectal cancer, IRIS, S-1, 3845
- First-line treatment, capecitabine, erlotinib, metastases, pancreatic cancer, 717
- First-line, metastatic breast cancer, *HER2*-positive, oral chemotherapy, 2657
- Fish meal, gastritis, *Helicobacter pylori*, calcium, Mongolian gerbils, 3667
- FK506 binding protein, GNMT, FKBP11, FKBP19, HCC, 2763

- FKBP11, GNMT, FKBP19, FK506 binding protein, HCC, 2763
- FKBP19, GNMT, FKBP11, FK506 binding protein, HCC, 2763
- Flavanone, bladder carcinoma, antimetabolic agents, cell cycle, tubulin, 4445
- Flow cytometry, CK2 inhibitors, pentabromobenzylisothiouras, apoptosis, KG-1 cells, 4891
- FLT-PET/CT, orthotopic lung cancer model, 4741
- Fluctuation, CEA, chemotherapy, metastatic colorectal cancer, tumor flare, 253
- Fluorescence, glioma, U87, RFP, orthotopic, craniotomy window, imaging, surgery, survival, 107
- Fluorescent *in situ* hybridization, Inv(3)(q21q26), chromosomal abnormality, myeloid hemopathies, 639
- Fluorophore, *HER2*, antibody, rhodamine, breast cancer, 4T1, GFP, orthotopic model, lymph node, metastasis, imaging, 419
- Fluoropyrimidine metabolism, biomarkers, gastric cancer, *HER2*, DNA repair systems, apoptotic pathway, chemotherapy, targeted therapy, review, 1257
- Fluoropyrimidine, biliary tract cancer, irinotecan, refractory, gemcitabine, cisplatin, 2619
- 5-Fluorouracil, colorectal cancer, capecitabine, oxaliplatin, comparative effectiveness research, treatment effectiveness, cost effectiveness, 1053
- 5-Fluorouracil, epirubicin, oxaliplatin, capecitabine, docetaxel, cisplatin, G-CSF, gastroesophageal cancer, adenocarcinoma, 3455
- 5-Fluorouracil, esophageal carcinoma, COX-2, cisplatin, chemosensitivity, gene transfer, TE13 cells, 537
- 5-Fluorouracil, mucinous colorectal cancer, thymidylate synthase, topoisomerase-1, microsatellite instability, 4611
- 5-Fluorouracil, postoperative chemotherapy, colorectal liver metastasis, irinotecan, synchronous metastasis, oxaliplatin, leucovorin, FOLFOX, FOLFIRI, 3317
- Fluorouracil, chemotherapy, mitomycin-C, colon cancer, capecitabine, 2743
- Fluorouracil, gastric cancer, cannabinoids, drug resistance, apoptosis, 2541
- Fluorouracil, vascular endothelial growth factor, platelet-derived growth factor, PDGFR α/β , head and neck squamous cell carcinoma, docetaxel, 1951
- Fluoxetine, hepatocellular carcinoma, apoptosis, mitogen-activated protein kinase, Hep3B cells, 3691
- Focus, GFP, 53BP1, UVC, DNA damage, pancreatic cancer, 1373
- Folate, breast cancer, homocysteine, MTHFR, FTO, polymorphism, Kazakhstan, 4049
- Folate, colorectal cancer, tegafur-uracil, leucovorin, γ -glutamyl hydrolase (GGH), gene expression, 3431
- FOLFIRI, postoperative chemotherapy, colorectal liver metastasis, irinotecan, synchronous metastasis, oxaliplatin, 5-fluorouracil, leucovorin, FOLFOX, 3317
- FOLFORINOX, pancreatic adenocarcinoma, chemotherapy, gemcitabine, combined therapy, clinical trials, review, 1785
- FOLFOX, postoperative chemotherapy, colorectal liver metastasis, irinotecan, synchronous metastasis, oxaliplatin, 5-fluorouracil, leucovorin, FOLFIRI, 3317
- Folic acid, hydrogel, ellagic acid, glycine, anti-oxidant, breast cancer, implant, 4847
- Follicular carcinoma, papillary carcinoma, nicotinamide phosphoribosyltransferase, NAD⁺, SIRT3, 3047
- Follicular-patterned thyroid lesions, *HRAS*, *KRAS*, *NRAS* mutations, *KRAS* codon 59 deletion, *BRAF* mutations, 4779
- Follow-up, rectal cancer, preoperative, chemotherapy, outcome, Alimta, pemetrexed, 325
- Forearm, musculoskeletal tumor, hand, limb salvage, microsurgery, tissue transfer, review, 4175
- Fotemustine, chemotherapy, glioblastoma, low-dose, second-line therapy, 4013
- FOXP3, tonsillar squamous cell carcinoma, regulatory T-cell, HPV, p16, 5667
- Fractionation, lung cancer, stereotactic body radiotherapy, re-irradiation, 5649
- Frameless stereotactic radiosurgery, margin, image guidance, image-guided intervention, 4639
- Free radical, dihydroartemisinin, N-tert-butyl-alpha-phenylnitron, deferoxamine, Molt-4 cells, iron, 4389
- Free radicals, testosterone, estrone, sex hormones, electron emission, hormone regeneration, carcinogenicity, 941
- Fresh-frozen plasma, prognosis, pancreatic cancer, pancreatic resection, blood transfusion, post-operative recurrence, 4041
- Frozen section, breast cancer, Sentinel lymph node, intraoperative examination, imprint cytology, 1045
- FTO, breast cancer, folate, homocysteine, MTHFR, polymorphism, Kazakhstan, 4049
- 5-FU, docetaxel, β -catenin, c-KIT, head and neck squamous cell carcinoma, extracellular matrix, protein tyrosine kinase, human papillomavirus (HPV), epithelial mesenchymal transition (EMT), 2457
- 5-FU, PNET, capecitabine, chemoradiation, 2175
- Fucosylated fraction of alpha-fetoprotein, alpha-fetoprotein, early hepatocellular carcinoma, Gd-EOB-DTPA-enhanced MRI, 997
- Fullerenes, ultrasound, nanomedicine, sonodynamic therapy, sarcoma 180, colon 26, 3145
- Fusion, dendritic cell, cancer vaccine, antigen presentation, 347
- G2/M arrest, curcumin, human gallbladder adenocarcinoma, apoptosis, 1861
- ⁶⁸Ga-DOTATOC, 18F-FDG, PET, SSTR2, immunohistochemistry, somatostatin analogs, 3015

- Galectin-7, ovarian cancer, siRNA, prognosis, 1555
- Gallbladder carcinoma, cholangiocarcinoma, hepatic arterial infusion, 1201
- Gallbladder carcinoma, lymphocyte count, prognosis, operation, 3439
- Gambogic acid, dihydrofolate reductase, methotrexate, hepatoma, synergy, 133
- Gamma secretase, RO492907, melanoma, *PTEN*, 1307
- Gamma-secretase inhibitor, ovarian cancer, Notch, model, 801
- Gap junctions, SRC, STAT3, *in situ* electroporation, lung cancer, 4401
- GAPDH, 3-bromopyruvate, glucose metabolism, glycolysis, HCC, locoregional therapy, molecular targeting, review, 13
- Gas gangrene, clostridium septicum, distant myonecrosis, ovarian cancer, distant myonecrosis in ovarian cancer, 1585
- Gastric adenocarcinoma, DNA ploidy index, overall survival, prognostic factor, response to chemotherapy, 1209
- Gastric adenocarcinoma, environmental factors, gastric tumorigenesis, lifestyle factors, microRNA, socioeconomic factors, 3195
- Gastric adenocarcinoma, Immunohistochemistry, (Smac) DIABLO, AIF, cytochrome *c*, 647
- Gastric cancer cell lines, paclitaxel-resistance, peritoneal metastasis, *in vivo* selection, gene expression profile, 4299
- Gastric cancer, adjuvant chemotherapy, S-1, recurrence, 1747
- Gastric cancer, atrophic gastritis, antrum, corpus, *Helicobacter pylori*, risk factors, biomarker panel, pepsinogens, gastrin-17, achlorhydria, blood test, 4595
- Gastric cancer, biomarkers, *HER2*, DNA repair systems, fluoropyrimidine metabolism, apoptotic pathway, chemotherapy, targeted therapy, review, 1257
- Gastric cancer, cannabinoids, fluorouracil, drug resistance, apoptosis, 2541
- Gastric cancer, chemoradiation, ethnicity, Israel, Ashkenazi, 5151
- Gastric cancer, endoscopic resection, adhesion, laparoscopic gastrectomy, perforation, 4023
- Gastric cancer, esophageal cancer, *EGFR*, trastuzumab, cetuximab, review, 4139
- Gastric cancer, irinotecan, mitomycin C, chemotherapy, 5107
- Gastric cancer, long non-coding RNAs, plasma, biomarker, 3185
- Gastric cancer, microRNA, plasma, biomarker, prognosis, circulating nucleic acids, miR-21, 271
- Gastric cancer, *NAT2*, cancer susceptibility, SNP, IAM, breast cancer, 3683
- Gastric cancer, paclitaxel, 5'-DFUR, phase II study, 2629
- Gastric cancer, paclitaxel, second-line therapy, 4547
- Gastric cancer, postoperative follow-up, nodal status, DFS, recurrence, 4645
- Gastric cancer, ribosomal protein S6 kinase, RPS6KB2, gene amplification, S6K2 mTOR signaling, 469
- Gastric cancer, single nucleotide polymorphism, VEGF, *VEGFR*, sunitinib, biliary tract cancer, 4619
- Gastric cancer, splenectomy, lymph node metastasis, 277
- Gastric cancer, total gastrectomy, oesophagojejunal anastomosis, stapling devices, minimally-invasive surgical technique, 3269
- Gastric cancer, tumour marker, surveillance, recurrence, chemotherapy, CA19-9, 1621
- Gastric cancer, urocortin, corticotrophin-releasing factor receptors, STKM-1 cell line, 5289
- Gastric gastrointestinal stromal tumor, gastric, GIST, meta-analysis, laparoscopy-assisted surgery, 5031
- Gastric tumorigenesis, environmental factors, gastric adenocarcinoma, lifestyle factors, microRNA, socioeconomic factors, 3195
- Gastric, gastric gastrointestinal stromal tumor, GIST, meta-analysis, laparoscopy-assisted surgery, 5031
- Gastrin, adjuvant chemotherapy, breast cancer, dyspepsia, ghrelin, leptin, motilin, pepsinogens, 4951
- Gastrin-17, gastric cancer, atrophic gastritis, antrum, corpus, *Helicobacter pylori*, risk factors, biomarker panel, pepsinogens, achlorhydria, blood test, 4595
- Gastritis, *Helicobacter pylori*, fish meal, calcium, Mongolian gerbils, 3667
- Gastroduodenal artery, extensive distal pancreatectomy, ExDP, pancreatic body cancer, 267
- Gastroenteropancreatic neuroendocrine tumor, pancreatic neuroendocrine tumor, ectopic ACTH syndrome, Cushing's syndrome, 4001
- Gastroesophageal cancer, epirubicin, oxaliplatin, capecitabine, adenocarcinoma, 1035
- Gastroesophageal cancer, epirubicin, oxaliplatin, capecitabine, docetaxel, cisplatin, 5-fluorouracil, G-CSF, adenocarcinoma, 3455
- Gastrointestinal stromal tumor, xenograft, mouse, imatinib, sunitinib, 175
- Gastrointestinal tumors, prokineticin 1, 5311
- Gastro-oesophageal cancer, brain metastases, GI cancer, molecules, targeted therapy, 1065
- GBM, phase II trial, perillyl alcohol, intranasal administration, glioma, glioblastoma multiforme, 5625
- GcMAF, degalactosylated/desialylated human serum, macrophage phagocytic activity, *in vivo* antitumor activity, 2881
- GcMAF, immunotherapy, hyper T/NK cells, high-dose vitamin C, alpha lipoic acid, 2917
- G-CSF, chemotherapy-induced neutropenia, febrile neutropenia, pegfilgrastim, secondary prophylaxis, 301
- G-CSF, epirubicin, oxaliplatin, capecitabine, docetaxel, cisplatin, 5-fluorouracil, gastroesophageal cancer, adenocarcinoma, 3455

- G-CSF, soft tissue sarcomas, febrile neutropenia, lenograstim, 679
- Gd-EOB-DTPA-enhanced MRI, alpha-fetoprotein, fucosylated fraction of alpha-fetoprotein, early hepatocellular carcinoma, 997
- Gefitinib, epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, non-small cell lung cancer, radiotherapy, 3279
- Gefitinib, erlotinib, H23 cells, apoptosis, cell cycle arrest, c-MYC, 1547
- Gefitinib, lung cancer, epidermal growth factor receptor, gefitinib, molecular targeted drug, *EGFR* inhibitor, 5057
- Gefitinib, lung cancer, epidermal growth factor receptor, molecular targeted drug, *EGFR* inhibitor, gefitinib, 5057
- Gefitinib, non-small lung cancer, epidermal growth factor receptor, erlotinib, acquired resistance to gefitinib, adverse events, 5083
- Gelfoam[®], green fluorescent protein, blood vessels, nestin, angiogenesis, anastomosis, red fluorescent protein, transgenic nude mice, confocal microscopy, color-coded imaging, vascularization, 3041
- Gelfoam[®], α v integrin, green fluorescent protein, blood vessels, red fluorescent protein, osteosarcoma, transgenic nude mouse, confocal microscopy, 1361
- Gemcitabine, advanced non-small cell lung cancer, non-platinum triplet chemotherapy, UFT, vinorelbine, 1163
- Gemcitabine, biliary tract cancer, irinotecan, refractory, cisplatin, fluoropyrimidine, 2619
- Gemcitabine, capecitabine, colorectal cancer, refractory, 4089
- Gemcitabine, DDX39, pancreatic cancer, drug-resistant KLM1 cells, 3133
- Gemcitabine, Kaposi's sarcoma, chemotherapy, case series, 5531
- Gemcitabine, leiomyosarcoma, chemotherapy, mesocolic, paclitaxel, recurrence, 2929
- Gemcitabine, pancreatic adenocarcinoma, chemotherapy, FOLFORINOX, combined therapy, clinical trials, review, 1785
- Gemcitabine, pancreatic ductal adenocarcinoma, hyperbaric oxygen therapy, apoptotic index, PANC-1, AsPc-1 cells, 4827
- Gemcitabine, pancreatic neoplasm, indole-3-carbinol, microRNA, chemotherapy, Panc-1 cells, 1473
- Gemcitabine, peroxiredoxin, pancreatic cancer, drug resistance, 4821
- Gene amplification, *ESR1*, ER/PR, endometrial carcinoma, 3775
- Gene amplification, pemetrexed, thymidylate synthase, non-small cell lung cancer, 1935
- Gene amplification, ribosomal protein S6 kinase, RPS6KB2, gastric cancer, S6K2 mTOR signaling, 469
- Gene amplification, screen-detected breast carcinoma, screening, *HER2*, targeted therapy, cost-effectiveness, 3705
- Gene expression profile, gastric cancer cell lines, paclitaxel-resistance, peritoneal metastasis, *in vivo* selection, 4299
- Gene expression, colorectal cancer, prognostic markers, 4855
- Gene expression, colorectal cancer, tegafur-uracil, leucovorin, folate, γ -glutamyl hydrolase (GGH), 3431
- Gene expression, dendritic cells, interleukin-10, differentiation, 4791
- Gene expression, olive oil, polyunsaturated fatty acids (PUFAs), colorectal cancer, lipid metabolism, 3739
- Gene expression, prostatic neoplasms, carcinoma, diagnostic markers, urine, 191
- Gene expression, rhabdomyosarcoma, PAX3-FOXO1, growth suppression, 2029
- Gene expression, tumor tissue, muscle tissue, histology, 5213
- Gene therapy, EAG1, glioma, glioblastoma multiforme, RNAi, IFN- γ , 865
- Gene therapy, hepatocellular carcinoma (HCC), intravenous intra-arterial, intra-tumoral, intra-portal, intra-biliary injection, delivery approach, review, 4711
- Gene transfer, esophageal carcinoma, COX-2, 5-fluorouracil, cisplatin, chemosensitivity, TE13 cells, 537
- Gene, vitamin D, sunlight, polymorphisms, breast cancer, case-control, 543
- Genomics, oral cancer, squamous cell carcinoma, miRNA expression, 1511
- Genotype, *ATM*, polymorphism, lung cancer, smoking, 4067
- Genotype, *CAVI*, polymorphism, upper urothelial track cancer, 4907
- Genotype, caveolin-1, hepatocellular carcinoma, polymorphism, real-time quantitative reverse transcription, western blot, 671
- Genotype, Cox-2, polymorphism, bladder cancer, 5401
- Genotype, protein tyrosine phosphorylation, LMW-PTP isoforms, mRNA expression, enzymatic activity, 1983
- Genotype, *XRCC6/Ku70*, non-homologous end-joining, hepatocellular carcinoma, polymorphism, real-time quantitative reverse transcription, Immunohistochemistry, 529
- Genotyping, *XRCC6/Ku70*, non-homologous end-joining, childhood leukemia, polymorphisms, 5395
- German gynaecologists, survey, uterine sarcoma, 3375
- GFP, 53BP1, focus, UVC, DNA damage, pancreatic cancer, 1373
- GFP, *HER2*, antibody, fluorophore, rhodamine, breast cancer, 4T1, orthotopic model, lymph node, metastasis, imaging, 419
- GFP, HT-1080, fibrosarcoma, intravascular, extravasation, RFP, mitosis, apoptosis, nude mice, confocal microscopy, 4229

- GFP, RFP, apoptosis, mitosis, subcellular dynamics, brain cancer, mouse models, temozolomide, *in vivo* imaging, 103
- GFP, RFP, mitosis, subcellular dynamics, brain cancer, brain metastasis, mouse model, craniotomy window, *in vivo* imaging, 1367
- GFP, *Salmonella typhimurium* A1-R, TCM, tumor targeting, combination, Lewis lung carcinoma, RFP, C57/BL6 mice, 1837
- GFP, *Salmonella typhimurium*, auxotroph, leucine, arginine, tumor-targeting, primer dosing, high dose, Lewis lung carcinoma, immunocompetent mice syngeneic mouse model, 97
- GFP, VEGF-C, ShRNA, pancreatic cancer, nude mice, orthotopic, 409
- Ghrelin, adjuvant chemotherapy, breast cancer, dyspepsia, gastrin, leptin, motilin, pepsinogens, 4951
- GI cancer, brain metastases, gastro-oesophageal cancer, molecules, targeted therapy, 1065
- Giant cell tumor of bone, peroxisome proliferator-activated receptor gamma (PPAR γ), apoptosis, 2169
- GIST, gastric gastrointestinal stromal tumor, gastric, meta-analysis, laparoscopy-assisted surgery, 5031
- GIST, mesenchymal tumor, sarcoma, spindle cell, round cell, pseudopapillary, 991
- GIST, SILS, intragastric, oncologic surgery, 3359
- Glasgow prognostic score, colorectal cancer, stage IV, asymptomatic primary tumor, palliative surgery, neutrophil to lymphocyte ratio, 5567
- Glasgow prognostic score, colorectal liver metastases, surgical site infection, systemic inflammatory response, 1697
- Glasgow prognostic score, prognosis, pancreaticoduodenectomy, carcinoma of the ampulla of Vater, 2715
- Gleason Score, prostate cancer, PCA3, radical prostatectomy, 4657
- GLI1, intrahepatic cholangiocarcinoma, hepatic resection, cancer stem cells, CD44, 2107
- Glioblastoma multiforme IV, astrocytoma, brain neoplasms, PTTG, pituitary tumor-transforming gene, 119
- Glioblastoma multiforme, anaplastic, high-grade glioma, etoposide, irinotecan, topotecan, teniposide, meta-analysis, 3307
- Glioblastoma multiforme, bevacizumab, temSirolimus, phase II study, PI3K, protein kinase B (AKT), mTOR, rapamycin, 1657
- Glioblastoma multiforme, EAG1, glioma, RNAi, IFN- γ , gene therapy, 865
- Glioblastoma multiforme, hypoxic radiosensitizer, intensity-modulated radiation therapy, simultaneous integrated boost, case report, 1685
- Glioblastoma multiforme, phase II trial, perillyl alcohol, intranasal administration, glioma, GBM, 5625
- Glioblastoma, characterization, immunotherapy, tumor-associated antigens, U251, U87, U343 cells, 2525
- Glioblastoma, chemotherapy, relapse, sorafenib, temozolomide, 3487
- Glioblastoma, *EGFR* amplification, *EGFRvIII*, polysomy 7p, 5343
- Glioblastoma, fotemustine, chemotherapy, low-dose, second-line therapy, 4013
- Glioblastoma, HDAC inhibition, antitumor immunity, 1351
- Glioblastoma, lobarstin, temozolomide, chemosensitivity, DNA repair, 5445
- Glioblastoma, RAD001, temozolomide, autophagy, γ -radiation, 1845
- Glioblastoma, temozolomide, radiochemotherapy, prolonged adjuvant therapy, 3467
- Glioma stem cell, apoptosis, CD95 ligand, temozolomide, 3563
- Glioma, EAG1, glioblastoma multiforme, RNAi, IFN- γ , gene therapy, 865
- Glioma, KSP inhibitors, LaSOM 65, antitumor activity, 4463
- Glioma, phase II trial, perillyl alcohol, intranasal administration, GBM, glioblastoma multiforme, 5625
- Glioma, U87, RFP, orthotopic, craniotomy window, imaging, fluorescence, surgery, survival, 107
- GLP, capecitabine, metabolites, 5'-DFCR, 5'-DFUR, pharmacokinetics, HPLC, 881
- Glucose metabolism, ^{18}F -FDG PET, pulmonary neuroendocrine tumor, GLUT1, hypoxia, angiogenesis, 4219
- Glucose metabolism, 3-bromopyruvate, GAPDH, glycolysis, HCC, locoregional therapy, molecular targeting, review, 13
- GLUT1, ^{18}F -FDG PET, pulmonary neuroendocrine tumor, hypoxia, angiogenesis, glucose metabolism, 4219
- Γ -glutamyl hydrolase (GGH), colorectal cancer, tegafur-uracil, leucovorin, folate, gene expression, 3431
- Glutathione depletion, substituted 6-chloropurines, carbocyclic nucleoside analogs, glutathione-S-transferase, 3163
- Glutathione S-transferase P1 (GSTP1), breast cancer, DNA methylation, microdissection, ER-positive breast cancer, 5617
- Glutathione, acetaminophen, chemo-enhancement, cisplatin, ovarian cancer, SKOV3 cells, 2391
- Glutathione-S-transferase, substituted 6-chloropurines, carbocyclic nucleoside analogs, glutathione depletion, 3163
- Glycine, hydrogel, ellagic acid, folic acid, anti-oxidant, breast cancer, implant, 4847
- Glycolysis, 3-bromopyruvate, GAPDH, glucose metabolism, HCC, locoregional therapy, molecular targeting, review, 13
- Glycolytic enzymes, oncogenes, signaling pathways, transcription factors, tumor suppressor genes, Warburg effect, review, 2855

- Glycosylation, apoptosis, invasion, lectin, prognosis, 3053
GNMT, FKBP11, FKBP19, FK506 binding protein, HCC, 2763
- Goblet cell carcinoid; colon, renal transplant, adenocarcinoma, 1753
- (–)Gossypol-enriched cottonseed oil, proliferation, adipogenesis, human breast pre-adipocytes, 949
- Granule formulation, head and neck cancer, S-1, nedaplatin, phase I study, 5699
- Greece, HPV, E6, E7, 4007
- Greek patients, fanconi anemia, FANCA gene, cytogenetic and molecular investigation, mutation, 3369
- Green fluorescent protein, blood vessels, nestin, angiogenesis, anastomosis, red fluorescent protein, Gelfoam[®], transgenic nude mice, confocal microscopy, color-coded imaging, vascularization, 3041
- Green fluorescent protein, lung cancer, mouse mode, bone marrow-derived cells, 831
- Green fluorescent protein, α v integrin, blood vessels, red fluorescent protein, Gelfoam[®], osteosarcoma, transgenic nude mouse, confocal microscopy, 1361
- Green fluorescent protein, α v integrin, osteosarcoma, fibronectin, *in vitro*, *in vivo*, nude mouse, metastasis, real-time imaging, confocal microscopy, 3021
- Green fluorescent protein, $\alpha_v\beta_3$ integrin, overexpression, red fluorescent protein, osteosarcoma, nude mice, lung metastasis, passage, variants, 3623
- Green tea, epigenetics, EGCG, colon cancer, epigallocatechin 3-gallate, DNMT3A, HDAC3, 5325
- Growth factor, *HMGA2* expression, proliferation, PC-3 cell line, prostate cancer, 3069
- Growth suppression, rhabdomyosarcoma, PAX3–FOXO1, gene expression, 2029
- Growth, BMP10, urothelial cancer of bladder, motility and adhesion, T24 cells, 1917
- Growth, secretory phospholipase A2, esophageal adenocarcinoma, proliferation, ERK 1/2, 1337
- Growth-inhibitory factor, non-small cell lung cancer, metallothionein, 965
- GS-9219, ADAL, deamination, PMEG, 1899
- Gynecological cancer, brachytherapy, high dose rate, late vaginal mucosal reaction, stenosis, pallor reaction, 3963
- Gynecological cancer, brachytherapy, high dose rate, late vaginal mucosal reaction, interstitial brachytherapy, re-irradiation, 5687
- Gynecological cancer, metronomic topotecan, pazopanib, drug drug interaction, pharmacokinetics, 3823
- H23 cells, gefitinib, erlotinib, apoptosis, cell cycle arrest, c-MYC, 1547
- H23, metastasis, migration, invasion, artonin E, lung cancer cells, H460, A549, H292 cells, 3079
- H292 cells, metastasis, migration, invasion, artonin E, lung cancer cells, H460, H23, A549, 3079
- H358 cells, ADSC, EMT, tumor microenvironment, cancer-associated fibroblasts, α SMA, 4421
- H460, metastasis, migration, invasion, artonin E, lung cancer cells, H23, A549, H292 cells, 3079
- H5C-2 oral carcinoma cells, ellagic acid, pro-oxidant, antioxidant, antiproliferative, apoptosis, 1829
- HaCaT, citric acid, cell cycle, apoptosis, cytotoxic effect, 4411
- Haematopoietic malignancies, ZFAT, transcription factor, haematopoietic system, angiogenesis, TAL1, review, 2833
- Haematopoietic system, ZFAT, transcription factor, angiogenesis, haematopoietic malignancies, TAL1, review, 2833
- HAI-1, castration-resistant prostate cancer, CRPC, prostate cancer, 575
- Hamster cheek pouch, chemoprevention, oral cancer, strawberries, 4757
- Hand, musculoskeletal tumor, forearm, limb salvage, microsurgery, tissue transfer, review, 4175
- Haplotype, *IL10*, prognosis, squamous cell carcinoma, adenocarcinoma, lung cancer, 2729
- HAVcR-1, hepatitis A virus cellular receptor-1, colorectal cancer, prognosis, invasion, 207
- HCC, 3-bromopyruvate, GAPDH, glucose metabolism, glycolysis, locoregional therapy, molecular targeting, review, 13
- HCC, celecoxib, sorafenib, AKT, apoptosis, hepatocellular carcinoma, synergism, 1387
- HCC, GNMT, FKBP11, FKBP19, FK506 binding protein, 2763
- HCC, hepatocellular carcinoma, immunotherapy, interleukin-2, IL-2, BCG, melatonin, 4531
- HCC, image-guided thermal ablation, microwave ablation, 1221
- HCC, VEGF, HCV infection, tumor marker, carcinogenesis, 1013
- HCG β , lentiviral siRNA, bladder carcinoma, silencing, stable gene knockdown SCaBER cells, 3611
- HCT116, cell signaling, ERK, U0126, CYP inhibitor, MEK/ERK inhibitor, colorectal cancer, HT29, 2499
- HCV infection, VEGF, tumor marker, HCC, carcinogenesis, 1013
- HDAC inhibition, glioblastoma, antitumor immunity, 1351
- HDAC3, epigenetics, EGCG, colon cancer, green tea, epigallocatechin 3-gallate, DNMT3A, 5325
- HDRA, chemosensitivity, histoculture drug response assay, epithelial ovarian cancer, taxol, carboplatin, prospective clinical trial, correlation, prediction, individualized therapy, 1029
- HE4, borderline ovarian tumors, ovarian cancer, 1673
- Head and neck cancer, brachytherapy, recurrence, 249

- Head and neck cancer, clinical predictors, swallowing disorder, dysphagia, post-surgical screening, 3347
- Head and neck cancer, dysphagia, swallowing disorder, postsurgical, screening, 4017
- Head and neck cancer, HIV, viral load, CD4, squamous cell carcinoma, radiation therapy, IMRT, chemotherapy, concurrent chemoradiotherapy, 5511
- Head and neck cancer, keratinocytes, differential regulation, PAI-1, uPA, 3113
- Head and neck cancer, micrometastasis, lymph node, laryngeal cancer, probability, 3213
- Head and neck cancer, PET, MRI, 1141
- Head and neck cancer, S-1, nedaplatin, phase I study, granule formulation, 5699
- Head and neck cancer, squamous cell carcinoma, collagen I, phosphoinositol-3 kinase, MD-1483 cells, 379
- Head and neck carcinoma, neopterin, radiotherapy, toxicity, 4097
- Head and neck carcinoma, squamous, ubiquitination, ubiquitin-proteasome system, ubiquitin ligases, carcinogenesis, review, 3527
- Head and neck squamous cell carcinoma (HNSCC), Hedgehog pathway, cyclopamine, cisplatin, docetaxel, synergism, 2415
- Head and neck squamous cell carcinoma, 5-FU, docetaxel, β -catenin, c-KIT, extracellular matrix, protein tyrosine kinase, human papillomavirus (HPV), epithelial mesenchymal transition (EMT), 2457
- Head and neck squamous cell carcinoma, *FANCC*, *PTCHI*, radiotherapy, prognosis, tumor suppressor genes 9q22.3, 1215
- Head and neck squamous cell carcinoma, tyrosine kinase inhibitor, mTOR, PDGFR, HIF, Everolimus, sorafenib, sunitinib, 5385
- Head and neck squamous cell carcinoma, vascular endothelial growth factor, platelet-derived growth factor, PDGFR α/β , docetaxel, fluorouracil, 1951
- Head and neck, *miR-146a*, polymorphism, squamous cell carcinoma, 341
- Health behavior, breast cancer, exercise intervention, cardiovascular risk factors, obesity, physical activity, physical health, 1595
- Health economics, mesothelioma, chemotherapy, pemetrexed, treatment outcome, quality of life, review, 3553
- Health, intestinal macrophage, intestinal microbiota, homeostasis, disease, review, 2849
- Heat-shock pre-treatment, heat-shock protein, liver regeneration, mouse model, hepatectomy, 2887
- Heat-shock protein HSPB1, androgen receptor, isoform, microRNA miR-1, 4921
- Heat-shock protein, heat-shock pre-treatment, liver regeneration, mouse model, hepatectomy, 2887
- Hedgehog pathway, head and neck squamous cell carcinoma (HNSCC), cyclopamine, cisplatin, docetaxel, synergism, 2415
- Hedgehog signaling pathway, CAFs, NFs, lung cancer, stromal NSCLC, direct co-culture, indirect co-culture, EMT, proliferation, SMAD3, 3715
- Helical tomotherapy, stereotactic body radiotherapy (SBRT), pulmonary neoplasms, metastatic lung cancer, 655
- Helicobacter pylori*, gastric cancer, atrophic gastritis, antrum, corpus, risk factors, biomarker panel, pepsinogens, gastrin-17, achlorhydria, blood test, 4595
- Helicobacter pylori*, gastritis, fish meal, calcium, Mongolian gerbils, 3667
- Helix-loop-helix, inhibitor of differentiation, inhibitor of DNA binding, ID1, ID2, qPCR, breast cancer, cell cycle, 2179
- Hematopoietic stem cell transplantation, chronic myeloid leukemia, tyrosine kinase inhibitor, imatinib, allotransplantation, 4663
- Hematuria, second malignancy, bladder cancer, urinary tract malignancy, repeat evaluation, screening, 5525
- Hemodialysis, upper tract urothelial carcinoma, p53, immuno-histochemistry, prognosis, 1091
- Hep3B cells, fluoxetine, hepatocellular carcinoma, apoptosis, mitogen-activated protein kinase, 3691
- Hepatectomy, heat-shock protein, heat-shock pre-treatment, liver regeneration, mouse model, 2887
- Hepatectomy, hepatocellular carcinoma, transarterial chemoembolization, repeat hepatectomy, long-term survival, 5097
- Hepatic and intestinal, pharmacokinetic interaction, ondansetron, tamoxifen, CYP2D, CYP3A1/2, DMBA rats, 521
- Hepatic arterial infusion chemotherapy, hepatocellular carcinoma, adjuvant chemotherapy, 5585
- Hepatic arterial infusion, cholangiocarcinoma, gallbladder carcinoma, 1201
- Hepatic metastasis, pancreatic neuroendocrine tumors, transcatheter arterial chemoembolization, chemotherapy, 3355
- Hepatic resection, blood transfusion, prognosis, colorectal cancer, liver metastasis, 2723
- Hepatic resection, C-reactive protein, hepatocellular carcinoma, 705
- Hepatic resection, intrahepatic cholangiocarcinoma, cancer stem cells, CD44, GLI1, 2107
- Hepatitis A virus cellular receptor-1, HAVcR-1, colorectal cancer, prognosis, invasion, 207
- Hepatitis B core antigen antibody, non-B non-C hepatocellular carcinoma, curative therapy, overall survival, recurrence-free survival, 2211
- Hepatocarcinoma, trehalose, liposome, apoptosis, Hep-G2, HuH-7 cells, 4727

- Hepatocellular carcinoma (HCC), boron neutron capture therapy (BNCT), boric acid, therapeutic efficacy, tumor size, blood vessels, 4799
- Hepatocellular carcinoma (HCC), gene therapy, intravenous intra-arterial, intra-tumoral, intra-portal, intra-biliary injection, delivery approach, review, 4711
- Hepatocellular carcinoma, adjuvant chemotherapy, hepatic arterial infusion chemotherapy, 5585
- Hepatocellular carcinoma, anatomical hepatectomy, surgery, preserved liver function, ICG-R15, 1689
- Hepatocellular carcinoma, animal model, rat, chemoembolization, 223
- Hepatocellular carcinoma, caveolin-1, polymorphism, genotype, real-time quantitative reverse transcription, western blot, 671
- Hepatocellular carcinoma, celecoxib, sorafenib, AKT, apoptosis, synergism, HCC, 1387
- Hepatocellular carcinoma, chemoembolization, blood oxygen level-dependent MRI, 1887
- Hepatocellular carcinoma, *c-MET*, hepatocyte growth factor (*HGF*), 3241
- Hepatocellular carcinoma, *c-MET*, Immunohistochemistry, copy number variation, prognosis, 5179
- Hepatocellular carcinoma, C-reactive protein, hepatic resection, 705
- Hepatocellular carcinoma, C-reactive protein, surgical resection, prognostic factor, 1181
- Hepatocellular carcinoma, fluoxetine, apoptosis, mitogen-activated protein kinase, Hep3B cells, 3691
- Hepatocellular carcinoma, HCC, immunotherapy, interleukin-2, IL-2, BCG, melatonin, 4531
- Hepatocellular carcinoma, hepatectomy, transarterial chemoembolization, repeat hepatectomy, long-term survival, 5097
- Hepatocellular carcinoma, percutaneous ethanol injection, survival, transcatheter arterial chemoembolization, Child-Pugh score, aspartate aminotransferase, 5171
- Hepatocellular carcinoma, peritracheal lymph node metastasis, tracheal obstruction, stent, 1761
- Hepatocellular carcinoma, phase I, sorafenib, orthotopic liver transplantation, adjuvant therapy, 2797
- Hepatocellular carcinoma, PIVKA-II, NX-PVKA-R, post-curative treatment change, disease-free survival, protein-induced vitamin K absence or antagonist-II, 2689
- Hepatocellular carcinoma, recurrence, survival, treatment modality, 4129
- Hepatocellular carcinoma, single nucleotide polymorphism, thioredoxin domain-containing-5, Korean, male population, 3983
- Hepatocellular carcinoma, sorafenib, metabolic ¹⁸⁸Rhenium, radiotherapy, synergy, N1S1, HepG2 cells, 3871
- Hepatocellular carcinoma, sorafenib, RAF kinases, short-term culture, tumour fragments, 1415
- Hepatocellular carcinoma, transcatheter arterial chemoembolization, miriplatin, suspension, emulsion, 5603
- Hepatocellular carcinoma, *XRCC6/Ku70*, non-homologous end-joining, polymorphism, genotype, real-time quantitative reverse transcription, Immunohistochemistry, 529
- Hepatocyte growth factor (*HGF*), *c-MET*, hepatocellular carcinoma, 3241
- Hepatocyte growth factor, *HGF* transgenic mice, lung tumor, c-Met, diethylnitrosamine, 895
- Hepatoma formation, chitosan, lung metastasis, xenograft models, 4867
- Hepatoma, gambogic acid, dihydrofolate reductase, methotrexate, synergy, 133
- Hep-G2, trehalose, liposome, hepatocarcinoma, apoptosis, HuH-7 cells, 4727
- HER-2 oncoprotein, breast cancer, SKBR-3 cells, trastuzumab resistance, proteomics, 489
- HER2* polymorphism, alcohol, trastuzumab, cardiac risk factors, 2569
- HER2*, antibody, fluorophore, rhodamine, breast cancer, 4T1, GFP, orthotopic model, lymph node, metastasis, imaging, 419
- HER2*, artemisinin, transferrin, breast cancer, survivin, c-Myc, cyclin D1, DV145, MCF7 cells, 123
- HER2*, biomarkers, gastric cancer, DNA repair systems, fluoropyrimidine metabolism, apoptotic pathway, chemotherapy, targeted therapy, review, 1257
- HER-2, breast cancer, locally advanced tumor, brain metastasis, neoadjuvant chemotherapy, pathological complete response, radiation, prophylactic cranial irradiation, 5119
- HER2*, breast cancer, phosphorylation, trastuzumab, 2509
- HER2*, breast cancer, TMA, ER, PgR, Ki67, 2139
- HER2*, esophagus, survival, metastasis, 4975
- HER2*, MALDI, breast cancer, lipid, profiles, 2467
- HER2*, screen-detected breast carcinoma, screening, gene amplification, targeted therapy, cost-effectiveness, 3705
- HER2*, trastuzumab, cardiotoxicity, breast cancer, 1717
- HER2/neu*, salivary ductal carcinoma, molecular-targeted therapy, trastuzumab, 2587
- HER2*-positive, metastatic breast cancer, first-line, oral chemotherapy, 2657
- Herniarin, high-performance counter current chromatography, umbelliferone, scoparone, laryngeal cancer cells, proliferation, migration, cell cycle, apoptosis, 4347
- Herpes simplex virus-1, encephalitis, small cell lung cancer, radiation, immunosuppression, 3263
- HGF* transgenic mice, hepatocyte growth factor, lung tumor, c-Met, diethylnitrosamine, 895
- HIF, leukaemia, echinomycin, NOTCH, NB4, Jurkat cells, 3099

- HIF, tyrosine kinase inhibitor, mTOR, PDGFR, head and neck squamous cell carcinoma, Everolimus, sorafenib, sunitinib, 5385
- High dose rate, brachytherapy, gynecological cancer, late vaginal mucosal reaction, stenosis, pallor reaction, 3963
- High dose rate, brachytherapy, gynecological cancer, late vaginal mucosal reaction, interstitial brachytherapy, re-irradiation, 5687
- High dose, *Salmonella typhimurium*, auxotroph, leucine, arginine, GFP, tumor-targeting, primer dosing, Lewis lung carcinoma, immunocompetent mice syngeneic mouse model, 97
- High grade glioma, pediatric neuro-oncology, dendritic cell vaccine, immunotherapy, 2047
- High-affinity human copper transporter 1 (hCtr1), cisplatin, copper chelator, review, 4157
- High-dose vitamin C, immunotherapy, GcMAF, hyper T/NK cells, alpha lipoic acid, 2917
- High-grade glioma, anaplastic, glioblastoma multiforme, etoposide, irinotecan, topotecan, teniposide, meta-analysis, 3307
- Highly active antiretroviral therapy (HAART), radiation therapy (RT), benign lymphoepithelial cysts (BLEC), parotid gland hyperplasia, HIV positive, 4927
- High-performance counter current chromatography, umbelliferone, herniarin, scoparone, laryngeal cancer cells, proliferation, migration, cell cycle, apoptosis, 4347
- High-throughput method, NSCLC, molecular genotyping, mutation, 5127
- HIPEC, peritoneal sarcomatosis, cytoreductive surgery, locoregional treatment, 3989
- Histoculture drug response assay, chemosensitivity, HDRA, epithelial ovarian cancer, taxol, carboplatin, prospective clinical trial, correlation, prediction, individualized therapy, 1029
- Histological grade, endometrial cancer, Immunohistochemistry, estrogen receptor, progesteron receptor, Ki67, p53, predictive model, 2191
- Histological regression grade, rectal carcinoma, neoadjuvant radiochemotherapy, ypTNM classification, 559
- Histology, adrenal, medulla, vagus, breast cancer, metastasis, 3675
- Histology, tumor tissue, muscle tissue, gene expression, 5213
- HIV positive, radiation therapy (RT), benign lymphoepithelial cysts (BLEC), parotid gland hyperplasia, highly active antiretroviral therapy (HAART), 4927
- HIV, Kaposi sarcoma, radiation therapy, 2153
- HIV, viral load, CD4, squamous cell carcinoma, head and neck cancer, radiation therapy, IMRT, chemotherapy, concurrent chemoradiotherapy, 5511
- HL-60 cells, *Rhinacanthus nasutus*, cytotoxicity, apoptosis induction, osteoclastogenesis, HSC-2, HSC-3, HSC-4, 453
- HL-60, bacteriophages, phage therapy, leukemia, phage-cancer interactions, phage-mammalian interactions, 1569
- HLA class-I expression, non-small cell lung cancer, surgery, prognosis, cancer/testis antigen, immune escape, 2123
- HLA class-I, antigenic peptide, cancer associated antigen, prostate cancer, mass spectrometric analysis, 1853
- HMGA, leukoplakia, oral cancer, 4261
- HMGA2 expression, growth factor, proliferation, PC-3 cell line, prostate cancer, 3069
- HMGB1, acute leukemias, miR-181a, CD4, 445
- HMM, *Pantoea agglomerans*, LPS, LPSP, O-antigen polysaccharide, serum-free, LMM, 2875
- HNSCC, apoptosis, ceramide, dihydroceramide desaturase, dihydroceramide, PDT, sphingolipids, UM-SCC-22A cells, 77
- HNSCC, cytokines, radio-/chemotherapeutic treatment head and neck cancer, 2481
- HOCl, superoxide anion, singlet oxygen, hydroxyl radical, SOD, MKN45, B16F10 cells, 3589
- Hodgkin lymphoma, brentuximab venodin, CD30 antibody, case report, ABVD, BEACOPP, CD30, 3879
- Homeostasis, intestinal macrophage, intestinal microbiota, health, disease, review, 2849
- Homocysteine, breast cancer, folate, MTHFR, FTO, polymorphism, Kazakhstan, 4049
- Hormone regeneration, testosterone, estrone, sex hormones, free radicals, electron emission, carcinogenicity, 941
- Hormone-refractory prostate cancer, chemoradiation, metronomic chemotherapy, phase I study, 4585
- Hospital volume, long-term outcome, laparoscopic gastrectomy, 5165
- HPLC, capecitabine, metabolites, 5'-DFCR, 5'-DFUR, pharmacokinetics, GLP, 881
- HPV infection, SCCHN, p16 expression, 913
- HPV, cervical cancer, microRNA expression, clinical grading, 2561
- HPV, E6, E7, Greece, 4007
- HPV, *EGFR*, phosphoryated *EGFR*, tonsillar cancer, 1575
- HPV, oral cancer, tumor sample screening, 3481
- HPV, tonsillar squamous cell carcinoma, regulatory T-cell, FOXP3, p16, 5667
- HRAS*, *KRAS*, *NRAS* mutations, *KRAS* codon 59 deletion, *BRAF* mutations, follicular-patterned thyroid lesions, 4779
- HRMA, cetuximab, colorectal cancer, *KRAS* mutation, sequencing, 2129
- HSC-2, *Rhinacanthus nasutus*, cytotoxicity, apoptosis induction, osteoclastogenesis, HSC-3, HSC-4, HL-60 cells, 453
- HSC-3, *Rhinacanthus nasutus*, cytotoxicity, apoptosis induction, osteoclastogenesis, HSC-2, HSC-4, HL-60 cells, 453

- HSC-4, *Rhinacanthus nasutus*, cytotoxicity, apoptosis induction, osteoclastogenesis, HSC-2, HSC-3, HL-60 cells, 453
- HT-1080, fibrosarcoma, intravascular, extravasation, GFP, RFP, mitosis, apoptosis, nude mice, confocal microscopy, 4229
- HT29, cell signaling, ERK, U0126, CYP inhibitor, MEK/ERK inhibitor, colorectal cancer, HCT116, 2499
- HTERT, AKT, iNOS, oxidative stress, 3295
- 5-HTRs, serotonin, malignant, non-malignant, invasive ductal carcinoma, invasive lobular carcinoma, breast cancer, 363
- HuH-7 cells, trehalose, liposome, hepatocarcinoma, apoptosis, Hep-G2, 4727
- Human acute leukemia cells, daunorubicin derivatives, apoptosis, necrosis, mitochondrial membrane potential, 4439
- Human breast pre-adipocytes, (–)-gossypol-enriched cottonseed oil, proliferation, adipogenesis, 949
- Human CDH1 protein; stomach neoplasm, methylation, diffuse gastric cancer, methylation-specific polymerase chain reaction, pyrosequencing, 3765
- Human colorectal adenocarcinoma, β -catenin, cardiac hormones, human pancreatic cancer, human renal adenocarcinoma, 2409
- Human epithelial ovarian cancer, EOC, mouse ovarian surface epithelium, MOSE, orthotopic ovarian cancer, immuno-competent C57BL/6, 1317
- Human gallbladder adenocarcinoma, curcumin, *G2/M* arrest, apoptosis, 1861
- Human oral squamous cell carcinoma, EZH2, BMI1, p53, 4309 Cell-free DNA, CpG-island, hypermethylation, kidney cancer, biomarker, serum, 4651
- Human pancreatic cancer, β -catenin, cardiac hormones, human colorectal adenocarcinoma, human renal adenocarcinoma, 2409
- Human papillomavirus (HPV), 5-FU, docetaxel, β -catenin, c-KIT, head and neck squamous cell carcinoma, extracellular matrix, protein tyrosine kinase, epithelial mesenchymal transition (EMT), 2457
- Human papillomavirus (HPV), vaginal intraepithelial neoplasia (VaIN), review, 29
- Human renal adenocarcinoma, β -catenin, cardiac hormones, human pancreatic cancer, human colorectal adenocarcinoma, 2409
- Humanized monoclonal antibody, lung cancer, non-small cell lung cancer, NSCLC, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, brain metastases, angiogenesis, vascular endothelial growth factor A (VEGF-A), pulmonary haemorrhage, 3275
- Human-specific, cytolysin, cholesterol-independent, ILY, VLY, Sm-hPAF, CD59, 2901
- Hyaluronic acid, CD44-targeted delivery, PLGA nanoparticles, surface decoration, SN-38, ovarian cancer, CTAB assay, 2425
- Hybrid imaging, renal cell carcinoma, 18F-FDG-PET/CT, prognosis, SUV_{max} , 2665
- Hybrid tumour, salivary gland, sublingual gland, 4567
- Hydrogel, ellagic acid, glycine, folic acid, anti-oxidant, breast cancer, implant, 4847
- Hydrogen peroxide, radiation, apoptosis, proliferation, melanoma, 1799
- Hydrogenated fish oil, carcinogenesis, C57BL/6J-*Min*+ mice, trans fatty acids, colorectal cancer, 477
- Hydronephrosis, bladder cancer, concurrent chemoradiotherapy, complete response, 2605
- Hydroxyl radical, HOCl, superoxide anion, singlet oxygen, SOD, MKN45, B16F10 cells, 3589
- 1-Hydroxypyrene, polycyclic aromatic hydrocarbon, oxidative stress, antioxidant capacity, lung cancer, nested case-control study, thiobarbituric acid, 8-hydroxydeoxyguanosine, cotinine, 2-Naphthol, 3089
- 2'-Hydroxyflavanone, prostate cancer, androgen receptor, androgen, 4453
- 5-Hydroxymethylcytosine, oral cancer, DNA methylation, ten-eleven-translocation 2, biological markers, 4325
- 8-Hydroxydeoxyguanosine, polycyclic aromatic hydrocarbon, oxidative stress, antioxidant capacity, lung cancer, nested case-control study, 1-hydroxypyrene, thiobarbituric acid, cotinine, 2-Naphthol, 3089
- Hyper T/NK cells, immunotherapy, GcMAF, high-dose vitamin C, alpha lipoic acid, 2917
- Hyperbaric oxygen therapy, pancreatic ductal adenocarcinoma, gemcitabine, apoptotic index, PANC-1, AsPc-1 cells, 4827
- Hypermethylation, bladder cancer, cell-free DNA, serum, 779
- Hypermethylation, cell-free DNA, CpG-island, kidney cancer, biomarker, serum, 4651
- Hypermethylation, RRAD, EAC, ESCC, 5199
- Hyperthermia, 5-aminolevulinic acid, ALA, protoporphyrin IX, animal tumor model, 2861
- Hyperthermia, hypopharyngeal cancer, chemoradiotherapy, larynx preservation, intra-arterial infusion chemotherapy, 5561
- Hyperthermic intraperitoneal chemotherapy, endometrial carcinoma, cytoreductive surgery, late wound recurrence, 1041
- Hyperthermotherapy, ALA, DCA, cellular immunotherapy, stomach cancer, 2957
- Hypofractionated radiotherapy, breast cancer, ductal carcinoma *in situ*, 3503
- Hypo-fractionation, post-operative radiotherapy, prostate cancer, SIB-IMRT, phase II trial, 2785
- Hypofractionation, prostate cancer, RapidArc, VMAT, 4537

- Hypopharyngeal cancer, chemoradiotherapy, larynx preservation, hyperthermia, intra-arterial infusion chemotherapy, 5561
- Hypoxia, ¹⁸F-FDG PET, pulmonary neuroendocrine tumor, GLUT1, angiogenesis, glucose metabolism, 4219
- Hypoxia, fenbendazole, benzamidazoles, tumor microenvironments, radiation therapy, EMT6 cells, 355
- Hypoxia-inducible factor, breast cancer, polymorphism, transcriptional activity, MCF-7 cells, 2549
- Hypoxic radiosensitizer, intensity-modulated radiation therapy, simultaneous integrated boost, glioblastoma multiforme, case report, 1685
- Hypoxic radiosensitizer, radiotherapy, oral administration, neuropathy, sanazole (AK-2123), 643
- Hypoxic radiosensitizer, reirradiation, brain metastases, stereotactic irradiation, CyberKnife, 1773
- I3C derivative CTet, synergy, triple-negative breast cancer, autophagy, *MAP1LC3B*, MDA-MB-231, BT-20 cells, 1867
- IAM, *NAT2*, cancer susceptibility, SNP, breast cancer, gastric cancer, 3683
- ICG-R15, hepatocellular carcinoma, anatomical hepatectomy, surgery, preserved liver function, 1689
- ID1, inhibitor of differentiation, inhibitor of DNA binding, ID2, qPCR, breast cancer, helix-loop-helix, cell cycle, 2179
- ID2, inhibitor of differentiation, inhibitor of DNA binding, ID1, qPCR, breast cancer, helix-loop-helix, cell cycle, 2179
- ID3*, double-hit lymphomas, unclassifiable B-cell lymphoma, 4771
- Id4, senescence, E2F1, apoptosis, DU145, 4271
- IFN- γ , EAG1, glioma, glioblastoma multiforme, RNAi, gene therapy, 865
- IFN- γ , equine melanoma, IL-12, bead-based-assay, 1325
- Ifosfamide, non-small cell lung cancer, cisplatin, docetaxel, survival, phase III trial, 5477
- IGF1Ec, prostate cancer, Immunohistochemistry, insulin-like growth factor 1 (IGF-1), mechano-growth factor (MGF), 2441
- IgG4, inflammation, lymphoma, orbit, 2779
- IHC, breast cancer, podoplanin, cancer-associated fibroblasts, assessment methods, 1447
- IHC, CRC, *COX2* expression, prognosis, 3137
- IL10*, haplotype, prognosis, squamous cell carcinoma, adenocarcinoma, lung cancer, 2729
- IL10*, polymorphism, nasopharyngeal carcinoma, 3391
- IL-12, equine melanoma, IFN- γ , bead-based-assay, 1325
- IL-2, hepatocellular carcinoma, HCC, immunotherapy, interleukin-2, BCG, melatonin, 4531
- IL-2, non-muscle invasive bladder carcinoma, NMIBC, interleukin-2, marker tumour, 2099
- IL-6, esophageal carcinoma, IL-8, invasiveness, KYSE170 cells, 1483
- IL-8, esophageal carcinoma, IL-6, invasiveness, KYSE170 cells, 1483
- ILY, cytolysin, cholesterol-independent, human-specific, VLY, Sm-hPAF, CD59, 2901
- Image guidance, margin, frameless stereotactic radiosurgery, image-guided intervention, 4639
- Image-guided IMRT, tomotherapy, prostate cancer, soft tissue matching, PTV margin, megavolt computed tomography, 5675
- Image-guided IMRT, tomotherapy, vertebral body metastases, stereotactic body radiotherapy, PTV margin, 2453
- Image-guided intensity-modulated radiotherapy, tomotherapy, prostate cancer, 5507
- Image-guided intervention, margin, frameless stereotactic radiosurgery, image guidance, 4639
- Image-guided intervention, prostate cancer, infra-fractional motion, 4117
- Image-guided thermal ablation, microwave ablation, HCC, 1221
- Imaging, glioma, U87, RFP, orthotopic, craniotomy window, fluorescence, surgery, survival, 107
- Imaging, *HER2*, antibody, fluorophore, rhodamine, breast cancer, 4T1, GFP, orthotopic model, lymph node, metastasis, 419
- Imatinib, chronic myeloid leukemia, hematopoietic stem cell transplantation, tyrosine kinase inhibitor, allotransplantation, 4663
- Imatinib, gastrointestinal stromal tumor, xenograft, mouse, sunitinib, 175
- Immune cell surveillance, metastasis of prostate cancer, regional pelvic nodes, immune cells: lymphocytes, macrophages, lysis/apoptosis of metastatic cancer cells, immune responsive, immune-unresponsive (resistant) cells, 3635
- Immune cells: lymphocytes, metastasis of prostate cancer, regional pelvic nodes, macrophages, immune cell surveillance, lysis/apoptosis of metastatic cancer cells, immune responsive, immune-unresponsive (resistant) cells, 3635
- Immune escape, non-small cell lung cancer, HLA class-I expression, surgery, prognosis, cancer/testis antigen, 2123
- Immune regulation, adipocytes, cytokines, inflammation, premalignant lesion cells, 1809
- Immune responsive, metastasis of prostate cancer, regional pelvic nodes, immune cells: lymphocytes, macrophages, immune cell surveillance, lysis/apoptosis of metastatic cancer cells, immune-unresponsive (resistant) cells, 3635
- Immune-unresponsive (resistant) cells, metastasis of prostate cancer, regional pelvic nodes, immune cells: lymphocytes, macrophages, immune cell surveillance, lysis/apoptosis of metastatic cancer cells, immune responsive, 3635

- Immuno-competent C57BL/6, human epithelial ovarian cancer, EOC, mouse ovarian surface epithelium, MOSE, orthotopic ovarian cancer, 1317
- Immunocompetent mice syngeneic mouse model, *Salmonella typhimurium*, auxotroph, leucine, arginine, GFP, tumor-targeting, primer dosing, high dose, Lewis lung carcinoma, 97
- Immunocytochemistry, non-small cell lung cancer, metallothionein, cisplatin resistance 97/97, DV90 cells, 5255
- Immunohistochemistry, ⁶⁸Ga-DOTATOC, 18F-FDG, PET, SSTR2, somatostatin analogs, 3015
- Immunohistochemistry, astrocytoma, aquaporin-1, angiogenesis, infiltration zone, 609
- Immunohistochemistry, clinicopathological features, luminal/*HER2*-negative breast cancer, p53 cut-off point, p53 overexpression, prognostic factor, 3891
- Immunohistochemistry, endometrial cancer, histological grade, estrogen receptor, progesteron receptor, Ki67, p53, predictive model, 2191
- Immunohistochemistry, gastric adenocarcinoma, (Smac) DIABLO, AIF, cytochrome *c*, 647
- Immunohistochemistry, hepatocellular carcinoma, *c-MET*, copy number variation, prognosis, 5179
- Immunohistochemistry, mTOR, phospho-mTOR, squamous cell carcinoma, basal cell carcinoma, Sirolimus, Everolimus, organ transplantation, immunosuppression, skin, 3711
- Immunohistochemistry, prostate cancer, angiogenesis, *VEGFR1*, NRP1, tissue array analysis, prostatectomy, 2065
- Immunohistochemistry, prostate cancer, insulin-like growth factor 1 (IGF-1), IGF1Ec, mechano-growth factor (MGF), 2441
- Immunohistochemistry, upper tract urothelial carcinoma, p53, prognosis, hemodialysis, 1091
- Immunohistochemistry, vitamin B12, transcobalamin II, transport protein, receptor, Ki-67, xenograft, 4203
- Immunohistochemistry, *XRCC6/Ku70*, non-homologous end-joining, hepatocellular carcinoma, polymorphism, genotype, real-time quantitative reverse transcription, 529
- Immunosuppression, herpes simplex virus-1, encephalitis, small cell lung cancer, radiation, 3263
- Immunosuppression, mTOR, phospho-mTOR, squamous cell carcinoma, basal cell carcinoma, Sirolimus, Everolimus, Immunohistochemistry, organ transplantation, skin, 3711
- Immunosurveillance, breast cancer, circulating tumor cell, tumor cell dormancy, T-cell, FAS, 2233
- Immunotherapy, characterization, glioblastoma, tumor-associated antigens, U251, U87, U343 cells, 2525
- Immunotherapy, GcMAF, hyper T/NK cells, high-dose vitamin C, alpha lipoic acid, 2917
- Immunotherapy, hepatocellular carcinoma, HCC, interleukin-2, IL-2, BCG, melatonin, 4531
- Immunotherapy, mastocytoma, interleukin-2, local therapy, dogs, 161
- Immunotherapy, pediatric neuro-oncology, high grade glioma, dendritic cell vaccine, 2047
- Implant, hydrogel, ellagic acid, glycine, folic acid, anti-oxidant, breast cancer, 4847
- Imprint cytology, breast cancer, Sentinel lymph node, intraoperative examination, frozen section, 1045
- IMRT, HIV, viral load, CD4, squamous cell carcinoma, head and neck cancer, radiation therapy, chemotherapy, concurrent chemoradiotherapy, 5511
- In situ* electroporation, gap junctions, SRC, STAT3, lung cancer, 4401
- In vitro* models, urinary bladder cancer, *in vivo* models, antineoplastic drugs, review, 1273
- In vitro*, renal cell carcinoma, nanoparticle, desacyl-saponin, BBE, *in vivo*, xenograft, 143
- In vitro*, α v integrin, green fluorescent protein, osteosarcoma, fibronectin, *in vivo*, nude mouse, metastasis, real-time imaging, confocal microscopy, 3021
- In vivo* antitumor activity, degalactosylated/desialylated human serum, GcMAF, macrophage phagocytic activity, 2881
- In vivo* antitumor activity, non-small cell lung cancer, elacytarabine, bevacizumab, cetuximab, trastuzumab, xenograft, 3615
- In vivo* imaging, GFP, RFP, apoptosis, mitosis, subcellular dynamics, brain cancer, mouse models, temozolomide, 103
- In vivo* imaging, GFP, RFP, mitosis, subcellular dynamics, brain cancer, brain metastasis, mouse model, craniotomy window, 1367
- In vivo* models, urinary bladder cancer, *in vitro* models, antineoplastic drugs, review, 1273
- In vivo* selection, gastric cancer cell lines, paclitaxel-resistance, peritoneal metastasis, gene expression profile, 4299
- In vivo*, renal cell carcinoma, nanoparticle, desacyl-saponin, BBE, *in vitro*, xenograft, 143
- In vivo*, α v integrin, green fluorescent protein, osteosarcoma, fibronectin, *in vitro*, nude mouse, metastasis, real-time imaging, confocal microscopy, 3021
- India internaional symposium, Udaipur, Rajasthan, cancer prevention, translational cancer research, 1777
- Indirect co-culture, CAFs, NFs, lung cancer, stromal NSCLC, direct co-culture, EMT, proliferation, SMAD3, Hedgehog signaling pathway, 3715
- Individualized therapy, chemosensitivity, HDRA, histoculture drug response assay, epithelial ovarian cancer, taxol, carboplatin, prospective clinical trial, correlation, prediction, 1029

- Individualized tumor response testing, *ex vivo* drug resistance, acute myeloid leukemia, children, relapse, minimal residual disease, 1189
- Indole-3-carbinol, pancreatic neoplasm, gemcitabine, microRNA, chemotherapy, Panc-1 cells, 1473
- Induction chemotherapy, extended field, cervical metastases, radiotherapy, unknown primary tumor, 1135
- Inferior alveolar nerve, numb chin syndrome, mental neuropathy, mandibular metastasis, orthopantomogram, cone beam tomography, colonic cancer, case report, 1757
- Infiltration zone, astrocytoma, Immunohistochemistry, aquaporin-1, angiogenesis, 609
- Inflammation, adipocytes, cytokines, immune regulation, premalignant lesion cells, 1809
- Inflammation, IgG4, lymphoma, orbit, 2779
- Inflammatory cell infiltration, colorectal cancer, antitumor immune response, CD3, CD8, lymph node retrieval, 5143
- Inflammatory response, tumor necrosis, colorectal cancer, 1099
- Infliximab, Crohn's disease, anal fistula, anorectal carcinoma, 685
- Infra-fractional motion, prostate cancer, image-guided intervention, 4117
- Inguinal canal, spermatic cord, paratesticular, sarcoma, review, 2361
- Inhibitor of differentiation, inhibitor of DNA binding, ID1, ID2, qPCR, breast cancer, helix-loop-helix, cell cycle, 2179
- Inhibitor of DNA binding, inhibitor of differentiation, ID1, ID2, qPCR, breast cancer, helix-loop-helix, cell cycle, 2179
- Initial experience, laparoscopic radical hysterectomy, laparoscopic lymph node dissection, learning curve, total mesometrial resection, 3449
- Injection route, degalactosylated Gc-globulin, a precursor of Gc-derived macrophage activating factor, subtypes of Gc-globulin, antitumor activity, 2911
- INOS, AKT, hTERT, oxidative stress, 3295
- Inositol requiring enzyme-1, cancer, endoplasmic reticulum, stress, unfolded protein response, molecular chaperones, activating transcription factor 6, PERK kinase, review, 4683
- Inpatient rehabilitation, cancer, fatigue, physical activity, dose response relationship, 3415
- Insufflation, colon cancer, CO₂, invasion, laparoscopy, 1881
- Insulin, chemotherapy, diabetes mellitus, pancreatic cancer, 287
- Insulin-like growth factor 1 (IGF-1), prostate cancer, Immunohistochemistry, IGF1Ec, mechano-growth factor (MGF), 2441
- Integrin $\alpha_v\beta_3$, malignant melanoma, RGD peptide, cell adhesion, cell migration, 871
- Integrins. NF- κ B activation, calcitonin, fibronectin, MG63 cells, matrix metallo-proteinase 9, 4901
- Intensity-modulated radiation therapy, hypoxic radiosensitizer, simultaneous integrated boost, glioblastoma multiforme, case report, 1685
- Interleukin-10, dendritic cells, gene expression, differentiation, 4791
- Interleukin-2, hepatocellular carcinoma, HCC, immunotherapy, IL-2, BCG, melatonin, 4531
- Interleukin-2, mastocytoma, local therapy, immunotherapy, dogs, 161
- Interleukin-2, non-muscle invasive bladder carcinoma, NMIBC, IL-2, marker tumour, 2099
- Intermediate risk factor, cervical cancer, simple hysterectomy, less radical surgery, 5135
- Interstitial brachytherapy, brachytherapy, gynecological cancer, high dose rate, late vaginal mucosal reaction, re-irradiation, 5687
- Interstitial lung disease, small cell lung cancer, chemotherapy, cisplatin, carboplatin, etoposide, acute exacerbation, 1175
- Intestinal macrophage, intestinal microbiota, homeostasis, health, disease, review, 2849
- Intestinal microbiota, intestinal macrophage, homeostasis, health, disease, review, 2849
- Intestinal obstruction, octreotide, steroids, palliative care, 5557
- Intra-arterial infusion chemotherapy, hypopharyngeal cancer, chemoradiotherapy, larynx preservation, hyperthermia, 5561
- Intra-biliary injection, gene therapy, hepatocellular carcinoma (HCC), intravenous intra-arterial, intra-tumoral, intra-portal, delivery approach, review, 4711
- Intracellular accumulation, LoVo, LoVo/DX, cyanine dyes, phenothiazines, 857
- Intra-CSF chemotherapy, leptomeningeal metastases, neoplastic meningitis, liposomal cytarabine, breast cancer, multimodality treatment, 2057
- Intragastric, GIST, SILS, oncologic surgery, 3359
- Intrahepatic cholangiocarcinoma, hepatic resection, cancer stem cells, CD44, GLI1, 2107
- Intramuscular, curcumin formulation, pharmacokinetics, 4285
- Intranasal administration, phase II trial, perillyl alcohol, glioma, GBM, glioblastoma multiforme, 5625
- Intraoperative examination, breast cancer, Sentinel lymph node, frozen section, imprint cytology, 1045
- Intraoperative radiotherapy, partial breast irradiation, breast cancer, 1229
- Intra-portal, gene therapy, hepatocellular carcinoma (HCC), intravenous intra-arterial, intra-tumoral, intra-biliary injection, delivery approach, review, 4711
- Intrathecal, brain tumor, liposomal cytarabine, medulloblastoma, relapse/progression, case series, 3515
- Intra-tumoral, gene therapy, hepatocellular carcinoma (HCC), intravenous intra-arterial, intra-portal, intra-biliary injection, delivery approach, review, 4711

- Intravascular, HT-1080, fibrosarcoma, extravasation, GFP, RFP, mitosis, apoptosis, nude mice, confocal microscopy, 4229
- Intravenous intra-arterial, gene therapy, hepatocellular carcinoma (HCC), intra-tumoral, intra-portal, intra-biliary injection, delivery approach, review, 4711
- Inv(3)(q21q26), fluorescent *in situ* hybridization, chromosomal abnormality, myeloid hemopathies, 639
- Invasion, apoptosis, glycosylation, lectin, prognosis, 3053
- Invasion, colon cancer, CO₂, laparoscopy, insufflation, 1881
- Invasion, colon cancer, polysaccharide K, 4841
- Invasion, colon carcinoma, *FERMT1*, DNA microarray, fermitin family, 167
- Invasion, HAVCr-1, hepatitis A virus cellular receptor-1, colorectal cancer, prognosis, 207
- Invasion, lung cancer, fibroblast, TGF-beta, TIG-3, LLC cells, 3791
- Invasion, metastasis, migration, artonin E, lung cancer cells, H460, H23, A549, H292 cells, 3079
- Invasion, pituitary adenoma, mTOR, RAPTOR, RICTOR, staging, 3123
- Invasion, pituitary adenoma, VEGI, death receptor-3, 3815
- Invasion, quercetin, migration, MMP-2, MMP-9, NF- κ B, SAS human oral cancer cells, 1941
- Invasion, zoledronic acid, metastasis, 3D culture assays, 5295
- Invasive carcinoma, advanced adenomas, microtubular configurations, colorectal adenoma, 5471
- Invasive ductal carcinoma, 5-HTRs, serotonin, malignant, non-malignant, invasive lobular carcinoma, breast cancer, 363
- Invasive front, colorectal cancer, WNT, β -catenin, prognosis, E-cadherin, SFRP, 4573
- Invasive lobular carcinoma, 5-HTRs, serotonin, malignant, non-malignant, invasive ductal carcinoma, breast cancer, 363
- Invasiveness, esophageal carcinoma, IL-6, IL-8, KYSE170 cells, 1483
- Ionization time-of-flight mass spectrometry, oral squamous cell carcinoma, mass spectrometry, matrix-assisted laser desorption, 837
- IORT, breast cancer, elderly, morbidity, short-term outcome, 3995
- IQWD1, breast cancer, androgen, microRNA, 4811
- Irinotecan, anaplastic, glioblastoma multiforme, high-grade glioma, etoposide, topotecan, teniposide, meta-analysis, 3307
- Irinotecan, biliary tract cancer, refractory, gemcitabine, cisplatin, fluoropyrimidine, 2619
- Irinotecan, carboplatin, chemotherapy, ovarian cancer, 1073
- Irinotecan, carboxyl esterase (CE), CNS lymphoma, neural stem cells, rabbit, 5335
- Irinotecan, colorectal cancer, IRIS, S-1, FIRIS, 3845
- Irinotecan, colorectal cancer, radiofrequency ablation, liver metastases, 1603
- Irinotecan, extensive-stage small cell lung cancer, alternating chemotherapy, amrubicin, cisplatin, 1117
- Irinotecan, gastric cancer, mitomycin C, chemotherapy, 5107
- Irinotecan, metastatic colorectal cancer, 5'-deoxy-5-fluorouridine (5'-DFUR), UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism, 3423
- Irinotecan, postoperative chemotherapy, colorectal liver metastasis, synchronous metastasis, oxaliplatin, 5-fluorouracil, leucovorin, FOLFOX, FOLFIRI, 3317
- Irinotecan, vitamin D analogs, combined treatment, oxaliplatin, anticancer activity, colonic cancer, 433
- Irinotecan, YHO-13351, side population cell, *ABCG2*, 1379
- IRIS, irinotecan, colorectal cancer, S-1, FIRIS, 3845
- Iron, dihydroartemisinin, N-tert-butyl-alpha-phenylnitron, deferoxamine, Molt-4 cells, free radical, 4389
- Irradiation, prostate cancer, metastatic spinal cord compression, extra-spinal organs, survival, prognosis, 4505
- Isoflavones, prostate cancer, soy phytoestrogens, daidzein genistein, diet, epigenetics, review, 39
- Isoform, androgen receptor, heat-shock protein HSPB1, microRNA miR-1, 4921
- Israel, gastric cancer, chemoradiation, ethnicity, Ashkenazi, 5151
- Japanese, pemetrexed, cisplatin, *ALK*, non-squamous NSCLC, 3327
- Jaws tumor, adenomatoid tumor, odontogenic tumor, 2673
- JCGC, esophagogastric junctional carcinoma, Siewert type II adenocarcinoma, AJCC, TNM, staging system, 3461
- JNK, p53, redox factor 1, selenomethionine, ubiquitination, cancer prevention, protein stability, 3645
- Junctional adhesion molecules (JAMs), brain metastasis blood-brain barrier (BBB), tight junctions (TJs), review, 2353
- Jurkat cells, leukaemia, HIF, echinomycin, NOTCH, NB4, 3099
- K2P channels, ovarian cancer, TASK-3, expression, survival, SKOV-3, OVCAR-3 cells, 1401
- K562, cryopreservation, feeder cells, natural killer cell, expansion, 2011
- Kaposi's sarcoma, gemcitabine, chemotherapy, case series, 5531
- Kaposi sarcoma, HIV, radiation therapy, 2153
- Kazakhstan, breast cancer, folate, homocysteine, MTHFR, FTO, polymorphism, 4049
- Keratinocytes, head and neck cancer, differential regulation, PAI-1, uPA, 3113
- KG-1 cells, CK2 inhibitors, pentabromobenzylisothioureas, apoptosis, flow cytometry, 4891

- Ki-67, artificial neural networks, cancer prognosis, p53, oestrogen/progesterone receptors, prediction of nodal status, 3925
- Ki-67, breast cancer, abdominal metastasis, E-cadherin, lymphatic vessel invasion, 1971
- Ki67, breast cancer, TMA, ER, PgR, *HER2*, 2139
- Ki-67, canine cutaneous histiocytoma, proliferation, apoptosis, TUNEL, 1397
- Ki67, endometrial cancer, Immunohistochemistry, histological grade, estrogen receptor, progesteron receptor, p53, predictive model, 2191
- Ki-67, esophagus, squamous cell carcinoma, definitive chemoradiotherapy, salvage esophagectomy, murine double minute 2, p16, 1463
- Ki-67, vitamin B12, Immunohistochemistry, transcobalamin II, transport protein, receptor, xenograft, 4203
- Ki67, *Withania somnifera*, chemoprevention, mammary cancer, rats, PCNA, 1519
- Kidney cancer, cell-free DNA, CpG-island, hypermethylation, biomarker, serum, 4651
- Kidney cancer, drug sequence, sorafenib, sunitinib, Everolimus, temisrolimus, 4999
- Kinase receptor family, disease-free survival, tumor suppressor, sporadic cancer, molecular markers, 5159
- Korean, hepatocellular carcinoma, single nucleotide polymorphism, thioredoxin domain-containing-5, male population, 3983
- KRAS* codon 59 deletion, *HRAS*, *KRAS*, and *NRAS* mutations, *BRAF* mutations, follicular-patterned thyroid lesions, 4779
- KRAS* mutation, HRMA, cetuximab, colorectal cancer, sequencing, 2129
- KRAS*, *HRAS*, *NRAS* mutations, *KRAS* codon 59 deletion, *BRAF* mutations, follicular-patterned thyroid lesions, 4779
- KRAS*, ovarian carcinoma, *PPP2RIA*, *PIK3CA*, *BRAF*, mutation, 113
- KRAS*, squamous cell lung cancer, NSCLC, targeted-therapy, *EGFR*, *PIK3CA*, mutation, *EGFR*-TKI, 1705
- Kroma iT, colorectal cancer, fecal occult hemoglobin, analyzer evaluation, 5633
- KSP inhibitors, glioma, LaSOM 65, antitumor activity, 4463
- KYSE170 cells, esophageal carcinoma, IL-6, IL-8, invasiveness, 1483
- L1CAM, afamin, mesothelin, serum marker, ovarian cancer, 329
- L929 murine cell line, multidrug resistance, modulating agents, drug accumulation, doxorubicin, vincristine, paclitaxel, MCF7 breast cancer cell line, 4381
- Laparoscopic gastrectomy, gastric cancer, endoscopic resection, adhesion, perforation, 4023
- Laparoscopic gastrectomy, hospital volume, long-term outcome, 5165
- Laparoscopic lymph node dissection, laparoscopic radical hysterectomy, learning curve, initial experience, total mesometrial resection, 3449
- Laparoscopic nephroureterectomy, upper urinary tract, urothelial carcinoma, 5501
- Laparoscopic radical hysterectomy, laparoscopic lymph node dissection, learning curve, initial experience, total mesometrial resection, 3449
- Laparoscopic supracervical hysterectomy, LASH, prophylactic salpingectomy, laparoscopy, surgical outcome, 2771
- Laparoscopic surgery, defunctioning ileostomy, low anterior resection, 5011
- Laparoscopic transhiatal approach, subcarinal and main bronchial lymph node dissection, esophageal cancer, 2577
- Laparoscopy, colon cancer, CO2, invasion, insufflation, 1881
- Laparoscopy, laparoscopic supracervical hysterectomy, LASH, prophylactic salpingectomy, surgical outcome, 2771
- Laparoscopy, surgical stress, ovarian carcinoma, mouse model, 3177
- Laparoscopy-assisted surgery, gastric gastrointestinal stromal tumor, gastric, GIST, meta-analysis, 5031
- Laryngeal cancer cells, high-performance counter current chromatography, umbelliferone, herniarin, scoparone, proliferation, migration, cell cycle, apoptosis, 4347
- Laryngeal cancer, larynx preservation, organ-preserving surgery, radiochemotherapy, 4701
- Laryngeal cancer, micrometastasis, lymph node, head and neck cancer, probability, 3213
- Larynx preservation, hypopharyngeal cancer, chemoradiotherapy, hyperthermia, intra-arterial infusion chemotherapy, 5561
- Larynx preservation, laryngeal cancer, organ-preserving surgery, radiochemotherapy, 4701
- LASH, laparoscopic supracervical hysterectomy, prophylactic salpingectomy, laparoscopy, surgical outcome, 2771
- LaSOM 65, glioma, KSP inhibitors, antitumor activity, 4463
- Late vaginal mucosal reaction, brachytherapy, gynecological cancer, high dose rate, stenosis, pallor reaction, 3963
- Late vaginal mucosal reaction, brachytherapy, gynecological cancer, high dose rate, interstitial brachytherapy, re-irradiation, 5687
- Late wound recurrence, endometrial carcinoma, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, 1041
- Lateral lymph node dissection, rectal cancer, strategy, meta-analysis, 2921
- LATS2, breast cancer, estrogen receptor, NCoR, ER α , 53
- LC-MS/MS, two-dimensional gel electrophoresis, 2-D western blotting, nucleophosmin, tumor progression, 153

- Learning curve, laparoscopic radical hysterectomy, laparoscopic lymph node dissection, initial experience, total mesometrial resection, 3449
- Lectin, apoptosis, glycosylation, invasion, prognosis, 3053
- Leiomyosarcoma, chemotherapy, mesocolic, paclitaxel, gemcitabine, recurrence, 2929
- Lenalidomide, multiple myeloma, autologous stem-cell transplantation, consolidation and maintenance therapy, bortezomib, 5681
- Lenograstim, soft tissue sarcomas, febrile neutropenia, G-CSF, 679
- Lentiviral siRNA, hCG β , bladder carcinoma, silencing, stable gene knockdown SCaBER cells, 3611
- Lentivirus, PROX1, small cell lung cancer, shRNA, cell proliferation, viral knockdown, 3169
- Leptin, adjuvant chemotherapy, breast cancer, dyspepsia, gastrin, ghrelin, motilin, pepsinogens, 4951
- Leptomeningeal metastases, neoplastic meningitis, intra-CSF chemotherapy, liposomal cytarabine, breast cancer, multimodality treatment, 2057
- Lesion, sarcoma, epidemiology, SEER, NCI, 2597
- Less radical surgery, cervical cancer, simple hysterectomy, intermediate risk factor, 5135
- Leucine, *Salmonella typhimurium*, auxotroph, arginine, GFP, tumor-targeting, primer dosing, high dose, Lewis lung carcinoma, immunocompetent mice syngeneic mouse model, 97
- Leucovorin, colorectal cancer, tegafur-uracil, folate, γ -glutamyl hydrolase (GGH), gene expression, 3431
- Leucovorin, postoperative chemotherapy, colorectal liver metastasis, irinotecan, synchronous metastasis, oxaliplatin, 5-fluorouracil, FOLFOX, FOLFIRI, 3317
- Leukaemia, cannabinoids, drug combination, drug schedule, 4373
- Leukaemia, HIF, echinomycin, NOTCH, NB4, Jurkat cells, 3099
- Leukemia, bacteriophages, phage therapy, HL-60, phage-cancer interactions, phage-mammalian interactions, 1569
- Leukemia, biliverdin reductase, multidrug resistance, reactive oxygen species, 4913
- Leukemia, mTOR, rapamycin, Notch, 809
- Leukemia, NOTCH, mTOR, siRNA, MYC, 4293
- Leukoplakia, oral cancer, HMGA, 4261
- Lewis lung carcinoma, *Salmonella typhimurium* A1-R, GFP, TCM, tumor targeting, combination, RFP, C57/BL6 mice, 1837
- Lewis lung carcinoma, *Salmonella typhimurium*, auxotroph, leucine, arginine, GFP, tumor-targeting, primer dosing, high dose, immunocompetent mice syngeneic mouse model, 97
- Licorice flavonoids, QSAR, cytotoxicity, tumor-specificity index, chemical descriptor, 3061
- Lifestyle factors, environmental factors, gastric adenocarcinoma, gastric tumorigenesis, microRNA, socioeconomic factors, 3195
- Limb salvage, musculoskeletal tumor, forearm, hand, microsurgery, tissue transfer, review, 4175
- Linoleate, prostate cancer, fatty acids, proliferation, 4395
- Lioblastoma, tamoxifen, temozolomide, dose-dense schedule, 3383
- Lipid metabolism, olive oil, polyunsaturated fatty acids (PUFAs), colorectal cancer, gene expression, 3739
- Lipid, MALDI, breast cancer, *HER2*, profiles, 2467
- LipoplatinTM, radiotherapy, chemotherapy, concomitant therapy, colorectal cancer, cisplatin, 3005
- Liposarcoma, sunitinib malate, soft tissue sarcomas, multi-target inhibitor of tyrosine kinases, 1061
- Liposomal curcumin, curcumin, pancreatic cancer, xenograft, annexin A2, MiaPaCa cells, 3603
- Liposomal cytarabine, brain tumor, intrathecal, medulloblastoma, relapse/progression, case series, 3515
- Liposomal cytarabine, leptomeningeal metastases, neoplastic meningitis, intra-CSF chemotherapy, breast cancer, multimodality treatment, 2057
- Liposomal photosensitizer, photodynamic therapy, phthalocyanine, 1563
- Liposome, trehalose, hepatocarcinoma, apoptosis, Hep-G2, HuH-7 cells, 4727
- Liposomes, cucumin, red blood cells, morphology, echinocyte, 3629
- Liver metastases, colorectal cancer, circulating tumor cells, tumor markers, AdnaGen, 2239
- Liver metastases, colorectal cancer, irinotecan, radiofrequency ablation, 1603
- Liver metastasis, blood transfusion, prognosis, colorectal cancer, hepatic resection, 2723
- Liver metastasis, colorectal cancer, oxaliplatin, S-1, SOX, molecular target, 3941
- Liver regeneration, heat-shock protein, heat-shock pretreatment, mouse model, hepatectomy, 2887
- Liver, biopsies, autoimmune hepatitis, plasma cells, plasma cell precursors, multiple myeloma oncogene-1 (MUM1), 665
- LLC cells, lung cancer, fibroblast, invasion, TGF-beta, TIG-3, 3791
- LMM, *Pantoea agglomerans*, LPS, LPSp, O-antigen polysaccharide, serum-free, HMM, 2875
- LMW-PTP isoforms, protein tyrosine phosphorylation, genotype, mRNA expression, enzymatic activity, 1983
- LNCAp cell line, periostin, prostate cancer, androgens, antiandrogens, 815
- Lobarstin, glioblastoma, temozolomide, chemosensitivity, DNA repair, 5445
- Local control, anal carcinoma, radiochemotherapy, prognosis, 4111

- Local control, anaplastic thyroid carcinoma, chemoradiation therapy, docetaxel, palliative management, 3445
- Local control, centrally-located lung tumor, SBRT, adverse effect, lung cancer, 4959
- Local therapy, mastocytoma, interleukin-2, immunotherapy, dogs, 161
- Locally advanced cervical cancer, cervical cancer, completion surgery, pelvic lymphadenectomy, para-aortic lymphadenectomy, 1661
- Locally advanced cervical cancer, PET/CT, para-aortic lymphadenectomy, staging, 283
- Locally advanced tumor, breast cancer, HER-2, brain metastasis, neoadjuvant chemotherapy, pathological complete response, radiation, prophylactic cranial irradiation, 5119
- Locoregional therapy, 3-bromopyruvate, GAPDH, glucose metabolism, glycolysis, HCC, molecular targeting, review, 13
- Locoregional treatment, peritoneal sarcomatosis, HIPEC, cytoreductive surgery, 3989
- LOH, ATP7B, cisplatin, chemotherapy, urothelial carcinoma, bladder cancer, 3731
- Long non-coding RNAs, gastric cancer, plasma, biomarker, 3185
- Long-term cancer survival, adjuvant chemotherapy, dysphagia, radical resection, small cell carcinoma of the esophagus, 595
- Long-term outcome, chemoradiation, combined treatment, neoadjuvant therapy, colorectal adenocarcinoma, 725
- Long-term outcome, hospital volume, laparoscopic gastrectomy, 5165
- Long-term results, low-dose-rate interstitial brachytherapy, mobile tongue cancer, 317
- Long-term survival, hepatocellular carcinoma, hepatectomy, transarterial chemoembolization, repeat hepatectomy, 5097
- LoVo, LoVo/DX, cyanine dyes, intracellular accumulation, phenothiazines, 857
- LoVo/DX, LoVo, cyanine dyes, intracellular accumulation, phenothiazines, 857
- Low anterior resection, defunctioning ileostomy, laparoscopic surgery, 5011
- Low-dose, fotemustine, chemotherapy, glioblastoma, second-line therapy, 4013
- Low-dose-rate interstitial brachytherapy, mobile tongue cancer, long-term results, 317
- Lower thoracic esophageal cancer, thoracoscopic esophagectomy, 2-field lymph node dissection, 601
- Low-grade B-cell lymphoma, Epstein-Barr virus, rituximab, 5693
- LPS, *Pantoea agglomerans*, LPSp, O-antigen polysaccharide, serum-free, HMM, LMM, 2875
- LPSp, *Pantoea agglomerans*, LPS, O-antigen polysaccharide, serum-free, HMM, LMM, 2875
- LQ model, prostate cancer, radiation therapy, alpha/beta, 1009
- ¹⁷⁷Lu, radioimmunotherapy, CD37, non-Hodgkin's lymphoma, 85
- Luminal/HER2-negative breast cancer, clinicopathological features, Immunohistochemistry, p53 cut-off point, p53 overexpression, prognostic factor, 3891
- Lumpectomy, mastopexy, breast-conserving surgery, breast cancer, 731
- Lung adenocarcinoma, brain metastases, EGFR, TKI, radiotherapy, resistance, 1649
- Lung cancer biology, chemoradiotherapy, lung cancer surgery, ERCC1, tubulin, TYMS, RRM1, 1107
- Lung cancer biology, chemotherapy, lung cancer surgery, biomarker, 5597
- Lung cancer cells, ecteinascidin, tetrahydroisoquinoline, MCL1, anoikis, metastasis, 505
- Lung cancer cells, metastasis, migration, invasion, artonin E, H460, H23, A549, H292 cells, 3079
- Lung cancer surgery, chemoradiotherapy, lung cancer biology, ERCC1, tubulin, TYMS, RRM1, 1107
- Lung cancer surgery, chemotherapy, lung cancer biology, biomarker, 5597
- Lung cancer, malignant mesothelioma, mesothelin, YKL-40, 5517
- Lung cancer, angiogenesis, EGFR, 1913
- Lung cancer, APEX1, single-nucleotide polymorphism, smoking habit, Taiwanese, 2775
- Lung cancer, apoptosis, cisplatin, estrogen, progesterone, A549 cells, 791
- Lung cancer, aryl hydrocarbon receptor, tumorigenesis, dioxin, polycyclic aromatic hydrocarbons, cigarette smoke, review, 1247
- Lung cancer, ATM, polymorphism, genotype, smoking, 4067
- Lung cancer, bone metastasis, NSCLC, CEA, CTX, CYFRA 21-1, PINP, TRAP5b, 2593
- Lung cancer, CAFs, NFs, stromal NSCLC, direct co-culture, indirect co-culture, EMT, proliferation, SMAD3, Hedgehog signaling pathway, 3715
- Lung cancer, cancer-associated fibroblasts, normal fibroblasts, NFs, NSCLC, co-culture, EMT, proliferation, SMAD3, 2001
- Lung cancer, centrally-located lung tumor, SBRT, adverse effect, local control, 4959
- Lung cancer, chemoprevention, experimental model, tobacco carcinogens, combination therapy, acetylsalicylic acid, vitamin D, calcium, 4767
- Lung cancer, chemotherapeutic resistance, cisplatin, doxorubicin, etoposide, nitric oxide, 5433
- Lung cancer, drug resistance, zoledronic acid, BAX, 5357
- Lung cancer, epidermal growth factor receptor, gefitinib, molecular targeted drug, EGFR inhibitor, gefitinib, 5057
- Lung cancer, fibroblast, invasion, TGF-beta, TIG-3, LLC cells, 3791

- Lung cancer, gap junctions, SRC, STAT3, *in situ* electroporation, 4401
- Lung cancer, *IL10*, haplotype, prognosis, squamous cell carcinoma, adenocarcinoma, 2729
- Lung cancer, mouse model, bone marrow-derived cells, green fluorescent protein, 831
- Lung cancer, non-small cell lung cancer, NSCLC, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, brain metastases, humanized monoclonal antibody, angiogenesis, vascular endothelial growth factor A (VEGF-A), pulmonary haemorrhage, 3275
- Lung cancer, panobinostat, carboplatin, etoposide, 4475
- Lung cancer, PET, lymph nodes, 18F-FDG, 5193
- Lung cancer, polycyclic aromatic hydrocarbon, oxidative stress, antioxidant capacity, nested case-control study, 1-hydroxypyrene, thiobarbituric acid, 8-hydroxydeoxyguanosine, cotinine, 2-Naphthol, 3089
- Lung cancer, prognosis, thrombocytosis, smoking, 1725
- Lung cancer, stereotactic body radiotherapy, re-irradiation, fractionation, 5649
- Lung cancer, survival, comorbidity, lung function, random forest method, 1609
- Lung cancer, volumetric modulated arc therapy, VMAT, 4491
- Lung function, lung cancer, survival, comorbidity, random forest method, 1609
- Lung malignancy, pulmonary blastoma, elderly, relapse, 3911
- Lung metastasis, chitosan, hepatoma formation, xenograft models, 4867
- Lung metastasis, $\alpha_v\beta_3$ integrin, overexpression, green fluorescent protein, red fluorescent protein, osteosarcoma, nude mice, passage, variants, 3623
- Lung tumor, hepatocyte growth factor, *HGF* transgenic mice, c-Met, diethylnitrosamine, 895
- Lung tumor, tomotherapy, stereotactic body radiotherapy, radiophotoluminescence glass dosimeter, Rando phantom, 1679
- Lung, telomerase, cancer, metastasis, 2643
- LXR, ApoE, MCF-7, proliferation, apoptosis, THP-1, MCF-7 cells, 3783
- Lycopene, prostate cancer, resveratrol, capsaicin, curcumin, dietary phytochemicals, review, 4163
- Lymph node harvest, colorectal cancer, lymph node metastasis, lymph node ratio, survival, population-based study, prospective study, review, 2839
- Lymph node level, primary unknown, cervical lymph node metastasis, chemoradiation, 5187
- Lymph node metastases, molecular staging, polymerase chain reaction, prostate cancer, reference gene, 5243
- Lymph node metastases, thyroid neoplasms, *BRAF* mutation, proteomics, chaperonin 60, 4357
- Lymph node metastasis, cervical cancer, chemotherapy, radiation therapy, consolidation, 4675
- Lymph node metastasis, colorectal cancer, lymph node harvest, lymph node ratio, survival, population-based study, prospective study, review, 2839
- Lymph node metastasis, gastric cancer, splenectomy, 277
- Lymph node ratio, colorectal cancer, lymph node metastasis, lymph node harvest, survival, population-based study, prospective study, review, 2839
- Lymph node retrieval, colorectal cancer, antitumor immune response, inflammatory cell infiltration, CD3, CD8, 5143
- Lymph node, *HER2*, antibody, fluorophore, rhodamine, breast cancer, 4T1, GFP, orthotopic model, metastasis, imaging, 419
- Lymph node, micrometastasis, laryngeal cancer, head and neck cancer, probability, 3213
- Lymph nodes, axilla, breast cancer, axillary clearance, surgeon, 3935
- Lymph nodes, lung cancer, PET, 18F-FDG, 5193
- Lymphatic invasion, prognosis, colorectal cancer, 2965
- Lymphatic microvessel density, breast cancer, mast cells, molecular classification, prognosis, 957
- Lymphatic vessel invasion, breast cancer, abdominal metastasis, E-cadherin, Ki-67, 1971
- Lymphedema of the upper limb, single-frequency bioelectrical impedance, breast cancer, 4553
- Lymphocyte count, gallbladder carcinoma, prognosis, operation, 3439
- Lymphoma, chemotherapy, radiation, elderly, performance status, 3251
- Lymphoma, IgG4, inflammation, orbit, 2779
- Lymphovascular, tumour, size, triple-negative, breast, cancer, 2737
- Lynch syndrome, endometrial cancer, ovarian cancer, synchronous tumour, microsatellite instability, 3977
- Lynch syndrome, NNPCC, colorectal cancer, clinical management, 2147
- Lysis/apoptosis of metastatic cancer cells, metastasis of prostate cancer, regional pelvic nodes, immune cells: lymphocytes, macrophages, immune cell surveillance, immune responsive, immune-unresponsive (resistant) cells, 3635
- Macrophage phagocytic activity, degalactosylated/desialylated human serum, GcMAF, *in vivo* antitumor activity, 2881
- Macrophages, metastasis of prostate cancer, regional pelvic nodes, immune cells: lymphocytes, immune cell surveillance, lysis/apoptosis of metastatic cancer cells, immune responsive, immune-unresponsive (resistant) cells, 3635
- Magnetic resonance imaging, collagenous fibroma, cytogenetics, desmoplastic fibroblastoma, trisomy 8, 3259

- 3T magnetic resonance, prostatic carcinoma, transrectal biopsy, PSA, 2791
- MALDI, breast cancer, *HER2*, lipid, profiles, 2467
- Male population, hepatocellular carcinoma, single nucleotide polymorphism, thioredoxin domain-containing-5, Korean, 3983
- Male, female, breast cancer, prognostic factors, survival, 2227
- Malignant melanoma, integrin $\alpha_v\beta_3$, RGD peptide, cell adhesion, cell migration, 871
- Malignant mesothelioma, α_1 -adrenoceptor blocker, apoptosis, caspase, NCI-H28, NCI-H2052, NCI-H2452, MSTO-211H, 887
- Malignant mesothelioma, lung cancer, mesothelin, YKL-40, 5517
- Malignant pleural effusion, pleural mesothelioma, mesothelin, Mesomark assay, 2707
- Malignant pleural mesothelioma, DDX39, DEAD-box RNA helicase, 2557
- Malignant pleural mesothelioma, E-cadherin, epidermal growth factor receptor, tyrosine kinase inhibitor, esophageal cancer, epithelial to mesenchymal transition (EMT), 2401
- Malignant, 5-HT_{2A} receptors, serotonin, non-malignant, invasive ductal carcinoma, invasive lobular carcinoma, breast cancer, 363
- MALT lymphoma, penile tumor, 2639
- MALT lymphoma, radiotherapy, ocular adnexal, 5575
- Mammary cancer, siRNA, VEGF-C, VEGF-D, metastasis, 4237
- Mammary cancer, *Withania somnifera*, chemoprevention, rats, Ki67, PCNA, 1519
- Mammary fibroblasts, breast cancer, phenotypic reversion, microenvironment, primary cells, 1525
- Mammograms, breast, tumor phantoms, tumor size, 1131
- Mammographic breast density, polychlorinated biphenyl, PCB, organochlorine, breast cancer, 5483
- Mandible, bisphosphonate, osteonecrosis, cytostatic therapy, risk factors, 3917
- Mandibular metastasis, numb chin syndrome, mental neuropathy, inferior alveolar nerve, orthopantomogram, cone beam tomography, colonic cancer, case report, 1757
- MAP1LC3B*, I3C derivative CTet, synergy, triple-negative breast cancer, autophagy, MDA-MB-231, BT-20 cells, 1867
- MAPK, *ABCG2*, ALL, BCRP, multidrug resistance, 5317
- MAPKs, naphthoquinones, chronic lymphocytic leukemia (CLL), cytochrome C, apoptosis, mitochondria, BCL2, 183
- Margin, frameless stereotactic radiosurgery, image guidance, image-guided intervention, 4639
- Marker tumour, non-muscle invasive bladder carcinoma, NMIBC, interleukin-2, IL-2, 2099
- Mass spectrometric analysis, HLA class-I, antigenic peptide, cancer associated antigen, prostate cancer, 1853
- Mass spectrometry, oral squamous cell carcinoma, matrix-assisted laser desorption, ionization time-of-flight mass spectrometry, 837
- Mast cells, breast cancer, lymphatic microvessel density, molecular classification, prognosis, 957
- Mastocytoma, interleukin-2, local therapy, immunotherapy, dogs, 161
- Mastopexy, breast-conserving surgery, lumpectomy, breast cancer, 731
- Matrix metallo-proteinase 9, calcitonin, fibronectin, MG63 cells, integrins. NF- κ B activation, 4901
- Matrix-assisted laser desorption, oral squamous cell carcinoma, mass spectrometry, ionization time-of-flight mass spectrometry, 837
- Maximum tolerated dose, aged patient, elderly, non-small cell lung cancer, chemotherapy, pharmacokinetics, quality of life, carboplatin, paclitaxel, 261
- MCF7 breast cancer cell line, multidrug resistance, modulating agents, drug accumulation, doxorubicin, vincristine, paclitaxel, L929 murine cell line, 4381
- MCF-7 cells, ApoE, LXR, MCF-7, proliferation, apoptosis, THP-1, 3783
- MCF7 cells, artemisinin, transferrin, breast cancer, *HER2*, survivin, c-Myc, cyclin D1, DV145, 123
- MCF-7 cells, breast cancer, hypoxia-inducible factor, polymorphism, transcriptional activity, 2549
- MCF-7, angio-associated migratory cell protein, AAMP, breast cancer, prognosis, MDA-MB-231 cells, 1499
- MCF-7, ApoE, LXR, proliferation, apoptosis, THP-1, MCF-7 cells, 3783
- MCF-7, breast cancer, zoledronic acid, mTOR, REDD1, endoplasmic reticulum stress, MDA-MB-231 cells, 3807
- MCF-7, ester conjugate, fatty acid, anticancer agent, cytotoxicity, cancer cell lines, MDA-MB-361, MDA-MB-231, 2517
- MCF-7, RANK, RANKL, osteoprotegerin, OPG, breast cancer, oestrogen, bone metastasis, MDA-MB-231, 199
- MCL1, ecteinascidin, tetrahydroisoquinoline, anoikis, metastasis, lung cancer cells, 505
- MCRC, bevacizumab, aflibercept, antiangiogenesis, TKI, VEGF, regorafenib, 2377
- MCRC, cetuximab, circulating tumor cells, colorectal cancer, 3905
- MCT4, colorectal cancer, VEGF, tumor growth, 2941
- MD-1483 cells, squamous cell carcinoma, head and neck cancer, collagen I, phosphoinositol-3 kinase, 379
- MDA-MB-231 cells, angio-associated migratory cell protein, AAMP, breast cancer, prognosis, MCF-7, 1499
- MDA-MB-231 cells, breast cancer, zoledronic acid, mTOR, REDD1, endoplasmic reticulum stress, MCF-7, 3807

- MDA-MB-231, ester conjugate, fatty acid, anticancer agent, cytotoxicity, cancer cell lines, MDA-MB-361, MCF-7, 2517
- MDA-MB-231, I3C derivative CTet, synergy, triple-negative breast cancer, autophagy, *MAP1LC3B*, BT-20 cells, 1867
- MDA-MB-231, RANK, RANKL, osteoprotegerin, OPG, breast cancer, oestrogen, bone metastasis, MCF-7, 199
- MDA-MB-361, ester conjugate, fatty acid, anticancer agent, cytotoxicity, cancer cell lines, MCF-7, MDA-MB-231, 2517
- MDA-MB453, cancer stem-like cells, OCT4, stemness, differentiation, asymmetric cell division, 763
- Mechano-growth factor (MGF), prostate cancer, Immunohistochemistry, insulin-like growth factor 1 (IGF-1), IGF1Ec, 2441
- Mediastinal lymph nodes, staging, surgical procedure, endosonographic evaluation, echoendoscope, review, 2369
- Medulla, adrenal, vagus, breast cancer, histology, metastasis, 3675
- Medulloblastoma, brain tumor, liposomal cytarabine, intrathecal, relapse/progression, case series, 3515
- Megavolt computed tomography, tomotherapy, prostate cancer, soft tissue matching, PTV margin, image-guided IMRT, 5675
- MEK/ERK inhibitor, cell signaling, ERK, U0126, CYP inhibitor, colorectal cancer, HT29, HCT116, 2499
- Melanoma of nasal cavity, metastatic pancreatic tumor, distal pancreatectomy, 567
- Melanoma, [N-methyl-11C]methylene blue, PET, TRACERlab FXc PRO module, 4267
- Melanoma, ABCB5, doxorubicin, NF- κ B, p53, parthenolide, 3205
- Melanoma, hydrogen peroxide, radiation, apoptosis, proliferation, 1799
- Melanoma, RO492907, gamma secretase, *PTEN*, 1307
- Melanoma-associated antigen (MAGE), papillary thyroid carcinoma, reverse transcriptase-polymerase chain reaction, 1731
- Melatonin, hepatocellular carcinoma, HCC, immunotherapy, interleukin-2, IL-2, BCG, 4531
- Melphalan, chemosaturation therapy, percutaneous hepatic perfusion, taxanes, platinum agents, 1989
- Mental neuropathy, numb chin syndrome, mandibular metastasis, inferior alveolar nerve, orthopantomogram, cone beam tomography, colonic cancer, case report, 1757
- Merlin, NF2, tumor suppressor, cell cycle, review, 1
- Mesenchymal tumor, GIST, sarcoma, spindle cell, round cell, pseudopapillary, 991
- Mesocolic, leiomyosarcoma, chemotherapy, paclitaxel, gemcitabine, recurrence, 2929
- Mesomark assay, pleural mesothelioma, mesothelin, malignant pleural effusion, 2707
- Mesothelial cells, peritoneal carcinomatosis, rat model, submesothelial layer, RCN-9 cells, fibroblast, 1439
- Mesothelin, afamin, L1CAM, serum marker, ovarian cancer, 329
- Mesothelin, malignant mesothelioma, lung cancer, YKL-40, 5517
- Mesothelin, pleural mesothelioma, malignant pleural effusion, Mesomark assay, 2707
- Mesothelioma, chemotherapy, pemetrexed, treatment outcome, quality of life, health economics, review, 3553
- Meta-analysis, anaplastic, glioblastoma multiforme, high-grade glioma, etoposide, irinotecan, topotecan, teniposide, 3307
- Meta-analysis, gastric gastrointestinal stromal tumor, gastric, GIST, laparoscopy-assisted surgery, 5031
- Meta-analysis, lateral lymph node dissection, rectal cancer, strategy, 2921
- Metabolic ¹⁸⁸Rhenium, sorafenib, radiotherapy, hepatocellular carcinoma, synergy, N1S1, HepG2 cells, 3871
- Metabolites, capecitabine, 5'-DFCR, 5'-DFUR, pharmacokinetics, HPLC, GLP, 881
- Metabotropic glutamate receptors, cell proliferation, tumor biology, neuroendocrine tumors, alternative therapy, review, 1267
- Metallothionein, minichromosome maintenance protein, ovarian cancer, 5375
- Metallothionein, non-small cell lung cancer, growth-inhibitory factor, 965
- Metallothionein, non-small cell lung cancer, immunocytochemistry, cisplatin resistance 97/97, DV90 cells, 5255
- Metastases, capecitabine, erlotinib, first-line treatment, pancreatic cancer, 717
- Metastasis of prostate cancer, regional pelvic nodes, immune cells: lymphocytes, macrophages, immune cell surveillance, lysis/apoptosis of metastatic cancer cells, immune responsive, immune-unresponsive (resistant) cells, 3635
- Metastasis, adrenal, medulla, vagus, breast cancer, histology, 3675
- Metastasis, breast cancer, paclitaxel, capecitabine, response, 4941
- Metastasis, breast cancer, paclitaxel, docetaxel, time-to-progression, survival, 2623
- Metastasis, circulating tumor cells, renal subcapsular implantation, murine model, RCC, 4751
- Metastasis, circulating tumor cells, TGF- β , CXCL1, breast cancer, chemokines, cytokines, 1491
- Metastasis, colorectal cancer, oxaliplatin, S-1, SOX, XELOX, 4029
- Metastasis, combination chemotherapy, esophageal squamous cell carcinoma, old age, risk factors, taxane, 4123
- Metastasis, ecteinascidin, tetrahydroisoquinoline, MCL1, anoikis, lung cancer cells, 505

- Metastasis, *HER2*, antibody, fluorophore, rhodamine, breast cancer, 4T1, GFP, orthotopic model, lymph node, imaging, 419
- Metastasis, *HER2*, esophagus, survival, 4975
- Metastasis, migration, invasion, artonin E, lung cancer cells, H460, H23, A549, H292 cells, 3079
- Metastasis, mitochondrial DNA, DNA repair, carcinogenesis, review, 3543
- Metastasis, monocyte, colon cancer cell, co-culture, angiogenesis, signaling pathway, DLD-1, THP-1 cells, 2895
- Metastasis, S-1, outpatient oral chemotherapy, unresectable head and neck cancer, 3285
- Metastasis, siRNA, VEGF-C, VEGF-D, mammary cancer, 4237
- Metastasis, telomerase, lung, cancer, 2643
- Metastasis, zoledronic acid, invasion, 3D culture assays, 5295
- Metastasis, αv integrin, green fluorescent protein, osteosarcoma, fibronectin, *in vitro*, *in vivo*, nude mouse, real-time imaging, confocal microscopy, 3021
- Metastatic breast cancer, breast cancer, non-pegylated liposomal doxorubicin, anthracycline, 4603
- Metastatic breast cancer, chemotherapy, *nab*-paclitaxel, 3407
- Metastatic breast cancer, *HER2*-positive, first-line, oral chemotherapy, 2657
- Metastatic colorectal cancer, CEA, chemotherapy, fluctuation, tumor flare, 253
- Metastatic colorectal cancer, elderly patients, oxaliplatin-based chemotherapy, 4627
- Metastatic colorectal cancer, irinotecan, 5'-deoxy-5-fluorouridine (5'-DFUR), UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism, 3423
- Metastatic disease, adjuvant treatment, chemotherapy, colorectal cancer, oxaliplatin, 1765
- Metastatic lung cancer, stereotactic body radiotherapy (SBRT), helical tomotherapy, pulmonary neoplasms, 655
- Metastatic neuroblastoma, PARP inhibition, radiation, MK-4827, DNA repair, 755
- Metastatic pancreatic tumor, melanoma of nasal cavity, distal pancreatectomy, 567
- Metastatic renal cell carcinoma, targeted therapies, angiogenesis, MRI, peak enhancement, 5663
- Metastatic spinal cord compression, prostate cancer, irradiation, extra-spinal organs, survival, prognosis, 4505
- Metformin, colon cancer, 3-bromopyruvate, phenformin, 2-deoxyglucose, 401
- Methotrexate, gambogic acid, dihydrofolate reductase, hepatoma, synergy, 133
- [*N*-Methyl-¹¹C]methylene blue, PET, TRACERlab FXc PRO module, melanoma, 4267
- Methylation, human CDH1 protein; stomach neoplasm, diffuse gastric cancer, methylation-specific polymerase chain reaction, pyrosequencing, 3765
- Methylation, prostate cancer, prognosis, PTGS2, RARB, DNA hypermethylation, 5249
- Methylation, thyroid cancer, SERPINA5, 4833
- Methylation-specific polymerase chain reaction, methylation, human CDH1 protein; stomach neoplasm, diffuse gastric cancer, pyrosequencing, 3765
- Metronomic chemotherapy, chemoradiation, hormone-refractory prostate cancer, phase I study, 4585
- Metronomic topotecan, pazopanib, drug drug interaction, pharmacokinetics, gynecological cancer, 3823
- MG63 cells, calcitonin, fibronectin, matrix metalloproteinase 9, integrins. NF- κ B activation, 4901
- MiaPaCa cells, curcumin, pancreatic cancer, xenograft, liposomal curcumin, annexin A2, 3603
- MICA/B, NK cell-enriched lymphocytes (NKL), NKG2D, docetaxel, NSCLC, phase II study, 2115
- Mice, curcumin, bone, morphometrics, remodeling, 3153
- Mice, soluble epoxide hydrolase, dextran sulfate sodium, colitis, carcinogenesis, 5261
- Microdissection, breast cancer, glutathione S-transferase P1 (GSTP1), DNA methylation, ER-positive breast cancer, 5617
- Microenvironment, breast cancer, phenotypic reversion, mammary fibroblasts, primary cells, 1525
- Micrometastases, sentinel lymph node, breast cancer staging, 4509
- Micrometastasis, lymph node, laryngeal cancer, head and neck cancer, probability, 3213
- MicroRNA expression, cervical cancer, HPV, clinical grading, 2561
- MicroRNA miR-1, androgen receptor, isoform, heat-shock protein HSPB1, 4921
- MicroRNA, breast cancer, androgen, IQWD1, 4811
- MicroRNA, colonic cancer, polymorphism, microRNA-binding site, rs1044129, prognosis, 513
- MicroRNA, environmental factors, gastric adenocarcinoma, gastric tumorigenesis, lifestyle factors, socioeconomic factors, 3195
- MicroRNA, gastric cancer, plasma, biomarker, prognosis, circulating nucleic acids, miR-21, 271
- MicroRNA, pancreatic neoplasm, indole-3-carbinol, gemcitabine, chemotherapy, Panc-1 cells, 1473
- microRNA-21, esophageal squamous cell carcinoma, Ruthenium, *PTEN*, *AKT*, 5407
- MicroRNA-binding site, colonic cancer, polymorphism, microRNA, rs1044129, prognosis, 513
- Microsatellite instability, Lynch syndrome, endometrial cancer, ovarian cancer, synchronous tumour, 3977
- Microsatellite instability, mucinous colorectal cancer, 5-fluorouracil, thymidylate synthase, topoisomerase-1, 4611
- Microsurgery, musculoskeletal tumor, forearm, hand, limb salvage, tissue transfer, review, 4175

- Microtubular configurations, advanced adenomas, invasive carcinoma, colorectal adenoma, 5471
- Microwave ablation, image-guided thermal ablation, HCC, 1221
- MIG2, breast cancer, mitogen-inducible gene-2, migfilin, 1977
- Migfilin, breast cancer, mitogen-inducible gene-2, MIG2, 1977
- Migration, high-performance counter current chromatography, umbelliferone, herniarin, scoparone, laryngeal cancer cells, proliferation, cell cycle, apoptosis, 4347
- Migration, metastasis, invasion, artonin E, lung cancer cells, H460, H23, A549, H292 cells, 3079
- Migration, osteosarcoma, quercetin, cell-cycle arrest, apoptosis, 143B cells, 1297
- Migration, quercetin, invasion, MMP-2, MMP-9, NF- κ B, SAS human oral cancer cells, 1941
- Minichromosome maintenance protein, metallothionein, ovarian cancer, 5375
- Minimal residual disease, *ex vivo* drug resistance, individualized tumor response testing, acute myeloid leukemia, children, relapse, 1189
- Minimally-invasive esophagectomy, esophageal cancer, outcome, 2085
- Minimally-invasive surgical technique, total gastrectomy, gastric cancer, oesophagojejunal anastomosis, stapling devices, 3269
- MiR-146a polymorphism, colorectal cancer, rs2910164, risk, prognosis, 3233
- MiR-146a, polymorphism, squamous cell carcinoma, head and neck, 341
- MiR-181a, acute leukemias, HMGB1, CD4, 445
- MiR-21, gastric cancer, microRNA, plasma, biomarker, prognosis, circulating nucleic acids, 271
- Miriplatin, hepatocellular carcinoma, transcatheter arterial chemoembolization, suspension, emulsion, 5603
- MiRNA expression, oral cancer, squamous cell carcinoma, genomics, 1511
- Mitochondria, naphthoquinones, chronic lymphocytic leukemia (CLL), MAPKs, cytochrome C, apoptosis, BCL2, 183
- Mitochondrial DNA, DNA repair, carcinogenesis, metastasis, review, 3543
- Mitochondrial membrane potential, daunorubicin derivatives, human acute leukemia cells, apoptosis, necrosis, 4439
- Mitochondrial membrane potential, piperaceae, *Piper sarmentosum*, dichamanetin, cytotoxicity, NF- κ B inhibition, DNA binding, PARP-1, ROS, 5349
- Mitogen-activated protein kinase, fluoxetine, hepatocellular carcinoma, apoptosis, Hep3B cells, 3691
- Mitogen-inducible gene-2, breast cancer, MIG2, migfilin, 1977
- Mitomycin C, gastric cancer, irinotecan, chemotherapy, 5107
- Mitomycin-C, chemotherapy, fluorouracil, colon cancer, capecitabine, 2743
- Mitosis, GFP, RFP, apoptosis, subcellular dynamics, brain cancer, mouse models, temozolomide, *in vivo* imaging, 103
- Mitosis, GFP, RFP, subcellular dynamics, brain cancer, brain metastasis, mouse model, craniotomy window, *in vivo* imaging, 1367
- Mitosis, HT-1080, fibrosarcoma, intravascular, extravasation, GFP, RFP, apoptosis, nude mice, confocal microscopy, 4229
- MK-4827, metastatic neuroblastoma, PARP inhibition, radiation, DNA repair, 755
- MKN45, HOCl, superoxide anion, singlet oxygen, hydroxyl radical, SOD, B16F10 cells, 3589
- MMP12, MMP13, SNP, colorectal cancer, 3247
- MMP13, MMP12, SNP, colorectal cancer, 3247
- MMP-2, quercetin, migration, invasion, MMP-9, NF- κ B, SAS human oral cancer cells, 1941
- MMP-9, quercetin, migration, invasion, MMP-2, NF- κ B, SAS human oral cancer cells, 1941
- Mobile tongue cancer, low-dose-rate interstitial brachytherapy, long-term results, 317
- Model, ovarian cancer, Notch, gamma-secretase inhibitor, 801
- Moderately emetic chemotherapy, colorectal cancer, chemotherapy-induced nausea and vomiting, adherence, dexamethasone, 5549
- Modulating agents, multidrug resistance, drug accumulation, doxorubicin, vincristine, paclitaxel, L929 murine cell line, MCF7 breast cancer cell line, 4381
- Molecular chaperones, cancer, endoplasmic reticulum, stress, unfolded protein response, activating transcription factor 6, PERK kinase, inositol requiring enzyme-1, review, 4683
- Molecular classification, breast cancer, lymphatic microvessel density, mast cells, prognosis, 957
- Molecular genotyping, NSCLC, mutation, high-throughput method, 5127
- Molecular markers, disease-free survival, kinase receptor family, tumor suppressor, sporadic cancer, 5159
- Molecular markers, epithelial-mesenchymal transition, cancer stem cells, quantitative PCR, endometrial cancer, 5461
- Molecular staging, lymph node metastases, polymerase chain reaction, prostate cancer, reference gene, 5243
- Molecular target, colorectal cancer, oxaliplatin, S-1, SOX, liver metastasis, 3941
- Molecular targeted drug, lung cancer, epidermal growth factor receptor, gefitinib, *EGFR* inhibitor, gefitinib, 5057
- Molecular targeting, 3-bromopyruvate, GAPDH, glucose metabolism, glycolysis, HCC, locoregional therapy, review, 13

- Molecular-targeted therapy, salivary ductal carcinoma, *HER2/neu*, trastuzumab, 2587
- Molecules, brain metastases, gastro-oesophageal cancer, GI cancer, targeted therapy, 1065
- Molt-4 cells, dihydroartemisinin, N-tert-butyl-alpha-phenylnitron, deferoxamine, free radical, iron, 4389
- Mongolian gerbils, gastritis, *Helicobacter pylori*, fish meal, calcium, 3667
- Monocyte chemoattractant protein-1 (MCP-1), ovarian cancer, SKOV-3 cell line, tumor-associated macrophages (TAMs), C-C motif chemokine receptor-2 (CCR2) antagonist, 4785
- Monocyte, colon cancer cell, co-culture, angiogenesis, metastasis, signaling pathway, DLD-1, THP-1 cells, 2895
- Morbid obesity, breast cancer, breast-conservation surgery, radiotherapy, chemotherapy, 3867
- Morbidity, IORT, breast cancer, elderly, short-term outcome, 3995
- Morphology, cucumin, liposomes, red blood cells, echinocyte, 3629
- Morphometrics, curcumin, bone, remodeling, mice, 3153
- MOSE, human epithelial ovarian cancer, EOC, mouse ovarian surface epithelium, orthotopic ovarian cancer, immuno-competent C57BL/6, 1317
- Motilin, adjuvant chemotherapy, breast cancer, dyspepsia, gastrin, ghrelin, leptin, pepsinogens, 4951
- Motility and adhesion, BMP10, urothelial cancer of bladder, growth, T24 cells, 1917
- Mouse mode, lung cancer, bone marrow-derived cells, green fluorescent protein, 831
- Mouse model, GFP, RFP, mitosis, subcellular dynamics, brain cancer, brain metastasis, craniotomy window, *in vivo* imaging, 1367
- Mouse model, heat-shock protein, heat-shock pre-treatment, liver regeneration, hepatectomy, 2887
- Mouse model, surgical stress, ovarian carcinoma, laparoscopy, 3177
- Mouse model, thyroid cancer, stem cells, xenografts, adipose tissue, 4213
- Mouse models, GFP, RFP, apoptosis, mitosis, subcellular dynamics, brain cancer, temozolomide, *in vivo* imaging, 103
- Mouse ovarian surface epithelium, human epithelial ovarian cancer, EOC, MOSE, orthotopic ovarian cancer, immuno-competent C57BL/6, 1317
- Mouse skin papillomas, benzophenone sunscreens, dioxybenzone, octabenzone, oral chemoprevention, antioxidants, 2535
- Mouse, gastrointestinal stromal tumor, xenograft, imatinib, sunitinib, 175
- MRD, WT-1, AML, relapse, 3335
- MRI, metastatic renal cell carcinoma, targeted therapies, angiogenesis, peak enhancement, 5663
- MRI, PET, head and neck cancer, 1141
- MRNA expression, protein tyrosine phosphorylation, LMW-PTP isoforms, genotype, enzymatic activity, 1983
- MRNA, survivin, non-small cell lung cancer, apoptosis, real-time RT-PCR, proliferation, 3475
- MSTO-211H, α 1-adrenoceptor blocker, apoptosis, mmalignant mesothelioma, caspase, NCI-H28, NCI-H2052, NCI-H2452, 887
- MTHFR, breast cancer, folate, homocysteine, FTO, polymorphism, Kazakhstan, 4049
- MTOR inhibitor, breast cancer, endocrine resistance, Everolimus, TemSirolimus, review, PI3K, AKT, 21
- MTOR, bevacizumab, temSirolimus, glioblastoma multiforme, phase II study, PI3K, protein kinase B (AKT), rapamycin, 1657
- MTOR, breast cancer, zoledronic acid, REDD1, endoplasmic reticulum stress, MCF-7, MDA-MB-231 cells, 3807
- MTOR, leukemia, NOTCH, siRNA, MYC, 4293
- MTOR, ovarian cancer, CDDO-Me, apoptosis, ROS, AKT, NF- κ B, 215
- MTOR, phospho-mTOR, squamous cell carcinoma, basal cell carcinoma, Sirolimus, Everolimus, Immunohistochemistry, organ transplantation, immunosuppression, skin, 3711
- MTOR, pituitary adenoma, RAPTOR, RICTOR, staging, invasion, 3123
- MTOR, rapamycin, Notch, leukemia, 809
- MTOR, tyrosine kinase inhibitor, PDGFR, HIF, head and neck squamous cell carcinoma, Everolimus, sorafenib, sunitinib, 5385
- Mucinous colorectal cancer, 5-fluorouracil, thymidylate synthase, topoisomerase-1, microsatellite instability, 4611
- Mullerian tumour, clear cell adenocarcinoma, endometrial neoplasm, bladder tumor, pelvic exenteration, 615
- Multidrug resistance, *ABCG2*, ALL, BCRP, MAPK, 5317
- Multidrug resistance, biliverdin reductase, leukemia, reactive oxygen species, 4913
- Multidrug resistance, modulating agents, drug accumulation, doxorubicin, vincristine, paclitaxel, L929 murine cell line, MCF7 breast cancer cell line, 4381
- Multidrug resistance-associated protein-2 (Mrp2), biliary excretion, cimetidine, drug interaction, pharmacokinetics, sunitinib, (Abcc2), 3105
- Multimodality treatment, brain metastases, pancreatic cancer, stereotactic radiosurgery, 3899
- Multimodality treatment, leptomeningeal metastases, neoplastic meningitis, intra-CSF chemotherapy, liposomal cytarabine, breast cancer, 2057
- Multiparametric MRI, prostate cancer, saturation prostate biopsy, pelvic phased-array MRI, 1195
- Multiple myeloma oncogene-1 (MUM1), liver, biopsies, autoimmune hepatitis, plasma cells, plasma cell precursors, 665

- Multiple myeloma, autologous stem-cell transplantation, consolidation and maintenance therapy, bortezomib, lenalidomide, 5681
- Multiple primary tumors, body-mass index, smoking, alcohol, neoplasms, esophageal cancer, colonoscopy, 5113
- Multi-target inhibitor of tyrosine kinases, sunitinib malate, soft tissue sarcomas, liposarcoma, 1061
- Murine double minute 2, esophagus, squamous cell carcinoma, definitive chemoradiotherapy, salvage esophagectomy, p16, Ki-67, 1463
- Murine model, circulating tumor cells, renal subcapsular implantation, metastasis, RCC, 4751
- Musashi, EMT, epithelial-mesenchymal transition, CSC, cancer stem cell, CD44, cadherin, 2867
- Muscle tissue, tumor tissue, histology, gene expression, 5213
- Muscle-invasive bladder cancer, MVAC chemotherapy, neoadjuvant chemotherapy, 4497
- Muscle-invasive, biomarker, bladder cancer, cyclin D1, 5235
- Musculoskeletal tumor, forearm, hand, limb salvage, microsurgery, tissue transfer, review, 4175
- Mutant p53, transcription, tumor cells, Saos-2 cells, 923
- mutation, fanconi anemia, FANCA gene, cytogenetic and molecular investigation, Greek patients, 3369
- Mutation, NSCLC, molecular genotyping, high-throughput method, 5127
- Mutation, ovarian carcinoma, *PPP2R1A*, *PIK3CA*, *KRAS*, *BRAF*, 113
- Mutation, squamous cell lung cancer, NSCLC, targeted-therapy, *EGFR*, *KRAS*, *PIK3CA*, *EGFR*-TKI, 1705
- MVAC chemotherapy, muscle-invasive bladder cancer, neoadjuvant chemotherapy, 4497
- MYC, leukemia, NOTCH, mTOR, siRNA, 4293
- Myeloid hemopathies, Inv(3)(q21q26), fluorescent *in situ* hybridization, chromosomal abnormality, 639
- 4N1K, CD47, CD36, TSP-1, autophagy, cancer, 1429
- N1S1, sorafenib, metabolic ¹⁸⁸Rhenium, radiotherapy, hepatocellular carcinoma, synergy, HepG2 cells, 3871
- Nab-paclitaxel, metastatic breast cancer, chemotherapy, 3407
- Nab-paclitaxel, peripheral neuropathy, paclitaxel, chemotherapy, opioids, 1153
- NAD⁺, follicular carcinoma, papillary carcinoma, nicotinamide phosphoribosyltransferase, SIRT3, 3047
- Nanomedicine, ultrasound, fullerenes, sonodynamic therapy, sarcoma 180, colon 26, 3145
- Nanoparticle, renal cell carcinoma, desacyl-saponin, BBE, *in vitro*, *in vivo*, xenograft, 143
- 2-Naphthol, polycyclic aromatic hydrocarbon, oxidative stress, antioxidant capacity, lung cancer, nested case-control study, 1-hydroxypyrene, thiobarbituric acid, 8-hydroxydeoxyguanosine, cotinine, 3089
- Naphthoquinones, chronic lymphocytic leukemia (CLL), MAPKs, cytochrome C, apoptosis, mitochondria, BCL2, 183
- Nasopharyngeal carcinoma, *IL10*, polymorphism, 3391
- NAT2*, cancer susceptibility, SNP, IAM, breast cancer, gastric cancer, 3683
- Native human interferon alpha, recombinant human interferon alpha, non-small cell lung cancer, tumor proliferation, apoptosis, *p21*, survivin, 2043
- Natural killer cell, cryopreservation, feeder cells, K562, expansion, 2011
- NB4, leukaemia, HIF, echinomycin, NOTCH, Jurkat cells, 3099
- NCI, sarcoma, lesion, epidemiology, SEER, 2597
- NCI-H2052, α 1-adrenoceptor blocker, apoptosis, mmalignant mesothelioma, caspase, NCI-H28, NCI-H2452, MSTO-211H, 887
- NCI-H2452, α 1-adrenoceptor blocker, apoptosis, mmalignant mesothelioma, caspase, NCI-H28, NCI-H2052, MSTO-211H, 887
- NCI-H28, α 1-adrenoceptor blocker, apoptosis, mmalignant mesothelioma, caspase, NCI-H2052, NCI-H2452, MSTO-211H, 887
- NCoR, LATS2, breast cancer, estrogen receptor, ER α , 53
- NEC, neuroendocrine, carcinoma, appendix, NET, 2635
- Necrosis, daunorubicin derivatives, human acute leukemia cells, apoptosis, mitochondrial membrane potential, 4439
- Nedaplatin, head and neck cancer, S-1, phase I study, granule formulation, 5699
- Neoadjuvant chemotherapy, breast cancer, chemoresponsiveness, S6 kinase 1 (S6K1), AKT, 4073
- Neoadjuvant chemotherapy, breast cancer, locally advanced tumor, HER-2, brain metastasis, pathological complete response, radiation, prophylactic cranial irradiation, 5119
- Neoadjuvant chemotherapy, muscle-invasive bladder cancer, MVAC chemotherapy, 4497
- Neoadjuvant radiochemotherapy, rectal carcinoma, ypTNM classification, histological regression grade, 559
- Neoadjuvant therapy, chemoradiation, combined treatment, colorectal adenocarcinoma, long-term outcome, 725
- Neoplasms, body-mass index, smoking, alcohol, multiple primary tumors, esophageal cancer, colonoscopy, 5113
- Neoplastic meningitis, leptomeningeal metastases, intra-CSF chemotherapy, liposomal cytarabine, breast cancer, multimodality treatment, 2057
- Neoplastic stem cells, prostatic neoplasms, radiotherapy, reactive oxygen species, DNA repair, radioresistance, 4469
- Neopterin, head and neck carcinoma, radiotherapy, toxicity, 4097
- Nested case-control study, polycyclic aromatic hydrocarbon, oxidative stress, antioxidant capacity, lung cancer, 1-hydroxypyrene, thiobarbituric acid, 8-hydroxydeoxyguanosine, cotinine, 2-Naphthol, 3089
- Nestin, green fluorescent protein, blood vessels, angiogenesis, anastomosis, red fluorescent protein, Gelfoam[®], transgenic nude mice, confocal microscopy, color-coded imaging, vascularization, 3041

- NET, neuroendocrine, carcinoma, appendix, NEC, 2635
- Neural stem cells, irinotecan, carboxyl esterase (CE), CNS lymphoma, rabbit, 5335
- Neuroendocrine differentiation, CD117, CD133, *ABCG2* antigens, non-small cell lung cancer, stem cell antigens, 981
- Neuroendocrine tumors, metabotropic glutamate receptors, cell proliferation, tumor biology, alternative therapy, review, 1267
- Neuroendocrine tumours, vasoactive intestinal peptide, VIP, radiolabelling, tumour targeting, 1537
- Neuroendocrine, carcinoma, appendix, NET, NEC, 2635
- Neuropathy, hypoxic radiosensitizer, radiotherapy, oral administration, sanazole (AK-2123), 643
- Neutrophil elastase inhibitor, CT26 murine colon cancer, sivelestat, cecal ligation and puncture, compensatory anti-inflammatory response syndrome, 3653
- Neutrophil to lymphocyte ratio, colorectal cancer, stage IV, asymptomatic primary tumor, palliative surgery, Glasgow prognostic score, 5567
- Neutrophil/lymphocyte ratio, C-reactive protein, platelet/lymphocyte ratio, rectal cancer, prognosis, chemoradiotherapy, 5065
- Neutrophil-to-lymphocyte ratio, colon cancer, 4591
- Neutrophil-to-lymphocyte ratio, colorectal cancer, systemic inflammatory response, 3291
- Nevus cutaneous, nevus superficialis, fibrolipoma, 3365
- Nevus superficialis, fibrolipoma, nevus cutaneous, 3365
- NF1, orbit, orbital rim, orbital neurofibromatosis, plexiform neurofibroma, sphenoid wing dysplasia, orbital dysplasia, plain radiographs, cephalometry, 1081
- NF2, merlin, tumor suppressor, cell cycle, review, 1
- NFs, CAFs, lung cancer, stromal NSCLC, direct co-culture, indirect co-culture, EMT, proliferation, SMAD3, Hedgehog signaling pathway, 3715
- NFs, cancer-associated fibroblasts, normal fibroblasts, lung cancer, NSCLC, co-culture, EMT, proliferation, SMAD3, 2001
- NF- κ B inhibition, piperaceae, *Piper sarmentosum*, dichamanetin, cytotoxicity, DNA binding, mitochondrial membrane potential, PARP-1, ROS, 5349
- NF- κ B, ABCB5, doxorubicin, melanoma, p53, parthenolide, 3205
- NF- κ B, *Ambrosia arborescens*, damsin, coronopilin, chemoselective bromination, sesquiterpenes, cell proliferation, STAT3, apoptosis, 3799
- NF- κ B, esophageal cancer, eicosapentaenoic acid, apoptosis, cytokines, TE-1 cells, 4319
- NF- κ B, ovarian cancer, CDDO-Me, apoptosis, ROS, AKT, mTOR, 215
- NF- κ B, quercetin, migration, invasion, MMP-2, MMP-9, SAS human oral cancer cells, 1941
- Nicotinamide phosphoribosyltransferase, follicular carcinoma, papillary carcinoma, NAD⁺, SIRT3, 3047
- NIH3T3, azatyrosinamides, ras, antitumour agent, SW620 human colon xenograft, angiogenesis, 425
- Nitric oxide, chemotherapeutic resistance, cisplatin, doxorubicin, etoposide, lung cancer, 5433
- NK cell-enriched lymphocytes (NKL), MICA/B, NKG2D, docetaxel, NSCLC, phase II study, 2115
- NKG2D, NK cell-enriched lymphocytes (NKL), MICA/B, docetaxel, NSCLC, phase II study, 2115
- NMIBC, non-muscle invasive bladder carcinoma, interleukin-2, IL-2, marker tumour, 2099
- NNPCC, Lynch syndrome, colorectal cancer, clinical management, 2147
- Nodal metastasis, T1 esophageal cancer, tumor budding, E-cadherin, 5023
- Nodal status, postoperative follow-up, gastric cancer, DFS, recurrence, 4645
- Node category (N-category), TNM classification, retrieved lymph node number (RLN), Dukes' C, colorectal cancer, 2949
- Nomogram, prostate cancer, diagnosis, prostate cancer antigen 3, 553
- Non-B non-C hepatocellular carcinoma, hepatitis B core antigen antibody, curative therapy, overall survival, recurrence-free survival, 2211
- Non-bulky, cervical cancer, stage IB1/II, radiotherapy, concurrent chemoradiotherapy, 5123
- Non-Hodgkin lymphoma, positron-emission tomography, FDG, beta-2 microglobulin, 3341
- Non-Hodgkin's lymphoma, radioimmunotherapy, CD37, ¹⁷⁷Lu, 85
- Non-homologous end-joining, *XRCC6/Ku70*, childhood leukemia, polymorphisms, genotyping, 5395
- Non-homologous end-joining, *XRCC6/Ku70*, hepatocellular carcinoma, polymorphism, genotype, real-time quantitative reverse transcription, Immunohistochemistry, 529
- Non-malignant, 5-HTRs, serotonin, malignant, invasive ductal carcinoma, invasive lobular carcinoma, breast cancer, 363
- Non-melanoma skin cancer, chemoprevention, UV radiation-induced skin tumors, experimental model, combination therapy, 3033
- Non-muscle invasive bladder carcinoma, NMIBC, interleukin-2, IL-2, marker tumour, 2099
- Non-pegylated liposomal doxorubicin, breast cancer, anthracycline, metastatic breast cancer, 4603
- Non-platinum triplet chemotherapy, advanced non-small cell lung cancer, UFT, vinorelbine, gemcitabine, 1163
- Non-small cell lung cancer (NSCLC), symptom control, docetaxel (Taxotere®), observational study, 3831
- Non-small cell lung cancer, aged patient, elderly, chemotherapy, pharmacokinetics, quality of life, carboplatin, paclitaxel, maximum tolerated dose, 261

- Non-small cell lung cancer, aryl hydrocarbon receptor, epidermal growth factor receptor, prognosis, 3953
- Non-small cell lung cancer, chemotherapy, randomized phase 2, ethnicity, docetaxel, paclitaxel carboplatin, 4631
- Non-small cell lung cancer, cisplatin, ifosfamide, docetaxel, survival, phase III trial, 5477
- Non-small cell lung cancer, *EGFR*-TKI resistance, erlotinib, amplification, copy-number alteration, CRKL, 5223
- Non-small cell lung cancer, HLA class-I expression, surgery, prognosis, cancers/testis antigen, immune escape, 2123
- Non-small cell lung cancer, *in vivo* antitumor activity, elacytarabine, bevacizumab, cetuximab, trastuzumab, xenograft, 3615
- Non-small cell lung cancer, lung cancer, NSCLC, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, brain metastases, humanized monoclonal antibody, angiogenesis, vascular endothelial growth factor A (VEGF-A), pulmonary haemorrhage, 3275
- Non-small cell lung cancer, metallothionein, growth-inhibitory factor, 965
- Non-small cell lung cancer, metallothionein, immunocytochemistry, cisplatin resistance 97/97, DV90 cells, 5255
- Non-small cell lung cancer, native human interferon alpha, recombinant human interferon alpha, tumor proliferation, apoptosis, *p21*, survivin, 2043
- Non-small cell lung cancer, neuroendocrine differentiation, CD117, CD133, *ABCG2* antigens, stem cell antigens, 981
- Non-small cell lung cancer, pemetrexed, thymidylate synthase, gene amplification, 1935
- Non-small cell lung cancer, surgery, early-onset, chemotherapy-induced neutropenia, prognosis, 2755
- Non-small cell lung cancer, survivin, apoptosis, real-time RT-PCR, mRNA, proliferation, 3475
- Non-small cell lung cancer, radiotherapy, epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, erlotinib, 3279
- Non-small lung cancer, epidermal growth factor receptor, erlotinib, gefitinib, acquired resistance to gefitinib, adverse events, 5083
- Non-squamous non-small cell lung cancer, carboplatin, pemetrexed, phase II trial, 5535
- Non-squamous NSCLC, pemetrexed, cisplatin, *ALK*, Japanese, 3327
- Normal fibroblasts, cancer-associated fibroblasts, NFs, lung cancer, NSCLC, co-culture, EMT, proliferation, SMAD3, 2001
- NOTCH, leukaemia, HIF, echinomycin, NB4, Jurkat cells, 3099
- NOTCH, leukemia, mTOR, siRNA, MYC, 4293
- Notch, mTOR, rapamycin, leukemia, 809
- Notch, ovarian cancer, gamma-secretase inhibitor, model, 801
- Nox4, EMT, TGF- β , pancreatic cancer, 4431
- NRAS* mutations, *KRAS*, BRAF mutations, *KRAS* codon 59, follicular pattern thyroid lesions, 4779
- NRP1, prostate cancer, Immunohistochemistry, angiogenesis, *VEGFR1*, tissue array analysis, prostatectomy, 2065
- NSAIDS, colon cancer, prevention, COX inhibition, apoptosis, ACF, rat model, 3581
- NSCLC, cancer-associated fibroblasts, normal fibroblasts, NFs, lung cancer, co-culture, EMT, proliferation, SMAD3, 2001
- NSCLC, lung cancer, bone metastasis, CEA, CTX, CYFRA 21-1, PINP, TRAP5b, 2593
- NSCLC, lung cancer, non-small cell lung cancer, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, brain metastases, humanized monoclonal antibody, angiogenesis, vascular endothelial growth factor A (VEGF-A), pulmonary haemorrhage, 3275
- NSCLC, molecular genotyping, mutation, high-throughput method, 5127
- NSCLC, NK cell-enriched lymphocytes (NKL), MICA/B, NKG2D, docetaxel, phase II study, 2115
- NSCLC, pemetrexed, erlotinib, adenocarcinoma, second-line, third-line, sequence, 3397
- NSCLC, squamous cell lung cancer, targeted-therapy, *EGFR*, *KRAS*, *PIK3CA*, mutation, *EGFR*-TKI, 1705
- N-tert-butyl-alpha-phenylnitron, dihydroartemisinin, deferoxamine, Molt-4 cells, free radical, iron, 4389
- Nucleophosmin, two-dimensional gel electrophoresis, LC-MS/MS, 2-D western blotting, tumor progression, 153
- Nude mice, HT-1080, fibrosarcoma, intravascular, extravasation, GFP, RFP, mitosis, apoptosis, confocal microscopy, 4229
- Nude mice, VEGF-C, ShRNA, pancreatic cancer, orthotopic, GFP, 409
- Nude mice, $\alpha_v\beta_3$ integrin, overexpression, green fluorescent protein, red fluorescent protein, osteosarcoma, lung metastasis, passage, variants, 3623
- Nude mouse, α_v integrin, green fluorescent protein, osteosarcoma, fibronectin, *in vitro*, *in vivo*, metastasis, real-time imaging, confocal microscopy, 3021
- Numb chin syndrome, mental neuropathy, mandibular metastasis, inferior alveolar nerve, orthopantomogram, cone beam tomography, colonic cancer, case report, 1757
- Nutrition, anemia, chemoradiotherapy, esophageal cancer, prognostic factor, 3495
- NX-PVKA-R, hepatocellular carcinoma, PIVKA-II, post-curative treatment change, disease-free survival, protein-induced vitamin K absence or antagonist-II, 2689
- NY-ESO-1, redirected T-cells, anti-idiotypic antibody, expansion, peptide specific, chimeric antigen receptor, 4189

- O-antigen polysaccharide, *Pantoea agglomerans*, LPS, LPSP, serum-free, HMM, LMM, 2875
- Obesity, breast cancer, exercise intervention, cardiovascular risk factors, health behavior, physical activity, physical health, 1595
- Obesity, early breast cancer, docetaxel, fat mass, dose intensity, toxicity, 5655
- Obesity, endometrial carcinoma, baby boomers, early stage, outcome, prognosis, 619
- Observational study, non-small cell lung cancer (NSCLC), symptom control, docetaxel (Taxotere®), 3831
- OCT4, cancer stem-like cells, MDA-MB453, stemness, differentiation, asymmetric cell division, 763
- OCT4B, cisplatin, chemoresistance, apoptosis, A549, 5365
- Octabenzene, benzophenone sunscreens, dioxybenzone, mouse skin papillomas, oral chemoprevention, antioxidants, 2535
- Octreotide, intestinal obstruction, steroids, palliative care, 5557
- Ocular adnexal, radiotherapy, MALT lymphoma, 5575
- Odontogenic tumor, adenomatoid tumor, jaws tumor, 2673
- Oesophagojejunal anastomosis, total gastrectomy, gastric cancer, stapling devices, minimally-invasive surgical technique, 3269
- Oestrogen, RANK, RANKL, osteoprotegerin, OPG, breast cancer, bone metastasis, MCF-7, MDA-MB-231, 199
- Oestrogen/progesterone receptors, artificial neural networks, cancer prognosis, ki-67, p53, prediction of nodal status, 3925
- Old age, combination chemotherapy, esophageal squamous cell carcinoma, metastasis, risk factors, taxane, 4123
- Olive oil, polyunsaturated fatty acids (PUFAs), colorectal cancer, lipid metabolism, gene expression, 3739
- Oncogene, caveolin-1, prostate cancer, polymorphism, 1023
- Oncogenes, glycolytic enzymes, signaling pathways, transcription factors, tumor suppressor genes, Warburg effect, review, 2855
- Oncologic surgery, GIST, SILS, intragastric, 3359
- Ondansetron, pharmacokinetic interaction, tamoxifen, hepatic and intestinal, CYP2D, CYP3A1/2, DMBA rats, 521
- ONJ, osteonecrosis of the jaw, denosumab, bevacizumab, sunitinib, risk factors, review, 1793
- Operation, gallbladder carcinoma, lymphocyte count, prognosis, 3439
- OPG, RANK, RANKL, osteoprotegerin, breast cancer, oestrogen, bone metastasis, MCF-7, MDA-MB-231, 199
- Opioids, peripheral neuropathy, paclitaxel, nab-paclitaxel, chemotherapy, 1153
- Oral absorption, curcumin, bioavailability, drug delivery system, review, 2807
- Oral administration, hypoxic radiosensitizer, radiotherapy, neuropathy, sanazole (AK-2123), 643
- Oral cancer, 5-hydroxymethylcytosine, DNA methylation, ten-eleven-translocation 2, biological markers, 4325
- Oral cancer, chemoprevention, strawberries, hamster cheek pouch, 4757
- Oral cancer, HPV, tumor sample screening, 3481
- Oral cancer, leukoplakia, HMGA, 4261
- Oral cancer, podoplanin, VEGF-C, oral squamous cell carcinoma, prognosis, 3969
- Oral cancer, Siah2, ubiquitin ligase, apoptosis, 4965
- Oral cancer, Sirolimus, oral topical delivery, saliva, 661
- Oral cancer, SNPs, coagulation factors, angiotensin-converting enzyme, angiotensinogen, serpine1, regression analysis, 4033
- Oral cancer, squamous cell carcinoma, miRNA expression, genomics, 1511
- Oral chemoprevention, benzophenone sunscreens, dioxybenzone, octabenzene, mouse skin papillomas, antioxidants, 2535
- Oral chemotherapy, metastatic breast cancer, *HER2*-positive, first-line, 2657
- Oral squamous cell carcinoma, mass spectrometry, matrix-assisted laser desorption, ionization time-of-flight mass spectrometry, 837
- Oral squamous cell carcinoma, podoplanin, VEGF-C, oral cancer, prognosis, 3969
- Oral topical delivery, Sirolimus, oral cancer, saliva, 661
- Orbit, IgG4, inflammation, lymphoma, 2779
- Orbit, orbital rim, orbital neurofibromatosis, NF1, plexiform neurofibroma, sphenoid wing dysplasia, orbital dysplasia, plain radiographs, cephalometry, 1081
- Orbital dysplasia, orbit, orbital rim, orbital neurofibromatosis, NF1, plexiform neurofibroma, sphenoid wing dysplasia, plain radiographs, cephalometry, 1081
- Orbital neurofibromatosis, orbit, orbital rim, NF1, plexiform neurofibroma, sphenoid wing dysplasia, orbital dysplasia, plain radiographs, cephalometry, 1081
- Orbital rim, orbit, orbital neurofibromatosis, NF1, plexiform neurofibroma, sphenoid wing dysplasia, orbital dysplasia, plain radiographs, cephalometry, 1081
- Orchiectomy, testicular neoplasms, small testicular masses, testis-sparing surgery, 5205
- Organ transplantation, mTOR, phospho-mTOR, squamous cell carcinoma, basal cell carcinoma, Sirolimus, Everolimus, Immunohistochemistry, immunosuppression, skin, 3711
- Organochlorine, polychlorinated biphenyl, PCB, mammographic breast density, breast cancer, 5483
- Organ-preserving surgery, laryngeal cancer, larynx preservation, radiochemotherapy, 4701
- Orthopantomogram, numb chin syndrome, mental neuropathy, mandibular metastasis, inferior alveolar nerve, cone beam tomography, colonic cancer, case report, 1757

- Orthotopic liver transplantation, phase I, sorafenib, hepatocellular carcinoma, adjuvant therapy, 2797
- Orthotopic lung cancer model, FLT-PET/CT, 4741
- Orthotopic model, *HER2*, antibody, fluorophore, rhodamine, breast cancer, 4T1, GFP, lymph node, metastasis, imaging, 419
- Orthotopic ovarian cancer, human epithelial ovarian cancer, EOC, mouse ovarian surface epithelium, MOSE, immunocompetent C57BL/6, 1317
- Orthotopic, glioma, U87, RFP, craniotomy window, imaging, fluorescence, surgery, survival, 107
- Orthotopic, VEGF-C, ShRNA, pancreatic cancer, nude mice, GFP, 409
- Osteoclastogenesis, *Rhinacanthus nasutus*, cytotoxicity, apoptosis induction, HSC-2, HSC-3, HSC-4, HL-60 cells, 453
- Osteonecrosis of the jaw, ONJ, denosumab, bevacizumab, sunitinib, risk factors, review, 1793
- Osteonecrosis, bisphosphonate, mandible, cytostatic therapy, risk factors, 3917
- Osteopontin, bone sialoprotein, prognosis, renal cell carcinoma, 2679
- Osteoprotegerin, RANK, RANKL, OPG, breast cancer, oestrogen, bone metastasis, MCF-7, MDA-MB-231, 199
- Osteosarcoma, quercetin, cell-cycle arrest, apoptosis, migration, 143B cells, 1297
- Osteosarcoma, α integrin, green fluorescent protein, blood vessels, red fluorescent protein, Gelfoam[®], transgenic nude mouse, confocal microscopy, 1361
- Osteosarcoma, α integrin, green fluorescent protein, fibronectin, *in vitro*, *in vivo*, nude mouse, metastasis, real-time imaging, confocal microscopy, 3021
- Osteosarcoma, $\alpha_v\beta_3$ integrin, overexpression, green fluorescent protein, red fluorescent protein, nude mice, lung metastasis, passage, variants, 3623
- Osteosarcoma, 143B cells, quercetin, cell-cycle arrest, apoptosis, migration, 1297
- Outcome, endometrial carcinoma, baby boomers, early stage, obesity, prognosis, 619
- Outcome, minimally-invasive esophagectomy, esophageal cancer, 2085
- Outcome, rectal cancer, preoperative, chemotherapy, follow-up, Alimta, pemetrexed, 325
- Outpatient oral chemotherapy, S-1, unresectable head and neck cancer, metastasis, 3285
- Ovarian cancer, acetaminophen, glutathione, chemoenhancement, cisplatin, SKOV3 cells, 2391
- Ovarian cancer, afamin, LICAM, mesothelin, serum marker, 329
- Ovarian cancer, andrographolide, cisplatin, apoptosis, synergism, anti-proliferative, 4365
- Ovarian cancer, carboplatin, selenite, xenografts, drug resistance, 4249
- Ovarian cancer, CD44-targeted delivery, PLGA nanoparticles, hyaluronic acid, surface decoration, SN-38, CTAB assay, 2425
- Ovarian cancer, CDDO-Me, apoptosis, ROS, AKT, NF- κ B, mTOR, 215
- Ovarian cancer, chemotherapy resistance, copper transporter, 1409
- Ovarian cancer, chinese medicine, β -elemene, taxanes, synergism, prostate cancer, apoptosis, cell cycle arrest, 929
- Ovarian cancer, clostridium septicum, distant myonecrosis, gas gangrene, distant myonecrosis in ovarian cancer, 1585
- Ovarian cancer, fascin-1, expression, prognosis Immunohistochemistry, 371
- Ovarian cancer, galectin-7, siRNA, prognosis, 1555
- Ovarian cancer, HE4, borderline ovarian tumors, 1673
- Ovarian cancer, irinotecan, carboplatin, chemotherapy, 1073
- Ovarian cancer, K2P channels, TASK-3, expression, survival, SKOV-3, OVCAR-3 cells, 1401
- Ovarian cancer, Lynch syndrome, endometrial cancer, synchronous tumour, microsatellite instability, 3977
- Ovarian cancer, metallothionein, minichromosome maintenance protein, 5375
- Ovarian cancer, Notch, gamma-secretase inhibitor, model, 801
- Ovarian cancer, salinomycin, DR4, DR5, apoptosis, A2780cis cells, 1457
- Ovarian cancer, SKOV-3 cell line, tumor-associated macrophages (TAMs), monocyte chemoattractant protein-1 (MCP-1), C-C motif chemokine receptor-2 (CCR2) antagonist, 4785
- Ovarian cancer, sphingolipids, chemoresistance, sphingosine kinase-2, experimental therapeutics, sphingosine-1-phosphate, ABC294640, BG-1, Caov-3 cells, 3573
- Ovarian cancer, WT1, DC immunotherapy, carcinosarcoma, 3855
- Ovarian carcinoma, *PPP2RIA*, *PIK3CA*, *KRAS*, *BRAF*, mutation, 113
- Ovarian carcinoma, surgical stress, laparoscopy, mouse model, 3177
- Ovarian carcinosarcomas, prophylactic pelvic irradiation, chemotherapy, surgery, prognosis, 1003
- OVCAR-3 cells, ovarian cancer, K2P channels, TASK-3, expression, survival, SKOV-3, 1401
- Overall survival, DNA ploidy index, gastric adenocarcinoma, prognostic factor, response to chemotherapy, 1209
- Overall survival, hepatitis B core antigen antibody, non-B non-C hepatocellular carcinoma, curative therapy, recurrence-free survival, 2211
- Overall survival, lung cancer, non-small cell lung cancer, NSCLC, bevacizumab, platinum-based chemotherapy, progression-free survival, brain metastases, humanized monoclonal antibody, angiogenesis, vascular endothelial growth factor A (VEGF-A), pulmonary haemorrhage, 3275

- Overall survival, renal cell carcinoma, vascular endothelial growth factor, distant metastasis-free survival, 5017
- Overall survival, retroperitoneal sarcoma, disease-free survival, soft tissue sarcoma, 4081
- Overexpression, $\alpha_v\beta_3$ integrin, green fluorescent protein, red fluorescent protein, osteosarcoma, nude mice, lung metastasis, passage, variants, 3623
- Oxaliplatin, adjuvant treatment, chemotherapy, colorectal cancer, metastatic disease, 1765
- Oxaliplatin, colorectal cancer, 5-fluorouracil, capecitabine, comparative effectiveness research, treatment effectiveness, cost effectiveness, 1053
- Oxaliplatin, colorectal cancer, S-1, SOX, molecular target, liver metastasis, 3941
- Oxaliplatin, colorectal cancer, S-1, SOX, XELOX, metastasis, 4029
- Oxaliplatin, epirubicin, capecitabine, docetaxel, cisplatin, 5-fluorouracil, G-CSF, gastroesophageal cancer, adenocarcinoma, 3455
- Oxaliplatin, epirubicin, capecitabine, gastroesophageal cancer, adenocarcinoma, 1035
- Oxaliplatin, postoperative chemotherapy, colorectal liver metastasis, irinotecan, synchronous metastasis, 5-fluorouracil, leucovorin, FOLFOX, FOLFIRI, 3317
- Oxaliplatin, vitamin D analogs, combined treatment, irinotecan, anticancer activity, colonic cancer, 433
- Oxaliplatin-based chemotherapy, C-reactive protein, survival, stage IV colorectal cancer, 5051
- Oxaliplatin-based chemotherapy, elderly patients, metastatic colorectal cancer, 4627
- Oxidative stress, AKT, hTERT, iNOS, 3295
- Oxidative stress, costello syndrome, potassium ascorbate with ribose, 691
- Oxidative stress, polycyclic aromatic hydrocarbon, antioxidant capacity, lung cancer, nested case-control study, 1-hydroxypyrene, thiobarbituric acid, 8-hydroxydeoxyguanosine, cotinine, 2-Naphthol, 3089
- P14, p16, cell cycle, cell senescence, qPCR, breast cancer, 2185
- P16 expression, HPV infection, SCCHN, 913
- P16, esophagus, squamous cell carcinoma, definitive chemoradiotherapy, salvage esophagectomy, murine double minute 2, Ki-67, 1463
- P16, p14, cell cycle, cell senescence, qPCR, breast cancer, 2185
- P16, renal cell carcinoma, PD-0322991, palbociclib, cell-cycle inhibition, CDKN2A, E2F1, 2997
- P16, tonsillar squamous cell carcinoma, regulatory T-cell, FOXP3, HPV, 5667
- P21, *ATM*, *ATR*, *Chk1*, p53, cell-cycle arrest, vinca alkaloids, DNA damage, 5273
- P21, esophageal squamous cell carcinoma, prognostic factor, 4329
- P21, native human interferon alpha, recombinant human interferon alpha, non-small cell lung cancer, tumor proliferation, apoptosis, survivin, 2043
- P53 cut-off point, clinicopathological features, Immunohistochemistry, luminal/*HER2*-negative breast cancer, p53 overexpression, prognostic factor, 3891
- P53 overexpression, clinicopathological features, Immunohistochemistry, luminal/*HER2*-negative breast cancer, p53 cut-off point, prognostic factor, 3891
- P53, ABCB5, doxorubicin, melanoma, NF- κ B, parthenolide, 3205
- P53, artificial neural networks, cancer prognosis, ki-67, oestrogen/progesterone receptors, prediction of nodal status, 3925
- P53, *ATM*, *ATR*, *Chk1*, *p21*, cell-cycle arrest, vinca alkaloids, DNA damage, 5273
- P53, endometrial cancer, Immunohistochemistry, histological grade, estrogen receptor, progesterone receptor, Ki67, predictive model, 2191
- P53, *EZH2*, *BMI1*, human oral squamous cell carcinoma, 4309
- P53, *JNK*, redox factor 1, selenomethionine, ubiquitination, cancer prevention, protein stability, 3645
- P53, upper tract urothelial carcinoma, immunohistochemistry, prognosis, hemodialysis, 1091
- P66shc, taxol, dichloroacetic acid, renal, toxicity, 3119
- Paclitaxel carboplatin, non-small cell lung cancer, chemotherapy, randomized phase 2, ethnicity, docetaxel, 4631
- Paclitaxel, 5'-DFUR, gastric cancer, phase II study, 2629
- Paclitaxel, aged patient, elderly, non-small cell lung cancer, chemotherapy, pharmacokinetics, quality of life, carboplatin, maximum tolerated dose, 261
- Paclitaxel, breast cancer, capecitabine, metastasis, response, 4941
- Paclitaxel, breast cancer, metastasis, docetaxel, time-to-progression, survival, 2623
- Paclitaxel, gastric cancer, second-line therapy, 4547
- Paclitaxel, leiomyosarcoma, chemotherapy, mesocolic, gemcitabine, recurrence, 2929
- Paclitaxel, multidrug resistance, modulating agents, drug accumulation, doxorubicin, vincristine, L929 murine cell line, MCF7 breast cancer cell line, 4381
- Paclitaxel, peripheral neuropathy, *nab*-paclitaxel, chemotherapy, opioids, 1153
- Paclitaxel-resistance, gastric cancer cell lines, peritoneal metastasis, *in vivo* selection, gene expression profile, 4299
- PAI-1, head and neck cancer, keratinocytes, differential regulation, uPA, 3113
- Pain, cancer-induced bone pain, sex differences, bone metastasis, 1963

- Palbociclib, renal cell carcinoma, PD-0322991, cell-cycle inhibition, CDKN2A, p16, E2F1, 2997
- Palliative care, octreotide, intestinal obstruction, steroids, 5557
- Palliative chemotherapy, palliative oncology, supportive care, 5639
- Palliative management, anaplastic thyroid carcinoma, chemoradiation therapy, docetaxel, local control, 3445
- Palliative oncology, palliative chemotherapy, supportive care, 5639
- Palliative surgery, colorectal cancer, stage IV, asymptomatic primary tumor, Glasgow prognostic score, neutrophil to lymphocyte ratio, 5567
- Pallor reaction, brachytherapy, gynecological cancer, high dose rate, late vaginal mucosal reaction, stenosis, 3963
- Palonosetron, dexamethasone, early breast cancer, 1721
- Panc-1 cells, pancreatic neoplasm, indole-3-carbinol, gemcitabine, microRNA, chemotherapy, 1473
- PANC-1, pancreatic ductal adenocarcinoma, gemcitabine, hyperbaric oxygen therapy, apoptotic index, AsPc-1 cells, 4827
- Pancreas, synchronous cancer, thyroid, breast, stomach, 2135
- Pancreatic adenocarcinoma, chemotherapy, gemcitabine, FOLFORINOX, combined therapy, clinical trials, review, 1785
- Pancreatic body cancer, extensive distal pancreatectomy, ExDP, gastroduodenal artery, 267
- Pancreatic cancer, ARP2/3 complex, cell migration, 45
- Pancreatic cancer, brain metastases, multimodality treatment, stereotactic radiosurgery, 3899
- Pancreatic cancer, capecitabine, erlotinib, first-line treatment, metastases, 717
- Pancreatic cancer, β -catenin, cardiac hormones, colorectal adenocarcinoma, renal cancer, 2409
- Pancreatic cancer, chemotherapy, diabetes mellitus, insulin, 287
- Pancreatic cancer, curcumin, xenograft, liposomal curcumin, annexin A2, MiaPaCa cells, 3603
- Pancreatic cancer, DDX39, gemcitabine, drug-resistant KLM1 cells, 3133
- Pancreatic cancer, disease outcome, adenocarcinoma, 5491
- Pancreatic cancer, fresh-frozen plasma, prognosis, pancreatic resection, blood transfusion, post-operative recurrence, 4041
- Pancreatic cancer, GFP, 53BP1, focus, UVC, DNA damage, 1373
- Pancreatic cancer, Nox4, EMT, TGF- β , 4431
- Pancreatic cancer, peroxiredoxin, gemcitabine, drug resistance, 4821
- Pancreatic cancer, tumor progression, CXCR4, β -catenin, 4103
- Pancreatic cancer, VEGF-C, ShRNA, nude mice, orthotopic, GFP, 409
- Pancreatic carcinomas, AKT, cardiac hormones, colorectal adenocarcinomas, renal adenocarcinoma, 785
- Pancreatic ductal adenocarcinoma, gemcitabine, hyperbaric oxygen therapy, apoptotic index, PANC-1, AsPc-1 cells, 4827
- Pancreatic neoplasm, indole-3-carbinol, gemcitabine, microRNA, chemotherapy, Panc-1 cells, 1473
- Pancreatic neuroendocrine tumor, ectopic ACTH syndrome, Cushing's syndrome, gastroenteropancreatic neuroendocrine tumor, 4001
- Pancreatic neuroendocrine tumors, transcatheter arterial chemoembolization, chemotherapy, hepatic metastasis, 3355
- Pancreatic resection, fresh-frozen plasma, prognosis, pancreatic cancer, blood transfusion, post-operative recurrence, 4041
- Pancreatic resection, postoperative pancreatic fistula, serum albumin, serum C-reactive protein, 5005
- Pancreatico-duodenectomy, glasgow prognostic score, prognosis, carcinoma of the ampulla of Vater, 2715
- Panobinostat, lung cancer, carboplatin, etoposide, 4475
- Pantoea agglomerans*, LPS, LPSp, O-antigen polysaccharide, serum-free, HMM, LMM, 2875
- Pap smear, acetic acid, dysplasia, colposcopy, cervical cancer, 1125
- Pap test, cervical sampling device, Ayre's spatula, cytobrush, 917
- Papillary carcinoma, follicular carcinoma, nicotinamide phosphoribosyltransferase, NAD⁺, SIRT3, 3047
- Papillary thyroid cancer, clinicopathological features, polymorphism, *XAF1*, 2205
- Papillary thyroid carcinoma, melanoma-associated antigen (MAGE), reverse transcriptase-polymerase chain reaction, 1731
- Papillary thyroid carcinoma, second neoplasm, synchronous tumours, 337
- Para-aortic lymphadenectomy, cervical cancer, completion surgery, pelvic lymphadenectomy, locally advanced cervical cancer, 1661
- Para-aortic lymphadenectomy, locally advanced cervical cancer, PET/CT, staging, 283
- Paratesticular, inguinal canal, spermatic cord, sarcoma, review, 2361
- Parotid gland hyperplasia, radiation therapy (RT), benign lymphoepithelial cysts (BLEC), HIV positive, highly active antiretroviral therapy (HAART), 4927
- PARP inhibition, metastatic neuroblastoma, radiation, MK-4827, DNA repair, 755
- PARP-1, piperaceae, *Piper sarmentosum*, dichamanetin, cytotoxicity, NF- κ B inhibition, DNA binding, mitochondrial membrane potential, ROS, 5349
- Parthenolide, ABCB5, doxorubicin, melanoma, NF- κ B, p53, 3205

- Partial breast irradiation, intraoperative radiotherapy, breast cancer, 1229
- Passage, $\alpha_v\beta_3$ integrin, overexpression, green fluorescent protein, red fluorescent protein, osteosarcoma, nude mice, lung metastasis, variants, 3623
- Pathological complete response, breast cancer, locally advanced tumor, HER-2, brain metastasis, neoadjuvant chemotherapy, radiation, prophylactic cranial irradiation, 5119
- PAX3–FOXO1, rhabdomyosarcoma, gene expression, growth suppression, 2029
- Pazopanib, metronomic topotecan, drug drug interaction, pharmacokinetics, gynecological cancer, 3823
- PC-3 cell line, *HMGA2* expression, growth factor, proliferation, prostate cancer, 3069
- PC3 cells, antioxidant protein, siRNA, apoptosis, redox status, anticancer agents, 847
- PC-3 cells, prostate cancer, curcumin analogues, proliferation, apoptosis, 1343
- PCA3, prostate cancer, Gleason Score, radical prostatectomy, 4657
- PCB, polychlorinated biphenyl, organochlorine, mammographic breast density, breast cancer, 5483
- PCNA, *Withania somnifera*, chemoprevention, mammary cancer, rats, Ki67, 1519
- PD-0322991, renal cell carcinoma, palbociclib, cell-cycle inhibition, CDKN2A, p16, E2F1, 2997
- PDGFR, tyrosine kinase inhibitor, mTOR, HIF, head and neck squamous cell carcinoma, Everolimus, sorafenib, sunitinib, 5385
- PDGFR α/β , vascular endothelial growth factor, platelet-derived growth factor, head and neck squamous cell carcinoma, docetaxel, fluorouracil, 1951
- PDT, apoptosis, ceramide, dihydroceramide desaturase, dihydroceramide, sphingolipids, UM-SCC-22A cells, HNSCC, 77
- Peak enhancement, metastatic renal cell carcinoma, targeted therapies, angiogenesis, MRI, 5663
- Pediatric neuro-oncology, high grade glioma, dendritic cell vaccine, immunotherapy, 2047
- Pegfilgrastim, chemotherapy-induced neutropenia, febrile neutropenia, G-CSF, secondary prophylaxis, 301
- Pelvic exenteration, clear cell adenocarcinoma, endometrial neoplasm, bladder tumor, Mullerian tumour, 615
- Pelvic lymphadenectomy, cervical cancer, completion surgery, para-aortic lymphadenectomy, locally advanced cervical cancer, 1661
- Pelvic phased-array MRI, prostate cancer, multiparametric MRI, saturation prostate biopsy, 1195
- Pemetrexed, thymidylate synthase, gene amplification, non-small cell lung cancer, 1935
- Pemetrexed, carboplatin, non-squamous non-small cell lung cancer, phase II trial, 5535
- Pemetrexed, cisplatin, *ALK*, non-squamous NSCLC, Japanese, 3327
- Pemetrexed, erlotinib, adenocarcinoma, NSCLC, second-line, third-line, sequence, 3397
- Pemetrexed, mesothelioma, chemotherapy, treatment outcome, quality of life, health economics, review, 3553
- Pemetrexed, radiotherapy, capecitabine, rectal cancer, thymidine phosphorylase, chemotherapy, 2447
- Pemetrexed, rectal cancer, preoperative, chemotherapy, follow-up, outcome, Alimta, 325
- Penile tumor, MALT lymphoma, 2639
- Pentabromobenzylisothiourreas, CK2 inhibitors, apoptosis, KG-1 cells, flow cytometry, 4891
- Pepsinogens, adjuvant chemotherapy, breast cancer, dyspepsia, gastrin, ghrelin, leptin, motilin, 4951
- Pepsinogens, gastric cancer, atrophic gastritis, antrum, corpus, *Helicobacter pylori*, risk factors, biomarker panel, gastrin-17, achlorhydria, blood test, 4595
- Peptide specific, redirected T-cells, anti-idiotypic antibody, expansion, NY-ESO-1, chimeric antigen receptor, 4189
- Peptide substrate, diagnosis, protein kinase, blood, phosphorylation, 485
- Percutaneous ethanol injection, hepatocellular carcinoma, survival, transcatheter arterial chemoembolization, Child-Pugh score, aspartate aminotransferase, 5171
- Percutaneous hepatic perfusion, chemosaturation therapy, melphalan, taxanes, platinum agents, 1989
- Percutaneous radiofrequency ablation, renal tumor, renal function, 4669
- Perforation, gastric cancer, endoscopic resection, adhesion, laparoscopic gastrectomy, 4023
- Performance status, lymphoma, chemotherapy, radiation, elderly, 3251
- Perillyl alcohol, phase II trial, intranasal administration, glioma, GBM, glioblastoma multiforme, 5625
- Perineural invasion, biliary tract cancer, CA19-9, CEA, 583
- Periostin, prostate cancer, LNCaP cell line, androgens, antiandrogens, 815
- Peripheral neuropathy, paclitaxel, *nab*-paclitaxel, chemotherapy, opioids, 1153
- Peritoneal carcinomatosis, colorectal cancer, peritonectomy, 975
- Peritoneal carcinomatosis, rat model, mesothelial cells, submesothelial layer, RCN-9 cells, fibroblast, 1439
- Peritoneal metastasis, gastric cancer cell lines, paclitaxel-resistance, *in vivo* selection, gene expression profile, 4299
- Peritoneal sarcomatosis, HIPEC, cytoreductive surgery, locoregional treatment, 3989
- Peritonectomy, colorectal cancer, peritoneal carcinomatosis, 975
- Peritracheal lymph node metastasis, hepatocellular carcinoma, tracheal obstruction, stent, 1761

- PERK kinase, cancer, endoplasmic reticulum, stress, unfolded protein response, molecular chaperones, activating transcription factor 6, inositol requiring enzyme-1, review, 4683
- Peroxiredoxin, gemcitabine, pancreatic cancer, drug resistance, 4821
- Peroxisome proliferator-activated receptor gamma (PPAR γ), giant cell tumor of bone, apoptosis, 2169
- Pesticides, cancer, angiogenesis, xenoestrogen, 231
- PET, [*N*-methyl-¹¹C]methylene blue, TRACERlab FXc PRO module, melanoma, 4267
- PET, ⁶⁸Ga-DOTATOC, 18F-FDG, SSTR2, immunohistochemistry, somatostatin analogs, 3015
- PET, lung cancer, lymph nodes, 18F-FDG, 5193
- PET, MRI, head and neck cancer, 1141
- PET/CT, locally advanced cervical cancer, para-aortic lymphadenectomy, staging, 283
- PgR, breast cancer, TMA, ER, *HER2*, Ki67, 2139
- Phage therapy, bacteriophages, leukemia, HL-60, phage-cancer interactions, phage-mammalian interactions, 1569
- Phage-cancer interactions, bacteriophages, phage therapy, leukemia, HL-60, phage-mammalian interactions, 1569
- Phage-mammalian interactions, bacteriophages, phage therapy, leukemia, HL-60, phage-cancer interactions, 1569
- Pharmacist, sunitinib, adverse events, early management, adherence, blood pressure, 5043
- Pharmacokinetic interaction, ondansetron, tamoxifen, hepatic and intestinal, CYP2D, CYP3A1/2, DMBA rats, 521
- Pharmacokinetics, aged patient, elderly, non-small cell lung cancer, chemotherapy, quality of life, carboplatin, paclitaxel, maximum tolerated dose, 261
- Pharmacokinetics, biliary excretion, cimetidine, drug interaction, multidrug resistance-associated protein-2 (Mrp2), sunitinib, (Abcc2), 3105
- Pharmacokinetics, capecitabine, metabolites, 5'-DFCR, 5'-DFUR, HPLC, GLP, 881
- Pharmacokinetics, curcumin formulation, intramuscular, 4285
- Pharmacokinetics, metronomic topotecan, pazopanib, drug drug interaction, gynecological cancer, 3823
- Phase I study, chemoradiation, hormone-refractory prostate cancer, metronomic chemotherapy, 4585
- Phase I study, head and neck cancer, S-1, nedaplatin, granule formulation, 5699
- Phase I, sorafenib, hepatocellular carcinoma, orthotopic liver transplantation, adjuvant therapy, 2797
- Phase II study, bevacizumab, temSirolimus, glioblastoma multiforme, PI3K, protein kinase B (AKT), mTOR, rapamycin, 1657
- Phase II study, NK cell-enriched lymphocytes (NKL), MICA/B, NKG2D, docetaxel, NSCLC, 2115
- Phase II study, paclitaxel, 5'-DFUR, gastric cancer, 2629
- Phase II trial, carboplatin, pemetrexed, non-squamous non-small cell lung cancer, 5535
- Phase II trial, perillyl alcohol, intranasal administration, glioma, GBM, glioblastoma multiforme, 5625
- Phase II trial, post-operative radiotherapy, prostate cancer, hypo-fractionation, SIB-IMRT, 2785
- Phase III trial, non-small cell lung cancer, cisplatin, ifosfamide, docetaxel, survival, 5477
- Phenformin, colon cancer, 3-bromopyruvate, metformin, 2-deoxyglucose, 401
- Phenothiazines, LoVo, LoVo/DX, cyanine dyes, intracellular accumulation, 857
- Phenotypic reversion, breast cancer, microenvironment, mammary fibroblasts, primary cells, 1525
- Phospho-histone H3, esophageal cancer, prognostic factor, 461
- Phosphoinositol-3 kinase, squamous cell carcinoma, head and neck cancer, collagen I, MD-1483 cells, 379
- Phospho-mTOR, mTOR, squamous cell carcinoma, basal cell carcinoma, Sirolimus, Everolimus, Immunohistochemistry, organ transplantation, immunosuppression, skin, 3711
- Phosphorylated *EGFR*, *EGFR*, HPV, tonsillar cancer, 1575
- Phosphorylation, breast cancer, *HER2*, trastuzumab, 2509
- Phosphorylation, diagnosis, protein kinase, blood, peptide substrate, 485
- Photodynamic therapy, drug delivery, photosensitizer, tumor targeting, review, 2823
- Photodynamic therapy, phthalocyanine, liposomal photosensitizer, 1563
- Photosensitizer, drug delivery, photodynamic therapy, tumor targeting, review, 2823
- Phthalocyanine, photodynamic therapy, liposomal photosensitizer, 1563
- Physical activity, breast cancer, exercise intervention, cardiovascular risk factors, health behavior, obesity, physical health, 1595
- Physical activity, cancer, fatigue, inpatient rehabilitation, dose response relationship, 3415
- Physical health, breast cancer, exercise intervention, cardiovascular risk factors, health behavior, obesity, physical activity, 1595
- PI3K, bevacizumab, temSirolimus, glioblastoma multiforme, phase II study, protein kinase B (AKT), mTOR, rapamycin, 1657
- PI3K, breast cancer, mTOR inhibitor, endocrine resistance, Everolimus, TemSirolimus, review, AKT, 21
- PicoGreen, prostate cancer, cell-free DNA, biomarker, screening, quantitative PCR, 4521
- PIK3CA*, ovarian carcinoma, *PPP2R1A*, *KRAS*, *BRAF*, mutation, 113
- PIK3CA*, squamous cell lung cancer, NSCLC, targeted-therapy, *EGFR*, *KRAS*, mutation, *EGFR*-TKI, 1705

- PINP, lung cancer, bone metastasis, NSCLC, CEA, CTX, CYFRA 21-1, TRAP5b, 2593
- Piper sarmentosum*, piperaceae, dichamanetin, cytotoxicity, NF- κ B inhibition, DNA binding, mitochondrial membrane potential, PARP-1, ROS, 5349
- Piperaceae, *Piper sarmentosum*, dichamanetin, cytotoxicity, NF- κ B inhibition, DNA binding, mitochondrial membrane potential, PARP-1, ROS, 5349
- Piperazine derivatives, antiproliferative activity, triphenyl derivatives, erythroid differentiation, anticancer agents, 3027
- Pituitary adenoma, mTOR, RAPTOR, RICTOR, staging, invasion, 3123
- Pituitary adenoma, VEG1, death receptor-3, invasion, 3815
- Pituitary tumor-transforming gene, astrocytoma, brain neoplasms, glioblastoma multiforme IV, PTTG, 119
- PIVKA-II, hepatocellular carcinoma, NX-PVKA-R, post-curative treatment change, disease-free survival, protein-induced vitamin K absence or antagonist-II, 2689
- Plain radiographs, orbit, orbital rim, orbital neurofibromatosis, NF1, plexiform neurofibroma, sphenoid wing dysplasia, orbital dysplasia, cephalometry, 1081
- Plasma cell precursors, liver, biopsies, autoimmune hepatitis, plasma cells, multiple myeloma oncogene-1 (MUM1), 665
- Plasma cells, liver, biopsies, autoimmune hepatitis, plasma cell precursors, multiple myeloma oncogene-1 (MUM1), 665
- Plasma, gastric cancer, long non-coding RNAs, biomarker, 3185
- Plasma, gastric cancer, microRNA, biomarker, prognosis, circulating nucleic acids, miR-21, 271
- Platelet/lymphocyte ratio, C-reactive protein, neutrophil/lymphocyte ratio, rectal cancer, prognosis, chemoradiotherapy, 5065
- Platelet-derived growth factor, vascular endothelial growth factor, PDGFR α/β , head and neck squamous cell carcinoma, docetaxel, fluorouracil, 1951
- Platinum agents, chemosaturating therapy, percutaneous hepatic perfusion, melphalan, taxanes, 1989
- Platinum-based chemotherapy, lung cancer, non-small cell lung cancer, NSCLC, bevacizumab, overall survival, progression-free survival, brain metastases, humanized monoclonal antibody, angiogenesis, vascular endothelial growth factor A (VEGF-A), pulmonary haemorrhage, 3275
- Pleural mesothelioma, mesothelin, malignant pleural effusion, Mesomark assay, 2707
- Plexiform neurofibroma, orbit, orbital rim, orbital neurofibromatosis, NF1, sphenoid wing dysplasia, orbital dysplasia, plain radiographs, cephalometry, 1081
- PLGA nanoparticles, CD44-targeted delivery, hyaluronic acid, surface decoration, SN-38, ovarian cancer, CTAB assay, 2425
- PMEG, ADAL, deamination, GS-9219, 1899
- PNET, capecitabine, 5-FU, chemoradiation, 2175
- PNT2, radiation effects, bisphosphonates, radiosensitizers, radioprotectors, TRAMP-C1, B16F10 cells, 3217
- Podoplanin, breast cancer, cancer-associated fibroblasts, IHC, assessment methods, 1447
- Podoplanin, VEGF-C, oral squamous cell carcinoma, oral cancer, prognosis, 3969
- Polychlorinated biphenyl, PCB, organochlorine, mammographic breast density, breast cancer, 5483
- Polycyclic aromatic hydrocarbon, oxidative stress, antioxidant capacity, lung cancer, nested case-control study, 1-hydroxypyrene, thiobarbituric acid, 8-hydroxydeoxyguanosine, cotinine, 2-Naphthol, 3089
- Polycyclic aromatic hydrocarbons, aryl hydrocarbon receptor, lung cancer, tumorigenesis, dioxin, cigarette smoke, review, 1247
- Polymerase chain reaction, lymph node metastases, molecular staging, prostate cancer, reference gene, 5243
- Polymorphism, *ATM*, genotype, lung cancer, smoking, 4067
- Polymorphism, breast cancer, folate, homocysteine, MTHFR, FTO, Kazakhstan, 4049
- Polymorphism, breast cancer, hypoxia-inducible factor, transcriptional activity, MCF-7 cells, 2549
- Polymorphism, *CAVI*, genotype, upper urothelial track cancer, 4907
- Polymorphism, caveolin-1, hepatocellular carcinoma, genotype, real-time quantitative reverse transcription, western blot, 671
- Polymorphism, caveolin-1, prostate cancer, oncogene, 1023
- Polymorphism, clinicopathological features, papillary thyroid cancer, *XAF1*, 2205
- Polymorphism, colonic cancer, microRNA, microRNA-binding site, rs1044129, prognosis, 513
- Polymorphism, Cox-2, bladder cancer, genotype, 5401
- Polymorphism, *IL10*, nasopharyngeal carcinoma, 3391
- Polymorphism, *miR-146a*, squamous cell carcinoma, head and neck, 341
- Polymorphism, *XRCC6/Ku70*, non-homologous end-joining, hepatocellular carcinoma, genotype, real-time quantitative reverse transcription, Immunohistochemistry, 529
- Polymorphisms, vitamin D, sunlight, breast cancer, gene, case-control, 543
- Polymorphisms, *XRCC6/Ku70*, non-homologous end-joining, childhood leukemia, genotyping, 5395
- Polysaccharide K, colon cancer, invasion, 4841
- Polysomy 7p, glioblastoma, *EGFR* amplification, *EGFRvIII*, 5343
- Polyunsaturated fatty acids (PUFAs), olive oil, colorectal cancer, lipid metabolism, gene expression, 3739
- Poorly- differentiated component, claudin, colorectal cancer, prognosis, recurrence, 3301

- Population-based study, colorectal cancer, lymph node metastasis, lymph node harvest, lymph node ratio, survival, prospective study, review, 2839
- Positron-emission tomography, Non-Hodgkin lymphoma, FDG, beta-2 microglobulin, 3341
- Post-curative treatment change, hepatocellular carcinoma, PIVKA-II, NX-PVKA-R, disease-free survival, protein-induced vitamin K absence or antagonist-II, 2689
- Postoperative chemotherapy, colorectal liver metastasis, irinotecan, synchronous metastasis, oxaliplatin, 5-fluorouracil, leucovorin, FOLFOX, FOLFIRI, 3317
- Postoperative follow-up, gastric cancer, nodal status, DFS, recurrence, 4645
- Postoperative pancreatic fistula, pancreatic resection, serum albumin, serum C-reactive protein, 5005
- Post-operative radiotherapy, prostate cancer, hypofractionation, SIB-IMRT, phase II trial, 2785
- Postoperative radiotherapy, radiation therapy, uterine cervical cancer, 2199
- Post-operative recurrence, fresh-frozen plasma, prognosis, pancreatic cancer, pancreatic resection, blood transfusion, 4041
- Post-surgical screening, clinical predictors, swallowing disorder, dysphagia, head and neck cancer, 3347
- Postsurgical, dysphagia, swallowing disorder, head and neck cancer, screening, 4017
- Potassium ascorbate with ribose, costello syndrome, oxidative stress, 691
- PPP2R1A*, ovarian carcinoma, *PIK3CA*, *KRAS*, *BRAF*, mutation, 113
- A precursor of Gc-derived macrophage activating factor, degalactosylated Gc-globulin, subtypes of Gc-globulin, antitumor activity, injection route, 2911
- Prediction of nodal status, artificial neural networks, cancer prognosis, ki-67, p53, oestrogen/progesterone receptors, 3925
- Prediction of progression, colorectal cancer, circulating tumor cell, 1769
- Prediction, chemosensitivity, HDRA, histoculture drug response assay, epithelial ovarian cancer, taxol, carboplatin, prospective clinical trial, correlation, individualized therapy, 1029
- Predictive marker, bevacizumab, colorectal cancer, proteinuria, 309
- Predictive model, endometrial cancer, Immunohistochemistry, histological grade, estrogen receptor, progesterone receptor, Ki67, p53, 2191
- Predictive value, thrombocytosis, breast cancer, 4545
- Pregnancy, dysplasia, cervical cancer, delivery, 711
- Premalignant lesion cells, adipocytes, cytokines, immune regulation, inflammation, 1809
- Preoperative, FDG-PET, carbon-ion radiotherapy, distant metastasis, prognostic factor, 5579
- Preoperative, rectal cancer, chemotherapy, follow-up, outcome, Alimta, pemetrexed, 325
- Preserved liver function, hepatocellular carcinoma, anatomical hepatectomy, surgery, ICG-R15, 1689
- Pretherapeutic *ex vivo* testing, CSRA, DiSC assay, chemotherapy, 2491
- Prevention, NSAIDS, colon cancer, COX inhibition, apoptosis, ACF, rat model, 3581
- Primary cells, breast cancer, phenotypic reversion, microenvironment, mammary fibroblasts, 1525
- Primary unknown, cervical lymph node metastasis, chemoradiation, lymph node level, 5187
- Primer dosing, *Salmonella typhimurium*, auxotroph, leucine, arginine, GFP, tumor-targeting, high dose, Lewis lung carcinoma, immunocompetent mice syngeneic mouse model, 97
- Probability, micrometastasis, lymph node, laryngeal cancer, head and neck cancer, 3213
- Profiles, MALDI, breast cancer, *HER2*, lipid, 2467
- Progesterone receptor, endometrial cancer, Immunohistochemistry, histological grade, estrogen receptor, Ki67, p53, predictive model, 2191
- Progesterone, apoptosis, cisplatin, estrogen, A549 cells, lung cancer, 791
- Prognosis, Immunohistochemistry, fascin-1, ovarian cancer, expression, 371
- Prognosis, AML, uric acid, 3947
- Prognosis, anal carcinoma, radiochemotherapy, local control, 4111
- Prognosis, angio-associated migratory cell protein, AAMP, breast cancer, MCF-7, MDA-MB-231 cells, 1499
- Prognosis, apoptosis, glycosylation, invasion, lectin, 3053
- Prognosis, aryl hydrocarbon receptor, epidermal growth factor receptor, non-small cell lung cancer, 3953
- Prognosis, blood transfusion, colorectal cancer, liver metastasis, hepatic resection, 2723
- Prognosis, bone sialoprotein, osteopontin, renal cell carcinoma, 2679
- Prognosis, breast cancer, CA15-3, 293
- Prognosis, breast cancer, lymphatic microvessel density, mast cells, molecular classification, 957
- Prognosis, claudin, colorectal cancer, recurrence, poorly-differentiated component, 3301
- Prognosis, colonic cancer, polymorphism, microRNA, microRNA-binding site, rs1044129, 513
- Prognosis, colorectal cancer, *miR-146a* polymorphism, rs2910164, risk, 3233
- Prognosis, colorectal cancer, WNT, β -catenin, E-cadherin, SFRP, invasive front, 4573
- Prognosis, CRC, *COX2* expression, IHC, 3137
- Prognosis, C-reactive protein, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, rectal cancer, chemoradiotherapy, 5065

- Prognosis, endometrial carcinoma, baby boomers, early stage, obesity, outcome, 619
- Prognosis, endometrial carcinoma, baby boomers, early stage, SEER, survival, 4983
- Prognosis, fresh-frozen plasma, pancreatic cancer, pancreatic resection, blood transfusion, post-operative recurrence, 4041
- Prognosis, galectin-7, ovarian cancer, siRNA, 1555
- Prognosis, gallbladder carcinoma, lymphocyte count, operation, 3439
- Prognosis, gastric cancer, microRNA, plasma, biomarker, circulating nucleic acids, miR-21, 271
- Prognosis, glasgow prognostic score, pancreatoduodenectomy, carcinoma of the ampulla of Vater, 2715
- Prognosis, HAVcR-1, hepatitis A virus cellular receptor-1, colorectal cancer, invasion, 207
- Prognosis, head and neck squamous cell carcinoma, *FANCC*, *PTCH1*, radiotherapy, tumor suppressor genes 9q22.3, 1215
- Prognosis, hepatocellular carcinoma, *c-MET*, Immunohistochemistry, copy number variation, 5179
- Prognosis, *IL10*, haplotype, squamous cell carcinoma, adenocarcinoma, lung cancer, 2729
- Prognosis, lung cancer, thrombocytosis, smoking, 1725
- Prognosis, lymphatic invasion, colorectal cancer, 2965
- Prognosis, non-small cell lung cancer, HLA class-I expression, surgery, cancer/testis antigen, immune escape, 2123
- Prognosis, non-small cell lung cancer, surgery, early-onset, chemotherapy-induced neutropenia, 2755
- Prognosis, ovarian carcinosarcomas, prophylactic pelvic irradiation, chemotherapy, surgery, 1003
- Prognosis, podoplanin, VEGF-C, oral squamous cell carcinoma, oral cancer, 3969
- Prognosis, prostate cancer, metastatic spinal cord compression, irradiation, extra-spinal organs, survival, 4505
- Prognosis, prostate cancer, methylation, *PTGS2*, *RARB*, DNA hypermethylation, 5249
- Prognosis, *PTK7*, triple-negative breast cancer, anthracycline resistance, 3759
- Prognosis, renal cell carcinoma, 18F-FDG-PET/CT, hybrid imaging, SUV_{max} , 2665
- Prognosis, stage IV gastric cancer, C-reactive protein, cut-off value, 5591
- Prognosis, tumor IL-6, chemoradiotherapy, esophageal squamous cell carcinoma, 2699
- Prognosis, upper tract urothelial carcinoma, p53, immunohistochemistry, hemodialysis, 1091
- Prognostic factor, anemia, chemoradiotherapy, esophageal cancer, nutrition, 3495
- Prognostic factor, clinicopathological features, Immunohistochemistry, luminal/*HER2*-negative breast cancer, p53 cut-off point, p53 overexpression, 3891
- Prognostic factor, C-reactive protein, hepatocellular carcinoma, surgical resection, 1181
- Prognostic factor, DNA ploidy index, gastric adenocarcinoma, overall survival, response to chemotherapy, 1209
- Prognostic factor, FDG-PET, carbon-ion radiotherapy, preoperative, distant metastasis, 5579
- Prognostic factor, *p21*, esophageal squamous cell carcinoma, 4329
- Prognostic factor, phospho-histone H3, esophageal cancer, 461
- Prognostic factors, brain metastases, breast cancer, surgical resection, 2159
- Prognostic factors, brain metastasis, SCLC, extracranial organs, survival, 3887
- Prognostic factors, breast cancer, TGF- β 1, 737
- Prognostic factors, male, female, breast cancer, survival, 2227
- Prognostic factors, rectal cancer, adjuvant therapy, staging, 4557
- Prognostic markers, colorectal cancer, gene expression, 4855
- Progression, caveolin-1, prostate cancer, ELISA, 1893
- Progression, cofilin-1, cofilin-2, regression, fibrosarcoma, 3661
- Progression-free survival, lung cancer, non-small cell lung cancer, NSCLC, bevacizumab, platinum-based chemotherapy, overall survival, brain metastases, humanized monoclonal antibody, angiogenesis, vascular endothelial growth factor A (VEGF-A), pulmonary haemorrhage, 3275
- Prokineticin 1, gastrointestinal tumors, 5311
- Proliferation, (-)-gossypol-enriched cottonseed oil, adipogenesis, human breast pre-adipocytes, 949
- Proliferation, ApoE, LXR, MCF-7, apoptosis, THP-1, MCF-7 cells, 3783
- Proliferation, CAFs, NFs, lung cancer, stromal NSCLC, direct co-culture, indirect co-culture, EMT, SMAD3, Hedgehog signaling pathway, 3715
- Proliferation, cancer-associated fibroblasts, normal fibroblasts, NFs, lung cancer, NSCLC, co-culture, EMT, SMAD3, 2001
- Proliferation, canine cutaneous histiocytoma, apoptosis, Ki-67, TUNEL, 1397
- Proliferation, endometrial carcinoma, E-cadherin, 5091
- Proliferation, high-performance counter current chromatography, umbelliferone, herniarin, scoparone, laryngeal cancer cells, migration, cell cycle, apoptosis, 4347
- Proliferation, *HMG2* expression, growth factor, PC-3 cell line, prostate cancer, 3069
- Proliferation, hydrogen peroxide, radiation, apoptosis, melanoma, 1799
- Proliferation, prostate cancer, curcumin analogues, apoptosis, PC-3 cells, 1343

- Proliferation, prostate cancer, fatty acids, linoleate, 4395
- Proliferation, secretory phospholipase A2, esophageal adenocarcinoma, growth, ERK 1/2, 1337
- Proliferation, survivin, non-small cell lung cancer, apoptosis, real-time RT-PCR, mRNA, 3475
- Prolonged adjuvant therapy, glioblastoma, temozolomide, radiochemotherapy, 3467
- Prone position, right aortic arch, esophageal cancer, thoracoscopic esophagectomy, 4515
- Pro-oxidant, ellagic acid, antioxidant, antiproliferative, apoptosis, H5C-2 oral carcinoma cells, 1829
- Propensity score, prostate cancer, delayed radiotherapy, 1629
- Prophylactic cranial irradiation, breast cancer, locally advanced tumor, HER-2, brain metastasis, neoadjuvant chemotherapy, pathological complete response, radiation, 5119
- Prophylactic pelvic irradiation, ovarian carcinosarcomas, chemotherapy, surgery, prognosis, 1003
- Prophylactic salpingectomy, laparoscopic supracervical hysterectomy, LASH, laparoscopy, surgical outcome, 2771
- Prospective clinical trial, chemosensitivity, HDRA, histoculture drug response assay, epithelial ovarian cancer, taxol, carboplatin, correlation, prediction, individualized therapy, 1029
- Prospective study, colorectal cancer, lymph node metastasis, lymph node harvest, lymph node ratio, survival, population-based study, review, 2839
- Prostaglandin inhibition, vitamin D, breast cancer prevention, 3861
- Prostate cancer antigen 3, prostate cancer, diagnosis, nomogram, 553
- Prostate cancer cell lines, cabazitaxel, ABCC4, docetaxel resistance, 387
- Prostate cancer, androgen deprivation therapy, radical prostatectomy, prostate-specific antigen, 1147
- Prostate cancer, androgen receptor, 2'-hydroxyflavanone, androgen, 4453
- Prostate cancer, cancer stem cells, stem cell marker, canine, CT1258, CT1258-EGFP, CT1258-EGFP-*HMGA2* cell lines, 5421
- Prostate cancer, castration-resistant prostate cancer, CRPC, HAI-1, 575
- Prostate cancer, caveolin-1, ELISA, progression, 1893
- Prostate cancer, caveolin-1, polymorphism, oncogene, 1023
- Prostate cancer, cell-free DNA, biomarker, screening, quantitative PCR, PicoGreen, 4521
- Prostate cancer, chinese medicine, β -elemene, taxanes, synergism, ovarian cancer, apoptosis, cell cycle arrest, 929
- Prostate cancer, combined androgen blockade, bone metastasis, zoledronic acid, 3837
- Prostate cancer, curcumin analogues, proliferation, apoptosis, PC-3 cells, 1343
- Prostate cancer, delayed radiotherapy, propensity score, 1629
- Prostate cancer, diagnosis, nomogram, prostate cancer antigen 3, 553
- Prostate cancer, fatty acids, proliferation, linoleate, 4395
- Prostate cancer, HLA class-I, antigenic peptide, cancer associated antigen, mass spectrometric analysis, 1853
- Prostate cancer, *HMGA2* expression, growth factor, proliferation, PC-3 cell line, 3069
- Prostate cancer, hypofractionation, RapidArc, VMAT, 4537
- Prostate cancer, image-guided intervention, infra-fractional motion, 4117
- Prostate cancer, Immunohistochemistry, angiogenesis, *VEGFR1*, NRP1, tissue array analysis, prostatectomy, 2065
- Prostate cancer, Immunohistochemistry, insulin-like growth factor 1 (IGF-1), IGF1Ec, mechano-growth factor (MGF), 2441
- Prostate cancer, lycopene, resveratrol, capsaicin, curcumin, dietary phytochemicals, review, 4163
- Prostate cancer, lymph node metastases, molecular staging, polymerase chain reaction, reference gene, 5243
- Prostate cancer, metastatic spinal cord compression, irradiation, extra-spinal organs, survival, prognosis, 4505
- Prostate cancer, methylation, prognosis, PTGS2, RARB, DNA hypermethylation, 5249
- Prostate cancer, multiparametric MRI, saturation prostate biopsy, pelvic phased-array MRI, 1195
- Prostate cancer, PCA3, Gleason Score, radical prostatectomy, 4657
- Prostate cancer, periostin, LNCaP cell line, androgens, antiandrogens, 815
- Prostate cancer, post-operative radiotherapy, hypofractionation, SIB-IMRT, phase II trial, 2785
- Prostate cancer, quinazoline, doxazosin, terazosin, DZ-50, vascularity, anoikis, review, 4695
- Prostate cancer, radiation therapy, alpha/beta, LQ model, 1009
- Prostate cancer, soy phytoestrogens, daidzein genistein, diet, epigenetics, isoflavones, review, 39
- Prostate cancer, tomotherapy, image-guided intensity-modulated radiotherapy, 5507
- Prostate cancer, tomotherapy, soft tissue matching, PTV margin, image-guided IMRT, megavolt computed tomography, 5675
- Prostatectomy, prostate cancer, Immunohistochemistry, angiogenesis, *VEGFR1*, NRP1, tissue array analysis, 2065
- Prostate-specific antigen, prostate cancer, androgen deprivation therapy, radical prostatectomy, 1147
- Prostatic carcinoma, 3T magnetic resonance, transrectal biopsy, PSA, 2791
- Prostatic neoplasms, carcinoma, gene expression, diagnostic markers, urine, 191
- Prostatic neoplasms, neoplastic stem cells, radiotherapy, reactive oxygen species, DNA repair, radioresistance, 4469

- Protection, transporters, cisplatin, tumor, uptake, toxicity, review, 4183
- Protein kinase B (AKT), bevacizumab, temsirolimus, glioblastoma multiforme, phase II study, PI3K, mTOR, rapamycin, 1657
- Protein kinase D, breast cancer, triple-negative breast cancer cells, 393
- Protein kinase, diagnosis, blood, peptide substrate, phosphorylation, 485
- Protein stability, JNK, p53, redox factor 1, selenomethionine, ubiquitination, cancer prevention, 3645
- Protein tyrosine kinase, 5-FU, docetaxel, β -catenin, c-KIT, head and neck squamous cell carcinoma, extracellular matrix, human papillomavirus (HPV), epithelial mesenchymal transition (EMT), 2457
- Protein tyrosine phosphorylation, LMW-PTP isoforms, genotype, mRNA expression, enzymatic activity, 1983
- Protein-induced vitamin K absence or antagonist-II, hepatocellular carcinoma, PIVKA-II, NX-PVKA-R, post-curative treatment change, disease-free survival, 2689
- Proteinuria, bevacizumab, colorectal cancer, predictive marker, 309
- Proteomics, HER-2 oncoprotein, breast cancer, SKBR-3 cells, trastuzumab resistance, 489
- Proteomics, thyroid neoplasms, *BRAF* mutation, chaperonin 60, lymph node metastases, 4357
- Protoporphyrin IX, 5-aminolevulinic acid, ALA, hyperthermia, animal tumor model, 2861
- PROX1, small cell lung cancer, shRNA, Lentivirus, cell proliferation, viral knockdown, 3169
- PSA, 3T magnetic resonance, prostatic carcinoma, transrectal biopsy, 2791
- Pseudopapillary, mesenchymal tumor, GIST, sarcoma, spindle cell, round cell, 991
- PTCHI*, head and neck squamous cell carcinoma, *FANCC*, radiotherapy, prognosis, tumor suppressor genes 9q22.3, 1215
- PTEN*, esophageal squamous cell carcinoma, Ruthenium, microRNA-21, AKT, 5407
- PTEN*, RO492907, gamma secretase, melanoma, 1307
- PTGS2, prostate cancer, methylation, prognosis, RARB, DNA hypermethylation, 5249
- PTK7, triple-negative breast cancer, anthracycline resistance, prognosis, 3759
- PTTG, astrocytoma, brain neoplasms, glioblastoma multiforme IV, pituitary tumor-transforming gene, 119
- PTV margin, tomotherapy, prostate cancer, soft tissue matching, image-guided IMRT, megavolt computed tomography, 5675
- PTV margin, tomotherapy, vertebral body metastases, stereotactic body radiotherapy, image-guided IMRT, 2453
- Pulmonary blastoma, elderly, lung malignancy, relapse, 3911
- Pulmonary haemorrhage, lung cancer, non-small cell lung cancer, NSCLC, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, brain metastases, humanized monoclonal antibody, angiogenesis, vascular endothelial growth factor A (VEGF-A), 3275
- Pulmonary neoplasms, stereotactic body radiotherapy (SBRT), helical tomotherapy, metastatic lung cancer, 655
- Pulmonary neuroendocrine tumor, ^{18}F -FDG PET, GLUT1, hypoxia, angiogenesis, glucose metabolism, 4219
- Pulsed reduced dose-rate radiotherapy, re-irradiation, ependymoma, 2611
- Pyrosequencing, methylation, human CDH1 protein, stomach neoplasm, diffuse gastric cancer, methylation-specific polymerase chain reaction, 3765
- QPCR, inhibitor of differentiation, inhibitor of DNA binding, ID1, ID2, breast cancer, helix-loop-helix, cell cycle, 2179
- QPCR, p14, p16, cell cycle, cell senescence, breast cancer, 2185
- QSAR, licorice flavonoids, cytotoxicity, tumor-specificity index, chemical descriptor, 3061
- Quality of life, aged patient, elderly, non-small cell lung cancer, chemotherapy, pharmacokinetics, carboplatin, paclitaxel, maximum tolerated dose, 261
- Quality of life, mesothelioma, chemotherapy, pemetrexed, treatment outcome, health economics, review, 3553
- Quality of life, zoledronic acid, breast cancer, bone metastases, 5543
- Quantitative PCR, epithelial-mesenchymal transition, cancer stem cells, molecular markers, endometrial cancer, 5461
- Quantitative PCR, prostate cancer, cell-free DNA, biomarker, screening, PicoGreen, 4521
- Quercetin, migration, invasion, MMP-2, MMP-9, NF- κ B, SAS human oral cancer cells, 1941
- Quercetin, osteosarcoma, cell-cycle arrest, apoptosis, migration, 143B cells, 1297
- Quinazoline, doxazosin, terazosin, DZ-50, prostate cancer, vascularity, anoikis, review, 4695
- Rabbit, irinotecan, carboxyl esterase (CE), CNS lymphoma, neural stem cells, 5335
- Rabdomyosarcoma, PAX3-FOXO1, gene expression, growth suppression, 2029
- RAD001, glioblastoma, temozolomide, autophagy, γ -radiation, 1845
- γ -Radiation, glioblastoma, RAD001, temozolomide, autophagy, 1845
- Radiation effects, bisphosphonates, radiosensitizers, radioprotectors, PNT2, TRAMP-C1, B16F10 cells, 3217
- Radiation induced dysphagia, carotidvasculopathy, radiation therapy, early glottic cancer, constrictors, 4483

- Radiation therapy (RT), benign lymphoepithelial cysts (BLEC), parotid gland hyperplasia, HIV positive, highly active antiretroviral therapy (HAART), 4927
- Radiation therapy, cervical cancer, FIGO IVA, bladder invasion, rectum invasion, EQD2, 4989
- Radiation therapy, cervical cancer, lymph node metastasis, chemotherapy, consolidation, 4675
- Radiation therapy, fenbendazole, benzamidazoles, tumor microenvironment, hypoxia, EMT6 cells, 355
- Radiation therapy, HIV, Kaposi sarcoma, 2153
- Radiation therapy, HIV, viral load, CD4, squamous cell carcinoma, head and neck cancer, IMRT, chemotherapy, concurrent chemoradiotherapy, 5511
- Radiation therapy, postoperative radiotherapy, uterine cervical cancer, 2199
- Radiation therapy, prostate cancer, alpha/beta, LQ model, 1009
- Radiation therapy, radiation induced dysphagia, carotidvasculopathy, early glottic cancer, constrictors, 4483
- Radiation, breast cancer, locally advanced tumor, HER-2, brain metastasis, neoadjuvant chemotherapy, pathological complete response, prophylactic cranial irradiation, 5119
- Radiation, *EGFR*, dimerization, cetuximab, radiosensitivity, A431 cells, 4337
- Radiation, herpes simplex virus-1, encephalitis, small cell lung cancer, immunosuppression, 3263
- Radiation, hydrogen peroxide, apoptosis, proliferation, melanoma, 1799
- Radiation, lymphoma, chemotherapy, elderly, performance status, 3251
- Radiation, metastatic neuroblastoma, PARP inhibition, MK-4827, DNA repair, 755
- Radical prostatectomy, prostate cancer, androgen deprivation therapy, prostate-specific antigen, 1147
- Radical prostatectomy, prostate cancer, PCA3, Gleason Score, 4657
- Radical resection, adjuvant chemotherapy, dysphagia, long-term cancer survival, small cell carcinoma of the esophagus, 595
- Radio-/chemotherapeutic treatment head and neck cancer, HNSCC, cytokines, 2481
- Radiochemotherapy, anal carcinoma, local control, prognosis, 4111
- Radiochemotherapy, glioblastoma, temozolomide, prolonged adjuvant therapy, 3467
- Radiochemotherapy, laryngeal cancer, larynx preservation, organ-preserving surgery, 4701
- Radiofrequency ablation, colorectal cancer, irinotecan, liver metastases, 1603
- Radioimmunotherapy, CD37, non-Hodgkin's lymphoma, ¹⁷⁷Lu, 85
- Radiolabelling, vasoactive intestinal peptide, VIP, neuroendocrine tumours, tumour targeting, 1537
- Radiophotoluminescence glass dosimeter, tomotherapy, lung tumor, stereotactic body radiotherapy, Rando phantom, 1679
- Radioprotectors, radiation effects, bisphosphonates, radiosensitizers, PNT2, TRAMP-C1, B16F10 cells, 3217
- Radioresistance, cancer stem cells, radiotherapy, therapeutic targets, review, 747
- Radioresistance, prostatic neoplasms, neoplastic stem cells, radiotherapy, reactive oxygen species, DNA repair, 4469
- Radiosensitivity, *EGFR*, dimerization, radiation, cetuximab, A431 cells, 4337
- Radiosensitizers, radiation effects, bisphosphonates, radioprotectors, PNT2, TRAMP-C1, B16F10 cells, 3217
- Radiotherapy, biliary tract neoplasms, brachytherapy, Yridium radioisotopes, expandable metallic stents, 2747
- Radiotherapy, breast cancer, adjuvant therapy, electrocardiography (ECG), cardiotoxicity, 4933
- Radiotherapy, cancer stem cells, radioresistance, therapeutic targets, review, 747
- Radiotherapy, chemotherapy, concomitant therapy, colorectal cancer, cisplatin, Lipoplatin™, 3005
- Radiotherapy, endometrial carcinoma, vaginal recurrence, brachytherapy, 241
- Radiotherapy, erlotinib, gefitinib, non-small cell lung cancer, *EGFR*-TKI, 3279
- Radiotherapy, extended field, induction chemotherapy, cervical metastases, unknown primary tumor, 1135
- Radiotherapy, head and neck carcinoma, neopterin, toxicity, 4097
- Radiotherapy, head and neck squamous cell carcinoma, *FANCC*, *PTCHI*, prognosis, tumor suppressor genes 9q22.3, 1215
- Radiotherapy, hypoxic radiosensitizer, oral administration, neuropathy, sanazole (AK-2123), 643
- Radiotherapy, lung adenocarcinoma, brain metastases, *EGFR*, TKI, resistance, 1649
- Radiotherapy, morbid obesity, breast cancer, breast-conservation surgery, chemotherapy, 3867
- Radiotherapy, non-bulky, cervical cancer, stage IB1/II, concurrent chemoradiotherapy, 5123
- Radiotherapy, ocular adnexal, MALT lymphoma, 5575
- Radiotherapy, pemetrexed, capecitabine, rectal cancer, thymidine phosphorylase, chemotherapy, 2447
- Radiotherapy, prostatic neoplasms, neoplastic stem cells, reactive oxygen species, DNA repair, radioresistance, 4469
- Radiotherapy, sorafenib, metabolic ¹⁸⁸Rhenium, hepatocellular carcinoma, synergy, N1S1, HepG2 cells, 3871
- Radiotherapy, tonsil cancer, surgery, concurrent chemoradiotherapy, 1237
- RAF kinases, hepatocellular carcinoma, sorafenib, short-term culture, tumour fragments, 1415
- Rajasthan, India internaional symposium, Udaipur, cancer prevention, translational cancer research, 1777

- Rando phantom, tomotherapy, lung tumor, stereotactic body radiotherapy, radiophotoluminescence glass dosimeter, 1679
- Random forest method, lung cancer, survival, comorbidity, lung function, 1609
- Randomized phase 2, non-small cell lung cancer, chemotherapy, ethnicity, docetaxel, paclitaxel carboplatin, 4631
- RANK, RANKL, osteoprotegerin, OPG, breast cancer, oestrogen, bone metastasis, MCF-7, MDA-MB-231, 199
- RANKL, RANK, osteoprotegerin, OPG, breast cancer, oestrogen, bone metastasis, MCF-7, MDA-MB-231, 199
- Rapamycin, bevacizumab, temSirolimus, glioblastoma multiforme, phase II study, PI3K, protein kinase B (AKT), mTOR, 1657
- Rapamycin, mTOR, Notch, leukemia, 809
- RapidArc, hypofractionation, prostate cancer, VMAT, 4537
- RAPTOR, pituitary adenoma, mTOR, RICTOR, staging, invasion, 3123
- RARB, prostate cancer, methylation, prognosis, PTGS2, DNA hypermethylation, 5249
- Ras, azatyrosinamides, antitumour agent, NIH3T3, SW620 human colon xenograft, angiogenesis, 425
- Rat model, NSAIDS, colon cancer, prevention, COX inhibition, apoptosis, ACF, 3581
- Rat model, peritoneal carcinomatosis, mesothelial cells, submesothelial layer, RCN-9 cells, fibroblast, 1439
- Rat, hepatocellular carcinoma, animal model, chemoembolization, 223
- Rats, *Withania somnifera*, chemoprevention, mammary cancer, Ki67, PCNA, 1519
- RCC, circulating tumor cells, renal subcapsular implantation, metastasis, murine model, 4751
- RCN-9 cells, peritoneal carcinomatosis, rat model, mesothelial cells, submesothelial layer, fibroblast, 1439
- Reactive oxygen species, biliverdin reductase, leukemia, multidrug resistance, 4913
- Reactive oxygen species, prostatic neoplasms, neoplastic stem cells, radiotherapy, DNA repair, radioresistance, 4469
- Real-time imaging, α v integrin, green fluorescent protein, osteosarcoma, fibronectin, *in vitro*, *in vivo*, nude mouse, metastasis, confocal microscopy, 3021
- Real-time quantitative reverse transcription, caveolin-1, hepatocellular carcinoma, polymorphism, genotype, western blot, 671
- Real-time quantitative reverse transcription, *XRCC6/Ku70*, non-homologous end-joining, hepatocellular carcinoma, polymorphism, genotype, Immunohistochemistry, 529
- Real-time RT-PCR, survivin, non-small cell lung cancer, apoptosis, mRNA, proliferation, 3475
- Receptor, vitamin B12, Immunohistochemistry, transcobalamin II, transport protein, Ki-67, xenograft, 4203
- Recombinant human interferon alpha, native human interferon alpha, non-small cell lung cancer, tumor proliferation, apoptosis, *p21*, survivin, 2043
- Recombination, telomere, chromatin, telomerase, trichostatin A, ALT mechanism, 821
- Rectal cancer, adjuvant therapy, staging, prognostic factors, 4557
- Rectal cancer, C-reactive protein, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, prognosis, chemoradiotherapy, 5065
- Rectal cancer, lateral lymph node dissection, strategy, meta-analysis, 2921
- Rectal cancer, preoperative, chemotherapy, follow-up, outcome, Alimta, pemetrexed, 325
- Rectal cancer, radiotherapy, pemetrexed, capecitabine, thymidine phosphorylase, chemotherapy, 2447
- Rectal carcinoma, neoadjuvant radiochemotherapy, ypTNM classification, histological regression grade, 559
- Rectum invasion, radiation therapy, cervical cancer, FIGO IVA, bladder invasion, EQD2, 4989
- Recurrence, brachytherapy, head and neck cancer, 249
- Recurrence, claudin, colorectal cancer, prognosis, poorly-differentiated component, 3301
- Recurrence, gastric cancer, adjuvant chemotherapy, S-1, 1747
- Recurrence, gastric cancer, tumour marker, surveillance, chemotherapy, CA19-9, 1621
- Recurrence, hepatocellular carcinoma, survival, treatment modality, 4129
- Recurrence, leiomyosarcoma, chemotherapy, mesocolic, paclitaxel, gemcitabine, 2929
- Recurrence, postoperative follow-up, gastric cancer, nodal status, DFS, 4645
- Recurrence, serum p53 antibody, colorectal cancer, tumor marker, curative resection, 2221
- Recurrence-free survival, hepatitis B core antigen antibody, non-B non-C hepatocellular carcinoma, curative therapy, overall survival, 2211
- Recurrent malignant glioma, bevacizumab, deep venous thrombosis, D-dimer, 2093
- Red blood cells, cucumin, liposomes, morphology, echinocyte, 3629
- Red fluorescent protein, green fluorescent protein, blood vessels, nestin, angiogenesis, anastomosis, Gelfoam[®], transgenic nude mice, confocal microscopy, color-coded imaging, vascularization, 3041
- Red fluorescent protein, α v integrin, green fluorescent protein, blood vessels, Gelfoam[®], osteosarcoma, transgenic nude mouse, confocal microscopy, 1361
- Red fluorescent protein, $\alpha_v\beta_3$ integrin, overexpression, green fluorescent protein, osteosarcoma, nude mice, lung metastasis, passage, variants, 3623
- REDD1, breast cancer, zoledronic acid, mTOR, endoplasmic reticulum stress, MCF-7, MDA-MB-231 cells, 3807

- Redirected T-cells, anti-idiotypic antibody, expansion, NY-ESO-1, peptide specific, chimeric antigen receptor, 4189
- Redox factor 1, JNK, p53, selenomethionine, ubiquitination, cancer prevention, protein stability, 3645
- Redox status, antioxidant protein, siRNA, apoptosis, anticancer agents, PC3 cells, 847
- Reference gene, lymph node metastases, molecular staging, polymerase chain reaction, prostate cancer, 5243
- Refractory, biliary tract cancer, irinotecan, gemcitabine, cisplatin, fluoropyrimidine, 2619
- Refractory, capecitabine, colorectal cancer, gemcitabine, 4089
- Regional pelvic nodes, metastasis of prostate cancer, immune cells: lymphocytes, macrophages, immune cell surveillance, lysis/apoptosis of metastatic cancer cells, immune responsive, immune-unresponsive (resistant) cells, 3635
- Regorafenib, bevacizumab, aflibercept, antiangiogenesis, mCRC, TKI, VEGF, 2377
- Regression analysis, oral cancer, SNPs, coagulation factors, angiotensin-converting enzyme, angiotensinogen, serpin1, 4033
- Regression, cofilin-1, cofilin-2, progression, fibrosarcoma, 3661
- Regulatory T-cell, tonsillar squamous cell carcinoma, FOXP3, HPV, p16, 5667
- Re-irradiation, brachytherapy, gynecological cancer, high dose rate, late vaginal mucosal reaction, interstitial brachytherapy, 5687
- Re-irradiation, ependymoma, pulsed reduced dose-rate radiotherapy, 2611
- Reirradiation, hypoxic radiosensitizer, brain metastases, stereotactic irradiation, CyberKnife, 1773
- Re-irradiation, lung cancer, stereotactic body radiotherapy, fractionation, 5649
- Relapse, chemotherapy, glioblastoma, sorafenib, temozolomide, 3487
- Relapse, *ex vivo* drug resistance, individualized tumor response testing, acute myeloid leukemia, children, minimal residual disease, 1189
- Relapse, pulmonary blastoma, elderly, lung malignancy, 3911
- Relapse, WT-1, AML, MRD, 3335
- Relapse/progression, brain tumor, liposomal cytarabine, intrathecal, medulloblastoma, case series, 3515
- Remodeling, curcumin, bone, morphometrics, mice, 3153
- Renal adenocarcinoma, AKT, cardiac hormones, colorectal adenocarcinomas, pancreatic carcinomas, 785
- Renal adenocarcinoma, β -catenin, pancreatic cancer, cardiac hormones, 2409
- Renal cancer, WNT inhibitors, targeted therapy, bi-functional peptide, 2435
- Renal cell carcinoma, 18F-FDG-PET/CT, hybrid imaging, prognosis, SUV_{max} , 2665
- Renal cell carcinoma, bone sialoprotein, osteopontin, prognosis, 2679
- Renal cell carcinoma, nanoparticle, desacyl-saponin, BBE, *in vitro*, *in vivo*, xenograft, 143
- Renal cell carcinoma, PD-0322991, palbociclib, cell-cycle inhibition, CDKN2A, p16, E2F1, 2997
- Renal cell carcinoma, vascular endothelial growth factor, distant metastasis-free survival, overall survival, 5017
- Renal function, renal tumor, percutaneous radiofrequency ablation, 4669
- Renal subcapsular implantation, circulating tumor cells, metastasis, murine model, RCC, 4751
- Renal transplant, adenocarcinoma, goblet cell carcinoid; colon, 1753
- Renal tumor, percutaneous radiofrequency ablation, renal function, 4669
- Renal, taxol, dichloroacetic acid, p66shc, toxicity, 3119
- Repeat evaluation, hematuria, second malignancy, bladder cancer, urinary tract malignancy, screening, 5525
- Repeat hepatectomy, hepatocellular carcinoma, hepatectomy, transarterial chemoembolization, long-term survival, 5097
- Replication stress, thymidine deprivation, uracil glycosylase, *Saccharomyces cerevisiae*, 2037
- Resistance, estrogen receptor, Y-box binding protein-1, transforming growth factor β , antiestrogen, 2473
- Resistance, lung adenocarcinoma, brain metastases, *EGFR*, TKI, radiotherapy, 1649
- Resorption, β -tricalcium phosphate, bone tumor, filling material, bone remodeling, 5075
- Response to chemotherapy, DNA ploidy index, gastric adenocarcinoma, overall survival, prognostic factor, 1209
- Response, breast cancer, paclitaxel, capecitabine, metastasis, 4941
- Resveratrol, prostate cancer, lycopene, capsaicin, curcumin, dietary phytochemicals, review, 4163
- Retrieved lymph node number (RLN), TNM classification, node category (N-category), Dukes' C, colorectal cancer, 2949
- Retroperitoneal sarcoma, disease-free survival, overall survival, soft tissue sarcoma, 4081
- Reverse transcriptase-polymerase chain reaction, papillary thyroid carcinoma, melanoma-associated antigen (MAGE), 1731
- Review, 3-bromopyruvate, GAPDH, glucose metabolism, glycolysis, HCC, locoregional therapy, molecular targeting, 13
- Review, aryl hydrocarbon receptor, lung cancer, tumorigenesis, dioxin, polycyclic aromatic hydrocarbons, cigarette smoke, 1247
- Review, biomarkers, gastric cancer, *HER2*, DNA repair systems, fluoropyrimidine metabolism, apoptotic pathway, chemotherapy, targeted therapy, 1257

- Review, breast cancer, mTOR inhibitor, endocrine resistance, Everolimus, Temsirolimus, PI3K, AKT, 21
- Review, cancer stem cells, radiotherapy, radioresistance, therapeutic targets, 747
- Review, cancer, endoplasmic reticulum, stress, unfolded protein response, molecular chaperones, activating transcription factor 6, PERK kinase, inositol requiring enzyme-1, 4683
- Review, cisplatin, high-affinity human copper transporter 1 (hCtr1), copper chelator, 4157
- Review, colorectal cancer, lymph node metastasis, lymph node harvest, lymph node ratio, survival, population-based study, prospective study, 2839
- Review, curcumin, oral absorption, bioavailability, drug delivery system, 2807
- Review, drug delivery, photodynamic therapy, photosensitizer, tumor targeting, 2823
- Review, epigenetics, DNA methylation, DNMT inhibitors, cancer therapy, 2989
- Review, esophageal cancer, gastric cancer, *EGFR*, trastuzumab, cetuximab, 4139
- Review, gene therapy, hepatocellular carcinoma (HCC), intravenous intra-arterial, intra-tumoral, intra-portal, intra-biliary injection, delivery approach, 4711
- Review, glycolytic enzymes, oncogenes, signaling pathways, transcription factors, tumor suppressor genes, Warburg effect, 2855
- Review, head and neck carcinoma, squamous, ubiquitination, ubiquitin-proteasome system, ubiquitin ligases, carcinogenesis, 3527
- Review, inguinal canal, spermatic cord, paratesticular, sarcoma, 2361
- Review, intestinal macrophage, intestinal microbiota, homeostasis, health, disease, 2849
- Review, junctional adhesion molecules (JAMs), brain metastasis blood-brain barrier (BBB), tight junctions (TJs), 2353
- Review, mesothelioma, chemotherapy, pemetrexed, treatment outcome, quality of life, health economics, 3553
- Review, metabotropic glutamate receptors, cell proliferation, tumor biology, neuroendocrine tumors, alternative therapy, 1267
- Review, mitochondrial DNA, DNA repair, carcinogenesis, metastasis, 3543
- Review, musculoskeletal tumor, forearm, hand, limb salvage, microsurgery, tissue transfer, 4175
- Review, NF2, merlin, tumor suppressor, cell cycle, 1
- Review, osteonecrosis of the jaw, ONJ, denosumab, bevacizumab, sunitinib, risk factors, 1793
- Review, pancreatic adenocarcinoma, chemotherapy, gemcitabine, FOLFIRINOX, combined therapy, clinical trials, 1785
- Review, prostate cancer, lycopene, resveratrol, capsaicin, curcumin, dietary phytochemicals, 4163
- Review, prostate cancer, soy phytoestrogens, daidzein genistein, diet, epigenetics, isoflavones, 39
- Review, quinazoline, doxazosin, terazosin, DZ-50, prostate cancer, vascularity, anoikis, 4695
- Review, staging, mediastinal lymph nodes, surgical procedure, endosonographic evaluation, echoendoscope, 2369
- Review, transporters, cisplatin, tumor, uptake, protection, toxicity, 4183
- Review, urinary bladder cancer, *in vitro* models, *in vivo* models, antineoplastic drugs, 1273
- Review, vaginal intraepithelial neoplasia (VaIN), human papillomavirus (HPV), 29
- Review, ZFAT, transcription factor, haematopoietic system, angiogenesis, haematopoietic malignancies, TAL1, 2833
- Review, zoledronic acid, anticancer therapy, denosumab, tumor growth, 2981
- RFP, GFP, apoptosis, mitosis, subcellular dynamics, brain cancer, mouse models, temozolomide, *in vivo* imaging, 103
- RFP, GFP, mitosis, subcellular dynamics, brain cancer, brain metastasis, mouse model, craniotomy window, *in vivo* imaging, 1367
- RFP, glioma, U87, orthotopic, craniotomy window, imaging, fluorescence, surgery, survival, 107
- RFP, HT-1080, fibrosarcoma, intravascular, extravasation, GFP, mitosis, apoptosis, nude mice, confocal microscopy, 4229
- RFP, *Salmonella typhimurium* A1-R, GFP, TCM, tumor targeting, combination, Lewis lung carcinoma, C57/BL6 mice, 1837
- RGD peptide, malignant melanoma, integrin $\alpha_v\beta_3$, cell adhesion, cell migration, 871
- Rhinacanthus nasutus*, cytotoxicity, apoptosis induction, osteoclastogenesis, HSC-2, HSC-3, HSC-4, HL-60 cells, 453
- Rhodamine, *HER2*, antibody, fluorophore, breast cancer, 4T1, GFP, orthotopic model, lymph node, metastasis, imaging, 419
- Ribosomal protein S6 kinase, RPS6KB2, gastric cancer, gene amplification, S6K2 mTOR signaling, 469
- RICTOR, pituitary adenoma, mTOR, RAPTOR, staging, invasion, 3123
- Right aortic arch, esophageal cancer, thoracoscopic esophagectomy, prone position, 4515
- Right aortic arch, esophageal cancer, video-assisted thoracoscopic surgery (VATS), 1635
- Risk factors, bisphosphonate, osteonecrosis, mandible, cytostatic therapy, 3917
- Risk factors, combination chemotherapy, esophageal squamous cell carcinoma, metastasis, old age, taxane, 4123

- Risk factors, gastric cancer, atrophic gastritis, antrum, corpus, *Helicobacter pylori*, biomarker panel, pepsinogens, gastrin-17, achlorhydria, blood test, 4595
- Risk factors, osteonecrosis of the jaw, ONJ, denosumab, bevacizumab, sunitinib, review, 1793
- Risk, breast cancer, screening, age groups, younger women, 2651
- Risk, colorectal cancer, *miR-146a* polymorphism, rs2910164, prognosis, 3233
- Risky lifestyle habits, sun habits, sun protection behaviour, skin cancer, social environment, 631
- Rituximab, Epstein-Barr virus, low-grade B-cell lymphoma, 5693
- RNAi, EAG1, glioma, glioblastoma multiforme, IFN- γ , gene therapy, 865
- RO492907, gamma secretase, melanoma, *PTEN*, 1307
- ROS, ovarian cancer, CDDO-Me, apoptosis, AKT, NF- κ B, mTOR, 215
- ROS, piperaceae, *Piper sarmentosum*, dichamanetin, cytotoxicity, NF- κ B inhibition, DNA binding, mitochondrial membrane potential, PARP-1, 5349
- Round cell, mesenchymal tumor, GIST, sarcoma, spindle cell, pseudopapillary, 991
- RPS6KB2, ribosomal protein S6 kinase, gastric cancer, gene amplification, S6K2 mTOR signaling, 469
- RRAD, hypermethylation, EAC, ESCC, 5199
- RRM1, chemoradiotherapy, lung cancer surgery, lung cancer biology, ERCC1, tubulin, TYMS, 1107
- Rs1044129, colonic cancer, polymorphism, microRNA, microRNA-binding site, prognosis, 513
- Rs2910164, colorectal cancer, *miR-146a* polymorphism, risk, prognosis, 3233
- Ruthenium, esophageal squamous cell carcinoma, microRNA-21, *PTEN*, AKT, 5407
- S-1, advanced gastric cancer, chemotherapy, docetaxel, elderly, 697
- S-1, colorectal cancer, oxaliplatin, SOX, molecular target, liver metastasis, 3941
- S-1, colorectal cancer, oxaliplatin, SOX, XELOX, metastasis, 4029
- S-1, gastric cancer, adjuvant chemotherapy, recurrence, 1747
- S-1, head and neck cancer, nedaplatin, phase I study, granule formulation, 5699
- S-1, irinotecan, colorectal cancer, IRIS, FIRIS, 3845
- S-1, outpatient oral chemotherapy, unresectable head and neck cancer, metastasis, 3285
- S6 kinase 1 (S6K1), breast cancer, neoadjuvant chemotherapy, chemo-responsiveness, AKT, 4073
- S6K2 mTOR signaling, ribosomal protein S6 kinase, RPS6KB2, gastric cancer, gene amplification, 469
- Saccharomyces cerevisiae*, thymidine deprivation, replication stress, uracil glycosylase, 2037
- Safety study, artesunate, cancer, dog, comparative oncology, 1819
- Salinomycin, DR4, DR5, apoptosis, ovarian cancer, A2780cis cells, 1457
- Saliva, Sirolimus, oral topical delivery, oral cancer, 661
- Salivary ductal carcinoma, molecular-targeted therapy, *HER2/neu*, trastuzumab, 2587
- Salivary gland, hybrid tumour, sublingual gland, 4567
- Salmonella typhimurium* A1-R, GFP, TCM, tumor targeting, combination, Lewis lung carcinoma, RFP, C57/BL6 mice, 1837
- Salmonella typhimurium*, auxotroph, leucine, arginine, GFP, tumor-targeting, primer dosing, high dose, Lewis lung carcinoma, immunocompetent mice syngeneic mouse model, 97
- Salvage esophagectomy, esophagus, squamous cell carcinoma, definitive chemoradiotherapy, murine double minute 2, p16, Ki-67, 1463
- Sanazole (AK-2123), hypoxic radiosensitizer, radiotherapy, oral administration, neuropathy, 643
- Saos-2 cells, mutant p53, transcription, tumor cells, 923
- Sarcoma 180, ultrasound, nanomedicine, fullerenes, sonodynamic therapy, colon 26, 3145
- Sarcoma, inguinal canal, spermatic cord, paratesticular, review, 2361
- Sarcoma, lesion, epidemiology, SEER, NCI, 2597
- Sarcoma, mesenchymal tumor, GIST, spindle cell, round cell, pseudopapillary, 991
- Sarcomatoid differentiation, clear cell renal carcinoma, xenotransplantation, cell line and clonal sublines, de-differentiation, epithelioid, fibroblastoid, 4875
- SAS human oral cancer cells, quercetin, migration, invasion, MMP-2, MMP-9, NF- κ B, 1941
- Saturation prostate biopsy, prostate cancer, multiparametric MRI, pelvic phased-array MRI, 1195
- SBRT, centrally-located lung tumor, adverse effect, local control, lung cancer, 4959
- SCCHN, HPV infection, p16 expression, 913
- SCLC, brain metastasis, extracranial organs, prognostic factors, survival, 3887
- Scoparone, high-performance counter current chromatography, umbelliferone, herniarin, laryngeal cancer cells, proliferation, migration, cell cycle, apoptosis, 4347
- Screen-detected breast carcinoma, screening, *HER2*, gene amplification, targeted therapy, cost-effectiveness, 3705
- Screening, breast cancer, age groups, risk, younger women, 2651
- Screening, dysphagia, swallowing disorder, head and neck cancer, postsurgical, 4017
- Screening, hematuria, second malignancy, bladder cancer, urinary tract malignancy, repeat evaluation, 5525

- Screening, prostate cancer, cell-free DNA, biomarker, quantitative PCR, PicoGreen, 4521
- Screening, screen-detected breast carcinoma, *HER2*, gene amplification, targeted therapy, cost-effectiveness, 3705
- Second malignancy, hematuria, bladder cancer, urinary tract malignancy, repeat evaluation, screening, 5525
- Second neoplasm, papillary thyroid carcinoma, synchronous tumours, 337
- Secondary prophylaxis, chemotherapy-induced neutropenia, febrile neutropenia, G-CSF, pegfilgrastim, 301
- Second-line therapy, fotemustine, chemotherapy, glioblastoma, low-dose, 4013
- Second-line therapy, gastric cancer, paclitaxel, 4547
- Second-line, pemetrexed, erlotinib, adenocarcinoma, NSCLC, third-line, sequence, 3397
- Secretory phospholipase A2, esophageal adenocarcinoma, growth, proliferation, ERK 1/2, 1337
- SEER, endometrial carcinoma, baby boomers, early stage, survival, prognosis, 4983
- SEER, sarcoma, lesion, epidemiology, NCI, 2597
- Segmental bioelectrical impedance analysis, whole-body bioelectrical impedance analysis, edema of the upper limb, breast cancer, 3403
- Selenite, carboplatin, ovarian cancer, xenografts, drug resistance, 4249
- Selenomethionine, JNK, p53, redox factor 1, ubiquitination, cancer prevention, protein stability, 3645
- Senescence, Id4, E2F1, apoptosis, DU145, 4271
- Sentinel lymph node, breast cancer staging, micrometastases, 4509
- Sentinel lymph node, breast cancer, intraoperative examination, frozen section, imprint cytology, 1045
- Sequence, pemetrexed, erlotinib, adenocarcinoma, NSCLC, second-line, third-line, 3397
- Sequencing, HRMA, cetuximab, colorectal cancer, *KRAS* mutation, 2129
- Serotonin, 5-HT₂s, malignant, non-malignant, invasive ductal carcinoma, invasive lobular carcinoma, breast cancer, 363
- SERPINA5, thyroid cancer, methylation, 4833
- Serpine1, oral cancer, SNPs, coagulation factors, angiotensin-converting enzyme, angiotensinogen, regression analysis, 4033
- Serrated adenoma, Barrett's mucosa, adenocarcinoma, 1743
- Serum albumin, postoperative pancreatic fistula, pancreatic resection, serum C-reactive protein, 5005
- Serum C-reactive protein, postoperative pancreatic fistula, pancreatic resection, serum albumin, 5005
- Serum marker, afamin, LICAM, mesothelin, ovarian cancer, 329
- Serum p53 antibody, colorectal cancer, tumor marker, recurrence, curative resection, 2221
- Serum, bladder cancer, hypermethylation, cell-free DNA, 779
- Serum, cell-free DNA, CpG-island, hypermethylation, kidney cancer, biomarker, 4651
- Serum-free, *Pantoea agglomerans*, LPS, LPSP, O-antigen polysaccharide, HMM, LMM, 2875
- Sesquiterpenes, *Ambrosia arborescens*, damsin, coronopilin, chemoselective bromination, cell proliferation, STAT3, NF- κ B, apoptosis, 3799
- Sevoflurane, anaesthesia, breast cancer, 4255
- Sex differences, cancer-induced bone pain, bone metastasis, pain, 1963
- Sex hormones, testosterone, estrone, free radicals, electron emission, hormone regeneration, carcinogenicity, 941
- SFRP, colorectal cancer, WNT, β -catenin, prognosis, E-cadherin, invasive front, 4573
- Short-term culture, hepatocellular carcinoma, sorafenib, RAF kinases, tumour fragments, 1415
- Short-term outcome, IORT, breast cancer, elderly, morbidity, 3995
- ShRNA, PROX1, small cell lung cancer, Lentivirus, cell proliferation, viral knockdown, 3169
- ShRNA, VEGF-C, pancreatic cancer, nude mice, orthotopic, GFP, 409
- Siah2, oral cancer, ubiquitin ligase, apoptosis, 4965
- SIB-IMRT, post-operative radiotherapy, prostate cancer, hypo-fractionation, phase II trial, 2785
- Side population cell, YHO-13351, irinotecan, *ABCG2*, 1379
- Siewert type II adenocarcinoma, esophagogastric junctional carcinoma, AJCC, TNM, JCGC, staging system, 3461
- Signaling pathway, monocyte, colon cancer cell, co-culture, angiogenesis, metastasis, DLD-1, THP-1 cells, 2895
- Signaling pathways, glycolytic enzymes, oncogenes, transcription factors, tumor suppressor genes, Warburg effect, review, 2855
- Silencing, lentiviral siRNA, hCG β , bladder carcinoma, stable gene knockdown SCaBER cells, 3611
- Silicate fiber scaffold, three-dimensional (3D) culture, drug resistance, anticancer drug screening, 5301
- SILS, GIST, intragastric, oncologic surgery, 3359
- Simple hysterectomy, cervical cancer, intermediate risk factor, less radical surgery, 5135
- Simultaneous integrated boost, hypoxic radiosensitizer, intensity-modulated radiation therapy, glioblastoma multiforme, case report, 1685
- Single nucleotide polymorphism, hepatocellular carcinoma, thioredoxin domain-containing-5, Korean, male population, 3983
- Single nucleotide polymorphism, VEGF, *VEGFR*, sunitinib, biliary tract cancer, gastric cancer, 4619
- Single-frequency bioelectrical impedance, lymphedema of the upper limb, breast cancer, 4553
- Single-nucleotide polymorphism, APEX1, lung cancer, smoking habit, Taiwanese, 2775

- Singlet oxygen, HOCl, superoxide anion, hydroxyl radical, SOD, MKN45, B16F10 cells, 3589
- SiRNA, antioxidant protein, apoptosis, redox status, anticancer agents, PC3 cells, 847
- SiRNA, galectin-7, ovarian cancer, prognosis, 1555
- SiRNA, leukemia, NOTCH, mTOR, MYC, 4293
- SiRNA, VEGF-C, VEGF-D, metastasis, mammary cancer, 4237
- Sirolimus, mTOR, phospho-mTOR, squamous cell carcinoma, basal cell carcinoma, Everolimus, Immunohistochemistry, organ transplantation, immunosuppression, skin, 3711
- Sirolimus, oral topical delivery, oral cancer, saliva, 661
- SIRT3, follicular carcinoma, papillary carcinoma, nicotinamide phosphoribosyltransferase, NAD⁺, 3047
- Sivelestat, CT26 murine colon cancer, neutrophil elastase inhibitor, cecal ligation and puncture, compensatory anti-inflammatory response syndrome, 3653
- Size, tumour, lymphovascular, triple-negative, breast, cancer, 2737
- SKBR-3 cells, HER-2 oncoprotein, breast cancer, trastuzumab resistance, proteomics, 489
- Skin cancer, sun habits, sun protection behaviour, social environment, risky lifestyle habits, 631
- Skin toxicity, *EGFR* gene polymorphism, colorectal cancer, *EGFR* antibody, 4995
- Skin, mTOR, phospho-mTOR, squamous cell carcinoma, basal cell carcinoma, Sirolimus, Everolimus, Immunohistochemistry, organ transplantation, immunosuppression, 3711
- SKOV-3 cell line, ovarian cancer, tumor-associated macrophages (TAMs), monocyte chemoattractant protein-1 (MCP-1), C-C motif chemokine receptor-2 (CCR2) antagonist, 4785
- SKOV3 cells, acetaminophen, glutathione, chemo-enhancement, cisplatin, ovarian cancer, 2391
- SKOV-3, ovarian cancer, K2P channels, TASK-3, expression, survival, OVCAR-3 cells, 1401
- (Smac) DIABLO, gastric adenocarcinoma, Immunohistochemistry, AIF, cytochrome *c*, 647
- SMAD3, CAFs, NFs, lung cancer, stromal NSCLC, direct co-culture, indirect co-culture, EMT, proliferation, Hedgehog signaling pathway, 3715
- SMAD3, cancer-associated fibroblasts, normal fibroblasts, NFs, lung cancer, NSCLC, co-culture, EMT, proliferation, 2001
- Small cell carcinoma of the esophagus, adjuvant chemotherapy, dysphagia, long-term cancer survival, radical resection, 595
- Small cell carcinoma, colon cancer, carcinoid tumor, 1713
- Small cell lung cancer, herpes simplex virus-1, encephalitis, radiation, immunosuppression, 3263
- Small cell lung cancer, interstitial lung disease, chemotherapy, cisplatin, carboplatin, etoposide, acute exacerbation, 1175
- Small cell lung cancer, PROX1, shRNA, Lentivirus, cell proliferation, viral knockdown, 3169
- Small intestine cancer, Crohn's disease, surgical operation, 2977
- Small testicular masses, testicular neoplasms, orchiectomy, testis-sparing surgery, 5205
- Sm-hPAF, cytolysin, cholesterol-independent, human-specific, ILY, VLY, CD59, 2901
- Smoking habit, APEX1, single-nucleotide polymorphism, lung cancer, Taiwanese, 2775
- Smoking, *ATM*, polymorphism, genotype, lung cancer, 4067
- Smoking, body-mass index, alcohol, neoplasms, multiple primary tumors, esophageal cancer, colonoscopy, 5113
- Smoking, lung cancer, prognosis, thrombocytosis, 1725
- SN-38, CD44-targeted delivery, PLGA nanoparticles, hyaluronic acid, surface decoration, ovarian cancer, CTAB assay, 2425
- SNP, MMP12, MMP13, colorectal cancer, 3247
- SNP, *NAT2*, cancer susceptibility, IAM, breast cancer, gastric cancer, 3683
- SNPs, oral cancer, coagulation factors, angiotensin-converting enzyme, angiotensinogen, serpine1, regression analysis, 4033
- Social environment, sun habits, sun protection behaviour, skin cancer, risky lifestyle habits, 631
- Socioeconomic factors, environmental factors, gastric adenocarcinoma, gastric tumorigenesis, lifestyle factors, microRNA, 3195
- SOD, HOCl, superoxide anion, singlet oxygen, hydroxyl radical, MKN45, B16F10 cells, 3589
- Soft tissue sarcomas, sunitinib malate, liposarcoma, multi-target inhibitor of tyrosine kinases, 1061
- Soft tissue matching, tomotherapy, prostate cancer, PTV margin, image-guided IMRT, megavolt computed tomography, 5675
- Soft tissue sarcoma, retroperitoneal sarcoma, disease-free survival, overall survival, 4081
- Soft tissue sarcomas, febrile neutropenia, lenograstim, G-CSF, 679
- Solid tumor, electroporation, dendritic cell vaccine, tumor lysate, 2971
- Soluble epoxide hydrolase, dextran sulfate sodium, colitis, carcinogenesis, mice, 5261
- Somatostatin analogs, ⁶⁸Ga-DOTATOC, 18F-FDG, PET, SSTR2, immuno-histochemistry, 3015
- Sonodynamic therapy, ultrasound, nanomedicine, fullerenes, sarcoma 180, colon 26, 3145
- Sorafenib, celecoxib, AKT, apoptosis, hepatocellular carcinoma, synergism, HCC, 1387

- Sorafenib, chemotherapy, glioblastoma, relapse, temozolomide, 3487
- Sorafenib, hepatocellular carcinoma, RAF kinases, short-term culture, tumour fragments, 1415
- Sorafenib, kidney cancer, drug sequence, sunitinib, Everolimus, temisolimus, 4999
- Sorafenib, metabolic ¹⁸⁸Rhenium, radiotherapy, hepatocellular carcinoma, synergy, N1S1, HepG2 cells, 3871
- Sorafenib, phase I, hepatocellular carcinoma, orthotopic liver transplantation, adjuvant therapy, 2797
- Sorafenib, tyrosine kinase inhibitor, mTOR, PDGFR, HIF, head and neck squamous cell carcinoma, Everolimus, sunitinib, 5385
- SOX, colorectal cancer, oxaliplatin, S-1, molecular target, liver metastasis, 3941
- SOX, colorectal cancer, oxaliplatin, S-1, XELOX, metastasis, 4029
- Soy phytoestrogens, prostate cancer, daidzein genistein, diet, epigenetics, isoflavones, review, 39
- Spermatic cord, inguinal canal, paratesticular, sarcoma, review, 2361
- Sphenoid wing dysplasia, orbit, orbital rim, orbital neurofibromatosis, NF1, plexiform neurofibroma, orbital dysplasia, plain radiographs, cephalometry, 1081
- Sphingolipids, apoptosis, ceramide, dihydroceramide desaturase, dihydroceramide, PDT, UM-SCC-22A cells, HNSCC, 77
- Sphingolipids, ovarian cancer, chemoresistance, sphingosine kinase-2, experimental therapeutics, sphingosine-1-phosphate, ABC294640, BG-1, Caov-3 cells, 3573
- Sphingosine kinase-2, ovarian cancer, sphingolipids, chemoresistance, experimental therapeutics, sphingosine-1-phosphate, ABC294640, BG-1, Caov-3 cells, 3573
- Sphingosine-1-phosphate, ovarian cancer, sphingolipids, chemoresistance, sphingosine kinase-2, experimental therapeutics, ABC294640, BG-1, Caov-3 cells, 3573
- Spindle cell, mesenchymal tumor, GIST, sarcoma, round cell, pseudopapillary, 991
- Splenectomy, gastric cancer, lymph node metastasis, 277
- Sporadic cancer, disease-free survival, kinase receptor family, tumor suppressor, molecular markers, 5159
- Squamous cell carcinoma, esophagus, definitive chemoradiotherapy, salvage esophagectomy, murine double minute 2, p16, Ki-67, 1463
- Squamous cell carcinoma, head and neck cancer, collagen I, phosphoinositol-3 kinase, MD-1483 cells, 379
- Squamous cell carcinoma, HIV, viral load, CD4, head and neck cancer, radiation therapy, IMRT, chemotherapy, concurrent chemoradiotherapy, 5511
- Squamous cell carcinoma, *IL10*, haplotype, prognosis, adenocarcinoma, lung cancer, 2729
- Squamous cell carcinoma, *miR-146a*, polymorphism, head and neck, 341
- Squamous cell carcinoma, mTOR, phospho-mTOR, basal cell carcinoma, Sirolimus, Everolimus, Immunohistochemistry, organ transplantation, immunosuppression, skin, 3711
- Squamous cell carcinoma, oral cancer, miRNA expression, genomics, 1511
- Squamous cell lung cancer, NSCLC, targeted-therapy, *EGFR*, *KRAS*, *PIK3CA*, mutation, *EGFR*-TKI, 1705
- Squamous cell, esophageal carcinoma, chemoradiotherapy, surgery, 1157
- Squamous, head and neck carcinoma, ubiquitination, ubiquitin-proteasome system, ubiquitin ligases, carcinogenesis, review, 3527
- SRC, gap junctions, STAT3, *in situ* electroporation, lung cancer, 4401
- SSTR2, ⁶⁸Ga-DOTATOC, 18F-FDG, PET, immunohistochemistry, somatostatin analogs, 3015
- Stable gene knockdown SCABER cells, lentiviral siRNA, hCG β , bladder carcinoma, silencing, 3611
- Stage IB1/II, non-bulky, cervical cancer, radiotherapy, concurrent chemoradiotherapy, 5123
- Stage IV colorectal cancer, C-reactive protein, survival, oxaliplatin-based chemotherapy, 5051
- Stage IV colorectal cancer, tumor necrosis, without residual disease (R0 status), inflammatory response 1099
- Stage IV gastric cancer, prognosis, C-reactive protein, cut-off value, 5591
- Stage IV, colorectal cancer, asymptomatic primary tumor, palliative surgery, Glasgow prognostic score, neutrophil to lymphocyte ratio, 5567
- Staging system, esophagogastric junctional carcinoma, Siewert type II adenocarcinoma, AJCC, TNM, JCGC, 3461
- Staging, locally advanced cervical cancer, PET/CT, para-aortic lymphadenectomy, 283
- Staging, mediastinal lymph nodes, surgical procedure, endosonographic evaluation, echoendoscope, review, 2369
- Staging, pituitary adenoma, mTOR, RAPTOR, RICTOR, invasion, 3123
- Staging, rectal cancer, adjuvant therapy, prognostic factors, 4557
- Stapling devices, total gastrectomy, gastric cancer, oesophagojejunal anastomosis, minimally-invasive surgical technique, 3269
- STAT3, *Ambrosia arborescens*, damsin, coronopilin, chemoselective bromination, sesquiterpenes, cell proliferation, NF- κ B, apoptosis, 3799
- STAT3, gap junctions, SRC, *in situ* electroporation, lung cancer, 4401
- STAT3, ursolic acid, colon cancer, cancer-initiating cells, 4279

- Stem cell antigens, neuroendocrine differentiation, CD117, CD133, *ABCG2* antigens, non-small cell lung cancer, 981
- Stem cell marker, prostate cancer, cancer stem cells, canine, CT1258, CT1258-EGFP, CT1258-EGFP-*HMGA2* cell lines, 5421
- Stem cells, thyroid cancer, xenografts, adipose tissue, mouse model, 4213
- Stemness, cancer stem-like cells, OCT4, MDA-MB453, differentiation, asymmetric cell division, 763
- Stenosis, brachytherapy, gynecological cancer, high dose rate, late vaginal mucosal reaction, pallor reaction, 3963
- Stent, hepatocellular carcinoma, peritracheal lymph node metastasis, tracheal obstruction, 1761
- Stereotactic body radiotherapy (SBRT), helical tomotherapy, pulmonary neoplasms, metastatic lung cancer, 655
- Stereotactic body radiotherapy, lung cancer, re-irradiation, fractionation, 5649
- Stereotactic body radiotherapy, tomotherapy, lung tumor, radiophotoluminescence glass dosimeter, Rando phantom, 1679
- Stereotactic body radiotherapy, tomotherapy, vertebral body metastases, PTV margin, image-guided IMRT, 2453
- Stereotactic irradiation, hypoxic radiosensitizer, reirradiation, brain metastases, CyberKnife, 1773
- Stereotactic radiosurgery, brain metastases, multimodality treatment, pancreatic cancer, 3899
- Steroids, octreotide, intestinal obstruction, palliative care, 5557
- STKM-1 cell line, urocortin, corticotrophin-releasing factor receptors, gastric cancer, 5289
- Stomach cancer, ALA, DCA, hyperthermotherapy, cellular immunotherapy, 2957
- Stomach, synchronous cancer, thyroid, breast, pancreas, 2135
- Strategy, lateral lymph node dissection, rectal cancer, meta-analysis, 2921
- Strawberries, chemoprevention, oral cancer, hamster cheek pouch, 4757
- Stress, cancer, endoplasmic reticulum, unfolded protein response, molecular chaperones, activating transcription factor 6, PERK kinase, inositol requiring enzyme-1, review, 4683
- Stromal NSCLC, CAFs, NFs, lung cancer, direct co-culture, indirect co-culture, EMT, proliferation, SMAD3, Hedgehog signaling pathway, 3715
- Subcarinal and main bronchial lymph node dissection, laparoscopic transhiatal approach, esophageal cancer, 2577
- Subcellular dynamics, GFP, RFP, apoptosis, mitosis, brain cancer, mouse models, temozolomide, *in vivo* imaging, 103
- Subcellular dynamics, GFP, RFP, mitosis, brain cancer, brain metastasis, mouse model, craniotomy window, *in vivo* imaging, 1367
- Sublingual gland, hybrid tumour, salivary gland, 4567
- Submesothelial layer, peritoneal carcinomatosis, rat model, mesothelial cells, RCN-9 cells, fibroblast, 1439
- Substituted 6-chloropurines, carbocyclic nucleoside analogs, glutathione-S-transferase, glutathione depletion, 3163
- Subtypes of Gc-globulin, degalactosylated Gc-globulin, a precursor of Gc-derived macrophage activating factor, antitumor activity, injection route, 2911
- Sun habits, sun protection behaviour, skin cancer, social environment, risky lifestyle habits, 631
- Sun protection behaviour, sun habits, skin cancer, social environment, risky lifestyle habits, 631
- Sunitinib malate, soft tissue sarcomas, liposarcoma, multi-target inhibitor of tyrosine kinases, 1061
- Sunitinib, adverse events, early management, pharmacist, adherence, blood pressure, 5043
- Sunitinib, biliary excretion, cimetidine, drug interaction, pharmacokinetics, multidrug resistance-associated protein-2 (Mrp2), (*Abcc2*), 3105
- Sunitinib, gastrointestinal stromal tumor, xenograft, mouse, imatinib, 175
- Sunitinib, kidney cancer, drug sequence, sorafenib, Everolimus, temisrolimus, 4999
- Sunitinib, osteonecrosis of the jaw, ONJ, denosumab, bevacizumab, risk factors, review, 1793
- Sunitinib, single nucleotide polymorphism, VEGF, *VEGFR*, biliary tract cancer, gastric cancer, 4619
- Sunitinib, tyrosine kinase inhibitor, mTOR, PDGFR, HIF, head and neck squamous cell carcinoma, Everolimus, sorafenib, 5385
- Sunlight, vitamin D, polymorphisms, breast cancer, gene, case-control, 543
- Superoxide anion, HOCl, singlet oxygen, hydroxyl radical, SOD, MKN45, B16F10 cells, 3589
- Supportive care, palliative chemotherapy, palliative oncology, 5639
- Surface decoration, CD44-targeted delivery, PLGA nanoparticles, hyaluronic acid, SN-38, ovarian cancer, CTAB assay, 2425
- Surgeon, axilla, lymph nodes, breast cancer, axillary clearance, 3935
- Surgery, esophageal carcinoma, chemoradiotherapy, squamous cell, 1157
- Surgery, glioma, U87, RFP, orthotopic, craniotomy window, imaging, fluorescence, survival, 107
- Surgery, hepatocellular carcinoma, anatomical hepatectomy, preserved liver function, ICG-R15, 1689
- Surgery, non-small cell lung cancer, early-onset, chemotherapy-induced neutropenia, prognosis, 2755
- Surgery, non-small cell lung cancer, HLA class-I expression, prognosis, cancer/testis antigen, immune escape, 2123

- Surgery, ovarian carcinosarcomas, prophylactic pelvic irradiation, chemotherapy, prognosis, 1003
- Surgery, tonsil cancer, radiotherapy, concurrent chemoradiotherapy, 1237
- Surgical approach, brain metastases, colorectal cancer, WBRT, 5645
- Surgical operation, Crohn's disease, small intestine cancer, 2977
- Surgical outcome, laparoscopic supracervical hysterectomy, LASH, prophylactic salpingectomy, laparoscopy, 2771
- Surgical procedure, staging, mediastinal lymph nodes, endosonographic evaluation, echoendoscope, review, 2369
- Surgical resection, brain metastases, breast cancer, prognostic factors, 2159
- Surgical resection, C-reactive protein, hepatocellular carcinoma, prognostic factor, 1181
- Surgical site infection, colorectal liver metastases, Glasgow prognostic score, systemic inflammatory response, 1697
- Surgical stress, ovarian carcinoma, laparoscopy, mouse model, 3177
- Surveillance, gastric cancer, tumour marker, recurrence, chemotherapy, CA19-9, 1621
- Survey, uterine sarcoma, German gynaecologists, 3375
- Survival, brain metastasis, SCLC, extracranial organs, prognostic factors, 3887
- Survival, breast cancer, paclitaxel, metastasis, docetaxel, time-to-progression, 2623
- Survival, colorectal cancer, lymph node metastasis, lymph node harvest, lymph node ratio, population-based study, prospective study, review, 2839
- Survival, C-reactive protein, stage IV colorectal cancer, oxaliplatin-based chemotherapy, 5051
- Survival, endometrial carcinoma, baby boomers, early stage, SEER, prognosis, 4983
- Survival, glioma, U87, RFP, orthotopic, craniotomy window, imaging, fluorescence, surgery, 107
- Survival, hepatocellular carcinoma, percutaneous ethanol injection, transcatheter arterial chemoembolization, Child-Pugh score, aspartate aminotransferase, 5171
- Survival, hepatocellular carcinoma, recurrence, treatment modality, 4129
- Survival, *HER2*, esophagus, metastasis, 4975
- Survival, lung cancer, comorbidity, lung function, random forest method, 1609
- Survival, male, female, breast cancer, prognostic factors, 2227
- Survival, non-small cell lung cancer, cisplatin, ifosfamide, docetaxel, phase III trial, 5477
- Survival, ovarian cancer, K2P channels, TASK-3, expression, SKOV-3, OVCAR-3 cells, 1401
- Survival, prostate cancer, metastatic spinal cord compression, irradiation, extra-spinal organs, prognosis, 4505
- Survivin, artemisinin, transferrin, breast cancer, *HER2*, c-Myc, cyclin D1, DV145, MCF7 cells, 123
- Survivin, native human interferon alpha, recombinant human interferon alpha, non-small cell lung cancer, tumor proliferation, apoptosis, *p21*, 2043
- Survivin, non-small cell lung cancer, apoptosis, real-time RT-PCR, mRNA, proliferation, 3475
- Suspension, hepatocellular carcinoma, transcatheter arterial chemoembolization, miriplatin, emulsion, 5603
- SUV_{max}, renal cell carcinoma, 18F-FDG-PET/CT, hybrid imaging, prognosis, 2665
- SW 480 cells, colorectal carcinoma, *EGFR* phosphorylation, chemotherapy, 3753
- SW420 cells, 15, 16-dihydrotanshinone I, colorectal cancer, activating transcription factor-3, SW480, SW620, 3225
- SW480, 15, 16-dihydrotanshinone I, colorectal cancer, activating transcription factor-3, SW620, SW420 cells, 3225
- SW620 human colon xenograft, azatyrosinamides, ras, antitumour agent, NIH3T3, angiogenesis, 425
- SW620, 15, 16-dihydrotanshinone I, colorectal cancer, activating transcription factor-3, SW480, SW420 cells, 3225
- Swallowing disorder, clinical predictors, dysphagia, head and neck cancer, post-surgical screening, 3347
- Swallowing disorder, dysphagia, head and neck cancer, postsurgical, screening, 4017
- Swedish, colorectal cancer, cytomegalovirus, viral DNA, Vietnamese, 4947
- Symptom control, non-small cell lung cancer (NSCLC), docetaxel (Taxotere®), observational study, 3831
- Synchronous cancer, thyroid, breast, stomach, pancreas, 2135
- Synchronous metastasis, postoperative chemotherapy, colorectal liver metastasis, irinotecan, oxaliplatin, 5-fluorouracil, leucovorin, FOLFOX, FOLFIRI, 3317
- Synchronous tumour, Lynch syndrome, endometrial cancer, ovarian cancer, microsatellite instability, 3977
- Synchronous tumours, papillary thyroid carcinoma, second neoplasm, 337
- Synergism, andrographolide, cisplatin, ovarian cancer, apoptosis, anti-proliferative, 4365
- Synergism, celecoxib, sorafenib, AKT, apoptosis, hepatocellular carcinoma, HCC, 1387
- Synergism, chinese medicine, β -elemene, taxanes, ovarian cancer, prostate cancer, apoptosis, cell cycle arrest, 929
- Synergism, head and neck squamous cell carcinoma (HNSCC), Hedgehog pathway, cyclopamine, cisplatin, docetaxel, 2415
- Synergy, gambogic acid, dihydrofolate reductase, methotrexate, hepatoma, 133
- Synergy, I3C derivative CTet, triple-negative breast cancer, autophagy, *MAP1LC3B*, MDA-MB-231, BT-20 cells, 1867

- Synergy, sorafenib, metabolic ¹⁸⁸Rhenium, radiotherapy, hepatocellular carcinoma, N1S1, HepG2 cells, 3871
- Synthetic analogs, apoptosis, brain cancer, Chinese medicine, β -elemene, A172, U-87MG, CCF-STTG1 cells, 65
- Systemic inflammatory response, colorectal cancer, neutrophil-to-lymphocyte ratio, 3291
- Systemic inflammatory response, colorectal liver metastases, surgical site infection, Glasgow prognostic score, 1697
- 4T1, *HER2*, antibody, fluorophore, rhodamine, breast cancer, GFP, orthotopic model, lymph node, metastasis, imaging, 419
- T1 esophageal cancer, tumor budding, E-cadherin, nodal metastasis, 5023
- T24 cells, BMP10, urothelial cancer of bladder, growth, motility and adhesion, 1917
- Taiwanese, APEX1, single-nucleotide polymorphism, lung cancer, smoking habit, 2775
- TAL1, ZFAT, transcription factor, haematopoietic system, angiogenesis, haematopoietic malignancies, review, 2833
- Tamoxifen, lioblastoma, temozolomide, dose-dense schedule, 3383
- Tamoxifen, pharmacokinetic interaction, ondansetron, hepatic and intestinal, CYP2D, CYP3A1/2, DMBA rats, 521
- Targeted therapies, metastatic renal cell carcinoma, angiogenesis, MRI, peak enhancement, 5663
- Targeted therapy, biomarkers, gastric cancer, *HER2*, DNA repair systems, fluoropyrimidine metabolism, apoptotic pathway, chemotherapy, review, 1257
- Targeted therapy, brain metastases, gastro-oesophageal cancer, GI cancer, molecules, 1065
- Targeted therapy, renal cancer, WNT inhibitors, bi-functional peptide, 2435
- Targeted therapy, screen-detected breast carcinoma, screening, *HER2*, gene amplification, cost-effectiveness, 3705
- Targeted-therapy, squamous cell lung cancer, NSCLC, *EGFR*, *KRAS*, *PIK3CA*, mutation, *EGFR*-TKI, 1705
- TASK-3, ovarian cancer, K2P channels, expression, survival, SKOV-3, OVCAR-3 cells, 1401
- Taxane, combination chemotherapy, esophageal squamous cell carcinoma, metastasis, old age, risk factors, 4123
- Taxanes, chemosaturtion therapy, percutaneous hepatic perfusion, melphalan, platinum agents, 1989
- Taxanes, chinese medicine, β -elemene, synergism, ovarian cancer, prostate cancer, apoptosis, cell cycle arrest, 929
- Taxol, chemosensitivity, HDRA, histoculture drug response assay, epithelial ovarian cancer, carboplatin, prospective clinical trial, correlation, prediction, individualized therapy, 1029
- Taxol, dichloroacetic acid, p66shc, renal, toxicity, 3119
- T-cell, breast cancer, circulating tumor cell, immunosurveillance, tumor cell dormancy, FAS, 2233
- TCM, *Salmonella typhimurium* A1-R, GFP, tumor targeting, combination, Lewis lung carcinoma, RFP, C57/BL6 mice, 1837
- TE-1 cells, esophageal cancer, eicosapentaenoic acid, apoptosis, NF- κ B, cytokines, 4319
- TE13 cells, esophageal carcinoma, COX-2, 5-fluorouracil, cisplatin, chemosensitivity, gene transfer, 537
- Tegafur-uracil, colorectal cancer, leucovorin, folate, γ -glutamyl hydrolase (GGH), gene expression, 3431
- Telomerase, lung, cancer, metastasis, 2643
- Telomerase, telomere, chromatin, trichostatin A, ALT mechanism, recombination, 821
- Telomere, chromatin, telomerase, trichostatin A, ALT mechanism, recombination, 821
- Temisrolimus, kidney cancer, drug sequence, sorafenib, sunitinib, Everolimus, 4999
- Temozolomide, chemotherapy, glioblastoma, relapse, sorafenib, 3487
- Temozolomide, GFP, RFP, apoptosis, mitosis, subcellular dynamics, brain cancer, mouse models, *in vivo* imaging, 103
- Temozolomide, glioblastoma, RAD001, autophagy, γ -radiation, 1845
- Temozolomide, glioblastoma, radiochemotherapy, prolonged adjuvant therapy, 3467
- Temozolomide, glioma stem cell, apoptosis, CD95 ligand, 3563
- Temozolomide, lioblastoma, tamoxifen, dose-dense schedule, 3383
- Temozolomide, lobarstin, glioblastoma, chemosensitivity, DNA repair, 5445
- TemSirolimus, bevacizumab, glioblastoma multiforme, phase II study, PI3K, protein kinase B (AKT), mTOR, rapamycin, 1657
- TemSirolimus, breast cancer, mTOR inhibitor, endocrine resistance, Everolimus, review, PI3K, AKT, 21
- Tenascin-C, TNC, colorectal cancer, EMT, 1927
- Ten-eleven-translocation 2, oral cancer, 5-hydroxymethylcytosine, DNA methylation, biological markers, 4325
- Teniposide, anaplastic, glioblastoma multiforme, high-grade glioma, etoposide, irinotecan, topotecan, meta-analysis, 3307
- Terazosin, quinazoline, doxazosin, DZ-50, prostate cancer, vascularity, anoikis, review, 4695
- Testicular neoplasms, small testicular masses, orchiectomy, testis-sparing surgery, 5205
- Testis-sparing surgery, testicular neoplasms, small testicular masses, orchiectomy, 5205
- Testosterone, estrone, sex hormones, free radicals, electron emission, hormone regeneration, carcinogenicity, 941

- Tetrahydroisoquinoline, ecteinascidin, MCL1, anoikis, metastasis, lung cancer cells, 505
- TGF-beta, lung cancer, fibroblast, invasion, TIG-3, LLC cells, 3791
- TGF- β , circulating tumor cells, CXCL1, metastasis, breast cancer, chemokines, cytokines, 1491
- TGF- β , Nox4, EMT, pancreatic cancer, 4431
- TGF- β 1, breast cancer, prognostic factors, 737
- Therapeutic efficacy, hepatocellular carcinoma (HCC), boron neutron capture therapy (BNCT), boric acid, tumor size, blood vessels, 4799
- Therapeutic targets, cancer stem cells, radiotherapy, radioresistance, review, 747
- Thiobarbituric acid, polycyclic aromatic hydrocarbon, oxidative stress, antioxidant capacity, lung cancer, nested case-control study, 1-hydroxypyrene, 8-hydroxydeoxyguanosine, cotinine, 2-Naphthol, 3089
- Thioredoxin domain-containing-5, hepatocellular carcinoma, single nucleotide polymorphism, Korean, male population, 3983
- Third-line, pemetrexed, erlotinib, adenocarcinoma, NSCLC, second-line, sequence, 3397
- Thoracoscopic esophagectomy, lower thoracic esophageal cancer, 2-field lymph node dissection, 601
- Thoracoscopic esophagectomy, right aortic arch, esophageal cancer, prone position, 4515
- THP-1 cells, monocyte, colon cancer cell, co-culture, angiogenesis, metastasis, signaling pathway, DLD-1, 2895
- THP-1, ApoE, LXR, MCF-7, proliferation, apoptosis, MCF-7 cells, 3783
- Three-dimensional (3D) culture, silicate fiber scaffold, drug resistance, anticancer drug screening, 5301
- Thrombocytosis, breast cancer, predictive value, 4545
- Thrombocytosis, lung cancer, prognosis, smoking, 1725
- Thrombosis, recurrent malignant glioma, bevacizumab, D-dimer, 2039
- Thymidine deprivation, replication stress, uracil glycosylase, *Saccharomyces cerevisiae*, 2037
- Thymidine phosphorylase, radiotherapy, pemetrexed, capecitabine, rectal cancer, chemotherapy, 2447
- Thymidylate synthase, mucinous colorectal cancer, 5-fluorouracil, topoisomerase-1, microsatellite instability, 4611
- Thymidylate synthase, pemetrexed, gene amplification, non-small cell lung cancer, 1935
- Thyroid cancer, methylation, SERPINA5, 4833
- Thyroid cancer, stem cells, xenografts, adipose tissue, mouse model, 4213
- Thyroid neoplasms, *BRAF* mutation, proteomics, chaperonin 60, lymph node metastases, 4357
- Thyroid, synchronous cancer, breast, stomach, pancreas, 2135
- TIG-3, lung cancer, fibroblast, invasion, TGF-beta, LLC cells, 3791
- Tight junctions (TJs), junctional adhesion molecules (JAMs), brain metastasis blood-brain barrier (BBB), review, 2353
- Time-to-progression, breast cancer, paclitaxel, metastasis, docetaxel, survival, 2623
- Tissue array analysis, prostate cancer, Immunohistochemistry, angiogenesis, *VEGFR1*, *NRP1*, prostatectomy, 2065
- Tissue microarray, FAK, breast cancer, 1169
- Tissue transfer, musculoskeletal tumor, forearm, hand, limb salvage, microsurgery, review, 4175
- TKI, bevacizumab, aflibercept, antiangiogenesis, mCRC, VEGF, regorafenib, 2377
- TKI, chronic-phase CML, complete molecular response, 3509
- TKI, lung adenocarcinoma, brain metastases, *EGFR*, radiotherapy, resistance, 1649
- TMA, breast cancer, ER, PgR, *HER2*, Ki67, 2139
- TNC, tenascin-C, colorectal cancer, EMT, 1927
- TNM classification, node category (N-category), retrieved lymph node number (RLN), Dukes' C, colorectal cancer, 2949
- TNM, esophagogastric junctional carcinoma, Siewert type II adenocarcinoma, AJCC, JCGC, staging system, 3461
- Tobacco carcinogens, chemoprevention, lung cancer, experimental model, combination therapy, acetylsalicylic acid, vitamin D, calcium, 4767
- Tomotherapy, lung tumor, stereotactic body radiotherapy, radiophotoluminescence glass dosimeter, Rando phantom, 1679
- Tomotherapy, prostate cancer, image-guided intensity-modulated radiotherapy, 5507
- Tomotherapy, prostate cancer, soft tissue matching, PTV margin, image-guided IMRT, megavolt computed tomography, 5675
- Tomotherapy, vertebral body metastases, stereotactic body radiotherapy, PTV margin, image-guided IMRT, 2453
- Tonsil cancer, surgery, radiotherapy, concurrent chemoradiotherapy, 1237
- Tonsillar cancer, *EGFR*, phosphorylated *EGFR*, HPV, 1575
- Tonsillar squamous cell carcinoma, regulatory T-cell, FOXP3, HPV, p16, 5667
- Topoisomerase-1, mucinous colorectal cancer, 5-fluorouracil, thymidylate synthase, microsatellite instability, 4611
- Topotecan, anaplastic, glioblastoma multiforme, high-grade glioma, etoposide, irinotecan, teniposide, meta-analysis, 3307
- Total gastrectomy, gastric cancer, oesophagojejunal anastomosis, stapling devices, minimally-invasive surgical technique, 3269
- Total mesometrial resection, laparoscopic radical hysterectomy, laparoscopic lymph node dissection, learning curve, initial experience, 3449

- Toxicity, early breast cancer, docetaxel, obesity, fat mass, dose intensity, 5655
- Toxicity, head and neck carcinoma, neopterin, radiotherapy, 4097
- Toxicity, taxol, dichloroacetic acid, p66shc, renal, 3119
- Toxicity, transporters, cisplatin, tumor, uptake, protection, review, 4183
- TRACERlab FXc PRO module, [*N*-methyl-¹¹C]methylene blue, PET, melanoma, 4267
- Tracheal obstruction, hepatocellular carcinoma, peritracheal lymph node metastasis, stent, 1761
- TRAIL, cervical cancer cells, equol, caspases, death receptors, apoptosis, 903
- TRAMP-C1, radiation effects, bisphosphonates, radiosensitizers, radioprotectors, PNT2, B16F10 cells, 3217
- Trans fatty acids, carcinogenesis, C57BL/6J-*Min*/+ mice, hydrogenated fish oil, colorectal cancer, 477
- Transarterial chemoembolization, drug eluting beads with irinotecan, colorectal cancer, 2077
- Transarterial chemoembolization, hepatocellular carcinoma, hepatectomy, repeat hepatectomy, long-term survival, 5097
- Transcatheter arterial chemoembolization, hepatocellular carcinoma, percutaneous ethanol injection, survival, Child-Pugh score, aspartate aminotransferase, 5171
- Transcatheter arterial chemoembolization, hepatocellular carcinoma, miriplatin, suspension, emulsion, 5603
- Transcatheter arterial chemoembolization, pancreatic neuroendocrine tumors, chemotherapy, hepatic metastasis, 3355
- Transcobalamin II, vitamin B12, Immunohistochemistry, transport protein, receptor, Ki-67, xenograft, 4203
- Transcription factor, ZFAT, haematopoietic system, angiogenesis, haematopoietic malignancies, TAL1, review, 2833
- Transcription factors, glycolytic enzymes, oncogenes, signaling pathways, tumor suppressor genes, Warburg effect, review, 2855
- Transcription, mutant p53, tumor cells, Saos-2 cells, 923
- Transcriptional activity, breast cancer, hypoxia-inducible factor, polymorphism, MCF-7 cells, 2549
- Transferrin, artemisinin, breast cancer, *HER2*, survivin, c-Myc, cyclin D1, DV145, MCF7 cells, 123
- Transforming growth factor β , estrogen receptor, Y-box binding protein-1, antiestrogen, resistance, 2473
- Transgenic nude mice, green fluorescent protein, blood vessels, nestin, angiogenesis, anastomosis, red fluorescent protein, Gelfoam[®], confocal microscopy, color-coded imaging, vascularization, 3041
- Transgenic nude mouse, α v integrin, green fluorescent protein, blood vessels, red fluorescent protein, Gelfoam[®], osteosarcoma, confocal microscopy, 1361
- Translational cancer research, India internaional symposium, Udaipur, Rajasthan, cancer prevention, 1777
- Transport protein, vitamin B12, Immunohistochemistry, transcobalamin II, receptor, Ki-67, xenograft, 4203
- Transporters, cisplatin, tumor, uptake, protection, toxicity, review, 4183
- Transrectal biopsy, 3T magnetic resonance, prostatic carcinoma, PSA, 2791
- Transurethral catheter, fallopian-tube patency, chromopertubation, 1591
- TRAP5b, lung cancer, bone metastasis, NSCLC, CEA, CTX, CYFRA 21-1, PINP, 2593
- Trastuzumab resistance, *HER-2* oncoprotein, breast cancer, SKBR-3 cells, proteomics, 489
- Trastuzumab, alcohol, *HER2* polymorphism, cardiac risk factors, 2569
- Trastuzumab, breast cancer, *HER2*, phosphorylation, 2509
- Trastuzumab, cardiotoxicity, breast cancer, *HER2*, 1717
- Trastuzumab, esophageal cancer, gastric cancer, *EGFR*, cetuximab, review, 4139
- Trastuzumab, non-small cell lung cancer, *in vivo* antitumor activity, elacytarabine, bevacizumab, cetuximab, xenograft, 3615
- Trastuzumab, salivary ductal carcinoma, molecular-targeted therapy, *HER2/neu*, 2587
- Treatment effectiveness, colorectal cancer, 5-fluorouracil, capecitabine, oxaliplatin, comparative effectiveness research, cost effectiveness, 1053
- Treatment modality, hepatocellular carcinoma, recurrence, survival, 4129
- Treatment outcome, mesothelioma, chemotherapy, pemetrexed, quality of life, health economics, review, 3553
- Trehalose, liposome, hepatocarcinoma, apoptosis, Hep-G2, HuH-7 cells, 4727
- Trichostatin A, telomere, chromatin, telomerase, ALT mechanism, recombination, 821
- Triphenyl derivatives, antiproliferative activity, piperazine derivatives, erythroid differentiation, anticancer agents, 3027
- Triple-negative breast cancer cells, protein kinase D, breast cancer, 393
- Triple-negative breast cancer, I3C derivative CTet, synergy, autophagy, *MAP1LC3B*, MDA-MB-231, BT-20 cells, 1867
- Triple-negative breast cancer, PTK7, anthracycline resistance, prognosis, 3759
- Triple-negative, tumour, size, lymphovascular, breast, cancer, 2737
- Trisomy 8, collagenous fibroma, cytogenetics, desmoplastic fibroblastoma, magnetic resonance imaging, 3259
- TSP-1, CD47, CD36, 4N1K, autophagy, cancer, 1429
- Tubulin, bladder carcinoma, antimitotic agents, cell cycle, flavanone, 4445

- Tubulin, chemoradiotherapy, lung cancer surgery, lung cancer biology, ERCC1, TYMS, RRM1, 1107
- Tumor biology, metabotropic glutamate receptors, cell proliferation, neuroendocrine tumors, alternative therapy, review, 1267
- Tumor budding, T1 esophageal cancer, E-cadherin, nodal metastasis, 5023
- Tumor cell dormancy, breast cancer, circulating tumor cell, immunosurveillance, T-cell, FAS, 2233
- Tumor cells, mutant p53, transcription, Saos-2 cells, 923
- Tumor flare, CEA, chemotherapy, fluctuation, metastatic colorectal cancer, 253
- Tumor growth, colorectal cancer, MCT4, VEGF, 2941
- Tumor growth, zoledronic acid, anticancer therapy, denosumab, review, 2981
- Tumor IL-6, chemoradiotherapy, esophageal squamous cell carcinoma, prognosis, 2699
- Tumor lysate, electroporation, dendritic cell vaccine, solid tumor, 2971
- Tumor marker, serum p53 antibody, colorectal cancer, recurrence, curative resection, 2221
- Tumor marker, VEGF, HCV infection, HCC, carcinogenesis, 1013
- Tumor markers, colorectal cancer, liver metastases, circulating tumor cells, AdnaGen, 2239
- Tumor microenvironment, ADSC, EMT, H358 cells, cancer-associated fibroblasts, α SMA, 4421
- Tumor microenvironments, fenbendazole, benzamidozoles, radiation therapy, hypoxia, EMT6 cells, 355
- Tumor necrosis factor- α , bortezomib-induced neuropathy, allodynia, anti-TNF α , 5453
- Tumor necrosis, stage IV colorectal cancer without residual disease (R0 status), inflammatory response 1099
- Tumor phantoms, breast, mammograms, tumor size, 1131
- Tumor progression, pancreatic cancer, CXCR4, β -catenin, 4103
- Tumor progression, two-dimensional gel electrophoresis, LC-MS/MS, 2-D western blotting, nucleophosmin, 153
- Tumor proliferation, native human interferon alpha, recombinant human interferon alpha, non-small cell lung cancer, apoptosis, *p21*, survivin, 2043
- Tumor sample screening, HPV, oral cancer, 3481
- Tumor size, breast, mammograms, tumor phantoms, 1131
- Tumor size, hepatocellular carcinoma (HCC), boron neutron capture therapy (BNCT), boric acid, therapeutic efficacy, blood vessels, 4799
- Tumor suppressor genes 9q22.3, head and neck squamous cell carcinoma, *FANCC*, *PTCH1*, radiotherapy, prognosis, 1215
- Tumor suppressor genes, glycolytic enzymes, oncogenes, signaling pathways, transcription factors, Warburg effect, review, 2855
- Tumor suppressor, disease-free survival, kinase receptor family, sporadic cancer, molecular markers, 5159
- Tumor suppressor, NF2, merlin, cell cycle, review, 1
- Tumor targeting, drug delivery, photodynamic therapy, photosensitizer, review, 2823
- Tumor targeting, *Salmonella typhimurium* A1-R, GFP, TCM, combination, Lewis lung carcinoma, RFP, C57/BL6 mice, 1837
- Tumor tissue, muscle tissue, histology, gene expression, 5213
- Tumor, transporters, cisplatin, uptake, protection, toxicity, review, 4183
- Tumor-associated antigens, characterization, glioblastoma, immunotherapy, U251, U87, U343 cells, 2525
- Tumor-associated macrophages (TAMs), ovarian cancer, SKOV-3 cell line, monocyte chemoattractant protein-1 (MCP-1), C-C motif chemokine receptor-2 (CCR2) antagonist, 4785
- Tumorigenesis, aryl hydrocarbon receptor, lung cancer, dioxin, polycyclic aromatic hydrocarbons, cigarette smoke, review, 1247
- Tumor-specificity index, licorice flavonoids, QSAR, cytotoxicity, chemical descriptor, 3061
- Tumor-targeting, *Salmonella typhimurium*, auxotroph, leucine, arginine, GFP, primer dosing, high dose, Lewis lung carcinoma, immunocompetent mice syngeneic mouse model, 97
- Tumour fragments, hepatocellular carcinoma, sorafenib, RAF kinases, short-term culture, 1415
- Tumour marker, gastric cancer, surveillance, recurrence, chemotherapy, CA19-9, 1621
- Tumour targeting, vasoactive intestinal peptide, VIP, radiolabelling, neuroendocrine tumours, 1537
- Tumour, size, lymphovascular, triple-negative, breast, cancer, 2737
- TUNEL, canine cutaneous histiocytoma, proliferation, apoptosis, Ki-67, 1397
- Two-dimensional gel electrophoresis, LC-MS/MS, 2-D western blotting, nucleophosmin, tumor progression, 153
- Two-stage mouse skin carcinogenesis, disiloxanes, chemoprevention, anti-promotion, EBV-induced early antigen, co-existence of tumor and normal cells, 2021
- TYMS, chemoradiotherapy, lung cancer surgery, lung cancer biology, ERCC1, tubulin, RRM1, 1107
- Tyrosine kinase inhibitor, chronic myeloid leukemia, hematopoietic stem cell transplantation, imatinib, allotransplantation, 4663
- Tyrosine kinase inhibitor, E-cadherin, epidermal growth factor receptor, esophageal cancer, malignant pleural mesothelioma, epithelial to mesenchymal transition (EMT), 2401
- Tyrosine kinase inhibitor, mTOR, PDGFR, HIF, head and neck squamous cell carcinoma, Everolimus, sorafenib, sunitinib, 5385

- U0126, cell signaling, ERK, CYP inhibitor, MEK/ERK inhibitor, colorectal cancer, HT29, HCT116, 2499
- U251, characterization, glioblastoma, immunotherapy, tumor-associated antigens, U87, U343 cells, 2525
- U343 cells, characterization, glioblastoma, immunotherapy, tumor-associated antigens, U251, U87, 2525
- U87, characterization, glioblastoma, immunotherapy, tumor-associated antigens, U251, U343 cells, 2525
- U87, glioma, RFP, orthotopic, craniotomy window, imaging, fluorescence, surgery, survival, 107
- U-87MG, apoptosis, brain cancer, Chinese medicine, β -elemene, A172, CCF-STTG1 cells, synthetic analogs, 65
- Ubiquitin ligase, oral cancer, Siah2, apoptosis, 4965
- Ubiquitin ligases, head and neck carcinoma, squamous, ubiquitination, ubiquitin-proteasome system, carcinogenesis, review, 3527
- Ubiquitination, head and neck carcinoma, squamous, ubiquitin-proteasome system, ubiquitin ligases, carcinogenesis, review, 3527
- Ubiquitination, JNK, p53, redox factor 1, selenomethionine, cancer prevention, protein stability, 3645
- Ubiquitin-proteasome system, head and neck carcinoma, squamous, ubiquitination, ubiquitin ligases, carcinogenesis, review, 3527
- Udaipur, India internaional symposium, Rajasthan, cancer prevention, translational cancer research, 1777
- UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism, metastatic colorectal cancer, irinotecan, 5'-deoxy-5-fluorouridine (5'-DFUR), 3423
- UFT, advanced non-small cell lung cancer, non-platinum triplet chemotherapy, vinorelbine, gemcitabine, 1163
- Ultrasound, nanomedicine, fullerenes, sonodynamic therapy, sarcoma 180, colon 26, 3145
- Umbelliferone, high-performance counter current chromatography, herniarin, scoparone, laryngeal cancer cells, proliferation, migration, cell cycle, apoptosis, 4347
- UM-SCC-22A cells, apoptosis, ceramide, dihydroceramide desaturase, dihydroceramide, PDT, sphingolipids, HNSCC, 77
- Unclassifiable B-cell lymphoma, *ID3*, double-hit lymphomas, 4771
- Unfolded protein response, cancer, endoplasmic reticulum, stress, molecular chaperones, activating transcription factor 6, PERK kinase, inositol requiring enzyme-1, review, 4683
- Unknown primary tumor, extended field, induction chemotherapy, cervical metastases, radiotherapy, 1135
- Unresectable head and neck cancer, S-1, outpatient oral chemotherapy, metastasis, 3285
- UPA, head and neck cancer, keratinocytes, differential regulation, PAI-1, 3113
- Upper tract urothelial carcinoma, p53, immunohistochemistry, prognosis, hemodialysis, 1091
- Upper urinary tract, laparoscopic nephroureterectomy, urothelial carcinoma, 5501
- Upper urothelial track cancer, *CAVI*, polymorphism, genotype, 4907
- Uptake, transporters, cisplatin, tumor, protection, toxicity, review, 4183
- Uracil glycosylase, thymidine deprivation, replication stress, *Saccharomyces cerevisiae*, 2037
- Uric acid, AML, prognosis, 3947
- Urinary bladder cancer, *in vitro* models, *in vivo* models, antineoplastic drugs, review, 1273
- Urinary tract malignancy, hematuria, second malignancy, bladder cancer, repeat evaluation, screening, 5525
- Urine, prostatic neoplasms, carcinoma, gene expression, diagnostic markers, 191
- Urocortin, corticotrophin-releasing factor receptors, gastric cancer, STKM-1 cell line, 5289
- Urothelial cancer of bladder, BMP10, growth, motility and adhesion, T24 cells, 1917
- Urothelial carcinoma, ATP7B, cisplatin, chemotherapy, LOH, bladder cancer, 3731
- Urothelial carcinoma, laparoscopic nephroureterectomy, upper urinary tract, 5501
- Ursolic acid, STAT3, colon cancer, cancer-initiating cells, 4279
- Uterine cancer, WT1, DC immunotherapy, endometrial carcinoma, uterine sarcoma, 5495
- Uterine cervical cancer, radiation therapy, postoperative radiotherapy, 2199
- Uterine sarcoma, survey, German gynaecologists, 3375
- Uterine sarcoma, WT1, DC immunotherapy, uterine cancer, endometrial carcinoma, 5495
- UV radiation-induced skin tumors, chemoprevention, non-melanoma skin cancer, experimental model, combination therapy, 3033
- UVC, GFP, 53BP1, focus, DNA damage, pancreatic cancer, 1373
- Vaginal intraepithelial neoplasia (VaIN), human papillomavirus (HPV), review, 29
- Vaginal recurrence, endometrial carcinoma, radiotherapy, brachytherapy, 241
- Vagus, adrenal, medulla, breast cancer, histology, metastasis, 3675
- Variants, $\alpha_v\beta_3$ integrin, overexpression, green fluorescent protein, red fluorescent protein, osteosarcoma, nude mice, lung metastasis, passage, 3623
- Vascular endothelial growth factor A (VEGF-A), lung cancer, non-small cell lung cancer, NSCLC, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, brain metastases, humanized monoclonal antibody, angiogenesis, pulmonary haemorrhage, 3275

- Vascular endothelial growth factor, platelet-derived growth factor, PDGFR α/β , head and neck squamous cell carcinoma, docetaxel, fluorouracil, 1951
- Vascular endothelial growth factor, renal cell carcinoma, distant metastasis-free survival, overall survival, 5017
- Vascular endothelial growth factor, α B-crystallin, conjunctival squamous cell carcinoma, 3745
- Vasculature, quinazoline, doxazosin, terazosin, DZ-50, prostate cancer, anoikis, review, 4695
- Vascularization, green fluorescent protein, blood vessels, nestin, angiogenesis, anastomosis, red fluorescent protein, Gelfoam[®], transgenic nude mice, confocal microscopy, color-coded imaging, 3041
- Vasoactive intestinal peptide, VIP, radiolabelling, neuroendocrine tumours, tumour targeting, 1537
- VEGF, bevacizumab, aflibercept, antiangiogenesis, mCRC, TKI, regorafenib, 2377
- VEGF, colorectal cancer, MCT4, tumor growth, 2941
- VEGF, HCV infection, tumor marker, HCC, carcinogenesis, 1013
- VEGF, single nucleotide polymorphism, *VEGFR*, sunitinib, biliary tract cancer, gastric cancer, 4619
- VEGF, *VEGFR1*, *VEGFR2*, bladder cancer, disease recurrence, angiogenesis, 2381
- VEGF-C, podoplanin, oral squamous cell carcinoma, oral cancer, prognosis, 3969
- VEGF-C, ShRNA, pancreatic cancer, nude mice, orthotopic, GFP, 409
- VEGF-C, siRNA, VEGF-D, metastasis, mammary cancer, 4237
- VEGF-D, siRNA, VEGF-C, metastasis, mammary cancer, 4237
- VEGFR*, single nucleotide polymorphism, VEGF, sunitinib, biliary tract cancer, gastric cancer, 4619
- VEGFR1*, prostate cancer, Immunohistochemistry, angiogenesis, NRP1, tissue array analysis, prostatectomy, 2065
- VEGFR1*, VEGF, *VEGFR2*, bladder cancer, disease recurrence, angiogenesis, 2381
- VEGFR2*, VEGF, *VEGFR1*, bladder cancer, disease recurrence, angiogenesis, 2381
- VEGI, pituitary adenoma, death receptor-3, invasion, 3815
- Vertebral body metastases, tomotherapy, stereotactic body radiotherapy, PTV margin, image-guided IMRT, 2453
- Video-assisted thoracoscopic surgery (VATS), right aortic arch, esophageal cancer, 1635
- Vietnamese, colorectal cancer, cytomegalovirus, viral DNA, Swedish, 4947
- Vinca alkaloids, *ATM*, *ATR*, Chk1, p53, *p21*, cell-cycle arrest, DNA damage, 5273
- Vincristine, multidrug resistance, modulating agents, drug accumulation, doxorubicin, paclitaxel, L929 murine cell line, MCF7 breast cancer cell line, 4381
- Vinorelbine, advanced non-small cell lung cancer, non-platinum triplet chemotherapy, UFT, gemcitabine, 1163
- VIP, vasoactive intestinal peptide, radiolabelling, neuroendocrine tumours, tumour targeting, 1537
- Viral DNA, colorectal cancer, cytomegalovirus, Vietnamese, Swedish, 4947
- Viral knockdown, *PROX1*, small cell lung cancer, shRNA, Lentivirus, cell proliferation, 3169
- Viral load, HIV, CD4, squamous cell carcinoma, head and neck cancer, radiation therapy, IMRT, chemotherapy, concurrent chemoradiotherapy, 5511
- Virchow lymph node metastasis, colon cancer, combination therapy, 2935
- Vitamin B12, Immunohistochemistry, transcobalamin II, transport protein, receptor, Ki-67, xenograft, 4203
- Vitamin D analogs, combined treatment, oxaliplatin, irinotecan, anticancer activity, colonic cancer, 433
- Vitamin D, chemoprevention, lung cancer, experimental model, tobacco carcinogens, combination therapy, acetylsalicylic acid, calcium, 4767
- Vitamin D, prostaglandin inhibition, breast cancer prevention, 3861
- Vitamin D, sunlight, polymorphisms, breast cancer, gene, case-control, 543
- VLY, cytolysin, cholesterol-independent, human-specific, ILY, Sm-hPAF, CD59, 2901
- VMAT, hypofractionation, prostate cancer, RapidArc, 4537
- VMAT, lung cancer, volumetric modulated arc therapy, 4491
- Volumetric modulated arc therapy, lung cancer, VMAT, 4491
- Warburg effect, glycolytic enzymes, oncogenes, signaling pathways, transcription factors, tumor suppressor genes, review, 2855
- WBRT, brain metastases, colorectal cancer, surgical approach, 5645
- Western blot, caveolin-1, hepatocellular carcinoma, polymorphism, genotype, real-time quantitative reverse transcription, 671
- Whole-body bioelectrical impedance analysis, segmental bioelectrical impedance analysis, edema of the upper limb, breast cancer, 3403
- Withania somnifera*, chemoprevention, mammary cancer, rats, Ki67, PCNA, 1519
- WNT inhibitors, renal cancer, targeted therapy, bi-functional peptide, 2435
- WNT, colorectal cancer, β -catenin, prognosis, E-cadherin, SFRP, invasive front, 4573
- WT-1, AML, MRD, relapse, 3335
- WT1, DC immunotherapy, ovarian cancer, carcinosarcoma, 3855
- WT1, DC immunotherapy, uterine cancer, endometrial carcinoma, uterine sarcoma, 5495

- XAF1*, clinicopathological features, papillary thyroid cancer, polymorphism, 2205
- XELOX, colorectal cancer, oxaliplatin, S-1, SOX, metastasis, 4029
- Xenoestrogen, pesticides, cancer, angiogenesis, 231
- Xenograft models, chitosan, lung metastasis, hepatoma formation, 4867
- Xenograft, curcumin, pancreatic cancer, liposomal curcumin, annexin A2, MiaPaCa cells, 3603
- Xenograft, gastrointestinal stromal tumor, mouse, imatinib, sunitinib, 175
- Xenograft, non-small cell lung cancer, *in vivo* antitumor activity, elacytarabine, bevacizumab, cetuximab, trastuzumab, 3615
- Xenograft, renal cell carcinoma, nanoparticle, desacyl-saponin, BBE, *in vitro*, *in vivo*, 143
- Xenograft, vitamin B12, Immunohistochemistry, transcobalamin II, transport protein, receptor, Ki-67, 4203
- Xenografts, carboplatin, selenite, ovarian cancer, drug resistance, 4249
- Xenografts, thyroid cancer, stem cells, adipose tissue, mouse model, 4213
- Xenotransplantation, clear cell renal carcinoma, sarcomatoid differentiation, cell line and clonal sublines, de-differentiation, epithelioid, fibroblastoid, 4875
- XRCC6/Ku70*, non-homologous end-joining, childhood leukemia, polymorphisms, genotyping, 5395
- XRCC6/Ku70*, non-homologous end-joining, hepatocellular carcinoma, polymorphism, genotype, real-time quantitative reverse transcription, Immunohistochemistry, 529
- Y-box binding protein-1, estrogen receptor, transforming growth factor β , antiestrogen, resistance, 2473
- YHO-13351, side population cell, irinotecan, *ABCG2*, 1379
- YKL-40, malignant mesothelioma, lung cancer, mesothelin, 5517
- Younger women, breast cancer, screening, age groups, risk, 2651
- YpTNM classification, rectal carcinoma, neoadjuvant radiochemotherapy, histological regression grade, 559
- Yridium radioisotopes, biliary tract neoplasms, brachytherapy, radiotherapy, expandable metallic stents, 2747
- Z-domain, cholesterol-dependent cytolysin, drug delivery system, chimera protein, 2905
- ZFAT, transcription factor, haematopoietic system, angiogenesis, haematopoietic malignancies, TAL1, review, 2833
- Zoledronic acid, anticancer therapy, denosumab, tumor growth, review, 2981
- Zoledronic acid, breast cancer, bone metastases, quality of life, 5543
- Zoledronic acid, breast cancer, mTOR, REDD1, endoplasmic reticulum stress, MCF-7, MDA-MB-231 cells, 3807
- Zoledronic acid, lung cancer, drug resistance, BAX, 5357
- Zoledronic acid, metastasis, invasion, 3D culture assays, 5295
- Zoledronic acid, prostate cancer, combined androgen blockade, bone metastasis, 3837

Authors Index

(Figures refer to page numbers)

- Abal M, 5295
 Abdalmeear MM, 317
 Abdelhameed AS, 2517
 Abdel-Mageed A, 3047
 Abe C, 2881
 Abe F, 2861, 3105
 Abe M, 4785
 Abe S, 1463
 Abe Tetsuya, 1099
 Abe Toshi, 5561
 Abo T, 2107, 2689
 Abou-Alfa GK, 3241
 Abramian A, 1971
 Absenger G, 4591
 Accurso BT, 4757
 Achel DG, 3217
 Adachi Y, 2839, 2965
 Adalsteinsson B, 1131
 Adamopoulou E, 1351
 Adamopoulou M, 4033
 Adamzik M, 609
 Aderhold C, 1951, 2457, 5385
 Adjakly M, 39
 Aere C, 3347
 Aessopos A, 3475
 Agarwal PK, 1421
 Aggarwal BB, 1777
 Agnese D, 655
 Agostinelli C, 2639
 Agostinelli S, 655
 Agrogiannis G, 1209
 Aguín S, 5295
 Ahluwalia MS, 3251
 Ahmadova Z, 3753
 Ahmed T, 231
 Ahn EH, 2029
 Ahn JB, 2499
 Ahn JS, 5127
 Ahn J-Y, 4751
 Ahn M-J, 5127
 Ahn SD, 1237
 Aibe H, 2453, 5675
 Aibe N, 643, 1679, 1685, 1773, 5507
 Aigner F, 5525
 Aigner J, 3407
 Aikata H, 1761
 Akada J, 3133, 3661, 4821
 Akagi Y, 2839, 2887, 2921, 2929, 2935, 2941, 2949, 2965
 Akahori T, 3355
 Akamatsu H, 3279
 Akemeyeva K, 4595
 Åkesson B, 3799
 Akiba T, 1769, 2221, 3941, 4029
 Akilzhanova A, 4049
 Akimoto T, 567, 4337
 Akiyama Hironori, 3963
 Akiyama Hirotooshi, 697, 1747, 5585, 5687
 Akiyoshi K, 2129, 5289
 Akriviadis E, 4573
 Aktas B, 329
 Al-Ahmadi A, 4779
 Ala-Luhtala T, 2623
 Alanazi AM, 2517
 Albanese NN, 489
 Alcaraz M, 3217
 Alcaraz-Saura M, 3217
 Alcindor T, 1765
 Alexander J, 477
 Al-Ghamdi K, 4779
 Al-Hamour OA, 4779
 Alho I, 1983
 Alinovi R, 5517
 Alkikhia L, 3137
 Allard N, 1267
 Allen P, 3241
 Aller L, 5091
 Allweis T, 293
 Al-Maghrabi J, 4779
 Al-Mansouri Z, 4779
 Almanza GR, 3799
 Almeida ADS, 3969
 Almendingen K, 477
 Alongi F, 4537
 Alonso MÁ, 4089
 Alonso-Alconada L, 5295
 Al-Qahtani MH, 4779
 Alscher MD, 1609
 Altavilla A, 5663
 Alves A, 1397
 Aman C, 3911
 Amano R, 1635, 5023, 5567
 Amant F, 3855, 5495
 Amanti C, 1229
 Amaral L, 2021
 Amatucci C, 2147
 Amatulli F, 3739
 Ambicka A, 1447
 Amoroso D, 3487
 Ampil F, 3867
 Ampollini L, 5517
 Amptoulach S, 1209
 Anagnostaki L, 363
 Anan T, 5011
 Anderson L, 2997
 Andersson RE, 3247
 Andersson S, 1003
 Ando K, 1641
 Ando M, 1117
 Ando R, 3745
 Andò S, 4847
 Ando T, 5107
 Andratschke M, 2481
 Andre C, 2057
 André S, 3053
 Andreae F, 1537
 Andrei G, 1899
 Andreuccetti M, 3487
 Ang CS-P, 3241
 Angelici AM, 2147
 Angelopoulou M, 3509, 5693
 Angerer R, 3759
 Angiero F, 2673, 3365
 Anichini C, 691
 Anselmi E, 725
 Antal A, 4163
 Antoon JW, 3573
 Aoki T, 2635
 Aoki Yoichi, 2199, 5123
 Aoki Yoshihiro, 1761, 3495
 Aoyagi T, 5357
 Apostolaki A, 191
 Appel C, 1963
 Aragona F, 1195
 Araho D, 3061
 Arai G, 3837
 Arai J, 2107, 2689
 Arakawa A, 1073
 Arakawa T, 3667
 Arakawa-Todo M, 3105, 5043
 Araki A, 3423
 Araki K, 3285
 Aranome AMF, 737
 Arantes-Rodrigues R, 1273
 Arany I, 2561, 3119
 Arao T, 469
 Aras G, 2643
 Arbab AS, 215
 Arbion F, 1045
 Ardisson V, 3871
 Ardizzoni A, 725, 1061, 4611
 Argellati F, 815
 Argenone A, 1135
 Argiris A, 4475
 Argyri E, 4007
 Ariga T, 2199, 5123
 Arima N, 3891
 Arimoto A, 1181, 2211
 Aristei C, 4557
 Arita T, 271, 3185
 Arlicot C, 1045
 Arnold N, 1525
 Arora G, 2077
 Arora VK, 231
 Asahi H, 1147
 Asai K, 1649, 5575, 5649
 Asakura K, 3791
 Asami K, 1163, 4631
 Asanuma H, 167
 Asari R, 1035, 2085, 3455
 Aschauer S, 3629
 Asher V, 1401
 Asić K, 2509
 Askoxylakis I, 1667
 Asola R, 2623
 Assaf AT, 1757, 3917
 Assorgi C, 29
 Assouline A, 2227
 Atagi S, 1163, 4631
 Ataseven B, 3759
 Athanassiou E, 1977
 Atsumi K, 5575
 Au J, 2227
 Audrain O, 3871
 Auf G, 2093
 Auge JM, 5633
 Augurio A, 4557
 Avgoustidis D, 4033
 Ayotte P, 5483
 Ayyappan S, 4139

- Azavedo E, 1131
 Azemoto R, 5603
 Azzoni C, 4611
- Baba H, 4627, 5051, 5591
 Baba T, 2123
 Babich H, 1829
 Baccini P, 4509
 Bach A, 731
 Badakhshi H, 4111, 4117, 4639
 Badalamenti G, 679
 Bae D-S, 1555, 3177, 4675
 Bae G-Y, 2001
 Bae SK, 2499
 Baek H-J, 2011
 Baek SJ, 3963
 Baertling F, 791
 Bai Q, 1799
 Baik HH, 2205
 Balacchi C, 2747
 Bali A, 1401
 Ballatore Z, 2737
 Ballester M, 1661, 2191
 Bamias A, 4999
 Banaszczyk M, 5343
 Bandopadhyay MN, 1215
 Banerjee BD, 231
 Bang G, 2467
 Bankfalvi A, 609
 Banning-Eichenseer U, 4791
 Barabé F, 2569
 Barba MC, 4557
 Barbare J-C, 1415
 Barbery K, 2077
 Barchetti F, 5663
 Bard J-M, 3783
 Barkan GA, 3675
 Baron B, 2557, 3661, 4821
 Barranger E, 283
 Barrios J, 379
 Bartnitzke S, 3069
 Bartscht T, 4505
 Basinko A, 639
 Ba-Ssalamah A, 1035, 2085, 3455
 Bassi C, 4827
 Basso SMM, 1041, 2593
 Bastian PJ, 5249
 Batistatou A, 2139
 Bats A-S, 3977
 Battastini AMO, 4463
 Battelli N, 2737
- Battolla E, 2707
 Bau D-T, 529, 671, 2775, 3391, 4067, 4907, 5395, 5401
 Bauer G, 3589
 Bauer JA, 4203
 Bauer M, 1525
 Baumann C, 3467
 Baumann FT, 3415
 Bearz A, 4999
 Beauchesne P, 3467
 Becker C, 3759
 Becker S, 371
 Beckeringh JJ, 3553
 Beckman BS, 3573
 Befrits R, 1743
 Beitler JJ, 4927
 Bektayeva R, 4595
 Bektic J, 5525
 Belgioia L, 655
 Bell EC, 4285
 Bella MA, 1061
 Bellagamba R, 2153
 Bellavita R, 4557
 Belldegrun AS, 2997
 Bellizzi A, 1491
 Bellmunt J, 4999
 Beltrami S, 1
 Benberin V, 4595
 Benczik M, 2561
 Bendifallah S, 2191
 Benes J, 1563
 Benesova L, 1705, 3397
 Benković V, 2509
 Benth JŠ, 477
 Berardi R, 2737
 Berenjian S, 143
 Berghmans T, 5477
 Berghoff AS, 1065
 Berlit S, 1591, 2771, 3403, 3995, 4553
 Bernal A, 5633
 Bernard V, 4771
 Bernard-Gallon D, 39
 Bernardi A, 4463
 Bernardi F, 3027
 Bernardo G, 1221
 Berndt K, 1297
 Berneman Z, 3855, 5495
 Berstad P, 477
 Berthou C, 639
 Berthune A, 301
 Bertozzi S, 1041
- Beyer C, 791
 Bharathi SP, 231
 Bhargava S, 755
 Bhatti G, 77
 Bhatti P, 543
 Bianchi G, 2747
 Bianchi L, 2639
 Bianconi M, 5017
 Bicho M, 1983
 Bielawski J, 77
 Bienkowski M, 5343
 Biernat W, 5461
 Bignon Y-J, 39
 Bijnsdorp IV, 387
 Bilbro J, 4695
 Biondani P, 1257
 Birk R, 1951, 5385
 Birner P, 1035, 1065, 2085, 3455
 Bischoff P, 1845
 Biscotti T, 2737
 Biswas J, 1215
 Bittner S, 183
 Blakaj DM, 4483, 4927
 Blandino G, 3503
 Blessmann M, 3917
 Bloch W, 3415
 Blomqvist C, 1595, 4933
 Blons H, 3977
 Blonski M, 3467
 Bobos M, 2139
 Boccoardo F, 815
 Bockhorn M, 4975
 Bockmayer A, 5385
 Body G, 1045
 Boeck S, 287
 Bogaerts E, 4683
 Bohlmann MK, 1125
 Boiteux J-P, 39
 Bollito E, 2679, 4657
 Bomholt N, 2491
 Bommareddy A, 4163
 Bonetti F, 3705
 Bonini S, 5517
 Bonnetterre J, 2057
 Boons CCLM, 3553
 Boorjian SA, 2381, 5235
 Booth MJ, 3611
 Borgatti M, 3027
 Borghesi M, 2361, 2639, 5205
 Born W, 1297
 Borst L, 831
- Bortlicek Z, 1705, 3397
 Borzási E, 1737
 Bosco G, 4827
 Bosetti D, 3503
 Bosio C, 4827
 Bossi I, 1257
 Bosso D, 1135
 Bottarelli L, 4611
 Boucher E, 3871
 Boulanger T, 2057
 Boulanger V, 301
 Boumendjel A, 4445
 Boura P, 2369
 Bouvet M, 97, 103, 107, 1361, 1367, 1373, 3021, 3041, 3623, 4229
 Bovo C, 639
 Bracci S, 1229
 Bradatsch A, 991
 Brade J, 1125, 2771, 3403, 4553
 Bradl J, 4921
 Braganhol E, 4463
 Braicu EI, 1585, 1673
 Brandi G, 1867, 2747
 Braun M, 1971
 Breen P, 77
 Brennan M, 2743
 Brennan MF, 975
 Brenner B, 5151
 Brenner RM, 5151
 Bria E, 3705
 Brinkmann F, 1609
 Brisigotti M, 3925
 Broccoli A, 2639
 Bronte G, 679
 Brouland J-F, 283
 Bruckner H, 3899
 Bruha J, 4855
 Bruheim S, 3615
 Bruland ØS, 85
 Brunelli M, 2679, 3705
 Brunello E, 3705
 Brunocilla E, 2361, 2639, 5205
 Buchner P, 881
 Buck MB, 2473
 Budach V, 4111, 4117, 4639
 Budroni M, 871
 Buekers T, 619
 Buggy DJ, 4255
 Buhmeida A, 3137
 Bui PH, 2997

- Bui S, 725
 Bullerdiel J, 3069
 Bulzonetti N, 4013
 Bundscherer A, 3201
 Buonerba C, 1135
 Buonocore G, 691
 Buosi Silva T, 2651
 Burattini L, 5017
 Burbano RMR, 3683
 Burbelko M, 5213
 Burchardt M, 4921
 Burchardt J, 3033, 4767
 Burckel H, 1845
 Burczynska B, 3611
 Burgers JA, 3553
 Burton G, 3867
 Butler SA, 3611
 Buxhoeveden M, 401
 Byeon J, 4073
 Byun Y, 4751
- Cadagan D, 4381
 Caffrey PB, 4249
 Cafiero F, 4509
 Caldito G, 3867
 Calzado MA, 3799
 Camisa R, 725
 Campana LG, 4081
 Campanella G, 4951
 Campanile C, 1297
 Campanini N, 4611
 Camporesi E, 4827
 Cancemi P, 489
 Candamio Folgar S, 717
 Candiano G, 1195
 Canessa PA, 2707
 Canlorbe G, 2191
 Cannato M, 4827
 Cannizzaro C, 1899
 Canta A, 5453
 Canto RFS, 4463
 Canuti D, 3925
 Cao E, 4727
 Cao Haixia, 419
 Cao Huynh, 1785, 3879
 Cao J, 3153
 Capanu M, 3241
 Capirci C, 4557
 Capobianco G, 1041
 Caponigro F, 1135
 Capper D, 1065
 Caravatta L, 2785, 4585
 Carbognani P, 5517
- Carbognin L, 3705
 Carey JP, 4271
 Carithers R, 2797
 Carli F, 4509
 Carlson R, 5421
 Carmichael A, 1717
 Carmona M, 5295
 Carnevale A, 1229
 Caroli M, 3383
 Carozzi V, 5453
 Carrabba G, 3383
 Caruso C, 2153
 Caruso MG, 3739
 Carvalho AL, 3969
 Casalini A, 5517
 Casarotto A, 4827
 Cascinu S, 725, 2737, 4611, 5017
 Cassano R, 4847
 Castells A, 5633
 Casto BC, 4757
 Catalano A, 29
 Catalano C, 5663
 Cattan S, 1603
 Cattaneo II R, 619, 4983
 Catuogno S, 3415
 Cavagnetto F, 655
 Cavaletti G, 5453
 Cazin JL, 2057
 Ceauşu R, 957
 Cecchini R, 737
 Cèfaro GA, 4557
 Ceppi P, 2679
 Cervantes EC, 1131
 Cha H-J, 2001
 Cha S-D, 1457
 Chae YS, 513, 3233
 Chai C-Y, 1091, 5611
 Chaker M, 5655
 Chakraborty A, 5385
 Chakraborty J, 1215
 Chakraborty S, 3263
 Chamberlain MC, 2057
 Chamming's F, 3977
 Chan A, 2657
 Chan HW, 4389
 Chan L, 3573
 Chan P, 4491
 Chan Y-C, 1169
 Chan Y-J, 2763
 Chang C-L, 3807
 Chang C-S, 4663
 Chang F-S, 425
- Chang H, 3953
 Chang H-C, 5171
 Chang H-W, 5611
 Chang J-B, 4867
 Chang K-J, 5543
 Chang L-L, 1091
 Chang S, 1107
 Chang S-H, 3089
 Chang Sheng-Chi, 529, 671
 Chang Shih-Chen, 543
 Chang W-S, 529, 671, 2775, 3391, 4067, 4907, 5401
 Chang Y-H, 4875
 Chang Y-T, 5401
 Chanvorachote P, 505, 3079, 5433
 Chao ST, 3251
 Chao T-C, 5543
 Chao T-Y, 5543
 Characiejus D, 2099
 Charaffe-Jauffret E, 2159
 Charalambous E, 4573
 Charalampakis V, 1667
 Chatelain D, 1415
 Chaudhary J, 4271
 Chauffert B, 1415, 3467
 Chauhan A, 2517
 Chayama K, 1761
 Chaze B, 1045
 Chekerov R, 1673, 3375
 Chen Chen, 1861
 Chen Chung, 4827
 Chen C-T, 3241
 Chen C-W, 4411
 Chen C-Y, 2729
 Chen D-R, 5543
 Chen FC-K, 3375
 Chen F-S, 3145
 Chen H-H, 5171
 Chen HHW, 4157
 Chen H-J, 2775
 Chen Hui-Chun, 1169
 Chen Hung-Chang, 4875
 Chen H-W, 2997
 Chen J, 755
 Chen J-S, 3317
 Chen S, 5199
 Chen S-C, 5543
 Chen SL-S, 5171
 Chen W-C, 2775, 4067
 Chen W-L, 4799
 Chen W-W, 4123
 Chen Y-L, 4867
- Chen Y-MA, 2763
 Chen Y-Y, 1941
 Cheng A-L, 4123
 Cheng W-E, 2775
 Cheng Y, 5199
 Cheng Y-W, 2729
 Chereau E, 1661, 3015
 Chessa F, 5205
 Chi C-W, 3807, 4799
 Chi S-Y, 1169
 Chiaffi L, 2707
 Chiara GB, 2593
 Chiba T, 5603
 Chika N, 4627, 5051
 Chikaishi Y, 2123
 Chilmonczyk Z, 4891
 Chilosi M, 3705
 Chinaranagari S, 4271
 Chiorazzi A, 5453
 Chis C, 283
 Chishima T, 103, 107, 1367, 5119
 Chiu SY-H, 5171
 Chiusa L, 2679
 Cho C-H, 1457
 Cho D, 2011, 2525
 Cho HR, 223, 1887
 Cho KJ, 5667
 Cho MY, 5143
 Cho S, 1317
 Cho S-B, 2135
 Cho SB, 4129
 Cho S-F, 4663
 Cho Y-J, 3177
 Cho YM, 4469
 Choe C, 2001, 3715
 Choi CH, 1555, 3177, 4675
 Choi CY, 763
 Choi EK, 1237
 Choi GS, 513, 3233
 Choi J-J, 3177
 Choi JW, 223, 1887
 Choi M-G, 2541
 Choi MK, 4619, 5127
 Choi S-H, 1237
 Choi SH, 1887, 2467
 Choi S-J, 2001, 3715
 Choi SK, 4129
 Choi Y-D, 2525
 Choi Y-N, 821
 Chou F-I, 4799
 Chou JF-L, 3241
 Chou W-C, 3317

- Chrisafi S, 2139, 4573
 Christ G, 1081
 Christensen JG, 2997
 Chu P-Y, 5611
 Chu Q, 3867
 Chuang C-K, 2605, 4875
 Chueh F-S, 1941
 Chung C-Y, 2135
 Chung H, 5445
 Chung HC, 821, 2499
 Chung J-G, 1941, 4411, 4867
 Chung J-H, 2205, 3983
 Chung JW, 223, 1887
 Chung K-W, 4357, 4833
 Chung MW, 4129
 Chung R, 1457
 Chunhacha P, 3079, 5433
 Ciarimboli G, 4183
 Cihlar T, 1899
 Cilla S, 2785, 4585
 Cimpean AM, 957
 Clark JS, 3119
 Clatot F, 5655
 Clawson GA, 3675
 Clement B, 3871
 Clemente C, 4951
 Clerici E, 4537
 Clingan PR, 1053
 Clivio A, 4537
 Coda R, 4657
 Coelho C, 1983
 Cognetti F, 21, 1721
 Cohen E, 379
 Colaço A, 1273
 Colafati GS, 3515
 Colan D, 3263
 Collado IG, 3799
 Collan Y, 3137
 Colombo F, 2639, 5205
 Comito T, 4537
 Concert C, 5511
 Conklin D, 2997
 Conney AH, 1343
 Conte P-F, 2657
 Cook KM, 1799
 Coosemans A, 3855, 5495
 Cope W, 3899
 Coppola D, 3047
 Corradi M, 5517
 Corsetti T, 3515
 Cortes-Dericks L, 5365
 Cortesi E, 5663
 Corvò R, 655, 3503
 Cosentino D, 4557
 Cossu A, 871
 Cossu S, 871
 Costa L, 1983
 Côté M-A, 2569
 Cote ML, 4983
 Coughlin G, 615
 Cozzi L, 4537
 Crafa P, 725
 Crippa R, 2673, 3365
 Csejtei A, 341
 Cuff CF, 929
 Cui X-X, 1343
 Culliney BE, 5511
 Cunha LC, 865
 Cunningham D, 4611
 Cusimano MD, 119
 Czabanka M, 2093
 Czejka M, 881
 Czerninski R, 661
 Czyn M, 3205
 Czyzewski K, 1189
 D'Adamo K, 4491
 D'Angelica M, 3241
 D'Assisi Cardillo F, 1721
 D'Attoma B, 4951
 D'Costa S, 831
 D'Elia A, 4013
 Da Costa Vieira RA, 2651
 Da Fonseca CO, 5625
 Da Prat V, 1257
 Da Silva LC, 647
 Dahan L, 5645
 Dahiya S, 3251
 Dahle J, 85
 Dahlhaus M, 445
 Dai L, 409
 Dalglish AG, 4373
 Dalianis T, 1575
 Daly KP, 4001
 Dancau A-M, 4975
 Daniele A, 1491
 Daponte A, 1135
 Darai E, 1661, 2191
 Darb-Esfahani S, 1673
 Darlix A, 3467
 Daskalakis M, 1667
 Daskalopoulou D, 4007
 Dasu A, 1009
 Datler P, 1035
 David M, 3375
 Davidson T, 2047
 Dawber JP, 1053
 Dawson H, 3053
 De Assumpção PP, 3683
 De Barros N, 2651
 De Blanco EJ, 5349
 De Braekeleer E, 639
 De Braekeleer M, 639, 2065
 De Braud F, 1257
 De Bree E, 1667
 De Carvalho DC, 3683
 De Castro Mattos JS, 2651
 De Felice F, 4013
 De Ioris MA, 3515
 De La Cámara Gómez J, 717
 De La Hosseraye C, 1661
 De La Orden V, 5159
 De Luca S, 4657
 De Paola I, 871
 De Paoli A, 4557
 De Pascalis G, 2153
 De Reijke TM, 2099
 De Saldanha Da Gama Fischer J, 5625
 De Sanctis V, 29, 1229
 De Santi M, 1867
 De Vogelaere K, 3359
 Debald M, 1971
 Decrey G, 3563
 Decristoforo C, 1537
 Deeb D, 215
 Deguchi K, 5165
 Del Bel E, 865
 Del Bufalo F, 3515
 Del Conte A, 2593
 Del Fiore P, 3989
 Del Gatto A, 871
 Delides A, 3213
 Dell'Abate P, 725
 Della Vittoria Scarpati G, 1135
 Delpech Y, 283
 Delvaux G, 3359
 Dematteo RP, 3241
 Demers É, 2569
 Den Otter W, 161, 2099, 4531
 Deng D, 5301
 Deng H, 1873
 Deng X, 1917
 Dengler J, 2093
 Denkert C, 1673
 Deodato F, 2785, 4585
 Depaoli F, 4509
 Derenzini E, 2639
 Derwinger K, 325, 2447
 Desai AJ, 2997
 Desai D, 615
 Desauw C, 1603
 Desbordes C, 401
 Deschatrette J, 133
 Dessanti P, 2707
 Devarakonda S, 3867
 Dezzi C, 2147
 Di Bartolomeo M, 1257
 Di Cara G, 489
 Di Cesare P, 1221
 Di Cristofori A, 3383
 Di Lorenzo G, 1135
 Di Nicola M, 4557
 Di Primio R, 5017
 Di Tommaso M, 4557
 Diamanti E, 2441
 Diamantopoulos PT, 3509, 5693
 Diedrich K, 1125
 Diensthuber M, 913, 3481
 Dierkesmann R, 1609
 Dietz A, 2415
 Digesù C, 2785
 Dimberg J, 3247, 4947
 Dimitriadis E, 191
 Dimitrova K, 2415
 Ding M, 1963
 Ding N, 1343
 Dinhof C, 1065
 Dionysopoulos D, 4573
 Diorio C, 2569, 5483
 Dippon J, 1609
 Dittrich C, 881
 Divella R, 1491
 Dizzeyi N, 363
 Dlay S, 3925
 Dmoszyńska-Graniczka M, 4347
 Do I-G, 1555
 Dobmeier M, 3027
 Dobrowolski Z, 2099
 Dodson MK, 1317
 Dognini J, 2153
 Doi K, 5699
 Doki Y, 1927
 Doležel M, 4097
 Donato V, 2153
 Dong H, 5261
 Dong M, 5199
 Dong Y, 3745
 Dong Z, 3745

- Donizy P, 5255
 Donner M, 3263
 Doody MM, 543
 Doran P, 4255
 Dornfeld K, 2037
 Dos Santos AKCR, 3683
 Dos Santos NPC, 3683
 Dos Santos SEB, 3683
 Doucet L, 2065
 Douet-Guilbert N, 639
 Downes M, 2381, 5235
 Dranitzki Elhalal M, 661
 Drieschner N, 3069
 Du Z-Y, 1343
 Duan F, 4711
 Duan Q, 355
 Duan R-D, 3799
 Dubois F, 2057
 Dudek AZ, 2981
 Dufour H, 5645
 Dumas I, 5483
 Dupont S, 1415
 Duran MC, 1325
 Durand L, 3015
 Duranti A, 1867
 Dvořáková A, 3163
 Dvořák J, 1201
 Dziegiel P, 965, 1447, 5375

 East Japan Chesters Group,
 1117
 Ebata A, 4811
 Eberle S, 3347, 4017
 Ecimovic P, 4255
 Eckardt M, 2997
 Eckermann S, 1053
 Edeline J, 3871
 Efferth T, 1819, 3027
 Efimova EV, 1373
 Egawa S, 1853
 Eggleston W, 4163
 Eghardt V, 4553
 Eguchi H, 1927
 Együd Z, 1737
 Ehrhardt H, 5273
 Eichhorn M, 4567
 Eichhorn W, 4567
 Eichler C, 731
 Eidukevičius R, 2099
 Eiermann W, 3759
 Eifler-Lima VL, 4463
 Eisele G, 3563
 El Hindy N, 609

 El Roz A, 3783
 Elbert T, 3163
 Eleftheraki AG, 2139
 El-Faitori O, 3137
 Ellinger J, 779, 4651, 5249
 Elme A, 1595, 4933
 El-Naggar A, 2587
 Elomaa L, 2623
 Elshaikh MA, 619, 4983
 Elzagheid A, 3137
 Emaetig F, 3137
 Ember I, 341, 1511, 2561,
 3119, 3195
 Emi M, 3495
 Endo I, 103, 107, 697, 1367,
 1747, 5119, 5585
 Endo M, 3279, 4219
 Endo S, 4995
 Endo T, 4719
 Endo Y, 2881
 Eng H-L, 1169
 Engi H, 2021
 Enomoto H, 2221, 3941,
 4029
 Enomoto N, 4547
 Enrici RM, 1229
 Eom S-Y, 3089
 Erben P, 1951
 Ercolani G, 2747
 Erich SA, 1819
 Erin N, 3675
 Escobar HM, 1325, 5421
 Espie M, 2657
 Estévez J, 5091
 Eto K, 5011
 Eto R, 3423
 European Lung Cancer
 Working Party, 5477
 Euvrard S, 3711
 Evangelista S, 1721
 Ewing SL, 3635
 Ezzoukhry Z, 1415

 Faber A, 1951, 2457, 5385
 Fabi A, 21, 1721
 Fabri E, 3027
 Falandry C, 301
 Falcone A, 3487
 Falk M, 631
 Falk S, 1963
 Fan X, 5199
 Fanetti G, 1257
 Fang Y, 1799

 Fang Y-Y, 5611
 Fann JC-Y, 5171
 Farashahi Yazd E, 5365
 Faresjö Å, 631
 Faresjö T, 631
 Farina P, 4061
 Farmakis D, 3475
 Fasoulis L, 191
 Fattoruso SIS, 1721
 Faustino SES, 3969
 Favero L, 1793
 Fechner G, 779, 4651
 Fedeli F, 2707
 Fehm T, 711, 2233
 Feige K, 1325
 Feldheiser A, 3449
 Felici C, 691
 Feller AC, 4771
 Feng X, 5199
 Fenig E, 5151
 Ferda J, 2665, 2791
 Ferdova E, 2665
 Ferko A, 1201
 Fernandes ET, 3635
 Fernandes MR, 3683
 Ferrarelli T, 4847
 Ferro A, 4061, 5531
 Ferro M, 2785, 4585
 Ferro P, 2707
 Fertel SR, 1829
 Fiala O, 1705, 3397
 Fichtl J, 2239
 Fiddy S, 4521
 Fiduccia P, 4061
 Fiegl M, 3831
 Figarella-Branger D, 2159
 Figueiró F, 4463
 Filella X, 5633
 Filippini D, 3705
 Filman N, 3481
 Fine RL, 3899
 Finek J, 1705
 Finek J, 2665, 2791, 3397
 Finotti A, 3027
 Fiorentino M, 2361
 Fiorio E, 3705
 Fisher JL, 2597
 Fiten P, 1899
 Fleckenstein L, 1819
 Flis S, 2989
 Focken T, 3069
 Fodor E, 1737
 Fodstad O, 3615

 Fogliata A, 4537
 Földi E, 3403
 Fong Y, 3241
 Fontana A, 3487
 Fontana E, 725
 Fontana V, 2707
 Forčić D, 2043
 Forones NM, 647
 Forte V, 5663
 Fotopoulou C, 1585, 1673
 Fountzilias G, 2139, 4573
 Fournier G, 2065
 Fowler JF, 1009
 Fozza A, 3503
 Fraggetta F, 1195
 Franceschelli A, 2639, 5205
 Franceschini MC, 2707
 Franzen A, 1141
 Frati A, 3015
 Freedman DM, 543
 Frega A, 29
 Frenkel GD, 4249
 Freund M, 445
 Frey CR, 1899
 Freyer G, 301
 Friedel G, 1609
 Friedl A, 1525
 Friedlander P, 4213
 Friedman D, 4509
 Friedman M, 661
 Friedrich RE, 1081, 1757,
 3917, 4567
 Fritz P, 1609, 2473
 Frozza RL, 4463
 Fryssira E, 3369
 Fu Y-P, 543
 Fuchs B, 1297
 Fuhrman BJ, 543
 Fujii H, 5549
 Fujii K, 3295
 Fujii M, 1023
 Fujimori K, 4785
 Fujimoto N, 3837
 Fujinami H, 5107
 Fujino S, 2921, 2935
 Fujino Y, 5317
 Fujioka K, 5289
 Fujisaka Y, 5699
 Fujishima F, 1463
 Fujita T, 5011
 Fujita Y, 1163, 4631
 Fujiuchi Y, 575
 Fujiwara H, 271, 461, 537,

- 1483, 1621, 1689, 2577,
2699, 3185, 3461, 4023,
4329, 4645, 5097, 5415
Fujiwara S, 3279
Fujiwara Yuki, 705, 1697,
2715, 2723, 3439, 4041,
5005
Fujiwara Yushi, 601
Fukagai T, 3837
Fukoe Y, 2635
Fuks D, 5645
Fukuchi M, 4627, 5051,
5113, 5591
Fukuda K, 3653
Fukuda S, 2629
Fukuda T, 1409
Fukuhara J, 3745
Fukuhara T, 2867
Fukui S, 923
Fukuoka K, 4631
Fukushima Tadao, 697
Fukushima Takanaru, 2949
Fukutome M, 4337
Fulciniti F, 1135
Fulfaro F, 679
Fulgenzi P, 3925
Fullerton DA, 1337
Fung W, 1899
Furák J, 1725, 1737
Furlanetto J, 3705
Furukawa H, 1439
Furukawa K, 705, 1697,
2715, 2723, 3439, 4041,
5005
Furukawa S, 4785
Furukawa T, 1547
Furuta Kazunori, 583
Furuta Koh, 2129
Furutani A, 537, 1483, 2699
Furuya T, 2629
Fusco V, 4557
Fuse H, 575
Fushiki H, 4741
Futagawa Y, 705, 2715, 3439,
4041, 5005
Futami K, 2977
Futatsuki R, 2977

Gabata T, 4669
Gabijs H-J, 3053
Gacci M, 5205
Gaje P, 957
Galdy S, 725

Galioto RL, 4757
Galleri G, 871
Galli C, 3487
Galli L, 3487
Gallis BM, 123
Gallo M, 4509
Galluzzi L, 1867
Galmiche A, 1415
Galuppi A, 2747
Gambacorta MA, 4557
Gambari R, 3027
Gamerith G, 3831
Gámez ME, 4483, 5511
Gan H, 393
Ganapathy-Kanniappan S, 13
Gandhi V, 1777
Gandini C, 4603
Ganju V, 2657
Gansukh T, 5255
Gao X, 215
Gao Y, 5199
Garcia D, 5295
Garcon MC, 2743
Garelli S, 655
Garetto G, 4827
Garg MK, 4927
Gari M, 4779
Gariboldi M, 1257
Garin E, 3871
Garlantezec R, 2065
Garrigue A, 1045
Garufi A, 1195
Gaspar JF, 2549
Gassner D, 913
Gautam SC, 215
Gawda P, 4347
Gaziel TB, 1657
Gebauer N, 4771
Geerts A, 4683
Geißler C, 913, 3481
Geldof AA, 387
Geletu M, 4401
Geleziunas R, 1899
Gemma A, 1117
Gengel N, 401
Genovesi D, 4557
Gentile G, 2361, 2639, 5205
Gerdan L, 3887
Gerdin B, 3113
Gerger A, 4591
Gerhards F, 3917
Gerlinger I, 341
Gerschpacher M, 941

Geschwind J-F, 13
Getoff N, 941
Gevensleben H, 371
Ghanem SM, 5205
Ghiringhelli F, 3467
Ghosh A, 1215
Gi Airo Working Group, 4557
Giamas G, 53
Giampalma E, 2747
Giannakopoulou N, 3509
Giannelli F, 3503
Giarnieri E, 917
Gibson Wood W, 4867
Giese M, 1081
Gil Gil M, 2657
Gimble JM, 4213
Giner Marco V, 5477
Ginter P, 3899
Ginther C, 2997
Giordano L, 4603
Giotta F, 1491, 4951
Giovagnoli MR, 917
Gipponi M, 4509
Girolami M, 2147
Gkiozos I, 2369
Gkretsi V, 1977
Glanzman J, 4483, 4927
Gluz O, 731
Gnyszka A, 2989
Go T, 1107, 5597
Gobin E, 2065
Göcze K, 1511, 2561
Gocze P, 2561
Godin C, 1415
Goi T, 1881, 4841, 5311
Goldoni M, 5517
Goletz S, 1609
Golfieri R, 2747
Gombos K, 1511, 2561,
3195
Gomes TS, 647
Gomulkiewicz A, 965
Gonçalves A, 2159
Gong J, 347
Gong Y, 123
González-Rodilla I, 5091
Gooding WE, 4475
Goodlett DR, 123
Gordon J, 1
Gorski A, 1569
Gotanda Y, 2941
Goto I, 469
Goto K, 1175

Goto S, 2957, 2971
Gotoh A, 887
Gotoh M, 5597
Gotohda N, 567
Goto-Koshino Y, 5317
Gottschling S, 981
Gouéran S, 5655
Gouya G, 3629
Grabarska A, 4347
Graefen M, 5249
Graeser M, 371
Graf BM, 3201
Graf R, 4111, 4117, 4639
Gräfin Zu Eulenburg C,
1081
Granot Y, 183
Grau J, 5633
Graziotti P, 4537
Greenberg AK, 1247
Grenman R, 3113
Grinwis GCM, 1819
Gröbe A, 3917
Grobschmidt GM, 5385
Gros S, 4975
Grott M, 791
Grubbs CJ, 1519
Gruber I, 2233
Gruber M, 3201
Grunert M, 5273
Grupo Gallego de
Investigaciones
Oncológicas, 4089
Gschwend J, 3731
Guarnaccia R, 2153
Gudas LJ, 2381, 5235
Gudz TI, 77
Gueganic N, 639
Guenzel T, 1141
Guenzi M, 3503
Guerrero G, 2077
Guillot A, 4445
Guizzon L, 4827
Gulczyński J, 5461
Gullbo J, 143
Gullo G, 4603
Gunesch A, 3759
Guo M, 1873
Gupta R, 3603
Gusinu M, 655
Gustavsson B, 325
Gutierrez ML, 5159
Guy L, 39
Guy S, 4401

- Haas HS, 1267
 Haas M, 287
 Haas-Kogan DA, 755
 Hadway P, 615
 Haese A, 5249
 Hafner M, 3753
 Hagen RM, 4395
 Hagiwara A, 5165
 Hagiwara S, 3327
 Haglund C, 253
 Hahn M, 2233
 Haikel RL, 2651
 Hajiyeva Y, 3753
 Hakelius M, 3113
 Hall C, 1673
 Hallak M, 183
 Halldorson J, 2797
 Halon A, 5255
 Hamada A, 261
 Hamaguchi S, 261
 Hamaguchi T, 309, 2129, 4547
 Hamai Y, 1761, 3495
 Hamasaki S, 1547
 Hamburger T, 293
 Hamidi H, 2997
 Hamilton G, 2021
 Hammock BD, 5261
 Han B, 1899
 Han DH, 763
 Hanafusa T, 469
 Hanagiri T, 2123
 Haneda S, 685
 Hanker LC, 371
 Hansen CK, 379
 Hao Q, 393
 Harada H, 3279
 Harada M, 975
 Harada-Shiba M, 4237
 Harbeck N, 3759
 Harrison LB, 4483, 5511
 Harstead KE, 3823
 Hartman ML, 3205
 Haruki K, 705, 1697, 2715, 2723, 3439, 4041, 5005, 5011
 Hasegawa S, 697, 1747
 Hasegawa Tadashi, 167
 Hasegawa Takaaki, 3105, 5043
 Hasegawa Takeo, 2861
 Hashimoto T, 4175, 5075
 Hashimoto Y, 4785
 Hassan SB, 143
 Hasselbalch B, 1657
 Hasséus B, 4261, 4325
 Hata M, 5187
 Hata S, 4811
 Hatachi G, 2107
 Hatake K, 3905
 Hatanaka K, 2779
 Hatano S, 4627, 5051, 5591
 Hattori N, 1099
 Hatzis C, 1667
 Hauch A, 4213
 Hauser S, 779, 4651
 Hay D, 1401
 Hayabuchi N, 5561
 Hayashi H, 5699
 Hayashi Katshuhiro, 1373
 Hayashi Kazumi, 1853
 Hayashida N, 4049
 Haybaeck J, 991
 Hayes L, 2611
 Hazama S, 2629, 3423
 Healey E, 1053
 Hebbbar M, 1603
 Heegaard A-M, 1963
 Heidegger I, 5525
 Heikkinen M, 2623
 Heiland M, 1757, 3917, 4567
 Heindryckx F, 4683
 Heinemann V, 287
 Hejna M, 1035, 1065, 2085, 3455
 Helbok A, 1537
 Held G, 4189
 Helson L, 3603, 3629
 Henaut L, 1415
 Henes M, 711
 Hennenlotter J, 5243
 Henry K, 3047
 Hermanek P, 559
 Hermunen K, 253
 Herpel E, 981
 Herrera AC, 737
 Herrick EJ, 1799
 Herring A, 609
 Herth FJF, 981
 Herzog TJ, 801
 Hes O, 2665, 2791
 Heubner M, 329
 Hey C, 3347, 3481, 4017
 Heyn R, 917
 Hickmann E, 4567
 Hida Y, 5193
 Hideghéty K, 1725, 1737
 Higashi D, 2977
 Higashida M, 4319
 Higuchi T, 1861
 Hihara J, 1761, 3495
 Hilbe W, 3831
 Hill DL, 1519
 Hino M, 1117
 Hinoda Y, 3423
 Hiraga R, 4431
 Hirai F, 2977
 Hirai S, 4995
 Hirai T, 4319, 5557
 Hirajima S, 271, 3185
 Hirakawa H, 4811
 Hirakawa K, 595, 1635, 3291, 3301, 3445, 5023, 5031, 5567
 Hirakawa M, 2199
 Hirano E, 5301
 Hirano K, 2619
 Hirano S, 5193
 Hirata H, 1649, 5649
 Hirata K, 167
 Hiro J, 5065
 Hirohashi Y, 167
 Hirono Y, 4841, 5311
 Hirose M, 4995
 Hiroshima Y, 107, 1361, 1373
 Hirota K, 2911
 Hirsh S, 3047
 Hishima T, 5057
 Hlavata I, 4855
 Ho AL, 1307
 Ho C-Y, 671
 Hoekstra OS, 387
 Hoellen F, 1125
 Hoelzle F, 3917
 Hoermann K, 2457
 Hoffman RM, 97, 103, 107, 409, 419, 1029, 1361, 1367, 1373, 1837, 3021, 3041, 3623, 4229
 Hoffmann J, 4567
 Hofheinz R-D, 1951, 2457
 Hofmann P, 3201
 Högel B, 3759
 Hohenberger W, 559
 Hohmann J, 2021
 Hojo H, 4785
 Holdenrieder S, 287
 Holečková P, 4097
 Holick MF, 3861
 Holtrich U, 371
 Homma S, 1853
 Honda H, 1649, 5575, 5579, 5649
 Honda K-I, 1409
 Honda Takeshi, 261
 Honda Teruko, 2895
 Hong HJ, 4129
 Hong JC, 1731
 Hong J-H, 2605
 Hong JY, 4619
 Hong JY, 5127
 Hong KD, 2935
 Hong TT, 4947
 Honma Y, 309, 2129, 4547
 Hora M, 2665, 2791
 Horai T, 3327
 Hori H, 2881, 2911, 2917
 Hori T, 601
 Horie S, 3837
 Horiguchi N, 895
 Horii H, 453
 Horiike A, 3327
 Horikawa N, 5107
 Höring E, 1351
 Hörmann K, 1951, 5385
 Horn T, 3731
 Hornemann A, 1125, 1591, 2771, 4553
 Horninger W, 5525
 Horváth R, 1511
 Horwath C, 1267
 Hosek P, 4855
 Hoshino S, 1157
 Hosokawa A, 5107
 Hosokawa T, 1153
 Hosomi Y, 5057
 Hosono N, 3335, 3947
 Hou M-F, 5543
 Hou Y-T, 5301
 Howard SP, 2611
 Hřebáček H, 3163
 Hsi E, 5611
 Hsia T-C, 2775, 4067
 Hsiao H-H, 4663
 Hsiao Y-P, 4411
 Hsieh C-H, 4875
 Hsieh S-C, 4965
 Hsu C-C, 3807
 Hsu C-H, 4123
 Hsu C-M, 529, 671
 Hsu H-C, 3317
 Hsu J-F, 4663
 Hsu NC-H, 5611

- Hsu S-C, 1941
Hsu Y-N, 5395
Hu K, 143
Hu KS, 4483, 5511
Hu Y, 3581
Huang C-C, 1169
Huang C-F, 425
Huang C-N, 1091
Huang C-T, 4663
Huang C-Y, 1169
Huang E-Y, 1169
Huang F, 1421
Huang T-C, 4123
Huang W, 5199
Huang W-T, 5543
Huang Y-C, 5611
Hugtenburg JG, 3553
Huh SJ, 4675
Huh YJ, 847
Huitzil-Melendez DF, 3241
Hummelsberger M, 301
Hundt W, 5213
Hung F-M, 4867
Hung H-F, 4867
Hung M, 1899
Hung S-J, 4411
Huovinen R, 1595
Huq F, 4365
Hussain A, 301
Husstedt W-D, 1125
Huusko M, 2623
Huvelin J-M, 3783
Huwait E, 4779
Hwang D, 3765
Hwang J-H, 1473
Hwang JW, 2499
Hyodo I, 4995
Iacono A, 3515
Iacovelli R, 5663
Iannaccio S, 917
Iannone T, 4557
Iannotto J-C, 639
Ibe H, 2971
Ibrahim SO, 837
Ibuki Y, 3495
Ichiishi E, 2535
Ichikawa A, 3327
Ichikawa D, 271, 461, 537, 1483, 1621, 1689, 2577, 2699, 3185, 3461, 4023, 4329, 4645, 5097, 5165, 5415
Ichikawa T, 2689
Ichikawa Y, 5119, 5585
Ichimura S, 5357
Ida S, 1641
Ide H, 3837
Idelevich E, 5151
Iftner T, 711
Iftode C, 4537
Ihara K, 4175
Ihara SS, 647
Iida A, 2535
Iida K, 113, 3775
Iida T, 4041
Iihara H, 5549
Iimuro M, 3667
Iitaka D, 461, 4329
Ikai A, 1483, 2699
Ikeda D, 3837
Ikeda H, 2169
Ikeda K, 5289
Ikeda Tetsuo, 1641
Ikeda Toshihiko, 3145
Ikegaya S, 3335, 3947
Ikeno H, 1679, 2453, 5675
Ikeya T, 5567
Ikoma H, 1621, 1689, 2577, 2699, 3461, 4023, 5097
Iles RK, 3611
Ilescu G, 1131
Ilhan-Mutlu A, 1065, 3455
Iliakis T, 3509, 5693
Illuminati G, 2147
Imai H, 625, 3279
Imaizumi T, 3145
Imamoto H, 1439
Imamura F, 5535
Imanishi Tatsuya, 4515
Imanishi Tsutomu, 5165
Imano M, 1439
Imarisio I, 4999
Inaba K, 4989
Inagawa H, 2849, 2875, 2895
Inai K, 3947
Inamine M, 2199, 5123
Incorvaia L, 679
Innamaa A, 1401
Inoda S, 167
Inose T, 5113
Inoue H, 277
Inoue Koji, 5165
Inoue Kouji, 1649
Inoue Tomio, 5187
Inoue Toru, 5567
Inoue Y, 5065
Inui T, 2881, 2917
Ionna F, 1135
Ippolito E, 2785, 4585
Iraha S, 2199
Isayama H, 2619
Ishibashi K, 4627, 5051, 5591
Ishibashi M, 1927
Ishibashi N, 2887
Ishibashi T, 113, 3775
Ishibashi Yoshiaki, 2921, 2935
Ishibashi Yukiko, 2977
Ishida H, 4627, 5051, 5591
Ishida K, 5011
Ishida S, 2779, 3745
Ishida Takanori, 4811
Ishida Takeyuki, 3837
Ishida Y, 705, 1697, 2715, 2723
Ishiguro T, 5591
Ishihara D, 5511
Ishihara M, 3061, 5549
Ishii K, 583
Ishii T, 2861
Ishijima K, 2779
Ishikawa H, 2929
Ishikawa Mami, 2867
Ishikawa Masako, 113, 3775
Ishikawa N, 3775
Ishikawa S, 1107, 5597
Ishikawa Takashi, 5119
Ishikawa Tsutomu, 3445
Ishikawa Y, 3327
Ishiko O, 1409
Ishimoto T, 5415
Ishioka C, 625
Ishiyama N, 2881
Isobe T, 261
Isohashi F, 747, 2453
Itai S, 5501
Itakura S, 1547
Itami J, 4989
Itani Y, 1073
Ito H, 277
Ito K, 1073
Ito S, 1099, 4299
Ito Yoshinori, 4989
Ito Yuichi, 1099
Itoh M, 809, 3099, 4293
Itoh T, 1439
Itoh Y, 5549
Ivarsson M, 3113
Iwai Y, 1679
Iwakuma N, 2887
Iwama K, 1679, 2453, 5675
Iwamoto S, 261
Iwamoto T, 1853
Iwasa S, 309, 2129, 4547
Iwasaki Hiromichi, 3335, 3947
Iwasaki Hiroshi, 3259
Iwase R, 2715, 2723, 3439, 4041, 5005
Iwase Y, 3145
Iwashita A, 2977
Iwaya T, 1927
Izbicki JR, 4975
Izumi K, 1147, 4453, 4497, 5501
Izumi N, 923
Izumi Y, 3791
Izumisawa Y, 697
Jääskeläinen A-S, 1595
Jabeen M, 2517
Jablonska K, 5375
Jackson L, 1401
Jacob S, 2569
Jacobs JJ, 161, 2099
Jacobson A, 5511
Jaeger D, 3407
Jahn JL, 1141
Jain S, 231
Jakka G, 4189
Jan KM, 5143
Janát-Amsbury MM, 1317
Jang JM, 763
Jang SH, 2755
Jankevičius F, 2099
Jankowska R, 965
Janssens S, 4683
Japan Multinational Trial Organization, 4631
Jaramillo E, 5471
Jarboe EA, 1317
Jarnagin W, 3241
Järvenpää S, 1595, 2623, 4933
Jasani B, 3705
Jastrzębski Z, 2989
Jauri MH, 4365
Jäwert F, 4261, 4325
Jeleniewicz W, 4347
Jelski W, 3725
Jenckel F, 4701

- Jeng L-B, 529, 671
 Jensen K, 981
 Jensen M, 3861
 Jeon C-H, 1731
 Jeon H-K, 1555
 Jeon HS, 2205
 Jeon H-S, 513, 3233
 Jeon HW, 5135
 Jeon M-J, 3715, 2001
 Jeong J-H, 4751
 Jeremias I, 5273
 Jethon A, 965
 Jeung H-C, 821
 Jezek P, 1563
 Ji H-X, 5401
 Jia G, 3123, 3815
 Jia N, 2797
 Jia W, 2353, 3123, 3815
 Jian Q, 5199
 Jiang P, 4229
 Jiang WG, 199, 207, 1499,
 1917, 2179, 2185, 2353,
 3123, 3815
 Jin J, 5335
 Jin Z, 5199
 Jing C, 419
 Jitsuoka M, 4741
 Jo S, 5445
 Joffroy C, 2473
 Johannessen AC, 837
 John MK, 4285
 Johnston DS, 1989
 Jonat W, 1525
 Joo KM, 5335
 Joo Y-E, 2135, 3765
 Jorge Fernández M, 717
 Jorge M, 4089
 Joseph K, 2227
 Joseph N, 77
 Josset E, 1845
 Jou D, 4279
 Jou W-J, 3225
 Jovenin N, 301
 Juhasz K, 1511, 2561, 3195
 Juhem A, 4445
 Jun CH, 4129
 Juncos LA, 3119
 Jung AR, 821
 Jung DH, 5143
 Jung HA, 4619, 5127
 Jung HJ, 3645
 Jung P-S, 1029
 Jung S, 2525
 Jung SB, 1731
 Jung T-Y, 2525
 Junghanss C, 445
 Kabarriti R, 4483, 4927
 Kabbinavar FF, 2997
 Kadakal F, 2643
 Kadokura M, 4547
 Kadono Y, 1147, 4453, 4497,
 4669, 5501
 Kadouri L, 293
 Kadowaki T, 2875
 Kafatos A, 1667
 Kaga K, 5193
 Kagara N, 5617
 Kagaya H, 3061
 Kage M, 2941
 Kagiya T, 643, 1685, 1773
 Kahán Z, 1725, 1737
 Kai W, 5179
 Kaino S, 4821
 Kaira K, 3279, 4219
 Kaiser C, 1971
 Kaizu H, 5187
 Kajikawa K, 5043
 Kajiura S, 5107
 Kajtar B, 2561
 Kakeji Y, 4515
 Kakinohana Y, 2199
 Kakizaki S, 895
 Kalábová H, 4097
 Kalala F, 5693
 Kalas W, 1429
 Kaleva-Kerola J, 2623
 Kaley K, 2743
 Kallioniemi A, 45
 Kalnicki S, 4927
 Kalogeropoulos T, 191
 Kamada M, 5289
 Kamada T, 5579
 Kamata T, 4431
 Kamata Y, 1853
 Kamei T, 1463
 Kamigaki T, 2957, 2971
 Kamijo A, 3431
 Kamoto T, 1023, 1893
 Kamposioras K, 4573
 Kanaji S, 4515
 Kanaseki T, 167
 Kanavakis E, 3369
 Kanaya F, 97, 1361, 3021,
 3041, 3623
 Kanbayashi Y, 1153
 Kanda A, 3745
 Kandil E, 3047, 4213
 Kanekawa T, 1013
 Kanekiyo S, 3423
 Kaneko T, 2971
 Kanemitsu Y, 1099
 Kanemoto A, 1629
 Kanesaka N, 1157
 Kang BW, 513, 3233
 Kang H-S, 3691
 Kang HS, 4833
 Kang JH, 2115
 Kang J-H, 485
 Kang J-W, 3089
 Kang K-H, 3177
 Kang KY, 3765
 Kang MJ, 4469
 Kang W, 5335
 Kang WK, 4619
 Kanitakis J, 3711
 Kanmaz D, 2643
 Kanno T, 887
 Kanogawa N, 5603
 Kapadia GJ, 2535
 Kapellos G, 3475
 Karabayeva R, 4595
 Karakaya S, 791
 Karamitopoulou E, 3053
 Karanikas G, 3341
 Karaskova M, 1563
 Karayannopoulou G, 3711
 Karino F, 261
 Karn T, 371
 Karoubi G, 5365
 Karstens JH, 4505
 Kasai D, 1935
 Kasai Y, 5597
 Kasamatsu T, 4989
 Kase S, 2779, 3745
 Kashiwagi S, 3445
 Kasimir-Bauer S, 329
 Kašparová M, 4097
 Kastner J, 2791
 Kasuya G, 2199, 5123
 Katagiri A, 113, 3775
 Katagiri Hiroshi, 113, 3775
 Katagiri Hiroyuki, 583
 Katano M, 1387, 3699
 Katayama K, 1881
 Katayama Y, 485
 Kates R, 3759
 Kato D, 3295
 Kato Hiroaki, 1439
 Kato Hiroyuki, 5113
 Kato Kan, 5057
 Kato Ken, 309, 2129, 4547
 Kato Masato, 3699
 Kato Masayoshi, 4431
 Kato Yoshiharu, 5043
 Kato Yuichiro, 567
 Katsoulakis E, 4483
 Katsura K, 1463
 Kattamis A, 3369
 Kaufeldt A, 665
 Kaul D, 4639
 Kautiainen H, 1595, 4933
 Kautio A-L, 4941
 Kavantzias N, 1209
 Kawabe M, 5301
 Kawaguchi K, 3837
 Kawaguchi R, 1073
 Kawaguchi Tomoya, 1163
 Kawaguchi Tsutomu, 271,
 3185, 3461
 Kawaguchi Y, 2901
 Kawahara A, 2941
 Kawahara H, 1769, 2221,
 3941, 4029
 Kawahara M, 4631
 Kawai K, 3791
 Kawai T, 2881
 Kawajiri H, 3445
 Kawakami H, 5699
 Kawakubo H, 3653
 Kawamata H, 583
 Kawamoto A, 5065
 Kawamura M, 5065
 Kawano H, 1641
 Kawano Y, 3327
 Kawano Y-I, 5575
 Kawaoka T, 2629
 Kawasaki M, 4631
 Kawase I, 5535
 Kaya Y, 3145
 Kazimierczuk Z, 4891
 Ke H-L, 1091
 Kechagias G, 1209
 Kędzia W, 5375
 Keese M, 3753
 Kehl S, 2771, 3995
 Keller ET, 4453
 Kellokumpu-Lehtinen P-L,
 1595, 2623, 4941
 Kenmotsu H, 3279
 Kennedy AM, 1317
 Keshet N, 661

- Khagi S, 4001
 Khan AA, 2517
 Khan R, 1401
 Khazal KF, 1519
 Khorsandi AS, 4483, 5511
 Kibe S, 2921, 2935
 Kichikawa K, 3355
 Kido A, 1439
 Kiełbus M, 4347
 Kies MS, 2587
 Kijima T, 5535
 Kiko Y, 4785
 Kikuchi K, 1629
 Kikuchi S, 3891
 Kim AK, 903
 Kim B-G, 1555, 3177, 4675
 Kim C-H, 2755
 Kim D-Y, 1029
 Kim DY, 3765
 Kim EK, 4073
 Kim EY, 903
 Kim G-B, 3691
 Kim GM, 223
 Kim H-A, 4073
 Kim Hark Kyun, 2467
 Kim H-C, 223, 1887
 Kim Heon, 3089
 Kim H-J, 1555
 Kim HL, 3645
 Kim Hojoong, 5127
 Kim Hoon Kuo, 2115
 Kim HR, 1473
 Kim H-S, 2525
 Kim Hyeong Su, 3089
 Kim Hyeonjin, 1887
 Kim Hyun Soo, 4129
 Kim IC, 2467
 Kim I-C, 5445
 Kim J, 2001, 3715
 Kim JG, 513, 3233
 Kim J-H, 1029
 Kim Ji Hyun, 4073
 Kim Jin-Shang, 3691
 Kim Jong Hoon, 1237
 Kim Jong-Sun, 2135
 Kim Ju-Sun, 2011, 2525
 Kim JW, 2205
 Kim K, 5135
 Kim KH, 5335
 Kim KP, 2467
 Kim K-Y, 2499
 Kim M-B, 1029
 Kim NK, 5143
 Kim R, 1
 Kim RH, 3867
 Kim S, 5445
 Kim Sang Ho, 4129
 Kim Sang-Ki, 2011, 2525
 Kim S-B, 1237, 5667
 Kim Seok Won, 4833
 Kim Seok-Ki, 4357
 Kim S-H, 2001, 3715, 4421
 Kim S-J, 3691
 Kim SJ, 5617
 Kim SK, 2205, 3983
 Kim So Hee, 521
 Kim Soon Yuhl, 1237
 Kim Su Ssan, 1237
 Kim SU, 5335
 Kim Sung Su, 4913
 Kim Sung Won, 1731
 Kim Sung Young, 4913
 Kim S-Y, 763
 Kim T-J, 1555, 3177, 4675
 Kim TU, 5445
 Kim Y-B, 5135
 Kim Y-D, 3089
 Kim YH, 2467
 Kim Y-H, 2525
 Kim Y-M, 1029
 Kim Yongbaek, 831
 Kim Young Wan, 5143
 Kim Young Wook, 5127
 Kim Young, 2435, 4719
 Kim YS, 1237, 4469
 Kim Y-T, 1029
 Kimmig R, 329
 Kimoto T, 1773
 Kimura H, 1367, 1373, 2169, 3623
 Kimura J, 697
 Kimura Kenjiro, 1635, 5023, 5567
 Kimura Kenya, 1099
 Kimura Takahiro, 1853
 Kimura Toru, 1181, 2211
 Kimura Yasue, 1641
 Kimura Youhei, 1881
 Kinghorn AD, 5349
 Kinn J, 1045
 Kinoshita S, 3355, 3745
 Kinoshita T, 567
 Kinugasa T, 2839, 2887, 2921, 2929, 2935, 2941, 2965
 Kipp M, 791
 Kiriya K, 167
 Kirpensteijn J, 161
 Kishi A, 2861
 Kishi S, 3335, 3947
 Kishimoto I, 1761, 3495
 Kishimoto M, 461, 4329, 5415
 Kiss I, 341
 Kita K, 5119
 Kita R, 1181, 2211
 Kitagawa K, 5165
 Kitagawa T, 153, 2557, 3133, 3661, 4821
 Kitagawa Yasuhide, 1147, 4453, 4497, 4669, 5501
 Kitagawa Yuko, 3653
 Kitaguchi M, 4959
 Kitajewski JK, 801
 Kitawaki J, 1153
 Kitayoshi M, 3295
 Kitazaki H, 485
 Kitsiou S, 3369
 Kivity S, 5151
 Kiyota A, 1387
 Kiyozuka M, 4337
 Kjeller G, 4261, 4325
 Klapsas V, 191
 Klatka J, 4347
 Klein A, 1525
 Klein RL, 1809
 Kleinschmit J, 401
 Klemke M, 3069
 Klickovic U, 3629
 Knabbe C, 2473
 Knackstedt RW, 5325
 Knecht R, 4701
 Knežević F, 2509
 Knobloch TJ, 4757
 Knowell AE, 4271
 Knyazev P, 3759
 Ko S-F, 1169
 Kobashi K, 1147
 Kobayashi I, 5043
 Kobayashi Kana, 643
 Kobayashi Kunihiko, 1117
 Kobayashi N, 1157
 Kobayashi T, 5107
 Kobayashi Y, 1761
 Kobierzycki C, 5375
 Koda W, 4669
 Kodani N, 643, 1773
 Kodeda K, 325
 Koderia Y, 4299
 Koenig B, 3027
 Kogej M, 779
 Kogure H, 2619
 Koh HR, 4129
 Koh JS, 4073
 Koh Y, 5223
 Kohchi C, 2875
 Kohyama A, 685
 Koido S, 347, 1853
 Koike K, 2619
 Koizumi M, 643, 1773
 Kojima A, 895
 Kojima D, 2977
 Kojima Masayuki, 3699
 Kojima Motohiro, 567
 Kokko R, 2623
 Kolialexi A, 3369
 Kolkowitz I, 755
 Koller CM, 2435
 Kollia P, 5693
 Kolsch M, 731
 Kolstad A, 85
 Komatsu M, 5187
 Komatsu S, 271, 461, 537, 1483, 1621, 1689, 2577, 2699, 3185, 3461, 4023, 4329, 4645, 5097, 5165, 5415
 Komatsu Y, 3845
 Komine K, 625
 Komiya A, 575
 Komori K, 1099
 Komuta K, 4631, 5535
 Konaka H, 4453, 4497, 4669, 5501
 Kondo E, 4299
 Kondo Haruhiko, 4219
 Kondo Hiroshi, 3423
 Kondo M, 997
 Kondo T, 2971
 Kondo Y, 3837
 König AM, 4975
 Konishi H, 271, 461, 1621, 1689, 2577, 2699, 3185, 3461, 4023, 4329, 4645, 5097, 5415
 Konishi M, 567
 Konishi Y, 2867
 Konkankit V, 2997
 Kono H, 267
 Konoshima T, 2535
 Konstantara A, 4573
 Konstantaras C, 4573

- Kook H, 2011
 Kopp H-G, 791
 Kopperapu PK, 363, 2381, 5235
 Körholz D, 4791
 Korkeila EA, 5491
 Kornprat P, 991
 Koronellos N, 4033
 Koronkiewicz M, 4891
 Kosaihira S, 1117
 Kosaka T, 697, 1747
 Koshida K, 1147
 Koskas M, 283
 Koskela A, 3113
 Koskela HM, 5491
 Kosuge M, 5011
 Kotani T, 2453
 Kotb R, 3005
 Koten J-W, 161, 2099
 Kotoula V, 4573
 Kotsuma T, 3963, 5687
 Kouikoglou O, 4007
 Koukoulis GK, 2139
 Koutsilieris M, 2441
 Kouvaras E, 2139
 Kouvatseas G, 4573
 Kouzis P, 5693
 Kovacs K, 119, 2561
 Kovel S, 5151
 Kowalski LP, 3969
 Koya N, 1387
 Koyama I, 975
 Koyama N, 5083
 Kraetschmer S, 1141
 Krajina A, 1201
 Kralickova M, 4855
 Krastev Z, 4531
 Kraveka JM, 77
 Krčmová L, 4097
 Kreuzberg B, 2665, 2791
 Krikelis D, 4573
 Kristen R, 1609
 Kruczak A, 1447
 Kubo K, 2881, 2917
 Kubo N, 595, 1635, 5023, 5031, 5567
 Kubo T, 167
 Kuboki Y, 3905
 Kubota H, 4319
 Kubota K, 1117, 4631
 Kubota T, 271, 461, 537, 1483, 1621, 1689, 2577, 2699, 3185, 3461, 4023, 4329, 4645, 5097, 5165, 5415
 Kuchiike D, 2881, 2917
 Kudaka W, 2199, 5123
 Kudo K, 3327
 Kudo SE, 277
 Kudo T, 923
 Kuehs U, 5243
 Kuhara A, 1853
 Kuhn W, 1971
 Kulda V, 2239
 Kumagai K, 3653
 Kumagai T, 5535
 Kumagai Y, 4627, 5051, 5591
 Kumaki M, 4453
 Kumamoto K, 4627, 5051
 Kumamoto T, 5585
 Kumamoto Y, 583
 Kumashiro R, 1641
 Kummer F, 3415
 Kundel Y, 5151
 Kunii E, 1935
 Kunisaki C, 697, 1747
 Kunitake N, 1649
 Kuniyasu H, 3295
 Kunjithapatham R, 13
 Kuo M-L, 4875
 Kuo MT, 4157
 Kuo S-N, 4965
 Kupferman M, 2587
 Kuraki T, 261
 Kuramitsu Y, 153, 2557, 3133, 3661, 4821
 Kurashige J, 1927
 Kurebayashi H, 4841
 Kurita T, 2807
 Kuriu Yoshiaki, 1621, 1689, 2577, 2699, 3461, 4023, 5097
 Kuroda Y, 1023, 1893
 Kuroki M, 2823, 2855
 Kurtsman J, 379
 Kurzepa-Skaradzinska A, 1569
 Kusumoto T, 1641
 Kusunoki M, 5065
 Kutner A, 433
 Kuwabara K, 5051, 5591
 Kuwano H, 5113
 Kwon H-J, 3089
 Kwon J, 1887
 Kwon KH, 2205
 Kwon OJ, 5127
 Kwon S-H, 1457
 Kwon YT, 763
 Kyprianou N, 4695
 Kyrtsionis M-C, 5693
 Laas E, 2191
 Lacoste E, 123
 Lademery MR, 4395
 Lafitte J-J, 5477
 Laflamme C, 2569
 Lage H, 5255
 Lah K, 615
 Lai H, 123
 Lai HC, 4389
 Lai W-W, 1941
 Lakis S, 4573
 Lam MGEH, 4711
 Lamanna G, 655
 Lambertz N, 609
 Lampronti I, 3027
 Lan Y-C, 3807
 Landeiro JA, 5625
 Landenberger N, 2233
 Landi L, 3487
 Lanfranchi G, 3383
 Lange BP, 3347, 4017
 Lange R, 3201
 Lange S, 445
 Łapińska-Szumczyk S, 5461
 Larsen RH, 85
 Larsson L, 4261, 4325
 Lasky III JL, 2047
 Lassen U, 1657
 Latkowski K, 5375
 Latto M, 3137
 Laubender RP, 287
 Laukens D, 4683
 Laurent-Puig P, 3977
 Lauridant G, 5655
 Lavi E, 3899
 Lavrenkov K, 5151
 Lazaris AC, 1209
 Lazarus C, 4483
 Le Bris M-J, 639
 Le D, 1785
 Le Frere-Belda M-A, 3977
 Le Leu RK, 3581
 Le Louarn A, 1045
 Le Rhun E, 2057
 Lea MA, 401
 Lebedev A, 4595
 Lechan RM, 4001
 Leclercq N, 5477
 Lecomte J, 5477
 Lecuru F, 3977
 Lee BW, 2205
 Lee CY, 2755
 Lee EK, 4357, 4833
 Lee H-C, 3807
 Lee H-G, 1457
 Lee Hongki, 5445
 Lee HS, 1731
 Lee Huei, 2729
 Lee H-Y, 4751
 Lee HY, 5127
 Lee J, 2001, 3715
 Lee Jae Hyuk, 3765
 Lee Jae-Woong, 2755
 Lee Jeeyun, 4619
 Lee Jeeyun, 5179
 Lee Jeong Hwa, 2467
 Lee Jeong-Won, 1555, 3177, 4675
 Lee J-I, 5335
 Lee J-J, 2011, 2525
 Lee J-K, 1555
 Lee J-Y, 4073
 Lee KD, 1731
 Lee K-D, 5543
 Lee KH, 3765
 Lee K-S, 3089
 Lee KS, 5127
 Lee Masahiro, 2635
 Lee MG, 521
 Lee M-H, 529
 Lee Miji, 5667
 Lee O, 425
 Lee RX, 65
 Lee S, 3335
 Lee Sang-Wook, 1237
 Lee SH, 1473
 Lee Shin, 3947
 Lee Shin-Wha, 1029
 Lee S-J, 3691
 Lee S-M, 3983
 Lee Soo Jung, 513, 3233
 Lee Soong, 3765
 Lee Su Jin, 5179
 Lee T, 1635
 Lee WK, 513
 Lee W-S, 2135
 Lee Y-C, 1091
 Lee Y-M, 5395
 Lee Yong Jun, 763
 Lee Yoo Jin, 513, 3233, 4357
 Lee Yugen, 2635

- Lee Yunjung, 1887
 Lee Y-W, 1169
 Lee Y-Y, 3177, 4675
 Leheurteur M, 5655
 Lehmann M, 1081
 Lehtinen I, 2623, 4941
 Leinung M, 3481
 Lemieux J, 2569
 Lenoir L, 3871
 Leonard A, 3307
 Leonardi C, 4557
 Leonardi F, 725
 Leong J, 949
 Leonhartsberger N, 5525
 Lepareur N, 3871
 Létal J, 4097
 Leto G, 679
 Levingston CA, 1809
 Levy I, 183
 Leweling H, 3403, 4553
 Li B, 3867
 Li BY, 801
 Li EI-C, 425
 Li F-J, 4907
 Li H, 5261
 Li JM, 929, 1421
 Li L, 77
 Li L-Y, 4907
 Li M, 929
 Li P, 4103
 Li QQ, 65, 929, 1421
 Li W-M, 1091
 Li X, 4103
 Li Z, 5511
 Lian J-F, 425
 Liang D, 4285
 Liang H, 65, 1421
 Liang J-L, 1169
 Liang S-J, 2775, 4067
 Liang Y-C, 3225
 Liao C-S, 5171
 Liao J, 5261
 Liao J-W, 4799
 Liao S-K, 4875
 Liao W-L, 4907, 5401
 Liao Y-J, 2763
 Liao C-T, 3317
 Liao LM, 2047
 Liaw C-C, 2605
 Lien C-S, 4907, 5401
 Lien J-C, 1941
 Lillig CH, 4921
 Lim HY, 4619, 5179
 Lim SH, 4913
 Lim SM, 2499
 Lin Cheng-Chieh, 3391
 Lin Chia-Chi, 4123
 Lin C-J, 4799
 Lin EH, 2797
 Lin H-H, 1091
 Lin H-L, 1091
 Lin I-Y, 2763
 Lin J, 4279
 Lin J-H, 4965
 Lin J-P, 1941
 Lin L, 4279
 Lin L-Y, 2775, 4067
 Lin P, 3953
 Lin R-J, 3225
 Lin S-E, 2763
 Lin S-F, 4663
 Lin S-H, 949
 Lin Shyr-Yi, 3225
 Lin S-S, 4907, 5395
 Lin Sy-Yu, 4799
 Lin W, 5511
 Lin Y, 409
 Lin Y-C, 3317, 2605, 4799
 Lin YC, 949
 Lin Y-M, 5171
 Lin Yueh-Shih, 5171
 Lin Yu-Sheng, 4965
 Lindh M, 3247
 Lindskog EB, 2447
 Lindström M-L, 665
 Linet MS, 543
 Linne H, 2185
 Linsalata M, 4951
 Lioce M, 1491
 Liou I, 2797
 Liou J-P, 425
 Lipczynski W, 2099
 Liska V, 4855
 Lit LC, 53
 Liu A, 215
 Liu D, 1107, 5597
 Liu J, 5199
 Liu JL, 2425
 Liu J-Y, 949
 Liu P, 215
 Liu T-C, 4663
 Liu W, 5421
 Liu WM, 4373
 Liu Xiao, 3123, 3815
 Liu Xiaohong, 1899
 Liu Yanfeng, 355
 Liu Y-C, 4663
 Liu Y-M, 4799
 Liu Yongbo, 215
 Liu Yongkang, 409
 Llombart A, 2657
 Llorca J, 5091
 Lloyd RV, 119
 Lo H-H, 5395
 Lo Re G, 1041
 Lo Rizzo C, 691
 Lobefalo F, 4537
 Locher P, 1971
 Löfgren S, 3247, 4947
 Logan JE, 2997
 Loibner H, 4591
 Lombardi A, 1229
 Lombardi D, 29
 Lombardi G, 3487, 4061
 London CA, 1819
 Longatto-Filho A, 2651
 Longini M, 691
 Löning T, 4567
 Lopes C, 1397
 López R, 717
 López-López R, 5295
 Lorand S, 1045
 Lorgis V, 3467
 Losardo PL, 725
 Losurdo A, 4603
 Lotti F, 691
 Louandre C, 1415
 Lu D, 4719
 Lu Hailing, 123
 Lu Haiyan, 379
 Lu H-F, 4867
 Lü J, 4279
 Lu M-C, 529
 Lu R, 3123, 3815
 Lucarini G, 5017
 Lueftenegger I, 1267
 Lühr I, 1525
 Łukawska M, 4439
 Lukens JJ, 5511
 Lukic A, 917
 Lumachi F, 1041, 1793, 2593
 Lümmen G, 779
 Lunde ML, 837
 Luo Y, 3295
 Luoto R, 1595
 Lupattelli M, 4557
 Luton D, 283
 Ma H-P, 2763
 Ma Q, 4103
 Ma R, 419
 Macchia G, 2785, 4585
 Machida M, 1131
 Maciejewska M, 433, 1569
 Maeda K, 1635, 3291, 3301, 5023, 5031, 5567
 Maeda M, 3285
 Maeda S, 997
 Maehara H, 97, 1361, 3021, 3041, 3623
 Maehara S-I, 3133, 4821
 Maehara Y, 1641, 3133, 4821
 Maekawa R, 2971
 Maekawa T, 2977
 Mælandsmo GM, 3615
 Maeng CH, 4619, 5127
 Maeno K, 1935
 Maestro ML, 5159
 Magerle M, 1065
 Maggi S, 1229
 Magnani M, 1867
 Magnusson B, 4261, 4325
 Mahan M, 619
 Maiche A, 2623
 Maimon O, 293
 Maiti GP, 1215
 Maj T, 1569
 Majewska H, 5461
 Majois F, 2657
 Makino H, 697, 1747
 Makino Y, 2807
 Malaguti P, 21
 Malamou-Mitsi V, 2139
 Malsy M, 3201
 Maltese G, 679
 Maly B, 293
 Mamalakis G, 1667
 Mancini R, 917
 Mancosu P, 4537
 Mandolesi A, 4611
 Manfrin E, 3705
 Mangar D, 4827
 Mangerini R, 815
 Maniadakis M, 3213
 Manolidis S, 5511
 Manome Y, 5289
 Mantello G, 4557
 Mantero E, 655
 Mantzourani M, 3475, 3509
 Mao M, 5179
 Maoka T, 2021
 Maolake A, 5501

- Marabeti MR, 489
 Maranzano E, 4557
 Maráz A, 1725, 1737
 Marcenaro M, 655
 Marcolini L, 3705
 Marcorelles P, 2065
 Marengo G, 489
 Margetis K, 3899
 Margiotta C, 1717
 Margulies A-L, 283
 Marmé F, 3407
 Marosi C, 1065
 Marston A, 4347
 Mart M, 4695
 Martel-Frchet V, 4445
 Martignoni G, 2679, 3705
 Martin JE, 3581
 Martin TA, 207, 2353
 Martínez N, 5295
 Martorana G, 2361, 5205
 Maruyama N, 5617
 Marx A, 4975
 Masachika E, 887
 Masci G, 4603
 Mason MD, 199
 Massa M, 4509
 Massaccesi M, 2785, 4585
 Massari F, 3705
 Mastronuzzi A, 3515
 Masuda M, 4811
 Masui K, 3963, 5687
 Mathiesen T, 1131
 Matsuda E, 2971
 Matsuda Y, 3335, 3947
 Matsui D, 1013
 Matsui K, 175
 Matsui T, 2977
 Matsui Y, 5193
 Matsuki K, 1629
 Matsumoto Hideo, 4319, 5557
 Matsumoto Hirofumi, 2107
 Matsumoto Kazuko, 469
 Matsumoto Keiji, 5575, 5649
 Matsumoto Y, 4727
 Matsumura T, 1927
 Matsunari I, 4741
 Matsunobu T, 3285
 Matsuo K, 5585
 Matsusaka S, 3905
 Matsuura K, 3105, 5043
 Matsuura N, 5597
 Matsuyama R, 5585
 Matsuyama T, 2867
 Matsuzaki T, 1379
 Matsuzawa T, 4627, 5051, 5591
 Matteucci E, 29
 Matthay KK, 755
 Matthew S, 5349
 Mattiucci GC, 2785, 4585
 Mattova J, 1563
 Mattsson L, 1131
 Matussek A, 3247, 4947
 Mauad EC, 2651
 Mauro L, 4847
 Maushagen R, 2481
 Mauz-Körholz C, 4791
 Mavrou A, 3369
 Maybury BD, 3543
 Mayer F, 791
 Mayerson JL, 2597
 Maziere J-C, 1415
 Mazur L, 4439
 Mazza F, 2593
 Mazzocca A, 1491
 Mazzucchelli R, 5017
 Mazzucco M, 1221
 McCune DF, 4163
 McHugh B, 4255
 McKenzie R, 393
 McLaughlin B, 4475
 McNamara KM, 4811
 Mediero B, 5159
 Meert A-P, 5477
 Mege D, 5645
 Mehta K, 1777
 Mei W, 5407
 Meirelles OC, 5625
 Melano A, 4557
 Melhus KB, 85
 Melichar B, 1201, 4097, 4999
 Meltzer SJ, 5199
 Mendes FB, 4463
 Mendez JC, 4089
 Méndez Méndez C, 717
 Meng X, 1337
 Menghetti C, 3383
 Meregalli C, 5453
 Merkel S, 559
 Merry S, 4381
 Mertlíková-Kaiserová H, 3163
 Merz H, 4771
 Mesa J, 337
 Meszaros P, 4509
 Metellus P, 2159, 5645
 Mette M, 2881, 2917
 Metterlein T, 3201
 Mian M, 3831
 Micaily B, 4491
 Michalak K, 857
 Michaud A, 2569
 Mignogna S, 2785, 4585
 Mihara H, 5107
 Mihola E, 881
 Mii S, 107, 1361, 1373, 3021, 3041
 Mikami R, 1157
 Miki Y, 4811
 Milanese ML, 3503
 Milazzo GN, 29
 Milczarek M, 433
 Milillo A, 4657
 Mimori K, 1927
 Min HS, 4833
 Min H-Y, 4751
 Min J-J, 2135
 Minami S, 5535
 Minardi D, 5017
 Minarik M, 1705, 3397
 Minato K, 4631
 Minegishi Y, 1117
 Minemura M, 5107
 Minomo S, 1163
 Minowa S, 3905
 Mirabelli D, 2679
 Miron T, 837
 Mironczuk R, 1141
 Mirza Z, 4779
 Misaki N, 1107
 Misawa K, 1099
 Misawa T, 705, 1697, 2715, 2723, 3439, 4041, 5005
 Misch M, 2093
 Mischinger H-J, 991
 Mischo A, 4189
 Mitsuhashi N, 4337
 Mitsuoka K, 4741
 Miura Kiyotaka, 261
 Miura Koh, 685
 Miwa S, 1361, 1373, 3041, 4497
 Miyagawa S, 4431
 Miyake S, 1679
 Miyake T, 5617
 Miyamoto S, 2855
 Miyanaga A, 1117
 Miyasho T, 3653
 Miyata G, 1463
 Miyata K, 2855
 Miyata M, 1547
 Miyata Y, 1761
 Miyazaki K, 113, 3775
 Miyazaki M, 1935
 Miyazaki T, 5113
 Miyoshi S, 4741
 Mizobe T, 2839, 2921, 2929, 2935
 Mizokami A, 1147, 3837, 4453, 4497, 4669, 5501
 Mizokami Y, 4995
 Mizunuma N, 3905
 Mizutani H, 1117
 Mocellin S, 4081
 Mochiki E, 4627, 5051, 5591
 Mochizuki K, 5357
 Modrzycka T, 857
 Modzelewski R, 5655
 Moerman P, 3855, 5495
 Mohamid W, 3911
 Mohindra P, 2611
 Mohn-Staudner A, 3831
 Mohri Y, 5065
 Mojarad S, 3925
 Mokbel K, 2179, 2185
 Mol JA, 1819
 Molin M, 477
 Molina R, 5633
 Molinaro AM, 755
 Molino A, 3705
 Mollatt CS, 85
 Molnar J, 2021
 Momiyama M, 97, 103, 107, 1367, 1747, 3021
 Momose Y, 3145
 Momynaliev K, 4049
 Monbaliu J, 5453
 Mongan NP, 2381, 5235
 Monnier L, 1661
 Montagna B, 1221
 Montes AF, 4089
 Montesco MC, 3989, 4081
 Monti F, 3925
 Montironi R, 5017
 Moon SI, 3089
 Moore BJ, 1799
 Moore TB, 2047
 Moossa AR, 3041
 Morabito A, 2707
 Moreau L-C, 1765
 Morein B, 143

- Morel F, 639
Morganti AG, 2785, 4585
Mori K, 3279
Mori Masaki, 1927
Mori Masatomo, 895
Mori R, 5585
Mori T, 485
Mori Y, 5199
Mori A, 575
Mori T, 5357
Morimoto J, 4237
Morimoto M, 997
Morimura R, 2577, 3461, 4023, 5097
Morinaga T, 5301
Morisaki T, 1387
Morishita K, 1893
Morita M, 1641
Moritz R, 5249
Moriwaki H, 4229
Moriwaki T, 4995
Moriya S, 997
Moriyama M, 175
Morota M, 4989
Morris J, 5325
Morrone A, 2153
Moscarini M, 29, 917
Mosconi C, 2747
Moseley VR, 5325
Mosiądz D, 857
Mostofizadeh N, 2997
Motegi A, 4337
Motohashi H, 4309
Motoi N, 3327
Motoyama T, 5603
Moulay M, 5421
Mourad WF, 4927, 5511, 4483
Mourati A, 1209
Mowla SJ, 5365
Möykkynen K, 2623
Mozet C, 2415
Msaouel P, 2441
Muallem MZ, 1673, 3375, 3449
Mucsi I, 2021
Mueller S, 755
Muff R, 1297
Muguruma K, 595, 1635, 5023, 5031, 5567
Muinelo-Romay L, 5295
Mukai H, 2881
Mukai Shoichiro, 1023, 1893
Mukai Shumpei, 277
Mukerjee A, 3603
Mukozy T, 1013
Mulders P, 553
Muldoon LL, 2391
Müller J-MV, 1325
Müller MH, 3069
Müller SC, 779, 4651, 5249
Mun AR, 3691
Munck-Wikland E, 1575
Munemoto S, 5681
Munkarah AR, 4983
Muñoz A-B, 5091
Munoz DG, 119
Muñoz E, 3799
Munz M, 5243
Murakami G, 2107
Murakami Haruaki, 4319, 5557
Murakami Haruyasu, 3279
Murakami Haruyasu, 4219
Murakami Hidetsugu, 2949
Murakami Hiroki, 4299
Murakami M, 2635
Murakami N, 4989
Murakami Y, 4741
Muramatsu K, 4175, 5075
Murata R, 5681
Murayama S, 2199
Murayama Y, 1621, 1689, 2577, 2699, 3461, 4023, 5097
Murelli F, 4509
Muro K, 3845
Murotani K, 2949
Murphy ES, 3251
Murray D, 4255
Musio D, 4013
Musso R, 489
Muszczyńska-Bernhard B, 965
Mutalip SSM, 4365
Muto J, 5193
Muto P, 1135
Mutoh M, 3667
Mutti A, 5517
Muzzonigro G, 5017
Myerson RJ, 4557
Myoung E, 4129
Myung D-S, 2135
Nadeau-Larochelle C, 2569
Nagahara H, 1635, 3291, 3301, 5023, 5031, 5567
Nagai H, 1013
Nagai M, 3355
Nagai Y, 2199, 5123
Nagakawa O, 575
Nagamata M, 5057
Nagamune H, 2901, 2905
Nagao M, 685
Nagaoka M, 1379
Nagase H, 3431
Nagashima Akira, 1649
Nagashima Atsushi, 3423
Nagashima K, 309
Nagata H, 271, 3185
Nagata T, 175
Nagata Y, 2123
Nagayasu T, 2107, 2689
Nagayoshi Y, 267
Nagle RB, 4203
Nair JS, 1307
Naito M, 3259
Naito T, 3279, 4219
Naitoh K, 2971
Nakada-Kubota R, 5193
Nakagawa Kazuhiko, 5699
Nakagawa Keiichi, 4959
Nakagawa Yasuo, 5023
Nakagawa Yoshinori, 2911
Nakai Y, 2619
Nakajima K, 5681
Nakajima Masanobu, 5113
Nakajima Motowo, 2861
Nakajima S, 5011
Nakajima T, 3279, 4219
Nakajima TE, 309
Nakajima Y, 3355
Nakamoto T, 5123
Nakamura Katsumasa, 1649, 5575, 5649
Nakamura Katsuya, 3699
Nakamura Kazunori, 583
Nakamura Kazuyuki, 153, 2557, 3133, 3661, 4821
Nakamura Kogenta, 5043
Nakamura Masafumi, 267, 5557
Nakamura Masahumi, 4319
Nakamura R, 3653
Nakamura Satoaki, 643, 1679, 1685, 1773, 2453, 3963, 5507, 5561, 5675, 5687
Nakamura Shiro, 3667
Nakamura T, 4515
Nakamura Yasuhiro, 1463
Nakamura Yukiko, 5617
Nakanishi H, 4299
Nakanishi M, 1621, 1689, 2577, 2699, 3461, 4023, 5097
Nakanishi Y, 485
Nakano K, 4811
Nakano M, 997
Nakano S, 1861
Nakano Takashi, 887
Nakano Toru, 1463
Nakao S, 5681
Nakashima H, 267, 4319
Nakashima M, 4049
Nakashima N, 1107
Nakashima S, 461, 4329, 5415
Nakashima T, 5561
Nakata K, 2849
Nakatani T, 5535
Nakatomi K, 3327
Nakatsugawa M, 167
Nakayama H, 1157, 1629
Nakayama K, 113, 3775
Nakayama N, 113, 3775
Nakayama S, 113
Nakayama T, 5617
Nakazawa E, 167
Nakazawa T, 1881, 4841, 5311
Nako Y, 4329, 5415
Nam D-H, 5335
Nam J-H, 1029
Nam SO, 2823, 2855
Nam SY, 1237
Namiki M, 1147, 3837, 4453, 4497, 4669, 5501
Nanashima A, 2107, 2689
Naoi Y, 5617
Nara N, 809, 3099, 4293
Narayanan G, 2077
Narjoz C, 3977
Narui K, 5119
Naruse T, 4841
Näsman A, 1575
Nasole E, 4827
Nassir M, 1673
Natali PG, 3195
Nathan I, 183
Naumann DN, 1717, 3935
Naumann U, 1351

- Navarria P, 4537
 Nazih H, 3783
 Negoro E, 3335, 3947
 Negri FV, 725, 4611
 Neis F, 711
 Nejc D, 3205
 Neki K, 1769
 Nekvasil M, 1563
 Nencka R, 3163
 Neto RA, 647
 Neuwelt AJ, 2391
 Neuwelt EA, 2391
 Nevill A, 1717
 Newbold RF, 2179, 2185
 Ng J, 2175
 Ng VY, 2597
 Ng-Bonaventure K, 133
 Ngezahayo A, 5421
 Ngollo M, 39
 Nguyen DM, 2401
 Ni M, 3815
 Niba J, 3989
 Nicholl MB, 1799
 Nieddu V, 871
 Niemelä S, 45
 Niespolo R, 4557
 Niho S, 1175
 Niidome T, 485
 Niimi A, 1935
 Nikander R, 1595
 Ninomiya H, 3327
 Nishi K, 3145
 Nishida H, 2169
 Nishida S, 1439
 Nishiguchi Y, 3291
 Nishikata I, 1893
 Nishikata T, 2867
 Nishikawa G, 5043
 Nishikawa H, 1181, 2211
 Nishikawa J, 5107
 Nishimura R, 3891
 Nishimura S, 4741
 Nishimura Taku, 2629
 Nishimura Takuya, 1679, 1685, 1773, 2453, 5507, 5675
 Nishimura Yasumasa, 5699
 Nishimura Yukihisa, 1621
 Nishina S, 5699
 Nishio J, 3259
 Nishio K, 469
 Nishio M, 3327
 Nishiofuku H, 3355
 Nishiyama H, 4785
 Nishiyama Y, 3891
 Nishizaki T, 887
 Nishizawa H, 3327
 Nisman B, 293
 Nisyrios T, 4033
 Nitti D, 3989, 4081
 Nkenke E, 4033
 No JH, 5135
 Nobili F, 917
 Noda A, 4741
 Noda E, 1635, 3291, 3301, 5031
 Noda K, 3745
 Noda M, 2779, 3745
 Noda S, 3445
 Noël G, 1845
 Nogami N, 4631
 Nogi S, 1157
 Noguchi S, 5617
 Noh WC, 4073
 Nojiri K, 5585
 Nolte I, 1325, 5421
 Nomori H, 3791
 Nomura H, 3105
 Nomura K, 1117
 Nonogaki S, 3969
 Nonoshita T, 1649
 Noro R, 1117
 Nørøxe DS, 3275
 Notarnicola M, 3739
 Note M, 5107
 Nottegar A, 3705
 Novak P, 4855
 Nowak-Markwitz E, 5375
 Nowinski D, 3113
 Nozaki A, 997
 Nudelman Z, 661
 Nuhn P, 5249
 Numata K, 997
 Nurkina Z, 4049
 Nuzzo M, 4557
 Nuzzo PV, 815
 Nygren P, 143
 O'Gorman K, 3911
 O'Reilly EM, 3241
 Oba MS, 5187
 Obata S, 1881
 Obayashi T, 5165
 Obiols G, 337
 Ocak M, 1537
 Och W, 5343
 Ochi T, 2921
 Ochiai A, 567
 Ochiai T, 537, 1483, 1689, 2699, 4023, 5097
 Odaka N, 277
 Odate S, 3699
 Ofude M, 4453, 4669, 5501
 Ogasawara S, 5603
 Ogata Y, 2949
 Ogawa H, 685
 Ogawa Kazuhiko, 747, 2199
 Ogawa Kohei, 5107
 Ogawa M, 1697, 2723
 Oggioni N, 5453
 Ogino I, 5187
 Ogo E, 5561
 Oguri T, 1935
 Ogushi F, 4631
 Oh B-K, 821
 Oh HC, 3089
 Ohchi T, 2935, 2965
 Ohde Y, 4219
 Ohe M, 261
 Ohe Y, 1175
 Ohga S, 1649, 5575, 5649
 Ohira M, 595, 1635, 5023, 5031
 Ohkubo H, 1935
 Ohkubo Y, 2905
 Ohkuma M, 2723, 5011
 Ohkura K, 2901, 2905
 Ohmatsu H, 1175
 Ohmori H, 3295
 Ohmura M, 3791
 Ohnishi H, 5357
 Ohno H, 3061
 Ohno K, 5317
 Ohno S, 2875
 Ohnuma S, 685
 Oh-Oka H, 3837
 Ohri N, 4927
 Ohshima K, 2929
 Ohtaka K, 5193
 Ohtani H, 1635, 3291, 3301, 5023, 5031
 Ohtsuka K, 5357
 Ohtsuka T, 267
 Ohuchi N, 1463, 4811
 Ohyanagi F, 3327
 Oike R, 809
 Ojima H, 5113
 Oka M, 2629, 3423
 Oka S, 2123
 Oka Yasuo, 4319
 Oka Yousuke, 2839, 2887, 2921, 2929, 2935
 Okabe H, 1679, 1685, 2453, 5507, 5675
 Okada F, 153, 3661
 Okada K, 3431
 Okada M, 1761, 3495
 Okada N, 4627
 Okaichi K, 923
 Okamoto H, 1463
 Okamoto I, 5699
 Okamoto Kazuma, 271, 461, 537, 1483, 1621, 1689, 2577, 2699, 3185, 3461, 4023, 4329, 4645, 5097, 5165, 5415
 Okamoto Kunio, 5699
 Okamoto S, 5193
 Okamura H, 537, 1483
 Okamura S, 537, 1483
 Okamura T, 5057
 Okano T, 1117
 Okayama N, 3423
 Oki E, 1641
 Okimoto K, 5603
 Okimoto T, 261
 Okishio K, 1163
 Okubo M, 1157
 Okuda M, 5597
 Okugawa Y, 5065
 Okuhashi Y, 809, 3099, 4293
 Okuma Y, 5057
 Okumura H, 4319
 Okumura T, 175
 Okumura Y, 3891
 Okuno K, 1439
 Olsasz L, 1511
 Olivares A, 3217
 Oliveira DT, 3969
 Oliveira PA, 1273
 Olow A, 755
 Olszewski U, 2021
 Omori M, 4959
 Omoto T, 277
 Omura N, 5011
 Omura T, 175
 Onishi H, 1387, 3699
 Onizuka S, 2911
 Ono Akira, 3279
 Ono Aya, 809, 3099
 Ono HA, 697, 1747
 Ono Minoru, 1649

- Ono Misaki, 1861
 Onoda N, 3445
 Oobu M, 5603
 Ooka Y, 5603
 Oota Y, 1679, 2453, 5675
 Ooyama T, 5123
 Opendakker G, 1899
 Oppermann E, 5243
 Oprea-Lager DE, 387
 Opydo-Chanek M, 4439
 Orbach S, 755
 Orito M, 3837
 Orlando A, 4951
 Orsós Z, 341
 Orywal K, 3725
 Osaka Y, 1157
 Osaki Y, 1181, 2211
 Osako T, 3891
 Oshima CT, 647
 Oshima T, 697, 1747
 Oshiro Y, 1629
 Osterlund P, 253
 Osti MF, 1229
 Oszczapowicz I, 4439
 Ota M, 697, 5585
 Otani H, 5567
 Otani Y, 5617
 Otowa Y, 4515
 Otsu H, 1641
 Otsuji E, 271, 461, 537, 1483,
 1621, 1689, 2577, 2699,
 3185, 3461, 4023, 4329,
 4645, 5097, 5165, 5415
 Otsuka K, 625
 Otsuki Y, 113
 Ott G, 1609
 Ouaiissi M, 5645
 Ove R, 2175
 Owen S, 199
 Oya T, 575
 Oyama S, 2689
 Ozasa H, 1935, 2629

 Pace MB, 2587
 Pacetti U, 1721
 Paesmans M, 5477
 Pagliacci A, 2737
 Paglino C, 4999
 Pahle E, 3269
 Paić F, 2509
 Paik WH, 1473
 Pajkos G, 1511
 Pála M, 4097
 Palakurthi S, 2425
 Pálföldi R, 1737
 Palma F, 1491
 Palmieri G, 871
 Palmqvist E, 2447
 Paloheimo L, 4595
 Palumbo P, 2147
 Palva T, 1595
 Pan L, 5349
 Pan S-L, 425
 Panayiotidis P, 3509
 Panda CK, 1215
 Pandis N, 191
 Panebianco V, 5663
 Pang S-T, 2605, 4875
 Pangalis G, 3509, 5693
 Pani G, 4557
 Panis C, 737
 Pannier D, 2057
 Pannullo SC, 3899
 Panosyan EH, 2047
 Panotopoulou E, 4007, 4573
 Papadopoulou V, 3509, 5693
 Papaleo R, 3925
 Papanikolaou V, 1977
 Papotti M, 2679, 4657
 Paquette B, 3005
 Paradiso A, 1491
 Parajuli B, 1457
 Pardo L, 865
 Parhofer KG, 287
 Paridaens A, 4683
 Park CH, 2499
 Park C-K, 5179
 Park G, 1237
 Park H, 2541
 Park H-C, 2135
 Park HJ, 2205
 Park I-C, 4073
 Park JC, 2115
 Park J-H, 1237
 Park JK, 1473
 Park JM, 2541
 Park JO, 4619
 Park JS, 513, 3233
 Park JW, 1731
 Park J-W, 847
 Park JY, 3233
 Park J-Y, 4675
 Park Keunchil, 5127
 Park Kwonoh, 5667
 Park MJ, 4833
 Park M-S, 3983
 Park SH, 4619
 Park SK, 3089
 Park So Young, 2755
 Park Suk Young, 2115
 Park Sung Young, 1731
 Park W, 4675
 Park W-J, 1457
 Park WS, 4357
 Park Y-A, 3177
 Park Y-B, 2755
 Park YM, 4421
 Park YS, 4619
 Pasqual EM, 1041
 Pasquali S, 3989, 4081
 Pass H, 1247
 Passaretti G, 2361
 Passera R, 4657
 Pašukonienė V, 2099
 Patczai B, 2561
 Patel FB, 4001
 Patel S, 619, 4483, 4927
 Pathak S, 1777
 Patsouris ES, 1209
 Paulsen JE, 477
 Paulsson G, 1003
 Peereboom DM, 3251
 Pei J-S, 5395
 Peir J-J, 4799
 Peled N, 5151
 Pelleggrinelli A, 1257
 Pellegrino M, 4847
 Pellise M, 5633
 Pellón ML, 4089
 Peltier J, 5645
 Pennisi M, 1195
 Penttinen HM, 1595
 Pepe P, 1195
 Pereira MC, 3969
 Pereira T, 2549
 Perera F, 2227
 Peres A, 283
 Peretz T, 293
 Perić Balja M, 2509
 Perissinotti AJ, 2587
 Perkins J, 2797
 Perotti B, 2147
 Perreti I, 283
 Perri F, 1135
 Perrone F, 1257
 Perry-Keene J, 615
 Perseus JM, 3415
 Persky MS, 5511
 Persson JL, 363, 2381, 5235
 Pesek M, 1705, 3397
 Pesta M, 2239
 Peters S, 4921
 Petersen TI, 3269
 Peterson CM, 1317
 Petraki C, 2441
 Petrausch U, 4189
 Petri E, 1591
 Petruzella L, 2657
 Pezzi R, 2707
 Pfannerstill A-C, 2481
 Pfeiffer S, 5273
 Pfragner R, 1267
 Phenekos C, 4901
 Philippe L, 133
 Photiou A, 53
 Piaskowski S, 5343
 Piatkowska M, 1189
 Picardi V, 2785, 4585
 Picci N, 4847
 Pichler M, 4591
 Pichler R, 5525
 Pierce JS, 77
 Pierce ML, 2587
 Piermattei A, 2785
 Pierotti MA, 1257
 Piessen G, 1603
 Pietrantonio F, 1257
 Pietrini A, 691
 Pietropaolo F, 1195
 Pilati P, 3989, 4081
 Pinelli C, 3467
 Pinto-Leite R, 1273
 Pircher A, 3831
 Pires I, 1397
 Pisano M, 871
 Pistelli M, 2737, 5017
 Pistillo MP, 2707
 Pitule P, 4855
 Plačková P, 3163
 Plaibua K, 3079
 Plant A, 2047
 Plíšek J, 4097
 Pluschnig U, 1035, 3455
 Podhorska-Okolow M, 965,
 1447, 5375
 Podlech O, 1351
 Poggi G, 1221
 Pogorzala M, 1189
 Poła A, 857
 Polberg K, 4347
 Polizos A, 3475
 Polonifi K, 3475, 5693

- Polychronis A, 3911
 Polychronopoulou S, 3369
 Pommergaard H-C, 3033, 4767
 Pongrakhananon V, 3079, 5433
 Popov A, 4445
 Popov D, 4531
 Popp SL, 2473
 Porpiglia F, 2679
 Porta C, 3487, 4999
 Porzio R, 1061
 Postlmayr U, 4591
 Pouckova P, 1563
 Poulsen HS, 1657
 Powan P, 505
 Prabhakar D, 4139
 Pracht M, 3871
 Prager G, 2085
 Precht C, 4567
 Prelewicz S, 4163
 Preusser M, 1035, 1065, 3455
 Pries R, 2481
 Prignon A, 3015
 Prins RM, 2047
 Priolo G, 1195
 Procopio G, 4999
 Proietti F, 691
 Provencher L, 2569
 Provenzano S, 679
 Pruvot F-R, 1603
 Psurski M, 433
 Pucci F, 725
 Pucci-Minafra I, 489
 Pula B, 965, 1447, 5375
 Pultrone CV, 5205
 Pupillo F, 3503
 Purim O, 5151
 Purisa S, 2643
 Püspök A, 3455
 Pyrhönen S, 3137

 Qi M, 409
 Qin W, 3861
 Quaranta M, 1491
 Queiroga FL, 1397
 Quint RM, 941
 Quintero Aldana G, 717
 Quintero G, 4089
 Quirico-Santos T, 5625
 Qureshi MS, 401

 Raderer M, 3341
 Rades D, 2481, 3887, 4505
 Radolf T, 1537
 Rafael S, 5159
 Ragnarsson C, 167
 Ragos V, 4033
 Rahman M, 113, 3775
 Rahman MT, 113, 3775
 Rahmaniyan M, 77
 Raica M, 957
 Raj HM, 231
 Rajan R, 1765
 Rajani R, 665
 Rajappa P, 3899
 Rajkumar A, 4545
 Rak J, 1429
 Rakhypbekov T, 4049
 Rakusan J, 1563
 Rall K, 711
 Ramachandran K, 4521
 Ramanculov E, 4049
 Ramić S, 2509
 Ramos M, 4089
 Ramos Vázquez M, 717
 Rampini P, 3383
 Ramqvist T, 1575
 Randén M, 5639
 Randone DF, 4657
 Rangger C, 1537
 Ranjan AP, 3603
 Ranson M, 1053
 Rao GS, 2535
 Rao S, 2797
 Raoul J-L, 3871
 Raptakis T, 2369
 Raptis L, 4401
 Raskov H, 3033, 4767
 Rassl D, 3911
 Rastrelli M, 3989, 4081
 Rathjens M, 4975
 Rau K-M, 1169, 5543
 Rauhala HE, 45
 Ravaioli A, 3925
 Rea D, 1717
 Reboredo M, 717, 4089
 Rech F, 3467
 Reece TB, 1337
 Reed D, 3119
 Reed E, 929, 1421
 Reeh M, 4975
 Reers S, 2481
 Reggiori G, 4537
 Regimbeau J-M, 1415, 5645
 Reinhard J, 371
 Reis IM, 4521
 Reiss SE, 1829
 Renner C, 4189
 Renninger M, 5243
 Renzulli M, 2747
 Repetto-Llamazares AHV, 85
 Ress AL, 4591
 Rew JS, 4129
 Reyes J, 2797
 Reynoso J, 3041
 Rha SY, 821, 2499
 Rhodes A, 4395
 Ribatti D, 957
 Ribeiro AL, 2549
 Ribeiro DA, 647
 Ribeiro V, 2549
 Riccardi A, 1221
 Ricchio E, 4847
 Ricci F, 815
 Ricciardi E, 29
 Richter R, 1673, 3375
 Riecke B, 1757, 3917
 Rieske P, 5343
 Riezzo G, 4951
 Rigal O, 5655
 Righi L, 2679
 Rinner B, 1267
 Riva G, 1221
 Ro J, 2467
 Robins HI, 2611
 Robinson BD, 2381, 5235
 Rockwell S, 355
 Rodrigo GC, 3799
 Rodriguez C, 5633
 Rodriguez G, 2743
 Rody A, 1125
 Rody A, 371
 Roh JK, 2499
 Roh J-L, 1237
 Rohrer K, 1267
 Rom WN, 1247
 Romagnoli D, 2639, 5205
 Roman E, 837
 Romanitan M, 1575
 Römer A-M, 1525
 Romero C, 4089
 Romero Reinoso C, 717
 Romero S, 3995
 Roncella S, 2707
 Roncoroni L, 725
 Ronot X, 4445
 Rösel F, 1525
 Rosenberg J, 3033, 4767
 Rosetto ME, 4557
 Rosińska S, 433
 Rossi CR, 3989, 4081
 Rossi G, 1061
 Rota IA, 1351
 Rota S, 4603
 Rotarski M, 301
 Rother J, 1081
 Rothmund R, 711
 Roussel H, 3977
 Rouzier R, 1661, 3015
 Rowan BG, 4213
 Roychoudhury S, 1215
 Rozkoš T, 1201
 Rozumová N, 3163
 Rozzo C, 871
 Rubagotti A, 815
 Rubin K, 3113
 Rubio CA, 665, 1131, 1743, 5471
 Ruckhäberle E, 371
 Runesdotter S, 5639
 Ruohola J, 1595
 Rusius V, 1717
 Russo F, 4951
 Russo S, 2175
 Russowsky D, 4463
 Ruterbusch J, 4983
 Rutteman GR, 1819
 Ryang D-W, 2011
 Rymowicz W, 1569
 Ryniak M, 5511
 Ryu Y, 2941

 Saab AM, 3027
 Saarto T, 1595, 4933
 Sabbagh C, 1415
 Sabbatini R, 4999
 Saczko J, 857
 Sadahiro S, 3431
 Sadamoto K, 2861
 Sadaria MR, 1337
 Sader R, 3347, 4017
 Sadjak A, 1267
 Saeed A, 4213
 Saeki H, 1641
 Sahmanovic A, 881
 Saif MW, 1713, 1753, 2175, 2377, 2743, 4001
 Saigusa S, 5065
 Saikawa Y, 3653
 Saito H, 5043
 Saito M, 2957

- Saito N, 505
Saito R, 4995
Saitou R, 1163
Saji S, 4229
Saka E, 167
Sakagami H, 453, 3061
Sakai M, 5113
Sakaida I, 4821
Sakakura C, 537, 2577, 3461, 4023, 5097
Sakamoto N, 2917
Sakatani T, 3327
Sakumi A, 4959
Sakurai K, 1635, 5023, 5031, 5567
Sakurai M, 4811
Sakurazawa A, 3145
Sala B, 5453
Šála M, 3163
Salagierski M, 553
Salama S, 4779
Salbego CG, 4463
Salehi F, 119
Salgado Fernández M, 717
Salgado M, 4089
Salvati M, 4013
Sameshima S, 3845
Samonigg H, 4591
Samuel T, 1519
Sanche L, 3005
Sand L, 4325
Sandalcioglu IE, 609
Sandanger TM, 5483
Sanders AJ, 199, 1499, 3123, 3815
Sandomenico F, 1135
Sandvold ML, 3615
Sanidas E, 1667
Sano A, 5113
Sano T, 1099
Sanpaolo P, 4557
Šantak G, 2043
Šantak M, 2043
Santeufemia DA, 1041, 2593
Santinelli A, 2737
Santoni M, 5017
Santoro A, 4603
Sarda-Mantel L-E, 283
Sasaki H, 4741
Sasaki K, 5301
Sasaki Takamitsu, 3295
Sasaki Takashi, 2619
Sasaki Takeshi, 5119
Sasaki Tomikazu, 123
Sasaki Tomonari, 1649, 5575, 5649
Sasano H, 1463, 4811
Sasatomi T, 2935
Sassu I, 871
Sastre B, 5645
Sato A, 1463
Sato E, 3775
Sato N, 167
Sato T, 975
Sato Y, 5301
Satodate H, 277
Satoh T, 3845, 5699
Satoh Y, 2619
Satomi K, 5357
Satou T, 1439
Sauerwald A, 731
Sauter A, 1951, 2457
Sauter ER, 3861
Sauter G, 4975
Saviano M, 871
Savino E, 1491
Savvani A, 2441
Sawada G, 1927
Sawada S, 175
Sawada T, 595
Scandolaro L, 4557
Scarpa A, 3705
Scarpa RM, 4657
Scartozzi M, 4611, 5017
Schaberl-Moser R, 4591
Schalken JA, 553
Schantz S, 5511
Scharschmidt TJ, 2597
Scheithauer BW, 119
Scherpereel A, 5477
Scheuer HA, 1081
Schiavina R, 2361, 2639, 5205
Schild SE, 3887, 4505
Schildhaus HU, 1971
Schilling D, 5243
Schinköthe T, 2491
Schittl H, 941
Schlichting U, 1585
Schlomm T, 5249
Schmeel FC, 4719
Schmeel LC, 4719
Schmid R, 2085
Schmid RA, 5365
Schmid SC, 3731
Schmidinger M, 4999
Schmidt A, 2491
Schmidt-Wolf IGH, 2435, 4719
Schmitz JC, 4475
Schnabel PA, 981
Schneeweiss A, 3407
Schneider J, 5091
Schoppmann SF, 1035, 1065, 2085, 3455
Schrembs D, 5273
Schrom T, 1141
Schuberth PC, 4189
Schuck AG, 1829
Schuetz F, 3407
Schult C, 445
Schulten H-J, 4779
Schultz JD, 1951, 2457, 5385
Schulz C, 287
Schuster T, 3731
Schwab M, 1609
Schwameis K, 1035, 2085, 3455
Schwartz GK, 1307
Schwartz TH, 3899
Schwarz AM, 4791
Schweiger LF, 4267
Sciacero P, 4557
Sciarra A, 5663
Scorsetti M, 4537
Scott KA, 4373
Scott S, 53
Sculier J-P, 5477
Sebens S, 1525
Secco DE, 3515
Šegedin B, 3887
Sehouli J, 1585, 1673, 3375, 3449
Seidel K, 4791
Seike M, 1117
Sekihara K, 5057
Sekine S, 175
Selenti N, 3369
Senda Y, 1099
Seo Y, 747
Seo YR, 3645
Seok H, 2205
Seol H, 4073
Seol HJ, 5335
Seong M-K, 4073
Seong S, 4913
Separovic D, 77
Sergent-Baudson G, 1603
Serizawa M, 5223
Serra A, 3515
Sesterhenn AM, 249
Seto S, 5075
Setojima K, 2929
Sha H, 4103
Shackelford R, 3047
Shah A, 3611
Shah M, 619
Shah MM, 801
Shah S, 4373
Shan C-J, 3169
Shang H-S, 4867
Sharma A, 3911
Sharma AK, 2179
Sharma N, 4139
Sharma S, 119
Shasha D, 4483, 5511
Sheen-Chen S-M, 1169
Sheets TP, 1989
Sheikh T, 1307
Shen Q, 5349
Shen Wen-Chi, 3317
Shen Wu-Chung, 5401
Sherbet GV, 3925
Sherr DL, 3899
Shi Y, 409
Shiba H, 705, 1697, 2715, 2723, 3439, 4041, 5005
Shibasaki H, 567
Shibata C, 685
Shibata E, 4237
Shibata Harumi, 3905
Shibata Hideki, 2689
Shibata Hiroyuki, 625
Shibata K, 4631
Shibata M-A, 4237
Shibata N, 1023
Shibata-Kobayashi S, 4959
Shibutani M, 3291, 3301, 5023, 5031, 5567
Shibuya H, 317
Shieh S-H, 2729
Shiga T, 5193
Shigematsu Y, 2123
Shih L-C, 3391
Shih T-C, 4907
Shih Y-L, 4867
Shiled A, 3611
Shim Y-H, 821
Shimada K, 5119
Shimada Yasuhiro, 309, 2129, 4547
Shimada Yutaka, 175

- Shimamura M, 3837
 Shimazu K, 5617
 Shimizu D, 5119
 Shimizu H, 4329, 5415
 Shimizu R, 2629, 3423
 Shimizu Y, 1099
 Shimoda M, 5617
 Shimomura A, 5617
 Shimoyama Y, 997
 Shin HP, 3983
 Shin M, 4453
 Shin M-G, 2011
 Shin S-J, 1457
 Shin SJ, 2499
 Shin TR, 2755
 Shin Y-S, 2001, 3715
 Shinohara S, 2123
 Shinoto M, 5579, 5649
 Shinozaki E, 3905
 Shintani S, 4309
 Shinya S, 3295
 Shiogama S, 4309
 Shiono O, 5187
 Shiotani A, 3285
 Shioyama Y, 1649, 5575, 5579, 5649
 Shiozaki A, 271, 461, 537, 1483, 1621, 1689, 2577, 2699, 3185, 3461, 4023, 4329, 4645, 5097, 5415
 Shiozaki H, 1439
 Shiozaki T, 1073
 Shirai Y, 5005
 Shirasawa S, 2833
 Shirasu N, 2823, 2855
 Shirataki Y, 453
 Shiratsuchi I, 2887, 2929, 2941
 Shirouzu K, 2839, 2887, 2921, 2929, 2935, 2941, 2949, 2965
 Shishido Y, 1379
 Sho M, 3355
 Shoda K, 3185, 4645
 Shourbaji RA, 4483, 4927, 5511
 Shpilberg O, 183
 Shukuya T, 3279
 Siakantaris MP, 3509, 5693
 Siddiqui F, 619
 Siegfried JM, 4475
 Sielezneff I, 5645
 Siffert W, 609
 Sigurdson AJ, 543
 Sihomi H, 1773
 Silini EM, 4611
 Silkenstedt B, 1351
 Silva F, 1397
 Silva JCT, 5625
 Sim DW, 4129
 Simoens C, 3359
 Simon H, 301
 Simon R, 4975
 Simone G, 1491
 Singal R, 4521
 Singh NP, 4389
 Sinha AA, 3635
 Sintler M, 1717, 3935
 Sivoilella S, 1793
 Skalicka-Wozniak K, 4347
 Skaradzinski G, 1569
 Skarstedt M, 3247, 4947
 Skelton IV WP, 785, 2409
 Skelton M, 785, 2409
 Skiba M, 5375
 Slamon DJ, 2997
 Slawek A, 1569
 Smeets R, 3917
 Smetanay K, 3407
 Smith C, 3861
 Smith TAD, 4267
 Snoeck R, 1899
 So T, 2123
 Socinski MA, 4475
 Söderström K, 241
 Soeda H, 625
 Soeda S, 4785
 Sofocleous C, 3369
 Sofotasiou M, 5693
 Soga D, 4309
 Soga K, 5165
 Sohda M, 5113
 Sohn I, 5179
 Sohn YJ, 4073
 Soisson AP, 1317
 Solari N, 4509
 Solichová D, 4097
 Soma G-I, 2849, 2875
 Somlai K, 1511
 Sommariva A, 3989, 4081
 Sommer JU, 1951, 2457
 Sommer T, 3269
 Son KR, 223
 Song BJ, 1473
 Song SY, 223, 1237
 Sopracordevole F, 29
 Sorbe B, 241, 1003
 Sørensen JB, 3275
 Sorensen M, 1657
 Sotiriou S, 191
 Soucek P, 4855
 Sougioultzis S, 1209
 Sowter H, 1401
 Spaczynski M, 5375
 Spartalis E, 3475
 Spee B, 1819
 Speer CG, 4521
 Sperk E, 3995
 Sritularak B, 3079
 Staebler A, 711, 2233
 Staeger MS, 4791
 Staib P, 2491
 Stamatian F, 1673
 Stánitz I, 3195
 Stathopoulos E, 3213
 Stebbing J, 53
 Steinbach S, 5213
 Steiner H, 5525
 Steiner T, 3917
 Steininger T, 881
 Stellini E, 1793
 Stenner F, 4189
 Stenzl A, 5243
 Stepulak A, 4347
 Sterenczak KA, 5421
 Sterner O, 3799
 Stern-Sträter J, 1951, 2457, 5385
 Stevens GHJ, 3251
 Stewart CF, 3823
 Stillfried GE, 1053
 Stitt L, 2227
 Stockhammer F, 2093
 Stoczynska-Fidelus E, 5343
 Stoehr M, 2415
 Stoffels M, 2093
 Stöhr B, 5525
 Stohr E, 2797
 Stojak M, 4439
 Stope MB, 2473, 4921
 Storka A, 3629
 Stotz M, 4591
 Stöver T, 913, 3347, 3481, 4017
 St-Pierre C, 2569
 Strang P, 5639
 Strassmann G, 249
 Strauss A, 1525
 Stravopodis DJ, 4007
 Strehler E, 1297
 Streitböcker A, 4921
 Strzdała L, 1429
 Študentová H, 4097
 Studnicka M, 3831
 Stuepp CS, 4463
 Stühmer W, 865
 Styczynski J, 1189
 Su J-M, 3953
 Su S, 1837
 Suda K, 3653
 Sudo T, 1927
 Suematsu M, 3791
 Suenaga M, 1547, 3905
 Suenaga S, 3133, 4821
 Suetsugu A, 103, 107, 1367, 4229
 Sugae S, 5119
 Sugahara S, 1157, 1629
 Sugano K, 5567
 Sugano S, 5317
 Sugie S, 1023, 1893
 Sugihara K, 3845
 Sugimachi K, 1927
 Sugimoto M, 567
 Sugimoto N, 3021, 3623
 Sugita K, 5317
 Sugiyama T, 5107
 Suh DH, 5135
 Suh JH, 521, 3251
 Suk F-M, 3225
 Sulkes A, 5151
 Sumi M, 4989
 Sumi T, 1409
 Sumi Y, 4515
 Sumino Y, 1013
 Sumitomo M, 5043
 Sun J-M, 5127
 Sun MY, 3241
 Sun Yongen, 1317
 Sun Yun, 409, 419
 Sung CO, 1555
 Sung M-T, 3807
 Sung W-W, 2729
 Supernat A, 5461
 Sure U, 609
 Surowiak P, 5255
 Sutani A, 261
 Suthar R, 2077
 Sutoris K, 1563
 Sütterlin M, 1591, 2771, 3403, 3995, 4553
 Suwanborirux K, 505

- Suzuiki N, 2021, 2535
 Suzuki A, 2861
 Suzuki E, 5603
 Suzuki G, 5561
 Suzuki H, 4995
 Suzuki O, 4785
 Suzuki R, 453
 Suzuki Saoshi, 4515
 Suzuki Shigemasa, 5113
 Suzuki Takashi, 4811
 Suzuki Toshiyuki, 3431
 Svane G, 1131
 Svobodník A, 4097
 Swanson SM, 5349
 Swartling T, 325
 Swiderek E, 1429
 Świtalska M, 1429, 1569
 Synesiou M, 191
 Syrigos KN, 2369
 Syrios J, 1209
 Syrjänen K, 2651, 3137, 4595, 5491
 Sysel AM, 4203
 Szabó I, 3119
 Szallasi A, 4545
 Szanyi I, 341
 Szele E, 1511
 Szkandera J, 4591
 Szmítowski M, 3725
 Szulawska-Mroczek A, 3205

 Tabata A, 2901, 2905
 Tabata S, 1547
 Tabata T, 1073
 Tabouret E, 2159
 Tabrizi-Wizsy NG, 1267
 Tachibana I, 5535
 Tachibana S, 1157
 Tada H, 1483, 2699
 Tada Minoru, 2619
 Tada Mitsuhiro, 261
 Tafaro A, 3739
 Taguchi Tetsuya, 1153
 Taguchi Toshihiko, 5075, 4175
 Tahtali A, 913, 3481
 Tai C-J, 5543
 Tai K, 3335, 3947
 Tai P, 2227
 Taillandier L, 3467
 Taillibert S, 2057
 Taira T, 3279
 Tajima T, 5357
 Tajima Y, 1157, 4627
 Takagawa R, 697, 1747
 Takagi Katsunori, 2107, 2689
 Takagi Kazutaka, 3335, 3847
 Takagi Kiyoshi, 4811
 Takahara M, 2971
 Takahara N, 2619
 Takahashi A, 167
 Takahashi K, 2861
 Takahashi M, 697
 Takahashi R, 5501
 Takahashi S, 567
 Takahashi Takao, 5549
 Takahashi Toshiaki, 3279, 4219, 5223
 Takahashi Tsunehiro, 3653
 Takahashi W, 4959
 Takahashi Yoshihito, 583
 Takahashi Yoshiko, 5501
 Takahashi Yoshitaka, 537
 Takahashi Yusuke, 809, 1927, 3099
 Takahata S, 267
 Takai D, 2619
 Takai M, 3335, 3947
 Takakuwa O, 1935
 Takamatsu H, 5681
 Takamatsu K, 2867
 Takamura N, 4049
 Takamura Y, 923
 Takano Y, 1927
 Takasaki M, 2535
 Takashima T, 3445
 Takashina S, 3745
 Takasu H, 167
 Takata S, 1163
 Takatsu N, 2977
 Takayama H, 895
 Takayama K, 485
 Takeda K, 5585
 Takeda M, 5699
 Takehara Y, 277
 Takemoto K, 4329
 Takemura M, 601
 Takenaka M, 2123
 Takenaka T, 1679
 Takenawa T, 153
 Takeshima H, 1629
 Takeshima M, 1861
 Takeshita H, 271
 Taketani K, 1641
 Takeuchi A, 2169
 Takeuchi H, 3653
 Takeuchi R, 2911
 Takeuchi S, 1073
 Takeuchi Y, 5535
 Takeyama Y, 1439
 Talagas M, 2065
 Talbot J-N, 3015
 Tallet-Richard A, 2159
 Tamai H, 5165
 Tamaki N, 5193
 Tamura A, 1163
 Tamura M, 2905
 Tamura Y, 167
 Tan JFV, 161
 Tanabe E, 3295
 Tanabe M, 5119
 Tanaka A, 3431
 Tanaka D, 2881
 Tanaka E, 1679, 3963, 5687
 Tanaka F, 1913
 Tanaka Harunari, 4299
 Tanaka Hiroaki, 595, 1635, 5023, 5031, 5567
 Tanaka Hiroto, 1387
 Tanaka Kaoru, 5699
 Tanaka Katsuaki, 997
 Tanaka Kenichi, 4515
 Tanaka Koji, 5065
 Tanaka Kuniya, 5585
 Tanaka Kyosuke, 1743
 Tanaka M, 267
 Tanaka Naritaka, 5113
 Tanaka Natsuki, 2921, 2935
 Tanaka Tohru, 2861
 Tanaka Toshihiro, 3355
 Tanaka Toshiyuki, 3133
 Tang H, 393
 Tang J, 419
 Tang J-Y, 5611
 Tang R-P, 1169
 Taniguchi H, 469, 2129
 Taniguchi K, 5585
 Taniguchi Y, 2875
 Tanimoto A, 3327
 Taniyama Y, 1463
 Tanner M, 4941
 Taomoto J, 1761, 3495
 Tarhini AA, 4475
 Tarumi S, 5597
 Tasaki K, 4785
 Tasaki T, 3335, 3947
 Taschereau E, 2997
 Taura N, 2689
 Tavaglione V, 2679
 Taverna G, 4537
 Tawada A, 5603
 Tchou-Wong K-M, 1247
 Teixeira RM, 5625
 Televantou D, 2139
 Tendler T, 379
 Teng C-M, 425
 Tenhuen M, 4933
 Teppo S, 45
 Ter Haar R, 2099
 Terada H, 2911
 Terada M, 5107
 Teramae M, 1409
 Terao K, 5699
 Terasaki Y, 5681
 Terashima K, 5575, 5649
 Terrone C, 2679
 Terzakis E, 4007
 Teshima J, 1463
 Teske E, 161
 Thakur BK, 183
 Thiel M, 4189
 Thirlwell MP, 1765
 Thiruchittampalam D, 2491
 Tholin M, 1131
 Thomas M, 981
 Thompson K, 77
 Thoury A, 283
 Throm SL, 3823
 Tian Y, 409
 Tilimidos G, 3509
 Tillmanns TD, 3823
 Tinelli C, 4611, 4999
 Tinzl M, 363
 Tippayamontri T, 3005
 Tiseo M, 5517
 Tiszlavicz L, 1725, 1737
 Titze-De-Almeida R, 865
 Toda Y, 1893
 Todo M, 537, 1483
 Tohda S, 809, 3099, 4293
 Toita T, 2199, 5123
 Toiyama Y, 5065
 Tojo K, 5289
 Tokuda H, 2021, 2535
 Tokuda K, 153, 2557, 3133, 3661, 4821
 Tokuhisa M, 697
 Tokunaga E, 1641
 Tokuyue K, 1157, 1629
 Toma-Dasu I, 1009
 Tomatis S, 4537
 Tombolini V, 4013

- Tomé WA, 2611
Tome Y, 97, 107, 1361, 1373, 3021, 3041, 3623
Tomifuji M, 3285
Tominaga T, 2107
Tominaga W, 2557
Tominaga Y, 4175, 5075
Tomioaka K, 2635
Tomita K, 97
Tomita M, 317
Tomiyasu H, 5317
Tomizawa Y, 4631
Tomobe M, 1629
Tomomura A, 453
Tomomura M, 453
Tomos P, 3475
Tomov B, 4531
Tomova R, 4531
Tomoyasu T, 2905
Tong M, 409
Toniolo L, 4827
Topolčan O, 2239, 2665, 2791
Torigoe T, 167
Torrise R, 4603
Tortora G, 3705
Toso S, 5531
Tóth C, 3195
Toth DF, 3341
Tötterman KJ, 4933
Toubet E, 283
Touboul E, 1661
Touquet B, 4445
Toyama Y, 1769, 2221, 3941, 4029
Toyoda S, 1073
Toyokawa T, 1635, 5023, 5031
Toyzumi Y, 3891
Tozzoli R, 2593
Tran T, 5511
Trangas T, 191
Treiber U, 3731
Tremblay-Lemay R, 2569
Treska V, 2239, 4855
Trignani M, 4557
Trippa F, 4557
Trombino S, 4847
Truant S, 1603
Truskaite K, 665
Tsagaraki I, 4901
Tsai Chang-Hai, 4067, 4907, 5401
Tsai Ching-Hua, 1169
Tsai Chung-Hung, 1941
Tsai C-W, 529, 671, 2775, 3391, 4067, 4907, 5401
Tsai F-J, 529, 671
Tsai M-H, 3391, 4965
Tsai Y, 529, 671
Tsai Y-F, 4663
Tsaur I, 5243
Tsavaris N, 1209
Tsay JJ, 1247
Tseng L-M, 3807, 5543
Tsezou A, 1977
Tsibinos G, 1667
Tsiftsis DD, 1667
Tsilibary E, 4901
Tsilimidos G, 5693
Tsimplaki E, 4007
Tsimpoukis S, 2369
Tsubaki M, 1439
Tsubamoto H, 1073
Tsubata Y, 261
Tsubokura T, 643, 1773
Tsuchida A, 1157
Tsuchida K, 697
Tsuchiya H, 97, 1373, 2169, 3021, 3623
Tsuchiya M, 4631
Tsuchiya T, 2107
Tsuji Y, 5051
Tsuji H, 5579
Tsuji moto H, 5317
Tsujiura M, 271
Tsukada K, 175
Tsukamoto S, 1629
Tsukino H, 1023, 1893
Tsukiyama I, 3105, 5043
Tsumagari K, 4213
Tsunoda T, 2833
Tsutsumi K, 267
Tu C-Y, 2775, 4067
Tubiana-Mathieu N, 2657
Tumolo S, 1041
Tuncay E, 2643
Turner DC, 3823
Tuschy B, 2771, 3403, 3995, 4553
Tutino V, 3739
Tuunanen T, 2623, 4941
Tuyaerts S, 3855, 5495
Tzeng F-Y, 3225
Tzinia A, 4901
Uchi R, 1927
Uchida J, 3431
Uchida Y, 5083
Uchiyama A, 3699
Uchiyama T, 3423
Ueda A, 5107
Ueda M, 5585
Ueda S, 5699
Ueda T, 3335, 3947
Uehara F, 1361, 1373, 3041
Ueki O, 3837
Uematsu K, 1117
Uemura N, 1099
Uemura T, 1935
Ueno M, 3905
Ueno Satoru, 1147, 3837, 4669, 5501
Ueno Satoshi, 1379
Ueno T, 4995
Ueo H, 1927
Ueoka R, 4727
Uesawa Y, 3061
Ueyama J, 153, 3105
Ugorski M, 1447
Uguen A, 2065
Uji K, 5617
Uldall M, 1963
Ulsperger E, 3831
Um S-W, 5127
Umbreit C, 1951, 2457, 5385
Umehayashi M, 1387
Umehara Seiji, 537, 1483
Umemura Shigeki, 1175
Umemura S-I, 3145
Umeno H, 5561
Ummaritchot V, 4001
Unno M, 685
Uno K, 2861
Uno Y, 5011
Uramoto H, 1913, 2123
Urasaki Y, 3335, 3947
Ürer HN, 2643
Urken M, 5511
Ushijima M, 2949
Uto Y, 2881, 2911, 2917
Utriainen M, 1595, 4933
Uwafuji S, 4841
Uzgare RP, 1989
Uzunoglu FG, 4975
Vagge S, 655
Vagnoni V, 2361
Vairaktaris E, 4033
Vaissiere N, 2657
Vajkoczy P, 2093
Valakh V, 4491
Valentini V, 2785, 4557, 4585
Valeriani M, 1229
Valin S, 3783
Valladares-Ayerbes M, 4089
Valli VE, 4203
Valvo F, 4557
Van Buren E, 77
Van De Velde H, 5453
Van De Winkel N, 3359
Van Den Broek M, 4189
Van Den Eertwegh AJM, 387
Van Gool SW, 3855, 5495
Van Moorselaar RJA, 387, 2099
Van Nguyen S, 3247
Van Shalkwyk G, 1401
Van Tulder MW, 3553
Van Vlierberghe H, 4683
Vanderstraeten A, 3855, 5495
Vandewynckel Y-P, 4683
Vangara KK, 2425
Vanwert AL, 4163
Varela S, 4089
Varga Z, 1725, 1737
Vari S, 21
Variami E, 3509
Varotto A, 4081
Vasas A, 2021
Vassilakopoulos T, 5693
Vassiliou E, 191
Vassiliou S, 4033
Vasstrand EN, 837
Vayopoulos G, 5693
Vcelar B, 3629
Vecchiato A, 4081
Veganzones S, 5159
Vehmanen L, 1595
Velaeti S, 191
Veltri E, 1721
Velutti L, 4603
Veninga T, 3887
Venturini B, 3925
Verano M, 1343
Vergine M, 3705
Vergote I, 3855, 5495
Verhelst X, 4683
Verna V, 5091
Verschuere T, 3855, 5495
Vesely DL, 785, 2409
Vetvicka D, 1563

- Veyret C, 5655
 Victorino VJ, 737
 Vidaurreta M, 5159
 Vieito M, 5295
 Vielma SA, 1809
 Viens P, 2159
 Villa E, 4537
 Villagomez R, 3799
 Villani S, 917
 Villanova G, 2657
 Villanueva C, 301
 Vinciguerra A, 4557
 Viniou NA, 3509, 5693
 Virgolini IJ, 1537
 Vishwanatha JK, 3603
 Vítek P, 4097
 Vladov N, 4531
 Vobořil Z, 1201
 Volant A, 2065
 Von Deimling A, 1065
 Von Euw E, 2997
 Von Guggenberg E, 1537
 Von Pezold J, 779
 Vorreuther R, 779
 Votruba I, 1899, 3163
 Voutsadakis IA, 3527
 Vrettou E, 4573
 Vujovic O, 2227
 Vycital O, 4855
 Vylliotis A, 4033
- Wachter F, 5273
 Wada N, 3653
 Wada T, 1747
 Wada Y, 2635
 Wadsak W, 3341
 Wagenblast J, 913, 3347,
 3481, 4017
 Wagner C, 3553
 Wakabayashi K, 3667
 Wakasa K, 595
 Wakasa T, 1181
 Wakayama A, 5123
 Wakiyama S, 705, 1697,
 2715, 3439
 Wakui M, 3791
 Walker F, 283
 Wallerek S, 3275
 Wallwiener D, 2233
 Walther R, 4921
 Walz-Eschenlohr U, 3403
 Wang C-L, 425
 Wang G, 1421
- Wang H-C, 5543
 Wang Hong, 1343
 Wang H-P, 425
 Wang Huaqian, 1343
 Wang K-C, 3807
 Wang Lee, 2729
 Wang Liang, 5199
 Wang M, 1873
 Wang S-M, 2775
 Wang W, 4279
 Wang X, 5407
 Wang Y-C, 2729
 Wang Youxin, 207
 Wang Yufeng, 153, 2557,
 3133, 3661, 4821
 Wang Zheng, 4103
 Wang Zhongqiu, 409
 Wang Zhuo, 419
 Wang Z-Y, 1873
 Wargovich MJ, 5325
 Warm M, 731
 Warnakulasauriya S, 837
 Warner BM, 4757
 Warren A, 1401
 Wasle IK, 3831
 Watanabe A, 575
 Watanabe K, 1769, 2221,
 3941, 4029
 Watanabe Manabu, 5317
 Watanabe Masahiko, 583
 Watanabe Mika, 1463
 Watanabe R, 5301
 Watanabe T, 4785
 Wazir U, 2179, 2185
 Weber A, 4505
 Weber R, 3879
 Weber–Dabrowska B, 1569
 Wehmeijer N, 755
 Wehrmann M, 4567
 Wei X, 1343
 Weirich G, 3731
 Weisburg JH, 1829
 Weise E, 3917
 Weiser MR, 3241
 Weiss M, 4921
 Weisshaar S, 3629
 Weller M, 3563
 Weng W, 5407
 Wensing KU, 4183
 Wenz F, 3995
 Werner JA, 249
 Wernicke G, 3899
 Werynska B, 965, 1447
- Wettergren Y, 2447
 Weyant MJ, 1337
 White MD, 3573
 Wichmann G, 2415
 Wieder R, 379
 Wiegand S, 249, 1141
 Wiener E, 4639
 Wietrzyk J, 433, 1429, 1569
 Wikner J, 3917
 Wilhelm T, 249, 1141
 Willenbrock S, 1325, 5421
 Wilson MJ, 3635
 Wimberger P, 329
 Winiecka-Klimek M, 5343
 Winn T, 183
 Winter N, 3069
 Witczak Z, 4163
 Witkiewicz W, 1447
 Wittwer J, 5349
 Wojnar A, 1447
 Wolf BJ, 1829
 Wolff JE, 3307
 Wolfgarten M, 1971
 Wolfrom C, 133
 Wollenberg B, 2481
 Wolpert F, 3563
 Wolzt M, 3629
 Wongvaranon P, 5433
 Woo L, 3925
 Woo S-H, 2205
 Woode R, 4483
 Wotherspoon A, 4611
 Wozniak M, 3205
 Wrba F, 2085
 Wright JD, 801
 Wu C, 1977
 Wu C-E, 2605, 3317
 Wu C-H, 4663
 Wu H-C, 4907, 5401
 Wu J, 419
 Wu L, 1917
 Wu M-F, 4867
 Wu Q, 5407
 Wu S-C, 1169
 Wu T-C, 2729
 Wu W-J, 1091
 Wu WY-Y, 5171
 Wu Y, 409
 Wu YJ, 2391
 Wu Z-F, 3169
 Wust P, 4111, 4117, 4639
 Wydra D, 5461
 Wysocki M, 1189
- Xian X-S, 2541
 Xie H, 3251, 4285
 Xin H-W, 2401
 Xoxakos I, 2441
 Xu J, 4103
 Xu P, 949
 Xu S-Z, 3169
 Xynos ID, 1209
- Yabushita K, 5107
 Yaegashi H, 1147
 Yagublu V, 3753
 Yamada K, 643
 Yamada Shigeru, 5579
 Yamada Sohsuke, 1913,
 2123, 5579
 Yamada T, 4995
 Yamada Yasuhide, 2129,
 4547
 Yamada Yasuhide, 309, 469
 Yamada Yoshiaki, 5043
 Yamada Yuko, 5057
 Yamaguchi A, 1881, 4841,
 5311
 Yamaguchi K, 3845
 Yamaguchi S, 975
 Yamaguchi T, 3905
 Yamaguchi Yoshie, 5301
 Yamaguchi Yoshiyuki, 5557
 Yamamoto A, 5031
 Yamamoto H, 1927
 Yamamoto I, 2895
 Yamamoto Kazuo, 1117
 Yamamoto Kenneth, 3879
 Yamamoto Mai, 2849
 Yamamoto Masaji, 3061
 Yamamoto Masashi, 4515
 Yamamoto Masatatsu, 1547
 Yamamoto Natsuyo, 2619
 Yamamoto Nobuyuki, 3279,
 4219, 5223
 Yamamoto Noriaki, 5617
 Yamamoto Norio, 2169
 Yamamoto Tatsuhito, 3423
 Yamamoto Teppei, 2779
 Yamamoto Y, 1689, 5097
 Yamamura M, 4319
 Yamanaka T, 4631
 Yamaoka N, 5165
 Yamashita H, 4959
 Yamashita Keishi, 583
 Yamashita Kimihiro, 4515
 Yamashita T, 3285

- Yamashita Yoshito, 595, 1635, 5023, 5031
 Yamashita Yuichi, 3295
 Yamato K, 4995
 Yamauchi M, 1409
 Yamauchi Takahiro, 3335, 3947
 Yamauchi Takenori, 1023, 1893
 Yamauchi Y, 3791
 Yamazaki H, 643, 747, 1679, 1685, 1773, 2453, 3963, 5507, 5561, 5675, 5687
 Yamazaki R, 1379
 Yamazoe S, 5023
 Yan L, 3153
 Yanaga K, 705, 1697, 1769, 2221, 2715, 2723, 3439, 3941, 4029, 4041, 5005, 5011
 Yanagitani N, 3327
 Yang ES, 847
 Yang G-Y, 5261
 Yang H, 5335
 Yang Jen-Hung, 4411
 Yang Jian-Hui, 2401
 Yang JJ, 3089
 Yang J-S, 1941
 Yang L-X, 1785
 Yang L-X, 3879
 Yang Mei-Due, 529, 671
 Yang SH, 521
 Yang SK, 4833
 Yang T-L, 5543
 Yang T-S, 3317
 Yang W-C, 4663, 5611
 Yang X, 755
 Yang Yi, 123
 Yang YJ, 2115
 Yang Yong, 1917
 Yang Zhijian, 409, 419
 Yang Zhongjin, 4827
 Yano K, 2957
 Yano Shintaro, 3259
 Yano Shuya, 107, 1361, 1373, 3021, 3041,
 Yano Y, 2977
 Yarpalvi R, 4927
 Yapijakis C, 4033
 Yasaei H, 2185
 Yashiro M, 1635, 5023
 Yasoshima T, 167
 Yasuda A, 1439
 Yasuda I, 2861
 Yasuda K, 575
 Yasuda S, 5579
 Yasui H, 3845
 Yasui T, 1409
 Yatomi Y, 2619
 Yazbek G, 301
 Ye L, 199, 1917
 Ye W, 949
 Yee JA, 3153
 Yeh C, 4867
 Yeh D-C, 5543
 Yeh K-H, 4123
 Yeh M, 2797
 Yeh M-Y, 4867
 Yen AM-F, 5171
 Yen C-H, 2763
 Yentürk E, 2643
 Yi JH, 4619
 Yim D-H, 3089
 Yim JH, 5445
 Yin P-H, 3807
 Yin Y, 1499
 Ying T-H, 4411
 Yoh K, 1175
 Yokobori T, 5113
 Yokomise H, 1107, 5597
 Yokosuka O, 5603
 Yokota S, 5535
 Yokoyama M, 4627
 Yoneda M, 537, 1483, 2699
 Yonei T, 4631
 Yonekura S, 3099
 Yoneyama S, 5119
 Yong WH, 2047
 Yong Y, 5349
 Yoo JE, 821
 Yoo K-Y, 3089
 Yoo R-E, 1887
 Yoo SH, 4421
 Yoo YD, 763
 Yoon A, 4675
 Yoon DH, 1237, 5667
 Yoon M, 2011
 Yoon SM, 1237
 Yoshida S, 4309
 Yoshida A, 3335, 3947
 Yoshida H, 1409
 Yoshida Kazuhiro, 5549
 Yoshida Ken, 643, 747, 1679, 1685, 1773, 2453, 3963,
 5507, 5561, 5675, 5687
 Yoshida Koji, 4175
 Yoshida Shin, 3423
 Yoshida Shuhei, 469
 Yoshida Takefumi, 2941
 Yoshida Tatsuya, 1175
 Yoshida Toru, 175
 Yoshikawa H, 5575
 Yoshikawa K, 5579
 Yoshikawa M, 5603
 Yoshimoto T, 537
 Yoshimura A, 1117
 Yoshino S, 2629, 3423
 Yoshioka H, 4631
 Yoshioka I, 175
 Yoshioka Y, 747, 3963,
 5687
 Yoshita H, 5107
 Yoshitake T, 1649, 5575,
 5649
 Yoshiyama A, 5357
 Yoshizawa T, 5043
 Yotsumoto F, 2855
 Youn J-W, 3089
 Young GP, 3581
 Young MRI, 1809
 Young MS, 4357
 Young R, 4483, 4927
 Younus J, 2227
 Yu E, 2227
 Yu H, 5199
 Yu JA, 1337
 Yu JQ, 4365
 Yu Y, 5407
 Yu Z, 4757
 Yuge K, 2921, 2935
 Yuh EL, 5213
 Yumita N, 3145
 Yunos NM, 4365
 Zabel M, 5375
 Zaccaro L, 871
 Zacharia LC, 1977
 Zacherl J, 1035, 2085, 3455
 Żaczek AJ, 5461
 Zaczek M, 1569
 Zadinova M, 1563
 Zafon C, 337
 Zagonel V, 3487, 4061
 Zahalka T, 4651
 Zahoor H, 4475
 Zairi F, 2057
 Zakrzewska A, 763
 Zar N, 3247, 4947
 Zaretsky Y, 3347, 4017
 Zdrodowski M, 3725
 Zeiss K, 287
 Zenda S, 567
 Zennami K, 5043
 Zerlin M, 801
 Zervakis K, 3509, 5693
 Zeuch J, 4567
 Zezulová M, 4097
 Zhang C, 4279
 Zhang G, 2353
 Zhang H, 53
 Zhang J, 4453
 Zhang K, 1343
 Zhang Nan, 1837
 Zhang Ning, 1917
 Zhang W, 5261
 Zhang Xiaojing, 5199
 Zhang Xintian, 1873
 Zhang Yong, 97, 409, 419,
 1837
 Zhang Yuan, 5199
 Zhao C, 4279
 Zhao J, 929
 Zhao M, 97, 1837
 Zhao Z, 5199
 Zheng X, 1343
 Zheng Y-H, 4965
 Zhong S, 949
 Zhong Y, 65, 1421
 Zhou D, 1343
 Zhu S-H, 3169
 Zhu Y, 609
 Zhumadilov Z, 4049
 Ziccarelli L, 4557
 Ziekman PGPM, 161
 Zilling T, 3269
 Zimmermann AP, 249
 Zimmermann U, 4921
 Zinzani PL, 2639
 Zlobec I, 3053
 Zou B, 929
 Zouaoui S, 3467
 Zuckerbraun HL, 1829
 Zuguchi M, 1463
 Zuradelli M, 4603
 Zurmeyer S, 1585
 Zustovich F, 3487, 4061,
 5531
 Zwolak P, 2981

Errata

Volume 30, No. 7, page 2488: The following Acknowledgements should be inserted before the References:

Acknowledgements

This work was supported by National Institutes of Health grant RO1HL86978 to M. L. Smith.

Volume 30, No. 10, page 4127: Lines 17 and 18 of Abstract should read:

univariate Cox regression analysis (p=0.013) and multivariate analysis (p=0.019). Overexpression of TIMP-1 thus correlated

Volume 30, No. 10, page 4128: The last paragraph of Results should read:

On univariate Cox regression analysis, high TIMP-1 expression was associated with significantly poorer overall survival than was low TIMP-1 expression (p=0.013) (Table II). Multivariate analysis with a Cox regression model also showed that high TIMP-1 expression was associated with significantly poorer overall survival and identified high TIMP-1 mRNA expression as a significant independent predictor of overall survival (p=0.019).

Volume 30, No. 10, page 4129: The last line of Table I should read:

Liver metastasis	Absent/present	82/19	80/21	0.724
------------------	----------------	-------	-------	-------

Volume 30, No. 10, page 4129: The 2nd and 3rd lines of Table II should read:

High <i>TIMP-1</i>	2.18 (0.248-0.850)	2.15 (0.245-0.883)
P-value	0.013	0.019

Volume 31, No. 1, page 191: The name of the fourth author should read:

SOTIRIOS K. SOTIRIOU

Volume 31, No. 1, page 327: The last line of Tables II should read:

Present	14	26
---------	----	----

Volume 32, No. 4, page 1392: Figure 4 should be replaced by:





Figure 4. Extra hepatic period free survival.

Volume 32, No. 8, page 3025: The following additional Figure should be placed on the upper part of this page:

YM182832



YM185453






Figure 10. Chemical structures of PI702 (YM182832) and PI701 (YM185453).

Volume 32, No. 10, page 4401: Figure 5 should be replaced with:



Volume 32, No. 11, page 4717: Figure 1 should be replaced with:



Volume 32, No. 12, page 5207: Acknowledgements should read:

Acknowledgements

This study was supported in part by a Grant-in-Aid from the Ministry of Education, Science, Sports, Culture, and Technology, Japan. We gratefully acknowledge Dr. Hiroyuki Miyoshi (RIKEN BioResource Center, Tsukuba, Japan) for providing Lentivirus vector (CSII-EF-MCS-IRES2-Venus) and its packaging plasmids (pCAG-HIVgp and pCMV-VSV-G-RSV-Rev).

Volume 32, No. 12, page 5281, right column: Line 16 should read: control group (Figure 4A). After treatment of 100 nM DTX-κ

Volume 32, No. 12, page 5283-4: The section of References should read:

References

- 1 Miller C: An overview of the potassium channel family. *Genome Biol* 1: REVIEWS0004.1-0004.5, 2000.
- 2 Shieh CC, Coghlan M, Sullivan JP and Gopalakrishnan M: Potassium channels: molecular defects, diseases, and therapeutic opportunities. *Pharmacol Rev* 52: 557-594, 2000.
- 3 Edwards G and Weston AH: The role of potassium channels in excitable cells. *Diabetes Res Clin Pract* 28 Suppl: S57-66, 1995.
- 4 O'Grady SM and Lee SY: Molecular diversity and function of voltage-gated (Kv) potassium channels in epithelial cells. *Int J Biochem Cell Biol* 37: 1578-1594, 2005.
- 5 Pongs O: Voltage-gated potassium channels: from hyperexcitability to excitement. *FEBS Lett* 452: 31-35, 1999.
- 6 Boland LM and Jackson KA: Protein kinase C inhibits Kv1.1 potassium channel function. *Am J Physiol* 277: C100-110, 1999.
- 7 Dubois JM and Rouzaire-Dubois B: Role of potassium channels in mitogenesis. *Prog Biophys Mol Biol* 59: 1-21, 1993.
- 8 Kunzelmann K: Ion channels and cancer. *J Membr Biol* 205: 159-173, 2005.
- 9 Pardo LA: Voltage-gated potassium channels in cell proliferation. *Physiology (Bethesda)* 19: 285-292, 2004.
- 10 Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F and Stuhmer W: Role of voltage-gated potassium channels in cancer. *J Membr Biol* 205: 115-124, 2005.
- 11 Camacho J: Ether a go-go potassium channels and cancer. *Cancer Lett* 233: 1-9, 2006.
- 12 Wonderlin WF and Strobl JS: Potassium channels, proliferation and G1 progression. *J Membr Biol* 154: 91-107, 1996.
- 13 Wang Z: Roles of K⁺ channels in regulating tumour cell proliferation and apoptosis. *Pflugers Arch* 448: 274-286, 2004.
- 14 Jang SH, Choi SY, Ryu PD and Lee SY: Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma *in vitro* and *in vivo*. *Eur J Pharmacol* 651: 26-32, 2011.
- 15 Jang SH, Ryu PD and Lee SY: Dendrotoxin-kappa suppresses tumor growth induced by human lung adenocarcinoma A549 cells in nude mice. *J Vet Sci* 12: 35-40, 2011.
- 16 Zhou Q, Kwan HY, Chan HC, Jiang JL, Tam SC and Yao X: Blockage of voltage-gated K⁺ channels inhibits adhesion and proliferation of hepatocarcinoma cells. *Int J Mol Med* 11: 261-266, 2003.
- 17 Rouzaire-Dubois B and Dubois JM: K⁺ channel block-induced mammalian neuroblastoma cell swelling: A possible mechanism to influence proliferation. *J Physiol* 510(Pt 1): 93-102, 1998.
- 18 Jang SH, Kang KS, Ryu PD and Lee SY: Kv1.3 voltage-gated K(+) channel subunit as a potential diagnostic marker and therapeutic target for breast cancer. *BMB Rep* 42: 535-539, 2009.
- 19 Jang SH, Choi C, Hong SG, Yarishkin OV, Bae YM, Kim JG, O'Grady SM, Yoon KA, Kang KS, Ryu PD and Lee SY: Silencing of Kv4.1 potassium channels inhibits cell proliferation of tumorigenic human mammary epithelial cells. *Biochem Biophys Res Commun* 384: 180-186, 2009.
- 20 Kim HJ, Jang SH, Jeong YA, Ryu PD, Kim DY and Lee SY: Involvement of Kv4.1 K(+) channels in gastric cancer cell proliferation. *Biol Pharm Bull* 33: 1754-1757, 2010.
- 21 Harvey AL: Recent studies on dendrotoxins and potassium ion channels. *Gen Pharmacol* 28: 7-12, 1997.
- 22 Smith LA, Reid PF, Wang FC, Parcej DN, Schmidt JJ, Olson MA and Dolly JO: Site-directed mutagenesis of dendrotoxin K reveals amino acids critical for its interaction with neuronal K⁺ channels. *Biochemistry* 36: 7690-7696, 1997.
- 23 Wang FC, Bell N, Reid P, Smith LA, McIntosh P, Robertson B and Dolly JO: Identification of residues in dendrotoxin K responsible for its discrimination between neuronal K⁺ channels containing Kv1.1 and 1.2 alpha subunits. *Eur J Biochem* 263: 222-229, 1999.
- 24 Armour AA and Watkins CL: The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. *Eur Respir Rev* 19: 186-196, 2010.
- 25 Sahu RP, Batra S, Kandala PK, Brown TL and Srivastava SK: The role of *K-ras* gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. *Cancer Chemother Pharmacol* 67: 481-487, 2011.
- 26 Furugaki K, Iwai T, Shirane M, Kondoh K, Moriya Y and Mori K: Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with *EGFR* mutation, *KRAS* mutation or both wild-type *EGFR* and *KRAS*. *Oncol Rep* 24: 1141-1146, 2010.
- 27 Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, van Bodegom PC and Bos JL: Incidence and possible clinical significance of *K-ras* oncogene activation in adenocarcinoma of the human lung. *Cancer Res* 48: 5738-5741, 1988.
- 28 Suzuki Y, Orita M, Shiraishi M, Hayashi K and Sekiya T: Detection of *RAS* gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. *Oncogene* 5: 1037-1043, 1990.
- 29 Rodenhuis S and Slebos RJ: The *RAS* oncogenes in human lung cancer. *Am Rev Respir Dis* 142: S27-30, 1990.
- 30 Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA and Giaccone G: Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidylinositol-3 kinase pathways in non-small cell lung cancer cells. *Int J Cancer* 118: 209-214, 2006.
- 31 Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway in cancer therapy. *Expert Opin Ther Targets* 16: 15-31, 2012.
- 32 Goldie JH and Coldman AJ: The genetic origin of drug resistance in neoplasms: implications for systemic therapy. *Cancer Res* 44: 3643-3653, 1984.
- 33 Park IH, Kim JY, Jung JI and Han JY: Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with *K-Ras* mutations. *Invest New Drugs* 28: 791-799, 2010.
- 34 Bill A, Schmitz A, Konig K, Heukamp LC, Hannam JS and Famulok M: Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells. *PLoS One* 7: e41179, 2012.
- 35 Ouadid-Ahidouch H, Chaussade F, Roudbaraki M, Slomianny C, Dewailly E, Delcourt P and Prevarskaya N: KV1.1 K(+) channels identification in human breast carcinoma cells: involvement in cell proliferation. *Biochem Biophys Res Commun* 278: 272-277, 2000.

- 36 Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci USA* 101: 13306-13311, 2004.
- 37 Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing *EGFR* mutations in lung cancer activate anti-apoptotic pathways. *Science* 305: 1163-1167, 2004.
- 38 Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisano D, Stinson JA, Zhang YR, Seshagiri S and Hillan KJ: Mutations in the epidermal growth factor receptor and in *KRAS* are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol* 23: 5900-5909, 2005.
- 39 Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS and Wistuba II: *KRAS* mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *Clin Cancer Res* 13: 2890-2896, 2007.
- 40 Giaccone G and Wang Y: Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. *Cancer Treat Rev* 37: 456-464, 2011.
- 41 Petrelli A and Giordano S: From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. *Curr Med Chem* 15: 422-432, 2008.
- 42 Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P and Raymond E: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. *J Clin Oncol* 24: 25-35, 2006.
- 43 Zimmermann GR, Lehar J and Keith CT: Multi-target therapeutics: when the whole is greater than the sum of the parts. *Drug Discov Today* 12: 34-42, 2007.
- 44 Zhang DY, Zhang YH, Sun HY, Lau CP and Li GR: Epidermal growth factor receptor tyrosine kinase regulates the human inward rectifier potassium K(IR)2.3 channel, stably expressed in HEK 293 cells. *Br J Pharmacol* 164: 1469-1478, 2011.
- 45 Bowlby MR, Fadoo DA, Holmes TC and Levitan IB: Modulation of the Kv1.3 potassium channel by receptor tyrosine kinases. *J Gen Physiol* 110: 601-610, 1997.

Received September 7, 2012
 Revised October 23, 2012
 Accepted October 24, 2012

Volume 33, No. 2, page 379: The name of the 5th Author should read:

JULIAN KERTSMAN^{2,3}

Volume 33, No. 3, page 1209: The address of the corresponding Author should read:

Correspondence to: John Syrios, MD, Ph.D., Pathophysiology Department, Athens University Medical School, 75 Mikras Asias str., 11527, Athens, Greece. Tel: +30 2106463191, Fax: +30 2107462664, e-mail: syriosi@yahoo.gr

Volume 33, No. 4, page 1585: Authors and affiliations should read:

SARAH ZURMEYER¹, CHRISTINA FOTOPOULOU¹, ELENA BRAICU¹,
 UWE SCHLICHTING² and JALID SEHOULI¹

¹*Department of Gynecological Oncology,*

²*Department of Pathology, Charité, Campus Virchow Hospital, Berlin, Germany*

Volume 33, No. 4, page 1621: Lines 26 and 27 of Abstract should read:

recurrence [p=0.0014, hazard ratio=0.39 (95% CI: 0.21-0.69)]. Particularly for peritoneal recurrence, those in REG

Volume 33, No. 4, page 1625: The last line of Table II should read:

Tumour marker elevation	Re-elevation <i>versus</i> Non-elevation	0.0109	0.3923	0.215-0.690	0.0014
-------------------------	--	---------------	--------	-------------	---------------

Volume 33, No. 5, page 2257: Title, authors and affiliations of abstract No 15 should read:

15

BELINOSTAT POTENTIATES HORMONAL THERAPY AND PREVENTS THE ONSET OF CASTRATION-RESISTANT PHENOTYPE MODULATING ANDROGEN RECEPTOR, HSP90 AND CRM1 IN PRECLINICAL MODELS OF PROSTATE CANCER

Giovanni Luca Gravina^{1,2}, Francesco Marampon^{1,2}, Paola Muzi³, Andrea Mancini⁴, Margherita Piccolella⁵, Paola Negri Cesi⁵, Marcella Motta⁵, Andrea Lenzi⁶, Vincenzo Tombolini⁷, Emmanuele Jannini⁸, Claudio Festuccia¹

¹Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy;

²Division of Radiotherapy; Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy;

³Laboratory of Genaral pathology, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy;

⁴Laboratory of Biochemistry; Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy;

⁵Department Of Endocrinology, Center Of Endocrinological Oncology, University Of Milano, Milan, Italy;

⁶Laboratorio of Endocrinology, Department Of Experimental Medicine, University La Sapienza, Rome;

⁷Division of Radiotherapy, Department Of Experimental Medicine, University La Sapienza, Rome;

⁸Course of Endocrinology and Medical Sexology, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy

Volume 33, No. 6, page 2651: The name of the 5th author should read:

RAPHAEL LUIZ HAIKEL Jr¹,

Volume 33, No. 8, page 3330: Figures 1 and 2 should read:




Figure 1. Kaplan-Meier curves for progression-free survival (PFS) (N=50). The median PFS (N=50) was 4.3 months (A). The median PFS in subgroups of with patients with anaplastic lymphoma kinase (ALK) translocation, epidermal growth factor receptor (EGFR) mutation, wild-type for both ALK and EGFR (WT/WT) were 3.0, 5.5 and 4.0 months, respectively (B).




Figure 2. Kaplan-Meier curves for overall survival (OS) (N=50). The overall median OS (N=50) was 22.2 months (A). The median OS had not yet been reached in the patients with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocation, but was 15.8 months in wild-type for both ALK and EGFR (WT/WT) patients (B).

Volume 33, No. 8, page 3462: The last two lines of Table I should read:

3-Year	44.3
5-Year	34.3

Volume 33, No. 8, page 3463: Table II should be replaced with:

Table II. *Cox proportional hazard regression analysis for overall survival in 47 consecutive patients with Siewert type II adenocarcinoma.*

Variable	Univariate <i>p</i> -value ¹	Multivariate ²		
		HR	95% CI	<i>p</i> -value ³
Gender				
Male vs. female	0.0561	-	-	-
Age				
<67 vs. >68	0.3494	-	-	-
Approach				
Abdominal vs. thoracotomy	0.1276	-	-	-
Histological type				
Undifferentiated and others vs. differentiated	0.3904	-	-	-
Macroscopic type				
Type 3-5 vs. type 0-2	0.0018	-	-	-
Tumor depth				
pT3-4 vs. pT1-2	0.0513	-	-	-
pT4 vs. pT1-3	0.0049	-	-	-
Lymph node involvement				
Positive vs. negative	0.0001	12.9270	1.512-110.533	0.0194
Lymphatic invasion				
Positive vs. negative	0.0077	-	-	-
Histological venous invasion				
Positive vs. negative	0.7160	-	-	-

¹Univariate analysis using the log-rank test. ²Cox proportional hazard regression analysis for overall survival. Considered significant at 0.05. HR, Hazard ratio; CI, 95% confidence interval.

Volume 33, No. 8, page 3463: Left column, lines 4 and 5 should read:

group of patients with tumor depth pT1-3 (n=24, 5-year overall survival rate; 51%) than in the group of patients with tumor depth pT4 (n=23, 5-year overall survival rate; 49%)

Volume 33, No. 8, page 3464: The legend of Figure 1 should read:

Figure 1. *Overall survival rates after surgery of Siewert type II adenocarcinoma (n=47). The 5-year overall survival rate is significantly better in the group of patients with tumor depth pT1-3 (n=24, 5-year overall survival rate; 51%) than in the group of patients with tumor depth pT4 (n=23, 5-year overall survival rate; 49%) (p=0.0049).*

Volume 33, No. 8, page 3481: The name of the 4th author should read:

NATALIE FILMANN²,

Volume 33, No. 9, page 3627: Acknowledgements should read:

Acknowledgements

This study was supported in part by National Cancer Institute grant CA132971. The technical assistance of Mr John J. Grzesiak is gratefully acknowledged.

Volume 33, No. 10, page 4216: Please add Acknowledgements before References:

Acknowledgements

We thank Mei Shang for expert technical assistance.

Volume 33, No. 10, page 4483: Authors' names should read:

WALEED F. MOURAD¹, DANIEL SHASHA¹, DUKAGJIN M. BLAKAJ¹, AZITA S. KHORSANDI¹,
RANIA A. SHOURBAJI¹, JONATHAN GLANZMAN¹, RAFI KABARRITI¹, REBEKAH YOUNG¹,
SHYAMAL PATEL¹, EVANGELIA KATSOULAKIS¹, MAURICIO GÁMEZ¹, RUDOLPH WOODE¹,
CATHY LAZARUS², CATHERINE CONCERT¹, KENNETH S. HU¹ and LOUIS B. HARRISON¹

Volume 33, No. 10, page 4639: The name of the 5th author should read:

VOLKER BUDACH¹,

Instructions to Authors 2013

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios
 International Institute of Anticancer Research (IIAR)
 Editorial Office of ANTICANCER RESEARCH,
 IN VIVO, CANCER GENOMICS and PROTEOMICS.
 1st km Kapandritiou-Kalamou Road
 P.O. Box 22, GR-19014 Kapandriti, Attiki
 GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Editorial Staff

Managing Editor and Executive Publisher: J.G. DELINASIOS, Athens, Greece

Assistant Managing Editor: S. AZOUDIS

Production Editor: E. ILIADIS, Athens, Greece

Editorial Office

International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd.,
Kapandriti, P.O.Box 22, Attiki 19014, Greece
Tel and Fax: +30-22950-53389

Please visit the IAR websites: www.iar-anticancer.org; www.iarjournals.org

E-mails:

Editor: editor@iar-anticancer.org; Journals: journals@iar-anticancer.org; IAR: iar@iar-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published monthly. Each annual volume contains twelve issues and index.

Copyright: Once a manuscript has been published in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

ANTICANCER RESEARCH is available in print (ISSN: 0250-7005) and online (ISSN: 1791-7530) through Stanford University HighWire Press with access to full text/PDF articles from all previous volumes since January 1st, 2004. For online/print subscription rates, please visit the IAR websites: www.iar-anticancer.org; www.ar.iarjournals.org

Annual Subscription Rates 2013: Institutional subscription online: Euro 1,650.00. Institutional subscription print: Euro 1,670.00. Institutional subscription online & print: Euro 1,700.00. Personal subscription online: Euro 780.00. Personal subscription print: Euro 800.00. Personal subscription online & print: Euro 830.00. Prices include rapid delivery and insurance. Previous volumes of Anticancer Research (Vol. 1-32, 1981-2012) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Executive Publisher of Anticancer Research, Athens, Greece and should be sent to the Editorial Office.

Correspondence: (subscription orders, reprint orders, change of address, disposition of submitted manuscripts, advertising rates requests, and general editorial matters) should be directed to Dr. J.G. Delinassios, Executive Publisher and Managing Editor, Editorial Office.

Advertising: Correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including *Current Contents (Life Sciences)*, *Science Citation Index*, *Index Medicus*, *Biological Abstracts*, *PubMed*, *Chemical Abstracts*, *Excerpta Medica*, *University of Sheffield Biomedical Information Service*, *Current Clinical Cancer*, *AIDS Abstracts*, *Elsevier Bibliographic Database*, *EMBASE*, *Compendex*, *GEODATABASE*, *EMBiology*, *Elsevier BIOBASE*, *FLUIDEX*, *World Textiles*, *Scopus*, *Progress in Palliative Care*, *Cambridge Scientific Abstracts*, *Cancergram (International Cancer Research Data Bank)*, *MEDLINE*, *Reference Update - RIS Inc.*, *PASCAL-CNRS*, *Inpharma-Reactions (Datastar, BRS)*, *CABS*, *Immunology Abstracts*, *Telegen Abstracts*, *Genetics Abstracts*, *Nutrition Research Newsletter*, *Dairy Science Abstracts*, *Current Titles in Dentistry*, *Inpharma Weekly*, *BioBase*, *MedBase*, *CAB Abstracts/Global Health Databases*, *Investigational Drugs Database*, *VINITI Abstracts Journal*, *Leeds Medical Information*, *PubsHub*, *Sociedad Iberoamericana de Información Científica (SIIC) Databases*.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2012 \$2.00 +0.40.

The Editors and Publishers of the journal ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

Editorial Office

International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd.,
Kapandriti, P.O.Box 22, Attiki 19014, Greece
Tel and Fax: +30-22950-53389

PHOTOCOMPOSITION BY IAR
PRINTED BY ENTYPPO, GREECE
PRINTED ON ACID-FREE PAPER